[
  {
    "Object1": "Hemoglobinopathies (Disorders of Hemoglobin)",
    "Object2": [
      "Qualitative defect (structurally abnormal hemoglobins)",
      "Quantitative defect (thalassemias)",
      "Combined qualitative and quantitative defects",
      "Acquired hemoglobinopathies"
    ],
    "Object3": [
      "Qualitative: Hemoglobin S, Hemoglobin C, Hemoglobin D Punjab",
      "Quantitative: Thalassemias (alpha, beta-thalassemia)",
      "Combined: Hemoglobin E, Sickle-cell beta-thalassemia",
      "Acquired: Methemoglobinemia (toxic exposures), Carboxyhemoglobinemia"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Hemoglobin electrophoresis",
      "High performance liquid chromatography (HPLC)"
    ],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Sickle Cell Disease (SCD)",
    "Object2": [
      "Sickle cell anemia (SS) (homozygous state)",
      "Sickle cell trait (AS) (heterozygous state)",
      "Compound heterozygous (e.g., Hb SC, HbS-β-thalassemia)"
    ],
    "Object3": [
      "Production of abnormal hemoglobin (HbS)",
      "Point mutation: Adenine (A) to thymidine (T) substitution in codon 6 of β-globin gene (GAG → GTG), replacing glutamic acid with valine in β-globin chain",
      "Deoxygenated HbS molecules polymerize to form 'tactoids'",
      "Dehydration of red cells (partly due to potassium leaving via Gárdos channel)",
      "Factors favoring sickling: Hypoxia, acidosis, dehydration, high HbS concentration, infection, inflammation, low temperature"
    ],
    "Object4": [
      "Infants (after 3 months): Prone to infections (pneumococcal pneumonia, meningitis, osteomyelitis due to Salmonella). Hand-foot syndrome (dactylitis). Acute chest syndrome. Acute coronary syndrome, stroke. Generalized impairment of growth and development (chronic hypoxia).",
      "Adults: Severe hemolytic anemia (fatigue, frequent infections, cardiomegaly, systolic murmurs). Crises (sickling/vaso-occlusive, aplastic, hemolytic, sequestration).",
      "Infarction crisis: Acute, severe pain (bones, lungs, liver, spleen). Bone pain (avascular necrosis of femur head). Acute chest syndrome (lung infection/infarction). Acute abdominal pain (splenic infarcts, mesenteric infarction). Cerebral infarctions (hemiplegia). Renal papillary infarction (hematuria). Retinal microinfarcts (loss of vision).",
      "Aplastic crisis: Temporary suppression of erythropoiesis by parvovirus B19.",
      "Hemolytic crisis: Increased hemolysis, sudden drop in Hb, rapid enlargement of liver/spleen, reticulocytosis.",
      "Sequestration crisis: Sudden trapping of blood in spleen/liver, rapid organ enlargement, drop in hematocrit, hypovolemic shock (in children).",
      "Other crises: Hypoplastic, megaloblastic (due to folate deficiency)."
    ],
    "Object5": [
      "Infants (after 3 months): Hand-foot syndrome (dactylitis of hands/feet). Splenomegaly (early childhood), then atrophy (autosplenectomy).",
      "Adults: Severe hemolytic anemia (pallor, mild jaundice). Pigmented bilirubin gallstones. Leg ulcers. Thalassemic facies (frontal bossing, maxillary hypertrophy). Hair on end appearance (skull X-ray). Cardiomegaly, systolic murmurs. Priapism (painful penile erection, due to leukostasis).",
      "Crises: Acute pain (vaso-occlusive). Acute chest syndrome (chest pain, fever, respiratory distress, hypoxemia). Rapid enlargement of spleen/liver, hypovolemic shock (sequestration crisis).",
      "Peripheral smear: Sickle cells (long, curved, pointed ends), Howell-Jolly bodies, target cells, ovalocytes (hyposplenism). Irreversibly sickled cells (ISCs) are dehydrated and dense."
    ],
    "Object6": [
      "Evidence of hemolysis: Hb 6-8 g/dL, high reticulocyte count (10-20%).",
      "Peripheral smear: Sickle cells (Fig. 8.21), Howell-Jolly bodies, target cells, ovalocytes. Polychromasia, nucleated red cells.",
      "ESR is low (sickle cells do not form rouleaux).",
      "Sickling test (induced by reducing agents like sodium metabisulfite).",
      "Sickle solubility test (HbS in reducing solution gives turbid appearance).",
      "Hemoglobin electrophoresis: No Hb-A, 80-95% Hb-SS, 2-20% HbF. (Sickle cell trait: 20-40% Hb-S, rest Hb-A).",
      "Tests for iron overload: Serum ferritin, transferrin saturation, liver iron concentration (biopsy/MRI).",
      "Prenatal diagnosis: Fetal DNA from amniocentesis or chorionic villous biopsy."
    ],
    "Object7": [
      "General Measures: Good nutrition, folic acid supplementation (5 mg daily). Immunizations (S. pneumoniae, influenza, N. meningitidis, H. influenzae type B, hepatitis B). Antibiotic prophylaxis (phenoxymethyl penicillin 500 mg daily from 2 months of age). Avoid/treat precipitating factors (cold, dehydration, hypoxia).",
      "Anemia: Transfusions only for clear indications (heart failure, TIAs, strokes, acute chest syndrome, severe aplastic/splenic sequestration crises). Not for chronic stable anemia/minor surgery/uncomplicated painful episodes. Repeated transfusions (maintain HbS <20%). Exchange transfusions for severe/recurrent crises, emergency surgery. Iron chelators (deferoxamine, deferasirox) for iron overload.",
      "Hydroxycarbamide (hydroxyurea): 10-30 mg/kg/day (increases HbF, suppresses neutrophils/reticulocytes, reduces pain/acute chest syndrome/transfusion need).",
      "Senicapoc (Gárdos channel inhibitor): Prevents erythrocyte dehydration (antiplasmodium activity).",
      "Acute Painful Crisis: IV fluids, oxygen, antimicrobial agents, adequate analgesia (morphine for severe, codeine/paracetamol/NSAIDs for milder). Inhaled nitric oxide (short-term pain relief, caution).",
      "Acute chest syndrome: Antibiotics, oxygenation, pain relief, bronchodilators, exchange transfusion.",
      "Chronic leg ulcers: Limb elevation, daily dressings with zinc sulfate, exchange transfusion (extreme cases).",
      "Curative: Bone marrow/stem cell transplantation (for severe complications in children/adolescents <16 years). Gene therapy (under research)."
    ],
    "Object8": [
      "Microvascular occlusions (tissue ischemia and infarction).",
      "Hemolytic anemia (shortened red cell survival).",
      "Children: Susceptibility to acute infections (S. pneumoniae, H. influenzae), septicemia, meningitis, osteomyelitis (Salmonella). Hand-foot syndrome (dactylitis). Sequestration crisis (hypovolemic shock). Autosplenectomy. Acute chest syndrome. Acute coronary syndrome, stroke. Impairment of growth and development.",
      "Adults: Pigmented bilirubin gallstones, cholecystitis. Recurrent crises (infarction, aplastic, hemolytic, sequestration).",
      "Long-term: Impaired growth/development, chronic infarcts of bones (avascular necrosis), infections (bones, lungs, kidneys), leg ulcers, cardiac issues (cardiomegaly, arrhythmias, MI, iron overload cardiomyopathy), neurological (TIAs, seizures, cerebral infarction/hemorrhage, coma), priapism, iron overload, eye problems (retinopathy, vitreous hemorrhages, retinal detachment), pregnancy complications (spontaneous abortion, IUGR, preeclampsia, fetal death)."
    ]
  },
  {
    "Object1": "Hereditary Spherocytosis (HS)",
    "Object2": "Most common inherited hemolytic anemia in adults",
    "Object3": [
      "Autosomal dominant inheritance (>75% cases)",
      "Defect in RBC membrane due to cytoskeleton protein deficiency (e.g., ankyrin, band 3, spectrin or band protein 4.2)",
      "Red cells lose part of cell membrane in spleen, assume spheroidal shape (spherocytes), less deformable, more susceptible to osmotic lysis"
    ],
    "Object4": [
      "May present from neonatal period to adulthood.",
      "Family history of anemia, jaundice, splenomegaly, cholelithiasis.",
      "Anemia (usually mild to moderate).",
      "Jaundice (intermittent attacks).",
      "Children: Growth retardation, bone changes (marrow hyperplasia).",
      "Leg ulcers."
    ],
    "Object5": [
      "Spherocytes (Fig. 8.22) and reticulocytes in peripheral blood film.",
      "Moderate splenomegaly (characteristic and constant feature).",
      "Mild jaundice."
    ],
    "Object6": [
      "Anemia (mild to moderate, occasionally severe).",
      "Peripheral blood film shows spherocytes and reticulocytes.",
      "MCHC increased.",
      "Evidence of hemolytic state (raised unconjugated bilirubin, urinary urobilinogen).",
      "Specific diagnostic tests (Box 8.5): Osmotic fragility testing, Ektacytometry, Acidified glycerol lysis test, Cryohemolysis test, Eosin-5-maleimide binding test.",
      "Negative Coombs test.",
      "Strong family history."
    ],
    "Object7": [
      "Splenectomy (treatment of choice, not before age 6). Preceded by pneumococcal and H. influenzae immunization, followed by lifelong penicillin prophylaxis. Corrects anemia and complications, but increases infection risk.",
      "Folic acid supplementation (in patients without splenectomy).",
      "Regular blood transfusions (few patients with severe disease).",
      "Cholecystectomy (only for symptomatic gallstones)."
    ],
    "Object8": [
      "Cholelithiasis (pigment gallstones).",
      "Chronic leg ulcers.",
      "Aplastic crises (due to parvovirus B19 infection).",
      "Hemolytic crises (rare).",
      "Growth retardation (children).",
      "Bone changes (children)."
    ]
  },
  {
    "Object1": "Thalassemia Syndrome",
    "Object2": [
      "Alpha-thalassemia syndromes (Silent carrier, α-thalassemia trait, HbH disease, Hb Barts/hydrops fetalis)",
      "Beta-thalassemia syndromes (B-Thalassemia major/Cooley's anemia, B-Thalassemia intermedia, B-Thalassemia minor/trait)"
    ],
    "Object3": [
      "Heterogeneous group of inherited disorders, autosomal recessive (rarely autosomal dominant HBB gene mutation).",
      "Reduced or absence of synthesis of one of the globin chains (α or β).",
      "Alpha-thalassemia: Deletion or affected number of α-globin genes (1 to 4).",
      "Beta-thalassemia: Genetic defect (B+ or B0) leading to no/markedly reduced β-chain production."
    ],
    "Object4": [
      "Alpha-thalassemia: Hydrops fetalis (incompatible with life). HbH disease (moderate microcytic anemia). Silent carrier/Minor (asymptomatic).",
      "Beta-thalassemia major: Severe anemia, retardation of growth/development, recurrent bacterial infections. Symptoms of iron overload (arrhythmias, heart blocks, CHF, cirrhosis, diabetes, hypogonadism).",
      "Beta-thalassemia intermedia: Mild to moderate anemia. Symptoms of splenomegaly, bone deformities, gallstones, chronic leg ulcers."
    ],
    "Object5": [
      "Alpha-thalassemia (Hb Barts): Pale, edematous, large liver/spleen (infants).",
      "Beta-thalassemia major: Thalassemic (Chipmunk) facies (frontal bossing, prominent malar eminence, depressed nasal bridge, maxillary hypertrophy). Hair on end ('crew-cut') appearance (skull X-ray). Massive splenomegaly, hepatomegaly, lymph nodes (extramedullary hematopoiesis). Signs of heart failure, cirrhosis, diabetes.",
      "Beta-thalassemia intermedia: Mild splenomegaly, bone deformities, gallstones, chronic leg ulcers.",
      "Beta-thalassemia minor: Asymptomatic, mild anemia."
    ],
    "Object6": [
      "Peripheral smear: Marked microcytic hypochromic anemia (Fig. 8.25), anisocytosis, poikilocytosis, target cells, nucleated red cells.",
      "Hb electrophoresis: Increased HbF (β-thalassemia major), reduced/absent HbA. Raised HbA2 (β-thalassemia minor). HbH (α-thalassemia, up to 30%), Hb Barts (α-thalassemia).",
      "Osmotic fragility test: Increased resistance to hemolysis.",
      "Skull radiograph: 'Hair on end'/crew cut appearance (Fig. 8.24).",
      "Red cell distribution width (RDW): Normal (in contrast to IDA).",
      "Genetic counseling and prenatal diagnosis (chorionic villi biopsy)."
    ],
    "Object7": [
      "Beta-thalassemia major: Maintain Hb level 10-12 g/dL by long-term folic acid supplements and regular blood transfusions (hypertransfusion to suppress ineffective erythropoiesis). Iron-chelating agents (desferrioxamine, deferiprone, deferasirox) for iron overload (if serum ferritin >1500 µg/L). Splenectomy for massive symptomatic splenomegaly, increasing transfusion requirement, or hypersplenism. Bone marrow transplantation in young patients. Management of complications (CHF, endocrinopathies).",
      "Beta-thalassemia minor: No iron unless iron deficiency. Genetic counseling. Prenatal diagnosis.",
      "Beta-thalassemia intermedia: Folic acid supplementation."
    ],
    "Object8": [
      "Alpha-thalassemia (Hb Barts): Incompatible with life.",
      "Beta-thalassemia major: Retardation of growth/development, recurrent bacterial infections, hemosiderosis (cardiac, hepatic, pancreatic, pituitary), arrhythmias, heart blocks, CHF, cirrhosis, diabetes, hypogonadism.",
      "Iron overload from repeated transfusions.",
      "Hypersplenism (requiring splenectomy).",
      "Progressive anemia in untreated/untransfused children."
    ]
  },
  {
    "Object1": "Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency",
    "Object2": [
      "Acute hemolytic anemia (AHA)",
      "Neonatal jaundice (NNJ)",
      "Chronic non-spherocytic hemolytic anemia (CNSHA) (rare)"
    ],
    "Object3": [
      "X-linked disorder, most common enzyme deficiency.",
      "RBCs deficient in G6PD (unable to keep glutathione in reduced state), susceptible to injury by oxidants (exogenous/endogenous).",
      "Genetic variants: G6PD A- (absence of enzyme activity), G6PD B- or G6PD Mediterranean (severe deficiency), G6PD Canton.",
      "Triggers for acute hemolytic anemia: Drugs (primaquine, quinine, chloroquine, sulfonamides, cotrimoxazole, nitrofurantoins, acetanilide, phenazopyridine, dapsone, quinidine, methylene blue, nitroglycerine), Fava beans, Infections (viral, bacterial)."
    ],
    "Object4": [
      "Most patients clinically asymptomatic.",
      "Acute hemolytic anemia: Rapid development of anemia, hemoglobinuria (cola colored urine). Rarely acute renal failure. Onset can be abrupt (favism in children).",
      "Neonatal jaundice.",
      "Chronic non-spherocytic hemolytic anemia: Chronic anemia (variable, some require intermittent transfusions). Jaundice, splenomegaly."
    ],
    "Object5": [
      "Acute hemolytic anemia: Hemoglobinuria (cola colored urine).",
      "Neonatal jaundice: Severe neonatal jaundice (risk of kernicterus).",
      "Chronic non-spherocytic hemolytic anemia: Reticulocytosis, gallstones, splenomegaly.",
      "Peripheral blood film: Normocytic and normochromic with anisocytosis, polychromasia (reticulocytosis), poikilocytes, spherocytes. Bite (blister) cells. Heinz bodies (precipitates of denatured hemoglobin, demonstrated by supravital staining)."
    ],
    "Object6": [
      "Evidence of intravascular hemolysis: Raised unconjugated bilirubin, hemoglobinemia, hemoglobinuria, high LDH, low/absent plasma haptoglobin.",
      "Anemia (moderate to extremely severe, due to intravascular/extravascular hemolysis).",
      "Peripheral blood film (mentioned above).",
      "Confirmation of diagnosis: G6PD activity of red cell (estimated after acute hemolytic episode to avoid falsely normal value from young RBCs/reticulocytes)."
    ],
    "Object7": [
      "Removal of triggering agent and avoiding further exposure. No specific treatment required once cause recognized.",
      "Management of neonatal jaundice (similar to other causes).",
      "Supportive therapy for anemia: Blood transfusion, regular folic acid supplements (in CNSHA).",
      "Treatment of infection and genetic counseling."
    ],
    "Object8": [
      "Acute hemolytic anemia (AHA): Hemoglobinuria, acute renal failure (rarely).",
      "Neonatal jaundice (NNJ): Severe neonatal jaundice (kernicterus, death if untreated).",
      "Chronic non-spherocytic hemolytic anemia (CNSHA): Gallstones.",
      "Oxidative stress can damage red cells."
    ]
  },
  {
    "Object1": "Normocytic Normochromic Anemia",
    "Object2": "Normal size RBCs and normal MCV",
    "Object3": [
      "Decreased red cell production: Anemia of chronic disease, Chronic renal failure, Chronic liver disease, Endocrine disorders (Hypopituitarism, Hypothyroidism, Hypoadrenalism), Hematological disorders (Marrow hypoplasia/aplasia, Myeloproliferative neoplasms, Myelofibrosis, Sideroblastic anemia), Expansion of plasma volume (Pregnancy).",
      "Increased red cell loss or destruction: Acute blood loss, Hypersplenism, Hematological disorders (Hemoglobinopathies - sickle cell disease, Hereditary spherocytosis, Glucose-6-Phosphate dehydrogenase deficiency), Microangiopathic anemias (DIC, TTP, HUS), Autoimmune hemolytic anemia, Paroxysmal nocturnal hemoglobinuria."
    ],
    "Object4": [
      "Symptoms of anemia."
    ],
    "Object5": [
      "Signs of anemia."
    ],
    "Object6": [
      "Complete blood count, peripheral smear."
    ],
    "Object7": [
      "Treatment of the underlying disease."
    ],
    "Object8": []
  },
  {
    "Object1": "Sideroblastic Anemias",
    "Object2": [
      "Hereditary sideroblastic anemias (X-linked, autosomal dominant/recessive)",
      "Acquired sideroblastic anemias (Primary/Idiopathic, Secondary)"
    ],
    "Object3": [
      "Rare inherited or acquired disorders of refractory anemia.",
      "Defective heme synthesis.",
      "Hereditary: Deficiency of 8-aminolevulinic acid synthase (ALAS) enzyme, leading to defective synthesis of hemoglobin. X-linked or autosomal inheritance.",
      "Acquired (secondary): Drugs (alcohol, chloramphenicol, isoniazid, cycloserine, pyrazinamide), Toxins (lead), Malignancies (myelodysplastic syndromes, AML, myelofibrosis, plasma cell myeloma), Inflammatory diseases (rheumatoid arthritis), Nutritional deficiencies (copper, pyridoxine).",
      "Primary (idiopathic) acquired sideroblastic anemia."
    ],
    "Object4": [],
    "Object5": [
      "Dimorphic peripheral blood picture (microcytic hypochromic RBCs in hereditary, macrocytic in acquired, mixed with normochromic cells).",
      "Ring sideroblasts in bone marrow (diagnostic, iron-laden mitochondria surrounding erythroblasts).",
      "Pappenheimer bodies (tiny iron-containing inclusions) in RBCs (stain positively by Prussian blue).",
      "Excess storage iron in bone marrow, increased serum iron concentration.",
      "Ineffective erythroid hyperplasia.",
      "Macrocytic RBCs (in myelodysplasia or Pearson's syndrome - rare X-linked hereditary form)."
    ],
    "Object6": [
      "Peripheral smear: Dimorphic anemia. Microcytic hypochromic RBCs, macrocytic in acquired forms. Macro-ovalocytes and hypersegmented neutrophils in megaloblastic variants.",
      "Bone marrow: Presence of ring sideroblasts (pathognomonic with Prussian blue staining). Excess storage iron. Ineffective erythroid hyperplasia.",
      "Serum iron and transferrin saturation: Increased.",
      "Assay of 8-aminolevulinic acid synthase (ALAS) enzyme activity (in hereditary forms).",
      "Red cell protoporphyrin: Elevated (in lead poisoning and iron deficiency)."
    ],
    "Object7": [
      "Withdrawal of causative agent (drugs, toxins, alcohol).",
      "Pyridoxine or folic acid (occasional cases respond).",
      "Supportive treatment with transfusions.",
      "Erythropoietin.",
      "Iron chelators for iron overload (in transfusion-dependent patients)."
    ],
    "Object8": [
      "Iron overload (if transfusion-dependent).",
      "Progression to acute myeloid leukemia (in acquired forms)."
    ]
  },
  {
    "Object1": "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "Object2": "Rare acquired non-malignant, genetic defect",
    "Object3": [
      "Mutation in the hematopoietic stem cell (in the pig-A gene responsible for synthesis of the GPI anchor).",
      "Clones of red cells are particularly sensitive to destruction by activated complement.",
      "Platelets and granulocytes also affected.",
      "Deficient synthesis of glycosylphosphatidylinositol (GPI) linked proteins (decay-accelerating factor (CD55), membrane inhibitor of reactive lysis (CD59)). CD59 is a potent inhibitor of C3, prevents alternative complement pathway activation.",
      "Hemolysis is due to reduced pH of blood during sleep (enhances complement activity)."
    ],
    "Object4": [
      "Intravascular hemolysis: Urine voided at night/morning is dark colored (nocturnal hemoglobinuria). Hemoglobin in acidic urine converted to acid hematin (dark brown).",
      "Abdominal pain/dysphagia, erectile dysfunction, pulmonary hypertension, renal insufficiency.",
      "Mild jaundice."
    ],
    "Object5": [
      "Mild hepatosplenomegaly (often present).",
      "Thrombocytopenia, neutropenia (platelets and granulocytes affected).",
      "Anemia, reticulocytosis (peripheral smear).",
      "Features of intravascular hemolysis (raised unconjugated bilirubin, hemoglobinemia, hemoglobinuria, high LDH, low/absent plasma haptoglobin).",
      "Bone marrow is sometimes hypoplastic (or even aplastic) despite hemolysis."
    ],
    "Object6": [
      "Peripheral smear: Anemia, reticulocytosis, varying degrees of thrombocytopenia and leukopenia (pancytopenia).",
      "Features of intravascular hemolysis (raised unconjugated bilirubin, hemoglobinemia, hemoglobinuria, high LDH, low/absent plasma haptoglobin).",
      "Bone marrow: Hypoplastic/aplastic (despite hemolysis).",
      "Ham's acidified serum test: Red cells become more fragile in mild acid (positive in PNH, congenital dyserythropoietic anemia).",
      "Sucrose hemolysis test: PNH red cells undergo lysis in low-tonic sucrose solution (can be positive in megaloblastic anemia and autoimmune hemolytic anemia).",
      "Flow cytometry: Detects red cells deficient in GPI-linked proteins (CD55 and CD59) (rapid and sensitive).",
      "NAP score: Neutrophil alkaline phosphatase (NAP) score is reduced (NAP is a GPI linked protein)."
    ],
    "Object7": [
      "Supportive measures: Blood transfusions (for severe anemia), control of infections.",
      "Iron therapy (often necessary due to loss in urine).",
      "Anti-complement therapy: Eculizumab (humanized monoclonal antibody, prevents C5 cleavage, reduces intravascular hemolysis, hemoglobinuria, transfusion need).",
      "Long-term anticoagulants (for recurrent thrombotic episodes).",
      "Steroids (may be useful in some cases).",
      "Bone marrow (stem cell) transplantation (curative)."
    ],
    "Object8": [
      "Thrombosis (very common, hepatic - Budd-Chiari syndrome, portal, cerebral veins - leading cause of death).",
      "Aplastic anemia, acute myelogenous leukemia, myelodysplastic syndrome (increased risk for developing).",
      "Iron deficiency (due to urinary iron loss).",
      "Pulmonary hypertension.",
      "Renal insufficiency."
    ]
  },
  {
    "Object1": "Methemoglobinemia",
    "Object2": "Not specified",
    "Object3": [
      "Increased amount of methemoglobin in RBCs (iron in hemoglobin in oxidized ferric form, unable to combine with oxygen).",
      "Hereditary: Deficiency of methemoglobin reductase, cytochrome B5 reductase deficiency.",
      "Acquired: Exposure to certain drugs and toxins (nitrites, nitrates, nitrofurantoin, chloroquine, naphthalene, local anesthetics, primaquine, dapsone, sulfa drugs, phenacetin, phenazopyridine, metoclopramide, nitroglycerine), copper sulfate."
    ],
    "Object4": [
      "Cyanosis (when methemoglobin >1.5 g/dL).",
      "Headache, weakness, breathlessness (higher levels).",
      "Respiratory depression, altered sensorium, coma, shock, seizures, death (at very high levels)."
    ],
    "Object5": [
      "Cyanosis."
    ],
    "Object6": [
      "Blood tests for methemoglobin levels.",
      "Spectrophotometry to confirm methemoglobin."
    ],
    "Object7": [
      "Methemoglobin reductase deficiency: Oral methylene blue or ascorbic acid.",
      "Severe methemoglobinemia: Intravenous methylene blue. Adequate tissue oxygenation."
    ],
    "Object8": [
      "Respiratory depression, altered sensorium, coma, shock, seizures, death (at very high levels)."
    ]
  },
  {
    "Object1": "Autoimmune Hemolytic Anemia (AIHA)",
    "Object2": [
      "Warm Antibody Immunohemolytic Anemia (most common, IgG antibodies active at 37°C)",
      "Cold Agglutinin Autoimmune Hemolytic Anemia (less common, IgM antibodies active at 4-18°C)",
      "Paroxysmal Cold Hemoglobinuria (rare, IgG autoantibodies against P antigen)"
    ],
    "Object3": [
      "Increased red cell destruction due to red cell autoantibodies.",
      "Idiopathic (Primary).",
      "Secondary (Box 8.9): Autoimmune disorders (SLE), Drugs (methyldopa, penicillins, quinidine), Lymphomas, Mycoplasmal infection, Infectious mononucleosis, Cytomegalovirus.",
      "Warm AIHA: Autoantibodies mainly IgG type.",
      "Cold Agglutinin AIHA: IgM antibodies bind to red cell antigens at low temperatures.",
      "Paroxysmal Cold Hemoglobinuria: Often follows childhood viral infections (measles, mumps, chickenpox). Autoantibodies (IgG type) against P antigen system."
    ],
    "Object4": [
      "Warm AIHA: Anemia, jaundice.",
      "Cold Agglutinin AIHA: Acrocyanosis (blue fingertips, toes, nose, ear lobes) after cold exposure.",
      "Paroxysmal Cold Hemoglobinuria: Hemoglobinuria (due to intravascular hemolysis)."
    ],
    "Object5": [
      "Warm AIHA: Hepatosplenomegaly.",
      "Peripheral blood: Spherocytosis and macrocytes (red cell damage), macrocytes (macrocytic anemia). Reticulocytosis. Nucleated red cells, polychromasia.",
      "Cold Agglutinin AIHA: Red cells agglutinate in cold/room temperature."
    ],
    "Object6": [
      "Evidence of hemolytic anemia.",
      "Peripheral blood: Spherocytosis and macrocytes. Spherocytosis and reticulocytes.",
      "Direct antiglobulin (Coombs) test: Positive (Warm AIHA: IgG and/or C3 complement. Cold Agglutinin: complement alone).",
      "Autoantibodies: May have specificity for Rh blood group system (Warm AIHA).",
      "Autoimmune thrombocytopenia and/or neutropenia (Evans' syndrome) may be present.",
      "Indirect (Coombs) antiglobulin test (IAT): Detects IgG antibody/C3 complement in patient's serum.",
      "Cold Agglutinin AIHA: Monoclonal IgM antibodies.",
      "Paroxysmal Cold Hemoglobinuria: Donath-Landsteiner test (hemolysis demonstrated by incubating red cells/serum at 4°C then warming to 37°C). DAT usually negative."
    ],
    "Object7": [
      "Warm AIHA:",
      "Corticosteroids (prednisolone 1 mg/kg daily for 2-4 weeks, then slow tapering). IV methylprednisolone for rapid hemolysis.",
      "Avoid blood transfusion (autoantibodies may cause cross-matching difficulty).",
      "Danazol (with prednisone as first line therapy to shorten prednisone duration).",
      "Splenectomy (if no response to corticosteroids, or high dose steroids needed, or severe bleeding).",
      "Intravenous immunoglobulin (temporary measure before splenectomy).",
      "Rituximab (monoclonal antibody against CD20) for refractory cases, secondary AIHA.",
      "Other immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporine) for refractory cases.",
      "Cold Agglutinin AIHA: Rituximab (successful in some). Does not respond to steroids, alkylating agents, splenectomy. Avoid cold exposure.",
      "Paroxysmal Cold Hemoglobinuria: Supportive transfusions of warmed blood. Avoid cold exposure."
    ],
    "Object8": [
      "Warm AIHA: Autoimmune thrombocytopenia and/or neutropenia (Evans' syndrome).",
      "Cold Agglutinin AIHA: Acrocyanosis.",
      "Paroxysmal Cold Hemoglobinuria: Intravascular hemolysis, hemoglobinuria."
    ]
  },
  {
    "Object1": "Anemias Due to Blood Loss",
    "Object2": [
      "Acute blood loss anemia",
      "Chronic blood loss anemia"
    ],
    "Object3": [
      "Acute blood loss (hemorrhage): Trauma, postpartum bleeding, internal bleeding. Rapid loss of intravascular volume, can lead to hypovolemic shock.",
      "Chronic blood loss: Continuous small volume loss over long period (GI tract lesions, gynecological disturbances, urinary blood loss), gradually depletes iron stores, leading to iron deficiency."
    ],
    "Object4": [
      "Acute: Hypovolemia (pale, cold, sweating, raised pulse rate, maintained BP, postural hypotension, tachycardia - early signs of internal bleeding). Anemia appears in 24-36 hours (hemodilution). If bleeding continues, hypovolemic shock.",
      "Chronic: Symptoms of iron deficiency anemia."
    ],
    "Object5": [
      "Acute: Pale, cold, sweating, tachycardia, normal BP (compensated), then reduced BP (decompensated).",
      "Peripheral smear: Normocytic normochromic anemia and polychromasia. Transient leukoerythroblastic blood picture (very early)."
    ],
    "Object6": [
      "Acute: Hemoglobin and hematocrit (normal early, reduced 24-36 hours). Peripheral smear (normocytic normochromic anemia, polychromasia, transient leukoerythroblastic).",
      "Chronic: Investigations for iron deficiency anemia."
    ],
    "Object7": [
      "Acute: Replacement of blood loss (whole blood or packed red cells).",
      "Chronic: Iron supplements, identification and treatment of the source of chronic blood loss."
    ],
    "Object8": [
      "Acute: Hypovolemic shock and death.",
      "Chronic: Iron deficiency anemia."
    ]
  },
  {
    "Object1": "Anemia of Chronic Disease (Anemia of Inflammation)",
    "Object2": "One of the most common types of anemia in developing countries",
    "Object3": [
      "Chronic infections (infective endocarditis, tuberculosis, osteomyelitis)",
      "Chronic immune disorders (Crohn's disease, rheumatoid arthritis, SLE)",
      "Malignant tumors (carcinoma of lung and breast)"
    ],
    "Object4": [],
    "Object5": [
      "Peripheral smear mainly shows normocytic normochromic red cells."
    ],
    "Object6": [
      "Peripheral smear: Normocytic normochromic red cells.",
      "Bone marrow: Increased storage iron (Prussian blue staining).",
      "Raised serum ferritin.",
      "Reduced total iron-binding capacity (TIBC).",
      "Reduced serum iron.",
      "Reduced transferrin levels.",
      "Normal serum soluble transferrin receptor level."
    ],
    "Object7": [
      "Treat the underlying disorder.",
      "Recombinant erythropoietin therapy (if anemia not corrected after treating underlying disorder)."
    ],
    "Object8": []
  },
  {
    "Object1": "Aplastic Anemia",
    "Object2": [
      "Congenital (Fanconi anemia, Diamond-Blackfan anemia, Telomerase defects)",
      "Acquired (Idiopathic, Immune mediated, Secondary)",
      "Severe aplastic anemia"
    ],
    "Object3": [
      "Pancytopenia with hypocellular (aplasia) bone marrow (<30% cellularity) and no leukemic/abnormal cells.",
      "Inherited: Fanconi anemia, Diamond-Blackfan anemia, Telomerase defects.",
      "Acquired (Idiopathic, Immune mediated).",
      "Secondary: Chemical agents (Cytotoxic drugs, Benzene, Inorganic arsenicals, Chloramphenicol - dose-related and idiosyncratic; Phenylbutazone, Penicillamine, Carbamazepine, Gold salts, Organic arsenicals, Methylphenylethylhydantoin - idiosyncratic), Physical agents (Whole-body irradiation), Viral infections (Hepatitis (unknown type), Epstein-Barr virus, Cytomegalovirus, Herpes zoster, HIV)."
    ],
    "Object4": [
      "Insidious onset.",
      "Anemia: Progressive weakness, lassitude, fatigability, pallor, dyspnea.",
      "Neutropenia: Frequent infections (mucocutaneous bacterial) or fatal infections (sore throat, oral/pharyngeal ulcers, fever with chills/sweating, chronic skin/respiratory infections, pneumonia, septicemia).",
      "Thrombocytopenia: Petechiae, bruises, ecchymoses, epistaxis, menorrhagia, bleeding gums, GI tract bleeding, retinal hemorrhage, cerebral hemorrhage (often predominant initial presentation)."
    ],
    "Object5": [
      "Pallor.",
      "Ecchymoses, bleeding gums, epistaxis. Mouth infections common. No lymphadenopathy or hepatosplenomegaly. (If present, consider other diagnoses).",
      "Fanconi's Anemia: Skeletal (short stature), renal (ectopic kidney, horse-shoe kidney), CNS (hydrocephalus) abnormalities. Progressive pancytopenia."
    ],
    "Object6": [
      "Diagnosis made with: (1) pancytopenia, (2) absence of reticulocytes, (3) hypocellular/aplastic bone marrow with increased fat spaces.",
      "Hemoglobin: Decreased.",
      "PCV: Decreased.",
      "Reticulocytopenia (0.5-1%) characteristic.",
      "Peripheral blood: Pancytopenia.",
      "Bone marrow: Marked hypocellularity (>70% fat). Paucity of erythroid, myeloid, megakaryocytic precursors. Lymphocytes/plasma cells prominent. Increased bone marrow iron stores.",
      "Serum iron and transferrin saturation: Increased.",
      "Ferrokinetic studies: Delayed clearance of radioactive iron from blood, increased uptake by liver.",
      "Severe aplastic anemia: Neutrophil count <0.5 x 10^9/L, platelet count <20 x 10^9/L, reticulocyte count <40 x 10^9/L, marrow cellularity <25% (2 of 4 needed)."
    ],
    "Object7": [
      "Removal of causative factor/agent.",
      "Supportive care: Prevention/treatment of infections, treatment of hemorrhage, red cell transfusion for anemia. Growth factors (G-CSF, TPO receptor agonists).",
      "Severe aplastic anemia: Bone marrow (stem cell) transplantation (treatment of choice for <40 years with HLA-identical sibling). Immunosuppressive therapy (for no HLA-matched siblings or >40 years). Eltrombopag, horse ATG, cyclosporine, prednisone (combination for 60-80% response). Androgens (oxymetholone) for non-responders to immunosuppression or moderately severe. Steroids (for congenital pure red cell aplasia, some adults with pure red cell aplasia and thymoma). Anti-IL-2 receptor antibody, arsenic trioxide + cyclosporine (tried).",
      "Acquired PRCA: Steroids, immunosuppressants."
    ],
    "Object8": [
      "Infections (life-threatening bacterial/fungal) due to neutropenia.",
      "Bleeding (intracranial, retinal, cerebral hemorrhage) due to thrombocytopenia.",
      "Transformation to clonal disorders (PNH, MDS, AML)."
    ]
  },
  {
    "Object1": "Pancytopenia",
    "Object2": "Combination of anemia, leukopenia and thrombocytopenia.",
    "Object3": [
      "Decreased bone marrow function: Aplastic anemia (idiopathic, secondary, inherited), Myelodysplastic syndromes (MDS), Bone marrow infiltration (Leukemia, Lymphoma, Myeloma, Tumors, Granulomatous diseases - disseminated TB, sarcoidosis), Nutritional deficiencies (Megaloblastic anemia), Paroxysmal nocturnal hemoglobinuria, Myelofibrosis (rare), Hemophagocytic syndrome, Overwhelming sepsis, Systemic lupus erythematosus, Drugs.",
      "Increased peripheral destruction: Hypersplenism (portal hypertension, lymphomas, myeloproliferative disorders), Dilutional (massive transfusions)."
    ],
    "Object4": [
      "Symptoms of anemia, leukopenia, thrombocytopenia."
    ],
    "Object5": [
      "Anemia, leukopenia, thrombocytopenia."
    ],
    "Object6": [
      "Complete blood count, peripheral smear, bone marrow examination (to identify underlying cause)."
    ],
    "Object7": [
      "Treatment of the underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Leukocytosis",
    "Object2": "Increase in total number of leukocytes >11,000/cu mm (usually neutrophils, rarely lymphocytes, monocytes, eosinophils).",
    "Object3": [
      "Infections (Bacterial, Viral - infectious mononucleosis).",
      "Leukemia (Acute, Chronic - CLL, CML).",
      "Leukemoid reactions.",
      "Physiological (Pregnancy, Exercise)."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Neutrophilia",
    "Object2": "Absolute neutrophil count >8000/cu mm.",
    "Object3": [
      "Pathological: Acute bacterial/fungal infections (Localized: pneumonias, pyogenic meningitis, cellulitis, diphtheria, abscess, tonsillitis; Generalized: septicemia, acute rheumatic fever), Acute inflammatory processes (acute appendicitis, vasculitis), Tissue necrosis (Burns, MI, gangrene, neoplasms), Acute stress/hypoxic states (following hemorrhage, hemolysis, surgery), Myeloproliferative neoplasms (CML, PV), Metabolic (Uremia, acidosis, gout), Miscellaneous (Eclampsia, steroid therapy).",
      "Physiological: Exercise, newborns, extremes of temperature, pain, emotional stress, obstetric labor."
    ],
    "Object4": [],
    "Object5": [
      "Usually accompanied by leukocytosis (15-30 x 10^9/L).",
      "Differential count shows >70% neutrophils."
    ],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Neutropenia and Agranulocytosis",
    "Object2": [
      "Neutropenia (absolute neutrophil count <1.5 x 10^9/L)",
      "Agranulocytosis (neutrophil count <0.5 x 10^9/L)"
    ],
    "Object3": [
      "Inadequate production: Suppression of stem cells (Aplastic anemia, Marrow infiltration - metastatic tumors, granulomatous disorders), Suppression of committed granulocytic precursors (Drugs - sulfonamides, analgesics, arsenicals, ionizing radiation), Diseases with ineffective hematopoiesis (Megaloblastic anemias, Myelodysplastic syndromes), Congenital (Kostmann syndrome), Severe infections (Bacterial - typhoid, septicemia; Viral - influenza, infectious mononucleosis, hepatitis, measles; Rickettsial - scrub typhus; Protozoal - malaria, kala-azar).",
      "Increased destruction: Immunologically mediated (Idiopathic, Secondary - drugs (chemotherapeutic, carbimazole, propylthiouracil, phenothiazines, antibiotics, naproxen), autoimmune disorders (SLE)).",
      "Splenic sequestration.",
      "Shift from circulating to marginating pool: Hemodialysis, cardiopulmonary bypass.",
      "Idiopathic: Hodgkin/non-Hodgkin lymphoma, CLL, viral infections (HIV, hepatitis), Cyclic neutropenia."
    ],
    "Object4": [
      "Frequent infections (bacterial/fungal), sore throat, oral/pharyngeal ulcers, fever with chills/sweating, chronic skin/respiratory infections, pneumonia, septicemia."
    ],
    "Object5": [],
    "Object6": [
      "Absolute neutrophil count.",
      "Bone marrow examination (to differentiate production vs destruction problems)."
    ],
    "Object7": [
      "Treat underlying cause.",
      "Growth factors (G-CSF/GM-CSF) to stimulate neutrophil production.",
      "Antibiotics for infections."
    ],
    "Object8": [
      "Highly susceptible to bacterial and fungal infections."
    ]
  },
  {
    "Object1": "Eosinophilia",
    "Object2": "Absolute eosinophil count >450/cu mm.",
    "Object3": [
      "Allergic/atopic conditions (Asthma, Urticaria, Hay fever, Drug reactions, Allergic rhinitis).",
      "Parasitic/helminthic infestations (with tissue invasion - Roundworm, Hookworm, Filariasis).",
      "Fungal infections (coccidioidomycosis).",
      "Skin diseases (Dermatitis, Pemphigus, Scabies, Dermatitis herpetiformis).",
      "Hematological diseases (CML, Polycythemia, Hodgkin lymphoma, Acute myelomonocytic leukemia, Eosinophilic leukemia).",
      "Miscellaneous (Tropical eosinophilia, Pulmonary eosinophilia, Löffler's syndrome, Hypereosinophilic syndrome, Eosinophilic granuloma).",
      "Drugs (Sulfonamides, aspirin, penicillins, cephalosporins, allopurinol, carbamazepine)."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Absolute eosinophil count."
    ],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Lymphocytosis",
    "Object2": "Lymphocyte count >4,000/cu mm (adults) or >8,000/cumm (children).",
    "Object3": [
      "Acute infections (Viral - Infectious mononucleosis, mumps, measles, chickenpox, Infectious hepatitis; Toxoplasmosis).",
      "Chronic infections/inflammatory diseases (Tuberculosis, Syphilis, Brucellosis, Inflammatory bowel disease - Crohn's, ulcerative colitis).",
      "Hematologic malignancies (ALL, CLL, NHL, Adult T-cell leukemia/lymphoma, Hairy cell leukemia)."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Lymphocyte count."
    ],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Basopenia (Decreased Basophils)",
    "Object2": "Not specified",
    "Object3": [
      "Hereditary absence of basophils (very rare)",
      "Elevated levels of glucocorticoids",
      "Hyperthyroidism or treatment with thyroid hormones"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Basophilia (Increased Basophils)",
    "Object2": "Not specified",
    "Object3": [
      "Allergy or inflammation (Ulcerative colitis, Drug/food/inhalant hypersensitivity, Erythroderma, urticaria, Juvenile rheumatoid arthritis).",
      "Infection (Chicken pox, Influenza, Smallpox, Tuberculosis).",
      "Iron deficiency.",
      "Ovulation.",
      "Hypersensitivity reactions.",
      "Leukocytosis (diverse disorders).",
      "Endocrinopathy (Diabetes mellitus, Estrogen administration, Hypothyroidism - myxedema).",
      "Exposure to ionizing radiation.",
      "Neoplasia (Basophilic leukemia, Myeloproliferative neoplasms - CML, PV, primary myelofibrosis, ET; Carcinoma)."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Acute Leukemias",
    "Object2": [
      "Acute myeloblastic/myelocytic leukemia (AML)",
      "Acute lymphoblastic/lymphocytic leukemia (ALL)",
      "Subleukemic/Aleukemic leukemia"
    ],
    "Object3": [
      "Malignant stem cell neoplasms (failure of cell maturation, proliferation of leukocyte precursors - blast/immature cells, abnormal numbers of immature WBCs).",
      "Etiology often unknown.",
      "Environmental factors: Ionizing radiation (X-rays, atomic bombing, therapeutic radiation), Drugs (Alkylating agents, Topoisomerase inhibitors), Chemicals (Benzene), Retroviruses (HTLV-1 for adult T-cell leukemia/lymphoma).",
      "Immunological: Immune deficiency states (hypogammaglobulinemia).",
      "Genetic disorders: Down's syndrome, Fanconi's anemia, ataxia telangiectasia, Klinefelter syndrome.",
      "Acquired disorders: PNH, aplastic anemia, myelodysplastic syndrome (MDS)."
    ],
    "Object4": [
      "Nonspecific 'flu-like' symptoms.",
      "Bone marrow failure: Anemia (shortness of breath, fatigue, weakness). Neutropenia (life-threatening bacterial/opportunistic fungal infections, fever, pneumonia, cellulitis, sepsis). Thrombocytopenia (petechiae, atraumatic ecchymosis, gum bleeding, epistaxis, GU/GI bleeding, retinal hemorrhage, cerebral hemorrhage - serious and fatal).",
      "Marrow expansion/subperiosteal infiltration: Bone pain (more common ALL), sternal tenderness.",
      "Leukostasis (blast count >50,000/cumm): Cerebral leukostasis (headache, confusion, visual disturbances), Pulmonary leukostasis (dyspnea at rest, tachypnea, chest pain, pulmonary infarction, ARDS).",
      "Coagulopathy (DIC, primary fibrinolysis): Hemorrhagic diathesis (AML-M3).",
      "Extramedullary leukemic infiltration: Gingival hypertrophy, skin infiltration (leukemia cutis), hepatosplenomegaly, generalized lymphadenopathy. Leukemic meningitis (headache, nausea, papilledema, cranial nerve palsies, seizures, altered consciousness).",
      "Metabolic abnormalities: Hyperuricemia."
    ],
    "Object5": [
      "Pallor, fever.",
      "Bleeding manifestations (petechiae, ecchymoses, gum bleeding, epistaxis). Oral infections.",
      "Hepatosplenomegaly, generalized lymphadenopathy.",
      "Leukemia cutis (skin infiltration).",
      "Chloromas (myeloblastomas/granulocytic sarcomas - localized solid soft-tissue tumor masses).",
      "Papilledema, cranial nerve palsies, seizures, altered consciousness (leukemic meningitis).",
      "Hyperuricemia, elevated serum liver transaminases, serum LDH (AML).",
      "Peripheral blood smear: Numerous blast cells (Figs. 8.28, 8.29). Auer rods (rod-shaped red inclusion in cytoplasm of myeloblast - AML). Severe normochromic anemia. Pancytopenia. Hypersegmented neutrophils.",
      "Bone marrow aspirate: Hypercellular with reduced erythropoiesis/megakaryocytes. Blast cells >20% (often ~100%)."
    ],
    "Object6": [
      "Confirmation of Diagnosis:",
      "Blood count: Hemoglobin low, TLC markedly raised (>20,000/µL, often >100,000/µL, leukopenia in AML). Platelet count markedly decreased.",
      "Peripheral blood smear: Numerous blast cells (lymphoblasts for ALL, myeloblasts for AML). Auer rods (in myeloblasts). Severe normochromic anemia. Pancytopenia. Hypersegmented neutrophils.",
      "Bone marrow aspirate: Hypercellular with reduced erythropoiesis/megakaryocytes. Blast cells >20% (often ~100%). Type of blast confirmed by flow cytometry, immunophenotyping (FISH), cytogenetic, molecular genetics.",
      "Chest X-ray: Mediastinal widening (T lymphoblastic leukemia).",
      "CSF examination: Rule out occult CNS involvement.",
      "For Planning Therapy: Biochemical parameters (serum urate, LFTs, RFTs, coagulation studies, serum LDH). Cardiac function (ECG, echocardiogram, MUGA scan)."
    ],
    "Object7": [
      "Palliative therapy: Symptomatic benefit (medications, transfusions, with/without chemotherapy).",
      "Curative intent: Chemotherapy +/- stem cell transplant.",
      "Supportive care: Treatment of anemia (PRBC transfusion to Hb >10 g/dL). Prevention/control of bleeding (platelet transfusions). Treatment of infection (prophylactic antibiotics/antifungals, barrier nursing; therapeutic for identified microorganisms). Monitor liver/kidney/hemostatic functions. Fluid/electrolyte balance (prevent tumor lysis syndrome). Treatment of hyperleukocytosis (chemotherapy, hydroxyurea, leukapheresis). Psychological support.",
      "Bone marrow transplantation (AML: intermediate/poor risk in 1st remission, <60 years. ALL: high risk in 1st/2nd/subsequent remission).",
      "Acute Lymphocytic Leukemia (ALL):",
      "Remission induction: Combination chemotherapy (vincristine, prednisolone/dexamethasone, asparaginase (crisantaspase), anthracycline - doxorubicin). TKIs (imatinib/dasatinib) for t(9;22)/BCR-ABL1 positive ALL. High-dose methotrexate for trisomy 21.",
      "CNS preventive therapy: High-dose systemic therapy, CNS-directed treatment (triple intrathecal chemotherapy - cytarabine/methotrexate/hydrocortisone, or 1800 cGy cranial radiation).",
      "Post-remission therapy (consolidation): Cytarabine, methotrexate, anthracyclines, alkylating agents, epipodophyllotoxins. Allogeneic HCT.",
      "Remission maintenance: Daily 6-mercaptopurine, weekly methotrexate, periodic vincristine/prednisone/intrathecal therapy.",
      "Acute Myeloid Leukemia (AML):",
      "Initial (Induction) chemotherapy: Intensive remission induction ('7+3 therapy' - cytarabine + daunorubicin). Alternative approaches (Gemtuzumab ozogamicin (GO), FLAG, FLAG-IDA, MITO-FLAG, FLAMSA, CLAG, Vorinostat, Bortezomib, Lenalidomide).",
      "Consolidation (Post-remission) therapy: Cytarabine + daunorubicin or GO. Allogeneic HCT for young patients achieving remission, or high-risk karyotypes. Maintenance therapy (GO, Midostaurin).",
      "Acute promyelocytic leukemia (M3): All-trans-retinoic acid (ATRA) + anthracyclines or ATRA + arsenic trioxide. Allogeneic transplant only if relapsed/refractory. Arsenic trioxide for relapsed.",
      "Alternative chemotherapy (not for remission): Hydroxyurea, L-asparaginase (curb excessive leukocyte proliferation).",
      "Radiotherapy for local problems."
    ],
    "Object8": [
      "Bone marrow failure: Anemia, life-threatening infections, bleeding (intracranial hemorrhage).",
      "Leukostasis (cerebral, pulmonary).",
      "Tumor lysis syndrome (hyperuricemia, hyperkalemia, hypocalcemia, hyperphosphatemia - renal injury, arrhythmias, seizures).",
      "Neurological complications (leukemic meningitis, chloromas).",
      "Side effects of chemotherapy (myelosuppression, nausea, vomiting, alopecia, mucositis, interstitial pneumonia, veno-occlusive disease of liver, infertility, ovarian failure, secondary malignancies, GVHD if allogeneic HCT).",
      "Survival outcomes variable (poor in recurrent leukemia, high-risk AML)."
    ]
  },
  {
    "Object1": "Subleukemic Leukemia/Aleukemic Leukemia",
    "Object2": "Acute leukemia with normal/low total leukocyte count and few abnormal blasts in peripheral blood.",
    "Object3": [
      "Acute leukemia where blast cells proliferate but fail to mature, replacing normal bone marrow hematopoietic cells."
    ],
    "Object4": [],
    "Object5": [
      "Total leukocyte count normal or <4 x 10^9/L.",
      "Very few abnormal blasts in peripheral smear.",
      "Bone marrow examination confirms replacement by leukemic cells."
    ],
    "Object6": [
      "Bone marrow examination (confirms diagnosis)."
    ],
    "Object7": [
      "Treatment for acute leukemia."
    ],
    "Object8": []
  },
  {
    "Object1": "Leukemoid Reaction",
    "Object2": [
      "Myeloid leukemoid reaction",
      "Lymphoid leukemoid reaction"
    ],
    "Object3": [
      "Benign leukocytic proliferation, response of normal healthy bone marrow to various stresses.",
      "Infections (including tuberculosis), acute hemorrhage, hematological/non-hematological malignancies, toxic states."
    ],
    "Object4": [],
    "Object5": [
      "Total leukocyte count >50 x 10^9/L, with many immature white cells (metamyelocytes, myelocytes, promyelocytes, few myeloblasts) in peripheral smear.",
      "Bone marrow normal with accelerated leukopoiesis.",
      "Leukocyte alkaline phosphatase (LAP) score increased.",
      "Philadelphia chromosome negative.",
      "No absolute eosinophilia or basophilia."
    ],
    "Object6": [
      "Total leukocyte count, peripheral smear, bone marrow examination, LAP score, Philadelphia chromosome analysis."
    ],
    "Object7": [
      "Treatment of underlying disorder corrects the blood picture."
    ],
    "Object8": []
  },
  {
    "Object1": "Hairy Cell Leukemia (HCL)",
    "Object2": "Uncommon chronic malignant disorder of mature B-cells",
    "Object3": [
      "Malignant transformation of mature B-cells with characteristic fine cytoplasmic projections.",
      "Affects middle-aged to elderly men (M:F ratio 5:1)."
    ],
    "Object4": [
      "Pancytopenia (fatigue, weakness, dyspnea, frequent infections, bleeding manifestations).",
      "Symptoms due to massive splenomegaly (fullness of abdomen, abdominal distension, post-prandial fullness, reflux esophagitis, dyspnea, dragging discomfort).",
      "Constitutional symptoms (fever, night sweats, fatigue)."
    ],
    "Object5": [
      "Massive splenomegaly (most common, due to leukemic infiltration and extramedullary hematopoiesis).",
      "Hepatosplenomegaly (less common).",
      "No lymphadenopathy.",
      "Pancytopenia (>50% of cases).",
      "Hairy cells in peripheral smear (medium-sized malignant B lymphocytes with filamentous hairy structures, reniform nucleus, abundant pale blue cytoplasm).",
      "Infections (especially atypical mycobacteria)."
    ],
    "Object6": [
      "Total leucocyte count: Normal or low. Pancytopenia.",
      "Peripheral smear: Hairy cells (medium-sized malignant B lymphocytes with filamentous hairy structures, reniform nucleus, pale blue cytoplasm).",
      "Cytochemistry: Hairy cells stain positive for tartrate-resistant acid phosphatase (TRAP).",
      "Bone marrow: Dry tap on aspirate. Biopsy shows fibrosis with infiltration by mononuclear cells and hairy cells ('fried-egg' or 'honeycomb' appearance).",
      "LAP score: Very high.",
      "Flow cytometry: CD11c, 25, 103, 123 positivity."
    ],
    "Object7": [
      "Indications for treatment: Cytopenia, symptomatic splenomegaly, constitutional symptoms, infections.",
      "Treatment of infections with antibiotics.",
      "Chemotherapy: Purine analogues (cladribine, pentostatin) (highly effective with single cycle). Rituximab for non-responders. Interferon alfa. Splenectomy.",
      "Contraindicated drugs: Corticosteroids and myelotoxic drugs."
    ],
    "Object8": [
      "Infections (most common cause of death, especially atypical mycobacteria).",
      "Risk of secondary malignancies (Hodgkin's lymphoma, non-Hodgkin's lymphoma, thyroid cancer).",
      "Pancytopenia (marrow failure, splenic sequestration)."
    ]
  },
  {
    "Object1": "Chronic Myeloid Leukemia (CML)",
    "Object2": [
      "Chronic stable phase",
      "Accelerated phase",
      "Blast crisis phase"
    ],
    "Object3": [
      "Acquired myeloproliferative neoplasm of pluripotent hematopoietic stem cell.",
      "Overproduction of myeloid lineages (erythroid, granulocytic, megakaryocytic) leading to panmyelosis.",
      "Presence of Philadelphia chromosome (Ph) (t 9,22, balanced reciprocal translocation between chromosomes 9 and 22).",
      "BCR-ABL1 fusion gene (hybrid oncogene with uncontrolled kinase activity, triggers excessive proliferation and reduced apoptosis)."
    ],
    "Object4": [
      "Chronic stable phase: Often asymptomatic (early). Nonspecific (fatigue, weakness, weight loss, anorexia). Massive splenomegaly (fullness of abdomen, post-prandial fullness, reflux esophagitis, dyspnea, dragging discomfort). Hypermetabolic state (fever, sweating, heat intolerance). Priapism (painful penile erection). Bleeding tendencies (late).",
      "Accelerated phase: Increasing anemia, white blood cell count, circulating immature cells. Spleen size increase. Basophil count increase (<20%). Persistent thrombocytopenia/thrombocytosis.",
      "Blast crisis phase: Refractory to treatment. Abrupt increase in spleen size. Bone pain, sternal tenderness. Anemia, bleeding tendencies. Generalized lymphadenopathy."
    ],
    "Object5": [
      "Chronic stable phase: Pallor (anemia). Splenomegaly (moderate to massive, non-tender). Mild hepatomegaly. Sternal tenderness, bone pain. Deep dusky cyanosis (late).",
      "Peripheral smear: Moderate normocytic normochromic anemia. Shift to left (granulocytes at all stages, neutrophils and myelocytes predominant). Blasts <10%. Increased basophils (<20%) and eosinophils. Platelets normal/increased/decreased.",
      "Accelerated phase: Blasts 10-19% in blood or bone marrow. Increasing anemia, WBC count. Increasing spleen size. Increased basophil count.",
      "Blast crisis phase: Blasts ≥20% (myeloid or lymphoid). Anemia, thrombocytopenia. Generalized lymphadenopathy."
    ],
    "Object6": [
      "Chronic stable phase:",
      "Hemoglobin <11 g/dL. TLC >20,000/µL (often >100,000/µL). Platelet count normal/increased/decreased.",
      "Peripheral smear: Normocytic normochromic anemia. Shift to left (granulocytes at all stages). Basophils/eosinophils increased. Blasts <10%.",
      "Bone marrow study: Markedly hypercellular (granulocytic hyperplasia). Fibrosis (20-30% in late stages).",
      "Philadelphia Chromosome (Ph): Positive in >95%. (Cytogenetics, RT-PCR, FISH for Ph negative cases).",
      "BCR-ABL1 fusion gene: Demonstrated in peripheral blood/bone marrow.",
      "Decreased NAP/LAP Score (<20, differentiates from leukemoid reaction).",
      "Biochemical: Serum LDH, uric acid increased. Serum alkaline phosphatase increased. Serum vitamin B12, transcobalamin I increased. False decrease in blood sugar (leukocyte metabolism).",
      "Monitoring (after treatment): Bone marrow biopsy (cytogenetic response), Quantitative RT-PCR (qPCR) (molecular response)."
    ],
    "Object7": [
      "Goal: Complete molecular remission, eradication of BCR-ABL1 transcript.",
      "Chemotherapy (Table 8.33):",
      "Imatinib mesylate (tyrosine kinase inhibitor, TKI): First-line for chronic phase CML (400 mg/d). Produces complete hematological response (>95%), complete cytogenetic response (>76%). Continued indefinitely. (Side effects: nausea, headaches, fluid retention, muscle cramps, diarrhea, skin rash, myelosuppression).",
      "Recombinant interferon-α (rINF-α): Considered if imatinib failure. Alone or with cytarabine. Reduces cellularity, Ph+ cells (20%), eradicates Ph chromosome (~5%). (Side effects: flu-like syndrome, weight loss, fatigue, nausea, vomiting, headache).",
      "Second-generation TKIs (dasatinib, nilotinib): For imatinib failure/progress.",
      "Cytotoxic drugs (hydroxycarbamide, interferon-α, melphalan, busulphan, Omacetaxine/homoharringtonine).",
      "Splenectomy: For symptomatic massive splenomegaly, repeated splenic infarctions.",
      "Stem cell transplantation (SCT): For patients <60 years with suitable donor, imatinib non-responders, accelerated phase, blast crisis. Best results in early chronic stable phase (~70% cure rate).",
      "Accelerated Phase: Hydroxyurea (most effective).",
      "Blast Crisis: Same as acute myeloblastic or lymphoblastic leukemia."
    ],
    "Object8": [
      "Thrombotic episodes (DVT, MI, hepatic vein thrombosis - Budd-Chiari syndrome).",
      "Bleeding manifestations.",
      "Peptic ulcer (5x more frequent).",
      "Hyperuricemia (urate stones, gout, uric acid nephropathy).",
      "Priapism.",
      "Splenic infarction.",
      "Acute myelogenous leukemia (2-5% of cases).",
      "Myelofibrosis (progression).",
      "Acute nonlymphocytic leukemia.",
      "Erythromelalgia (thrombocytosis).",
      "Accelerated phase (more aggressive).",
      "Blast crisis (resembles acute leukemia, poor prognosis).",
      "Complications of chemotherapy (myelosuppression, fluid retention, hepatotoxicity, flu-like syndrome, GVHD with SCT)."
    ]
  },
  {
    "Object1": "Primary Myelofibrosis (agnogenic myeloid metaplasia, myelofibrosis with myeloid metaplasia)",
    "Object2": "Clonal MPN",
    "Object3": [
      "Increased fibrosis within the marrow, replacing hematopoietic cells leading to cytopenias, splenomegaly and extensive extramedullary hematopoiesis.",
      "Can arise from polycythemia vera (PV) or essential thrombocytosis (ET).",
      "Etiology not known."
    ],
    "Object4": [
      "Usually found above 60 years of age.",
      "Anemia: Fatigue, weakness, anorexia.",
      "Massive splenomegaly: Abdominal distension, postprandial fullness, reflux esophagitis, dyspnea, dragging discomfort.",
      "Hypermetabolic state: Fever, fatigue, weight loss, night sweats, heat intolerance.",
      "Bleeding tendencies (late stages) due to thrombocytopenia."
    ],
    "Object5": [
      "Massive splenomegaly and hepatomegaly.",
      "Anemia, lymphadenopathy, bleeding manifestations, ascites, cardiac failure, jaundice.",
      "Hyperuricemia and secondary gout.",
      "Extramedullary hematopoiesis (paraspinal masses with spinal cord compression, ascites, effusions)."
    ],
    "Object6": [
      "Hemoglobin level: Normal (early), reduced (late).",
      "Total leukocyte count: Normal/increased (early), decreased (late).",
      "Platelet count: Increased (early), decreased (late).",
      "Peripheral smear: Normochromic normocytic anemia with leukoerythroblastic blood picture (granulocyte precursors, nucleated RBCs), tear drop-shaped red cells (dacryocytes), basophilic stippling, giant platelets with vacuoles.",
      "Bone marrow: Biopsy is diagnostic. Hypercellular (cellular phase) then hypocellular/diffusely fibrotic (hypocellular phase). Megakaryocytes are large, dysplastic, abnormally clustered.",
      "LAP score: Raised.",
      "Philadelphia chromosome: Negative.",
      "JAK2 V617F mutation (~50% patients). CALR mutation.",
      "Serum vitamin B12: Moderately increased.",
      "Radiological examination: Increased bone density of vertebrate, proximal ends of long bones."
    ],
    "Object7": [
      "No specific therapy.",
      "Treatment of anemia: Correct other causes (GI blood loss, folic acid deficiency). PRBC transfusions. Recombinant erythropoietin, androgens (Danazol) (some patients). Glucocorticoids (prednisolone) +/- low-dose thalidomide (control anemia, splenomegaly).",
      "Treatment of splenomegaly: Busulphan (for cellular marrow, marked leukocytosis). Splenectomy for hypersplenism, if splenomegaly impairs alimentation (before cachexia). Splenic irradiation for unfit for splenectomy. Hydroxyurea (controls splenomegaly, may exacerbate anemia).",
      "Treatment of extramedullary hematopoiesis: Low dose irradiation.",
      "Curative treatment: Allogeneic bone marrow transplantation (younger patients).",
      "Others: Allopurinol (hyperuricemia). Etanercept (TNF-α antagonist) (for severe constitutional features). JAK2 inhibitors (ruxolitinib)."
    ],
    "Object8": [
      "Acute myeloid leukemia (significant number of cases).",
      "Portal hypertension and infections (leading causes of death).",
      "Progressive anemia, splenomegaly, hepatomegaly.",
      "Bleeding tendencies.",
      "Hyperuricemia and secondary gout.",
      "Spinal cord compression (extramedullary hematopoiesis).",
      "Death (median survival ~5 years)."
    ]
  },
  {
    "Object1": "Myelophthisis (Secondary Myelofibrosis)",
    "Object2": "Secondary reactive process of bone marrow fibrosis",
    "Object3": [
      "Malignant conditions: Hematological (Leukemia - Acute, CML, Hairy cell leukemia; Multiple myeloma; Polycythemia vera; Hodgkin's lymphoma; Essential thrombocytosis), Non-hematological (Metastasis to marrow - Carcinoma breast, lung, prostate, Neuroblastoma).",
      "Non-malignant conditions: Infections (HIV, Tuberculosis), Exposure to thorium dioxide, SLE, Renal osteodystrophy, Hyperparathyroidism, Radiation therapy or treatment with radiomimetic drugs, Gaucher disease."
    ],
    "Object4": [],
    "Object5": [
      "Peripheral smear: Leukoerythroblastosis with tear drop cells.",
      "Splenomegaly (may be present)."
    ],
    "Object6": [
      "Peripheral smear, bone marrow biopsy."
    ],
    "Object7": [
      "Treatment of the underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Myelodysplastic Syndromes (MDS)",
    "Object2": "Heterogeneous group of acquired clonal stem cell disorders",
    "Object3": [
      "Progressive cytopenias (low blood cell counts).",
      "Dysplasia in one or more major cell lines (erythroid, myeloid and megakaryocytic forms).",
      "Ineffective hematopoiesis.",
      "Increased risk of development of AML.",
      "Primary MDS: Exact cause unknown, genetic factors may play a role.",
      "Secondary/t-MDS: Exposure to radiation, benzene, postchemotherapy (alkylating agents, topoisomerase inhibitors), viruses, cigarette smoking, PNH."
    ],
    "Object4": [
      "Usually asymptomatic, detected incidentally on routine blood examination (~50%).",
      "Symptoms due to cytopenias (single-lineage, bicytopenia or pancytopenia): Weakness (anemia), Infections (leukopenia), Hemorrhage (thrombocytopenia)."
    ],
    "Object5": [
      "Peripheral smear: Mild to moderate macrocytic or dimorphic anemia with evidence of dyspoiesis. Neutropenia with few blasts (hypogranular/agranular cytoplasm, hyposegmentation/hypersegmentation/ringed nuclei - Pseudo-Pelger-Hüet cells). Variable thrombocytopenia, large hypogranular/giant platelets.",
      "NAP score: Moderately or severely decreased.",
      "Bone marrow: Varying degree of dyspoietic (disordered) differentiation affecting all non-lymphoid lineages (erythroid, granulocytic, monocytic, megakaryocytic) associated with cytopenias."
    ],
    "Object6": [
      "Minimal morphologic criterion for diagnosis: Dysplasia in ≥10% of cells of any one myeloid lineage.",
      "Complete blood count (clues for diagnosis).",
      "Peripheral smear: Macrocytic/dimorphic anemia with dyspoiesis. Neutropenia with few blasts (hypogranular/agranular cytoplasm, Pseudo-Pelger-Hüet cells, ringed neutrophils). Thrombocytopenia with large hypogranular/giant platelets.",
      "NAP score: Decreased.",
      "Bone marrow: Dyspoietic differentiation in non-lymphoid lineages. Cytogenic study (most important, chromosome 5 or 7 abnormalities frequent)."
    ],
    "Object7": [
      "Supportive therapy: PRBC transfusion for anemia. Platelet transfusions for bleeding. Antibiotic therapy for infections. Iron chelators for iron overload (from transfusions).",
      "EPO and G-CSF (some patients, to ameliorate symptoms).",
      "Others: Thalidomide, lenalidomide (5q-syndrome), 5-azacitidine, decitabine (hypomethylating agents - reduce transfusion needs, retard progression to AML).",
      "Allogeneic hematopoietic stem cell transplantation (curative, in <5-10% due to age)."
    ],
    "Object8": [
      "Progressive cytopenias.",
      "Increased risk of development of AML (10-40% progress).",
      "Extramedullary hematopoiesis (rare hepatomegaly/splenomegaly).",
      "Iron overload (from multiple transfusions)."
    ]
  },
  {
    "Object1": "Multiple Myeloma (MM)",
    "Object2": [
      "IgG (55%)",
      "IgA (25%)",
      "IgD (uncommon)",
      "IgE (uncommon)",
      "Light chain disease (20%)",
      "Non-secretory myeloma",
      "Smoldering (asymptomatic) multiple myeloma",
      "Osteosclerotic Myeloma (POEMS Syndrome)"
    ],
    "Object3": [
      "Malignant plasma cell neoplasm derived from single clone plasma cells of bone marrow.",
      "Produces multiple, lytic bone lesions.",
      "Plasma cells synthesize excess of light (L) or heavy (H) chains along with complete Igs (rarely only L or H chains).",
      "Cause unclear: Exposure to radiation, benzene, organic solvents, herbicides, insecticides. Familial clusters. Genetic predisposition (e.g., in identical twins)."
    ],
    "Object4": [
      "Insidious onset, peak incidence 6th-7th decade.",
      "Asymptomatic (preclinical phase).",
      "Bone pain (backache due to vertebral involvement - 60%, pathological fractures).",
      "Neurological symptoms of sensory/motor loss (spinal cord/root compression from vertebral lesions).",
      "Anemia, leukopenia, thrombocytopenia.",
      "Humoral immune deficiency (increased susceptibility to recurrent infections, respiratory/urinary tract).",
      "Renal damage (renal insufficiency in 20-30%, nephrotic syndrome).",
      "Bleeding tendency (purpura, epistaxis, GI bleeding).",
      "Hyperviscosity syndrome (CNS: confusion, headache, vertigo, nystagmus, postural hypotension, dizziness; Retinal: blurred vision, venous congestion, papilledema; CVS: CHF).",
      "Amyloid peripheral neuropathy, carpal tunnel syndrome, compressive myelopathy.",
      "POEMS Syndrome: Polyneuropathy (predominantly motor disability), organomegaly, endocrinopathy, M-protein, skin changes."
    ],
    "Object5": [
      "Localized bony swellings (vertebrae, skull, sternum, ribs, clavicle).",
      "Pallor (anemia).",
      "Ecchymoses, bleeding gums, epistaxis (bleeding tendency).",
      "Fundal hemorrhages (due to hyperviscosity or thrombocytopenia).",
      "Rouleaux formation (peripheral smear) (due to increased immunoglobulins).",
      "Plasmacytosis (>10% plasma cells in bone marrow or plasmacytoma).",
      "CRAB (Hypercalcemia, Renal insufficiency, Anemia, Bone lesions).",
      "Osteosclerotic Myeloma: Sclerotic skeletal lesions."
    ],
    "Object6": [
      "Diagnosis: ≥2 of: (1) Monoclonal immunoglobulin (M protein) or light chains in blood (>3 g/dL) and/or urine. (2) Infiltration of bone marrow with clonal plasma cells (≥10%) or plasmacytoma. (3) Evidence of myeloma-related organ/tissue impairment (≥1 - CRAB: hypercalcemia, renal insufficiency, anemia, lytic bone lesions/osteoporosis).",
      "Other criteria: Free light chain ratio >100, >1 bone lesion on MRI, bone marrow plasma cell percentage >60%.",
      "Smoldering MM: Serum M-protein <3 g/dL and/or clonal plasma cells <10% in BM, asymptomatic, no CRAB. High risk of progression.",
      "Peripheral blood: Anemia, leukopenia, thrombocytopenia, raised ESR. Rouleaux formation.",
      "Bone marrow: Hypercellular with increased plasma cells/myeloma cells (≥30% diagnostic).",
      "Urine: Bence-Jones proteins.",
      "Serum: β2 microglobulin (prognostic, high values = poor prognosis). Hypercalcemia. Serum alkaline phosphatase (usually normal). Blood urea, serum creatinine, electrolytes. Serum proteins (increased total, decreased albumin, markedly increased globulins). Serum uric acid. Reduced normal immunoglobulins.",
      "Electrophoretic studies (serum/urine): M-protein 'spikes'. Immunofixation for Ig type.",
      "Radiological: Generalized osteoporosis. Punched-out osteolytic lesions (skull, vertebral bodies, ribs, pelvis) (Fig. 8.33). Collapse of multiple vertebrae. MRI/PET may detect bone involvement when skeletal survey normal."
    ],
    "Object7": [
      "General measures: High fluid intake (3 L/day). Prompt treatment of infections. Blood transfusion/erythropoietin for anemia. Analgesics for bone pain. Allopurinol (prevent hyperuricemia/urate nephropathy). Plasmapheresis for hyperviscosity syndrome. Bisphosphonates (zoledronate, pamidronate, clodronate) to inhibit osteoclast activity, reduce skeletal events (risk of osteonecrosis of jaw). Orthopedic assistance/physiotherapy. Renal failure treated by rehydration/prednisolone.",
      "Autologous stem cell transplantation: For young patients (<65 years) without renal failure (first-line high-dose chemotherapy + autologous SCT).",
      "Chemotherapy (Older patients): Thalidomide + alkylating agent (melphalan/cyclophosphamide/chlorambucil) + prednisolone. Bortezomib + doxorubicin + dexamethasone. Lenalidomide + steroids. (Younger patients): Bortezomib, cyclophosphamide, dexamethasone. Newer drugs (carfilzomib, ixazomib, pomalidomide, daratumumab, elotuzumab). Oral CTD (cyclophosphamide, thalidomide, dexamethasone) + high-dose melphalan autograft.",
      "Radiotherapy: For local problems (bone pain, pathological fractures, tumorous lesions). Emergency for spinal cord compression."
    ],
    "Object8": [
      "Bone lesions (lytic, osteoporosis, pathological fractures, spinal cord compression).",
      "Bone marrow failure (anemia, leukopenia, thrombocytopenia).",
      "Humoral immune deficiency (recurrent infections).",
      "Renal damage (tubular damage from Bence-Jones proteinuria, hypercalcemia, amyloid deposition, hyperuricemia, UTIs, myeloma cell infiltration).",
      "Bleeding tendency (purpura, epistaxis, GI bleeding, intracranial bleeding).",
      "Hyperviscosity syndrome (CNS, retinal, CVS).",
      "Amyloid peripheral neuropathy, carpal tunnel syndrome, compressive myelopathy.",
      "Progression of smoldering myeloma to overt myeloma or related malignancy.",
      "Osteonecrosis of jaw (bisphosphonates).",
      "Poor prognosis factors: high β2-microglobulin, low albumin, high serum calcium, low hemoglobin, advanced lytic bone lesions, thrombocytopenia, renal failure, plasma cell leukemia."
    ]
  },
  {
    "Object1": "Monoclonal Gammopathy of Uncertain Significance (MGUS)",
    "Object2": [
      "Benign (IgG, IgA, IgD, IgM, free light chains)",
      "Biclonal gammopathies",
      "Idiopathic Bence-Jones proteinuria"
    ],
    "Object3": [
      "Presence of serum M-protein concentration <3 g/dL, bone marrow clonal plasma cells <10%, and no end organ damage (CRAB criteria negative) or other B-cell neoplasms."
    ],
    "Object4": [
      "Asymptomatic (by definition)."
    ],
    "Object5": [
      "Serum M-protein concentration <3 g/dL.",
      "Bone marrow clonal plasma cells <10%.",
      "No hypercalcemia, renal impairment, anemia, or bone lesions."
    ],
    "Object6": [
      "Serum protein electrophoresis (detects M-protein).",
      "Bone marrow biopsy (clonal plasma cells <10%).",
      "Serum-free light chain ratio (kappa/lambda ratio - normal 0.26-1.65).",
      "Follow-up with serum protein electrophoresis at 6 months, then 1-2 years if stable."
    ],
    "Object7": [
      "No treatment indicated."
    ],
    "Object8": [
      "Progression to multiple myeloma, Waldenstrom's macroglobulinemia, primary AL amyloidosis, or a lymphoproliferative disorder (1-1.5% per year)."
    ]
  },
  {
    "Object1": "Solitary Plasmacytoma (Osseous Plasmacytoma)",
    "Object2": "Solitary tumor in bone",
    "Object3": [
      "Collection of monoclonal plasma cells in bone.",
      "Common sites: Bones with active hematopoiesis (vertebrae, ribs, skull, pelvis, femur, clavicle, scapula)."
    ],
    "Object4": [
      "Localized bone pain.",
      "Pathological fracture.",
      "Neurologic symptoms (spinal cord or root compression from vertebral lesions)."
    ],
    "Object5": [],
    "Object6": [
      "M-protein in serum or urine (24-72% of patients) by immunofixation.",
      "MRI (useful to rule out occult systemic disease).",
      "Biopsy confirms monoclonal plasma cells."
    ],
    "Object7": [
      "Local control by radiotherapy."
    ],
    "Object8": [
      "Progression to systemic disease (up to two-thirds of patients develop multiple myeloma)."
    ]
  },
  {
    "Object1": "Solitary Extraosseous Plasmacytoma",
    "Object2": "Localized plasma cell neoplasm arising in tissues other than bone",
    "Object3": [
      "Upper respiratory tract (80%): Oropharynx, nasopharynx, sinuses, larynx.",
      "Other sites: GI tract, lymph nodes, bladder, CNS, breast, thyroid, testis, parotid, skin."
    ],
    "Object4": [],
    "Object5": [
      "Presents as a localized plasma cell mass."
    ],
    "Object6": [
      "M-protein (most commonly IgA) in serum or urine (only ~20% of patients).",
      "Extensive radiographic imaging (required to exclude occult systemic disease)."
    ],
    "Object7": [
      "Local radiation therapy."
    ],
    "Object8": [
      "Progression to multiple myeloma (~15% of patients)."
    ]
  },
  {
    "Object1": "Plasma Cell Leukemia (PCL)",
    "Object2": [
      "Primary plasma cell leukemia (without preceding multiple myeloma)",
      "Secondary plasma cell leukemia (leukemic transformation in multiple myeloma patients)"
    ],
    "Object3": [
      "Peripheral blood has >20% plasma cells with absolute plasma cell count ≥2000/µl.",
      "Primary PCL: Develops in younger individuals, presents with hepatosplenomegaly, lymphadenopathy, higher platelet count, few bone lesions.",
      "Secondary PCL: Develops in patients with multiple myeloma."
    ],
    "Object4": [],
    "Object5": [
      "Primary PCL: Hepatosplenomegaly, lymphadenopathy.",
      "Aggressive disease with high tumor burden and extramedullary dissemination."
    ],
    "Object6": [
      "Peripheral blood: >20% plasma cells, absolute plasma cell count ≥2000/µl."
    ],
    "Object7": [
      "Treatment as per acute leukemia, but specific regimens are less well established."
    ],
    "Object8": [
      "Aggressive disease with poor prognosis."
    ]
  },
  {
    "Object1": "Waldenstrom Macroglobulinemia",
    "Object2": "Syndrome with IgM monoclonal gammopathy and bone marrow infiltration",
    "Object3": [
      "Associated with lymphoplasmacytic lymphoma (tumor cells differentiate to plasma cells and secrete monoclonal IgM).",
      "Occurs in older adults (median age 60 years)."
    ],
    "Object4": [
      "Asymptomatic (may be).",
      "Nonspecific: Weakness, fatigue, weight loss (due to marrow infiltration). Fever, night sweats.",
      "Monoclonal protein: Autoimmune hemolysis (10%, cold agglutinins). Systemic amyloidosis (IgM). Hyperviscosity syndrome (visual impairment, neurologic problems - dizziness, headache, vertigo, nystagmus, hearing loss, ataxia, paresthesias, diplopia, bleeding).",
      "Cryoglobulinemia (Raynaud phenomenon, cold urticaria)."
    ],
    "Object5": [
      "Tumor infiltration: Lymphadenopathy, hepatomegaly, splenomegaly.",
      "Hyperviscosity syndrome: Retinal venous congestion, papilledema (visual impairment).",
      "Organ infiltration: Hepatosplenomegaly, lymphadenopathy (~20%)."
    ],
    "Object6": [
      "Demonstration of monoclonal IgM: Serum electrophoresis (sample may require warming to 37°C), immunofixation.",
      "Bone marrow aspirate/biopsy: >10% lymphoplasmacytic cells (CD20+)."
    ],
    "Object7": [
      "Chemotherapy- and immunotherapy-sensitive disease (controllable).",
      "No specific treatment for asymptomatic patients.",
      "Single agent therapy with rituximab (symptomatic patients with modest hematologic compromise, IgM-related neuropathy, hemolytic anemia unresponsive to corticosteroids).",
      "Combination chemotherapy + rituximab (for severe constitutional symptoms, profound hematologic compromise, bulky disease, hyperviscosity syndrome): Dexamethasone, rituximab, cyclophosphamide OR Bortezomib, dexamethasone, rituximab OR Bendamustine, rituximab.",
      "Plasmapheresis: For symptoms due to high IgM levels (hyperviscosity, hemolysis)."
    ],
    "Object8": [
      "Hyperviscosity syndrome (visual impairment, neurologic problems, bleeding).",
      "Autoimmune hemolysis (10%, cold agglutinins).",
      "Systemic amyloidosis (IgM).",
      "Transformation to large-cell lymphoma (uncommon)."
    ]
  },
  {
    "Object1": "Hodgkin Lymphoma (HL)",
    "Object2": [
      "Classical Hodgkin lymphoma (>95%) (Nodular sclerosis, Mixed cellularity, Lymphocyte-rich, Lymphocyte depletion)",
      "Nodular lymphocyte predominance (LP) Hodgkin's lymphoma"
    ],
    "Object3": [
      "Malignant lymphoma characterized by specific neoplastic cells (Hodgkin cells and Reed-Sternberg cells) in a background of reactive non-neoplastic cells.",
      "Cell of origin: Germinal center or immediate post-germinal center B-cells.",
      "EBV: Increased risk in young adults with previous EBV infection, EBV genome often in Reed-Sternberg cells.",
      "Genetic factors: HLA subtypes (HLA-B18).",
      "Immune status: More frequent in immunocompromised patients or with autoimmune diseases (RA)."
    ],
    "Object4": [
      "Painless enlargement of one lymph node group (unifocal origin, usually cervical).",
      "Constitutional 'B' symptoms (unexplained weight loss >10% in 6 months, recurrent unexplained fever >38°C in previous month, recurrent heavy night sweats in previous month) (may be prominent as disease advances).",
      "Alcohol-induced pain at site of lymphadenopathy.",
      "Pruritus (troublesome).",
      "Symptoms due to compression/infiltration of organs by lymph node masses (dysphagia, dyspnea, Horner's syndrome, hoarseness of voice, SVC syndrome, IVC obstruction).",
      "Pel-Ebstein fever (cyclical pattern, rare)."
    ],
    "Object5": [
      "Painless enlarged lymph node group ('Indian rubber' consistency). Spreads contiguously.",
      "Localized disease of mediastinum (cough). Axillary, abdominal, pelvic, inguinal nodes.",
      "Generalized disease (hepatosplenomegaly, 'B' symptoms - uncommon early).",
      "Extralymphatic organ involvement (not common, later stages).",
      "Nephrotic syndrome (immune complex deposition).",
      "Lymphadenopathy (mediastinal, axillary, abdominal, pelvic, inguinal).",
      "EBV genome in Reed-Sternberg cells.",
      "Immunophenotype: Reed-Sternberg cells in classical HL are CD15+, CD30+. In LP HL are CD15-ve, CD30-ve."
    ],
    "Object6": [
      "Peripheral blood: Normocytic normochromic anemia (early), microcytic anemia (late, iron utilization defect). Normal/neutrophil leukocytosis. Eosinophilia (~20%). Thrombocytosis. Lymphopenia (bad prognosis). Leukopenia/thrombocytopenia (terminal stages).",
      "Serum alkaline phosphatase (raised in marrow/liver involvement).",
      "Erythrocyte sedimentation rate (ESR): May be raised.",
      "Biopsy: Fine needle aspiration (helpful for diagnosis). Lymph node biopsy (surgical or percutaneous) confirms diagnosis. Liver biopsy (if hepatomegaly).",
      "Staging (Cotswolds modification of Ann Arbor Classification - Table 8.53): Physical exam, chest X-rays, LFTs, RFTs, abdominal ultrasound, bone marrow trephine/aspirate (for advanced disease, 'B' symptoms, HIV+). CT scans of neck, chest, abdomen, pelvis.",
      "Positron emission tomography (PET) scan: Staging and management."
    ],
    "Object7": [
      "Aim: Curative intent.",
      "Localized/good prognosis: Brief chemotherapy + radiotherapy (cured in >90%).",
      "All stages: Initially chemotherapy. Extensive disease/'B' symptoms: complete course of chemotherapy.",
      "Chemotherapy (Combination): ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), MOPP (mechlorethamine, vincristine, procarbazine, prednisone), ABVD/MOPP alternating cycles, BEACOPP escalated.",
      "Treatment plan (Table 8.55): Stage IA/IIA no bulky disease (ABVD x 4 or ABVD x 2 + IRRT). IB/IIB/any stage III/IV (≤3 adverse factors): ABVD until 2 cycles past complete remission. Bulky disease/any stage (≥4 adverse factors): BEACOPP escalated.",
      "Autologous bone marrow transplantation: For relapsed chemosensitive disease (~40% success)."
    ],
    "Object8": [
      "Immune depression (increased risk of infections: herpes zoster, TB, Cryptococci/CMV/Candida).",
      "Secondary malignancies (acute leukemia, solid organ cancers) due to alkylating agents + radiotherapy.",
      "Cardiac failure and accelerated coronary artery disease (post-radiotherapy).",
      "Pulmonary fibrosis and hypothyroidism (post-radiotherapy)."
    ]
  },
  {
    "Object1": "Non-Hodgkin Lymphoma (NHL)",
    "Object2": [
      "B-cell origin (~80%)",
      "T-cell origin (~20%)",
      "Low-grade (indolent) NHL",
      "High-grade (aggressive) NHL"
    ],
    "Object3": [
      "Solid tumors of the immune system.",
      "Etiology (Table 8.56): Genetic factors/inherited immune disorders (family history, ataxia-telangiectasia, Wiskott-Aldrich syndrome). Acquired immune disorders (immune suppression, immunosuppressant drugs, AIDS, RA, SLE, Sjögren syndrome, Hashimoto thyroiditis). Infectious agents (EBV - Burkitt lymphoma, HTLV-1 - adult T-cell leukemia/lymphoma, HHV-8 - primary effusion lymphoma, Hepatitis C virus - lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, Helicobacter pylori - gastric MALT lymphoma). Occupational/environmental exposure (ionizing radiation, herbicides, organic solvents, hair dyes, UV light, high-fat diets, nitrates, heavy smoking)."
    ],
    "Object4": [
      "Age peak ~60 years.",
      "Painless firm, lymph node enlargement or symptoms due to lymph node mass (most common).",
      "Extranodal involvement (bone marrow, gut, thyroid, lung, skin, testis, brain, bone).",
      "Cytopenia (due to bone marrow involvement).",
      "Soft tissue masses, symptoms relevant to site (primary extranodal lymphomas).",
      "Pressure effects: Gut obstruction, ascites, SVC obstruction, spinal cord compression.",
      "'B' symptoms (weight loss, sweats, fever, itching).",
      "Immunologic abnormalities (autoimmune hemolytic anemia, immune thrombocytopenia).",
      "Paraneoplastic neurologic complications (demyelinating polyneuropathy, GBS, autonomic dysfunction, peripheral neuropathy).",
      "Paraneoplastic syndromes (skin - pemphigus, kidney - glomerulonephritis, vasculitis, dermatomyositis, cholestatic jaundice)."
    ],
    "Object5": [
      "Painless, firm, lymph node enlargement (cervical, mediastinal, para-aortic, axillary, inguinal, Waldeyer's ring, epitrochlear).",
      "Hepatosplenomegaly (liver/spleen involvement).",
      "Anterior mediastinal mass (lymphoblastic lymphoma).",
      "Bone marrow involvement (cytopenia).",
      "Autoimmune hemolytic anemia (pallor, jaundice, splenomegaly).",
      "Immunophenotyping of surface antigens to distinguish T- and B-cell tumors.",
      "Characteristic histological features from biopsy."
    ],
    "Object6": [
      "Same as for Hodgkin lymphoma (Laparotomy rarely needed, only for retroperitoneal nodes).",
      "Peripheral blood: Moderate anemia (marrow involvement). Lymphocytosis (some). Splenomegaly with hypersplenism or AIHA (reduced Hb, reticulocytosis, positive Coombs test).",
      "Bone marrow aspiration and trephine biopsy (early, common involvement).",
      "Immunophenotyping (flow cytometry/immunohistochemistry for B, T, NK subtypes).",
      "Immunoglobulin determination (IgG or IgM paraproteins).",
      "Uric acid levels (high in aggressive NHL, can precipitate renal failure).",
      "HIV testing.",
      "Serum LDH, β2-macroglobulin, serum protein electrophoresis.",
      "Diagnostic spinal tap (prophylactic intrathecal chemotherapy, high-risk patients)."
    ],
    "Object7": [
      "Low-grade NHL:",
      "Radiotherapy (localized stage I disease).",
      "Chemotherapy (oral chlorambucil - not curative; intensive IV chemotherapy - better quality of life. Bendamustine rituximab as first-line).",
      "Humanized monoclonal antibody therapy (rituximab - anti-CD20 alone or with chemotherapy (R-CVP) as first-line). 131I-tositumomab, 90Y-ibritumomab.",
      "Bone marrow transplantation.",
      "High-grade NHL:",
      "Chemotherapy: Intravenous combination chemotherapy (CHOP regimen - cyclophosphamide, doxorubicin, vincristine, prednisolone).",
      "Radiotherapy: Residual localized bulky disease, spinal cord/other compression syndromes.",
      "Humanized monoclonal antibody therapy: Rituximab (R) with CHOP chemotherapy (R-CHOP) as first-line for stage II+ diffuse large-cell lymphoma (improves overall survival).",
      "Autologous bone marrow transplantation: For relapsed chemosensitive disease."
    ],
    "Object8": [
      "Cytopenia due to marrow involvement.",
      "Gut obstruction, ascites, SVC obstruction, spinal cord compression (pressure effects).",
      "Autoimmune hemolytic anemia, immune thrombocytopenia.",
      "Neurologic complications (demyelinating polyneuropathy, GBS, autonomic dysfunction, peripheral neuropathy).",
      "Secondary malignancies."
    ]
  },
  {
    "Object1": "Burkitt Lymphoma (BL)",
    "Object2": [
      "Endemic (African) Burkitt lymphoma",
      "Sporadic (nonendemic) Burkitt lymphoma",
      "Immunodeficiency-associated (HIV) lymphomas"
    ],
    "Object3": [
      "Highly aggressive, often extranodal B-cell lymphoma.",
      "Associated with specific chromosomal translocation involving MYC oncogene from chromosome 8 to immunoglobulin (Ig) heavy chain region on chromosome 14 [t(8;14)].",
      "Endemic form: Associated with Epstein-Barr virus (EBV) infection, corresponds to malaria distribution. Affects children/adolescents.",
      "Immunodeficiency-associated (HIV) form: Usually occurs with CD4 counts >200/mm³."
    ],
    "Object4": [
      "Endemic: Rapidly growing jaw tumor in young child (4-7 years), deformity, loosening of teeth, eye extrusion, vision loss. Involvement of extranodal sites (jaw, GI tract, gonads).",
      "Sporadic: Abdominal mass.",
      "Immunodeficiency-associated (HIV): Abdominal involvement.",
      "Abdominal involvement: Mass due to bilateral involvement of kidneys, adrenals, ovaries, bowel, lymph nodes.",
      "Other sites: CNS (headache, nausea, papilledema, cranial nerve palsies, seizures, altered consciousness), long bones, salivary glands, thyroid, testes, heart, breast, bone marrow."
    ],
    "Object5": [
      "Endemic: Rapidly growing jaw tumor, deformity, loosening of teeth, eye extrusion, vision loss. Extranodal involvement (jaw, GI tract, gonads).",
      "Histological examination: Diffuse monotonous infiltrate of medium-sized lymphoid cells, numerous mitoses, apoptotic tumor cells phagocytosed by benign macrophages ('starry sky' pattern) (Fig. 8.35).",
      "Chromosome analysis: t(8;14)(q24;q32) (MYC oncogene to IGH gene).",
      "Antibodies to EB viral capsid antigen (in endemic, sporadic, HIV-associated)."
    ],
    "Object6": [
      "Histological examination: 'Starry sky' pattern (Fig. 8.35).",
      "Chromosome analysis: t(8;14)(q24;q32).",
      "Antibodies to EB viral capsid antigen (endemic, sporadic, HIV-associated).",
      "Imaging for tumor location and extent."
    ],
    "Object7": [
      "Urgent initiation of treatment with curative intent.",
      "Adequate hydration prior to specific therapy (prevent tumor lysis syndrome).",
      "High-intensity, brief-duration cyclical combination chemotherapy. Regimens: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) OR Rituximab + EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin) OR CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, methotrexate/ifosfamide, etoposide, cytarabine).",
      "Prophylactic central nervous system therapy (intrathecal methotrexate/cytosine arabinoside) + high dose systemic administration."
    ],
    "Object8": [
      "Rapidly growing tumor, bone deformity, vision loss.",
      "Tumor lysis syndrome (due to chemotherapy).",
      "High tumor burden with rapid growth.",
      "CNS involvement."
    ]
  },
  {
    "Object1": "Adult T-cell Lymphoma/Leukemia",
    "Object2": [
      "Acute aggressive form",
      "Lymphomatous form",
      "Chronic form",
      "Smoldering form"
    ],
    "Object3": [
      "Neoplasm of CD4+ T-cells, develops in adults infected by human T-cell leukemia virus type 1 (HTLV-1).",
      "Mode of infection of HTLV-1: Transplacental, blood transfusion, sexual contact.",
      "Long latency period (10-30 years) between infection and lymphoma development."
    ],
    "Object4": [
      "Acute aggressive: Peripheral blood lymphocytosis, lymphadenopathy, hepatosplenomegaly, skin infiltration, hypercalcemia, lytic bone lesions, raised LDH. Opportunistic infections common.",
      "Lymphomatous: Generalized lymphadenopathy (without leukemia).",
      "Chronic: Low level absolute lymphocytosis, exfoliative skin rash.",
      "Smoldering: Normal peripheral blood lymphocyte count, small number of circulating tumor cells, skin rashes."
    ],
    "Object5": [
      "Acute aggressive: Characteristic neoplastic cells with multilobulated nuclei ('cloverleaf' or 'flower' cells) in involved tissues and peripheral blood. Hepatosplenomegaly, lymphadenopathy, skin infiltration.",
      "Chronic/Smoldering: Exfoliative skin rash."
    ],
    "Object6": [
      "Peripheral smear: Neoplastic cells with multilobulated nuclei ('cloverleaf' or 'flower' cells).",
      "Immunophenotype: Tumor cells express pan-T-cell markers CD3, CD5, CD2."
    ],
    "Object7": [
      "Combination chemotherapy prolongs life but does not produce remissions.",
      "Combination antiretroviral drugs (zidovudine + interferon-α) may be helpful in some patients."
    ],
    "Object8": [
      "Rapid progression, often fatal.",
      "Opportunistic infections (acute aggressive form).",
      "Hypercalcemia, lytic bone lesions."
    ]
  },
  {
    "Object1": "Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (Primary Gastric Lymphoma)",
    "Object2": "Small-cell NHL of B-cells (extranodal origin)",
    "Object3": [
      "Often localized to organ of origin (~40% cases) and surrounding lymph nodes (~30%). Bone marrow involvement uncommon (~15%).",
      "Gastric type of MALT lymphoma: Associated with H. pylori infection.",
      "Salivary gland MALT: Associated with Sjögren's syndrome."
    ],
    "Object4": [
      "Gastric type: Upper abdominal discomfort, dyspepsia (may mimic benign conditions like chronic gastritis or peptic ulcer)."
    ],
    "Object5": [
      "Gastric type: May present as a mass on endoscopy."
    ],
    "Object6": [
      "Endoscopy: Multiple biopsies required for diagnosis.",
      "Endoscopic ultrasound (EUS) (useful for staging gastric MALT lymphoma).",
      "H. pylori test."
    ],
    "Object7": [
      "Localized MALT lymphomas: Surgery or local radiotherapy.",
      "Gastric MALT lymphoma: Anti-H. pylori therapy (can achieve remission in 80% of low-grade cases).",
      "Extensive disease: Single chemotherapy agents (chlorambucil, cyclophosphamide, fludarabine or cladribine).",
      "Combination regimens including rituximab (highly effective)."
    ],
    "Object8": []
  },
  {
    "Object1": "Mycosis Fungoides",
    "Object2": "Rare type of cutaneous T-cell NHL",
    "Object3": [
      "Composed of small to medium-sized lymphoid cells with irregular nuclear outlines.",
      "Derived from CD4+ T cells of skin-associated lymphoid tissue.",
      "Tumor cells show epidermotropism (predilection for epidermis) and dermis."
    ],
    "Object4": [
      "Intensely pruritic (in plaque stage)."
    ],
    "Object5": [
      "Patch stage (inflammatory premycotic phase): Erythematous macules (usually on non-sun exposed areas).",
      "Plaque stage: Elevated scaly plaques (pink or red/brown).",
      "Tumor stage: Dome-shaped firm tumors (may ulcerate).",
      "Sézary syndrome: Generalized erythroderma, malignant T-cells with serpentine nuclei in peripheral blood."
    ],
    "Object6": [
      "Immunophenotype: Tumor cells express pan-T-cell markers CD3, CD5, CD2."
    ],
    "Object7": [
      "Localized early-stage: Radiotherapy (total-skin electron beam irradiation).",
      "More advanced stage: Palliative treatment (topical glucocorticoids, topical nitrogen mustard, phototherapy, psoralen with ultraviolet A (PUVA), systemic cytotoxic therapy)."
    ],
    "Object8": [
      "Sézary syndrome (progression to generalized erythroderma and malignant T-cells)."
    ]
  },
  {
    "Object1": "Castleman's Disease (Angiofollicular Lymph Node Hyperplasia)",
    "Object2": "Localized lymphoid mass or systemic illness",
    "Object3": [],
    "Object4": [
      "Systemic illness: Fevers, night sweats, weight loss, fatigue (related to excessive production of IL-6)."
    ],
    "Object5": [
      "Localized lymphoid mass."
    ],
    "Object6": [],
    "Object7": [
      "Localized: Surgical removal or radiotherapy.",
      "Systemic disease: May respond to high-dose corticosteroids."
    ],
    "Object8": [
      "Progression to lymphoma (disseminated and plasma cell-rich forms).",
      "Frequently associated with HHV-8 in HIV-infected patients."
    ]
  },
  {
    "Object1": "Sinus Histiocytosis with Massive Lymphadenopathy (Rosal-Dorfman Disease)",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Bulky lymphadenopathy (in children and young adults).",
      "Extranodal sites (skin, upper airways, GI tract, CNS) can be involved.",
      "Lymphoid proliferation with thick fibrous capsule, distention of lymphoid sinuses, accumulation of plasma cells, proliferation of large/atypical histiocytes."
    ],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Associated with autoimmune hemolytic anemia."
    ]
  },
  {
    "Object1": "Kikuchi's Disease (Histiocytic Necrotizing Lymphadenitis)",
    "Object2": "Disease of unknown origin",
    "Object3": [],
    "Object4": [
      "Painless cervical lymphadenopathy (most common)",
      "Fever, flu-like symptoms, rash (often accompanied by)."
    ],
    "Object5": [
      "Painless cervical lymphadenopathy.",
      "Lymph node biopsies reveal foci of necrotic histiocytes."
    ],
    "Object6": [
      "Lymph node biopsies."
    ],
    "Object7": [
      "Symptomatic treatment. Symptoms usually resolve within weeks or months."
    ],
    "Object8": [
      "Associated with SLE (sometimes)."
    ]
  },
  {
    "Object1": "Bleeding Disorders (Hemorrhagic Diatheses)",
    "Object2": [
      "Coagulation defects",
      "Platelet disorders",
      "Vessel wall abnormalities"
    ],
    "Object3": [],
    "Object4": [
      "Generalized hemostatic defect (bleeding from multiple sites, spontaneous, excessive after injury).",
      "Platelet/vascular disorders: Spontaneous onset, immediately after trauma/surgery, petechiae, purpura, ecchymosis, bleeding from nose/mouth/GI/GU tracts. No bleeding into joints/muscles.",
      "Coagulation disorders: Delayed bleeding after trauma/surgery, hematomas, bleeding into deep tissues, common into joints/muscles, uncommon from mucous membranes."
    ],
    "Object5": [
      "Petechiae (Fig. 8.40A), purpura (Fig. 8.40B), ecchymoses (Fig. 8.40C).",
      "Hemarthrosis (joints - knees, ankles, elbows).",
      "Scars over elbows/knees (factor XIII deficiency).",
      "Signs of liver cell disease.",
      "Neurological signs.",
      "Hepatosplenomegaly and lymphadenopathy."
    ],
    "Object6": [
      "History: Generalized hemostatic defect? Inherited or acquired? Bleeding pattern (platelet/vascular vs. coagulation defect)?",
      "Screening tests (Table 8.63): Blood count and film (platelet count, morphology), Bleeding time (<9 min normal, prolonged in platelet disorders), Prothrombin time (PT - 12-14 sec normal, extrinsic pathway factors II, V, VII, X), Activated partial thromboplastin time (APTT - 33-45 sec normal, intrinsic pathway factors II, V, VIII, IX, X, XI, XII), Thrombin time (TT - 3-5 sec > control, common pathway factors I, II), Clot retraction (platelets), Fibrinogen concentration, Fibrin degradation products (FDPs).",
      "Correction tests/mixing studies (differentiates factor deficiency from inhibitor).",
      "Factor assays (confirms coagulation defects).",
      "Special tests of coagulation (fibrinogen, FDPs)."
    ],
    "Object7": [
      "Treat underlying cause.",
      "Replacement therapy for specific factor deficiencies."
    ],
    "Object8": [
      "Hemarthrosis (coagulation disorders).",
      "Cerebral hemorrhage (severe thrombocytopenia)."
    ]
  },
  {
    "Object1": "Thrombocytopenia",
    "Object2": [
      "Immune mediated (Primary ITP - acute/chronic; Secondary - SLE, AIDS, Hepatitis C, viral infections, drug-induced)",
      "Non-immune mediated (DIC, TTP, HUS, mechanical destruction, microangiopathic hemolytic anemias)",
      "Decreased production (Generalized BM diseases - aplastic anemia, marrow infiltration, selective impairment - drug-induced, infections, ineffective megakaryopoiesis - megaloblastic anemia, MDS; Congenital - Kostmann syndrome)",
      "Sequestration (Hypersplenism)",
      "Dilutional"
    ],
    "Object3": [
      "Decrease in platelet count below 150,000/µL.",
      "Increased platelet destruction.",
      "Decreased production of platelets.",
      "Sequestration (hypersplenism).",
      "Dilutional (massive transfusion)."
    ],
    "Object4": [
      "Bleeding into skin (purpura, petechiae, ecchymoses).",
      "Bleeding into mucous membranes (epistaxis, hemorrhagic bullae in oral mucosa, GU bleeding, GI bleeding).",
      "Fundal hemorrhage, intracranial bleeding (severe thrombocytopenia)."
    ],
    "Object5": [
      "Purpura, petechiae, ecchymoses.",
      "Hemorrhagic bullae in oral mucosa."
    ],
    "Object6": [
      "Platelet count (reduced, correlates with clinical manifestations).",
      "Hess test (capillary fragility test/tourniquet test) (positive in vascular purpura, defective platelet function, thrombocytopenia, scurvy).",
      "Bleeding time (prolonged, relates to platelet count).",
      "Bone marrow (normal/increased megakaryocytes indicates increased destruction/hypersplenism/ineffective production; decreased megakaryocytes indicates reduced production)."
    ],
    "Object7": [
      "Treatment of underlying cause.",
      "Platelet transfusions (for severe bleeding, or to achieve safe counts for procedures).",
      "Corticosteroids (for immune-mediated thrombocytopenia).",
      "Splenectomy (for refractory immune-mediated thrombocytopenia).",
      "Immunosuppressants (for secondary or refractory cases)."
    ],
    "Object8": [
      "Intracranial bleeding (serious and fatal, with platelet count <10,000/µL)."
    ]
  },
  {
    "Object1": "Qualitative Platelet Defects",
    "Object2": [
      "Hereditary (Disorders of platelet adhesion - Bernard-Soulier syndrome; Disorders of platelet secretion - Storage pool deficiency; Disorders of platelet aggregation - Glanzmann thrombasthenia)",
      "Acquired (Drugs - Aspirin, NSAID, dipyridamole, sulfinpyrazone; Renal failure (uremia); Hematologic malignancies - myeloproliferative, myelodysplastic disorders)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Bleeding time (prolonged).",
      "Platelet function tests."
    ],
    "Object7": [
      "Treatment of underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Immune Thrombocytopenic Purpura (ITP)",
    "Object2": [
      "Primary (Acute, Chronic)",
      "Secondary (SLE, AIDS, Hepatitis C, viral infections, drug therapy)"
    ],
    "Object3": [
      "Autoimmune disorder, increased destruction of platelets by autoantibodies (against platelet membrane GPIIb/IIIa and GPIb/IX).",
      "Antiplatelet antibodies (IgG type, in ~80% patients)."
    ],
    "Object4": [
      "Nonspecific symptoms due to thrombocytopenia in general.",
      "Bleeding into skin (purpura, petechiae, ecchymoses), mucous membranes (epistaxis, hemorrhagic bullae, GU/GI bleeding), fundal hemorrhage, intracranial bleeding (ICH), hematuria.",
      "Malaise, fatigue.",
      "Menorrhagia, epistaxis."
    ],
    "Object5": [
      "No physical signs other than those due to bleeding and anemia.",
      "No splenomegaly or lymphadenopathy (in primary ITP).",
      "Petechiae, purpura, ecchymoses.",
      "Hemorrhagic bullae in oral mucosa.",
      "Anemia (following hemorrhage)."
    ],
    "Object6": [
      "Diagnosis by exclusion (isolated thrombocytopenia without another cause).",
      "Platelet count: Markedly reduced (<80 x 10^9/L, often <20,000/µL). Repeat count with sodium citrate to exclude pseudothrombocytopenia.",
      "Tourniquet test (Hess test): Positive.",
      "Bleeding time (BT): Prolonged.",
      "Bone marrow examination: Normal or increased megakaryocytes (indicates increased destruction/ineffective production, rather than decreased production).",
      "Antiplatelet antibodies (not widely available, negative test does not exclude ITP).",
      "Exclude secondary causes (HIV, HCV, etc.)."
    ],
    "Object7": [
      "Children with mild acute ITP: Usually no treatment.",
      "Adults with platelet counts >30 x 10^9/L: Usually no treatment. Treat lower counts if spontaneous bruising/bleeding.",
      "Indications for treatment: Overt hemorrhage (platelet concentrates). Platelet counts <20,000/mm3. Organ/life-threatening bleeding (irrespective of count).",
      "Platelet transfusion (if platelet count <3,000/mm3 or bleeding).",
      "First-line therapy: Oral corticosteroids (prednisolone 1-2 mg/kg/day for 2-4 weeks, then slow reduction).",
      "Second-line therapy: Splenectomy (for chronic ITP failing corticosteroids, or needing high doses, or severe bleeding/threatening cerebral hemorrhage, or during pregnancy).",
      "Third-line therapy (for non-responders to splenectomy): High dose corticosteroids, Intravenous immunoglobulin (IVIg) (0.4 g/kg/day for 5 days) (transient response). Rho(D) immune globulin (anti-D) (75 µg/kg IV for Rh-positive patients). Immunosuppressive drugs (vinca alkaloids, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil). Plasmapheresis. TPO mimetic drugs (eltrombopag, romiplostim). Rituximab. Danazol. Dapsone.",
      "Emergency treatment: IV methylprednisolone (30 mg/kg) + platelet transfusion, followed by IV immunoglobulin (1 g/kg)."
    ],
    "Object8": [
      "Intracranial hemorrhage (serious and fatal).",
      "Autoimmune hemolytic anemia and/or neutropenia (Evan's syndrome) (may be associated).",
      "Relapse common after corticosteroid dose reduction.",
      "Neutropenia, hemolytic anemia (IVIg side effects)."
    ]
  },
  {
    "Object1": "Thrombocytosis",
    "Object2": [
      "Idiopathic/primary (autonomous production - myeloproliferative neoplasms)",
      "Secondary (reactive thrombocytosis)"
    ],
    "Object3": [
      "Platelet count >4,50,000/cumm.",
      "Primary (autonomous production): Myeloproliferative neoplasms (Essential thrombocytosis, Polycythemia vera, CML, Myelodysplastic syndrome).",
      "Secondary (reactive thrombocytosis): Iron deficiency, Malignancy (paraneoplastic), Following hemorrhage (acute or chronic), Following splenectomy, Following major surgery, Inflammatory disorders (RA, IBD)."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Platelet count."
    ],
    "Object7": [
      "Treat underlying cause (for secondary thrombocytosis).",
      "For primary thrombocytosis, treatment depends on specific MPN."
    ],
    "Object8": [
      "Thrombotic and hemorrhagic complications (especially in primary thrombocytosis)."
    ]
  },
  {
    "Object1": "Hereditary Coagulation Disorders",
    "Object2": [
      "von Willebrand disease (vWD)",
      "Hemophilia A (Factor VIII deficiency)",
      "Hemophilia B (Factor IX deficiency)",
      "Hemophilia C (Factor XI deficiency - Rosenthal syndrome)"
    ],
    "Object3": [
      "Genetic defects leading to deficiency or dysfunction of specific coagulation factors.",
      "Hemophilia A: X-linked recessive, reduction in factor VIII amount/activity. ~30% de novo mutations.",
      "Hemophilia B: X-linked disorder, deficiency of factor IX.",
      "Hemophilia C: Autosomal recessive, deficiency of factor XI."
    ],
    "Object4": [
      "Hemophilia A: Excessive bleeding (unusual <6 months). 'Delayed' post-traumatic bleeding. Spontaneous hemorrhage into large joints (knees, elbows, ankles, wrists, hips - hemarthrosis). Bleeding into muscles (calf, psoas hematomas). Easy bruising. Massive bleeding after trauma/surgery. Cerebral hemorrhage. Hematuria, ureteric colic (blood clots).",
      "Hemophilia B: Similar to Hemophilia A. Muscle hematomas, hemarthrosis (severe disease)."
    ],
    "Object5": [
      "Hemophilia A: Hemarthrosis (swollen, hot, tender, restricted movements). Psoas hematomas (femoral nerve compression - sensory disturbances, quadriceps weakness). Calf hematomas (Achilles tendon shortening).",
      "Hemophilia B: Crippling joint deformities."
    ],
    "Object6": [
      "Hemophilia A: Bleeding time normal. Clotting time prolonged. Platelet count normal. PT normal. APTT increased (50s to minutes). Factor VIII assay (confirms diagnosis, assesses level/severity). Antenatal Diagnosis: Chorionic villous sampling (sexing, factor VIII probes). Amniocentesis (sexing, fetal blood sampling).",
      "Hemophilia B: Factor IX assay (confirms deficiency)."
    ],
    "Object7": [
      "Hemophilia A:",
      "Local treatment: Local pressure/bandages/sutures for wounds/mucous membrane bleeding. Immobilize wounds. Elevate/immobilize hematomas/hemarthrosis; analgesics; physiotherapy (recovery).",
      "Replacement therapy (Factor VIII concentrate): Recombinant products are treatment of choice. IV infusion to correct deficiency. Indications: Early spontaneous bleeding, severe/prolonged wound/tissue bleeding, bleeding during/after surgery/trauma, prophylaxis (in severe hemophilia). Dose: Factor VIII (1 unit/kg increases activity by 2%). Calculated as: Desired factor level (%) x body weight (kg) x 0.5.",
      "Nontransfusion therapy: DDAVP (desmopressin) (0.3 µg/kg IV) (transient rise in factor VIII activity 3-5x) for minor bleeding/surgery. Antifibrinolytic drugs (epsilon aminocaproic acid (EACA), tranexamic acid) (inhibit plasmin) for local hemostasis in gums, nasal/GI bleeding, oral surgery/menstruation. Contraindicated in hematuria, DIC, thromboembolic disease.",
      "Treatment for Factor VIII inhibitors: Immune tolerance induction (ITI). Emicizumab (bifunctional monoclonal antibody, substitutes for factor VIII).",
      "Hemophilia B: Similar to Hemophilia A. Replacement therapy: Fresh frozen plasma (mild-moderate bleeding). Recombinant factor IX (moderate-severe bleeding). Gene therapy. Desmopressin ineffective."
    ],
    "Object8": [
      "Hemophilia A: Recurrent bleeding into joints (crippling deformities, disuse atrophy). Muscle hematomas (femoral nerve compression, Achilles tendon shortening). Cerebral hemorrhage. Viral Hepatitis (HBV, HCV), HIV. Factor VIII inhibitors (15%). Arthropathy.",
      "Hemophilia B: Crippling joint deformities."
    ]
  },
  {
    "Object1": "von Willebrand's Disease (vWD)",
    "Object2": [
      "Type 1 (autosomal dominant, quantitative deficiency in vWF, relatively mild)",
      "Type 2 (qualitative defects/dysfunction in vWF, autosomal dominant, ~25% cases, subtypes: 2a - defective multimer assembly, 2b - abnormal vWF with increased platelet affinity)",
      "Type 3 (autosomal recessive, quantitative deficiency in vWF, severe)"
    ],
    "Object3": [
      "Deficiency or dysfunction of von Willebrand factor (vWF). VWF gene located on chromosome 12, numerous mutations.",
      "Acquired causes (Box 8.26): Hematologic disorders (lymphoproliferative, myeloproliferative neoplasms - ET), SLE/autoimmune, Cardiovascular disease (congenital heart disease, aortic stenosis, LV assist device, ECMO), Wilms tumor, Hypothyroidism, Valproic acid and other medications."
    ],
    "Object4": [
      "Variable (mild asymptomatic to severe hemorrhagic disorder).",
      "Spontaneous bleeding from mucous membranes (epistaxis), excessive bleeding from wounds, menorrhagia. In severe cases, similar to hemophilia A."
    ],
    "Object5": [],
    "Object6": [
      "Platelet count: Normal (Type 2b may have thrombocytopenia).",
      "Bleeding time: Prolonged (despite normal platelet count) due to defect in platelet function.",
      "Tourniquet test (Hess test): Positive (defect in platelet adhesion).",
      "APTT: Prolonged (vWF deficiency causes secondary reduction of factor VIII).",
      "vWF assay: Plasma level of active vWF decreased.",
      "Platelet function test: Defective ristocetin-induced platelet aggregation (diagnostic)."
    ],
    "Object7": [
      "Management of bleeding:",
      "Mild bleeding: Desmopressin.",
      "Severe bleeding: IV cryoprecipitate or plasma-derived concentrates containing vWF and factor VIII. Recombinant activated factor VII (rFVIIa) for severe hemorrhage refractory to vWF replacement.",
      "Vitamin K deficiency: Vitamin K 5-10 mg stops bleeding in 1-2 days. Fresh blood/FFP for severe blood loss or inadequate vitamin K response."
    ],
    "Object8": [
      "Severe hemorrhagic disorder (in severe forms).",
      "Secondary reduction of factor VIII (due to vWF deficiency).",
      "Thrombocytopenia (Type 2b)."
    ]
  },
  {
    "Object1": "Microangiopathic Hemolytic States and Thrombocytopenias",
    "Object2": [
      "Thrombotic Thrombocytopenic Purpura (TTP)",
      "Hemolytic-Uremic Syndrome (HUS)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Thrombotic Thrombocytopenic Purpura (TTP)",
    "Object2": "Severe microangiopathic hemolytic anemia (MAHA)",
    "Object3": [
      "Inherited or acquired deficiency of ADAMTS-13 (plasma protease enzyme that regulates vWF activity by cleaving large multimers).",
      "Accumulation of unusually large multimers of vWF in plasma.",
      "Promotes platelet adhesion/intravascular platelet aggregation, spontaneous activation of coagulation cascade.",
      "Results in hyaline thrombi throughout microcirculation, leading to tissue ischemia and infarction.",
      "Secondary causes: Pregnancy, oral contraceptives, SLE, infection, drugs (ticlopidine, clopidogrel)."
    ],
    "Object4": [
      "Transient neurologic symptoms (CNS ischemia).",
      "Fever.",
      "Renal abnormalities (hematuria and/or proteinuria)."
    ],
    "Object5": [
      "Classic five symptoms: (1) Microangiopathic hemolytic anemia (MAHA) with schistocytosis (≥3 cells/100). (2) Severe thrombocytopenia. (3) Transient neurologic symptoms. (4) Fever. (5) Renal abnormalities.",
      "Profound thrombocytopenia (often <20,000/µL).",
      "Fragmentation of erythrocytes (schistocytes in peripheral blood).",
      "Organ ischemia (due to systemic platelet aggregation, hyaline thrombi)."
    ],
    "Object6": [
      "Platelet count: Markedly reduced (often <20,000/µL).",
      "Peripheral blood smear: Fragmented red cells (schistocytes), numerous reticulocytes.",
      "Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen concentration: Normal (coagulation system not activated).",
      "Urine: Moderate proteinuria, gross/microscopic hematuria.",
      "Serum LDH: Raised (release from ischemic tissues).",
      "ADAMTS-13 activity: Reduced below 5-10% of normal.",
      "Schistocytes and elevated serum LDH (out of proportion to hemolysis) suggest diagnosis."
    ],
    "Object7": [
      "Plasma exchange (daily, removing 40 ml/kg plasma, replacing with FFP) (treatment of choice). Continued for ≥2 days after remission (stabilization of symptoms, normal platelet count/LDH, rising Hb).",
      "Cryoprecipitate and FFP (also contain ADAMTS-13).",
      "Corticosteroids: Pulsed IV methylprednisolone (acutely, with plasma exchange) to suppress antibody formation.",
      "Rituximab (monoclonal antibody against CD20): For refractory to plasma exchange/corticosteroids.",
      "Splenectomy: For resistant cases (removes antibody-producing cells).",
      "Platelet concentrates are contraindicated."
    ],
    "Object8": [
      "Organ ischemia (transient neurologic symptoms, renal abnormalities).",
      "Tissue ischemia and infarction.",
      "Mortality up to 90% if untreated (reduced to ~10% with modern management)."
    ]
  },
  {
    "Object1": "Hemolytic-Uremic Syndrome (HUS)",
    "Object2": "Not specified",
    "Object3": [
      "Damage to endothelium by toxins, drugs or radiation.",
      "Infectious gastroenteritis caused by Escherichia coli strain 0157:H7 (main cause in children/elderly).",
      "E. coli produces Shiga-like toxin, absorbed from inflamed GI mucosa, damages endothelial cells of microvasculature (mainly renal glomerular capillaries), initiates platelet activation and thrombi formation."
    ],
    "Object4": [
      "Children (1-5 years): Few days after bloody diarrhea.",
      "Adults: After certain drugs, radiation therapy.",
      "Classic triad: Microangiopathic hemolytic anemia, thrombocytopenia, acute renal failure (oliguria).",
      "Hematuria and hypertension (common).",
      "Bleeding manifestations (rare, despite thrombocytopenia)."
    ],
    "Object5": [
      "Absence of fever and neurological symptoms (distinguishes from TTP).",
      "Prominence of acute renal failure (uremia).",
      "Oliguria.",
      "Pulmonary edema, hypertensive encephalopathy (fluid overload complications)."
    ],
    "Object6": [
      "Hemoglobin levels: Decreased (anemia).",
      "Platelet count: Markedly reduced (often <20,000/µL).",
      "Peripheral blood smear: Fragmented red cells (schistocytes), numerous reticulocytes.",
      "LDH: Elevated.",
      "Blood urea and creatinine: Elevated.",
      "Urine: Proteinuria, red blood cells.",
      "PT and aPTT: Normal.",
      "Stool: Culture for enterohemorrhagic E.coli (positive); Shiga toxin (positive)."
    ],
    "Object7": [
      "Supportive care: For renal and hematological complications.",
      "Antibiotics: If shigellosis suspected/detected (caution, may worsen toxin release).",
      "Experimental: Eculizumab (monoclonal antibody to C5)."
    ],
    "Object8": [
      "Acute renal failure (uremia).",
      "Fluid overload (pulmonary edema, hypertensive encephalopathy).",
      "Renal damage (in severe cases, may lead to death)."
    ]
  },
  {
    "Object1": "Disseminated Intravascular Coagulation (DIC)",
    "Object2": "Widespread acute or chronic thrombohemorrhagic disorder",
    "Object3": [
      "Secondary complication of a wide variety of disorders (Table 8.74): Infections (Gram-negative bacterial sepsis, Meningococcemia, other bacteria, Fungi, viruses, Rocky mountain spotted fever, Malaria), Obstetric complications (Retained dead fetus, Septic abortion, Abruptio placentae, Amniotic fluid embolism, Toxemia and preeclampsia), Neoplasms (Carcinomas of pancreas, prostate, lung, stomach, Acute promyelocytic leukemia), Massive tissue injury (Traumatic, Burns, Fat embolism, Surgery), Vascular disorders (Aortic aneurysm, giant hemangioma), Miscellaneous (Snakebite, liver disease, acute intravascular hemolysis, shock, heat stroke, hypersensitivity vasculitis).",
      "Procoagulants enter circulation, tissue injury releases tissue factor, endothelial injury activate coagulation.",
      "Circulating thrombi form, occluding microvasculature. RBCs trapped in thrombi undergo fragmentation.",
      "Exposure to subendothelial tissue, platelet activation. Consumption of coagulation factors, thrombocytopenia. Activation of secondary fibrinolysis, fibrin degradation products."
    ],
    "Object4": [
      "Symptoms depend on nature, intensity, duration of underlying disorder.",
      "Acute DIC: Bleeding (most common): ecchymoses, petechiae, bleeding from mucous membranes/venipuncture sites.",
      "Microvascular thrombi: Ischemic necrosis of organ, resultant dysfunction (hepatic, renal, cardiac, respiratory failure, neurological disturbances), gangrene of extremities, hemorrhagic necrosis of skin.",
      "Organ dysfunction: Multifocal, delirium, coma (CNS). Cortical necrosis-oliguria, azotemia (renal). Focal ischemic necrosis, gangrene (skin). Acute ulceration (GI). ARDS (respiratory).",
      "Hemorrhagic diathesis: Intracerebral bleeding, hematuria, petechiae, ecchymoses, bleeding at venipuncture sites, massive bleeding (epistaxis, gingival bleeding)."
    ],
    "Object5": [
      "Bleeding manifestations (petechiae, ecchymoses, bleeding from mucous membranes or venipuncture sites).",
      "Signs of organ dysfunction (hepatic, renal, cardiac, respiratory, neurological).",
      "Gangrene of extremities and hemorrhagic necrosis of the skin.",
      "Waterhouse-Friderichsen syndrome (occult thrombosis of adrenal vein, adrenal hemorrhage).",
      "Trousseau sign (migratory venous thrombosis in cancers).",
      "Multiorgan dysfunction syndrome (MODS) (frequent consequence)."
    ],
    "Object6": [
      "ESR: Low.",
      "Peripheral smear: Presence of schistocytes (fragmented RBCs).",
      "Screening assays:",
      "Platelet count: Decreased.",
      "Prothrombin time (PT): Increased.",
      "APTT: Increased.",
      "Thrombin time (TT): Increased.",
      "Plasma fibrinogen: Decreased.",
      "Confirmatory tests:",
      "FDP (fibrin degradation products): Elevated.",
      "D-dimer test: Elevated (specific for DIC)."
    ],
    "Object7": [
      "Control or elimination of underlying cause.",
      "Correction of precipitating factors (acidosis, dehydration, sepsis, hypoxia).",
      "Management of hemorrhagic symptoms: Maintain blood volume and tissue perfusion. Transfusions (platelet concentrates 1-2 units/10 kg, FFP 15-20 mL/kg, cryoprecipitate 1 unit/10 kg, red cell concentrates).",
      "Drugs to control coagulation (heparin, antifibrinolytic drugs - in specific cases).",
      "Heparin (low doses, 5-10 U/kg per h IV infusion) for thrombotic manifestations, after bleeding corrected. Indications: Purpura fulminans, surgical resection of giant hemangiomas, dead fetus removal, acute promyelocytic leukemia.",
      "Antifibrinolytic drugs (EACA, tranexamic acid): Prevent fibrin degradation. Increase risk of thrombosis, concomitant heparin indicated."
    ],
    "Object8": [
      "Thrombosis and hemorrhage.",
      "Microvascular thrombi lead to ischemic tissue necrosis and organ dysfunction.",
      "Waterhouse-Friderichsen syndrome.",
      "Multiorgan dysfunction syndrome (MODS) (frequent consequence).",
      "Bleeding into organs or thrombotic alteration in various organ systems."
    ]
  },
  {
    "Object1": "Blood Transfusion Complications",
    "Object2": [
      "Immunological Complications (Immediate: Acute hemolytic transfusion reaction, Febrile non-hemolytic reaction, Allergic reaction - urticaria, Anaphylactic reactions, Transfusion-related acute lung injury (TRALI); Delayed: Alloimmunization, Delayed hemolytic transfusion reactions, Transfusion associated graft versus host disease, Post-transfusion purpura)",
      "Non-Immunological Complications (Immediate: Circulatory overload, Air embolism; Late: Iron overload - transfusion hemosiderosis, Thrombophlebitis, Infections - Hepatitis (HBV, HCV, HDV), HIV, Malaria, Cytomegalovirus, Syphilis)"
    ],
    "Object3": [
      "Immunological:",
      "Acute hemolytic: Transfusion of incompatible donor red cells (ABO incompatibility), clerical errors.",
      "Febrile non-hemolytic (FNHTR): Leukocyte antibodies in recipient (previous transfusions/pregnancy), release of cytokines from donor leukocytes.",
      "Allergic (urticaria): Plasma-protein incompatibility, antibodies to infused plasma proteins, allergens reacting with IgE antibodies.",
      "Anaphylactic: Antibodies against IgA in IgA deficient recipients.",
      "TRALI: Donor plasma with high-titer anti-HLA antibodies binding recipient leukocytes, causing aggregation in pulmonary vasculature and mediator release.",
      "Delayed hemolytic: Previously sensitized to RBC alloantigens (Rh, Kidd, Kell, Duffy), low antibody level undetectable by pretransfusion testing.",
      "TA-GVHD: Donor blood products with mature T lymphocytes recognizing host HLA antigens.",
      "Post-transfusion purpura: Antibodies against human platelet antigens (HPAs).",
      "Non-immunological:",
      "Circulatory overload: Elderly, pregnant, reduced cardiac/renal function.",
      "Air embolism: Old transfusion from glass bottle.",
      "Iron overload (transfusion siderosis): Multiple transfusions over years.",
      "Thrombophlebitis: Indwelling catheters.",
      "Infections: Transfusion of infected blood (AIDS, hepatitis, HTLV-I/II, malaria, CMV, syphilis).",
      "Massive transfusion (>10 units RBCs or 1 blood volume in 24h): Dilutional coagulopathy, circulatory overload, hyperkalemia, hypoglycemia, hypothermia, citrate-induced hypocalcemia."
    ],
    "Object4": [
      "Acute Hemolytic: Fever with chills, pain in lumbar region, dyspnea, pruritus, burning sensation at transfusion site/along vein, chest pain. In unconscious: hypotension, shock, intravascular hemolysis (hemoglobinuria, oliguria, acute renal failure), excessive bleeding (DIC).",
      "Febrile Non-Hemolytic (FNHTR): Flushing, tachycardia, fever (>38°C), chills, rigors.",
      "Allergic (Urticaria): Hives, itching.",
      "Anaphylactic: Difficulty breathing, coughing, nausea/vomiting, hypotension, bronchospasm, loss of consciousness, respiratory arrest, shock.",
      "TRALI: Acute respiratory distress, fever, cough, shortness of breath.",
      "TA-GVHD: Fever, generalized skin rash, jaundice (abnormal LFTs), diarrhea, pancytopenia.",
      "Post-transfusion purpura: Thrombocytopenia, bleeding.",
      "Circulatory overload: Acute pulmonary edema.",
      "Iron overload: Symptoms of organ damage (heart/liver failure, endocrinopathies)."
    ],
    "Object5": [
      "Acute Hemolytic: Fever, chills, lumbar pain, dyspnea, pruritus, burning sensation, chest pain. Hemoglobinuria, oliguria, hypotension, shock, DIC. Incompatibility.",
      "Febrile Non-Hemolytic (FNHTR): Flushing, tachycardia, fever, chills, rigors.",
      "TRALI: Bilateral interstitial infiltrates on chest X-ray.",
      "TA-GVHD: Generalized skin rash, jaundice, diarrhea, pancytopenia (marrow failure).",
      "Post-transfusion purpura: Severe thrombocytopenia, bleeding.",
      "Iron overload: Signs of organ damage from iron deposition."
    ],
    "Object6": [
      "Acute Hemolytic: Hemoglobinuria, incompatibility (donor/recipient). Coagulation screening (PT, platelet count, fibrinogen, FDPs). LDH, haptoglobin, indirect bilirubin.",
      "TRALI: Chest X-ray (bilateral interstitial infiltrates).",
      "Post-transfusion purpura: Antibodies against human platelet antigens (HPAs)."
    ],
    "Object7": [
      "Acute Hemolytic: Stop transfusion, change set, maintain venous access with normal saline. Physical exam (BP, urine output, bleeding). Withdraw new blood samples from patient, send with donor units to lab. Centrifuge sample for free hemoglobin. Coagulation screen for DIC. Lab evaluation for hemolysis. IV fluids, vasopressors for hypotension. Furosemide for urine output. Emergency treatment as needed.",
      "Febrile Non-Hemolytic (FNHTR): Antipyretics (acetaminophen). Leukocyte-reduced blood products for future transfusions.",
      "Allergic (Urticaria): Stop/slow transfusion. Chlorpheniramine 10 mg IV. Antihistamines for future transfusions.",
      "Anaphylactic: Stop transfusion, maintain vascular access. Epinephrine (adrenaline) 0.5 mg IM, chlorpheniramine 10 mg IV, IV glucocorticoids, endotracheal intubation (severe cases). Transfuse IgA-deficient patients with IgA-deficient blood.",
      "TRALI: Supportive. Recover usually without sequelae.",
      "Delayed Hemolytic: No specific therapy usually. Corticosteroids for severe cases.",
      "TA-GVHD: Highly resistant to immunosuppressive therapies. Prevention: Irradiated blood/components for at-risk patients.",
      "Post-transfusion purpura: High-dose IVIg (0.4 g/kg/day for 5 days). Plasmapheresis. Platelet transfusions ineffective, worsen thrombocytopenia.",
      "Circulatory overload: Reduce infusion rate, sit patient up, diuretics. Phlebotomy if severe.",
      "Iron overload: Iron chelating agents.",
      "Infections: Prevention by screening donors."
    ],
    "Object8": [
      "Acute Hemolytic: Acute renal failure, DIC, shock, death.",
      "Anaphylactic: Respiratory arrest, shock, death.",
      "TRALI: Life-threatening acute respiratory distress syndrome.",
      "TA-GVHD: Potentially fatal, develops 8-10 days after transfusion, death at 3-4 weeks. Pancytopenia (marrow failure).",
      "Iron overload: Heart/liver failure, endocrinopathies.",
      "Massive transfusion: Dilutional coagulopathy, circulatory overload, hyperkalemia, hypoglycemia, hypothermia, citrate-induced hypocalcemia."
    ]
  },
  {
    "Object1": "Hematopoietic Stem Cell (HSC) Transplantation",
    "Object2": [
      "Autologous ('from self')",
      "Allogeneic ('from different genes')",
      "Syngeneic ('from same genes')"
    ],
    "Object3": [
      "Purpose: Repopulate or replace totally or partly recipient's hematopoietic system.",
      "Stem cells obtained from bone marrow, peripheral blood, or umbilical cord blood.",
      "Autologous: Patient's own HSCs removed, stored, reinfused after high-dose therapy. Does not require immunosuppression.",
      "Allogeneic: HSCs from HLA-matched (sibling/unrelated) or HLA-mismatched donor. Requires immunosuppression to prevent graft rejection and GVHD.",
      "Conditioning regimens (myeloablative or non-myeloablative) before transplant: Eradicate malignant cells, make space for HSCs, induce immunosuppression."
    ],
    "Object4": [
      "Complications of conditioning regimens: Infections, nausea, vomiting, alopecia, mucositis, interstitial pneumonia, veno-occlusive disease of liver.",
      "Acute GVHD: Exfoliative dermatitis, diarrhea, hepatitis, cholestasis.",
      "Chronic GVHD: Affects skin, GI tract, liver, eyes, lungs, joints. May develop bacterial/opportunistic viral/fungal infections.",
      "Infections: Bacterial, viral, fungal (during 3 phases after transplant).",
      "VOD: Jaundice, ascites, tender hepatomegaly."
    ],
    "Object5": [
      "Engraftment (recovery of neutrophil count >500 mm³ for 3 consecutive days).",
      "Conditioning regimens: Alopecia, mucositis, interstitial pneumonia, veno-occlusive disease of liver (jaundice, ascites, tender hepatomegaly).",
      "Acute GVHD: Exfoliative dermatitis, diarrhea, hepatitis, cholestasis.",
      "Pancytopenia (after conditioning)."
    ],
    "Object6": [
      "HLA matching (for allogeneic transplantation).",
      "Immunophenotyping (CD34+ for HSCs).",
      "Blood tests (monitor for infections, organ toxicity, GVHD).",
      "Biopsies (liver, skin, gut for GVHD, interstitial pneumonitis).",
      "Imaging (lung for interstitial pneumonitis, liver for VOD)."
    ],
    "Object7": [
      "Autologous HSC transplant: High-dose chemotherapy/radiation (myeloablation).",
      "Allogeneic HSC transplant: Conditioning (immunosuppression).",
      "GVHD: Methotrexate, cyclosporine, antithymocyte globulin, corticosteroids, monoclonal antibodies against T-cells.",
      "VOD: Tissue plasminogen activator (successful).",
      "Infections: Prophylactic and therapeutic antibiotics, antifungals, antivirals.",
      "Supportive care for pancytopenia, mucositis."
    ],
    "Object8": [
      "Autologous: Fewer immunological complications, higher relapse rates.",
      "Allogeneic: Lower relapse rates, more immunological complications (GVHD).",
      "GVHD (major complication of allogeneic): Acute (before 100 days, affects skin, GI tract, liver, causes exfoliative dermatitis, diarrhea, hepatitis, cholestasis). Chronic (after 100 days, affects skin, GI tract, liver, eyes, lungs, joints). Can be fatal.",
      "Infections: Bacterial, viral, fungal (during 3 phases post-transplant).",
      "Organ toxicity: GI tract, liver (VOD - often fatal), lungs (interstitial pneumonitis - fatal in some), kidneys.",
      "Late complications: Infertility, ovarian failure, secondary malignancies (AML, solid organ malignancies), osteoporosis/osteopenia, avascular necrosis, dental problems, cataracts, chronic fatigue, psychosocial effects, neurologic complications."
    ]
  },
  {
    "Object1": "Antiplatelet Drugs",
    "Object2": [
      "Cyclooxygenase Inhibitors (Aspirin)",
      "Adenosine Diphosphate (ADP) Receptor Antagonists on Platelets (Thienopyridines: Ticlopidine, Clopidogrel, Prasugrel)",
      "Adenosine Reuptake Inhibitors (Dipyridamole)",
      "Glycoprotein IIb/IIIa Receptor Antagonists (Inhibitors) (Abciximab, Eptifibatide, Tirofiban)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Platelet aggregation tests."
    ],
    "Object7": [
      "Aspirin (75-325 mg/day): Inhibits COX, prevents thromboxane A2 synthesis. For arthritis, secondary prevention of cardiovascular events (ACS, stable angina, CVA, PVD). Side effects: dyspepsia, gastritis, peptic ulcers with bleeding/perforation.",
      "Thienopyridines (Ticlopidine 250 mg BID; Clopidogrel 75 mg OD, loading dose 300 mg; Prasugrel loading dose 60 mg, maintenance 10 mg OD): Inhibit ADP-induced platelet aggregation. Reduces cardiovascular death, MI, stroke in atherosclerotic disease. Side effects: GI, hematologic (neutropenia, thrombocytopenia, TTP - ticlopidine). Clopidogrel/prasugrel have fewer side effects.",
      "Dipyridamole (25-75 mg 3-4x/day): Inhibits phosphodiesterase, blocks cAMP breakdown. Used with aspirin. Indications: CAD, ischemic stroke/TIA. Side effects: hypotension, GI, headache, dizziness.",
      "GPIIb/IIIa receptor antagonists (Abciximab, Eptifibatide, Tirofiban): Parenteral, used in ACS, unstable angina, NSTEMI, PCI. Side effects: bleeding, thrombocytopenia, hypotension (eptifibatide)."
    ],
    "Object8": [
      "Bleeding (major side effect for all).",
      "TTP (Ticlopidine).",
      "Neutropenia, thrombocytopenia (Ticlopidine).",
      "Gastric bleeding/ulceration (Aspirin).",
      "Hypotension (Dipyridamole, Eptifibatide)."
    ]
  },
  {
    "Object1": "Anticoagulants",
    "Object2": [
      "Parenteral (rapidly acting: Heparin - unfractionated/LMWH; Hirudins; Heparinoids; Indirect factor Xa inhibitors - fondaparinux/idraparinux)",
      "Oral (slow acting: Coumarin derivatives - warfarin sodium/dicoumarol; Indandione derivatives; Direct thrombin inhibitors - ximelagatran/dabigatran; Direct factor Xa inhibitors - rivaroxaban)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "APTT (unfractionated heparin, direct thrombin inhibitors).",
      "PT/INR (warfarin).",
      "Anti-Xa assay (LMWH, fondaparinux, rivaroxaban)."
    ],
    "Object7": [
      "Heparin (unfractionated): Mechanism: Activates antithrombin. Administered SC or continuous IV infusion. Dose: 5,000-10,000 units IV loading, then maintenance (continuous IV 1000 units/hr, or intermittent). Prophylaxis: 5000 units 12-8 hourly SC. Monitored by aPTT (1.5-2x control). Antidote: Protamine sulfate.",
      "Low-molecular weight heparins (LMWH): Mechanism: Inhibits factor Xa. Administered SC 1-2x/day. Predictable pharmacokinetics, no aPTT monitoring. Common: Enoxaparin, dalteparin, tinzaparin.",
      "Warfarin: Mechanism: Vitamin K antagonist, prevents synthesis of factors II, VII, IX, X, protein C/S. Monitored by PT (INR 1.5-3x control). Dose: 5 mg oral loading, adjusted daily. Duration: 3 months to lifelong. Antidotes: Vitamin K1 IV, FFP, prothrombin complex concentrate. Reversing warfarin (Table 8.87).",
      "Direct thrombin inhibitors (parenteral: Hirudin, lepirudin, bivalirudin, desirudin; oral: Ximelagatran, dabigatran etexilate). Mechanism: Directly inhibits thrombin. Monitoring: aPTT (hirudin), ACT (bivalirudin). Idarucizumab (monoclonal antibody) for dabigatran reversal.",
      "Direct factor Xa inhibitors (oral: Rivaroxaban). Mechanism: Reversible binds/inhibits factor Xa. Administered orally.",
      "Indirect factor Xa inhibitors (fondaparinux, idraparinux): Mechanism: Inactivates factor Xa by antithrombin. Use: HIT-type II."
    ],
    "Object8": [
      "Bleeding (major side effect for all).",
      "Heparin induced thrombocytopenia (HIT) (Type I: benign, platelet aggregation; Type II: immune-mediated, promotes thrombosis, can cause gangrene/necrosis with warfarin).",
      "Osteoporosis and osteomalacia (long-term heparin).",
      "Skin necrosis (warfarin).",
      "Teratogenic (warfarin in pregnancy).",
      "Drug interactions (many).",
      "Hemorrhage (dabigatran)."
    ]
  },
  {
    "Object1": "Fibrinolytic or Thrombolytic Agents",
    "Object2": [
      "Plasminogen activators (Streptokinase (STK), Urokinase (UK), human tissue plasminogen activator (tPA-alteplase), recombinant plasminogen activator (rPA-reteplase), tenecteplase, anisoylated plasminogen streptokinase activator complex (APSAC, anistreplase), single-chain urokinase plasminogen activator (scu-PA))"
    ],
    "Object3": [
      "Goal of therapy: Rapid dissolution of thrombus, restore blood flow.",
      "Mechanism: Convert proenzyme plasminogen to active enzyme plasmin. Plasmin degrades fibrin of thrombi, produces soluble fibrin degradation products.",
      "Fibrin-specific fibrinolytics (rPA, tenecteplase, scu-PA) generate plasmin at thrombus site.",
      "Non-fibrin-specific fibrinolytics (STK, UK) generate plasmin in systemic circulation."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Assessment of thrombus formation (angiography, CT).",
      "Monitoring of coagulation parameters (PT, APTT, fibrinogen, D-dimer)."
    ],
    "Object7": [
      "STK: From β-hemolytic streptococci, forms complex with plasminogen. Uses: Acute ST-elevation MI, pulmonary embolism. Side effects: allergic reactions, hypotension (if infused rapidly).",
      "UK: For patients who received STK in past 6 months. No allergic reaction.",
      "APSAC (anistreplase).",
      "rtPA (alteplase/activase): Acute thrombotic strokes (within 3 hours), acute MI, pulmonary embolism.",
      "Prourokinase (pro-UK).",
      "Others: Tenecteplase, desmoteplase, reteplase."
    ],
    "Object8": [
      "Hemorrhage (major complication).",
      "Allergic reactions (STK, APSAC).",
      "Hypotension (rapid STK infusion).",
      "Systemic lytic state (STK, UK) (reduction in blood viscosity, anticoagulant/antiplatelet effects)."
    ]
  },
  {
    "Object1": "Erythropoietin (EPO)",
    "Object2": [
      "Recombinant Human Erythropoietin (rHuEPO) (erythropoietin-α and erythropoietin-β)",
      "Darbepoietin Alpha"
    ],
    "Object3": [
      "Predominantly produced by juxtatubular interstitial cells of renal cortex, lesser in liver.",
      "Stimulus: Hypoxia (most potent), Anemia.",
      "Ectopic sources: Polycystic kidneys, Cerebellar hemangioblastoma, Uterine leiomyoma, Renal cell carcinoma, Hepatocellular carcinoma, Pheochromocytoma."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Serum EPO levels.",
      "Hemoglobin concentrations."
    ],
    "Object7": [
      "rHuEPO: For anemia associated with chronic renal failure, chronic inflammation, malignancy, zidovudine-induced anemia (HIV), anemic patients undergoing non-vascular surgery.",
      "Darbepoietin Alpha: Longer half-life, given less frequently. Not approved for zidovudine-induced anemia or perioperative blood loss."
    ],
    "Object8": [
      "Hypertension, bleeding, headache, arthralgia, nausea, edema, diarrhea.",
      "Increased risk of thrombosis.",
      "Pure red cell aplasia.",
      "Progression of cancers."
    ]
  },
  {
    "Object1": "Hemopoietic Growth Factors (HGFs)",
    "Object2": [
      "Erythropoietin (EPO)",
      "Granulocyte Colony Stimulating Factor (G-CSF)",
      "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)",
      "Thrombopoietin (TPO)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "EPO: Refer previous discussion.",
      "G-CSF: Primary prophylaxis (reduce febrile neutropenia post-chemotherapy). Accelerate hemopoietic recovery (post-chemotherapy, autologous HCT). Secondary prophylaxis (solid tumors, previous febrile neutropenia). For neutropenia with fever (high risk of infection-related complications, prolonged/severe neutropenia). Mobilizing stem cells from bone marrow for SCT. Dose: 15 µg/kg daily SC. Pegylated form for longer action.",
      "GM-CSF: Similar efficacy and indications to G-CSF. Dose: 250 µg/m² daily SC.",
      "TPO: Reduces post-chemotherapy thrombocytopenia duration. Undergoing clinical trials for ITP."
    ],
    "Object8": [
      "G-CSF: May develop AML/MDS (chemotherapy for breast carcinoma). Fever, bone/joint pains (side effects).",
      "TPO: Antibodies against TPO (disadvantage in treatment)."
    ]
  },
  {
    "Object1": "Vitamin K Deficiency",
    "Object2": "Not specified",
    "Object3": [
      "Inadequate stores (hemorrhagic disease of newborn, severe malnutrition with antibiotics).",
      "Defective absorption (diseases interfering with fat absorption: obstructive jaundice (lack of bile salts), pancreatic disease, small bowel disease).",
      "Oral anticoagulant drugs (warfarin therapy)."
    ],
    "Object4": [
      "Bleeding/hemorrhagic state (manifestation of deficiency)."
    ],
    "Object5": [
      "Ecchymoses, bleeding from injection sites, bruises, gum bleeding, hematemesis, melaena, hematuria."
    ],
    "Object6": [
      "Prothrombin time (PT) prolonged.",
      "Activated partial thromboplastin time (APTT) prolonged."
    ],
    "Object7": [
      "Dramatic response to parenteral vitamin K therapy. Dose: Daily 10 mg injections of vitamin K.",
      "Vitamin K may not be effective in liver cell disease."
    ],
    "Object8": [
      "Hemorrhagic disease of the newborn."
    ]
  },
  {
    "Object1": "Splenomegaly",
    "Object2": "Not specified",
    "Object3": [
      "Increased splenic weight (>250g in adult)",
      "Immune response work hypertrophy (SBE, infectious mononucleosis).",
      "RBC destruction work hypertrophy (hereditary spherocytosis, thalassemia major).",
      "Congestive (Splenic vein thrombosis, portal hypertension).",
      "Myeloproliferative (Chronic myeloid metaplasia).",
      "Infiltrative (Sarcoidosis, some neoplasms).",
      "Neoplastic (CLL, lymphomas).",
      "Miscellaneous (Trauma, cysts).",
      "Diseases (Table 8.92): Acute infections (IM, viral hepatitis, septicemia, typhoid, CMV, toxoplasmosis). Subacute/chronic infections (miliary TB, SBE, brucellosis, syphilis, HIV). Tropical/parasitic (malaria, leishmaniasis/kala-azar, schistosomiasis). Hematological disorders (MPN, lymphoma, leukemia, RBC disorders). Congestive (cirrhosis, splenic/portal/hepatic vein thrombosis, CHF). Inflammatory (collagen diseases, granulomatous - sarcoidosis). Neoplastic (hemangioma, metastasis). Infiltrative (Gaucher's, amyloidosis). Miscellaneous (cysts).",
      "Asymptomatic (Table 8.93): Liver disease with portal hypertension, splenic vein thrombosis, agnogenic myeloid metaplasia, Gaucher's disease, splenic cysts, sarcoidosis, amyloidosis, mild hereditary spherocytosis, early stages of polycythemia vera.",
      "Massively enlarged spleen (Table 8.94 and Fig. 8.46): CML, myelofibrosis, hyper-reactive malarial splenomegaly syndrome, Gaucher's disease, lymphoma (mantle cell, marginal B cell), hairy cell leukemia, kala-azar, beta thalassemia major, AIDS with MAC, splenic cysts."
    ],
    "Object4": [
      "Symptoms of underlying cause."
    ],
    "Object5": [
      "Palpable spleen (>16% palpable spleens normal size on radiology).",
      "Craniocaudal length on ultrasound >11-14 cm.",
      "Signs of hypersplenism (pancytopenia)."
    ],
    "Object6": [
      "Splenic weight (at splenectomy or post-mortem).",
      "Ultrasound (craniocaudal length).",
      "Blood counts (for pancytopenia)."
    ],
    "Object7": [
      "Treat underlying cause.",
      "Splenectomy (indications in Table 8.95): Isolated thrombocytopenia, ITP, hemolytic anemia, AIHA, hereditary spherocytosis, thalassemia major/intermedia, neutropenia, primary myelofibrosis, HCL, splenic marginal zone lymphoma, CLL, painfully enlarged spleen, traumatic/atraumatic splenic rupture, splenic artery aneurysm, hypersplenism, primary treatment of isolated splenic vascular/parenchymal lesion, splenic abscess, acute splenic torsion, splenic vein thrombosis with bleeding esophageal varices, splenorenal shunting for portal hypertension."
    ],
    "Object8": [
      "Hypersplenism (pancytopenia)."
    ]
  },
  {
    "Object1": "Hypersplenism",
    "Object2": "Complication of splenomegaly",
    "Object3": [
      "Splenomegaly."
    ],
    "Object4": [
      "Symptoms of cytopenias (anemia, leukopenia, thrombocytopenia).",
      "Symptoms of underlying disease causing splenomegaly."
    ],
    "Object5": [
      "Pancytopenia.",
      "Hypercellular bone marrow with compensatory hyperplasia.",
      "Splenomegaly (primary event)."
    ],
    "Object6": [
      "Blood counts (anemia, leukopenia, thrombocytopenia).",
      "Bone marrow examination (hypercellularity)."
    ],
    "Object7": [
      "Splenectomy (if symptomatic and other treatments fail)."
    ],
    "Object8": []
  },
  {
    "Object1": "Splenic Rupture",
    "Object2": [
      "Traumatic splenic rupture",
      "Atraumatic splenic rupture"
    ],
    "Object3": [
      "Traumatic: Blunt abdominal trauma.",
      "Atraumatic: Neoplasm (leukemia, lymphoma), Infection (infectious mononucleosis, CMV, HIV, endocarditis, malaria), Inflammatory disease/noninfectious disorders (acute/chronic pancreatitis, primary amyloidosis), Drug/treatment related (anticoagulation, G-CSF, thrombolytic therapy, dialysis), Mechanical causes (pregnancy-related, congestive splenomegaly), Idiopathic (normal spleen)."
    ],
    "Object4": [
      "Abdominal pain, left shoulder pain (Kehr's sign), shock."
    ],
    "Object5": [
      "Splenomegaly (pre-existing, in atraumatic cases).",
      "Hypotension, tachycardia."
    ],
    "Object6": [
      "Ultrasound, CT scan of abdomen.",
      "Peritoneal lavage (for hemoperitoneum)."
    ],
    "Object7": [
      "Surgical intervention (splenectomy or splenic repair)."
    ],
    "Object8": [
      "Hypovolemic shock, hemorrhage."
    ]
  },
  {
    "Object1": "Porphyrias (Disorders of Heme Synthesis)",
    "Object2": [
      "Hepatic porphyrias (5-ALA dehydratase-deficient, Acute intermittent, Porphyria cutanea tarda, Hereditary coproporphyria, Variegate)",
      "Erythropoietic porphyrias (Congenital erythropoietic, Erythropoietic protoporphyria, X-linked protoporphyria)",
      "Acute neurovisceral syndrome",
      "Cutaneous photosensitivity"
    ],
    "Object3": [
      "Deficiencies of enzymes involved in heme synthesis (inherited autosomal dominant, recessive, or X-linked traits).",
      "Build-up of porphyrins and metabolites.",
      "Triggering factors for acute attacks: Alcohol, fasting, drugs (anticonvulsants, sulphonamides, estrogen, progesterone)."
    ],
    "Object4": [
      "Cutaneous photosensitivity: Pain, erythema, bullae, skin erosions, hirsutism, hyperpigmentation (on sun-exposed skin). Blistering (uro-/coproporphyrins). Burning sensations (protoporphyrins).",
      "Acute Neurovisceral Syndrome: Acute abdominal pain, autonomic dysfunction (tachycardia, hypertension, constipation). Acute motor polyneuropathy (quadriparesis mimicking GB syndrome). Neuropsychiatric manifestations (insomnia, anxiety, restlessness, agitation, hallucinations, hysteria, disorientation, delirium, apathy, depression, phobias)."
    ],
    "Object5": [
      "Cutaneous photosensitivity: Blistering, skin erosions, hirsutism, hyperpigmentation on sun-exposed areas. Skin sensitive to trauma.",
      "Acute Neurovisceral Syndrome: Tachycardia, hypertension, constipation.",
      "Urine color changes on exposure to sunlight (Fig. 8.48)."
    ],
    "Object6": [
      "Diagnosis/classification depends on pattern of porphyrins and precursors in blood, urine, stool (Table 8.97).",
      "Measurement of deficient enzymes.",
      "Genetic testing."
    ],
    "Object7": [
      "Neurovisceral Acute:",
      "Supportive: Analgesics, avoid aggravating drugs.",
      "Specific: IV glucose (inhibits ALA synthase), IV haem (human haematin/haem arginate) (reduces ALA/PBG excretion, relieves pain, accelerates recovery).",
      "Maintain calorie/fluid intake.",
      "Cyclical attacks in females: Suppression of menstrual cycle with GnRH analogs.",
      "Cutaneous Photosensitivity Episodes:",
      "Acute attack: Symptomatic treatment.",
      "Venesection (reduces urinary porphyria) for PCT (acute/remission).",
      "Prolonged low-dose chloroquine (forms water-soluble complex with uroporphyrins, aids excretion).",
      "Liver transplantation (severe cases).",
      "Prevention:",
      "Avoid sunlight (sun exposure), skin trauma.",
      "Barrier sun creams (zinc/titanium oxide), protective clothing.",
      "Oral β-carotene (prevents free radicals, effective protection).",
      "Afamelanotide (synthetic α-MSH analogue) for erythropoietic protoporphyria."
    ],
    "Object8": [
      "Neurologic damage (from acute neurovisceral syndrome).",
      "Skin damage (cutaneous photosensitivity).",
      "Acute attacks can be triggered by alcohol, fasting, drugs."
    ]
  },
  {
    "Object1": "Pseudoporphyria",
    "Object2": "Not specified",
    "Object3": [
      "Medications (NSAIDs, especially naproxen; tetracycline).",
      "Hemodialysis."
    ],
    "Object4": [
      "Blistering and skin fragility identical to PCT."
    ],
    "Object5": [
      "Blistering and skin fragility.",
      "Normal urine and serum porphyrins.",
      "No hypertrichosis, dyspigmentation, or cutaneous sclerosis."
    ],
    "Object6": [
      "Histological features similar to PCT, but normal urine and serum porphyrins."
    ],
    "Object7": [
      "Withdrawal of causative medications (NSAIDs, tetracycline)."
    ],
    "Object8": []
  },
  {
    "Object1": "Klinefelter's Syndrome",
    "Object2": [
      "Chromosomal anomaly (47, XXY karyotype, most common)",
      "Mosaicism (e.g., 46, XY/47, XXY)"
    ],
    "Object3": [
      "Hypogonadism",
      "Infertility (due to azoospermia)",
      "Tall stature with disproportionately long limbs",
      "Gynecomastia",
      "Reduced facial and body hair",
      "Small, firm testes (testicular atrophy)",
      "Learning disabilities, speech difficulties, mild intellectual impairment",
      "Increased risk of breast cancer, germ cell tumors, autoimmune diseases, osteoporosis"
    ],
    "Object4": [
      "Karyotyping (confirmatory)",
      "Hormone levels (low testosterone, elevated FSH and LH)",
      "Semen analysis (azoospermia)"
    ],
    "Object5": [
      "Testosterone replacement therapy (from puberty onwards) to promote virilization and bone density",
      "Mastectomy for significant gynecomastia",
      "Fertility preservation options (e.g., testicular sperm extraction) for some men"
    ],
    "Object6": [
      "Infertility",
      "Osteoporosis",
      "Increased risk of breast cancer",
      "Learning disabilities"
    ]
  },
  {
    "Object1": "Turner's Syndrome",
    "Object2": [
      "Chromosomal anomaly (45, XO karyotype, most common)",
      "Mosaicism (e.g., 45, XO/46, XX)",
      "Deletion of part of an X chromosome"
    ],
    "Object3": [
      "Short stature (characteristic)",
      "Ovarian dysgenesis (streak gonads, leading to primary amenorrhea and infertility)",
      "Webbed neck, low hairline, widely spaced nipples, shield chest",
      "Lymphedema of hands and feet (at birth)",
      "Cardiac defects (bicuspid aortic valve, coarctation of the aorta)",
      "Renal anomalies (horseshoe kidney)",
      "Learning difficulties (spatial perception, math), normal intelligence",
      "Increased risk of osteoporosis, thyroiditis, diabetes mellitus, hypertension"
    ],
    "Object4": [
      "Karyotyping (confirmatory)",
      "Hormone levels (elevated FSH and LH, low estrogen)",
      "Echocardiography (for cardiac defects)",
      "Renal ultrasound (for renal anomalies)"
    ],
    "Object5": [
      "Growth hormone therapy (to increase final adult height)",
      "Estrogen replacement therapy (from puberty onwards) to induce secondary sexual characteristics and maintain bone density",
      "Management of cardiac and renal anomalies",
      "Fertility options (e.g., oocyte donation)"
    ],
    "Object6": [
      "Infertility",
      "Cardiovascular disease",
      "Osteoporosis",
      "Thyroid disease",
      "Renal dysfunction"
    ]
  },
  {
    "Object1": "Mental Retardation/Insufficiency (Intellectual Disability)",
    "Object2": [
      "Genetic syndromes (Down syndrome, fragile X syndrome, Rett syndrome, Klinefelter's syndrome, inborn errors of metabolism)",
      "Prenatal factors (infections like rubella, toxoplasmosis, CMV; alcohol/drug exposure; malnutrition; maternal phenylketonuria)",
      "Perinatal factors (prematurity, birth asphyxia, very low birth weight, neonatal jaundice/kernicterus)",
      "Postnatal factors (CNS infections like meningitis/encephalitis; head trauma; severe malnutrition; lead poisoning; severe hypothyroidism; child abuse)",
      "Idiopathic (cause unknown in many cases)"
    ],
    "Object3": [
      "Impairment in intellectual functioning (reasoning, problem-solving, planning, abstract thinking, judgment, academic learning, learning from experience)",
      "Impairment in adaptive functioning (communication, social participation, independent living across multiple environments)",
      "Delays in developmental milestones (language, motor skills, social skills)",
      "Difficulties in school performance",
      "Challenges in daily living activities (self-care, home activities, community use, safety)"
    ],
    "Object4": [
      "Developmental assessment, psychological testing (IQ scores, adaptive functioning scales)",
      "Genetic testing (karyotyping, specific gene panels, whole exome sequencing)",
      "Neuroimaging (MRI brain to detect structural anomalies)",
      "Metabolic screening (for inborn errors of metabolism)",
      "Sensory evaluations (hearing, vision)",
      "Clinical examination for dysmorphic features or signs of syndromic conditions"
    ],
    "Object5": [
      "Early intervention programs (special education, individualized therapies - speech, occupational, physical therapy)",
      "Behavioral therapy (for maladaptive behaviors)",
      "Vocational training and supported employment",
      "Support for families and caregivers",
      "Management of co-occurring conditions (e.g., seizures, psychiatric disorders, sensory impairments)",
      "Gene therapy (investigational for specific genetic causes)"
    ],
    "Object6": [
      "Functional dependence and disability",
      "Co-occurring mental health conditions (anxiety, depression)",
      "Behavioral challenges",
      "Increased vulnerability to abuse and exploitation",
      "Associated medical conditions (e.g., seizures, sensory deficits)"
    ]
  },
  {
    "Object1": "Inborn Errors of Metabolism (IEM)",
    "Object2": [
      "Genetic mutations leading to deficiencies or defects in specific enzymes or transport proteins involved in metabolic pathways",
      "Inherited as autosomal recessive (most common), X-linked, or autosomal dominant traits",
      "Affect various metabolic pathways: amino acid, organic acid, fatty acid, carbohydrate, lysosomal, peroxisomal metabolism"
    ],
    "Object3": [
      "Highly variable, depending on the specific disorder and severity of enzyme defect, can range from asymptomatic to severe, life-threatening crises",
      "Neonatal onset: Poor feeding, lethargy, vomiting, seizures, hypotonia, metabolic acidosis, hyperammonemia, unusual odor",
      "Infancy/Childhood onset: Developmental delay, intellectual disability, seizures, organomegaly, coarse facial features, vision/hearing loss, chronic vomiting/diarrhea, recurrent infections",
      "Adult onset: Ataxia, peripheral neuropathy, psychiatric symptoms, cardiomyopathy, stroke-like episodes",
      "Specific examples:",
      "Phenylketonuria (PKU): Intellectual disability, seizures, fair skin, eczema (if untreated)",
      "Maple Syrup Urine Disease (MSUD): Sweet-smelling urine, feeding difficulties, seizures, coma",
      "Urea Cycle Disorders: Hyperammonemia, lethargy, seizures, coma",
      "Lysosomal Storage Disorders (e.g., Gaucher, Hurler): Organomegaly, skeletal deformities, neurological regression, coarse features"
    ],
    "Object4": [
      "Newborn screening (tandem mass spectrometry for various IEMs)",
      "Specific biochemical tests (amino acid analysis, organic acid analysis, acylcarnitine profile, ammonia, lactate, glucose, LFTs)",
      "Enzyme assays (in blood, fibroblasts, liver tissue)",
      "Genetic testing (confirmatory, identifies specific gene mutations)",
      "Urinalysis (for reducing substances, ketones, specific odors)",
      "Neuroimaging (MRI brain for white matter changes, atrophy)",
      "Organ biopsies (liver, muscle, skin for histological/ultrastructural analysis)"
    ],
    "Object5": [
      "Dietary management: Restricted diets (e.g., low protein for PKU, low specific amino acids for MSUD, special formulas)",
      "Enzyme replacement therapy (ERT): For some lysosomal storage disorders (e.g., Gaucher, Fabry)",
      "Cofactor supplementation: Vitamins (e.g., biotin, vitamin B12, pyridoxine) for certain enzyme deficiencies",
      "Substrate reduction therapy (SRT): For some lysosomal storage disorders",
      "Scavenger therapy (e.g., sodium benzoate for urea cycle disorders to reduce ammonia)",
      "Allogeneic hematopoietic stem cell transplantation (HSCT): For some lysosomal storage disorders, peroxisomal disorders",
      "Symptomatic management (anticonvulsants for seizures, physical therapy)",
      "Gene therapy (investigational)"
    ],
    "Object6": [
      "Severe, irreversible neurological damage (intellectual disability, developmental delay, seizures)",
      "Metabolic crises (life-threatening acidosis, hyperammonemia, hypoglycemia)",
      "Organ damage (liver, heart, kidney)",
      "Failure to thrive, growth retardation",
      "Increased risk of infections",
      "Death"
    ]
  },
  {
    "Object1": "Gene Therapy",
    "Object2": "Gene therapy is a therapeutic approach that involves modifying an individual's genes to treat or prevent disease. It typically works by introducing new genetic material into a patient's cells to replace a faulty gene, inactivate a harmful gene, or introduce a new gene to fight a disease. The delivery of genetic material is often achieved using viral (e.g., adenoviruses, retroviruses, adeno-associated viruses) or non-viral vectors. While still largely experimental, it holds promise for treating a wide range of genetic disorders, cancers, and infectious diseases.",
    "Object3": [
      "Monogenic disorders (e.g., cystic fibrosis, spinal muscular atrophy, severe combined immunodeficiency - SCID)",
      "Cancers (e.g., CAR T-cell therapy for leukemia/lymphoma, oncolytic viruses)",
      "Infectious diseases (e.g., HIV, hepatitis B)",
      "Cardiovascular diseases (e.g., promoting angiogenesis)"
    ],
    "Object4": [
      "Delivery efficiency and specificity",
      "Immune response to viral vectors",
      "Off-target effects (insertional mutagenesis)",
      "Cost and ethical considerations"
    ]
  },
  {
    "Object1": "Human Genome Project",
    "Object2": "The Human Genome Project (HGP) was an international scientific research project that aimed to determine the sequence of nucleotide base pairs that make up human DNA, and to map all of the genes of the human genome. It officially began in 1990 and was completed in 2003, two years ahead of its original schedule. The project revolutionized biology and medicine by providing a foundational understanding of human genetics.",
    "Object3": [
      "Identify all human genes",
      "Determine the sequences of the 3 billion chemical base pairs in human DNA",
      "Store this information in public databases",
      "Develop tools for data analysis",
      "Address ethical, legal, and social issues (ELSI) arising from the project"
    ],
    "Object4": [
      "Accelerated discovery of disease-related genes",
      "Facilitated development of new diagnostic tests and therapies",
      "Laid groundwork for personalized medicine",
      "Enabled advancements in genomics, proteomics, and bioinformatics"
    ]
  },
  {
    "Object1": "Polymerase Chain Reaction (PCR) and its Applications",
    "Object2": "Polymerase Chain Reaction (PCR) is a molecular biology technique used to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. It is an in vitro method for enzymatic synthesis of specific DNA sequences. The process involves cycles of heating and cooling in a thermal cycler, using a DNA polymerase (typically Taq polymerase), DNA primers, and nucleotide bases.",
    "Object3": [
      "Genetic testing (e.g., paternity testing, forensic science, genetic disease diagnosis)",
      "Infectious disease diagnosis (e.g., HIV viral load, COVID-19 testing, tuberculosis, hepatitis viruses)",
      "Cancer detection and monitoring (e.g., detecting chromosomal translocations, minimal residual disease)",
      "Gene cloning and sequencing",
      "DNA fingerprinting",
      "Research and biotechnology"
    ],
    "Object4": [
      "Real-time PCR (qPCR) for quantitative analysis",
      "Reverse transcription PCR (RT-PCR) for RNA detection",
      "Multiplex PCR for multiple targets simultaneously"
    ]
  },
  {
    "Object1": [
      "Urticaria, angioedema, pruritus, bronchospasm, hypotension, anaphylactic shock"
    ],
    "Object2": [
      "Hemolysis (anemia, jaundice, hemoglobinuria), thrombocytopenia, neutropenia, glomerulonephritis"
    ],
    "Object3": [
      "Vasculitis, glomerulonephritis, arthritis, fever, rash"
    ],
    "Object4": [
      "Contact dermatitis (erythema, itching, blistering at contact site), granulomatous inflammation, graft rejection"
    ]
  },
  {
    "Object1": "Autoimmunity (General)",
    "Object2": [
      "Loss of self-tolerance, leading to immune response against body's own tissues",
      "Genetic predisposition (HLA genes, non-HLA genes)",
      "Environmental triggers (infections - molecular mimicry, bystander activation; toxins, drugs, smoking)",
      "Hormonal factors (gender differences, e.g., estrogen)",
      "Immunological dysregulation (defects in T-cell selection, regulatory T cells, B cell activation)"
    ],
    "Object3": [
      "Highly variable, depending on affected organ/system",
      "Constitutional: Fatigue, fever, weight loss",
      "Systemic: Arthralgia, arthritis, rash, dry eyes/mouth, myalgia",
      "Organ-specific: Thyroid dysfunction (Hashimoto's, Graves'), type 1 diabetes, lupus nephritis, rheumatoid arthritis, multiple sclerosis, autoimmune hepatitis"
    ],
    "Object4": [
      "Laboratory: Autoantibodies (ANA, RF, anti-CCP, anti-dsDNA, anti-thyroid antibodies, anti-GAD), ESR/CRP, complement levels, CBC (anemia, leukopenia, thrombocytopenia)",
      "Biopsy of affected tissue (e.g., synovium, kidney, skin, liver)",
      "Imaging (MRI for MS, X-rays for RA, ultrasound for thyroid)"
    ],
    "Object5": [
      "Corticosteroids (for acute flares and severe inflammation)",
      "Immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide) (for long-term control and steroid-sparing)",
      "Biological agents (TNF inhibitors, rituximab, IL-6 inhibitors, T-cell costimulation blockers) (targeted therapies for specific autoimmune diseases)",
      "IVIG, plasma exchange (for severe, refractory cases)",
      "Symptomatic management",
      "Lifestyle modifications"
    ],
    "Object6": [
      "Organ damage and failure",
      "Increased risk of infections",
      "Malignancies",
      "Cardiovascular disease",
      "Functional disability"
    ]
  },
  {
    "Object1": [
      "Immunosuppressive therapy (calcineurin inhibitors - tacrolimus, cyclosporine; antimetabolites - azathioprine, mycophenolate mofetil; mTOR inhibitors - sirolimus, everolimus; corticosteroids; antibody therapies - basiliximab, alemtuzumab)",
      "For acute rejection: High-dose corticosteroids, antibody therapies (e.g., antithymocyte globulin - ATG)",
      "Retransplantation for failed grafts"
    ],
    "Object2": [
      "Corticosteroids (first-line for acute GVHD)",
      "Other immunosuppressants (cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil)",
      "Extracorporeal photopheresis (for chronic GVHD)",
      "Rituximab, JAK inhibitors (e.g., ruxolitinib)"
    ]
  },
  {
    "Object1": "Amyloidosis (General)",
    "Object2": [
      "Deposition of insoluble fibrillar proteins (amyloid) in extracellular spaces of various tissues and organs",
      "Types of amyloidosis (defined by precursor protein):",
      "AL amyloidosis (light chain amyloidosis): Due to monoclonal immunoglobulin light chains, associated with plasma cell dyscrasias (multiple myeloma, MGUS)",
      "AA amyloidosis (secondary amyloidosis): Due to Serum Amyloid A (SAA) protein, associated with chronic inflammatory/infectious diseases (rheumatoid arthritis, IBD, chronic infections, FMF)",
      "ATTR amyloidosis (transthyretin amyloidosis): Due to transthyretin protein (hereditary or wild-type/senile forms), affecting heart and nerves",
      "Aβ2M amyloidosis: Due to beta-2 microglobulin, in long-term dialysis patients",
      "Apolipoprotein A-I, A-II, Fibrinogen, Lysozyme, Gelsolin amyloidosis (rare hereditary forms)"
    ],
    "Object3": [
      "Highly variable, depending on organs involved, often insidious onset",
      "Constitutional: Fatigue, weight loss, edema",
      "Cardiac: Cardiomyopathy (restrictive), heart failure, arrhythmias, sudden cardiac death",
      "Renal: Proteinuria (nephrotic syndrome), renal failure",
      "Neurological: Peripheral neuropathy (sensory, motor, autonomic), carpal tunnel syndrome, autonomic dysfunction (orthostatic hypotension, GI dysmotility)",
      "Gastrointestinal: Malabsorption, diarrhea, hepatomegaly, macroglossia (AL amyloidosis)",
      "Hepatic: Hepatomegaly, liver dysfunction",
      "Pulmonary: Dyspnea, pleural effusions, restrictive lung disease",
      "Skin: Purpura (periorbital 'raccoon eyes'), waxy skin, easy bruising",
      "Endocrine: Thyroid dysfunction, adrenal insufficiency"
    ],
    "Object4": [
      "Tissue biopsy (subcutaneous fat aspiration is common, organ biopsy e.g., kidney, heart, GI tract) with Congo red stain (shows apple-green birefringence under polarized light, diagnostic)",
      "Immunohistochemistry/mass spectrometry on biopsy to identify amyloid type",
      "Blood/urine tests for precursor protein: Serum/urine protein electrophoresis and immunofixation for monoclonal light chains (for AL amyloidosis), SAA levels (for AA amyloidosis), genetic testing for transthyretin mutations (for ATTR amyloidosis)",
      "Organ-specific tests: Echocardiography (for cardiac amyloidosis), renal function, urinalysis (proteinuria), nerve conduction studies/EMG"
    ],
    "Object5": [
      "Depends on amyloid type and underlying cause",
      "AL amyloidosis: Chemotherapy (melphalan, bortezomib, cyclophosphamide, lenalidomide, daratumumab), autologous stem cell transplantation (for eligible patients) to reduce light chain production",
      "AA amyloidosis: Treat underlying inflammatory/infectious disease (e.g., TNF inhibitors for RA, antibiotics for chronic infections)",
      "ATTR amyloidosis: Tafamidis, inotersen, patisiran (gene silencers/stabilizers for hereditary ATTR), liver transplantation (for hereditary ATTR)",
      "Supportive care: Diuretics for heart failure/edema, pacemakers for arrhythmias, pain management for neuropathy, dialysis for renal failure",
      "Organ transplantation (heart, kidney) for end-stage organ involvement"
    ],
    "Object6": [
      "Organ failure (cardiac, renal, liver, neurological)",
      "Sudden cardiac death",
      "Malabsorption, malnutrition",
      "Bleeding diathesis",
      "Severe disability",
      "Death"
    ]
  },
  {
    "Object1": "Cytokines",
    "Object2": "Cytokines are a broad and loose category of small proteins (~5-20 kDa) that are important in cell signaling. They are peptides and cannot cross the lipid bilayer of cells to enter the cytoplasm, requiring that they bind to cell surface receptors to exert their effects. They are produced by a wide range of cells, including immune cells (e.g., T-helper cells, macrophages) as well as endothelial cells, fibroblasts, and other non-immune cells. Cytokines act as messengers, playing crucial roles in immunity, inflammation, hematopoiesis, and tissue repair. Their actions can be autocrine, paracrine, or endocrine.",
    "Object3": [
      "Interleukins (ILs)",
      "Interferons (IFNs)",
      "Tumor Necrosis Factors (TNFs)",
      "Chemokines",
      "Colony-Stimulating Factors (CSFs)"
    ],
    "Object4": [
      "Regulate immune and inflammatory responses",
      "Mediate communication between immune cells",
      "Promote cell growth, differentiation, and survival",
      "Coordinate hematopoiesis"
    ],
    "Object5": [
      "Pro-inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6) in sepsis, autoimmune diseases, chronic inflammation",
      "Anti-inflammatory cytokines (e.g., IL-10, TGF-beta) in immune regulation",
      "Therapeutic targets (e.g., anti-TNF agents in rheumatoid arthritis, IL-6 inhibitors)"
    ]
  },
  {
    "Object1": "Complement System",
    "Object2": "The complement system is a part of the innate immune system that enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane. It consists of a cascade of approximately 50 plasma proteins that are activated in a sequential manner. The system's activation is tightly regulated to prevent damage to host cells.",
    "Object3": [
      "Classical pathway (activated by antibody-antigen complexes or C-reactive protein)",
      "Alternative pathway (activated directly by pathogen surfaces in absence of antibodies)",
      "Lectin pathway (activated by mannose-binding lectin binding to microbial carbohydrates)"
    ],
    "Object4": [
      "Opsonization (enhances phagocytosis of microbes)",
      "Chemotaxis (recruits immune cells to sites of infection/inflammation)",
      "Cell lysis (formation of membrane attack complex - MAC, leading to pathogen destruction)",
      "Inflammation (releases anaphylatoxins C3a, C5a, which promote vasodilation and mast cell degranulation)",
      "Clearance of immune complexes and apoptotic cells"
    ],
    "Object5": [
      "Deficiencies can lead to increased susceptibility to infections (e.g., Neisseria with MAC deficiency)",
      "Overactivity can cause autoimmune diseases (e.g., lupus nephritis, atypical hemolytic uremic syndrome)",
      "Therapeutic targets (e.g., eculizumab for PNH)"
    ]
  },
  {
    "Object1": "Biology of Aging",
    "Object2": "The biology of aging refers to the complex and multifaceted processes that lead to a progressive decline in physiological function, increased susceptibility to disease, and decreased fertility over time in living organisms. It involves a range of molecular, cellular, and systemic changes that contribute to senescence.",
    "Object3": [
      "Telomere shortening and cellular senescence",
      "Oxidative stress and accumulation of reactive oxygen species (ROS)",
      "Accumulation of cellular damage (DNA damage, protein aggregation, mitochondrial dysfunction)",
      "Inflammaging (chronic low-grade inflammation)",
      "Altered nutrient sensing pathways (mTOR, IGF-1, sirtuins)",
      "Epigenetic changes",
      "Loss of proteostasis (impaired protein quality control)"
    ],
    "Object4": [
      "Decreased organ function (e.g., renal, cardiac, pulmonary)",
      "Increased susceptibility to chronic diseases (e.g., cardiovascular disease, cancer, diabetes, neurodegeneration)",
      "Frailty, sarcopenia (muscle loss), osteopenia/osteoporosis",
      "Impaired immune function (immunosenescence)",
      "Cognitive decline"
    ]
  },
  {
    "Object1": "Comprehensive Geriatric Assessment",
    "Object2": "Comprehensive Geriatric Assessment (CGA) is a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional limitations of a frail older person in order to develop a coordinated plan for care and follow-up. It aims to improve outcomes for older adults by addressing the complexities of their health and social needs.",
    "Object3": [
      "Physical health (medical conditions, medications, nutrition, vision, hearing, continence)",
      "Functional status (ADLs - Activities of Daily Living, IADLs - Instrumental Activities of Daily Living)",
      "Cognitive function (memory, executive function, delirium, dementia)",
      "Psychological health (depression, anxiety)",
      "Social support and resources",
      "Environmental safety",
      "Spiritual well-being"
    ],
    "Object4": [
      "Improved diagnostic accuracy",
      "Better functional outcomes",
      "Reduced mortality",
      "Decreased hospitalizations and nursing home admissions",
      "Improved quality of life for older adults and their caregivers"
    ],
    "Object5": [
      "Conducted by a multidisciplinary team (physicians, nurses, social workers, physical/occupational therapists, pharmacists)",
      "Involves patient, family, and caregiver input",
      "Leads to individualized care plans"
    ]
  },
  {
    "Object1": "Lichen Planus",
    "Object2": [
      "Chronic inflammatory mucocutaneous disorder (autoimmune-mediated, T-cell driven)",
      "Exact etiology unknown",
      "Associated with Hepatitis C virus infection (especially oral LP)",
      "Drugs (thiazides, gold salts, antimalarials, ACE inhibitors, NSAIDs, penicillamine) (drug-induced lichenoid reactions)",
      "Stress, dental materials"
    ],
    "Object3": [
      "Pruritus (often severe)",
      "Characteristic lesions (6 P's: Pruritic, Polygonal, Planar, Purple, Papules/Plaques)",
      "Wickham's striae (fine white lines/reticulations on surface of papules)",
      "Common sites: Flexor surfaces of wrists/forearms, ankles, oral mucosa (buccal mucosa - lacy white pattern, erosions), genitals, nails, scalp",
      "Nail changes: Thinning, longitudinal ridging, pterygium formation",
      "Scalp involvement (lichen planopilaris): Scarring alopecia",
      "Oral lesions (erosive LP) can be painful and increase risk of squamous cell carcinoma"
    ],
    "Object4": [
      "Clinical diagnosis based on characteristic lesions",
      "Skin biopsy (diagnostic, shows hyperkeratosis, acanthosis, 'sawtooth' rete ridges, lichenoid interface dermatitis with band-like lymphocytic infiltrate, Civatte bodies)",
      "Rule out Hepatitis C (anti-HCV testing)"
    ],
    "Object5": [
      "Topical corticosteroids (first-line for localized cutaneous/oral lesions)",
      "Intralesional corticosteroids (for hypertrophic lesions)",
      "Systemic corticosteroids (for severe, generalized, or erosive oral LP)",
      "Phototherapy (UVB, PUVA) (for widespread cutaneous LP)",
      "Systemic agents (methotrexate, azathioprine, cyclosporine, retinoids) (for severe or refractory cases)",
      "Topical calcineurin inhibitors (tacrolimus, pimecrolimus) for oral/genital LP",
      "Antihistamines (for pruritus)"
    ],
    "Object6": [
      "Post-inflammatory hyperpigmentation",
      "Scarring alopecia (lichen planopilaris)",
      "Increased risk of squamous cell carcinoma (in erosive oral/genital LP)",
      "Chronic pain (erosive oral/genital LP)",
      "Esophageal strictures (esophageal LP)"
    ]
  },
  {
    "Object1": "Acanthosis Nigricans",
    "Object2": [
      "Insulin resistance (most common cause): Obesity, type 2 diabetes mellitus, metabolic syndrome, polycystic ovary syndrome (PCOS)",
      "Endocrine disorders (Cushing's syndrome, acromegaly, hypothyroidism)",
      "Drug-induced (nicotinic acid, corticosteroids, oral contraceptives, growth hormone)",
      "Malignancy (paraneoplastic, associated with adenocarcinomas, especially gastric, lung, breast, ovarian)",
      "Genetic syndromes (rare inherited forms)",
      "Idiopathic"
    ],
    "Object3": [
      "Velvety, hyperpigmented (dark brown to black) thickening of skin",
      "Characteristic locations: Axillae, neck (nape), groin, flexural areas, knuckles, submammary folds, umbilicus",
      "Skin may be slightly elevated or verrucous",
      "Usually asymptomatic, but can be pruritic",
      "Onset can be gradual or rapid (rapid onset, widespread suggests malignancy)"
    ],
    "Object4": [
      "Clinical diagnosis based on characteristic skin lesions",
      "Laboratory: Fasting glucose, HbA1c, insulin levels (to assess insulin resistance), lipid profile, thyroid function tests, pituitary hormones (if endocrine disorder suspected)",
      "Rule out malignancy (if rapid onset, severe, or widespread AN, especially in non-obese individuals, perform age-appropriate cancer screening: endoscopy, CT scans)",
      "Skin biopsy (rarely needed, shows hyperkeratosis, papillomatosis, acanthosis)"
    ],
    "Object5": [
      "Treat underlying cause (e.g., weight loss, glycemic control for insulin resistance, manage endocrine disorders, treat malignancy)",
      "Topical therapies (for cosmetic improvement): Retinoids (tretinoin), calcipotriene, salicylic acid, urea creams, alpha hydroxy acids",
      "Laser therapy (for cosmetic improvement)"
    ],
    "Object6": [
      "Psychological distress due to cosmetic appearance",
      "Associated medical complications of underlying cause (e.g., diabetes, cardiovascular disease, malignancy)"
    ]
  },
  {
    "Object1": [
      "Flaccid blisters and erosions (intraepidermal, easily rupture)",
      "Positive Nikolsky's sign (skin shears off with lateral pressure)",
      "Often starts in oral mucosa, can be widespread, severe pain, can be life-threatening"
    ],
    "Object2": [
      "Tense blisters (subepidermal, resistant to rupture), often with urticarial base",
      "Negative Nikolsky's sign",
      "Pruritus, common in elderly, favors flexural areas"
    ],
    "Object3": [
      "Intensely pruritic papules, vesicles, bullae (grouped, symmetrical)",
      "Favors elbows, knees, buttocks, scalp",
      "Associated with celiac disease symptoms"
    ]
  },
  {
    "Object1": [
      "Tender, erythematous nodules (deep, firm, typically on shins)",
      "Often bilateral, symmetrical",
      "Fever, malaise, arthralgia, myalgia",
      "Lesions resolve without scarring, leaving bruising-like discoloration"
    ],
    "Object2": [
      "Target lesions (concentric rings of erythema and edema, 'iris' lesion) (classic)",
      "Papules, vesicles, bullae",
      "Common on extremities (palms, soles), face, oral mucosa",
      "Often follows HSV infection or drug exposure",
      "Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) (severe forms with extensive epidermal detachment, mucosal involvement, life-threatening)"
    ],
    "Object3": [
      "Urticaria: Pruritic, erythematous, edematous wheals (hives), transient, migratory",
      "Angioedema: Swelling of deeper dermis/subcutaneous tissue, often involving face, lips, tongue, larynx, genitals (can be life-threatening if airway involved)"
    ]
  },
  {
    "Object1": [
      "Surgical excision (most common, curative for localized lesions)",
      "Mohs micrographic surgery (for high-risk lesions, cosmetically sensitive areas)",
      "Electrocautery and curettage",
      "Cryosurgery",
      "Radiation therapy (for unresectable lesions, adjuvant therapy)",
      "Topical therapies (imiquimod, 5-fluorouracil for superficial BCC, AK)",
      "Systemic therapies (vismodegib, sonidegib for advanced BCC; checkpoint inhibitors, targeted therapy for advanced SCC)"
    ],
    "Object2": [
      "Surgical excision (wide local excision with clear margins, sentinel lymph node biopsy for staging)",
      "Adjuvant therapy (immunotherapy - pembrolizumab, nivolumab, ipilimumab; targeted therapy - BRAF/MEK inhibitors for specific mutations)",
      "Systemic therapies (immunotherapy, targeted therapy, chemotherapy for metastatic melanoma)",
      "Radiation therapy (for brain metastases, palliative)"
    ],
    "Object3": [
      "Cryosurgery, topical 5-fluorouracil, imiquimod, diclofenac gel, chemical peels, photodynamic therapy"
    ]
  },
  {
    "Object1": "Phakomatoses (Neurocutaneous Syndromes)",
    "Object2": [
      "Genetic disorders affecting nervous system, skin, and other organs",
      "Inherited (autosomal dominant is common)",
      "Examples: Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), Tuberous Sclerosis Complex (TSC), Von Hippel-Lindau (VHL) disease, Sturge-Weber syndrome"
    ],
    "Object3": [
      "Highly variable, progressive, multi-system involvement",
      "Neurofibromatosis Type 1 (NF1): Cafe-au-lait macules (6 or more >5mm before puberty, >15mm after puberty), axillary/inguinal freckling, Lisch nodules (iris hamartomas), neurofibromas (cutaneous, plexiform), optic pathway gliomas, bone deformities (scoliosis)",
      "Neurofibromatosis Type 2 (NF2): Bilateral vestibular schwannomas (hearing loss, balance issues), meningiomas, ependymomas",
      "Tuberous Sclerosis Complex (TSC): Facial angiofibromas (adenoma sebaceum), ash-leaf macules (hypopigmented), shagreen patches, ungual fibromas, renal angiomyolipomas, brain tubers, subependymal giant cell astrocytomas (SEGA), epilepsy, intellectual disability, autism",
      "Von Hippel-Lindau (VHL) disease: Hemangioblastomas (cerebellar, retinal, spinal cord), renal cell carcinoma, pheochromocytoma, pancreatic neuroendocrine tumors",
      "Sturge-Weber syndrome: Port-wine stain (facial nevus flammeus), leptomeningeal angioma (seizures, neurological deficits), glaucoma"
    ],
    "Object4": [
      "Clinical diagnosis based on specific diagnostic criteria for each syndrome",
      "Genetic testing (for NF1, NF2, TSC, VHL)",
      "Neuroimaging (MRI brain/spine for tumors, lesions, tubers, hemangioblastomas)",
      "Ophthalmological examination (Lisch nodules, retinal hemangioblastomas, glaucoma)",
      "Renal ultrasound/CT (for angiomyolipomas, RCC)",
      "Audiometry, evoked potentials (for NF2)",
      "EEG (for epilepsy in TSC, Sturge-Weber)"
    ],
    "Object5": [
      "Multidisciplinary approach, lifelong surveillance and management of complications",
      "Surgical resection of tumors (neurofibromas, schwannomas, meningiomas, SEGAs, RCC)",
      "Radiation therapy (for some unresectable tumors)",
      "Targeted therapy (e.g., everolimus for SEGA/renal AML in TSC; BRAF inhibitors for plexiform neurofibromas in NF1)",
      "Symptomatic management (antiepileptic drugs for seizures, antihypertensives for pheochromocytoma, laser therapy for port-wine stain)",
      "Genetic counseling"
    ],
    "Object6": [
      "Neurological impairment, intellectual disability, epilepsy",
      "Malignancies (RCC, pheochromocytoma, astrocytomas, MPNST in NF1)",
      "Vision and hearing loss",
      "Hydrocephalus",
      "Renal failure",
      "Disfigurement from skin lesions/tumors",
      "Cardiovascular complications (renal artery stenosis in NF1)"
    ]
  },
  {
    "Object1": "Leg Ulcers",
    "Object2": [
      "Venous insufficiency (venous leg ulcers, most common, due to venous hypertension, incompetent valves)",
      "Arterial insufficiency (arterial leg ulcers, due to peripheral artery disease, atherosclerosis)",
      "Neuropathic ulcers (diabetic foot ulcers, due to peripheral neuropathy, trauma, abnormal pressure)",
      "Pressure ulcers (bedsores, due to prolonged pressure on bony prominences)",
      "Vasculitis (e.g., polyarteritis nodosa, cryoglobulinemia)",
      "Infections (ecthyma, deep fungal infections, atypical mycobacteria)",
      "Malignancy (squamous cell carcinoma, basal cell carcinoma, lymphoma)",
      "Other: Livedo vasculopathy, pyoderma gangrenosum, sickle cell disease, rheumatoid arthritis"
    ],
    "Object3": [
      "Open sore or wound on the leg/foot that fails to heal",
      "Venous: Irregular shape, shallow, often on medial malleolus, associated with edema, hyperpigmentation, lipodermatosclerosis, varicose veins",
      "Arterial: 'Punched-out' appearance, deep, often on toes, heels, bony prominences, associated with pain (worse with elevation, relieved by dependency), pallor, absent pulses, cold limb",
      "Neuropathic/Diabetic: 'Punched-out' with callus rim, on pressure points (sole of foot), often painless, associated with neuropathy, foot deformities",
      "Pain (variable, from severe to painless in neuropathic)",
      "Exudate, foul odor (if infected)",
      "Edema, cellulitis, osteomyelitis"
    ],
    "Object4": [
      "Clinical examination (assess ulcer characteristics, peripheral pulses, ankle-brachial index - ABI, neurological exam, signs of venous insufficiency)",
      "Doppler ultrasound (for venous/arterial insufficiency)",
      "Wound culture (for infection)",
      "Biopsy of ulcer edge (to rule out malignancy, vasculitis)",
      "Blood tests (HbA1c for diabetes, CBC, ESR/CRP, thrombophilia workup for vasculitis)",
      "Transcutaneous oximetry"
    ],
    "Object5": [
      "Treat underlying cause (e.g., compression therapy for venous, revascularization for arterial, glycemic control/offloading for neuropathic)",
      "Wound care: Debridement (remove necrotic tissue), appropriate dressings (maintain moist wound environment), infection control (topical/systemic antibiotics)",
      "Pain management",
      "Nutrition optimization",
      "Surgical interventions (skin grafting, amputation for severe unhealing ulcers/gangrene)",
      "Hyperbaric oxygen therapy (for selected chronic wounds, diabetic foot ulcers)"
    ],
    "Object6": [
      "Infection (cellulitis, osteomyelitis, sepsis)",
      "Amputation (especially arterial, neuropathic)",
      "Chronic pain",
      "Impaired mobility",
      "Recurrence"
    ]
  },
  {
    "Object1": "Xerostomia (Dry Mouth)",
    "Object2": [
      "Medications (most common): Anticholinergics (antihistamines, antidepressants, antipsychotics), diuretics, antihypertensives, opioids, decongestants, sedatives",
      "Sjögren's syndrome (autoimmune destruction of salivary glands)",
      "Radiation therapy to head and neck (salivary gland damage)",
      "Dehydration, fever",
      "Diabetes mellitus",
      "Anxiety, depression",
      "HIV infection",
      "Sarcoidosis",
      "Aging",
      "Oral infections (candidiasis), smoking, alcohol"
    ],
    "Object3": [
      "Dryness in mouth, difficulty speaking, chewing, swallowing",
      "Sore throat, hoarseness",
      "Altered taste",
      "Increased dental caries, gingivitis, periodontal disease",
      "Oral candidiasis",
      "Cracked lips, dry, fissured tongue",
      "Halitosis (bad breath)",
      "Difficulty wearing dentures"
    ],
    "Object4": [
      "Clinical examination (dry oral mucosa, absence of pooling saliva, foamy saliva)",
      "Salivary flow rate measurement (sialometry)",
      "Sialography or salivary gland scintigraphy (to assess salivary gland function/anatomy)",
      "Blood tests (ANA, anti-Ro/SSA, anti-La/SSB for Sjögren's, blood glucose, thyroid function)",
      "Lip biopsy (for minor salivary glands, to diagnose Sjögren's syndrome)"
    ],
    "Object5": [
      "Treat underlying cause/modify medications (if possible)",
      "Symptomatic relief:",
      "Saliva substitutes (artificial saliva sprays, gels)",
      "Sialogogues (pilocarpine, cevimeline) (stimulate saliva production for functional salivary glands)",
      "Frequent sips of water, sugar-free gum/candies",
      "Good oral hygiene (fluoride toothpaste, regular dental visits) to prevent caries",
      "Humidifier at night",
      "Avoid caffeine, alcohol, tobacco"
    ],
    "Object6": [
      "Severe dental caries, tooth loss",
      "Oral candidiasis, recurrent oral infections",
      "Dysphagia, malnutrition",
      "Speech difficulties",
      "Reduced quality of life"
    ]
  },
  {
    "Object1": "Pruritus (Itching)",
    "Object2": [
      "Dermatological conditions (most common): Eczema, psoriasis, urticaria, scabies, dry skin (xerosis), contact dermatitis, lichen planus, fungal infections",
      "Systemic diseases:",
      "Liver disease (cholestasis, e.g., PBC, PSC)",
      "Chronic kidney disease (uremic pruritus)",
      "Hematological disorders (iron deficiency anemia, polycythemia vera, lymphoma, leukemia)",
      "Endocrine disorders (hyperthyroidism, diabetes mellitus)",
      "Malignancy (lymphoma, leukemia, solid tumors - paraneoplastic)",
      "Neurological disorders (brachioradial pruritus, notalgia paresthetica, post-herpetic neuralgia, multiple sclerosis)",
      "Infections (HIV, parasites like pinworms)",
      "Drugs (opioids, aspirin, NSAIDs, ACE inhibitors, statins)",
      "Psychogenic pruritus",
      "Idiopathic"
    ],
    "Object3": [
      "Unpleasant sensation that provokes the desire to scratch",
      "Can be localized or generalized, acute or chronic",
      "Skin lesions from scratching (excoriations, lichenification, prurigo nodules)",
      "Associated skin changes (rash in eczema/psoriasis, jaundice in liver disease, xerosis in CKD)",
      "Sleep disturbance, irritability, anxiety, depression",
      "Pruritus often worse at night"
    ],
    "Object4": [
      "Thorough history (onset, duration, triggers, associated symptoms, drug history, travel, systemic disease review)",
      "Complete skin examination (to identify primary skin conditions, excoriations, secondary changes)",
      "Laboratory (to rule out systemic causes): CBC, ESR/CRP, LFTs (bilirubin, ALP, GGT), renal function, thyroid function, fasting glucose, iron studies, HIV/HCV serology, serum protein electrophoresis (for myeloma/lymphoma)",
      "Chest X-ray (for lymphoma, sarcoidosis)",
      "Skin biopsy (for specific dermatoses, exclude malignancy)",
      "Allergy testing (if allergic cause suspected)"
    ],
    "Object5": [
      "Treat underlying cause/remove offending agent",
      "Topical therapies: Emollients and moisturizers (for dry skin), topical corticosteroids, calcineurin inhibitors, pramoxine, menthol/camphor",
      "Systemic therapies: Antihistamines (H1 blockers, sedating ones for nocturnal pruritus - e.g., hydroxyzine, diphenhydramine), gabapentin/pregabalin (for neuropathic pruritus, uremic pruritus), SSRIs (for psychogenic or refractory pruritus), naltrexone (for cholestatic pruritus), rifampin (for cholestatic pruritus), cholestyramine (for cholestatic pruritus)",
      "Phototherapy (UVB) (for generalized chronic pruritus, uremic pruritus)",
      "Lifestyle modifications (lukewarm baths, avoid harsh soaps, loose clothing, humidifiers, stress reduction)"
    ],
    "Object6": [
      "Skin infections (cellulitis, impetigo)",
      "Lichenification, scarring",
      "Sleep disturbance, fatigue",
      "Anxiety, depression",
      "Reduced quality of life"
    ]
  },
  {
    "Object1": "Panniculitis (General)",
    "Object2": [
      "Inflammation of the subcutaneous fat (panniculus adiposus)",
      "Types: Septal panniculitis (inflammation predominantly in septa) or lobular panniculitis (inflammation predominantly in fat lobules)",
      "Erythema Nodosum (most common septal panniculitis, associated with infections, drugs, IBD, sarcoidosis)",
      "Erythema Induratum (lobar panniculitis, associated with tuberculosis, vasculitis)",
      "Panniculitis of connective tissue diseases (lupus panniculitis, scleroderma)",
      "Pancreatic panniculitis (associated with pancreatic disease, e.g., pancreatitis, pancreatic cancer)",
      "Alpha-1 antitrypsin deficiency panniculitis",
      "Cold panniculitis, pressure panniculitis, post-steroid panniculitis",
      "Infectious panniculitis (bacterial, fungal)"
    ],
    "Object3": [
      "Erythematous, tender nodules or plaques (deep, firm, often on lower legs)",
      "Pain, warmth, swelling",
      "Fever, malaise, arthralgia (in some types)",
      "Lesions may resolve without scarring (erythema nodosum) or with atrophy/scarring (lobar panniculitis, lupus panniculitis)",
      "Ulceration (in severe cases like erythema induratum, pancreatic panniculitis)",
      "Oily discharge (in pancreatic panniculitis)"
    ],
    "Object4": [
      "Skin biopsy (deep incisional biopsy, excisional biopsy) (diagnostic, crucial for classifying panniculitis type and identifying underlying cause, shows inflammation pattern - septal vs. lobular)",
      "Laboratory (to rule out systemic causes): ESR/CRP, ASO titer, PPD, CBC, amylase/lipase, ANA, RF, A1AT levels, stool culture for IBD, HIV/HCV serology",
      "Imaging (chest X-ray for sarcoidosis, abdominal imaging for pancreatic disease)"
    ],
    "Object5": [
      "Treat underlying cause (e.g., antibiotics for infection, manage IBD, pancreatic disease, corticosteroids for lupus panniculitis)",
      "Symptomatic management: Rest, elevation, compression, NSAIDs (for pain and inflammation)",
      "Corticosteroids (systemic or intralesional for various types, e.g., lupus panniculitis, refractory EN)",
      "Potassium iodide (for erythema nodosum)",
      "Antitubercular drugs (for erythema induratum if associated with TB)"
    ],
    "Object6": [
      "Scarring, atrophy, disfigurement",
      "Ulceration, secondary infection",
      "Chronic pain",
      "Systemic complications of underlying disease"
    ]
  },
  {
    "Object1": "Drugs Used in Liver Disorder (General Principles)",
    "Object2": "When using drugs in patients with liver disorders, careful consideration is needed due to the liver's central role in drug metabolism, synthesis of clotting factors, and protein binding. Liver dysfunction can alter drug pharmacokinetics and increase the risk of adverse drug reactions or toxicity.",
    "Object3": [
      "Reduced hepatic metabolism (Phase I - oxidation, reduction, hydrolysis; Phase II - conjugation)",
      "Reduced protein binding (due to hypoalbuminemia)",
      "Altered biliary excretion",
      "Increased sensitivity to CNS depressants (due to impaired ammonia clearance and increased BBB permeability)",
      "Increased risk of GI bleeding (due to coagulopathy, varices)",
      "Fluid retention and electrolyte imbalance"
    ],
    "Object4": [
      "Use lower initial doses, slowly titrate based on clinical response and liver function",
      "Prefer drugs eliminated by renal route or minimal hepatic metabolism",
      "Avoid drugs with known hepatotoxicity or high first-pass metabolism",
      "Monitor drug levels (if therapeutic drug monitoring is available)",
      "Treat underlying liver disease and complications"
    ]
  },
  {
    "Object1": "Drugs Used in Kidney Disorders (General Principles)",
    "Object2": "In patients with kidney disorders, drug dosing and selection must be carefully managed due to altered drug elimination, fluid and electrolyte imbalances, and increased sensitivity to nephrotoxic agents. Kidney dysfunction can affect drug pharmacokinetics and pharmacodynamics.",
    "Object3": [
      "Reduced renal excretion (most common effect of kidney disease on drugs)",
      "Altered drug metabolism (some drugs are metabolized by kidneys)",
      "Reduced protein binding (due to uremia, hypoalbuminemia)",
      "Accumulation of active metabolites",
      "Increased sensitivity to certain drugs (e.g., CNS depressants, opioids)",
      "Fluid and electrolyte imbalances",
      "Acid-base disturbances"
    ],
    "Object4": [
      "Adjust drug dosages based on Glomerular Filtration Rate (GFR) or creatinine clearance",
      "Avoid or use with extreme caution known nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, contrast media)",
      "Monitor drug levels, renal function, electrolytes, and fluid balance closely",
      "Prefer drugs eliminated by non-renal routes or minimal renal elimination",
      "Patient education about medications"
    ]
  },
  {
    "Object1": "Drugs Used in Pregnancy (General Principles)",
    "Object2": "Drug use during pregnancy requires careful consideration due to potential teratogenic effects on the fetus and altered pharmacokinetics in the pregnant mother. The goal is to use the safest and most effective medications at the lowest effective dose for the shortest duration, with a focus on risk-benefit assessment.",
    "Object3": [
      "Teratogenicity (potential to cause birth defects, highest risk in first trimester)",
      "Fetotoxicity (adverse effects on fetal development or function, e.g., growth restriction, organ toxicity)",
      "Maternal pharmacokinetic changes (increased blood volume, altered protein binding, increased GFR, altered hepatic metabolism)",
      "Placental drug transfer",
      "Effects on labor and delivery",
      "Effects on breastfeeding infant"
    ],
    "Object4": [
      "Avoid unnecessary medications",
      "Use drugs with established safety profiles in pregnancy (e.g., FDA Pregnancy Categories or ACOG/ACR recommendations)",
      "Always weigh potential benefits against risks",
      "Prefer single-agent therapy at lowest effective dose",
      "Monitor mother and fetus for adverse effects",
      "Counsel patient about drug risks and benefits"
    ],
    "Object5": [
      "Insulin: Preferred for diabetes in pregnancy (does not cross placenta).",
      "Antibiotics: Penicillins, cephalosporins (generally safe). Macrolides (erythromycin, azithromycin) (generally safe).",
      "Antihypertensives: Labetalol, nifedipine, methyldopa (preferred). ACE inhibitors/ARBs (contraindicated due to fetotoxicity).",
      "Anticoagulants: Heparin/LMWH (preferred, do not cross placenta). Warfarin (contraindicated due to teratogenicity).",
      "Antidepressants: SSRIs (some preferred, but risk-benefit discussed).",
      "Thyroxine: Safe for hypothyroidism."
    ]
  },
  {
    "Object1": "Clinical Trials Basic Concepts",
    "Object2": "Clinical trials are research studies conducted in human volunteers (participants) to evaluate the safety and efficacy of new medical interventions (drugs, vaccines, devices, procedures) or new uses of existing ones. They are essential for generating evidence-based medicine and are regulated by ethical guidelines and regulatory bodies.",
    "Object3": [
      "Phase 0: Exploratory, very small doses in humans, microdosing, to understand pharmacokinetics/pharmacodynamics (optional)",
      "Phase I: Small group (20-100 healthy volunteers), assesses safety, dosage range, pharmacokinetics",
      "Phase II: Larger group (100-300 patients with disease), assesses efficacy, safety, optimal dosage",
      "Phase III: Large group (hundreds-thousands of patients), confirms efficacy, monitors adverse effects, compares to standard treatment, pivotal for regulatory approval",
      "Phase IV: Post-marketing surveillance, ongoing monitoring after drug approval, detects rare/long-term side effects"
    ],
    "Object4": [
      "Ethical considerations (informed consent, IRB/ethics committee approval)",
      "Randomization (to minimize bias)",
      "Blinding (single-blind, double-blind to reduce bias)",
      "Control groups (placebo-controlled, active-controlled)",
      "Data collection and analysis (statistical rigor)",
      "Regulatory oversight (FDA, EMA, ICH guidelines)"
    ],
    "Object5": [
      "Ensure safety and efficacy of new treatments",
      "Advance medical knowledge",
      "Inform clinical practice guidelines",
      "Protect patient rights and well-being"
    ]
  },
  {
    "Object1": "Metabolic Acidosis (Emergency Management)",
    "Object2": [
      "See Metabolic Acidosis (Fluid and Electrolyte Disturbances section)"
    ],
    "Object3": [
      "See Metabolic Acidosis (Fluid and Electrolyte Disturbances section)",
      "Kussmaul respirations (compensatory)",
      "Neurological depression (confusion, coma)",
      "Cardiovascular depression (hypotension, arrhythmias)"
    ],
    "Object4": [
      "Arterial Blood Gas (ABG): Low pH (<7.35), low bicarbonate, compensatory low PaCO2",
      "Anion gap calculation",
      "Lactate, ketones, renal function, toxicology screen"
    ],
    "Object5": [
      "Treat underlying cause immediately (e.g., insulin for DKA, fluids/antibiotics for sepsis)",
      "Sodium bicarbonate (IV) (for severe acidosis, typically pH <7.1, or specific causes like RTA, certain intoxications - use with caution)",
      "Manage fluid and electrolyte imbalances (hyperkalemia, hypocalcemia)",
      "Hemodialysis (for severe renal failure, refractory acidosis, certain intoxications)"
    ],
    "Object6": [
      "Life-threatening arrhythmias, reduced cardiac contractility, coma"
    ]
  },
  {
    "Object1": "Hypoglycemia (Emergency Management)",
    "Object2": [
      "See Hypoglycemia (Diabetes Mellitus section)"
    ],
    "Object3": [
      "See Hypoglycemia (Diabetes Mellitus section)",
      "Neurogenic symptoms: Sweating, tremor, tachycardia, anxiety, hunger",
      "Neuroglycopenic symptoms: Dizziness, headache, confusion, abnormal behavior, seizures, loss of consciousness (hypoglycemic coma)"
    ],
    "Object4": [
      "Blood glucose level (≤70 mg/dL, often much lower in severe cases)",
      "Serum insulin, C-peptide (if insulinoma suspected)"
    ],
    "Object5": [
      "Oral carbohydrates (if patient conscious and able to swallow safely)",
      "Intravenous dextrose (50 mL of 50% dextrose) for impaired mental function/unconscious patients, followed by 5-10% dextrose infusion",
      "Glucagon (0.5-1 mg SC/IM) for severe hypoglycemia (if IV access difficult, not effective if liver glycogen depleted)",
      "Octreotide (for recurrent hypoglycemia after dextrose infusion, e.g., sulfonylurea overdose)",
      "Identify and prevent recurrence"
    ],
    "Object6": [
      "Permanent brain damage",
      "Seizures, coma",
      "Falls and injuries"
    ]
  },
  {
    "Object1": "Acute Pulmonary Edema (Management)",
    "Object2": [
      "See Pulmonary Edema (Cardiology section)"
    ],
    "Object3": [
      "See Pulmonary Edema (Cardiology section)",
      "Extreme breathlessness, orthopnea, paroxysmal nocturnal dyspnea",
      "Pink frothy sputum",
      "Tachypnea, tachycardia, hypertension (often)",
      "Basal crackles, diffuse rhonchi, wheezing",
      "S3 gallop, elevated JVP"
    ],
    "Object4": [
      "Clinical diagnosis based on acute dyspnea and characteristic signs",
      "Chest X-ray (shows diffuse alveolar infiltrates, Kerley B lines, cardiomegaly)",
      "ABG (hypoxia, respiratory alkalosis initially, then respiratory acidosis in severe cases)",
      "ECG (for ischemic heart disease, arrhythmias)",
      "Echocardiography (to assess LV function, valvular disease)",
      "BNP (elevated in cardiogenic PE)"
    ],
    "Object5": [
      "Oxygenation (high flow oxygen, noninvasive ventilation - BiPAP/CPAP, or mechanical ventilation)",
      "Preload reduction: Nitroglycerin (sublingual, IV infusion), Furosemide (IV diuretic, venodilator)",
      "Morphine (IV) (reduces anxiety, preload)",
      "Afterload reduction: ACE inhibitors (enalaprilat IV), nitroprusside (IV infusion) (for hypertensive PE)",
      "Inotropic support (dobutamine) for cardiogenic shock",
      "Treat underlying cause (e.g., revascularization for MI, arrhythmia control)"
    ],
    "Object6": [
      "Respiratory failure, ARDS",
      "Cardiogenic shock",
      "Cardiac arrest",
      "Death"
    ]
  },
  {
    "Object1": "Severe Hypercalcemia (Management)",
    "Object2": [
      "Hyperparathyroidism (primary, tertiary)",
      "Malignancy (PTHrP secretion, bone metastases, multiple myeloma)",
      "Vitamin D excess (intoxication, sarcoidosis)",
      "Thiazide diuretics",
      "Immobilization",
      "Lithium therapy",
      "Adrenal insufficiency, hyperthyroidism"
    ],
    "Object3": [
      "Gastrointestinal: Nausea, vomiting, anorexia, constipation",
      "Renal: Polyuria, polydipsia, nephrolithiasis, renal failure",
      "Neurological: Lethargy, confusion, weakness, fatigue, stupor, coma",
      "Cardiac: Shortened QT interval, arrhythmias",
      "Joint and muscle pains"
    ],
    "Object4": [
      "Serum calcium (total and ionized, severe >14 mg/dL)",
      "PTH levels (elevated in hyperparathyroidism, suppressed in malignancy/other causes)",
      "Renal function, electrolytes, phosphate, albumin",
      "ECG (for arrhythmias, QT interval)"
    ],
    "Object5": [
      "Hydration (IV normal saline) (first-line, promotes calciuresis)",
      "Loop diuretics (e.g., furosemide, after rehydration) (enhances calcium excretion)",
      "Bisphosphonates (IV pamidronate, zoledronic acid) (inhibits osteoclast activity, for malignancy-associated hypercalcemia)",
      "Calcitonin (short-term, rapid onset, reduces bone resorption)",
      "Corticosteroids (for specific causes like sarcoidosis, vitamin D intoxication, multiple myeloma)",
      "Dialysis (for severe, refractory hypercalcemia with renal failure)"
    ],
    "Object6": [
      "Acute renal failure",
      "Life-threatening arrhythmias, cardiac arrest",
      "Coma",
      "Nephrocalcinosis"
    ]
  },
  {
    "Object1": "Tension Pneumothorax (Management)",
    "Object2": [
      "See Pneumothorax (Respiratory System section)"
    ],
    "Object3": [
      "See Pneumothorax (Respiratory System section)",
      "Acute dyspnea, cyanosis, severe chest pain",
      "Marked tachycardia, hypotension, signs of shock",
      "Tracheal deviation away from affected side",
      "Absent breath sounds on affected side, hyper-resonant percussion",
      "Distended neck veins",
      "Pulsus paradoxus"
    ],
    "Object4": [
      "Clinical diagnosis (do not delay treatment for imaging)",
      "Chest X-ray (if stable, shows collapsed lung, mediastinal shift, absence of lung markings)",
      "ABG (hypoxia, hypercapnia)"
    ],
    "Object5": [
      "Emergency needle decompression (large-bore needle inserted into 2nd intercostal space, midclavicular line, to release trapped air)",
      "Followed by chest tube insertion with underwater seal drainage",
      "Oxygen administration",
      "Supportive care for shock"
    ],
    "Object6": [
      "Cardiovascular collapse, cardiac arrest",
      "Respiratory failure",
      "Death"
    ]
  },
  {
    "Object1": "Myxedema Coma (Management)",
    "Object2": [
      "See Hypothyroidism (Endocrinology section)",
      "Precipitating factors: Infections, drugs (amiodarone, beta-blockers, diuretics, sedatives), cardiac failure, hypoxia, hyponatremia, hypercapnia"
    ],
    "Object3": [
      "See Hypothyroidism (Endocrinology section)",
      "Severe hypothermia (body temperature <35°C)",
      "Depressed level of consciousness (lethargy, stupor, coma)",
      "Hypoventilation, respiratory acidosis, hypercapnia",
      "Bradycardia, hypotension, cardiomegaly, pericardial effusions",
      "Hypoglycemia, hyponatremia",
      "Myxedema (non-pitting edema)",
      "Myxedema madness (psychosis, delusions, hallucinations)"
    ],
    "Object4": [
      "Clinical diagnosis (do not delay treatment for lab confirmation)",
      "Serum free T4 (low), TSH (high in primary, low/normal in secondary)",
      "Hypoglycemia, hyponatremia, increased CO2, increased CPK",
      "ABG (respiratory acidosis, hypoxia, hypercapnia)",
      "ECG (bradycardia, low voltage QRS)"
    ],
    "Object5": [
      "Thyroid hormone replacement: IV loading dose of T4 (300-500 µg), may add T3 if no response",
      "IV Hydrocortisone (100-200 mg every 6 hours) (to cover for potential adrenal insufficiency)",
      "External warming (gentle, passive rewarming)",
      "Respiratory support (intubation, mechanical ventilation for hypoventilation)",
      "Management of hypoglycemia (IV glucose), hyponatremia (fluid restriction)",
      "Treat precipitating factors (antibiotics for infection)",
      "Monitor cardiac output and pressures"
    ],
    "Object6": [
      "Respiratory failure, cardiac arrest",
      "Severe hypothermia",
      "Death"
    ]
  },
  {
    "Object1": "Thyrotoxic Crisis/Thyroid Storm (Management)",
    "Object2": [
      "See Thyrotoxicosis (Endocrinology section)",
      "Precipitating factors: Infections, surgery, radioactive iodine therapy, iodine contrast agents, diabetic ketoacidosis, acute coronary syndrome, sudden withdrawal of antithyroid medications, severe stress"
    ],
    "Object3": [
      "See Thyrotoxicosis (Endocrinology section)",
      "Hyperpyrexia (104-106°F), flushing, sweating",
      "Marked tachycardia, atrial fibrillation, high pulse pressure, cardiac failure",
      "CNS symptoms: Agitation, restlessness, delirium, psychosis, coma",
      "Gastrointestinal: Nausea, vomiting, diarrhea, jaundice"
    ],
    "Object4": [
      "Clinical diagnosis (do not delay treatment for lab confirmation)",
      "Serum TSH (very low/undetectable), free T3/T4 (markedly elevated)",
      "LFTs, blood glucose, electrolytes, CBC"
    ],
    "Object5": [
      "Control hyperthermia (external cooling, avoid salicylates)",
      "Antithyroid drugs: Propylthiouracil (PTU) (high dose, inhibits synthesis and peripheral conversion of T4 to T3) or Methimazole (inhibits synthesis)",
      "Iodine solution (Lugol's iodine, sodium iopodate) (inhibits hormone release, given 1 hour after PTU/methimazole)",
      "Beta-adrenergic blockers (Propranolol IV/oral) (controls sympathetic symptoms, blocks T4 to T3 conversion)",
      "Corticosteroids (IV hydrocortisone) (suppresses manifestations, reduces T4 to T3 conversion)",
      "Benzodiazepines (for agitation)",
      "Cholestyramine (decreases thyroid hormone levels)",
      "Manage cardiac failure (digoxin), treat precipitating infections"
    ],
    "Object6": [
      "Heart failure, cardiac arrest",
      "Multi-organ failure",
      "Death (high mortality rate)"
    ]
  },
  {
    "Object1": "Acute Adrenal Insufficiency (Adrenal Crisis, Management)",
    "Object2": [
      "See Adrenocortical Insufficiency (Endocrinology section)",
      "Often in patients with underlying Addison's disease exposed to stress (infection, trauma, surgery, dehydration)",
      "Bilateral adrenal infarction or hemorrhage (Waterhouse-Friderichsen syndrome)"
    ],
    "Object3": [
      "See Adrenocortical Insufficiency (Endocrinology section)",
      "Profound shock (hypotension, tachycardia, cold clammy skin)",
      "Severe fatigue, weakness, lethargy, confusion, coma",
      "Nausea, vomiting, severe abdominal pain",
      "Fever (often), severe dehydration",
      "Hyponatremia, hyperkalemia, hypoglycemia",
      "Pigmentation (if chronic primary insufficiency)"
    ],
    "Object4": [
      "Clinical diagnosis (do not delay treatment for lab confirmation)",
      "Serum cortisol (low), ACTH (high in primary, low in secondary), renin (high), aldosterone (low)",
      "Hyponatremia, hyperkalemia, hypoglycemia",
      "CBC (eosinophilia, lymphocytosis)",
      "Blood cultures (if infection suspected)"
    ],
    "Object5": [
      "IV Hydrocortisone (100 mg IV bolus, then 100 mg every 6-8 hours, followed by tapering)",
      "Fluid resuscitation (IV normal saline, often 2-3 L in first hour) to correct hypovolemia and hyponatremia",
      "IV Glucose (25% dextrose) for hypoglycemia",
      "Treat precipitating cause (e.g., antibiotics for infection)",
      "Monitor vital signs, electrolytes, glucose closely"
    ],
    "Object6": [
      "Hypovolemic shock, cardiac arrest",
      "Severe hyponatremia, hyperkalemia, hypoglycemia",
      "Death"
    ]
  },
  {
    "Object1": "Status Epilepticus (Management)",
    "Object2": [
      "See Seizures and Epilepsy (Neurology section)"
    ],
    "Object3": [
      "Continuous seizure activity or repeated seizures without recovery of consciousness for >5 minutes",
      "Generalized tonic-clonic movements, or subtle non-convulsive signs",
      "Respiratory distress, hypoxia",
      "Tachycardia, hypertension, hyperthermia",
      "Metabolic acidosis, rhabdomyolysis"
    ],
    "Object4": [
      "Clinical diagnosis (time seizures accurately)",
      "Blood tests (glucose, electrolytes, renal/liver function, anticonvulsant drug levels, toxicology screen, CK, ABG, lactate)",
      "EEG (for nonconvulsive status epilepticus)",
      "CT/MRI brain (to identify underlying cause: hemorrhage, stroke, tumor, infection)",
      "Lumbar puncture (if infection suspected)"
    ],
    "Object5": [
      "Immediate airway management, oxygen, IV access",
      "First-line: IV Benzodiazepines (lorazepam, diazepam, midazolam)",
      "Second-line: IV Anticonvulsants (fosphenytoin, levetiracetam, valproate, lacosamide)",
      "Third-line (refractory): Continuous IV infusions (midazolam, propofol, pentobarbital) in ICU, often with EEG monitoring",
      "Treat underlying cause (e.g., correct hypoglycemia, electrolytes, antibiotics for infection)",
      "Supportive care (temperature control, fluid balance, DVT prophylaxis)"
    ],
    "Object6": [
      "Permanent brain damage",
      "Respiratory failure, aspiration pneumonia",
      "Multi-organ failure (rhabdomyolysis, AKI, cardiac arrhythmias)",
      "Death"
    ]
  },
  {
    "Object1": "Coma (Emergency Management)",
    "Object2": [
      "See Coma (Neurology section)"
    ],
    "Object3": [
      "See Coma (Neurology section)",
      "Unarousable unresponsiveness, absence of voluntary movement",
      "Variable brainstem reflexes, abnormal breathing patterns"
    ],
    "Object4": [
      "Immediate neurological examination (GCS, pupils, brainstem reflexes, motor response)",
      "Blood tests (electrolytes, glucose, renal/liver function, CBC, ABG, toxicology screen, ammonia, thyroid function)",
      "Neuroimaging (CT scan immediately to rule out hemorrhage, mass, hydrocephalus)",
      "Lumbar puncture (if meningitis/encephalitis suspected with negative CT)",
      "EEG (to detect nonconvulsive status epilepticus)"
    ],
    "Object5": [
      "Emergency management (ABCs: Airway, Breathing, Circulation)",
      "Identify and treat reversible causes urgently:",
      "IV Glucose for hypoglycemia",
      "Naloxone for opioid overdose",
      "Thiamine for Wernicke's encephalopathy",
      "Flumazenil for benzodiazepine overdose (with caution)",
      "Antimicrobial therapy for infections",
      "Manage increased intracranial pressure",
      "Antiepileptic drugs for seizures",
      "Supportive care (ventilatory support, fluid/electrolyte balance, temperature control, nutritional support)",
      "Consider neurosurgical intervention for mass lesions"
    ],
    "Object6": [
      "Brain death",
      "Permanent neurological deficits",
      "Aspiration pneumonia",
      "Death"
    ]
  },
  {
    "Object1": "Snake Bite (Emergency Management)",
    "Object2": [
      "See Snakebite (Toxicology section)"
    ],
    "Object3": [
      "See Snakebite (Toxicology section)",
      "Neurotoxic: Progressive flaccid paralysis, respiratory failure, ptosis, dysphagia",
      "Hemotoxic/Cytotoxic: Local pain/swelling/necrosis, coagulopathy, bleeding, hypotension, shock, AKI"
    ],
    "Object4": [
      "See Snakebite (Toxicology section)",
      "20-minute Whole Blood Clotting Test (20WBCT)",
      "Coagulation profile, renal function, CK, ABG"
    ],
    "Object5": [
      "Immobilize bitten limb, keep below heart level",
      "Antivenom (ASV) (given IV, titrated to response, crucial for systemic envenomation)",
      "Airway management and ventilatory support (mechanical ventilation often required for neurotoxic bites)",
      "Supportive care: Fluid resuscitation for shock, pain control, antibiotics for secondary infection, manage AKI, rhabdomyolysis",
      "Tetanus prophylaxis"
    ],
    "Object6": [
      "Respiratory failure, aspiration pneumonia",
      "Coagulopathy, severe bleeding, intracranial hemorrhage",
      "Acute kidney injury, rhabdomyolysis",
      "Local tissue necrosis, amputation",
      "Anaphylaxis to antivenom"
    ]
  },
  {
    "Object1": "Hypovolemia (Emergency Management)",
    "Object2": [
      "See Volume Depletion (Fluid and Electrolyte Disturbances section)"
    ],
    "Object3": [
      "See Volume Depletion (Fluid and Electrolyte Disturbances section)",
      "Thirst, dry mucous membranes, decreased skin turgor",
      "Oliguria, concentrated urine",
      "Orthostatic hypotension, tachycardia",
      "Cool extremities, prolonged capillary refill time",
      "Hypotension, signs of hypovolemic shock"
    ],
    "Object4": [
      "CBC (hemoglobin/hematocrit), BUN/creatinine ratio, electrolytes",
      "Urine specific gravity and osmolality",
      "CVP measurement (low)"
    ],
    "Object5": [
      "Fluid replacement: Rapid IV crystalloids (normal saline, Ringer's lactate) or colloids",
      "Treat underlying cause (e.g., antiemetics, antidiarrheals, control bleeding)",
      "Monitor vital signs, urine output, fluid balance"
    ],
    "Object6": [
      "Hypovolemic shock, prerenal AKI",
      "Electrolyte disturbances"
    ]
  },
  {
    "Object1": "Shock (Emergency Management)",
    "Object2": [
      "See Circulatory Failure: Shock (Cardiology section)"
    ],
    "Object3": [
      "See Circulatory Failure: Shock (Cardiology section)",
      "Hypotension, tachycardia (except neurogenic shock), altered mental status",
      "Cool, clammy skin (hypovolemic, cardiogenic, obstructive) or warm skin (distributive early)",
      "Oliguria",
      "Metabolic acidosis (lactic acidosis)"
    ],
    "Object4": [
      "ABG (lactic acidosis, hypoxia)",
      "Lactate levels (elevated)",
      "Cardiac enzymes (if cardiogenic shock)",
      "CBC, electrolytes, renal function",
      "ECG, echocardiography",
      "CVP monitoring, urine output",
      "Blood cultures (if septic shock)",
      "Imaging (CT for trauma, PE, pancreatitis)"
    ],
    "Object5": [
      "ABCs of resuscitation (Airway, Breathing, Circulation)",
      "Fluid resuscitation (IV crystalloids, titrated to volume status, avoid excessive fluids in cardiogenic/ARDS)",
      "Vasopressors (norepinephrine, dopamine, vasopressin) (for hypotension refractory to fluids)",
      "Inotropes (dobutamine) (for cardiogenic shock with low cardiac output)",
      "Treat underlying cause immediately (e.g., antibiotics for sepsis, thrombolysis/embolectomy for PE, pericardiocentesis for tamponade, revascularization for MI)",
      "Corticosteroids (for septic shock, anaphylactic shock)",
      "Supportive care (oxygenation, ventilatory support, temperature control, glycemic control)"
    ],
    "Object6": [
      "Multi-organ dysfunction syndrome (MODS)",
      "Acute kidney injury, ARDS, liver failure",
      "Cardiac arrest",
      "Death"
    ]
  },
  {
    "Object1": "Ischemic Stroke (Emergency Management)",
    "Object2": [
      "See Stroke and Cerebrovascular Disease (Neurology section)"
    ],
    "Object3": [
      "See Stroke and Cerebrovascular Disease (Neurology section)",
      "Sudden onset focal neurological deficits (hemiparesis, aphasia, visual field deficits)",
      "Altered consciousness",
      "Severe headache (less common than hemorrhagic)"
    ],
    "Object4": [
      "Emergency CT scan brain (to rule out hemorrhage)",
      "MRI brain (for ischemic stroke, if CT negative)",
      "CT angiography / MR angiography (for large vessel occlusion)",
      "Blood tests (glucose, coagulation, CBC)"
    ],
    "Object5": [
      "IV Thrombolysis (tPA) (within 4.5 hours of symptom onset, if eligible)",
      "Mechanical thrombectomy (for large vessel occlusion, within 6-24 hours)",
      "Blood pressure management (permissive hypertension initially, then control)",
      "Antiplatelet agents (aspirin) after thrombolysis or if not eligible for thrombolysis",
      "Glycemic control, temperature management",
      "Supportive care (airway, breathing, circulation, prevent aspiration)",
      "DVT prophylaxis"
    ],
    "Object6": [
      "Hemorrhagic transformation of infarct",
      "Brain edema, increased ICP",
      "Seizures",
      "Aspiration pneumonia",
      "Long-term neurological disability",
      "Death"
    ]
  },
  {
    "Object1": "Hyperventilation (Acute)",
    "Object2": [
      "Anxiety, panic attack (most common, psychogenic)",
      "Pain",
      "Hypoxia (asthma, COPD exacerbation, pulmonary embolism, pneumonia)",
      "Metabolic acidosis (compensatory, e.g., DKA, lactic acidosis)",
      "Fever, sepsis",
      "Drugs (salicylates)",
      "CNS disorders (stroke, head injury)"
    ],
    "Object3": [
      "Rapid, deep breathing (tachypnea)",
      "Dyspnea, sensation of suffocation",
      "Lightheadedness, dizziness, faintness",
      "Paresthesias (tingling in fingers, circumoral area) (due to respiratory alkalosis and hypocalcemia)",
      "Muscle cramps, carpopedal spasm, tetany (due to hypocalcemia)",
      "Chest pain, palpitations",
      "Anxiety, panic, fear"
    ],
    "Object4": [
      "ABG (respiratory alkalosis: high pH, low PaCO2, normal or slightly low bicarbonate)",
      "Blood tests (electrolytes, glucose, lactate, cardiac enzymes to rule out other causes)",
      "ECG (for cardiac causes)",
      "Chest X-ray (for pulmonary causes)"
    ],
    "Object5": [
      "Address underlying cause (e.g., treat pain, anxiety, hypoxia, acidosis)",
      "Reassurance and breathing retraining (slow, diaphragmatic breathing)",
      "Breathing into a paper bag (for psychogenic hyperventilation, to re-breathe CO2, not recommended if underlying organic cause)",
      "Anxiolytics (benzodiazepines) for severe anxiety/panic",
      "Correct hypoxia (oxygen therapy for organic causes)"
    ],
    "Object6": [
      "Fainting, collapse",
      "Tetany, seizures (rare)",
      "Exacerbation of underlying cardiac or pulmonary conditions",
      "Anxiety spiral"
    ]
  },
  {
    "Object1": "Acute Pulmonary Embolism (Management)",
    "Object2": [
      "See Pulmonary Embolism and Venous Thrombosis (Cardiology section)"
    ],
    "Object3": [
      "See Pulmonary Embolism and Venous Thrombosis (Cardiology section)",
      "Sudden onset dyspnea, pleuritic chest pain",
      "Tachypnea, tachycardia",
      "Hypoxia, cyanosis",
      "Hemoptysis",
      "Syncope, hypotension, signs of shock (in massive PE)",
      "Elevated JVP, right ventricular heave (acute cor pulmonale)"
    ],
    "Object4": [
      "D-dimer (elevated, but non-specific)",
      "CT Pulmonary Angiography (CTPA) (diagnostic gold standard)",
      "ABG (hypoxia, hypocapnia)",
      "ECG (sinus tachycardia, S1Q3T3 pattern, right heart strain)",
      "Echocardiography (for right ventricular dysfunction, not diagnostic of PE itself)",
      "Wells score/Geneva score (clinical probability)"
    ],
    "Object5": [
      "Oxygen administration (to maintain SaO2 >90%)",
      "Anticoagulation (IV unfractionated heparin or LMWH, followed by oral anticoagulants like warfarin or DOACs for 3-6 months)",
      "Thrombolytic therapy (IV streptokinase, alteplase, tenecteplase) (for massive PE with hemodynamic instability, or submassive PE with RV dysfunction)",
      "Surgical pulmonary embolectomy (for massive PE if thrombolysis contraindicated or failed)",
      "Catheter-directed thrombolysis/embolectomy (alternative to systemic thrombolysis/surgery)",
      "IVC filter placement (for patients with contraindications to anticoagulation or recurrent PE despite anticoagulation)",
      "Supportive care (fluid resuscitation, vasopressors if shock)"
    ],
    "Object6": [
      "Cardiovascular collapse, cardiac arrest",
      "Acute right heart failure (cor pulmonale)",
      "Recurrent PE",
      "Chronic thromboembolic pulmonary hypertension (CTEPH)",
      "Bleeding from anticoagulation/thrombolysis",
      "Death"
    ]
  },
  {
    "Object1": "Hemoptysis (Emergency Management)",
    "Object2": [
      "See Hemoptysis (Respiratory System section)"
    ],
    "Object3": [
      "See Hemoptysis (Respiratory System section)",
      "Coughing up blood (blood-streaked sputum to gross blood)",
      "Massive hemoptysis (>150 mL/time or >600 mL/24 hours, or any amount threatening airway/hemodynamics)",
      "Dyspnea, hypoxia",
      "Anxiety, panic",
      "Signs of aspiration or respiratory compromise"
    ],
    "Object4": [
      "Immediate assessment of airway, breathing, circulation",
      "Chest X-ray (may show localized lesion, infiltrates, effusion)",
      "CT scan chest (locates bleeding site, identifies underlying cause)",
      "Bronchoscopy (identifies bleeding site, allows therapeutic intervention)",
      "CBC (hemoglobin/hematocrit), coagulation profile, ABG",
      "Sputum studies (for TB, infection, malignancy)"
    ],
    "Object5": [
      "Maintain airway, oxygenation, intubation if massive hemoptysis/airway compromise",
      "Position patient with bleeding side down (to prevent aspiration into contralateral lung)",
      "Secure IV access, fluid resuscitation, blood transfusion if needed",
      "Antitussives (benzodiazepines) for severe cough",
      "Identify and control bleeding source:",
      "Bronchoscopy (cold saline lavage, balloon tamponade, laser photocoagulation)",
      "Bronchial artery embolization (most effective for massive hemoptysis)",
      "Surgical resection (for localized, refractory bleeding)",
      "Treat underlying cause (e.g., antitubercular drugs for TB, antibiotics for infection)"
    ],
    "Object6": [
      "Airway obstruction, asphyxiation",
      "Aspiration pneumonia",
      "Hypovolemic shock, cardiac arrest",
      "Recurrence",
      "Death"
    ]
  },
  {
    "Object1": "Hypertensive Emergency/Crisis (Management)",
    "Object2": [
      "See Hypertension (Cardiology section)",
      "Abrupt, severe elevation of blood pressure (SBP >180 mmHg or DBP >120 mmHg) with acute end-organ damage",
      "Causes: Non-adherence to antihypertensives, renovascular disease, pheochromocytoma, preeclampsia/eclampsia, acute glomerulonephritis, stimulant use, aortic dissection"
    ],
    "Object3": [
      "Severe headache, nausea, vomiting",
      "Neurological: Confusion, seizures, focal neurological deficits (hypertensive encephalopathy, stroke)",
      "Cardiovascular: Chest pain (ACS, aortic dissection), dyspnea (acute pulmonary edema)",
      "Renal: Acute kidney injury (AKI), hematuria",
      "Ophthalmic: Papilledema, retinal hemorrhages/exudates (hypertensive retinopathy grade III/IV)"
    ],
    "Object4": [
      "Immediate BP measurement (repeated, bilateral)",
      "ECG (for ischemia, LVH)",
      "Urinalysis (proteinuria, hematuria)",
      "Blood tests (renal function, electrolytes, CBC, cardiac enzymes, toxicology screen)",
      "Neuroimaging (CT brain for hemorrhage, edema)",
      "Chest X-ray (for pulmonary edema, aortic dissection)",
      "Fundoscopy (for papilledema, retinopathy)"
    ],
    "Object5": [
      "Immediate hospitalization, often ICU",
      "Gradual reduction of Mean Arterial Pressure (MAP) by 20-25% over the first hour (to prevent hypoperfusion), then to 160/100-110 mmHg over 24-48 hours (except aortic dissection, acute PE, pheochromocytoma where rapid BP reduction is needed)",
      "IV Antihypertensive agents (nicardipine, labetalol, fenoldopam, clevidipine, nitroprusside, hydralazine, enalaprilat) (titrated to BP target)",
      "Specific agents for specific emergencies (e.g., esmolol/labetalol + nitroprusside for aortic dissection, nitroglycerine for ACS/pulmonary edema)",
      "Supportive care, continuous monitoring"
    ],
    "Object6": [
      "Stroke (ischemic or hemorrhagic)",
      "Acute myocardial infarction, acute heart failure, aortic dissection",
      "Acute kidney injury",
      "Hypertensive encephalopathy",
      "Death"
    ]
  },
  {
    "Object1": "Severe Dehydration (Emergency Management)",
    "Object2": [
      "See Volume Depletion (Fluid and Electrolyte Disturbances section)"
    ],
    "Object3": [
      "See Volume Depletion (Fluid and Electrolyte Disturbances section)",
      "Extreme thirst, very dry mucous membranes, absent skin turgor",
      "Oliguria or anuria",
      "Orthostatic hypotension to overt hypotension and shock",
      "Marked tachycardia, weak peripheral pulses",
      "Sunken eyes, lethargy, confusion, coma",
      "Associated electrolyte disturbances (hypernatremia, hyponatremia, hyper/hypokalemia)"
    ],
    "Object4": [
      "Clinical assessment of severe dehydration",
      "Blood tests (elevated hematocrit, BUN/creatinine ratio, variable electrolytes, glucose, osmolality)",
      "Urinalysis (high specific gravity, high osmolality)",
      "ABG (metabolic acidosis if hypoperfusion)"
    ],
    "Object5": [
      "Rapid intravenous fluid resuscitation (normal saline or Ringer's lactate) to restore circulating volume",
      "Correct associated electrolyte imbalances (especially hypernatremia or severe hyponatremia, hyperkalemia)",
      "Treat underlying cause (e.g., antiemetics, antidiarrheals, control bleeding)",
      "Monitor vital signs, urine output, fluid balance, and mental status closely"
    ],
    "Object6": [
      "Hypovolemic shock, multi-organ failure",
      "Acute kidney injury",
      "Severe electrolyte disturbances (can cause seizures, arrhythmias)",
      "Death"
    ]
  },
  {
    "Object1": "Cardiac Arrest (Management)",
    "Object2": [
      "See Cardiac Arrest (Cardiology section)",
      "Hypoxia, hypovolemia, hypothermia, hypo/hyperkalemia, acidosis, hypoglycemia",
      "Toxins, tamponade, tension pneumothorax, thrombosis (coronary, pulmonary)"
    ],
    "Object3": [
      "Sudden loss of consciousness",
      "Absence of apical and central pulsations (carotid, femoral)",
      "Apnea (no breathing or only gasping)"
    ],
    "Object4": [
      "ECG (to identify rhythm: ventricular fibrillation, pulseless VT, asystole, pulseless electrical activity)",
      "ABG (for hypoxia, acidosis)",
      "Blood tests (electrolytes, glucose, toxicology screen, cardiac enzymes)"
    ],
    "Object5": [
      "Immediate initiation of Chain of Survival:",
      "Early recognition and activation of Emergency Response System (ERS)",
      "High-quality Cardiopulmonary Resuscitation (CPR) (CAB: Chest compressions, Airway, Breathing - minimal interruptions, compressions 100-120/min, depth 5-6 cm, ratio 30:2 for single rescuer)",
      "Rapid Defibrillation (for shockable rhythms: VF/pulseless VT)",
      "Advanced Cardiac Life Support (ACLS) (IV access, drugs - epinephrine, amiodarone for arrhythmias, correct reversible causes (H's and T's))",
      "Integrated Post-Cardiac Arrest Care (therapeutic hypothermia, optimal oxygenation/ventilation/hemodynamics, manage seizures, treat underlying cause)"
    ],
    "Object6": [
      "Brain death, permanent neurological damage",
      "Multi-organ failure",
      "Complications of CPR (rib/sternal fractures, lung/liver injury)",
      "Death"
    ]
  },
  {
    "Object1": "Ventricular Fibrillation (Management)",
    "Object2": [
      "See Ventricular Fibrillation (Cardiology section)"
    ],
    "Object3": [
      "See Ventricular Fibrillation (Cardiology section)",
      "Rapid, irregular, uncoordinated ventricular movements (ECG)",
      "No mechanical cardiac output",
      "Pulseless, unconscious, apneic"
    ],
    "Object4": [
      "ECG (shows chaotic, shapeless, rapid oscillations)",
      "Clinical assessment (pulselessness, unresponsiveness)"
    ],
    "Object5": [
      "Immediate Defibrillation (high energy DC shock) (most critical intervention)",
      "High-quality CPR (before and immediately after defibrillation attempts)",
      "Epinephrine (IV) (vasopressor, given after initial shocks)",
      "Amiodarone (IV) (antiarrhythmic, given after refractory VF/pulseless VT)",
      "Lidocaine (alternative to amiodarone)",
      "Correct reversible causes (hypoxia, electrolyte imbalances, ischemia)",
      "Advanced airway management and ventilatory support"
    ],
    "Object6": [
      "Cardiac arrest, asystole",
      "Anoxic brain injury",
      "Death"
    ]
  },
  {
    "Object1": "Upper Gastrointestinal Bleed (UGIB, Emergency Management)",
    "Object2": [
      "See Gastrointestinal Bleeding (Gastroenterology section)"
    ],
    "Object3": [
      "See Gastrointestinal Bleeding (Gastroenterology section)",
      "Hematemesis (bright red blood or coffee-ground vomitus)",
      "Melena (black, tarry stools)",
      "Hematochezia (if massive UGIB with rapid transit)",
      "Symptoms of hypovolemia/shock (tachycardia, hypotension, pallor, dizziness, syncope)",
      "Epigastric pain, nausea, vomiting"
    ],
    "Object4": [
      "Immediate assessment of hemodynamic stability",
      "CBC (hemoglobin/hematocrit), coagulation profile (PT/INR, aPTT), BUN/creatinine",
      "Blood type and crossmatch",
      "Upper endoscopy (diagnostic and therapeutic, performed urgently)",
      "Nasogastric tube lavage (assess for ongoing bleeding)",
      "Angiography (if endoscopy fails or for massive bleeding)"
    ],
    "Object5": [
      "Fluid resuscitation (IV crystalloids, blood transfusion for significant blood loss)",
      "Airway protection (intubation if high risk of aspiration)",
      "IV Proton Pump Inhibitor (PPI) (e.g., pantoprazole, esomeprazole) (for non-variceal bleeding)",
      "Endoscopic therapy (epinephrine injection, thermal coagulation, hemostatic clips, band ligation for varices)",
      "IV Octreotide (for variceal bleeding)",
      "Antibiotics (for variceal bleeding prophylaxis)",
      "Surgical intervention (for refractory bleeding or complications like perforation)",
      "TIPS (Transjugular Intrahepatic Portosystemic Shunt) (for refractory variceal bleeding)"
    ],
    "Object6": [
      "Hypovolemic shock, cardiac arrest",
      "Severe anemia",
      "Aspiration pneumonia",
      "Perforation",
      "Recurrent bleeding",
      "Death"
    ]
  },
  {
    "Object1": "Emergency Management of Acute Myocardial Infarction (AMI)",
    "Object2": [
      "See Acute Coronary Syndrome (Cardiology section)"
    ],
    "Object3": [
      "See Acute Coronary Syndrome (Cardiology section)",
      "Prolonged cardiac chest pain (>20 minutes, constricting, crushing, radiating to left arm/jaw, not relieved by rest/nitrates)",
      "Nausea, vomiting, diaphoresis, dyspnea, anxiety, sense of impending doom",
      "Signs of heart failure (rales, S3), hypotension, tachycardia/bradycardia"
    ],
    "Object4": [
      "ECG (12-lead, immediately - within 10 minutes) (ST elevation, new LBBB, ST depression/T inversion)",
      "Plasma cardiac biomarkers (Troponin I/T, CK-MB) (serial measurements)",
      "Blood tests (CBC, electrolytes, renal function, lipid profile, glucose)",
      "Chest X-ray (for pulmonary edema, cardiomegaly)",
      "Echocardiography (for ventricular function, complications)"
    ],
    "Object5": [
      "Immediate admission to ICU/CCU",
      "MONA: Morphine (for pain), Oxygen (if hypoxic), Nitroglycerin (sublingual/IV for pain), Aspirin (chewable, antiplatelet)",
      "Antiplatelet therapy (Aspirin + P2Y12 inhibitor - clopidogrel, prasugrel, ticagrelor)",
      "Anticoagulation (heparin, LMWH)",
      "Reperfusion therapy (for STEMI, within optimal timeframes):",
      "Primary Percutaneous Coronary Intervention (PCI) (preferred, angioplasty/stent)",
      "Fibrinolytic therapy (streptokinase, alteplase, tenecteplase) (if PCI not available)",
      "Beta-blockers (oral, unless contraindicated)",
      "ACE inhibitors/ARBs",
      "Statins (high-dose)",
      "Management of complications (arrhythmias, heart failure, cardiogenic shock, mechanical complications)"
    ],
    "Object6": [
      "Arrhythmias (VF, VT, heart blocks)",
      "Heart failure, pulmonary edema, cardiogenic shock",
      "Cardiac rupture (papillary muscle, septum, free wall)",
      "Mitral regurgitation, ventricular septal defect",
      "Ventricular aneurysm",
      "Pericarditis",
      "Thromboembolism (systemic, pulmonary)",
      "Death"
    ]
  },
  {
    "Object1": "Anaphylaxis (Management)",
    "Object2": [
      "See Hypersensitivity Reactions (Immunology section) - Type I IgE-mediated",
      "Allergens: Food (peanuts, tree nuts, shellfish, milk, eggs), insect venom (bees, wasps), drugs (penicillins, NSAIDs, contrast media), latex, physical stimuli (cold, exercise)",
      "Non-IgE mediated (anaphylactoid reactions): NSAIDs, opioids, contrast media"
    ],
    "Object3": [
      "Rapid onset (minutes to hours), multi-system involvement",
      "Cutaneous: Urticaria, angioedema (face, lips, tongue, larynx), pruritus, flushing",
      "Respiratory: Bronchospasm, dyspnea, wheezing, stridor, hoarseness, upper airway obstruction",
      "Cardiovascular: Hypotension, tachycardia, dizziness, syncope, shock, cardiac arrest",
      "Gastrointestinal: Nausea, vomiting, abdominal cramps, diarrhea",
      "Neurological: Anxiety, confusion, feeling of impending doom"
    ],
    "Object4": [
      "Clinical diagnosis (rapid onset, multi-system involvement, exposure to trigger)",
      "Serum mast cell tryptase (elevated, confirms mast cell degranulation, peaks 1-2 hours post-reaction)",
      "Plasma histamine (short half-life, less reliable)",
      "Allergy testing (skin prick, specific IgE) (after recovery, to identify trigger)"
    ],
    "Object5": [
      "Immediate administration of Epinephrine (Adrenaline) (IM, 0.3-0.5 mg in adults, 0.01 mg/kg in children) (first-line, repeated every 5-15 minutes if needed)",
      "Remove trigger (e.g., stop drug infusion)",
      "Airway management, oxygen administration, ventilatory support if needed",
      "IV fluids (for hypotension, shock)",
      "H1 and H2 antihistamines (IV diphenhydramine, ranitidine) (adjunctive for skin/GI symptoms)",
      "Corticosteroids (IV methylprednisolone, oral prednisone) (adjunctive to prevent protracted or biphasic reactions)",
      "Bronchodilators (albuterol nebulization) for bronchospasm",
      "Monitor vital signs, respiratory status, mental status"
    ],
    "Object6": [
      "Airway obstruction, respiratory arrest",
      "Cardiovascular collapse, cardiac arrest",
      "Anoxic brain injury",
      "Biphasic reactions",
      "Death"
    ]
  },
  {
    "Object1": "Angina (Emergency Management)",
    "Object2": [
      "See Ischemic Heart Disease (Cardiology section)",
      "Stable angina (exacerbation by increased demand)",
      "Unstable angina (new onset, worsening, rest angina, often due to plaque rupture/thrombosis)"
    ],
    "Object3": [
      "See Ischemic Heart Disease (Cardiology section)",
      "Chest discomfort (constricting, squeezing, pressure, burning)",
      "Radiation to left arm, jaw, neck, back",
      "Associated symptoms: Dyspnea, diaphoresis, nausea, vomiting, palpitations, anxiety",
      "Atypical symptoms in women, elderly, diabetics"
    ],
    "Object4": [
      "ECG (12-lead, immediately) (ST depression, T wave inversion in unstable angina; normal in stable angina)",
      "Cardiac biomarkers (Troponin I/T) (normal in stable angina, may be elevated in NSTEMI if progressing)",
      "Blood tests (CBC, electrolytes, renal function, glucose)",
      "Chest X-ray (rule out other causes)"
    ],
    "Object5": [
      "MONA: Morphine, Oxygen, Nitroglycerin (sublingual/IV), Aspirin",
      "Antiplatelet therapy (Aspirin, P2Y12 inhibitors)",
      "Anticoagulation (heparin, LMWH) (for unstable angina/NSTEMI)",
      "Beta-blockers (oral/IV, unless contraindicated)",
      "Calcium channel blockers (for vasospastic angina or if beta-blockers contraindicated)",
      "Risk stratification (TIMI score, GRACE score for ACS)",
      "Consider early revascularization (PCI or CABG) for high-risk unstable angina"
    ],
    "Object6": [
      "Progression to myocardial infarction (NSTEMI/STEMI)",
      "Arrhythmias",
      "Heart failure",
      "Cardiac arrest"
    ]
  },
  {
    "Object1": "Acute Severe Asthma (Status Asthmaticus, Management)",
    "Object2": [
      "See Bronchial Asthma (Respiratory System section)",
      "Triggers: Viral respiratory infections (most common), allergens, irritants, medications (NSAIDs, beta-blockers), non-adherence to controller medications"
    ],
    "Object3": [
      "See Bronchial Asthma (Respiratory System section)",
      "Severe, persistent dyspnea, wheezing, cough, chest tightness, refractory to standard bronchodilators",
      "Tachypnea, tachycardia",
      "Use of accessory muscles of respiration, suprasternal retractions",
      "Pulsus paradoxus",
      "Cyanosis",
      "Altered mental status (lethargy, confusion, agitation) (ominous sign)",
      "'Silent chest' (ominous sign, severe airflow obstruction)"
    ],
    "Object4": [
      "Clinical assessment of severity (PEF, O2 saturation, mental status, accessory muscle use)",
      "ABG (hypoxia, hypocapnia initially, then normal PaCO2, then hypercapnia - ominous sign)",
      "Chest X-ray (rule out pneumothorax, pneumonia, atelectasis)",
      "Pulmonary function tests (PEF/FEV1 very low)"
    ],
    "Object5": [
      "Oxygen (high flow, to maintain SaO2 >92-95%)",
      "Inhaled short-acting beta-agonists (SABAs, e.g., salbutamol/albuterol) (high dose, nebulized or MDI with spacer, frequent administration)",
      "Inhaled anticholinergics (e.g., ipratropium bromide) (added to SABA)",
      "Systemic corticosteroids (oral prednisone or IV methylprednisolone/hydrocortisone) (early administration)",
      "Magnesium sulfate (IV) (for severe cases refractory to initial therapy)",
      "IV aminophylline (for refractory cases)",
      "Consider non-invasive ventilation (NIV) or mechanical ventilation (for impending/actual respiratory failure)",
      "Treat precipitating factors (antibiotics for infection)"
    ],
    "Object6": [
      "Respiratory failure, cardiac arrest",
      "Pneumothorax, pneumomediastinum",
      "Aspiration pneumonia",
      "Arrhythmias",
      "Death"
    ]
  },
  {
    "Object1": "Diabetic Ketoacidosis (DKA, Emergency Management)",
    "Object2": [
      "See Diabetic Ketoacidosis (Diabetes Mellitus section)",
      "Absolute insulin deficiency or profound insulin resistance",
      "Precipitating factors: Infection, inadequate insulin, infarction (MI, stroke), severe stress, drugs, undiagnosed diabetes"
    ],
    "Object3": [
      "See Diabetic Ketoacidosis (Diabetes Mellitus section)",
      "Hyperglycemia (>250 mg/dL)",
      "Ketonemia/Ketonuria (fruity breath odor)",
      "High anion gap metabolic acidosis (pH <7.3, HCO3 <18 mEq/L)",
      "Polyuria, polydipsia, dehydration",
      "Nausea, vomiting, abdominal pain",
      "Kussmaul respirations",
      "Altered mental status, confusion, coma"
    ],
    "Object4": [
      "Blood glucose (>250 mg/dL)",
      "Ketones (blood and urine)",
      "ABG (high anion gap metabolic acidosis)",
      "Electrolytes (hyponatremia, hyperkalemia initially, then hypokalemia with treatment)",
      "BUN/creatinine (for dehydration)",
      "Infection screen (CBC, urinalysis, cultures)",
      "ECG (for hyperkalemia)"
    ],
    "Object5": [
      "IV Fluid resuscitation (normal saline, then 0.45% saline, then D5W + 0.45% saline when glucose <250 mg/dL)",
      "IV Insulin infusion (regular insulin, 0.1 U/kg/hr, to lower glucose gradually and resolve ketosis)",
      "Potassium repletion (start once K+ <5.2 mEq/L and urine output established, aggressive replacement needed as K+ shifts into cells)",
      "Sodium bicarbonate (IV) (only for severe acidosis, pH <6.9, or specific indications)",
      "Treat precipitating cause (e.g., antibiotics for infection)",
      "Monitor glucose, electrolytes, ABG every 1-2 hours"
    ],
    "Object6": [
      "Cerebral edema (especially in children, if rapid fluid/glucose shifts)",
      "Severe electrolyte imbalances (hypokalemia, hyperkalemia, hyponatremia)",
      "Acute respiratory distress syndrome (ARDS)",
      "Vascular thrombosis",
      "Death"
    ]
  },
  {
    "Object1": "FLUID AND ELECTROLYTE DISTURBANCES",
    "Object2": "This section was already provided in the previous turn."
  },
  {
    "Object1": "Vertigo",
    "Object2": [
      "Peripheral causes (most common): Benign Paroxysmal Positional Vertigo (BPPV), Meniere's disease, vestibular neuritis, labyrinthitis, otitis media, acoustic neuroma",
      "Central causes (less common, more serious): Stroke (vertebrobasilar ischemia), multiple sclerosis, migraine, brainstem tumors, vestibular migraine, epilepsy",
      "Other: Drugs (aminoglycosides, salicylates, alcohol), head trauma, anxiety"
    ],
    "Object3": [
      "Sensation of spinning or swaying (patient or environment)",
      "Nausea, vomiting, imbalance",
      "Nystagmus (involuntary eye movements)",
      "Hearing loss, tinnitus, aural fullness (in Meniere's disease)",
      "Headache (in migraine-associated vertigo)",
      "Focal neurological deficits (in central vertigo)"
    ],
    "Object4": [
      "Clinical examination (Dix-Hallpike maneuver for BPPV, HINTS exam for central vs. peripheral, neurological exam)",
      "Audiometry (for hearing loss)",
      "Electronystagmography (ENG) or Videonystagmography (VNG)",
      "MRI brain (if central cause suspected, e.g., stroke, MS, tumor)",
      "Blood tests (thyroid function, glucose, autoimmune markers)"
    ],
    "Object5": [
      "Treat underlying cause",
      "Vestibular suppressants (meclizine, dimenhydrinate, benzodiazepines) for acute symptom relief",
      "Antiemetics (ondansetron)",
      "Epley maneuver (for BPPV)",
      "Vestibular rehabilitation therapy",
      "For Meniere's disease: Salt restriction, diuretics, betahistine, intratympanic injections (corticosteroids, gentamicin)"
    ],
    "Object6": [
      "Falls and injuries",
      "Chronic imbalance",
      "Anxiety and depression",
      "Hearing loss (in Meniere's disease, labyrinthitis)"
    ]
  },
  {
    "Object1": [
      "NSAIDs (ibuprofen, naproxen)",
      "Triptans (sumatriptan, zolmitriptan) for migraine",
      "Ergotamines for migraine",
      "Oxygen (for cluster headache)",
      "Antiemetics (ondansetron)",
      "Corticosteroids (for severe cluster headache, giant cell arteritis)",
      "Opioids (use with caution, risk of medication overuse headache)"
    ],
    "Object2": [
      "Beta-blockers (propranolol, metoprolol) for migraine",
      "Antidepressants (amitriptyline, venlafaxine) for chronic tension-type headache, migraine",
      "Anticonvulsants (topiramate, valproate) for migraine",
      "Calcium channel blockers (verapamil) for cluster headache",
      "CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) for migraine",
      "Botulinum toxin (for chronic migraine)",
      "Lifestyle modifications (stress management, regular sleep, avoid triggers)",
      "Treat underlying cause for secondary headaches"
    ]
  },
  {
    "Object1": [
      "Thrombolysis (IV tPA within 4.5 hours of symptom onset for eligible patients)",
      "Mechanical thrombectomy (for large vessel occlusion, within 6-24 hours)",
      "Antiplatelet agents (aspirin, clopidogrel)",
      "Anticoagulation (for cardioembolic stroke after acute phase)",
      "Blood pressure management (permissive hypertension in acute phase, then control)",
      "Glycemic control, temperature management",
      "Supportive care (airway, breathing, circulation)"
    ],
    "Object2": [
      "Blood pressure control (aggressive to prevent rebleeding)",
      "Surgical intervention (clipping/coiling for aneurysms, evacuation of ICH)",
      "Reversal of anticoagulation",
      "Management of intracranial pressure, seizures"
    ],
    "Object3": [
      "Antiplatelet agents (aspirin, clopidogrel, aspirin-dipyridamole)",
      "Anticoagulation (for AF)",
      "Statins (lipid lowering)",
      "Antihypertensives (BP control)",
      "Diabetes management",
      "Lifestyle modifications (smoking cessation, diet, exercise)",
      "Carotid endarterectomy or stenting (for symptomatic carotid stenosis)"
    ]
  },
  {
    "Object1": "Cerebral Venous Thrombosis (CVT)",
    "Object2": [
      "Prothrombotic conditions (most common): Inherited thrombophilias (Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin deficiency), acquired thrombophilias (antiphospholipid syndrome, oral contraceptives, pregnancy, puerperium, malignancy, inflammatory bowel disease, nephrotic syndrome, myeloproliferative neoplasms)",
      "Infections (local - otitis, sinusitis, meningitis; systemic - sepsis)",
      "Dehydration, head trauma, neurosurgery",
      "Autoimmune diseases, drugs (tamoxifen, corticosteroids)"
    ],
    "Object3": [
      "Highly variable and non-specific, leading to delayed diagnosis",
      "Headache (most common, often severe, progressive, thunderclap-like, or diffuse)",
      "Seizures (focal or generalized)",
      "Focal neurological deficits (hemiparesis, aphasia, visual field defects)",
      "Papilledema (due to increased intracranial pressure)",
      "Altered consciousness, confusion, stupor, coma",
      "Signs of increased intracranial pressure (nausea, vomiting)"
    ],
    "Object4": [
      "Neuroimaging: MRI brain with MR venography (MRV) (gold standard, shows thrombus in venous sinuses, venous infarcts, edema, hemorrhage), CT venography (CTV) (alternative to MRV)",
      "Blood tests: D-dimer (elevated, but non-specific), full thrombophilia workup (after acute phase), CBC, electrolytes, renal/liver function",
      "Lumbar puncture (if meningitis suspected, or isolated intracranial hypertension with negative imaging, CSF may show elevated protein, normal glucose, pleocytosis)"
    ],
    "Object5": [
      "Anticoagulation: Heparin (LMWH or UFH) (initial treatment, even if hemorrhagic infarcts present, then switch to oral anticoagulants like warfarin for 3-12 months, depending on risk factors and recurrence risk)",
      "Treat underlying cause (e.g., antibiotics for infection, manage thrombophilia)",
      "Management of complications: Anticonvulsants for seizures, manage increased intracranial pressure (mannitol, hypertonic saline), decompressive craniectomy for severe cerebral edema/herniation",
      "Thrombolysis (local thrombolysis via catheter, rarely for severe cases)"
    ],
    "Object6": [
      "Hemorrhagic venous infarcts",
      "Increased intracranial pressure, cerebral edema, brain herniation",
      "Seizures, status epilepticus",
      "Long-term neurological deficits, cognitive impairment",
      "Recurrence of thrombosis",
      "Death"
    ]
  },
  {
    "Object1": [
      "Benzodiazepines (lorazepam, diazepam, midazolam) (first-line for status epilepticus)",
      "Followed by IV anticonvulsants (fosphenytoin, levetiracetam, valproate, lacosamide)"
    ],
    "Object2": [
      "Antiepileptic Drugs (AEDs): Numerous options, choice depends on seizure type, epilepsy syndrome, side effect profile, comorbidities (e.g., valproate, lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, topiramate, phenytoin)",
      "Lifestyle modifications (sleep hygiene, avoid triggers, stress management)",
      "Vagus nerve stimulation (VNS) (for refractory focal epilepsy)",
      "Responsive neurostimulation (RNS) or deep brain stimulation (DBS) (for highly refractory cases)",
      "Epilepsy surgery (for eligible patients with focal epilepsy not controlled by AEDs)",
      "Ketogenic diet (for refractory epilepsy, especially in children)"
    ]
  },
  {
    "Object1": [
      "Empiric intravenous antibiotics immediately (e.g., ceftriaxone/cefotaxime + vancomycin, with ampicillin for Listeria risk groups), then tailored based on CSF culture and sensitivity",
      "Dexamethasone (adjunctive, reduces mortality/neurological sequelae in bacterial meningitis, given prior to or with first antibiotic dose)",
      "Management of increased ICP, seizures, fluid/electrolyte balance"
    ],
    "Object2": [
      "Supportive care (pain relief, hydration)",
      "Antivirals for specific viral causes (e.g., acyclovir for HSV/VZV meningitis)"
    ],
    "Object3": [
      "Antifungal agents (e.g., amphotericin B + flucytosine for Cryptococcus, fluconazole for maintenance)"
    ],
    "Object4": [
      "Multi-drug antituberculous chemotherapy (e.g., RIPE regimen) for prolonged duration (9-12 months), with adjunctive corticosteroids (dexamethasone)"
    ]
  },
  {
    "Object1": "Encephalitis",
    "Object2": [
      "Viral infections (most common): Herpes Simplex Virus (HSV, especially HSV-1), Varicella-Zoster Virus (VZV), Enteroviruses, Arboviruses (West Nile virus, Japanese encephalitis virus, Eastern/Western equine encephalitis virus), Mumps virus, Measles virus, HIV",
      "Autoimmune encephalitis (anti-NMDA receptor encephalitis, Hashimoto's encephalopathy, limbic encephalitis)",
      "Bacterial (Listeria, Mycobacterium tuberculosis, mycoplasma)",
      "Parasitic (Toxoplasma gondii in immunocompromised, Neurocysticercosis)",
      "Fungal (Cryptococcus, Candida)",
      "Paraneoplastic syndromes"
    ],
    "Object3": [
      "Fever, headache",
      "Altered mental status (confusion, disorientation, lethargy, stupor, coma) (hallmark symptom)",
      "Seizures (focal or generalized)",
      "Focal neurological deficits (hemiparesis, aphasia, cranial nerve palsies)",
      "Behavioral changes, psychosis",
      "Movement disorders",
      "Signs of increased intracranial pressure (nausea, vomiting, papilledema)",
      "Meningeal signs (neck stiffness, photophobia) (if meningoencephalitis)"
    ],
    "Object4": [
      "Neuroimaging: MRI brain (gold standard, shows characteristic lesions in temporal lobes for HSV, edema, hemorrhage), CT scan (for acute settings, hemorrhage, mass effect)",
      "Lumbar puncture with Cerebrospinal Fluid (CSF) analysis (elevated WBC with lymphocytic predominance, normal/mildly elevated protein, normal glucose, PCR for HSV, VZV, Enteroviruses, specific antibodies for autoimmune encephalitis)",
      "Electroencephalogram (EEG): Shows generalized slowing, focal discharges, or periodic lateralized epileptiform discharges (PLEDs) in HSV encephalitis",
      "Blood tests: CBC, electrolytes, liver/renal function, viral serology, autoimmune markers, toxicology screen",
      "Brain biopsy (rarely, if diagnosis unclear and treatable cause suspected)"
    ],
    "Object5": [
      "Antiviral therapy immediately (e.g., acyclovir for HSV/VZV encephalitis) (crucial for outcome)",
      "Empiric broad-spectrum antibiotics (if bacterial meningitis cannot be ruled out)",
      "Immunomodulatory therapy (corticosteroids, IVIG, plasma exchange) for autoimmune encephalitis",
      "Antiepileptic drugs for seizures",
      "Management of increased intracranial pressure (mannitol, hypertonic saline, decompressive craniectomy)",
      "Supportive care (airway management, ventilation, fluid/electrolyte balance, temperature control)",
      "Rehabilitation"
    ],
    "Object6": [
      "Severe neurological deficits (cognitive impairment, memory loss, personality changes, motor deficits)",
      "Refractory epilepsy",
      "Increased intracranial pressure, cerebral edema, brain herniation",
      "Hydrocephalus",
      "Syndrome of inappropriate antidiuretic hormone (SIADH)",
      "Death (especially with HSV encephalitis if untreated)"
    ]
  },
  {
    "Object1": "Diseases of the Spinal Cord (Myelopathies)",
    "Object2": [
      "Compressive myelopathy: Spinal cord tumors (primary, metastatic), herniated intervertebral discs, spinal epidural abscess, spinal epidural hematoma, vertebral fractures, spondylosis, ligamentum flavum hypertrophy",
      "Inflammatory/Autoimmune myelopathy: Multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), transverse myelitis, sarcoidosis, Sjögren's syndrome, SLE",
      "Infectious myelopathy: HIV-associated myelopathy (vacuolar myelopathy), HTLV-1 associated myelopathy (HAM), viral myelitis (VZV, CMV, enterovirus), tuberculosis (Pott's disease with cord compression), syphilis (tabes dorsalis)",
      "Vascular myelopathy: Spinal cord infarction, spinal arteriovenous malformation (AVM), dural arteriovenous fistula (DAVF)",
      "Nutritional/Metabolic myelopathy: Vitamin B12 deficiency (subacute combined degeneration), copper deficiency",
      "Toxin-induced: Lathyrism, heavy metals",
      "Radiation myelopathy"
    ],
    "Object3": [
      "Sensory disturbances: Numbness, tingling, paresthesias, sensory level, band-like dysesthesia",
      "Motor weakness: Paraparesis or quadriparesis, spasticity, hyperreflexia, Babinski sign (UMN signs below lesion)",
      "Autonomic dysfunction: Bladder and bowel dysfunction (urgency, retention, constipation), erectile dysfunction, orthostatic hypotension",
      "Pain: Radicular pain (nerve root compression), localized back/neck pain, neuropathic pain",
      "Gait disturbance, imbalance"
    ],
    "Object4": [
      "Neuroimaging: MRI spine (gold standard, shows cord compression, demyelinating lesions, tumors, inflammation, vascular abnormalities)",
      "Lumbar puncture with Cerebrospinal Fluid (CSF) analysis (pleocytosis, elevated protein, oligoclonal bands for MS, specific markers for infections/autoimmune causes)",
      "Electromyography (EMG) and Nerve Conduction Studies (NCS) (to rule out peripheral neuropathy, assess LMN involvement)",
      "Blood tests (vitamin B12, copper, HIV, HTLV-1, autoimmune markers, inflammatory markers)",
      "Biopsy (of mass lesions or specific inflammatory conditions)"
    ],
    "Object5": [
      "Treat underlying cause: Surgical decompression for compressive lesions (tumors, severe disc herniation, epidural abscess/hematoma)",
      "Immunosuppressive therapy (corticosteroids, IVIG, plasma exchange) for inflammatory/autoimmune myelopathies (MS, NMOSD, transverse myelitis)",
      "Antimicrobial therapy for infections (antibiotics for abscess, antitubercular drugs for Pott's disease, antivirals for viral myelitis)",
      "Vitamin supplementation (B12, copper for deficiency states)",
      "Symptomatic management: Antispasticity medications (baclofen, tizanidine), pain management, bladder/bowel management (catheterization, laxatives)",
      "Physical therapy, occupational therapy, rehabilitation"
    ],
    "Object6": [
      "Permanent motor and sensory deficits, paraplegia/quadriplegia",
      "Severe bladder and bowel dysfunction",
      "Chronic pain",
      "Spasticity, contractures",
      "Aspiration pneumonia, pressure sores",
      "Recurrence (in inflammatory/autoimmune causes)"
    ]
  },
  {
    "Object1": "Motor Neuron Diseases (MND)",
    "Object2": [
      "Amyotrophic Lateral Sclerosis (ALS) (most common, sporadic > familial, SOD1, C9orf72 gene mutations)",
      "Progressive Bulbar Palsy (PBP)",
      "Progressive Muscular Atrophy (PMA)",
      "Primary Lateral Sclerosis (PLS)",
      "Spinal Muscular Atrophy (SMA) (inherited, often in children)"
    ],
    "Object3": [
      "Progressive weakness and atrophy of muscles",
      "Mixture of Upper Motor Neuron (UMN) signs (spasticity, hyperreflexia, Babinski) and Lower Motor Neuron (LMN) signs (fasciculations, atrophy, flaccidity) (classical for ALS)",
      "Dysphagia, dysarthria (bulbar involvement)",
      "Respiratory muscle weakness (leading to dyspnea, orthopnea, recurrent chest infections)",
      "Cramps, fasciculations (muscle twitching visible under skin)",
      "Sensory system, eye movements, and sphincter control are typically spared (important for differential diagnosis)",
      "Cognitive and behavioral changes (frontotemporal dementia in some C9orf72 ALS)"
    ],
    "Object4": [
      "Electromyography (EMG) and Nerve Conduction Studies (NCS): Show widespread denervation and reinnervation (fibrillations, fasciculations, large motor unit potentials) in multiple limbs and bulbar muscles (diagnostic for LMN involvement)",
      "Blood tests (rule out mimics: elevated CK, normal autoimmune markers, normal B12, copper, thyroid function)",
      "Neuroimaging: MRI brain and spinal cord (to rule out other treatable causes, e.g., structural lesions, cervical myelopathy)",
      "Lumbar puncture (CSF typically normal)",
      "Genetic testing (for familial forms)"
    ],
    "Object5": [
      "No cure for most MNDs, management is supportive and aims to slow progression",
      "Riluzole (glutamate inhibitor) (modestly slows progression and prolongs survival in ALS)",
      "Edaravone (free radical scavenger) (may slow functional decline in some ALS patients)",
      "Symptomatic management:",
      "Spasticity: Baclofen, tizanidine",
      "Sialorrhea (excessive salivation): Anticholinergics, botulinum toxin",
      "Dysphagia: Gastrostomy tube (PEG) for feeding",
      "Dysarthria: Speech therapy, augmentative communication devices",
      "Respiratory support: Non-invasive ventilation (NIV) (BiPAP) (improves quality of life, prolongs survival), eventually tracheostomy and mechanical ventilation",
      "Physical therapy, occupational therapy, nutritional support",
      "Clinical trials for new therapies"
    ],
    "Object6": [
      "Respiratory failure (major cause of death)",
      "Aspiration pneumonia (due to dysphagia)",
      "Severe malnutrition and weight loss",
      "Communication difficulties, social isolation",
      "Pressure sores, contractures",
      "Deep vein thrombosis (DVT)"
    ]
  },
  {
    "Object1": "Neurogenic Bladder",
    "Object2": [
      "Spinal cord injury (trauma, transverse myelitis, tumors, MS)",
      "Stroke",
      "Parkinson's disease",
      "Multiple Sclerosis (MS)",
      "Diabetes mellitus (diabetic neuropathy affecting bladder innervation)",
      "Spina bifida and other congenital anomalies",
      "Peripheral neuropathies (Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy)",
      "Pelvic surgery (damage to autonomic nerves)",
      "Brain tumors, hydrocephalus"
    ],
    "Object3": [
      "Overactive bladder (spastic/reflex neurogenic bladder): Urinary frequency, urgency, urge incontinence, small volume voids",
      "Underactive bladder (flaccid/atonic neurogenic bladder): Urinary retention, overflow incontinence, large volume voids, absent sensation of bladder fullness",
      "Recurrent urinary tract infections (UTIs)",
      "Hydronephrosis, renal damage (if high pressure/reflux)",
      "Autonomic dysreflexia (in high spinal cord injury)"
    ],
    "Object4": [
      "Urinalysis and urine culture (for UTIs)",
      "Post-void residual (PVR) volume (ultrasound or catheterization)",
      "Urodynamic studies (cystometry, pressure-flow studies) (gold standard for classifying bladder dysfunction)",
      "Renal ultrasound (to assess for hydronephrosis, kidney damage)",
      "Cystoscopy (to rule out bladder stones, strictures, or tumors)",
      "Neuroimaging (MRI brain/spine to identify neurological cause)"
    ],
    "Object5": [
      "Depends on type of bladder dysfunction and underlying cause",
      "For overactive bladder:",
      "Anticholinergic medications (oxybutynin, tolterodine, solifenacin) (to reduce bladder spasms)",
      "Beta-3 agonists (mirabegron)",
      "Botulinum toxin injections into bladder",
      "Sacral neuromodulation",
      "For underactive bladder:",
      "Intermittent catheterization (clean intermittent catheterization - CIC) (most common and effective)",
      "Crede maneuver, Valsalva maneuver (to assist voiding)",
      "Alpha-blockers (e.g., tamsulosin) (to relax bladder neck/prostate)",
      "Cholinergic agents (bethanechol) (to stimulate bladder contraction, limited use)",
      "Surgical procedures (e.g., urinary diversion, artificial sphincter, bladder augmentation) for complex cases or refractory incontinence/retention",
      "Management of UTIs"
    ],
    "Object6": [
      "Recurrent urinary tract infections (UTIs), pyelonephritis",
      "Hydronephrosis, renal damage, chronic kidney disease",
      "Bladder stones, bladder cancer (long-term catheterization)",
      "Urinary incontinence, skin breakdown",
      "Autonomic dysreflexia (in spinal cord injury)"
    ]
  },
  {
    "Object1": "Guillain-Barré Syndrome (GBS)",
    "Object2": [
      "Acute inflammatory demyelinating polyneuropathy (autoimmune, post-infectious)",
      "Preceding infections (most common trigger, 1-3 weeks prior):",
      "Campylobacter jejuni (most common bacterial trigger, associated with severe form and anti-GM1 antibodies)",
      "Cytomegalovirus (CMV), Epstein-Barr virus (EBV)",
      "Zika virus",
      "Mycoplasma pneumoniae",
      "Influenza virus",
      "Other: Vaccines (rare), surgery, trauma, Hodgkin's lymphoma"
    ],
    "Object3": [
      "Rapidly progressive, symmetrical ascending weakness (starting in legs, progressing to arms, trunk, face)",
      "Areflexia or hyporeflexia (loss of deep tendon reflexes) (hallmark symptom)",
      "Sensory symptoms (numbness, tingling, paresthesias, pain) (often preceding weakness)",
      "Facial weakness (bilateral, causing dysphagia, dysarthria, ophthalmoplegia)",
      "Respiratory muscle weakness (leading to respiratory failure, dyspnea)",
      "Autonomic dysfunction (tachycardia, bradycardia, hypertension, hypotension, urinary retention, bowel dysfunction)",
      "Pain (neuropathic, musculoskeletal)"
    ],
    "Object4": [
      "Lumbar puncture (LP) with Cerebrospinal Fluid (CSF) analysis: Albuminocytological dissociation (elevated protein with normal cell count) (classic finding, may be delayed in early stages)",
      "Electromyography (EMG) and Nerve Conduction Studies (NCS): Show demyelinating changes (reduced nerve conduction velocity, prolonged distal latencies, conduction blocks), axonal damage in severe forms",
      "Blood tests (anti-ganglioside antibodies - anti-GM1, anti-GQ1b for Miller-Fisher variant, rule out other causes)",
      "Pulmonary function tests (monitor vital capacity, negative inspiratory force for respiratory compromise)"
    ],
    "Object5": [
      "Hospitalization, often in ICU for close monitoring of respiratory and autonomic function",
      "Immunomodulatory therapy (to reduce severity and accelerate recovery):",
      "Intravenous Immunoglobulin (IVIG) (first-line)",
      "Plasma Exchange (PLEX) (first-line, equally effective as IVIG)",
      "Corticosteroids (not effective, may worsen outcome)",
      "Respiratory support: Mechanical ventilation for respiratory failure (monitor vital capacity, negative inspiratory force)",
      "Symptomatic management: Pain relief, DVT prophylaxis, bladder/bowel management, physical therapy, occupational therapy, rehabilitation"
    ],
    "Object6": [
      "Respiratory failure (major cause of morbidity and mortality)",
      "Autonomic instability (life-threatening arrhythmias, severe BP fluctuations)",
      "Deep vein thrombosis (DVT) and pulmonary embolism (PE)",
      "Recurrent GBS (rare)",
      "Chronic neurological deficits (foot drop, hand weakness, fatigue)",
      "Aspiration pneumonia",
      "Pressure sores"
    ]
  },
  {
    "Object1": "Chorea",
    "Object2": [
      "Huntington's Disease (inherited, progressive neurodegenerative, most common genetic cause)",
      "Sydenham's Chorea (post-streptococcal, autoimmune, acute rheumatic fever, 'St. Vitus dance')",
      "Wilson's Disease (copper overload)",
      "Drug-induced (neuroleptics, levodopa, oral contraceptives, anticonvulsants)",
      "Systemic Lupus Erythematosus (SLE) (neuropsychiatric lupus)",
      "Hyperthyroidism (thyrotoxic chorea)",
      "Infections (HIV, toxoplasmosis, encephalitis)",
      "Stroke (basal ganglia lesions)",
      "Electrolyte disturbances (hyperglycemia, hyponatremia)",
      "Pregnancy (chorea gravidarum)"
    ],
    "Object3": [
      "Involuntary, irregular, unpredictable, non-rhythmic, jerky movements that flow from one body part to another",
      "Can affect limbs, trunk, face, speech (dysarthria), swallowing (dysphagia)",
      "Often appear dance-like",
      "Associated features depend on underlying cause (e.g., dementia, psychiatric symptoms in Huntington's; carditis, arthritis in Sydenham's; liver disease, Kayser-Fleischer rings in Wilson's)",
      "Can interfere with voluntary movements, balance, and gait"
    ],
    "Object4": [
      "Clinical neurological examination",
      "Neuroimaging: MRI brain (to rule out structural lesions, assess basal ganglia involvement)",
      "Genetic testing (for Huntington's disease)",
      "Blood tests (thyroid function, electrolytes, ceruloplasmin/copper for Wilson's, autoimmune markers, streptococcal antibodies for Sydenham's)",
      "Lumbar puncture (if infection/inflammation suspected)"
    ],
    "Object5": [
      "Treat underlying cause (e.g., antibiotics for streptococcal infection, thyroid antagonists for hyperthyroidism, copper chelation for Wilson's)",
      "Symptomatic management for chorea:",
      "Dopamine-depleting agents (tetrabenazine, deutetrabenazine) (for Huntington's chorea)",
      "Antidopaminergics (antipsychotics like haloperidol, risperidone, olanzapine) (reduce chorea)",
      "Benzodiazepines (clonazepam) (for symptom control)",
      "Anticonvulsants (valproate, levetiracetam) (may help in some cases)",
      "Physical therapy, occupational therapy"
    ],
    "Object6": [
      "Falls and injuries",
      "Dysphagia, aspiration pneumonia",
      "Speech difficulties, communication impairment",
      "Psychiatric symptoms (depression, irritability, psychosis)",
      "Progression of underlying disease (e.g., dementia in Huntington's)"
    ]
  },
  {
    "Object1": "Brain Death",
    "Object2": [
      "Irreversible cessation of all brain function (cerebral hemispheres and brainstem) due to severe, irreversible brain injury",
      "Causes of catastrophic brain injury: Traumatic brain injury, massive intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke, anoxic brain injury (cardiac arrest), severe central nervous system infection, brain tumors, status epilepticus, severe increased intracranial pressure"
    ],
    "Object3": [
      "Coma (unarousable, unresponsive)",
      "Absence of all brainstem reflexes (pupillary light reflex, corneal reflex, vestibulo-ocular reflex/oculocephalic reflex, gag reflex, cough reflex, absence of respiratory drive during apnea test)",
      "Apnea (no spontaneous breathing with PaCO2 > 60 mmHg during apnea test)",
      "Fixed and dilated pupils",
      "No motor response to painful stimuli (except spinal reflexes)"
    ],
    "Object4": [
      "Clinical diagnosis (performed by two licensed physicians, typically involves two separate examinations, excluding confounding factors like hypothermia, drugs, metabolic derangements)",
      "Ancillary tests (may be used to confirm absence of cerebral blood flow or electrical activity, but not required for diagnosis if clinical criteria met and confounders excluded):",
      "Electroencephalogram (EEG) (electrocerebral silence)",
      "Cerebral angiography (absence of intracranial blood flow)",
      "Transcranial Doppler (absence of blood flow)",
      "Nuclear medicine brain scan (absence of intracranial blood flow)"
    ],
    "Object5": [
      "No treatment as it's an irreversible state",
      "Maintenance of physiological parameters for organ donation (if patient is an organ donor candidate)",
      "Emotional and psychological support for family"
    ],
    "Object6": [
      "Death (definitive diagnosis)"
    ]
  },
  {
    "Object1": "Bell's Palsy (Cranial Nerve Disorder)",
    "Object2": [
      "Idiopathic acute unilateral facial nerve (VII cranial nerve) paralysis",
      "Believed to be due to viral infection (most commonly Herpes Simplex Virus - HSV, also Varicella-Zoster Virus - VZV in Ramsay Hunt syndrome, CMV, EBV, HIV, Lyme disease)",
      "Inflammation and edema of the facial nerve (often at the geniculate ganglion) leading to compression and demyelination"
    ],
    "Object3": [
      "Sudden onset, acute unilateral facial weakness or paralysis (within 48-72 hours)",
      "Inability to close the eye on affected side (lagophthalmos)",
      "Drooping of the corner of the mouth, difficulty smiling, wrinkling forehead",
      "Loss of nasolabial fold",
      "Difficulty with speech, eating, drinking (food collects in buccal sulcus)",
      "Loss of taste sensation on anterior 2/3 of tongue on affected side",
      "Hyperacusis (increased sensitivity to sound) on affected side",
      "Pain behind the ear (mastoidalgia) may precede weakness",
      "Dry eye or excessive tearing (due to lacrimal gland dysfunction)"
    ],
    "Object4": [
      "Clinical diagnosis based on history and physical examination (exclude other causes of facial paralysis)",
      "Neurological examination (assess cranial nerves, especially facial nerve function)",
      "Blood tests (rule out Lyme disease, HIV, sarcoidosis, diabetes, thyroid disease if suspected)",
      "Electromyography (EMG) and Nerve Conduction Studies (NCS) (to assess severity of nerve damage, prognosis, not for acute diagnosis)",
      "MRI brain (to rule out other causes of facial palsy, e.g., stroke, tumor, MS)"
    ],
    "Object5": [
      "Corticosteroids (e.g., prednisone) (first-line, initiated within 72 hours of symptom onset, reduces inflammation and improves recovery)",
      "Antiviral medications (e.g., acyclovir, valacyclovir) (controversial when used alone, often combined with corticosteroids, especially for severe cases)",
      "Eye care (lubricating eye drops, eye patch, tape eye shut at night) (to prevent corneal drying and damage due to lagophthalmos)",
      "Physical therapy, facial exercises (to maintain muscle tone and prevent contractures)",
      "Surgical decompression (rarely, for severe cases with clear evidence of nerve compression and no response to medical therapy)"
    ],
    "Object6": [
      "Incomplete recovery of facial function (residual weakness, synkinesis - involuntary co-contraction of facial muscles)",
      "Corneal ulceration and vision loss (due to lagophthalmos and dry eye)",
      "Crocodile tears (gustatory lacrimation - tearing while eating)",
      "Social and psychological impact due to facial disfigurement"
    ]
  },
  {
    "Object1": [
      "Headache (often severe, generalized, worse in morning, with coughing/straining)",
      "Nausea, vomiting (often projectile)",
      "Papilledema (swelling of optic disc, late sign)",
      "Altered mental status (confusion, lethargy, stupor, coma)",
      "Cushing's triad (hypertension, bradycardia, irregular respiration - in severe cases)",
      "Focal neurological deficits (depending on underlying cause)",
      "Diplopia (VI nerve palsy)"
    ],
    "Object2": [
      "Orthostatic headache (worse upright, relieved by lying down)",
      "Nausea, vomiting, dizziness",
      "Diplopia, tinnitus"
    ]
  },
  {
    "Object1": [
      "Treat underlying cause (surgery for mass lesions, antibiotics for abscess, shunting for hydrocephalus)",
      "Medical management to reduce ICP: Head elevation (30 degrees), hyperventilation (temporary, to reduce PaCO2), mannitol (osmotic diuretic), hypertonic saline, sedation, neuromuscular blockade, external ventricular drain (EVD) or decompressive craniectomy (for refractory cases)",
      "Avoid hypotension, hypoxemia"
    ],
    "Object2": [
      "Bed rest, hydration, caffeine",
      "Epidural blood patch (for CSF leak post-LP or spontaneous)"
    ]
  },
  {
    "Object1": "Tumors of the Nervous System (Brain Tumors)",
    "Object2": [
      "Primary Brain Tumors (arise from brain tissue): Gliomas (glioblastoma, astrocytoma, oligodendroglioma), meningiomas, schwannomas, pituitary adenomas, medulloblastomas (children), ependymomas",
      "Metastatic Brain Tumors (spread from other cancers): Lung cancer (most common), breast cancer, melanoma, renal cell carcinoma, colorectal cancer",
      "Genetic syndromes (neurofibromatosis, von Hippel-Lindau, tuberous sclerosis, Li-Fraumeni syndrome)"
    ],
    "Object3": [
      "Highly variable, depends on location, size, and growth rate",
      "Headache (new onset, progressive, worse in morning, with nausea/vomiting)",
      "Seizures (focal or generalized, often initial symptom in slow-growing tumors)",
      "Focal neurological deficits (hemiparesis, sensory loss, aphasia, visual field deficits, cranial nerve palsies) (progressive)",
      "Altered mental status (confusion, personality changes, cognitive decline)",
      "Nausea, vomiting (due to increased ICP)",
      "Papilledema (due to increased ICP)",
      "Endocrine dysfunction (pituitary tumors)",
      "Hydrocephalus"
    ],
    "Object4": [
      "Neuroimaging: MRI brain with contrast (gold standard for diagnosis, delineates tumor size, location, characteristics, edema), CT scan (for acute settings, hemorrhage, calcifications)",
      "Biopsy: Stereotactic biopsy or open surgical biopsy (essential for definitive histological diagnosis and grading)",
      "Blood tests (tumor markers for specific metastases, genetic testing for inherited syndromes, pituitary hormones for pituitary tumors)",
      "Lumbar puncture (CSF cytology for leptomeningeal spread, especially in medulloblastoma, lymphoma)",
      "Electroencephalogram (EEG) (if seizures present)"
    ],
    "Object5": [
      "Surgical resection (primary treatment for most accessible tumors, aims for maximal safe resection to debulk tumor and reduce mass effect)",
      "Radiation therapy (external beam radiation, stereotactic radiosurgery) (adjuvant after surgery, or primary for unresectable tumors, or for metastases)",
      "Chemotherapy (temozolomide for glioblastoma, specific regimens for lymphoma, medulloblastoma, germ cell tumors, systemic chemotherapy for metastases)",
      "Targeted therapy (e.g., EGFR inhibitors for specific mutations in some gliomas, melanoma)",
      "Supportive care: Corticosteroids (dexamethasone) to reduce cerebral edema, antiepileptic drugs for seizures, pain management, physical/occupational/speech therapy",
      "Clinical trials for novel therapies"
    ],
    "Object6": [
      "Increased intracranial pressure (ICP), cerebral edema, brain herniation",
      "Seizures",
      "Neurological deficits and disability (can be permanent)",
      "Hydrocephalus",
      "Cognitive impairment, personality changes",
      "Side effects of radiation and chemotherapy (fatigue, nausea, hair loss, neurotoxicity)",
      "Recurrence of tumor",
      "Death"
    ]
  },
  {
    "Object1": "Lathyrism (Neurological Disorder)",
    "Object2": [
      "Toxin-induced neurological disorder caused by excessive consumption of Lathyrus sativus (grass pea) seeds, which contain the neurotoxin Beta-N-Oxalylamino-L-Alanine (BOAA)",
      "Associated with poverty and famine conditions where L. sativus is a staple food"
    ],
    "Object3": [
      "Gradual onset of progressive spastic paraparesis (weakness and stiffness in the legs)",
      "Hyperreflexia, clonus, Babinski sign (UMN signs)",
      "Gait disturbance (scissor gait, difficulty walking, eventual paralysis)",
      "Muscle cramps, fasciculations (less common)",
      "Upper limb involvement is rare, sensory loss is typically absent",
      "No cognitive impairment"
    ],
    "Object4": [
      "Clinical diagnosis based on history of Lathyrus sativus consumption and characteristic neurological symptoms",
      "Neurological examination (shows UMN signs in legs, sparing of sensory/upper limb/cranial nerves)",
      "MRI spinal cord (typically normal, to rule out other myelopathies)",
      "EMG/NCS (usually normal or mild non-specific changes)",
      "Analysis of BOAA in urine/blood (if available, for diagnostic confirmation in research settings)"
    ],
    "Object5": [
      "No specific antidote or cure",
      "Immediate and complete cessation of Lathyrus sativus consumption (essential to prevent progression)",
      "Nutritional support, especially with protein-rich foods",
      "Symptomatic management for spasticity (baclofen, tizanidine)",
      "Physical therapy, rehabilitation to maximize function"
    ],
    "Object6": [
      "Permanent spastic paraparesis and paralysis (if consumption continues or severe at onset)",
      "Significant disability and functional impairment"
    ]
  },
  {
    "Object1": "Organochlorine Poisoning",
    "Object2": [
      "Exposure to organochlorine insecticides (e.g., DDT, lindane, endosulfan)",
      "Occupational exposure, accidental ingestion, suicidal attempts"
    ],
    "Object3": [
      "Primarily neurotoxic effects:",
      "Central nervous system (CNS) stimulation: Tremors, hyperreflexia, ataxia, dizziness, headache, seizures, coma",
      "Gastrointestinal: Nausea, vomiting, abdominal pain",
      "Respiratory: Respiratory depression, pulmonary edema",
      "Cardiac: Arrhythmias"
    ],
    "Object4": [
      "Clinical diagnosis based on history of exposure and neurological symptoms",
      "Toxicology screen (blood/urine for organochlorines)",
      "Blood tests: Electrolytes, glucose, renal/liver function, ABG",
      "Electroencephalogram (EEG) (may show seizure activity)"
    ],
    "Object5": [
      "Decontamination (remove clothing, wash skin, gastric lavage if recent ingestion, activated charcoal)",
      "Supportive care: Airway management, ventilatory support for respiratory depression, benzodiazepines for seizures, manage fluid/electrolyte balance",
      "Avoid epinephrine (due to risk of cardiac arrhythmias)"
    ],
    "Object6": [
      "Seizures, status epilepticus",
      "Respiratory failure",
      "Cardiac arrhythmias",
      "Long-term neurological deficits (rare)",
      "Death"
    ]
  },
  {
    "Object1": "Scorpion Bite",
    "Object2": [
      "Bite by venomous scorpions (e.g., Mesobuthus tamulus in India)",
      "Severity depends on scorpion species, amount of venom injected, patient's age and health"
    ],
    "Object3": [
      "Local pain, swelling, redness, paresthesias at bite site (often severe, burning)",
      "Neurotoxic effects:",
      "Autonomic storm: Tachycardia, hypertension, profuse sweating, salivation, vomiting, priapism, fasciculations (sympathetic or parasympathetic overactivity)",
      "CNS effects: Restlessness, anxiety, tremors, seizures, altered consciousness",
      "Respiratory: Tachypnea, pulmonary edema, respiratory depression (late)",
      "Cardiovascular: Myocarditis, heart failure, arrhythmias, hypertension or hypotension"
    ],
    "Object4": [
      "Clinical diagnosis based on history of bite and symptoms",
      "Blood tests: CBC (leukocytosis), electrolytes (hyperglycemia), CK-MB/troponins (if myocarditis suspected), renal function, ABG",
      "ECG (for arrhythmias, myocarditis signs)",
      "Chest X-ray (for pulmonary edema)"
    ],
    "Object5": [
      "Pain control (local anesthetics, paracetamol, opioids, phentolamine for local pain)",
      "Antivenom (specific scorpion antivenom, given intravenously, reduces systemic effects)",
      "Symptomatic management for autonomic storm: Prazosin (alpha-blocker for hypertension, pulmonary edema), dobutamine (for heart failure), benzodiazepines (for tremors, seizures)",
      "Airway management and ventilatory support (if respiratory depression/pulmonary edema)",
      "Supportive care (fluid management, cardiac monitoring)"
    ],
    "Object6": [
      "Pulmonary edema, respiratory failure",
      "Myocarditis, heart failure, arrhythmias, hypertension",
      "Seizures",
      "Pancreatitis (rare)",
      "Death"
    ]
  },
  {
    "Object1": "Sedative Drug Poisoning",
    "Object2": [
      "Overdose of sedative-hypnotic drugs: Benzodiazepines (diazepam, lorazepam, alprazolam), barbiturates (phenobarbital), non-benzodiazepine hypnotics ('Z-drugs' like zolpidem, zopiclone), alcohol",
      "Accidental or intentional ingestion (suicidal attempts)"
    ],
    "Object3": [
      "Central nervous system (CNS) depression (dose-dependent): Drowsiness, lethargy, confusion, slurred speech, ataxia, nystagmus, stupor, coma",
      "Respiratory depression (hypoventilation, apnea, aspiration pneumonia)",
      "Cardiovascular depression: Bradycardia, hypotension, hypothermia, shock",
      "Pupils may be constricted (opioids often co-ingested), normal, or dilated"
    ],
    "Object4": [
      "Clinical diagnosis based on history of ingestion and CNS depression",
      "Toxicology screen (blood/urine for specific sedatives, alcohol level)",
      "Blood tests: ABG (respiratory acidosis, hypoxia), electrolytes, glucose, renal/liver function, CK (if prolonged immobility/rhabdomyolysis)",
      "ECG (for arrhythmias, QT prolongation with some drugs)"
    ],
    "Object5": [
      "Decontamination (gastric lavage if early, activated charcoal)",
      "Airway management and ventilatory support (intubation for respiratory depression, GCS <8)",
      "Antidotes: Flumazenil (for benzodiazepine overdose, use with caution due to seizure risk in chronic users), Naloxone (for opioid overdose, often co-ingested)",
      "Supportive care: Fluid resuscitation for hypotension, vasopressors if refractory shock, passive rewarming for hypothermia, DVT prophylaxis, manage aspiration pneumonia"
    ],
    "Object6": [
      "Respiratory failure, aspiration pneumonia",
      "Hypotension, shock, cardiac arrest",
      "Hypothermia",
      "Rhabdomyolysis, acute kidney injury",
      "Permanent neurological damage from prolonged hypoxia/hypotension",
      "Death"
    ]
  },
  {
    "Object1": [
      "Decontamination (activated charcoal if early)",
      "Antidote: N-acetylcysteine (NAC) (most effective if given within 8-10 hours, can be given up to 24 hours)",
      "Supportive care: Fluid and electrolyte management, manage liver failure, dialysis for severe renal failure"
    ],
    "Object2": [
      "Decontamination (gastric lavage if early, activated charcoal, whole bowel irrigation for sustained-release forms)",
      "Alkaline diuresis: Intravenous sodium bicarbonate (to alkalinize urine, increase salicylate excretion)",
      "Hemodialysis (for severe salicylate poisoning, especially with neurological symptoms, renal failure, severe acidosis, very high levels)",
      "Supportive care: Fluid and electrolyte management, correct acidosis, benzodiazepines for seizures, external cooling for hyperthermia"
    ]
  },
  {
    "Object1": [
      "Acute liver failure, hepatic encephalopathy, coagulopathy",
      "Acute kidney injury",
      "Death"
    ],
    "Object2": [
      "Severe metabolic acidosis, respiratory failure",
      "Cerebral edema, seizures, coma",
      "Death"
    ]
  },
  {
    "Object1": "Cyanide Poisoning",
    "Object2": [
      "Exposure to cyanide (e.g., hydrogen cyanide gas from fires, industrial exposure, ingestion of cyanide salts, nitriles, certain plants like cassava with improper preparation, amygdalin - present in apricot kernels)",
      "Accidental or intentional ingestion/inhalation"
    ],
    "Object3": [
      "Rapid onset, severe symptoms (cellular hypoxia, inhibition of cytochrome c oxidase)",
      "Central nervous system (CNS): Headache, dizziness, confusion, seizures, coma, respiratory arrest",
      "Cardiovascular: Tachycardia, hypertension (early), then bradycardia, hypotension, cardiac arrest",
      "Respiratory: Tachypnea, dyspnea, then respiratory depression",
      "Gastrointestinal: Nausea, vomiting, abdominal pain",
      "Skin: Pink or cherry-red skin (due to increased venous oxygen saturation, as tissues cannot extract oxygen)",
      "Characteristic bitter almond odor on breath (not everyone can smell it)"
    ],
    "Object4": [
      "Clinical diagnosis based on history of exposure and rapid onset of severe multi-organ failure, especially with metabolic acidosis and normal venous oxygen saturation",
      "Blood tests: High anion gap metabolic acidosis (lactic acidosis is prominent), elevated lactate levels, elevated venous oxygen saturation (paradoxical, as tissues cannot use oxygen)",
      "Toxicology screen (blood cyanide levels, if available)",
      "ABG (severe metabolic acidosis, hypoxia)",
      "ECG (arrhythmias)"
    ],
    "Object5": [
      "Immediate and aggressive treatment is critical",
      "Decontamination (remove clothing, wash skin, fresh air)",
      "Airway management and ventilatory support (100% oxygen, mechanical ventilation)",
      "Antidotes (administered immediately, often empirically):",
      "Cyanide Antidote Kit (amyl nitrite, sodium nitrite, sodium thiosulfate): Nitrites induce methemoglobinemia, which binds cyanide; sodium thiosulfate provides sulfur for rhodanese to convert cyanide to thiocyanate.",
      "Hydroxocobalamin (IV): Binds cyanide to form cyanocobalamin, non-toxic. Preferred antidote, especially in fire victims.",
      "Supportive care: Fluid resuscitation for hypotension, sodium bicarbonate for severe acidosis."
    ],
    "Object6": [
      "Rapid onset of cellular hypoxia, multi-organ failure",
      "Cardiovascular collapse, cardiac arrest",
      "Respiratory arrest",
      "Severe metabolic acidosis, lactic acidosis",
      "Permanent neurological damage (if prolonged hypoxia)",
      "Death (rapidly fatal)"
    ]
  },
  {
    "Object1": "Opioid Poisoning",
    "Object2": [
      "Overdose of opioid analgesics (morphine, heroin, fentanyl, oxycodone, hydrocodone, tramadol, codeine, methadone)",
      "Accidental or intentional ingestion/injection (suicidal attempts, recreational drug use)",
      "Polypharmacy with other CNS depressants (benzodiazepines, alcohol)"
    ],
    "Object3": [
      "Classic triad: Miosis (pinpoint pupils), Respiratory depression (hypoventilation, bradypnea, apnea), Altered mental status (drowsiness, lethargy, stupor, coma)",
      "Central nervous system (CNS): Hypothermia, seizures (rare), flaccid paralysis",
      "Cardiovascular: Bradycardia, hypotension",
      "Gastrointestinal: Nausea, vomiting, constipation, decreased bowel sounds",
      "Skin: Cool, clammy skin, track marks (IV drug use)"
    ],
    "Object4": [
      "Clinical diagnosis based on history of exposure and classic triad",
      "Toxicology screen (urine drug screen for opioids, blood levels if available)",
      "Blood tests: ABG (respiratory acidosis, hypoxia), electrolytes, glucose, renal/liver function, CK (if prolonged immobility/rhabdomyolysis)",
      "ECG (for arrhythmias, QT prolongation with methadone)"
    ],
    "Object5": [
      "Decontamination (activated charcoal if early ingestion, gastric lavage if massive overdose)",
      "Airway management and ventilatory support (intubation for respiratory depression, GCS <8)",
      "Antidote: Naloxone (opioid receptor antagonist, given IV, IM, IN, titrated to response to reverse respiratory depression and mental status, may need repeat doses or continuous infusion due to short half-life)",
      "Supportive care: Fluid resuscitation for hypotension, vasopressors if refractory shock, passive rewarming for hypothermia, DVT prophylaxis, manage aspiration pneumonia, treat pulmonary edema"
    ],
    "Object6": [
      "Respiratory arrest, aspiration pneumonia, noncardiogenic pulmonary edema",
      "Hypoxia, anoxic brain injury",
      "Hypotension, shock, cardiac arrest",
      "Rhabdomyolysis, acute kidney injury",
      "Withdrawal symptoms (if naloxone given to opioid-dependent individuals)",
      "Death"
    ]
  },
  {
    "Object1": "Aluminium Phosphide Poisoning (Celphos Poisoning)",
    "Object2": [
      "Ingestion of aluminium phosphide (ALP) (a highly toxic pesticide, often used for rodent control and grain fumigation)",
      "Accidental or intentional (suicidal attempts, common in India and developing countries)"
    ],
    "Object3": [
      "Rapid onset, severe multi-organ failure (release of phosphine gas upon contact with gastric acid)",
      "Gastrointestinal: Severe nausea, vomiting, abdominal pain, diarrhea, GI bleeding",
      "Cardiovascular: Severe refractory hypotension, cardiogenic shock, myocarditis, arrhythmias (bradycardia, ventricular tachycardia/fibrillation)",
      "Respiratory: Acute respiratory distress syndrome (ARDS), pulmonary edema, tachypnea",
      "Metabolic: Severe refractory metabolic acidosis (lactic acidosis), hyperglycemia",
      "Central nervous system (CNS): Dizziness, headache, confusion, seizures, coma",
      "Renal: Acute kidney injury (AKI)",
      "Liver: Hepatic dysfunction",
      "Characteristic garlic-like odor on breath (from phosphine gas)"
    ],
    "Object4": [
      "Clinical diagnosis based on history of ingestion and rapid onset of severe multi-organ failure, garlic-like odor",
      "Blood tests: Severe metabolic acidosis (high anion gap, lactic acidosis), hyperglycemia, hyperkalemia, elevated CK-MB/troponins (myocarditis), renal/liver function tests, ABG (severe acidosis, hypoxia)",
      "ECG (for arrhythmias, conduction abnormalities)",
      "Chest X-ray (for pulmonary edema, ARDS)"
    ],
    "Object5": [
      "Immediate and aggressive supportive care is critical, no specific antidote",
      "Decontamination (gastric lavage with potassium permanganate or coconut oil, activated charcoal is not effective)",
      "Airway management and ventilatory support (100% oxygen, mechanical ventilation for ARDS, respiratory failure)",
      "Management of severe hypotension/shock: IV fluids, vasopressors (norepinephrine, dopamine), high-dose magnesium sulfate (cardioprotective, anti-arrhythmic), sodium bicarbonate for acidosis",
      "Management of arrhythmias",
      "Supportive care for multi-organ failure (AKI, hepatic dysfunction)",
      "Avoid direct contact with gastric contents/vomitus (phosphine gas is toxic)"
    ],
    "Object6": [
      "Severe refractory cardiogenic shock, cardiac arrest",
      "Acute respiratory distress syndrome (ARDS), pulmonary edema",
      "Severe metabolic acidosis, multi-organ failure",
      "Arrhythmias",
      "Acute kidney injury",
      "Death (very high mortality rate, often within hours)"
    ]
  },
  {
    "Object1": "Oncologic Emergencies",
    "Object2": [
      "Direct tumor effects (mass effect, obstruction, invasion): Spinal cord compression, superior vena cava (SVC) syndrome, malignant pericardial effusion/tamponade, airway obstruction, cerebral edema",
      "Metabolic complications of cancer or its treatment: Hypercalcemia of malignancy, tumor lysis syndrome, SIADH (hyponatremia), hypoglycemia",
      "Hematological complications: Disseminated intravascular coagulation (DIC), severe thrombocytopenia with bleeding, hyperviscosity syndrome",
      "Infections (neutropenic fever, sepsis) (due to immunosuppression)"
    ],
    "Object3": [
      "Rapid onset of severe symptoms that are life-threatening or can cause permanent disability",
      "Spinal cord compression: Back pain (often radiating), progressive weakness, sensory loss, bladder/bowel dysfunction",
      "SVC syndrome: Facial/neck/upper extremity swelling, dyspnea, plethora, dilated collateral veins",
      "Cardiac tamponade: Dyspnea, chest pain, elevated JVP, hypotension, pulsus paradoxus",
      "Airway obstruction: Stridor, dyspnea, wheezing",
      "Cerebral edema: Headache, altered mental status, focal neurological deficits, seizures",
      "Hypercalcemia: Nausea, vomiting, constipation, polyuria, confusion, lethargy, arrhythmias",
      "Tumor lysis syndrome: Nausea, vomiting, diarrhea, muscle cramps, weakness, arrhythmias, seizures (due to hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia)",
      "Neutropenic fever: Fever, chills, signs of infection (may be minimal)",
      "Bleeding: Petechiae, ecchymoses, GI bleeding, intracranial hemorrhage"
    ],
    "Object4": [
      "Immediate clinical assessment (ABCs), neurological examination",
      "Imaging: MRI spine (for spinal cord compression), CT scan of chest/abdomen (for SVC syndrome, airway obstruction, intra-abdominal masses), echocardiography (for cardiac tamponade), CT brain (for cerebral edema)",
      "Laboratory: Electrolytes (calcium, potassium, phosphate), uric acid, renal function, CBC (neutropenia), coagulation profile, specific tumor markers, blood cultures",
      "ECG (for arrhythmias)"
    ],
    "Object5": [
      "Immediate, aggressive intervention to stabilize patient and treat underlying cause",
      "Spinal cord compression: High-dose corticosteroids (dexamethasone), emergent radiation therapy, surgical decompression",
      "SVC syndrome: Head elevation, diuretics, corticosteroids, radiation therapy, chemotherapy, endovascular stenting",
      "Cardiac tamponade: Pericardiocentesis (urgent fluid drainage)",
      "Airway obstruction: Airway management (intubation, tracheostomy), corticosteroids, radiation, stent placement",
      "Cerebral edema: High-dose corticosteroids, mannitol/hypertonic saline",
      "Hypercalcemia: IV fluids (saline), bisphosphonates, calcitonin",
      "Tumor lysis syndrome: Hydration (IV fluids), allopurinol/rasburicase, correct electrolyte imbalances, dialysis if severe",
      "Neutropenic fever: Empiric broad-spectrum antibiotics (immediately)",
      "Bleeding: Platelet transfusion, FFP/cryoprecipitate, specific factor replacement, treat underlying coagulopathy"
    ],
    "Object6": [
      "Permanent neurological deficits, disability",
      "Respiratory failure, cardiac arrest",
      "Renal failure",
      "Severe electrolyte disturbances",
      "Death"
    ]
  },
  {
    "Object1": "Oncogenic Viruses",
    "Object2": [
      "Infection with specific viruses that can transform normal cells into cancer cells",
      "Mechanism: Viral integration into host genome, production of viral oncoproteins, chronic inflammation, immunosuppression"
    ],
    "Object3": [
      "Symptoms related to the specific cancer caused by the virus",
      "Examples:",
      "Human Papillomavirus (HPV): Cervical cancer, anal cancer, oropharyngeal cancer",
      "Hepatitis B Virus (HBV) / Hepatitis C Virus (HCV): Hepatocellular carcinoma (HCC)",
      "Epstein-Barr Virus (EBV): Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, post-transplant lymphoproliferative disorder (PTLD)",
      "Human Immunodeficiency Virus (HIV): Kaposi's sarcoma (via HHV-8), non-Hodgkin lymphoma, invasive cervical cancer (via HPV)",
      "Human Herpesvirus 8 (HHV-8) / Kaposi's Sarcoma-Associated Herpesvirus (KSHV): Kaposi's sarcoma, primary effusion lymphoma, multicentric Castleman's disease",
      "Human T-lymphotropic Virus Type 1 (HTLV-1): Adult T-cell leukemia/lymphoma (ATL)"
    ],
    "Object4": [
      "Specific viral testing (PCR, serology for viral DNA/RNA/antibodies)",
      "Biopsy of tumor (for histological confirmation of cancer and presence of viral components)",
      "Imaging (for staging of cancer)"
    ],
    "Object5": [
      "Treatment for the specific cancer (surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy)",
      "Antiviral therapy (e.g., for HBV, HCV to reduce risk of HCC; for HIV to manage infection and associated cancers)",
      "Vaccination (e.g., HPV vaccine to prevent cervical/anal/oropharyngeal cancers; HBV vaccine to prevent HCC)",
      "Management of immunosuppression (in HIV, PTLD)"
    ],
    "Object6": [
      "Development of cancer",
      "Metastasis, organ failure",
      "Complications related to cancer treatment",
      "Increased morbidity and mortality"
    ]
  },
  {
    "Object1": [
      "Antidepressants (SSRIs, SNRIs, bupropion, mirtazapine) for depression (use with caution in bipolar, risk of inducing mania)",
      "Mood stabilizers (lithium, valproate, lamotrigine, carbamazepine) for bipolar disorder",
      "Atypical antipsychotics (quetiapine, olanzapine, lurasidone) for bipolar depression, mania, or psychotic features"
    ],
    "Object2": [
      "Cognitive Behavioral Therapy (CBT)",
      "Interpersonal Therapy (IPT)",
      "Dialectical Behavior Therapy (DBT)",
      "Family-Focused Therapy (FFT) (for bipolar disorder)"
    ],
    "Object3": [
      "Electroconvulsive Therapy (ECT) (for severe, refractory depression or mania, catatonia)",
      "Transcranial Magnetic Stimulation (TMS) (for refractory depression)",
      "Vagus Nerve Stimulation (VNS)",
      "Light therapy (for seasonal affective disorder)",
      "Lifestyle modifications (sleep hygiene, exercise, stress reduction, avoid substance abuse)"
    ]
  },
  {
    "Object1": [
      "First-generation antipsychotics (FGAs) (haloperidol, chlorpromazine) (primarily block D2 dopamine receptors)",
      "Second-generation antipsychotics (SGAs) (risperidone, olanzapine, quetiapine, aripiprazole, clozapine) (block D2 and serotonin 5-HT2A receptors, generally have better side effect profile and treat negative symptoms better)",
      "Long-acting injectable antipsychotics (for adherence issues)",
      "Clozapine (for refractory schizophrenia, requires regular blood monitoring due to agranulocytosis risk)"
    ],
    "Object2": [
      "Cognitive Behavioral Therapy (CBT) for psychosis",
      "Family psychoeducation",
      "Social skills training",
      "Supported employment and education"
    ],
    "Object3": [
      "Electroconvulsive Therapy (ECT) (for severe catatonia or refractory psychosis)",
      "Transcranial Magnetic Stimulation (TMS) (under investigation)",
      "Crisis intervention, hospitalization for acute episodes"
    ]
  },
  {
    "Object1": "Somatoform Disorders (now Somatic Symptom and Related Disorders)",
    "Object2": [
      "Complex interplay of psychological, biological, and social factors",
      "Psychological factors (stress, trauma, cognitive distortions, emotional dysregulation, alexithymia - difficulty identifying/expressing emotions)",
      "Genetic predisposition (family history)",
      "Neurobiological factors (altered pain processing, heightened sensitivity to bodily sensations, dysregulation of central nervous system mechanisms)",
      "History of childhood adversity, abuse",
      "Comorbidity with depression, anxiety, personality disorders"
    ],
    "Object3": [
      "Prominent somatic symptoms (pain, fatigue, gastrointestinal upset, neurological symptoms) causing significant distress or functional impairment",
      "Excessive thoughts, feelings, or behaviors related to the somatic symptoms (e.g., disproportionate thoughts about seriousness, high anxiety about health, excessive time/energy devoted to symptoms)",
      "Symptoms are often chronic and debilitating",
      "Not intentionally produced or feigned (distinguishing from factitious disorder or malingering)",
      "Medical explanations for symptoms may be absent or insufficient to explain the severity/distress"
    ],
    "Object4": [
      "Thorough medical evaluation (to rule out underlying medical conditions, often repeated due to patient's anxiety)",
      "Psychiatric evaluation (to assess psychological factors, distress, functional impairment)",
      "Screening tools (PHQ-15 for somatic symptoms)",
      "Avoid excessive or repeated invasive medical investigations once organic causes are ruled out"
    ],
    "Object5": [
      "Psychotherapy (Cognitive Behavioral Therapy - CBT is most effective, focuses on cognitive restructuring, stress management, improving coping skills, reducing health anxiety)",
      "Regular, consistent follow-up with a primary care physician (to provide reassurance, coordinate care, avoid unnecessary tests)",
      "Pharmacological (treat comorbid depression, anxiety, or specific somatic symptoms, e.g., SSRIs, SNRIs)",
      "Physical therapy (for pain, functional improvement)",
      "Mindfulness-based interventions"
    ],
    "Object6": [
      "Chronic pain and disability",
      "Significant functional impairment (social, occupational)",
      "High health care utilization and costs (due to repeated medical evaluations)",
      "Comorbidity with depression, anxiety, other psychiatric disorders",
      "Strained patient-physician relationships",
      "Misdiagnosis and delayed treatment of actual medical conditions"
    ]
  },
  {
    "Object1": "Factitious Disorder",
    "Object2": [
      "Psychological disorder where individuals intentionally feign or induce symptoms of illness (physical or psychological) for the primary purpose of assuming the sick role",
      "Internal psychological need for attention, sympathy, or care (not for external gain like financial or legal benefits - which would be malingering)",
      "Often associated with personality disorders (e.g., borderline personality disorder), history of childhood trauma, chronic illness, or medical employment"
    ],
    "Object3": [
      "Presentation of false or exaggerated symptoms (physical or psychological)",
      "Inconsistencies between reported history and objective findings",
      "Eagerness to undergo invasive procedures or surgeries",
      "Symptoms often unusual, dramatic, or inconsistent with known medical conditions",
      "Knowledge of medical terminology and diseases",
      "Reluctance to allow collateral information, seeking multiple doctors/hospitals",
      "Symptoms often resolve when patient feels they are not being observed",
      "Munchausen syndrome (severe, chronic form of factitious disorder, often involving extensive hospitalizations and self-harm)"
    ],
    "Object4": [
      "Thorough medical evaluation (to rule out genuine medical conditions, but with increasing suspicion)",
      "Careful documentation of inconsistencies, observed behaviors, and collateral information",
      "Review of medical records from multiple facilities",
      "Psychiatric consultation (for diagnosis and management, often challenging as patients may deny intentional feigning)"
    ],
    "Object5": [
      "Psychotherapy (long-term, aims to address underlying psychological needs and personality issues)",
      "Gentle confrontation (if appropriate, done with empathy and support, focusing on patient's emotional distress rather than accusation)",
      "Collaboration among healthcare providers (to avoid repeated unnecessary interventions)",
      "Management of any co-occurring psychiatric disorders",
      "Protect patient from iatrogenic harm from unnecessary medical procedures"
    ],
    "Object6": [
      "Significant medical harm (from induced symptoms or unnecessary procedures)",
      "Iatrogenic complications (infections, surgical complications, drug side effects)",
      "Strained patient-physician relationships",
      "Chronic disability and functional impairment",
      "Increased morbidity and mortality",
      "Legal issues (if health fraud is involved)"
    ]
  },
  {
    "Object1": "Delirium",
    "Object2": [
      "Acute, fluctuating disturbance in attention and cognition, caused by an underlying medical condition or substance",
      "Infections (UTIs, pneumonia, sepsis, meningitis, encephalitis)",
      "Metabolic disturbances (electrolyte imbalances - hyponatremia, hypernatremia, hypoglycemia, hepatic encephalopathy, uremia, thyroid dysfunction, hypoxia, hypercapnia)",
      "Drug intoxication (anticholinergics, sedatives, opioids, alcohol, illicit drugs, corticosteroids)",
      "Drug withdrawal (alcohol, benzodiazepines)",
      "Postoperative state, pain",
      "Neurological conditions (stroke, hemorrhage, seizures, head trauma)",
      "Environmental factors (sleep deprivation, sensory overload/deprivation, unfamiliar environment, restraints)",
      "Dehydration, malnutrition",
      "Multiple comorbidities (elderly, critically ill patients are high risk)"
    ],
    "Object3": [
      "Disturbance in attention (reduced ability to direct, focus, sustain, shift attention)",
      "Acute onset and fluctuating course (symptoms worsen at night, 'sundowning')",
      "Disturbance in cognition (memory deficit, disorientation, language disturbance, visuospatial deficit)",
      "Altered level of consciousness (hyperactive, hypoactive, or mixed psychomotor activity)",
      "Emotional lability, irritability, fear, anxiety, paranoid delusions, hallucinations (visual most common)",
      "Sleep-wake cycle disturbance (insomnia, fragmented sleep)",
      "Impaired judgment"
    ],
    "Object4": [
      "Clinical diagnosis (Confusion Assessment Method - CAM, Mini-Mental State Exam - MMSE, or other cognitive screens)",
      "Thorough medical workup to identify underlying cause (CBC, electrolytes, glucose, renal/liver function, thyroid function, urinalysis, urine culture, blood cultures, ABG, toxicology screen)",
      "Neuroimaging (CT/MRI brain for neurological causes)",
      "Electroencephalogram (EEG) (generalized slowing, to rule out nonconvulsive seizures)",
      "Lumbar puncture (if CNS infection suspected)"
    ],
    "Object5": [
      "Treat underlying cause (most critical step)",
      "Environmental management: Provide calm, quiet, familiar environment; reorientation; sleep hygiene; adequate hydration/nutrition; avoid restraints",
      "Pharmacological (for agitation, psychosis, if non-pharmacological methods fail and patient is a danger to self/others):",
      "Antipsychotics (haloperidol, olanzapine, quetiapine, risperidone) (low doses, short-term)",
      "Benzodiazepines (lorazepam) (especially for alcohol/benzodiazepine withdrawal delirium, but use with caution in other delirium types as it can worsen symptoms)",
      "Avoid anticholinergic medications",
      "Close monitoring of vital signs and mental status"
    ],
    "Object6": [
      "Increased mortality and morbidity (especially in hospitalized elderly)",
      "Increased length of hospital stay",
      "Increased risk of falls and injuries",
      "Long-term cognitive impairment, increased risk of dementia",
      "Functional decline",
      "Aspiration pneumonia, pressure sores",
      "Development of PTSD (post-traumatic stress disorder) in survivors"
    ]
  },
  {
    "Object1": [
      "Supportive care (airway, breathing, circulation, prevent aspiration, monitor vital signs)",
      "Thiamine (IV) (to prevent Wernicke-Korsakoff syndrome)"
    ],
    "Object2": [
      "Benzodiazepines (lorazepam, diazepam, chlordiazepoxide) (first-line, titrated to symptom control, prevents seizures/DTs)",
      "Thiamine (IV) and other vitamin supplements",
      "Fluid and electrolyte management",
      "Hospitalization for moderate-severe withdrawal or DTs"
    ],
    "Object3": [
      "Pharmacological (to reduce craving, prevent relapse): Naltrexone, acamprosate, disulfiram",
      "Psychotherapy (CBT, motivational interviewing, relapse prevention)",
      "Support groups (Alcoholics Anonymous - AA)",
      "Treatment of complications (liver disease, Wernicke-Korsakoff syndrome, psychiatric comorbidities)"
    ]
  },
  {
    "Object1": [
      "Supportive care (ABCs, monitor vital signs, prevent aspiration)",
      "Antidotes (naloxone for opioid overdose, flumazenil for benzodiazepine overdose - with caution)",
      "Decontamination (activated charcoal, gastric lavage, whole bowel irrigation)"
    ],
    "Object2": [
      "Pharmacological management (benzodiazepines for alcohol/benzodiazepine withdrawal; buprenorphine/methadone for opioid withdrawal; symptomatic for stimulants)",
      "Supportive care (hydration, nutrition, seizure precautions)"
    ],
    "Object3": [
      "Pharmacological (to reduce cravings, prevent relapse): Methadone, buprenorphine/naloxone (for opioid use disorder); naltrexone (for alcohol/opioid use disorder); disulfiram (for alcohol use disorder)",
      "Psychotherapy (CBT, motivational interviewing, contingency management, relapse prevention)",
      "Support groups (NA, AA, SMART Recovery)",
      "Harm reduction strategies",
      "Treatment of comorbidities (psychiatric disorders, infections, organ damage)"
    ]
  },
  {
    "Object1": [
      "Cognitive Behavioral Therapy for Insomnia (CBT-I) (first-line, addresses cognitive and behavioral factors)",
      "Pharmacological: Hypnotics (Z-drugs like zolpidem, eszopiclone; benzodiazepines - short-term; melatonin agonists - ramelteon; antidepressants with sedative properties - trazodone, mirtazapine)",
      "Improve sleep hygiene"
    ],
    "Object2": [
      "Treat OSA (CPAP)",
      "Pharmacological for narcolepsy/idiopathic hypersomnia: Stimulants (modafinil, armodafinil), sodium oxybate (for narcolepsy with cataplexy), solriamfetol, pitolisant",
      "Improve sleep hygiene"
    ],
    "Object3": [
      "RBD: Clonazepam, melatonin",
      "Sleepwalking/terrors: Address triggers, benzodiazepines (clonazepam) for severe cases",
      "RLS: Dopamine agonists (pramipexole, ropinirole, rotigotine), gabapentin, iron supplementation for deficiency"
    ]
  },
  {
    "Object1": [
      "Hospitalization, refeeding (slowly to prevent refeeding syndrome)",
      "Fluid and electrolyte management"
    ],
    "Object2": [
      "Family-Based Treatment (FBT) for adolescents with AN",
      "Cognitive Behavioral Therapy (CBT) for BN and BED",
      "Dialectical Behavior Therapy (DBT)",
      "Interpersonal Therapy (IPT) for BN and BED"
    ],
    "Object3": [
      "SSRIs (e.g., fluoxetine) for BN (reduces binge-purge frequency, treats comorbidity)",
      "Lisdexamfetamine (for BED)",
      "Topiramate (may help with binge eating, but side effects)",
      "Atypical antipsychotics (olanzapine) (for AN, to promote weight gain and reduce obsessive thoughts, off-label)",
      "Antidepressants for comorbid depression/anxiety"
    ]
  },
  {
    "Object1": "Nipah Virus Encephalitis",
    "Object2": [
      "Nipah virus (NiV) infection, a paramyxovirus",
      "Zoonotic disease, primary reservoir is fruit bats (Pteropus species)",
      "Transmission: Direct contact with infected animals (pigs, bats) or their bodily fluids, consumption of contaminated food (e.g., raw date palm sap contaminated with bat excreta), human-to-human transmission (especially in healthcare settings or close family contact)"
    ],
    "Object3": [
      "Incubation period 4-14 days (range 1-45 days)",
      "Prodromal: Fever, headache, muscle pain, vomiting, sore throat",
      "Neurological: Acute encephalitis (confusion, disorientation, dizziness, drowsiness, rapid progression to coma), seizures, brainstem dysfunction",
      "Respiratory: Acute respiratory distress syndrome (ARDS), severe pneumonia, cough, dyspnea",
      "Rapid progression to coma and death",
      "Relapsed encephalitis (delayed onset or recurrence of neurological symptoms months to years after initial recovery)"
    ],
    "Object4": [
      "Clinical diagnosis based on symptoms and exposure history",
      "Laboratory (definitive diagnosis):",
      "RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) for NiV RNA (from throat swab, CSF, urine, blood)",
      "Serology (ELISA for IgM and IgG antibodies to NiV) (for later stages or retrospective diagnosis)",
      "CSF analysis (pleocytosis, elevated protein, normal glucose)",
      "Neuroimaging: MRI brain (shows characteristic lesions in the brainstem, thalamus, deep white matter)",
      "Blood tests: CBC (leukocytosis), LFTs, renal function, ABG (for respiratory compromise)"
    ],
    "Object5": [
      "No specific antiviral treatment available",
      "Supportive care: Admission to ICU, aggressive management of encephalitis (manage cerebral edema, seizures), respiratory support (mechanical ventilation for ARDS), fluid and electrolyte management, fever control",
      "Ribavirin (antiviral) (used empirically in some cases, but efficacy is not proven)",
      "Monoclonal antibody therapy (under investigation)",
      "Strict infection control measures to prevent human-to-human transmission"
    ],
    "Object6": [
      "Severe acute encephalitis, coma, brainstem dysfunction",
      "Acute respiratory distress syndrome (ARDS), respiratory failure",
      "Relapsed encephalitis (can lead to permanent neurological deficits)",
      "Increased mortality (high case fatality rate, 40-75%)",
      "Permanent neurological sequelae in survivors"
    ]
  },
  {
    "Object1": "Acute Pancreatitis",
    "Object2": [
      "Gallstones (most common)",
      "Alcohol abuse (second most common)",
      "Hypertriglyceridemia (usually >1000 mg/dL)",
      "Drugs (thiazide diuretics, sulfonamides, furosemide, azathioprine, 6-mercaptopurine, pentamidine, metronidazole, valproic acid, estrogens, tetracycline, didanosine, asparaginase, corticosteroids)",
      "Post-endoscopic retrograde cholangiopancreatography (ERCP)",
      "Trauma (blunt abdominal trauma)",
      "Viral infections (mumps, coxsackievirus, HIV, CMV, HBV)",
      "Autoimmune diseases (systemic lupus erythematosus, inflammatory bowel disease, Sjögren's syndrome)",
      "Pancreatic cancer",
      "Hypercalcemia",
      "Genetic factors (mutations in PRSS1, SPINK1, CFTR genes)",
      "Pancreatic divisum (congenital anomaly)",
      "Ischemia (post-cardiac surgery, vasculitis)",
      "Toxins (scorpion venom, organophosphates)",
      "Idiopathic"
    ],
    "Object3": [
      "Acute, severe epigastric abdominal pain (radiates to back, left shoulder, or left flank)",
      "Nausea, vomiting, abdominal distension",
      "Low-grade fever, tachycardia, hypotension",
      "Mild jaundice (if biliary obstruction)",
      "Tenderness and guarding on abdominal palpation",
      "Absent bowel sounds (in ileus)",
      "Grey-Turner sign (flank ecchymoses)",
      "Cullen's sign (periumbilical ecchymoses)",
      "Pancreatic mass (palpable)"
    ],
    "Object4": [
      "Serum amylase and lipase (elevated >3 times normal, lipase is more specific)",
      "Complete blood count (leukocytosis, hemoconcentration)",
      "Blood glucose (hyperglycemia)",
      "Electrolytes (hypocalcemia, hypokalemia)",
      "Liver function tests (elevated bilirubin, ALP, ALT if biliary obstruction)",
      "Serum triglycerides",
      "C-reactive protein (CRP) (marker of severity)",
      "Abdominal ultrasound (to detect gallstones, bile duct dilation)",
      "CT scan of abdomen (diagnostic, assesses severity, complications like necrosis, fluid collections)",
      "MRI/MRCP (if CT is inconclusive or for biliary pathology)",
      "ERCP (therapeutic for gallstone pancreatitis)"
    ],
    "Object5": [
      "Supportive care: Fluid resuscitation (intravenous fluids), pain control (opioids), nutritional support (enteral nutrition preferred, parenteral if unable to tolerate enteral)",
      "Treat underlying cause: ERCP with sphincterotomy for gallstone pancreatitis, alcohol cessation counseling",
      "Antibiotics (only for documented infection of necrotic tissue or extrapancreatic infection)",
      "Surgery (for severe complications like infected necrosis, persistent collections, or severe gallstone disease not amenable to ERCP)"
    ],
    "Object6": [
      "Local: Pseudocyst, pancreatic necrosis (sterile or infected), abscess, fluid collections, splenic/portal vein thrombosis, pseudoaneurysm, colonic necrosis, gastrointestinal bleeding",
      "Systemic: Acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), shock, disseminated intravascular coagulation (DIC), metabolic disturbances (hypocalcemia, hyperglycemia), multi-organ failure, death"
    ]
  },
  {
    "Object1": "Chronic Pancreatitis",
    "Object2": [
      "Alcohol abuse (most common cause)",
      "Genetic factors (mutations in PRSS1, SPINK1, CFTR genes)",
      "Autoimmune pancreatitis (IgG4-related disease)",
      "Idiopathic (often related to unrecognized genetic factors or early alcohol exposure)",
      "Obstructive causes (pancreatic divisum, strictures, stones, tumors)",
      "Hypercalcemia, hypertriglyceridemia",
      "Severe acute pancreatitis (recurrent episodes can lead to chronic)",
      "Malnutrition (tropical pancreatitis)",
      "Toxins"
    ],
    "Object3": [
      "Recurrent or persistent epigastric abdominal pain (radiates to back, often severe, post-prandial)",
      "Malabsorption (steatorrhea, weight loss, fat-soluble vitamin deficiencies) due to exocrine insufficiency",
      "Diabetes mellitus (due to endocrine insufficiency)",
      "Nausea, vomiting, anorexia",
      "Abdominal tenderness, muscle wasting",
      "Jaundice (if common bile duct obstruction)",
      "Palpable epigastric mass (pseudocyst)"
    ],
    "Object4": [
      "Pancreatic function tests (fecal elastase, secretin-cholecystokinin test - gold standard for exocrine function)",
      "Blood tests: Amylase and lipase (may be normal or mildly elevated, less reliable than in acute pancreatitis), blood glucose/HbA1c (for diabetes), liver function tests (if cholestasis), fat-soluble vitamins (A, D, E, K)",
      "Imaging: CT scan of abdomen (shows pancreatic calcifications, ductal dilation, atrophy, pseudocysts)",
      "MRI/MRCP (better for soft tissue, ductal anatomy, pseudocysts)",
      "Endoscopic ultrasound (EUS) (highly sensitive for early changes, small stones, strictures)",
      "ERCP (can be diagnostic and therapeutic for ductal stones/strictures)"
    ],
    "Object5": [
      "Pain management (NSAIDs, opioids, gabapentin, pregabalin, pancreatic enzyme supplementation)",
      "Pancreatic enzyme replacement therapy (PERT) (for malabsorption and steatorrhea)",
      "Nutritional support (dietary modification, fat-soluble vitamin supplementation)",
      "Diabetes management (insulin, oral hypoglycemics)",
      "Alcohol cessation",
      "Endoscopic interventions (ERCP for ductal stones, strictures, pseudocyst drainage)",
      "Surgical interventions (drainage procedures for ductal obstruction, resectional procedures for intractable pain or malignancy concern)"
    ],
    "Object6": [
      "Exocrine insufficiency (malabsorption, steatorrhea, malnutrition)",
      "Endocrine insufficiency (diabetes mellitus)",
      "Pancreatic pseudocyst",
      "Bile duct obstruction, duodenal obstruction",
      "Pancreatic cancer (increased risk)",
      "Splenic vein thrombosis (leading to gastric varices and bleeding)",
      "Pancreatic ascites or pleural effusion",
      "Narcotic addiction (due to chronic pain management)"
    ]
  },
  {
    "Object1": "Pancreatic Cancer",
    "Object2": [
      "Smoking (major risk factor)",
      "Chronic pancreatitis (increases risk significantly)",
      "Diabetes mellitus (long-standing)",
      "Obesity",
      "Family history of pancreatic cancer (genetic predisposition, e.g., BRCA2, PALB2, Lynch syndrome)",
      "Certain inherited syndromes (Peutz-Jeghers syndrome, Familial Atypical Multiple Mole Melanoma - FAMMM syndrome)",
      "Exposure to certain chemicals (e.g., pesticides)",
      "Age (risk increases with age)",
      "Race (higher in African Americans)"
    ],
    "Object3": [
      "Often asymptomatic in early stages, leading to late diagnosis",
      "Painless jaundice (if tumor obstructs common bile duct, especially in head of pancreas)",
      "Weight loss, anorexia, fatigue",
      "Epigastric or back pain (dull, gnawing, radiates to back, worse at night)",
      "New-onset diabetes or worsening of existing diabetes",
      "Steatorrhea (due to pancreatic exocrine insufficiency)",
      "Courvoisier's sign (palpable, non-tender gallbladder in jaundiced patient, suggests malignant obstruction)",
      "Trousseau's syndrome (migratory thrombophlebitis)",
      "Nausea, vomiting, dyspepsia"
    ],
    "Object4": [
      "Laboratory: Elevated CA 19-9 (tumor marker, not diagnostic alone, can be elevated in cholangitis, pancreatitis, normal in early stages), elevated bilirubin, ALP, GGT (if biliary obstruction), elevated ALT/AST, amylase/lipase (if pancreatitis), blood glucose/HbA1c",
      "Imaging: CT scan of abdomen (multi-phase CT is crucial for diagnosis and staging), MRI/MRCP (more sensitive for small lesions, ductal anatomy), Endoscopic Ultrasound (EUS) with fine-needle aspiration (FNA) (highly sensitive for small lesions, obtaining tissue diagnosis, local staging)",
      "ERCP (can be diagnostic and therapeutic for biliary drainage, biopsy)",
      "Laparoscopy (for staging, to detect peritoneal metastasis)"
    ],
    "Object5": [
      "Surgical resection (Whipple procedure for head of pancreas, distal pancreatectomy for body/tail) (only curative option, feasible in ~15-20% of cases at diagnosis)",
      "Chemotherapy (adjuvant after surgery, neoadjuvant before surgery for borderline resectable tumors, or palliative for advanced/metastatic disease)",
      "Radiation therapy (adjuvant, neoadjuvant, or palliative)",
      "Palliative care: Pain management, endoscopic biliary stenting (for jaundice), gastric bypass (for duodenal obstruction), enzyme replacement for exocrine insufficiency, insulin for diabetes",
      "Clinical trials for new targeted therapies and immunotherapies"
    ],
    "Object6": [
      "Metastasis (liver, peritoneum, lungs, bones)",
      "Biliary obstruction, jaundice, cholangitis",
      "Gastric outlet obstruction",
      "Cachexia, malnutrition",
      "Deep vein thrombosis (DVT) and pulmonary embolism (PE) (due to hypercoagulable state)",
      "Pancreatitis",
      "Diabetes mellitus",
      "Pain (often severe and difficult to control)",
      "Death"
    ]
  },
  {
    "Object1": [
      "Alkali supplementation: Sodium bicarbonate or citrate (to correct acidosis, prevent bone disease, reduce stone formation)",
      "Potassium supplementation (to correct hypokalemia)"
    ],
    "Object2": [
      "Dietary potassium restriction, loop diuretics, fludrocortisone (if hypoaldosteronism)",
      "Avoid drugs that cause hyperkalemia (ACE inhibitors, ARBs, potassium-sparing diuretics)"
    ]
  },
  {
    "Object1": "Chronic Kidney Disease (CKD)",
    "Object2": [
      "Diabetes mellitus (diabetic nephropathy, most common cause)",
      "Hypertension (hypertensive nephrosclerosis, second most common cause)",
      "Glomerulonephritis (primary and secondary)",
      "Polycystic kidney disease (PKD) (genetic, leading cause of ESRD)",
      "Obstructive uropathy (BPH, stones, strictures, tumors)",
      "Tubulointerstitial diseases (AIN, chronic pyelonephritis, analgesic nephropathy)",
      "Vascular diseases (renal artery stenosis, atheroembolic disease)",
      "Genetic disorders (Alport syndrome, Fabry disease)",
      "Systemic diseases (SLE, amyloidosis, scleroderma, multiple myeloma)"
    ],
    "Object3": [
      "Often asymptomatic in early stages, detected by abnormal lab tests",
      "Fatigue, weakness, malaise, lethargy",
      "Anorexia, nausea, vomiting, metallic taste in mouth",
      "Pruritus (itching)",
      "Edema (peripheral, periorbital, ascites, pulmonary edema) due to fluid overload",
      "Hypertension (common, often difficult to control)",
      "Nocturia, polyuria (early CKD), oliguria/anuria (advanced CKD)",
      "Muscle cramps, restless legs syndrome",
      "Altered mental status, confusion, concentration difficulties, neuropathy (uremic encephalopathy, peripheral neuropathy)",
      "Bone pain, pathological fractures (renal osteodystrophy)",
      "Pallor (anemia)",
      "Skin changes (uremic frost, hyperpigmentation)"
    ],
    "Object4": [
      "Blood tests: Elevated serum creatinine/BUN (persistently), estimated Glomerular Filtration Rate (eGFR <60 mL/min/1.73m2 for >3 months), hyperkalemia, hyperphosphatemia, hypocalcemia, metabolic acidosis, anemia (normochromic normocytic), elevated PTH, elevated uric acid, low vitamin D",
      "Urinalysis: Proteinuria (persistent, often >150 mg/24h), hematuria (if glomerular disease), casts (broad casts in advanced CKD)",
      "Imaging: Renal ultrasound (assesses kidney size, cortical thickness, hydronephrosis, structural abnormalities), CT/MRI abdomen",
      "Kidney biopsy (if diagnosis unclear, for glomerular/tubulointerstitial disease)",
      "Bone mineral density (BMD) assessment (DEXA scan) for renal osteodystrophy"
    ],
    "Object5": [
      "Slow progression of CKD:",
      "Tight blood pressure control (target <130/80 mmHg, ACE inhibitors/ARBs are renoprotective)",
      "Glycemic control in diabetes (HbA1c target usually <7.0%)",
      "Dietary modifications (protein restriction - 0.8 g/kg/day, sodium restriction, potassium/phosphate restriction in advanced CKD)",
      "Manage dyslipidemia (statins)",
      "Treat underlying cause (e.g., immunosuppression for GN, remove obstruction)",
      "Manage complications:",
      "Anemia: Erythropoiesis-stimulating agents (ESAs), iron supplementation",
      "Mineral and bone disorders: Phosphate binders, vitamin D analogs, cinacalcet (calcimimetic)",
      "Acidosis: Sodium bicarbonate supplementation",
      "Fluid overload: Diuretics",
      "Renal Replacement Therapy (RRT) for End-Stage Renal Disease (ESRD) (eGFR <15 mL/min/1.73m2 or severe uremic symptoms): Dialysis (hemodialysis, peritoneal dialysis), Kidney transplantation"
    ],
    "Object6": [
      "End-stage renal disease (ESRD) requiring dialysis or transplantation",
      "Cardiovascular disease (leading cause of death in CKD, includes heart failure, MI, stroke, arrhythmias)",
      "Hypertension (often difficult to control)",
      "Anemia",
      "Mineral and bone disorders (renal osteodystrophy, fractures)",
      "Metabolic acidosis",
      "Fluid and electrolyte imbalances (hyperkalemia, hyperphosphatemia)",
      "Uremic complications (encephalopathy, pericarditis, coagulopathy, neuropathy, pruritus)",
      "Infections (leading cause of hospitalization and death)",
      "Malnutrition"
    ]
  },
  {
    "Object1": "Acute Pyelonephritis",
    "Object2": [
      "Bacterial infection ascending from the lower urinary tract (E. coli is most common, Klebsiella, Proteus, Enterococcus, Pseudomonas)",
      "Risk factors: Female gender, pregnancy, urinary tract obstruction (stones, BPH, strictures), vesicoureteral reflux (children), diabetes mellitus, immunosuppression, indwelling urinary catheters, neurogenic bladder"
    ],
    "Object3": [
      "Fever (often high-grade, with chills and rigors)",
      "Flank pain (unilateral or bilateral, dull ache to severe tenderness, radiates to back or abdomen)",
      "Nausea, vomiting",
      "Malaise, fatigue",
      "Dysuria, urinary frequency, urgency (lower UTI symptoms may precede or coexist)",
      "Costovertebral angle tenderness (CVAT) (pain on percussion over kidney area)"
    ],
    "Object4": [
      "Urinalysis: Leukocyturia (pyuria), bacteriuria, often white blood cell (WBC) casts (diagnostic for renal parenchymal inflammation), hematuria, nitrites, leukocyte esterase",
      "Urine culture and sensitivity: Gold standard for diagnosis, identifies pathogen and guides antibiotic choice",
      "Blood tests: CBC (leukocytosis, left shift), elevated ESR/CRP, blood cultures (positive in 20-30% of cases, indicates bacteremia/urosepsis), renal function tests (if AKI)",
      "Imaging: Renal ultrasound (to rule out obstruction, abscesses, hydronephrosis), CT scan (with contrast, if complications suspected - abscess, emphysematous pyelonephritis, obstruction, or severe/atypical presentation)"
    ],
    "Object5": [
      "Antibiotics: Empiric intravenous antibiotics (e.g., fluoroquinolones, ceftriaxone, piperacillin-tazobactam, aminoglycosides) for moderate-severe cases or those requiring hospitalization, then switch to oral based on culture/sensitivity. Duration typically 7-14 days.",
      "For mild cases: Oral fluoroquinolones or trimethoprim-sulfamethoxazole (if susceptible).",
      "Hydration (oral or intravenous fluids)",
      "Pain management (NSAIDs, paracetamol)",
      "Hospitalization for severe cases, immunocompromised, pregnant women, inability to tolerate oral intake, or suspected obstruction/complications.",
      "Address underlying complications (e.g., drain abscess, relieve obstruction)."
    ],
    "Object6": [
      "Urosepsis, septic shock (life-threatening)",
      "Perinephric abscess, intrarenal abscess",
      "Emphysematous pyelonephritis (gas in kidney parenchyma, severe form, especially in diabetics)",
      "Acute kidney injury (AKI)",
      "Chronic kidney disease (CKD) (with recurrent episodes or underlying structural abnormalities)",
      "Recurrence"
    ]
  },
  {
    "Object1": "Chronic Pyelonephritis",
    "Object2": [
      "Chronic or recurrent bacterial infections of the renal parenchyma, usually associated with predisposing factors:",
      "Vesicoureteral reflux (VUR) (most common cause in children, leading to recurrent infections and renal scarring)",
      "Urinary tract obstruction (nephrolithiasis, BPH, strictures, neurogenic bladder)",
      "Anatomical abnormalities of the urinary tract",
      "Analgesic nephropathy (historical cause, due to chronic NSAID abuse leading to papillary necrosis and infection)",
      "Frequent or inadequately treated acute pyelonephritis",
      "Diabetes mellitus"
    ],
    "Object3": [
      "Often asymptomatic for many years, discovered incidentally on imaging or during CKD workup",
      "Symptoms of chronic kidney disease: Fatigue, weakness, nausea, vomiting, pruritus, edema, hypertension, nocturia",
      "Recurrent episodes of acute pyelonephritis (fever, flank pain, dysuria)",
      "Polyuria (due to impaired urine concentrating ability)",
      "Hypertension (common)",
      "Growth retardation (children with VUR and recurrent infections)"
    ],
    "Object4": [
      "Urinalysis: Pyuria, bacteriuria (may be intermittent), mild proteinuria, sometimes casts",
      "Urine culture and sensitivity: To identify causative organisms during active infection",
      "Blood tests: Elevated serum creatinine/BUN, eGFR (reflects CKD stage), anemia, hyperkalemia, metabolic acidosis (in advanced CKD)",
      "Imaging: Renal ultrasound (shows small, scarred, irregular kidneys, cortical thinning, hydronephrosis if obstruction), CT scan (confirms scarring, focal atrophy, hydronephrosis, can detect stones/obstruction), Voiding Cystourethrography (VCUG) (to detect VUR, especially in children)",
      "Dimercaptosuccinic Acid (DMSA) scan (renal scintigraphy) (detects renal scarring)"
    ],
    "Object5": [
      "Treat and prevent recurrent UTIs (long-term low-dose antibiotics, manage VUR, relieve obstruction)",
      "Manage hypertension (ACE inhibitors/ARBs)",
      "Manage complications of chronic kidney disease (anemia, bone disease, acidosis, fluid/electrolyte imbalance)",
      "Surgical correction of VUR or obstruction (if needed)",
      "Renal replacement therapy (dialysis, transplantation) for ESRD"
    ],
    "Object6": [
      "Chronic kidney disease (CKD) and end-stage renal disease (ESRD) (due to progressive renal scarring)",
      "Hypertension",
      "Recurrent urinary tract infections (UTIs) and acute pyelonephritis",
      "Renal stones",
      "Growth retardation (children)",
      "Increased risk of transitional cell carcinoma of the renal pelvis (rare, especially with analgesic nephropathy)"
    ]
  },
  {
    "Object1": "Tuberculosis of the Urinary Tract",
    "Object2": [
      "Mycobacterium tuberculosis infection (hematogenous spread from primary pulmonary tuberculosis is most common)",
      "Can affect any part of the genitourinary tract (kidneys, ureters, bladder, epididymis, prostate, seminal vesicles, fallopian tubes)"
    ],
    "Object3": [
      "Often asymptomatic in early stages, with gradual onset of symptoms",
      "Sterile pyuria (most common clue: pyuria without bacteria on routine culture)",
      "Hematuria (microscopic or macroscopic)",
      "Urinary frequency, urgency, dysuria (bladder involvement)",
      "Flank pain (kidney involvement)",
      "Symptoms of chronic kidney disease (fatigue, malaise, hypertension) if extensive renal damage",
      "Epididymitis (tender, palpable mass), scrotal pain, sinus tract formation (male genital involvement)",
      "Prostatitis, hematospermia (prostate involvement)",
      "Constitutional symptoms (fever, night sweats, weight loss) (may be present but often mild or absent)",
      "Symptoms of pulmonary tuberculosis (may or may not be present simultaneously)"
    ],
    "Object4": [
      "Urinalysis: Sterile pyuria (pyuria with negative routine bacterial cultures), hematuria, mild proteinuria",
      "Urine cultures for Mycobacterium tuberculosis: Multiple early morning urine samples (3-5) for Acid-Fast Bacilli (AFB) smear and culture (gold standard for diagnosis)",
      "Blood tests: Elevated ESR/CRP, anemia (anemia of chronic disease), renal function tests (if renal impairment), HIV test (increased risk with HIV)",
      "Imaging: Intravenous Urography (IVU) (classic findings: papillary necrosis, strictures, hydronephrosis, 'moth-eaten' calyces, 'beaded' ureter, contracted bladder), CT scan of kidneys/bladder (more sensitive for lesions, calcifications, hydronephrosis), Retrograde pyelography (to visualize ureteral strictures)",
      "Cystoscopy with bladder biopsy (if bladder involvement)",
      "Genital ultrasound (for epididymitis, prostatic involvement)",
      "Biopsy of affected tissue (e.g., epididymis, prostate, bladder) (shows caseating granulomas, AFB on histology)",
      "PCR for M. tuberculosis DNA on urine or tissue samples"
    ],
    "Object5": [
      "Antituberculous chemotherapy: Standard multi-drug regimen (isoniazid, rifampicin, pyrazinamide, ethambutol) for 6-9 months (similar to pulmonary TB). Longer courses may be needed for severe or complicated cases.",
      "Corticosteroids: May be considered for ureteral strictures to prevent fibrosis and obstruction.",
      "Surgical intervention: For severe ureteral strictures, hydronephrosis, severe bladder contraction, or non-functional kidneys (e.g., nephrectomy for auto-nephrectomy or severely damaged kidney).",
      "Management of complications of CKD."
    ],
    "Object6": [
      "Ureteral strictures and obstruction, leading to hydronephrosis and renal damage",
      "Bladder contracture (small, fibrotic bladder, leading to urinary frequency/urgency)",
      "Chronic kidney disease (CKD) and end-stage renal disease (ESRD)",
      "Loss of kidney function (auto-nephrectomy)",
      "Infertility (due to epididymal or fallopian tube involvement)",
      "Recurrent infections"
    ]
  },
  {
    "Object1": "Rheumatoid Arthritis",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Genetic predisposition (HLA-DRB1 alleles)",
      "Environmental factors (smoking, infections like Porphyromonas gingivalis, Epstein-Barr virus)"
    ],
    "Object3": [
      "Symmetrical polyarthritis (small joints of hands and feet, wrists, ankles, elbows, shoulders, knees)",
      "Morning stiffness (lasting >30 minutes, improves with activity)",
      "Joint pain, swelling, tenderness, warmth, redness",
      "Rheumatoid nodules (subcutaneous, firm, non-tender, in pressure areas like elbows, fingers, Achilles tendon)",
      "Systemic symptoms (fatigue, malaise, low-grade fever, weight loss, anorexia)",
      "Specific joint deformities: ulnar deviation of fingers, swan-neck deformity, boutonnière deformity, Z-thumb deformity, hammer toes, hallux valgus",
      "Extra-articular manifestations: Scleritis, episcleritis, Sjögren's syndrome, pericarditis, pleuritis, vasculitis, anemia, Felty's syndrome, pulmonary fibrosis, carpal tunnel syndrome, cervical myelopathy"
    ],
    "Object4": [
      "Laboratory: Elevated ESR/CRP, normochromic normocytic anemia, thrombocytosis (active disease), rheumatoid factor (RF) positive (70-80%), anti-citrullinated protein antibodies (ACPA/anti-CCP) positive (highly specific)",
      "Imaging: X-rays (soft tissue swelling, juxta-articular osteopenia, joint space narrowing, erosions), MRI (early synovitis, erosions), ultrasound (synovitis, effusions, erosions)"
    ],
    "Object5": [
      "Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate (first-line), sulfasalazine, hydroxychloroquine, leflunomide",
      "Biological DMARDs: TNF-alpha inhibitors (adalimumab, etanercept, infliximab), rituximab, tocilizumab, abatacept",
      "Corticosteroids: Bridging therapy during DMARD initiation, or for flare-ups (prednisone, methylprednisolone)",
      "NSAIDs: Symptomatic relief for pain and inflammation",
      "Physical and occupational therapy, joint protection strategies",
      "Surgery: Synovectomy, joint reconstruction (arthroplasty), joint fusion (arthrodesis) for severe damage"
    ],
    "Object6": [
      "Joint deformities and disability",
      "Cardiovascular disease (increased risk of MI, stroke, heart failure)",
      "Infections (due to immunosuppression from disease and treatment)",
      "Rheumatoid vasculitis, Felty's syndrome, amyloidosis",
      "Ocular (scleritis, episcleritis), pulmonary (fibrosis, nodules), neurological (entrapment neuropathies, cervical myelopathy)"
    ]
  },
  {
    "Object1": "Systemic Lupus Erythematosus",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Genetic predisposition (HLA-DR2, DR3, complement deficiencies)",
      "Environmental factors (UV light, infections, drugs like procainamide, hydralazine, isoniazid, chlorpromazine, quinidine)"
    ],
    "Object3": [
      "Constitutional: Fatigue, fever, weight loss, malaise",
      "Cutaneous: Malar rash (butterfly rash), discoid lupus, photosensitivity, oral/nasal ulcers, Raynaud's phenomenon, alopecia, vasculitis lesions",
      "Musculoskeletal: Arthritis (non-erosive polyarthritis, symmetrical, small joints), arthralgia, myalgia, myositis",
      "Renal: Lupus nephritis (proteinuria, hematuria, renal failure)",
      "Neurological: Seizures, psychosis, stroke, cognitive dysfunction, headaches, peripheral neuropathy",
      "Hematological: Anemia (hemolytic, anemia of chronic disease), leukopenia, lymphopenia, thrombocytopenia",
      "Cardiopulmonary: Pericarditis, pleuritis, myocarditis, endocarditis (Libman-Sacks), pulmonary hypertension, interstitial lung disease",
      "Gastrointestinal: Nausea, vomiting, abdominal pain, lupus enteritis, pancreatitis, hepatomegaly",
      "Ocular: Retinal vasculitis, dry eyes (secondary Sjögren's)"
    ],
    "Object4": [
      "Laboratory: Elevated ESR/CRP, positive ANA (highly sensitive, not specific), anti-dsDNA (highly specific for active disease), anti-Sm (highly specific), antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I), low complement (C3, C4) in active disease, Coombs' test (hemolytic anemia), urinalysis (proteinuria, hematuria, casts)",
      "Biopsy: Skin biopsy (lupus band test), renal biopsy (for lupus nephritis)"
    ],
    "Object5": [
      "NSAIDs: For mild arthritis and serositis",
      "Antimalarials: Hydroxychloroquine (for skin, joint, and constitutional symptoms, reduces flares)",
      "Corticosteroids: For active disease, organ involvement (prednisone, methylprednisolone pulses for severe flares)",
      "Immunosuppressants: Methotrexate, azathioprine, mycophenolate mofetil (for renal, severe skin, joint involvement, and steroid-sparing)",
      "Biologics: Belimumab (for active, autoantibody-positive SLE)",
      "Rituximab (off-label for severe refractory disease)",
      "Management of complications: Anticoagulation for antiphospholipid syndrome, antihypertensives for renal involvement, dialysis/transplantation for ESRD."
    ],
    "Object6": [
      "Lupus nephritis (leading cause of morbidity and mortality)",
      "Cardiovascular disease (accelerated atherosclerosis, MI, stroke)",
      "Infections (major cause of mortality)",
      "Neuropsychiatric manifestations (seizures, psychosis, cognitive impairment)",
      "Thromboembolism (especially with antiphospholipid syndrome)",
      "Organ damage (renal failure, interstitial lung disease, avascular necrosis)"
    ]
  },
  {
    "Object1": "Spondyloarthropathies (Spondyloarthritides)",
    "Object2": [
      "Genetic predisposition (HLA-B27, strong association)",
      "Environmental triggers (infections, especially gastrointestinal or genitourinary, e.g., Klebsiella, Salmonella, Shigella, Yersinia, Chlamydia trachomatis)"
    ],
    "Object3": [
      "Axial skeleton involvement: Inflammatory back pain (insidious onset, morning stiffness, improves with activity, worse with rest), sacroiliitis, spondylitis, peripheral arthritis (asymmetrical, oligoarticular, predominantly lower limbs)",
      "Enthesitis (inflammation at tendon/ligament insertion sites, e.g., Achilles tendonitis, plantar fasciitis)",
      "Dactylitis (sausage digits)",
      "Extra-articular manifestations: Acute anterior uveitis (iritis), inflammatory bowel disease (Crohn's, ulcerative colitis), psoriasis, aortic insufficiency, pulmonary fibrosis, amyloidosis"
    ],
    "Object4": [
      "Laboratory: Elevated ESR/CRP, HLA-B27 testing (supports diagnosis, not diagnostic alone), anemia of chronic disease",
      "Imaging: X-rays (sacroiliac joint erosions/sclerosis, syndesmophytes in spine, 'bamboo spine', 'dagger sign'), MRI (early sacroiliitis, spinal inflammation)"
    ],
    "Object5": [
      "NSAIDs: First-line for pain and stiffness (indomethacin particularly effective for axial symptoms)",
      "DMARDs: Sulfasalazine, methotrexate (for peripheral arthritis, less effective for axial)",
      "Biological DMARDs: TNF-alpha inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) (highly effective for axial and peripheral disease, enthesitis, uveitis)",
      "Corticosteroids: Local injections for peripheral arthritis/enthesitis, systemic rarely for severe flares",
      "Physical therapy and exercise: Crucial for maintaining mobility and posture"
    ],
    "Object6": [
      "Spinal fusion and severe functional impairment ('bamboo spine')",
      "Aortic insufficiency, conduction defects",
      "Acute anterior uveitis (vision loss if recurrent)",
      "Inflammatory bowel disease, psoriasis"
    ]
  },
  {
    "Object1": "Vasculitis",
    "Object2": [
      "Primary (idiopathic) vasculitis",
      "Secondary vasculitis: Infections (Hepatitis B/C, HIV), drugs, autoimmune diseases (SLE, RA, Sjögren's), malignancy"
    ],
    "Object3": [
      "Constitutional: Fever, fatigue, weight loss, malaise",
      "Organ-specific symptoms depending on affected vessels: skin (palpable purpura, livedo reticularis, ulcers), joints (arthralgia, arthritis), muscles (myalgia, weakness), kidneys (glomerulonephritis, renal failure), nervous system (mononeuritis multiplex, stroke, neuropathy), GI tract (abdominal pain, bleeding, infarction), lungs (hemoptysis, infiltrates, pulmonary hemorrhage), eyes (vision changes, episcleritis, uveitis), heart (myocarditis, pericarditis)",
      "Large vessel vasculitis (e.g., giant cell arteritis, Takayasu arteritis): headaches, jaw claudication, visual loss, unequal pulses, claudication in limbs",
      "Small vessel vasculitis (e.g., ANCA-associated vasculitis): palpable purpura, rapidly progressive glomerulonephritis, pulmonary hemorrhage"
    ],
    "Object4": [
      "Laboratory: Elevated ESR/CRP, anemia, leukocytosis, thrombocytopenia, urinalysis (proteinuria, hematuria, RBC casts), specific autoantibodies (ANCA for GPA, MPA, EGPA; anti-GBM for Goodpasture's), cryoglobulins",
      "Biopsy: Affected tissue (skin, nerve, muscle, kidney, lung) is diagnostic, showing inflammation and necrosis of vessel walls",
      "Imaging: Angiography (CT, MR) for large/medium vessel involvement"
    ],
    "Object5": [
      "Corticosteroids: High-dose for induction of remission (prednisone, methylprednisolone pulses)",
      "Immunosuppressants: Cyclophosphamide (for severe/life-threatening disease), methotrexate, azathioprine, mycophenolate mofetil (for maintenance/less severe disease)",
      "Biologics: Rituximab (for ANCA-associated vasculitis), anti-TNF agents (for some forms)",
      "Plasma exchange: For rapidly progressive glomerulonephritis, diffuse alveolar hemorrhage",
      "Management of complications: Antihypertensives, dialysis, antibiotics for infections"
    ],
    "Object6": [
      "Organ damage and failure (renal, neurological, gastrointestinal, pulmonary)",
      "Infections (due to immunosuppression)",
      "Thromboembolism, aneurysms, dissections",
      "Relapse of disease"
    ]
  },
  {
    "Object1": "Osteoarthritis",
    "Object2": [
      "Mechanical stress and joint overuse (obesity, repetitive joint loading, prior joint injury)",
      "Age (most significant risk factor)",
      "Genetic predisposition",
      "Inflammatory conditions (e.g., rheumatoid arthritis, gout leading to secondary OA)",
      "Metabolic disorders (e.g., hemochromatosis, Wilson's disease)",
      "Other structural abnormalities (e.g., developmental hip dysplasia)"
    ],
    "Object3": [
      "Joint pain (worsens with activity, relieved by rest, typically 'mechanical' in nature)",
      "Morning stiffness (brief, <30 minutes, or after inactivity, 'gelling')",
      "Crepitus (grinding sensation or sound with joint movement)",
      "Reduced range of motion",
      "Joint tenderness, bony enlargement (osteophytes, Heberden's/Bouchard's nodes in hands)",
      "Swelling (mild, due to effusion)",
      "Functional impairment (difficulty walking, grasping, performing daily tasks)",
      "Commonly affected joints: knees, hips, hands (DIP, PIP, base of thumb), spine (cervical, lumbar)"
    ],
    "Object4": [
      "Laboratory: Usually normal ESR/CRP (unless secondary inflammation), rule out inflammatory arthritis",
      "Imaging: X-rays (joint space narrowing, osteophytes, subchondral sclerosis, subchondral cysts)"
    ],
    "Object5": [
      "Non-pharmacological: Patient education, exercise (strengthening, aerobic), weight loss, physical therapy, occupational therapy, assistive devices, heat/cold therapy",
      "Pharmacological: Acetaminophen (first-line for mild-moderate pain), NSAIDs (oral or topical, for moderate-severe pain), duloxetine (for chronic pain), intra-articular corticosteroid injections (for knee/hip flares), topical capsaicin",
      "Surgery: Arthroscopy (for mechanical symptoms), osteotomy (to realign joint), arthroplasty (total joint replacement for severe, disabling OA)"
    ],
    "Object6": [
      "Chronic pain and disability",
      "Joint deformity and instability",
      "Loss of joint function",
      "Secondary inflammation or infection of the joint"
    ]
  },
  {
    "Object1": "Systemic Sclerosis (Scleroderma)",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Genetic predisposition",
      "Environmental factors (exposure to silica, vinyl chloride, solvents)"
    ],
    "Object3": [
      "Cutaneous: Skin thickening and hardening (sclerodactyly, facial tightening, microstomia), Raynaud's phenomenon (initial symptom in most), digital ulcers, calcinosis, telangiectasias",
      "Musculoskeletal: Arthralgia, myalgia, inflammatory arthritis, muscle weakness (myositis)",
      "Gastrointestinal: Esophageal dysmotility (dysphagia, reflux), gastroparesis, malabsorption, constipation, pseudo-obstruction",
      "Pulmonary: Interstitial lung disease (ILD), pulmonary hypertension (PAH), pleurisy",
      "Renal: Scleroderma renal crisis (acute hypertension, renal failure)",
      "Cardiac: Myocardial fibrosis, pericarditis, arrhythmias, heart failure",
      "Other: Dry eyes/mouth (secondary Sjögren's), fatigue, weight loss"
    ],
    "Object4": [
      "Laboratory: Positive ANA (nucleolar pattern), anti-centromere antibodies (ACA) (associated with limited cutaneous SSc), anti-Scl-70 (topoisomerase I) antibodies (associated with diffuse cutaneous SSc and ILD), elevated ESR/CRP, anemia",
      "Imaging: Chest HRCT (for ILD), echocardiography (for PAH, cardiac involvement), barium swallow/manometry (for esophageal dysmotility)",
      "Nailfold capillaroscopy (characteristic changes)"
    ],
    "Object5": [
      "Immunosuppressants: Methotrexate, mycophenolate mofetil, cyclophosphamide (for ILD, skin involvement)",
      "Vascular therapy: Calcium channel blockers (nifedipine, amlodipine) for Raynaud's, PDE-5 inhibitors (sildenafil, tadalafil) for digital ulcers and PAH, endothelin receptor antagonists (bosentan, ambrisentan) for PAH, prostaglandin analogs (iloprost, treprostinil) for severe Raynaud's/digital ulcers and PAH",
      "GI management: PPIs for reflux, prokinetics for gastroparesis",
      "Scleroderma renal crisis: ACE inhibitors (captopril is drug of choice for urgent management)",
      "Physical therapy, skin emollients"
    ],
    "Object6": [
      "Interstitial lung disease (ILD) and pulmonary hypertension (PAH) (major causes of mortality)",
      "Digital ulcers and gangrene",
      "Scleroderma renal crisis",
      "Malabsorption and malnutrition",
      "Cardiac fibrosis and heart failure"
    ]
  },
  {
    "Object1": "Sjögren's Syndrome",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Genetic predisposition (HLA-DR3)",
      "Viral infections (Epstein-Barr virus, hepatitis C virus, HIV) proposed as triggers"
    ],
    "Object3": [
      "Sicca symptoms (dryness): Dry eyes (xerophthalmia, keratoconjunctivitis sicca), dry mouth (xerostomia, difficulty swallowing, dental caries, oral candidiasis), dry skin, dry nasal passages, dry vagina",
      "Systemic symptoms: Fatigue, arthralgia, myalgia, polyarthritis (non-erosive)",
      "Glandular enlargement: Parotid and submandibular gland swelling",
      "Extra-glandular manifestations: Cutaneous (vasculitis, palpable purpura), pulmonary (interstitial lung disease, tracheobronchitis), renal (renal tubular acidosis, glomerulonephritis), neurological (neuropathy, CNS involvement), gastrointestinal (dysphagia, pancreatitis), hematological (anemia, leukopenia, thrombocytopenia)"
    ],
    "Object4": [
      "Laboratory: Positive ANA, positive RF, positive anti-Ro/SSA antibodies, positive anti-La/SSB antibodies (highly specific), hypergammaglobulinemia, elevated ESR/CRP",
      "Ocular tests: Schirmer's test (measures tear production), Lissamine green or fluorescein staining (to detect corneal/conjunctival damage)",
      "Salivary tests: Salivary flow rate measurement, salivary gland scintigraphy",
      "Biopsy: Minor salivary gland biopsy (lip biopsy) (diagnostic, showing focal lymphocytic sialadenitis)"
    ],
    "Object5": [
      "Symptomatic: Artificial tears/lubricants (cyclosporine eye drops), artificial saliva, good oral hygiene, sialogogues (pilocarpine, cevimeline) for dry mouth",
      "NSAIDs: For arthralgia/myalgia",
      "Hydroxychloroquine: For arthralgia, myalgia, fatigue",
      "Corticosteroids/Immunosuppressants (methotrexate, azathioprine): For severe systemic involvement (vasculitis, ILD, renal disease)",
      "Biologicals (rituximab): For refractory systemic disease"
    ],
    "Object6": [
      "Increased risk of non-Hodgkin lymphoma (especially MALT lymphoma)",
      "Corneal ulceration and vision loss (due to severe dry eyes)",
      "Severe dental caries and tooth loss",
      "Systemic organ damage (ILD, renal failure, neuropathy)",
      "Chronic fatigue and fibromyalgia"
    ]
  },
  {
    "Object1": [
      "Acute monoarthritis (sudden onset, severe pain, swelling, redness, warmth)",
      "Podagra (first MTP joint of the big toe, most common site)",
      "Other affected joints: ankle, knee, wrist, elbow, small joints of hands/feet",
      "Tophi (chronic, painless urate crystal deposits in soft tissues, cartilage, bones)",
      "Uric acid nephrolithiasis (kidney stones)"
    ],
    "Object2": [
      "Acute monoarthritis or oligoarthritis (less severe than gout, but similar symptoms)",
      "Commonly affected joints: knee, wrist, shoulder, ankle, elbow, hand (MCP joints)",
      "Chronic arthropathy (resembling osteoarthritis)"
    ]
  },
  {
    "Object1": [
      "Laboratory: Elevated serum uric acid (not diagnostic alone, may be normal during acute attack), elevated ESR/CRP",
      "Synovial fluid analysis: Needle-shaped, strongly negatively birefringent monosodium urate crystals (diagnostic)",
      "Imaging: X-rays (punched-out erosions with overhanging edges in chronic gout)"
    ],
    "Object2": [
      "Laboratory: Elevated ESR/CRP",
      "Synovial fluid analysis: Rhomboid or rod-shaped, weakly positively birefringent calcium pyrophosphate dihydrate crystals (diagnostic)",
      "Imaging: X-rays (chondrocalcinosis - calcification of articular cartilage)"
    ]
  },
  {
    "Object1": [
      "NSAIDs (indomethacin, naproxen, ibuprofen)",
      "Colchicine (for acute attacks, especially if started early)",
      "Corticosteroids (oral or intra-articular) for severe attacks or contraindications to NSAIDs"
    ],
    "Object2": [
      "Xanthine oxidase inhibitors (allopurinol, febuxostat) (reduces uric acid production)",
      "Uricosurics (probenecid, lesinurad) (increases uric acid excretion)",
      "Pegloticase (for refractory chronic gout)",
      "Lifestyle modifications (dietary changes, weight loss, avoid alcohol)"
    ],
    "Object3": [
      "NSAIDs",
      "Colchicine",
      "Intra-articular corticosteroid injections"
    ],
    "Object4": [
      "No specific urate-lowering therapy for CPPD",
      "Manage symptoms similar to OA"
    ]
  },
  {
    "Object1": [
      "Chronic tophaceous gout (joint destruction, functional impairment)",
      "Uric acid nephropathy, kidney stones",
      "Increased risk of cardiovascular disease, metabolic syndrome"
    ],
    "Object2": [
      "Chronic arthropathy mimicking OA",
      "Acute severe arthritis",
      "Spinal pseudogout (cervical myelopathy)"
    ]
  },
  {
    "Object1": "Osteoporosis",
    "Object2": [
      "Primary Osteoporosis:",
      "Postmenopausal osteoporosis (estrogen deficiency)",
      "Senile (age-related) osteoporosis",
      "Idiopathic osteoporosis (rare, in young adults)",
      "Secondary Osteoporosis:",
      "Endocrine disorders (hyperthyroidism, hyperparathyroidism, Cushing's syndrome, hypogonadism, diabetes mellitus)",
      "Gastrointestinal diseases (malabsorption, inflammatory bowel disease, celiac disease, bariatric surgery)",
      "Medications (corticosteroids, heparin, anticonvulsants, PPIs, SSRIs, GnRH agonists, aromatase inhibitors)",
      "Hematological disorders (multiple myeloma, lymphoma, leukemia)",
      "Rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis)",
      "Lifestyle factors (low calcium/vitamin D intake, sedentary lifestyle, smoking, excessive alcohol consumption)",
      "Chronic kidney disease"
    ],
    "Object3": [
      "Often asymptomatic until a fracture occurs",
      "Fractures (vertebral compression fractures causing back pain and height loss, hip fractures, wrist fractures)",
      "Loss of height, kyphosis (dowager's hump)",
      "Chronic back pain"
    ],
    "Object4": [
      "Bone Mineral Density (BMD) measurement: Dual-energy X-ray absorptiometry (DEXA) scan (T-score ≤ -2.5 SD at hip, spine, or forearm for osteoporosis; T-score between -1.0 and -2.5 SD for osteopenia)",
      "Laboratory tests (to rule out secondary causes): Calcium, phosphate, alkaline phosphatase, TSH, PTH, 25-hydroxyvitamin D, serum/urine protein electrophoresis (for myeloma), kidney function tests, CBC"
    ],
    "Object5": [
      "Non-pharmacological: Adequate calcium and vitamin D intake (dietary, supplements), weight-bearing and muscle-strengthening exercise, avoid smoking and excessive alcohol",
      "Pharmacological (Antiresorptive Agents):",
      "Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) (first-line, inhibit osteoclast activity)",
      "Denosumab (RANKL inhibitor) (for high-risk patients, given subcutaneously)",
      "Estrogen agonists/antagonists (Raloxifene) (for postmenopausal women, reduces vertebral fractures)",
      "Calcitonin (nasal spray, for pain from acute vertebral fractures)",
      "Pharmacological (Anabolic Agents):",
      "Teriparatide (PTH analog) (stimulates bone formation, for severe osteoporosis)",
      "Romosozumab (sclerostin inhibitor) (for high-risk postmenopausal women)",
      "Management of fractures (pain relief, physical therapy, surgical repair)"
    ],
    "Object6": [
      "Vertebral compression fractures (pain, height loss, kyphosis)",
      "Hip fractures (significant morbidity, mortality, disability)",
      "Wrist fractures (Colles' fracture)",
      "Chronic pain, loss of independence",
      "Increased risk of mortality following hip fracture"
    ]
  },
  {
    "Object1": "Antiphospholipid Antibody Syndrome",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Primary APS (no associated autoimmune disease)",
      "Secondary APS (associated with other autoimmune diseases, especially SLE, infections, drugs, malignancy)"
    ],
    "Object3": [
      "Vascular thrombosis: Arterial thrombosis (stroke, TIA, MI, peripheral arterial occlusion), venous thrombosis (DVT, pulmonary embolism, Budd-Chiari syndrome)",
      "Pregnancy morbidity: Recurrent fetal loss (miscarriage), preeclampsia, eclampsia, placental insufficiency",
      "Non-thrombotic manifestations: Livedo reticularis, thrombocytopenia, hemolytic anemia, cardiac valvular disease (Libman-Sacks endocarditis), neurological manifestations (headaches, seizures, cognitive dysfunction), nephropathy"
    ],
    "Object4": [
      "Laboratory (persistent presence of at least one):",
      "Lupus anticoagulant (LAC) (measured by aPTT-based assays)",
      "Anticardiolipin antibodies (aCL) (IgG and/or IgM)",
      "Anti-beta2-glycoprotein I antibodies (anti-β2GPI) (IgG and/or IgM)",
      "Other relevant tests to rule out associated conditions (e.g., ANA for SLE)"
    ],
    "Object5": [
      "Anticoagulation: Lifelong oral anticoagulation with warfarin (INR target 2.0-3.0 for venous events, 2.5-3.5 for arterial events, especially recurrent)",
      "Antiplatelet agents: Low-dose aspirin (for asymptomatic carriers with high risk factors, or after first arterial event)",
      "Pregnancy management: Low-dose aspirin plus low molecular weight heparin (LMWH) or unfractionated heparin (UFH) (to prevent pregnancy complications)",
      "Corticosteroids/Immunosuppressants: For catastrophic APS, or severe non-thrombotic manifestations (e.g., nephritis, hemolytic anemia)",
      "Hydroxychloroquine: May be beneficial in secondary APS (e.g., SLE-associated APS)"
    ],
    "Object6": [
      "Recurrent thrombosis (stroke, MI, DVT, PE)",
      "Recurrent pregnancy loss and obstetric complications",
      "Catastrophic antiphospholipid syndrome (CAPS) (multisystem organ failure due to widespread microthrombosis, high mortality)",
      "Long-term organ damage (renal failure, heart failure, cognitive impairment)"
    ]
  },
  {
    "Object1": "Inflammatory Muscle Diseases (e.g., Polymyositis, Dermatomyositis)",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown)",
      "Genetic predisposition",
      "Environmental triggers (viral infections, drugs, malignancy)"
    ],
    "Object3": [
      "Progressive, symmetrical proximal muscle weakness (difficulty climbing stairs, rising from chair, lifting arms, combing hair)",
      "Muscle pain, tenderness, fatigue",
      "Dermatomyositis-specific skin rashes: Heliotrope rash (periorbital edema with reddish-purple discoloration), Gottron's papules (erythematous papules over extensor surfaces of MCP and IP joints), Shawl sign (erythema over neck and shoulders), V-sign (erythema over anterior chest/neck), nailfold abnormalities",
      "Systemic symptoms: Fever, weight loss, arthralgia, dysphagia (esophageal muscle weakness), dyspnea (interstitial lung disease, respiratory muscle weakness), cardiac involvement (myocarditis, arrhythmias)",
      "Associated malignancy (especially with dermatomyositis, paraneoplastic syndrome)"
    ],
    "Object4": [
      "Laboratory: Elevated muscle enzymes (CK, LDH, AST, ALT), positive autoantibodies (ANA, anti-Jo-1, anti-Mi-2, anti-SRP), elevated ESR/CRP",
      "Electromyography (EMG): Myopathic changes (fibrillation potentials, positive sharp waves, low-amplitude polyphasic motor unit potentials)",
      "Muscle biopsy: Diagnostic, showing inflammatory infiltrates (polymyositis: endomysial, dermatomyositis: perimysial/perivascular) and muscle fiber necrosis",
      "Imaging: MRI of muscles (to detect inflammation, edema, fatty infiltration)",
      "Cancer screening: Age-appropriate screening for malignancy, especially with dermatomyositis"
    ],
    "Object5": [
      "Corticosteroids: High-dose for induction of remission (prednisone, methylprednisolone pulses for severe weakness, dysphagia, respiratory involvement)",
      "Immunosuppressants: Methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide (steroid-sparing, or for refractory disease)",
      "Intravenous immunoglobulin (IVIG): For severe, refractory weakness, or acute flares",
      "Rituximab: For refractory disease",
      "Physical therapy and exercise: To maintain muscle strength and prevent atrophy (initiated after acute inflammation controlled)",
      "Management of complications: PPIs for reflux, speech/swallowing therapy for dysphagia, oxygen/immunosuppressants for ILD"
    ],
    "Object6": [
      "Progressive muscle weakness and atrophy, leading to disability",
      "Interstitial lung disease and respiratory failure",
      "Cardiac involvement (myocarditis, heart failure, arrhythmias)",
      "Dysphagia and aspiration pneumonia",
      "Associated malignancy"
    ]
  },
  {
    "Object1": "Achalasia",
    "Object2": [
      "Idiopathic (most common, loss of ganglion cells in Auerbach's plexus)",
      "Chagas disease (Trypanosoma cruzi infection)",
      "Malignancy (pseudoachalasia)",
      "Post-vagotomy"
    ],
    "Object3": [
      "Dysphagia (for both solids and liquids, progressive)",
      "Regurgitation of undigested food (often nocturnal)",
      "Chest pain (non-cardiac, squeezing, often after meals)",
      "Weight loss",
      "Nocturnal cough, recurrent aspiration pneumonia"
    ],
    "Object4": [
      "Barium swallow (shows esophageal dilatation, 'bird's beak' or 'rat tail' appearance at LES, absent peristalsis)",
      "Esophageal manometry (diagnostic, shows absent esophageal peristalsis and incomplete LES relaxation with swallowing)",
      "Endoscopy (to rule out pseudoachalasia caused by malignancy, may show dilated esophagus)"
    ],
    "Object5": [
      "Pharmacological (less effective): Nitrates, calcium channel blockers (e.g., nifedipine) to relax LES",
      "Endoscopic interventions: Pneumatic dilation (LES stretching), botulinum toxin injection (relaxes LES muscle), peroral endoscopic myotomy (POEM)",
      "Surgical: Heller myotomy (laparoscopic section of LES muscle)"
    ],
    "Object6": [
      "Aspiration pneumonia",
      "Esophageal dilatation and retention esophagitis",
      "Increased risk of esophageal squamous cell carcinoma (long-standing achalasia)",
      "Weight loss and malnutrition"
    ]
  },
  {
    "Object1": "Gastroesophageal Reflux Disease (GERD)",
    "Object2": [
      "Transient lower esophageal sphincter (LES) relaxations (most common mechanism)",
      "Hiatus hernia",
      "Impaired esophageal motility/clearance of acid",
      "Decreased LES tone",
      "Increased intra-abdominal pressure (obesity, pregnancy, tight clothing)",
      "Dietary factors (fatty foods, caffeine, chocolate, citrus, spicy foods, alcohol)",
      "Medications (calcium channel blockers, nitrates, anticholinergics, NSAIDs, bisphosphonates)"
    ],
    "Object3": [
      "Heartburn (burning sensation behind sternum, post-prandial, worse when lying down/bending over)",
      "Regurgitation (sour/bitter fluid or food into mouth/throat)",
      "Dysphagia (difficulty swallowing)",
      "Chest pain (non-cardiac, mimicking angina)",
      "Extra-esophageal symptoms: Chronic cough, hoarseness, laryngitis, globus sensation, asthma-like symptoms, dental erosions"
    ],
    "Object4": [
      "Clinical diagnosis based on symptoms and response to PPIs",
      "Upper endoscopy with biopsy (to assess for esophagitis, strictures, Barrett's esophagus)",
      "24-hour esophageal pH monitoring / impedance-pH monitoring (diagnostic for atypical symptoms or refractory GERD)",
      "Barium swallow (less sensitive, may show hiatus hernia or stricture)",
      "Esophageal manometry (to assess LES pressure and esophageal motility, not for diagnosis of GERD itself)"
    ],
    "Object5": [
      "Lifestyle modifications: Elevate head of bed, avoid trigger foods/drinks, weight loss, avoid eating close to bedtime, smoking cessation, limit alcohol",
      "Antacids (for immediate symptom relief)",
      "H2-receptor blockers (e.g., ranitidine, famotidine) (for mild-moderate GERD)",
      "Proton pump inhibitors (PPIs, e.g., omeprazole, lansoprazole, pantoprazole) (most effective for healing esophagitis and symptom control)",
      "Prokinetics (e.g., metoclopramide, domperidone) (for patients with motility disorders, limited use due to side effects)",
      "Surgical: Fundoplication (e.g., Nissen fundoplication) for refractory GERD or complications"
    ],
    "Object6": [
      "Esophagitis (inflammation, erosion)",
      "Esophageal stricture (narrowing due to scarring)",
      "Barrett's esophagus (metaplasia, premalignant condition)",
      "Esophageal adenocarcinoma",
      "Aspiration pneumonia",
      "Chronic cough, laryngitis, asthma exacerbations"
    ]
  },
  {
    "Object1": "Malabsorption Syndrome",
    "Object2": [
      "Pancreatic exocrine insufficiency (chronic pancreatitis, cystic fibrosis, pancreatic cancer)",
      "Small bowel mucosal disease (celiac disease, tropical sprue, Crohn's disease, Whipple's disease, giardiasis, radiation enteritis, lymphoma)",
      "Bile acid deficiency (cholestatic liver disease, bile duct obstruction, ileal resection, bacterial overgrowth)",
      "Lymphatic obstruction (intestinal lymphangiectasia, lymphoma, tuberculosis)",
      "Bacterial overgrowth (blind loop syndrome, diverticula, strictures, dysmotility)",
      "Short bowel syndrome (extensive small bowel resection)",
      "Disaccharidase deficiencies (lactase deficiency)",
      "Drugs (cholestyramine, neomycin, metformin)"
    ],
    "Object3": [
      "Chronic diarrhea, steatorrhea (bulky, foul-smelling, fatty stools, difficult to flush)",
      "Weight loss, muscle wasting, failure to thrive (children)",
      "Abdominal pain, bloating, flatulence, abdominal distension",
      "Specific nutrient deficiencies: Anemia (iron, B12, folate), osteomalacia/osteoporosis (calcium, vitamin D), edema (protein), neurological symptoms (B12, vitamin E), night blindness (vitamin A), bleeding (vitamin K)",
      "Glossitis, cheilosis"
    ],
    "Object4": [
      "Stool tests (24-hour quantitative fecal fat, qualitative Sudan stain, elastase for pancreatic function, ova and parasites)",
      "Blood tests (CBC, albumin, electrolytes, calcium, phosphate, magnesium, iron studies, B12, folate, fat-soluble vitamins - A, D, E, K, PT/INR)",
      "D-xylose absorption test (assesses mucosal integrity)",
      "Small bowel biopsy (diagnostic for celiac, Whipple's, lymphoma)",
      "Breath tests (hydrogen breath test for bacterial overgrowth or lactase deficiency)",
      "Pancreatic function tests (secretin-cholecystokinin test, fecal elastase)",
      "Imaging (CT/MRI enterography, barium studies, ERCP/MRCP for biliary/pancreatic disease)"
    ],
    "Object5": [
      "Treat underlying cause (e.g., gluten-free diet for celiac, antibiotics for bacterial overgrowth or tropical sprue, pancreatic enzyme replacement for pancreatic insufficiency)",
      "Nutritional support: High-calorie, high-protein diet; medium-chain triglycerides (MCTs); vitamin and mineral supplementation (especially fat-soluble vitamins, B12, folate, iron, calcium)",
      "Anti-diarrheal agents (loperamide)",
      "Bile acid sequestrants (for bile acid malabsorption)"
    ],
    "Object6": [
      "Severe malnutrition and cachexia",
      "Specific vitamin/mineral deficiencies with associated systemic effects (e.g., severe anemia, bone fractures, neurological damage)",
      "Growth retardation and developmental delays (children)",
      "Increased susceptibility to infections"
    ]
  },
  {
    "Object1": "Celiac Disease (Gluten-Sensitive Enteropathy)",
    "Object2": [
      "Autoimmune reaction to gluten (gliadin protein in wheat, barley, rye) in genetically susceptible individuals (HLA-DQ2 and/or HLA-DQ8)",
      "Genetic predisposition"
    ],
    "Object3": [
      "Gastrointestinal: Chronic diarrhea, steatorrhea, abdominal pain, bloating, flatulence, nausea, vomiting, weight loss, malabsorption symptoms",
      "Non-gastrointestinal: Fatigue, iron deficiency anemia (refractory), osteopenia/osteoporosis, dermatitis herpetiformis (itchy blistering skin rash), short stature/delayed puberty (children), neurological symptoms (ataxia, neuropathy), infertility, recurrent aphthous stomatitis, elevated liver enzymes"
    ],
    "Object4": [
      "Serological tests: Anti-tissue transglutaminase (tTG) IgA antibody (first-line), Endomysial antibody (EMA) IgA, Deamidated gliadin peptide (DGP) IgA/IgG. Total IgA level (to rule out IgA deficiency)",
      "Small bowel biopsy: Diagnostic, showing villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes (Marsh classification)",
      "Genetic testing: HLA-DQ2/DQ8 (high negative predictive value, useful for ruling out celiac disease)",
      "CBC (for anemia), iron studies, vitamin D, calcium, folate, B12 levels"
    ],
    "Object5": [
      "Strict, lifelong gluten-free diet (avoiding wheat, barley, rye)",
      "Nutritional supplementation (iron, folate, calcium, vitamin D, B12) to correct deficiencies",
      "Corticosteroids (rarely, for refractory celiac disease)"
    ],
    "Object6": [
      "Refractory celiac disease",
      "Enteropathy-associated T-cell lymphoma (EATL) (rare, but severe)",
      "Small bowel adenocarcinoma (rare)",
      "Osteoporosis and increased fracture risk",
      "Infertility and adverse pregnancy outcomes",
      "Neurological complications (gluten ataxia, peripheral neuropathy)"
    ]
  },
  {
    "Object1": "Tropical Sprue",
    "Object2": [
      "Environmental enteropathy, possibly due to infectious agents in tropical and subtropical regions (exact pathogen unknown)",
      "Associated with living in or visiting endemic areas"
    ],
    "Object3": [
      "Chronic watery diarrhea, steatorrhea",
      "Weight loss, malaise, fatigue",
      "Malnutrition, vitamin deficiencies (especially folate and B12, leading to megaloblastic anemia)",
      "Glossitis, stomatitis",
      "Abdominal distension, cramps"
    ],
    "Object4": [
      "Small bowel biopsy (shows partial villous atrophy, crypt hyperplasia, inflammatory infiltrate, less severe than celiac disease)",
      "D-xylose absorption test (abnormal)",
      "Schilling test (abnormal for B12 absorption)",
      "Stool studies (to rule out other infectious causes, typically negative for specific pathogens)",
      "CBC (for megaloblastic anemia, iron deficiency if chronic blood loss), B12 and folate levels"
    ],
    "Object5": [
      "Broad-spectrum antibiotics (tetracycline, trimethoprim-sulfamethoxazole) for several months",
      "Folic acid supplementation",
      "Vitamin B12 supplementation (parenteral if malabsorption is severe)",
      "Nutritional support"
    ],
    "Object6": [
      "Severe malnutrition and specific vitamin deficiencies",
      "Megaloblastic anemia",
      "Electrolyte imbalance",
      "Increased susceptibility to infections"
    ]
  },
  {
    "Object1": "Irritable Bowel Syndrome (IBS)",
    "Object2": [
      "Multifactorial, involving interplay of:",
      "Altered gut motility (too fast or too slow)",
      "Visceral hypersensitivity (increased pain perception from gut stimuli)",
      "Brain-gut axis dysregulation (abnormal communication between brain and gut)",
      "Psychosocial factors (stress, anxiety, depression)",
      "Post-infectious (some cases develop after gastroenteritis)",
      "Alterations in gut microbiota",
      "Genetic predisposition"
    ],
    "Object3": [
      "Chronic or recurrent abdominal pain (associated with defecation, change in stool frequency or consistency)",
      "Bloating and abdominal distension",
      "Flatulence",
      "Altered bowel habits (IBS-C: constipation-predominant; IBS-D: diarrhea-predominant; IBS-M: mixed bowel habits)",
      "Mucus in stool",
      "Feeling of incomplete evacuation",
      "Fatigue, headaches, dyspepsia, fibromyalgia (extra-intestinal symptoms)"
    ],
    "Object4": [
      "Diagnosis of exclusion, based on Rome IV diagnostic criteria (recurrent abdominal pain, on average, at least one day per week in the last 3 months, associated with two or more of the following: related to defecation; a change in frequency of stool; a change in form of stool)",
      "Routine laboratory tests (CBC, ESR, CRP, thyroid function, stool tests for infection/inflammation, celiac serology) typically normal",
      "Colonoscopy (only for alarm symptoms like weight loss, nocturnal diarrhea, GI bleeding, anemia, family history of IBD/cancer, new onset >50 years)"
    ],
    "Object5": [
      "Lifestyle and dietary modifications: Regular meals, adequate fiber (soluble fiber for IBS-C), low FODMAP diet (reduces fermentable carbohydrates), avoid trigger foods (caffeine, alcohol, fatty foods, artificial sweeteners)",
      "Pharmacological for symptom relief:",
      "Anti-diarrheals (loperamide for IBS-D)",
      "Laxatives (osmotic laxatives for IBS-C)",
      "Antispasmodics (dicyclomine, hyoscyamine for abdominal pain/cramps)",
      "Tricyclic antidepressants (TCAs) or Selective Serotonin Reuptake Inhibitors (SSRIs) (for pain, motility, and mood)",
      "Gut-specific antibiotics (rifaximin for bloating, diarrhea)",
      "Lubiprostone, linaclotide (for IBS-C)",
      "Eluxadoline (for IBS-D)",
      "Psychotherapy (CBT, hypnotherapy) for managing stress and symptoms"
    ],
    "Object6": [
      "Significantly reduced quality of life and functional impairment",
      "No serious organic or life-threatening complications",
      "Increased risk of anxiety and depression"
    ]
  },
  {
    "Object1": "Congenital Nonhemolytic Hyperbilirubinemias",
    "Object2": [
      "Genetic defects affecting bilirubin metabolism, specifically conjugation and excretion of bilirubin by the liver"
    ],
    "Object3": [
      "Generally benign, chronic or intermittent jaundice",
      "No evidence of hemolysis or underlying liver disease"
    ],
    "Object4": [
      "Elevated unconjugated or conjugated bilirubin levels in serum",
      "Normal liver function tests (ALT, AST, ALP, GGT)",
      "Normal complete blood count (CBC) and reticulocyte count",
      "Specific genetic tests or functional assays (e.g., phenobarbital challenge for Crigler-Najjar Type II)"
    ],
    "Object5": [
      "Gilbert's syndrome, Dubin-Johnson syndrome, Rotor syndrome: No specific treatment, reassurance is key",
      "Crigler-Najjar syndrome Type I: Phototherapy (lifelong), liver transplantation",
      "Crigler-Najjar syndrome Type II: Phenobarbital (induces UGT activity to increase bilirubin conjugation)"
    ],
    "Object6": [
      "Crigler-Najjar syndrome Type I: Kernicterus (bilirubin encephalopathy) leading to severe neurological damage if untreated",
      "Other syndromes: Generally none, normal life expectancy"
    ]
  },
  {
    "Object1": "Gilbert's Syndrome",
    "Object2": [
      "Autosomal recessive disorder, mutation in the UGT1A1 gene (UDP-glucuronosyltransferase 1A1)",
      "Reduced activity (approx. 30%) of UGT1A1 enzyme in the liver, leading to impaired bilirubin conjugation"
    ],
    "Object3": [
      "Intermittent, mild unconjugated hyperbilirubinemia",
      "Usually asymptomatic, often discovered incidentally",
      "Mild jaundice may be triggered by stress, fasting, dehydration, illness, vigorous exercise, or alcohol consumption",
      "No other signs of liver disease or hemolysis"
    ],
    "Object4": [
      "Elevated unconjugated (indirect) bilirubin (typically <3-5 mg/dL)",
      "Normal liver function tests (ALT, AST, ALP, GGT)",
      "Normal complete blood count (CBC) and reticulocyte count",
      "Genetic testing for UGT1A1 promoter region polymorphism (not routinely needed for diagnosis)"
    ],
    "Object5": [
      "No specific treatment is needed as it is a benign condition",
      "Reassurance and education about the condition"
    ],
    "Object6": [
      "No serious complications",
      "Normal life expectancy"
    ]
  },
  {
    "Object1": [
      "Lifelong phototherapy (daily for many hours) to convert unconjugated bilirubin to water-soluble isomers",
      "Oral bilirubin-binding agents (e.g., calcium phosphate)",
      "Liver transplantation (definitive cure)",
      "TIPS (Transjugular Intrahepatic Portosystemic Shunt) can be used as a bridge to transplant"
    ],
    "Object2": [
      "Phenobarbital (induces UGT1A1 enzyme activity, significantly reduces bilirubin levels)",
      "Phototherapy (for severe exacerbations or if phenobarbital is ineffective/not tolerated)"
    ]
  },
  {
    "Object1": "Dubin-Johnson Syndrome",
    "Object2": [
      "Autosomal recessive disorder, mutation in the MRP2 (multidrug resistance-associated protein 2) gene",
      "Defect in canalicular excretion of conjugated bilirubin into the bile, leading to its reflux into the blood"
    ],
    "Object3": [
      "Chronic, mild conjugated hyperbilirubinemia",
      "Usually asymptomatic, often discovered incidentally",
      "Episodes of jaundice may be triggered by stress, pregnancy, oral contraceptives, or illness",
      "Characteristic black-pigmented liver (due to accumulation of epinephrine metabolites, often seen on biopsy but not affecting function)",
      "No pruritus or fatigue usually"
    ],
    "Object4": [
      "Elevated conjugated (direct) bilirubin levels (typically 2-5 mg/dL, often >50% of total bilirubin)",
      "Normal liver function tests (ALT, AST, ALP, GGT) or mildly elevated GGT",
      "Normal complete blood count (CBC)",
      "Urine: Presence of normal amounts of coproporphyrin I but decreased coproporphyrin III, reversed coproporphyrin isomer ratio (coproporphyrin I > coproporphyrin III)",
      "Oral cholecystography: Non-visualization of the gallbladder is common"
    ],
    "Object5": [
      "No specific treatment is needed as it is a benign condition",
      "Reassurance and education about the condition",
      "Avoid drugs that impair bilirubin excretion or induce cholestasis"
    ],
    "Object6": [
      "No serious complications or progression to liver failure",
      "Normal life expectancy"
    ]
  },
  {
    "Object1": "Rotor Syndrome",
    "Object2": [
      "Autosomal recessive disorder, mutations in SLCO1B1 and SLCO1B3 genes",
      "Defect in hepatic uptake and storage of conjugated bilirubin from the blood (involves impaired transport of bilirubin across the sinusoidal membrane into hepatocytes and impaired intrahepatic storage)"
    ],
    "Object3": [
      "Chronic, mild conjugated hyperbilirubinemia",
      "Usually asymptomatic, often discovered incidentally",
      "Episodes of jaundice, often fluctuating in intensity",
      "No pruritus, no dark liver pigmentation"
    ],
    "Object4": [
      "Elevated conjugated (direct) bilirubin levels (typically 2-5 mg/dL, often >50% of total bilirubin)",
      "Normal liver function tests (ALT, AST, ALP, GGT)",
      "Normal complete blood count (CBC)",
      "Urine: Markedly increased urinary coproporphyrin excretion, with coproporphyrin I > coproporphyrin III (similar to Dubin-Johnson, but total coproporphyrin is higher)"
    ],
    "Object5": [
      "No specific treatment is needed as it is a benign condition",
      "Reassurance and education about the condition"
    ],
    "Object6": [
      "No serious complications or progression to liver failure",
      "Normal life expectancy"
    ]
  },
  {
    "Object1": "Acute Liver Failure (ALF)",
    "Object2": [
      "Drug-induced liver injury (DILI): Paracetamol (acetaminophen) overdose (most common cause in Western countries), isoniazid, NSAIDs, ecstasy, certain antibiotics",
      "Acute viral hepatitis: Hepatitis A virus (HAV), Hepatitis B virus (HBV, especially reactivated), Hepatitis E virus (HEV, particularly in pregnant women), Herpes Simplex virus (HSV), Cytomegalovirus (CMV)",
      "Autoimmune hepatitis (acute presentation)",
      "Mushroom poisoning (Amanita phalloides)",
      "Metabolic disorders: Wilson's disease (acute presentation), acute fatty liver of pregnancy, Reye's syndrome (children, aspirin use)",
      "Vascular events: Ischemic hepatitis ('shock liver'), Budd-Chiari syndrome (hepatic vein thrombosis)",
      "Other: Sepsis, malignancy (lymphoma, metastatic), toxins (carbon tetrachloride)"
    ],
    "Object3": [
      "Rapid onset of jaundice",
      "Coagulopathy (INR ≥1.5)",
      "Hepatic encephalopathy (altered mental status, confusion, asterixis, coma)",
      "Nausea, vomiting, right upper quadrant pain",
      "Fetor hepaticus (distinctive breath odor)",
      "Cerebral edema (leading to increased intracranial pressure, neurological deterioration)",
      "Acute kidney injury (hepatorenal syndrome)"
    ],
    "Object4": [
      "Liver Function Tests (LFTs): Markedly elevated ALT/AST (often thousands), rapidly rising bilirubin (total and conjugated), severely prolonged Prothrombin Time (PT)/INR (critical indicator of synthetic dysfunction)",
      "Blood tests: Hypoglycemia, metabolic acidosis, elevated ammonia (venous), elevated lactate, CBC (leukocytosis, thrombocytopenia)",
      "Viral serology: HAV IgM, HBsAg, HCV RNA, HEV IgM, HSV PCR (to identify specific viral causes)",
      "Drug screen (especially for paracetamol), ceruloplasmin (for Wilson's), autoimmune markers (ANA, ASMA, LKM1)",
      "Imaging: Abdominal ultrasound (to rule out biliary obstruction, Budd-Chiari syndrome), CT/MRI brain (for cerebral edema)"
    ],
    "Object5": [
      "Admission to Intensive Care Unit (ICU) for aggressive supportive care and monitoring",
      "Specific antidotes: N-acetylcysteine (for paracetamol overdose)",
      "Management of hepatic encephalopathy: Lactulose, rifaximin, restrict protein (temporary)",
      "Management of cerebral edema: Head elevation, hypertonic saline, mannitol, close monitoring of intracranial pressure",
      "Management of coagulopathy: Fresh frozen plasma (FFP), vitamin K, recombinant factor VIIa (caution)",
      "Management of hypoglycemia: Intravenous glucose infusion",
      "Management of acute kidney injury: Fluid and electrolyte balance, renal replacement therapy (dialysis)",
      "Infection prophylaxis and aggressive treatment of infections",
      "Liver transplantation (definitive treatment for irreversible ALF, urgent referral is critical)"
    ],
    "Object6": [
      "Hepatic encephalopathy and cerebral edema (major cause of death)",
      "Coagulopathy and bleeding (GI bleeding, intracranial hemorrhage)",
      "Sepsis and multi-organ failure (renal failure, respiratory failure, cardiovascular collapse)",
      "Acute kidney injury (hepatorenal syndrome)",
      "Electrolyte disturbances (hypoglycemia, hypokalemia, hyponatremia)"
    ]
  },
  {
    "Object1": "Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic Steatohepatitis (NASH)",
    "Object2": [
      "Insulin resistance (central pathogenic mechanism)",
      "Obesity (major risk factor, particularly visceral adiposity)",
      "Type 2 Diabetes Mellitus",
      "Dyslipidemia (hypertriglyceridemia, low HDL cholesterol)",
      "Metabolic syndrome",
      "Rapid weight loss, bariatric surgery",
      "Genetic predisposition",
      "Certain medications (amiodarone, methotrexate, tamoxifen, corticosteroids)"
    ],
    "Object3": [
      "Often asymptomatic, discovered incidentally on imaging or abnormal LFTs",
      "Fatigue, malaise",
      "Right upper quadrant (RUQ) discomfort or dull pain",
      "Hepatomegaly (on physical exam or imaging)",
      "NASH (more severe form with inflammation and fibrosis) may have more symptoms or signs of progression to cirrhosis",
      "Signs of cirrhosis if disease progresses: jaundice, ascites, edema, splenomegaly, variceal bleeding"
    ],
    "Object4": [
      "Liver Function Tests (LFTs): Elevated ALT/AST (typically ALT>AST, often mild to moderate elevation), normal or mildly elevated ALP/GGT. May fluctuate.",
      "Blood tests: Fasting glucose/HbA1c, lipid profile, insulin resistance markers, rule out other liver diseases (viral hepatitis serology, autoimmune markers, ceruloplasmin, A1AT levels)",
      "Imaging: Abdominal ultrasound (shows hyperechoic 'bright' liver, often first detected), CT scan, MRI (more sensitive for fat detection, e.g., proton density fat fraction - PDFF)",
      "Non-invasive fibrosis assessment (elastography - FibroScan, ARFI, MR elastography; serum fibrosis markers - FIB-4, APRI) to identify NASH with advanced fibrosis",
      "Liver biopsy: Gold standard for diagnosing NASH and staging fibrosis, essential for definitive diagnosis and prognosis."
    ],
    "Object5": [
      "Lifestyle modifications (cornerstone of therapy):",
      "Weight loss (5-10% body weight can improve NASH, >10% for fibrosis regression)",
      "Dietary changes (reduce refined carbohydrates, sugary drinks, saturated/trans fats, increase fruit, vegetables, whole grains)",
      "Regular physical activity (aerobic and resistance exercise)",
      "Management of associated metabolic conditions: Glycemic control in diabetes, lipid-lowering therapy for dyslipidemia, antihypertensives for hypertension",
      "Pharmacological agents (under investigation or for specific cases): Vitamin E (for non-diabetic NASH), pioglitazone (for diabetic NASH), GLP-1 agonists (liraglutide for diabetic NASH), obeticholic acid (for NASH with fibrosis)",
      "Avoid alcohol"
    ],
    "Object6": [
      "Progression to NASH (inflammation and fibrosis)",
      "Cirrhosis (15-25% of NASH patients progress to cirrhosis)",
      "Hepatocellular carcinoma (HCC) (can occur even in non-cirrhotic NAFLD, but higher risk with cirrhosis)",
      "Liver failure",
      "Increased risk of cardiovascular disease (major cause of death in NAFLD patients)"
    ]
  },
  {
    "Object1": "Hepatic Encephalopathy (HE)",
    "Object2": [
      "Acute or chronic liver failure (e.g., cirrhosis, acute viral hepatitis, drug-induced liver injury)",
      "Portosystemic shunting (e.g., Transjugular Intrahepatic Portosystemic Shunt - TIPS, surgical shunts)",
      "Precipitating factors (increase ammonia production/absorption, worsen liver function, or affect brain function):",
      "Gastrointestinal bleeding (increased protein load, ammonia production)",
      "Infection (especially spontaneous bacterial peritonitis - SBP)",
      "Constipation (increased ammonia production/absorption)",
      "Electrolyte disturbances (hypokalemia, alkalosis, hyponatremia)",
      "Diuretics (can cause hypokalemia, hypovolemia)",
      "Excessive dietary protein intake",
      "Drugs (sedatives, benzodiazepines, opiates)",
      "Dehydration, acute kidney injury"
    ],
    "Object3": [
      "Spectrum of neuropsychiatric abnormalities, graded by severity (West Haven criteria):",
      "Minimal HE: Subtle cognitive/psychomotor deficits, usually undetected clinically",
      "Grade 1: Mild confusion, irritability, short attention span, altered sleep patterns",
      "Grade 2: Lethargy, disorientation, inappropriate behavior, asterixis (flapping tremor), slurred speech",
      "Grade 3: Stupor, marked confusion, severe disorientation, hyperreflexia, rigidity",
      "Grade 4: Coma",
      "Fetor hepaticus (sweet, musty breath odor)",
      "Slowed movements, dysarthria"
    ],
    "Object4": [
      "Clinical diagnosis based on neuropsychiatric symptoms in a patient with liver disease",
      "Blood ammonia levels (venous preferred, interpret with caution as it's not perfectly correlated with severity and can be affected by lab handling)",
      "Electrolyte panel (to identify precipitating factors like hypokalemia, hyponatremia)",
      "Blood glucose (to rule out hypoglycemia)",
      "Liver function tests, PT/INR (to assess liver disease severity)",
      "Rule out other causes of altered mental status (infection, GI bleeding, stroke, drug overdose)",
      "Electroencephalogram (EEG) (shows slowing of brain waves, triphasic waves in severe HE)",
      "Imaging (CT/MRI brain) (to rule out structural brain lesions, cerebral edema in ALF)"
    ],
    "Object5": [
      "Identify and treat precipitating factors (e.g., stop GI bleeding, treat infection, relieve constipation, correct electrolyte imbalances, discontinue sedatives)",
      "Reduce ammonia production/absorption:",
      "Lactulose (first-line, non-absorbable disaccharide, acidifies colon to trap ammonia, osmotic laxative)",
      "Rifaximin (non-absorbable antibiotic, reduces ammonia-producing bacteria in gut)",
      "Dietary protein restriction (controversial, typically not long-term unless severe and refractory)",
      "Nutritional support (adequate calories, consider vegetable protein or branched-chain amino acids)",
      "Avoid sedatives and benzodiazepines",
      "For severe HE/ALF: Liver transplantation"
    ],
    "Object6": [
      "Cerebral edema (especially in acute liver failure, life-threatening)",
      "Coma",
      "Increased risk of falls and injuries",
      "Permanent neurological damage (rare with proper management)",
      "Recurrent episodes, leading to cumulative neurological deficits"
    ]
  },
  {
    "Object1": "Ascites (Condition)",
    "Object2": [
      "Cirrhosis (most common cause, 80% of cases, due to portal hypertension and splanchnic vasodilation)",
      "Heart failure (right-sided, biventricular, constrictive pericarditis) (due to elevated central venous pressure)",
      "Malignancy (peritoneal carcinomatosis, primary peritoneal cancer, liver metastasis) (due to peritoneal involvement, lymphatic obstruction, portal hypertension)",
      "Nephrotic syndrome (due to severe hypoalbuminemia)",
      "Pancreatitis (acute, chronic) (due to leakage of pancreatic fluid into peritoneal cavity)",
      "Budd-Chiari syndrome (hepatic venous outflow obstruction)",
      "Tuberculosis (peritoneal tuberculosis)",
      "Hypothyroidism (myxedema ascites)",
      "Dialysis (peritoneal dialysis complications)",
      "Severe malnutrition (hypoalbuminemia)"
    ],
    "Object3": [
      "Abdominal distension and increased abdominal girth",
      "Weight gain",
      "Abdominal discomfort, fullness, or pressure",
      "Dyspnea (due to upward displacement of diaphragm, especially with tense ascites)",
      "Ankle edema, peripheral edema",
      "Early satiety (due to abdominal pressure)",
      "Hernias (umbilical, inguinal) (due to increased intra-abdominal pressure)",
      "Fluid wave, shifting dullness (on physical examination)"
    ],
    "Object4": [
      "Physical examination (abdominal distension, fluid wave, shifting dullness)",
      "Imaging: Abdominal ultrasound (first-line, detects fluid, assesses liver/spleen/portal vein), CT scan, MRI (more detailed assessment)",
      "Diagnostic paracentesis (aspiration of ascitic fluid for analysis):",
      "Cell count and differential (neutrophil count >250 cells/µL suggests SBP)",
      "Total protein, albumin (to calculate Serum-Ascites Albumin Gradient - SAAG)",
      "Culture (for SBP), cytology (for malignancy), glucose, LDH, amylase (for specific causes)",
      "SAAG (Serum-Ascites Albumin Gradient): SAAG ≥1.1 g/dL indicates portal hypertension (cirrhosis, heart failure, Budd-Chiari); SAAG <1.1 g/dL indicates non-portal hypertensive causes (malignancy, pancreatitis, nephrotic syndrome)"
    ],
    "Object5": [
      "Treat underlying cause (e.g., diuretics for heart failure, chemotherapy for malignancy)",
      "For cirrhosis-related ascites:",
      "Sodium restriction (first-line, <2g/day)",
      "Diuretics: Spironolactone (aldosterone antagonist, first-line), furosemide (loop diuretic, added for greater diuresis), titrated to weight loss (0.5 kg/day)",
      "Therapeutic paracentesis (for large or tense ascites, relieves symptoms, often with albumin infusion to prevent post-paracentesis circulatory dysfunction)",
      "TIPS (Transjugular Intrahepatic Portosystemic Shunt) (for refractory ascites)",
      "Liver transplantation (for end-stage cirrhosis)",
      "Management of SBP: Antibiotics (cefotaxime), SBP prophylaxis (norfloxacin, ciprofloxacin)"
    ],
    "Object6": [
      "Spontaneous bacterial peritonitis (SBP) (life-threatening infection of ascitic fluid)",
      "Tense ascites (causing severe discomfort, dyspnea)",
      "Umbilical hernia (rupture risk)",
      "Hepatorenal syndrome (renal failure in advanced cirrhosis)",
      "Electrolyte disturbances (hyponatremia, hyperkalemia from diuretics)",
      "Malnutrition (due to strict dietary restrictions)"
    ]
  },
  {
    "Object1": "Drug and Toxin-induced Hepatitis (DILI)",
    "Object2": [
      "Paracetamol (acetaminophen) overdose (most common cause of acute liver failure in Western countries)",
      "Antibiotics (isoniazid, amoxicillin/clavulanate, nitrofurantoin, sulfonamides, erythromycin, tetracyclines)",
      "NSAIDs (diclofenac, ibuprofen)",
      "Antiepileptics (phenytoin, carbamazepine, valproic acid)",
      "Statins (simvastatin, atorvastatin)",
      "Herbal and dietary supplements (green tea extract, kava, ma huang)",
      "Antidepressants (tricyclics, SSRIs)",
      "Immunosuppressants (methotrexate, azathioprine)",
      "Antifungals (ketoconazole, fluconazole)",
      "Toxins (carbon tetrachloride, industrial chemicals, mushroom poisoning - Amanita phalloides)",
      "Corticosteroids (can cause fatty liver and mild transaminitis)"
    ],
    "Object3": [
      "Highly variable, from asymptomatic transaminitis to acute hepatitis, chronic hepatitis, or acute liver failure",
      "Jaundice, pruritus",
      "Fatigue, malaise, anorexia, nausea, vomiting, abdominal pain (especially RUQ)",
      "Dark urine, pale stools (if cholestatic)",
      "Fever, rash, eosinophilia (in idiosyncratic DILI with hypersensitivity features)",
      "Hepatic encephalopathy, coagulopathy (in severe cases)"
    ],
    "Object4": [
      "Detailed drug and supplement history (crucial)",
      "Liver Function Tests (LFTs): Elevated ALT/AST (patterns can be hepatocellular, cholestatic, or mixed), elevated bilirubin (total and direct), elevated ALP/GGT, prolonged PT/INR (in severe cases)",
      "Blood tests: CBC (eosinophilia in hypersensitivity, cytopenias in marrow toxicity), autoantibodies (ANA, ASMA, AMA) (to rule out autoimmune hepatitis or drug-induced autoimmune hepatitis), viral hepatitis serology (to rule out viral causes)",
      "Drug levels (e.g., paracetamol level in overdose)",
      "Liver biopsy: Not routinely performed but can be diagnostic in idiosyncratic reactions or when diagnosis is uncertain, showing characteristic patterns of injury"
    ],
    "Object5": [
      "Discontinue offending agent immediately (most critical step)",
      "Specific antidotes: N-acetylcysteine (for paracetamol overdose)",
      "Supportive care: Rest, hydration, antiemetics, management of pruritus",
      "Corticosteroids (e.g., prednisone): May be considered for idiosyncratic DILI with autoimmune or hypersensitivity features, or severe inflammation, but role is debated and specific for certain DILI types",
      "Management of acute liver failure (ALF) or chronic liver disease complications",
      "Liver transplantation (for irreversible ALF)"
    ],
    "Object6": [
      "Acute liver failure (ALF) (life-threatening)",
      "Chronic liver disease, cirrhosis (from chronic DILI)",
      "Cholestasis and pruritus",
      "Hypersensitivity reactions (DRESS syndrome)",
      "Hepatocellular carcinoma (rarely, from chronic DILI)"
    ]
  },
  {
    "Object1": "Hepatocellular Carcinoma (HCC)",
    "Object2": [
      "Chronic liver disease, especially cirrhosis (primary risk factor, ~80-90% of HCC occurs in cirrhotic liver)",
      "Major underlying etiologies leading to cirrhosis:",
      "Chronic Hepatitis B virus (HBV) infection (can cause HCC even without cirrhosis)",
      "Chronic Hepatitis C virus (HCV) infection",
      "Alcoholic liver disease (ALD)",
      "Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH) (increasing cause)",
      "Hemochromatosis (iron overload)",
      "Alpha-1 antitrypsin deficiency",
      "Other: Aflatoxin exposure (fungal toxin), Wilson's disease (less common cause), hereditary tyrosinemia"
    ],
    "Object3": [
      "Often asymptomatic in early stages, detected during surveillance",
      "Symptoms of worsening cirrhosis: unexplained weight loss, fatigue, malaise, anorexia, jaundice, increasing ascites, variceal bleeding, hepatic encephalopathy",
      "Right upper quadrant (RUQ) abdominal pain or discomfort",
      "Palpable abdominal mass (hepatomegaly)",
      "Fever (paraneoplastic or due to tumor necrosis)",
      "Paraneoplastic syndromes (rare): Hypoglycemia, erythrocytosis (due to EPO production), hypercalcemia"
    ],
    "Object4": [
      "Surveillance in high-risk patients (cirrhosis, chronic HBV): Abdominal ultrasound and Alpha-fetoprotein (AFP) every 6 months",
      "Laboratory: Elevated AFP (tumor marker, not diagnostic alone, can be elevated in chronic hepatitis or cirrhosis flares), elevated LFTs (may be normal if liver function preserved, or abnormal if large tumor burden/decompensation), CBC (anemia, thrombocytopenia)",
      "Imaging (diagnostic): Dynamic CT scan (multi-phase CT), Dynamic MRI (Gadolinium-enhanced) - show characteristic arterial enhancement and venous washout pattern. Essential for diagnosis and staging.",
      "Liver biopsy: Diagnostic for HCC, especially when imaging is atypical or AFP is normal (histological confirmation)",
      "Staging: TNM classification (tumor, node, metastasis) and Barcelona Clinic Liver Cancer (BCLC) staging system (integrates tumor burden, liver function, performance status, guides treatment decisions)"
    ],
    "Object5": [
      "Depends on tumor stage, liver function, and patient's overall health/performance status",
      "Curative options (for early-stage HCC):",
      "Surgical resection (for solitary tumors in non-cirrhotic or compensated cirrhotic patients)",
      "Liver transplantation (for early-stage HCC within Milan/UNOS criteria, offers best long-term survival for selected patients)",
      "Locoregional therapies (for intermediate-stage or bridge to transplant):",
      "Radiofrequency ablation (RFA), Microwave ablation (MWA) (for small tumors)",
      "Transarterial chemoembolization (TACE) (delivers chemotherapy directly to tumor via hepatic artery, blocks blood supply)",
      "Transarterial radioembolization (TARE) (delivers radiation using Y-90 microspheres)",
      "Systemic therapy (for advanced-stage HCC or metastatic disease):",
      "Tyrosine kinase inhibitors (sorafenib, lenvatinib) (first-line)",
      "Immunotherapy (pembrolizumab, nivolumab, ipilimumab) (emerging options)",
      "Supportive care and management of cirrhosis complications"
    ],
    "Object6": [
      "Liver failure, hepatic encephalopathy",
      "Portal vein thrombosis (can worsen portal hypertension, limit treatment options)",
      "Metastasis (lungs, bones, lymph nodes, brain)",
      "Tumor rupture and hemorrhage",
      "Cachexia, pain",
      "Complications related to underlying cirrhosis (variceal bleeding, ascites, SBP)"
    ]
  },
  {
    "Object1": [
      "Antibiotics: Broad-spectrum intravenous antibiotics initially (e.g., combination of third-generation cephalosporin/piperacillin-tazobactam with metronidazole), tailored based on culture and sensitivity results. Duration typically 4-6 weeks, sometimes longer.",
      "Drainage: Percutaneous catheter drainage (for large or multiple abscesses, first-line if feasible). Surgical drainage (if percutaneous fails or for rupture)."
    ],
    "Object2": [
      "Pharmacological: Metronidazole (first-line, highly effective), followed by a luminal amoebicide (e.g., paromomycin, diloxanide furoate) to eradicate intestinal cysts.",
      "Drainage: Aspiration (rarely needed, only for large abscesses at risk of rupture, non-response to therapy, or diagnostic uncertainty)."
    ]
  },
  {
    "Object1": "Hemochromatosis (Hereditary)",
    "Object2": [
      "Autosomal recessive genetic disorder, most commonly due to mutations in the HFE gene (C282Y mutation, less commonly H63D mutation)",
      "Leads to increased intestinal iron absorption and progressive iron overload in various organs"
    ],
    "Object3": [
      "Often asymptomatic in early stages (especially females due to menstrual blood loss)",
      "Symptoms usually appear after significant iron accumulation (often >10-20g total body iron)",
      "Constitutional: Fatigue, malaise, weakness",
      "Liver: Hepatomegaly, cirrhosis, right upper quadrant pain, increased risk of hepatocellular carcinoma (HCC)",
      "Skin: Hyperpigmentation ('bronze diabetes', grayish discoloration)",
      "Joints: Arthralgia, arthritis (chondrocalcinosis, mimicking osteoarthritis, often in MCP joints)",
      "Endocrine: Diabetes mellitus ('bronze diabetes'), hypogonadism (loss of libido, impotence, amenorrhea, testicular atrophy, due to pituitary iron deposition)",
      "Heart: Cardiomyopathy (dilated, restrictive), arrhythmias, heart failure",
      "Other: Hypothyroidism, adrenal insufficiency, increased susceptibility to certain infections (e.g., Yersinia, Vibrio)"
    ],
    "Object4": [
      "Laboratory (key screening tests):",
      "Elevated serum ferritin (most sensitive marker of iron stores, often >1000 µg/L in symptomatic disease)",
      "Elevated transferrin saturation (TSAT) (early and sensitive indicator, often >45% in men, >40% in women)",
      "Liver Function Tests (LFTs) (may be abnormal in advanced liver disease)",
      "Blood glucose/HbA1c (for diabetes)",
      "Genetic testing for HFE gene mutations (C282Y, H63D) (confirmatory)",
      "Liver biopsy: Gold standard for iron quantification (hepatic iron index) and assessment of fibrosis/cirrhosis (not always needed if non-invasive markers are conclusive)",
      "Imaging: MRI of liver (non-invasive measure of liver iron concentration), echocardiography (for cardiomyopathy), X-rays (for arthropathy)"
    ],
    "Object5": [
      "Therapeutic phlebotomy (venesection): First-line treatment, removes excess iron. Initially, weekly removal of 500 mL blood until iron stores are depleted (serum ferritin <50 µg/L). Then, maintenance phlebotomy (every 1-3 months) for life.",
      "Iron chelation therapy (deferoxamine, deferasirox, deferiprone): For patients who cannot tolerate phlebotomy (e.g., severe anemia, severe heart disease) or for specific organ iron overload (e.g., cardiac)",
      "Dietary modifications: Avoid iron supplements, vitamin C supplements (increases iron absorption), raw shellfish, and excessive alcohol",
      "Management of complications: Diabetes management, heart failure treatment, HCC surveillance."
    ],
    "Object6": [
      "Cirrhosis and hepatocellular carcinoma (HCC) (major cause of morbidity/mortality if untreated)",
      "Heart failure and arrhythmias",
      "Diabetes mellitus",
      "Hypogonadism and infertility",
      "Arthropathy",
      "Increased susceptibility to certain bacterial infections"
    ]
  },
  {
    "Object1": "Wilson's Disease",
    "Object2": [
      "Autosomal recessive genetic disorder, mutation in the ATP7B gene (copper-transporting ATPase 2 gene)",
      "Leads to impaired biliary excretion of copper from the liver and impaired incorporation of copper into ceruloplasmin, resulting in copper accumulation in liver, brain, eyes, and other organs"
    ],
    "Object3": [
      "Highly variable, often presenting between 5 and 35 years of age",
      "Hepatic manifestations (most common initial presentation, especially in children): Acute hepatitis, chronic hepatitis, cirrhosis, fulminant hepatic failure (acute presentation)",
      "Neurological manifestations (more common in adolescents/adults): Tremor (wing-beating tremor), dystonia, dysarthria, dysphagia, ataxia, parkinsonism, chorea",
      "Psychiatric manifestations: Depression, anxiety, mood swings, psychosis, cognitive impairment",
      "Ocular: Kayser-Fleischer rings (golden-brown copper deposits in Descemet's membrane of the cornea, diagnostic, may be absent in purely hepatic presentations)",
      "Hematological: Coombs-negative hemolytic anemia (acute, transient)",
      "Renal: Renal tubular acidosis, nephrolithiasis",
      "Musculoskeletal: Osteopenia, osteoporosis, arthropathy"
    ],
    "Object4": [
      "Laboratory (key diagnostic tests):",
      "Low serum ceruloplasmin (most cases, but can be normal in acute hepatitis, or elevated in inflammation/pregnancy)",
      "Elevated 24-hour urinary copper excretion (gold standard, >100 µg/day in symptomatic patients)",
      "Elevated hepatic copper concentration (liver biopsy is diagnostic, >250 µg/g dry weight)",
      "Slit-lamp examination for Kayser-Fleischer rings",
      "CBC (for hemolytic anemia), LFTs, PT/INR, renal function, fasting glucose",
      "Imaging: MRI brain (shows characteristic lesions in basal ganglia), MRI abdomen (for liver abnormalities)",
      "Genetic testing for ATP7B gene mutations (confirmatory, for family screening)"
    ],
    "Object5": [
      "Lifelong copper chelation therapy: D-penicillamine (first-line, must supplement with pyridoxine due to potential deficiency), Trientine (alternative if penicillamine intolerance)",
      "Zinc salts (e.g., zinc acetate, zinc sulfate): Blocks intestinal copper absorption, used for maintenance therapy or initial therapy in asymptomatic/presymptomatic patients",
      "Dietary modifications: Avoid high-copper foods (organ meats, shellfish, nuts, chocolate, mushrooms)",
      "For acute liver failure: Liver transplantation (only curative option in ALF)",
      "For advanced cirrhosis: Liver transplantation"
    ],
    "Object6": [
      "Cirrhosis, liver failure, hepatocellular carcinoma (HCC)",
      "Severe neurological and psychiatric impairment (if untreated)",
      "Fulminant hepatic failure (life-threatening)",
      "Hemolytic anemia (acute)",
      "Renal tubular acidosis",
      "Adverse effects from D-penicillamine (fever, rash, nephrotoxicity, bone marrow suppression, lupus-like syndrome)"
    ]
  },
  {
    "Object1": "Alpha-1 Antitrypsin Deficiency (Liver Disease)",
    "Object2": [
      "Autosomal recessive genetic disorder, mutation in the SERPINA1 gene (encoding alpha-1 antitrypsin - A1AT)",
      "Leads to misfolding of A1AT protein, which accumulates in hepatocytes, causing liver damage (PiZZ phenotype is most common and severe for liver disease)",
      "Reduced circulating A1AT levels lead to lung damage (emphysema) due to unchecked protease activity"
    ],
    "Object3": [
      "Highly variable presentation, can affect liver and/or lungs",
      "Neonatal cholestasis (prolonged jaundice in infancy)",
      "Childhood hepatitis or cirrhosis",
      "Adult chronic hepatitis or cirrhosis, leading to liver failure",
      "Hepatocellular carcinoma (HCC) (increased risk in cirrhotic patients)",
      "Lung manifestations (often prominent in adults): Early-onset emphysema (basilar predominance), bronchiectasis",
      "Fatigue, malaise, anorexia, ascites, variceal bleeding (in advanced liver disease)"
    ],
    "Object4": [
      "Laboratory: Low serum alpha-1 antitrypsin levels (diagnostic for severe deficiency), Pi phenotype testing (e.g., PiZZ, PiMZ, PiSS), elevated LFTs (ALT, AST, ALP, GGT), elevated bilirubin, prolonged PT/INR, low albumin (in advanced liver disease)",
      "Liver biopsy: Diagnostic, shows PAS-diastase resistant globules in hepatocytes (representing accumulated A1AT polymers) and assessment of inflammation/fibrosis/cirrhosis",
      "Genetic testing: SERPINA1 gene sequencing",
      "For lung involvement: Pulmonary function tests (shows obstructive pattern, reduced DLCO), Chest CT (shows basilar emphysema, bronchiectasis)"
    ],
    "Object5": [
      "No specific treatment to prevent A1AT accumulation in the liver",
      "Supportive care for liver disease:",
      "Management of complications of cirrhosis (ascites, variceal bleeding, hepatic encephalopathy)",
      "Regular HCC surveillance",
      "Liver transplantation (definitive treatment for end-stage liver disease or HCC)",
      "For lung disease: Augmentation therapy with intravenous pooled human A1AT (to slow emphysema progression), bronchodilators, smoking cessation, vaccinations"
    ],
    "Object6": [
      "Cirrhosis, liver failure, hepatocellular carcinoma (HCC) (major cause of liver-related morbidity/mortality)",
      "Early-onset emphysema (major cause of lung-related morbidity/mortality)",
      "Increased risk of panniculitis (subcutaneous fat inflammation)"
    ]
  },
  {
    "Object1": "Primary Biliary Cholangitis (PBC)",
    "Object2": [
      "Autoimmune disorder (exact etiology unknown), characterized by progressive immune-mediated destruction of small intrahepatic bile ducts",
      "Genetic predisposition (HLA-DR8, various non-HLA genes)",
      "Environmental triggers (e.g., bacterial infections, xenobiotics) proposed"
    ],
    "Object3": [
      "Often asymptomatic in early stages, detected incidentally by abnormal LFTs",
      "Fatigue (most common and debilitating symptom)",
      "Pruritus (itching, especially nocturnal, can be severe)",
      "Jaundice (occurs in late-stage disease, indicating progression)",
      "Right upper quadrant (RUQ) discomfort",
      "Xanthelasma (cholesterol deposits around eyes), xanthomas (on eyelids, palms, soles, elbows)",
      "Hepatomegaly, splenomegaly",
      "Associated autoimmune conditions: Sjögren's syndrome (dry eyes/mouth), autoimmune thyroiditis, Raynaud's phenomenon, celiac disease, scleroderma",
      "Osteopenia/osteoporosis (due to chronic cholestasis and inflammation)"
    ],
    "Object4": [
      "Laboratory: Elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) (cholestatic pattern, early and persistent finding), positive Anti-Mitochondrial Antibodies (AMA) (highly specific, diagnostic in >90% of cases), positive AMA-M2 subtype, elevated IgM, elevated cholesterol (often high in early stages), elevated bilirubin (in late stages), prolonged PT/INR, low albumin (in advanced disease)",
      "Imaging: Abdominal ultrasound, MRCP (Magnetic Resonance Cholangiopancreatography) (to rule out extrahepatic biliary obstruction)",
      "Liver biopsy: Not always necessary if AMA is positive and typical LFTs, but can be diagnostic and helpful for staging fibrosis",
      "Bone mineral density (BMD) assessment (DEXA scan) for osteoporosis"
    ],
    "Object5": [
      "Ursodeoxycholic acid (UDCA): First-line therapy, slows disease progression, improves LFTs, reduces need for liver transplantation. Lifelong treatment.",
      "Obeticholic acid (OCA): For patients with an inadequate response to UDCA (fewer than 1 year of treatment) or who are intolerant to UDCA. Can cause severe pruritus.",
      "Management of symptoms:",
      "Pruritus: Cholestyramine, rifampin, naltrexone, sertraline, UVB light",
      "Fatigue: Address contributing factors, symptomatic management",
      "Fat-soluble vitamin supplementation (A, D, E, K) (due to malabsorption from cholestasis)",
      "Calcium and vitamin D supplementation, bisphosphonates (for osteoporosis)",
      "Management of associated autoimmune conditions",
      "Liver transplantation (definitive treatment for end-stage PBC or complications like HCC)"
    ],
    "Object6": [
      "Cirrhosis and liver failure",
      "Portal hypertension and its complications (ascites, variceal bleeding, hepatic encephalopathy)",
      "Hepatocellular carcinoma (HCC) (increased risk with cirrhosis)",
      "Osteoporosis and fractures",
      "Malabsorption of fat-soluble vitamins and steatorrhea",
      "Increased risk of cholangitis",
      "Associated autoimmune diseases"
    ]
  },
  {
    "Object1": "Primary Sclerosing Cholangitis (PSC)",
    "Object2": [
      "Autoimmune disease (exact etiology unknown), characterized by chronic inflammation and fibrosis of intrahepatic and/or extrahepatic bile ducts, leading to strictures and cholestasis",
      "Strong association with inflammatory bowel disease (IBD), especially ulcerative colitis (70-80% of PSC patients have IBD)",
      "Genetic predisposition (HLA-B8, DR3, DR2)",
      "Environmental triggers (e.g., bacterial infections, toxins) proposed"
    ],
    "Object3": [
      "Often asymptomatic in early stages, detected incidentally by abnormal LFTs (elevated ALP) or during IBD workup",
      "Fatigue, pruritus (itching)",
      "Jaundice (intermittent or progressive)",
      "Right upper quadrant (RUQ) pain, recurrent episodes of cholangitis (fever, RUQ pain, jaundice)",
      "Hepatomegaly, splenomegaly",
      "Weight loss (in advanced stages or with cholangiocarcinoma)",
      "Symptoms of underlying IBD (diarrhea, abdominal pain, rectal bleeding)"
    ],
    "Object4": [
      "Laboratory: Elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) (cholestatic pattern, persistent finding), elevated bilirubin (in advanced disease or obstruction), elevated ALT/AST (mildly elevated), pANCA (perinuclear anti-neutrophil cytoplasmic antibodies, positive in 30-80% but non-specific), elevated IgM",
      "Imaging (diagnostic for biliary strictures):",
      "Magnetic Resonance Cholangiopancreatography (MRCP) (first-line non-invasive imaging, shows characteristic 'beading' and strictures of bile ducts)",
      "Endoscopic Retrograde Cholangiopancreatography (ERCP) (diagnostic and therapeutic, can dilate strictures, place stents, obtain biopsies)",
      "Liver biopsy: Not always diagnostic for PSC but can confirm cholestasis, fibrosis, and rule out other diseases (shows 'onion-skin' fibrosis around bile ducts)",
      "Colonoscopy: To screen for and manage associated IBD"
    ],
    "Object5": [
      "No specific medical therapy has been proven to slow disease progression or improve survival (UDCA use is controversial)",
      "Management of symptoms and complications:",
      "Pruritus: Cholestyramine, rifampin, naltrexone",
      "Recurrent cholangitis: Antibiotics (ciprofloxacin, metronidazole)",
      "Dominant strictures: ERCP with balloon dilation and/or stent placement",
      "Fat-soluble vitamin supplementation (A, D, E, K)",
      "Calcium and vitamin D supplementation (for bone health)",
      "Management of associated IBD (immunosuppressants, biologics, surgery)",
      "Surveillance for cholangiocarcinoma (ultrasound, CA 19-9, MRCP every 6-12 months)",
      "Liver transplantation (definitive treatment for end-stage liver disease or cholangiocarcinoma/dysplasia within criteria)"
    ],
    "Object6": [
      "Cholangiocarcinoma (bile duct cancer, high lifetime risk in PSC, often difficult to diagnose early)",
      "Colorectal cancer (increased risk due to association with ulcerative colitis)",
      "Recurrent bacterial cholangitis and sepsis",
      "Dominant bile duct strictures (requiring endoscopic intervention)",
      "Cirrhosis and liver failure",
      "Portal hypertension and its complications (ascites, variceal bleeding, hepatic encephalopathy)",
      "Osteoporosis and fractures",
      "Gallstones"
    ]
  },
  {
    "Object1": "Noncirrhotic Portal Fibrosis (NCPF) / Idiopathic Portal Hypertension (IPH)",
    "Object2": [
      "Unknown etiology (idiopathic, hence the name)",
      "May be associated with genetic factors, immunological dysregulation, thrombophilic conditions (e.g., portal vein thrombosis), or chronic exposure to certain drugs/toxins (e.g., arsenic, azathioprine)",
      "Characterized by portal tract fibrosis without regenerative nodules (unlike cirrhosis) and relatively preserved liver function"
    ],
    "Object3": [
      "Symptoms primarily relate to portal hypertension:",
      "Variceal bleeding (hematemesis, melena) (most common presentation)",
      "Splenomegaly (often massive, leading to hypersplenism)",
      "Ascites (may be intermittent or chronic)",
      "Hepatic encephalopathy (less common than in cirrhosis, but can occur)",
      "Fatigue, malaise",
      "Normal liver function (no jaundice or signs of synthetic dysfunction usually, until late stages)"
    ],
    "Object4": [
      "Liver Function Tests (LFTs): Typically normal or mildly elevated (ALT, AST, bilirubin, ALP, GGT), normal albumin, normal PT/INR (reflecting preserved synthetic function)",
      "Blood tests: CBC (thrombocytopenia, leukopenia due to hypersplenism), serology for viral hepatitis, autoimmune markers (to rule out other causes of chronic liver disease)",
      "Imaging: Doppler ultrasound (shows signs of portal hypertension - dilated portal vein, splenomegaly, ascites, presence of collateral vessels, normal liver parenchyma), CT/MRI abdomen (confirms imaging findings, rules out other pathology)",
      "Endoscopy: Upper endoscopy (to screen for and manage esophageal/gastric varices)",
      "Liver biopsy: Crucial for diagnosis, showing portal tract fibrosis, obliteration of portal venules, and absence of regenerative nodules or cirrhosis",
      "Hepatic Venous Pressure Gradient (HVPG) measurement: May show portal hypertension, but often normal or mildly elevated compared to cirrhosis"
    ],
    "Object5": [
      "Management is primarily focused on controlling portal hypertension and its complications, as liver function is usually preserved:",
      "Primary prevention of variceal bleeding: Non-selective beta-blockers (propranolol, nadolol)",
      "Management of acute variceal bleeding: Endoscopic variceal ligation (EVL) or sclerotherapy, vasoactive drugs (octreotide, terlipressin), balloon tamponade (temporary)",
      "TIPS (Transjugular Intrahepatic Portosystemic Shunt): For refractory variceal bleeding or ascites",
      "Management of ascites: Sodium restriction, diuretics",
      "Management of hypersplenism: Splenectomy (rarely, for severe symptomatic cytopenias), partial splenic embolization",
      "Avoid hepatotoxic drugs and alcohol"
    ],
    "Object6": [
      "Variceal bleeding (major cause of morbidity and mortality)",
      "Hypersplenism (leading to anemia, leukopenia, thrombocytopenia)",
      "Ascites",
      "Hepatic encephalopathy",
      "Portal vein thrombosis",
      "Increased risk of infections due to leukopenia/neutropenia"
    ]
  },
  {
    "Object1": "Tuberculosis in HIV Infection",
    "Object2": "Not specified (pulmonary, extrapulmonary, disseminated)",
    "Object3": [
      "Mycobacterium tuberculosis",
      "Most common opportunistic infection in HIV",
      "Accelerated course of HIV infection subsequent to TB development",
      "Higher prevalence of multidrug-resistant TB in HIV-positive persons"
    ],
    "Object4": [
      "Symptoms depend on level of immunosuppression.",
      "Pulmonary TB: Upper lobe infiltrates and cavitation (similar to HIV-negative), lower lobes frequently involved.",
      "Extrapulmonary TB: Increasingly common with immune suppression, often disseminated.",
      "Matted cervical lymph nodes, cutaneous tuberculosis-lupus vulgaris (Fig. 5.15C,D)."
    ],
    "Object5": [
      "Upper lobe infiltrates and cavitation (Chest X-ray)",
      "Lower lobe involvement (Chest X-ray)",
      "Sputum smears often positive for acid-fast bacilli",
      "Tuberculoma (CT head: space occupying lesion) (Fig. 5.15B)",
      "Matted cervical lymph nodes (Fig. 5.15C)",
      "Cutaneous tuberculosis-lupus vulgaris (Fig. 5.15D)"
    ],
    "Object6": [
      "Chest X-ray (Fig. 5.15A)",
      "Sputum smears for acid-fast bacilli",
      "CT head (for tuberculoma) (Fig. 5.15B)"
    ],
    "Object7": [
      "Antiretroviral therapy (ART) commenced in all HIV-infected individuals with active tuberculosis irrespective of CD4 cell count.",
      "TB treatment commenced first, ART subsequently (within 8 weeks of starting TB treatment).",
      "Recommended preferred ART regimen: AZT + 3TC + EFV or TDF + 3TC or FTC + EFV.",
      "If EFV intolerance/contraindication: NVP-based regimen or triple NRTI (AZT + 3TC + ABC or AZT + 3TC + TDF).",
      "Rifampicin induces CYP450, may decrease blood levels of PIs and some NNRTIs (NRTIs not affected).",
      "Rifampicin can be used with NNRTI efavirenz and two NRTIs; or PI ritonavir and one or more NRTIs; or two PIs (ritonavir and saquinavir, if not used in most cases).",
      "Rifabutin-based TB treatment recommended if boosted PI-based regimen needed (with additional RTV dosing, close monitoring).",
      "Rifabutin dose: 300 mg/day (on NRTIs, NVP, SQV alone). Reduced to 150 mg 2-3x/week (with ritonavir or ritonavir/lopinavir). Increased to 450-600 mg daily (with efavirenz)."
    ],
    "Object8": [
      "Immune reconstitution inflammatory syndrome (IRIS)",
      "Reduced adherence (high pill burden)",
      "Increased laboratory monitoring needed (LFTs, Hb estimation)"
    ]
  },
  {
    "Object1": "Immune Reconstitution Inflammatory Syndrome (IRIS)",
    "Object2": [
      "Related to underlying opportunistic infection (inflammatory 'unmasking' of untreated infection, paradoxical clinical deterioration of treated infection)",
      "Autoimmune (e.g., Graves' disease)",
      "Malignancies (e.g., worsening of Kaposi's sarcoma)"
    ],
    "Object3": [
      "Pathologic inflammatory immune recognition of antigens associated with known/unknown replicating infection or persistent non-replicating antigens from previous infection.",
      "Results from initiating cART in HIV patients, leading to immune restoration.",
      "Most common in patients with CD4+ T-cell counts <50 cells/µl and a sudden drop in HIV-RNA levels following cART initiation."
    ],
    "Object4": [
      "Clinical worsening of a treated opportunistic infection",
      "Atypical presentation of an unrecognized opportunistic infection",
      "Localized lymphadenitis, prolonged fever, pulmonary infiltrates, hepatitis, increased intracranial pressure, uveitis, sarcoidosis, Graves' disease (may develop 2 weeks - 2 years after cART initiation)"
    ],
    "Object5": [
      "Spectrum of presentations ranging from clinical worsening to atypical presentations or autoimmune disorders."
    ],
    "Object6": [],
    "Object7": [
      "Continue HAART in majority of cases (discontinuation sometimes necessary if life/organ-threatening).",
      "Corticosteroids or NSAIDs may help decrease inflammatory response.",
      "Treat the infection or malignancy."
    ],
    "Object8": [
      "Life or organ-threatening manifestations",
      "Fatal cases (in severe cases)"
    ]
  },
  {
    "Object1": "Postexposure Care of a Healthcare Worker (HCW) for HIV",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Determine Risk Associated with Exposure: Type of fluid (blood, visibly bloody fluid, other potentially infectious fluid/tissue), Type of exposure (percutaneous injury, mucous membrane, non-intact skin), Infection status of source (Class 1: asymptomatic/low viral load; Class 2: symptomatic/AIDS/acute seroconversion/high viral load).",
      "Source patient testing: Anti-HIV, HBsAg, anti-HCV with consent.",
      "Monitoring HCW: Complete blood counts, renal/hepatic function tests (baseline, then 2 weeks post-prophylaxis). Baseline HIV-antibody, Hepatitis B/C tests (repeated at 6 weeks, 12 weeks, 6 months postexposure)."
    ],
    "Object7": [
      "Decontamination: Wash area with soap and water, avoid squeezing wound, do not use caustic agents.",
      "Initiating Postexposure Prophylaxis (PEP): Start within 72 hours. 2-3 drug regimen based on risk for 28 days. First dose offered while evaluation underway. Not delayed awaiting source patient/baseline HIV test results.",
      "Basic PEP regimen: One nNRTI and one NRTI (tenofovir + emtricitabine) or Two NRTIs (zidovudine + lamivudine).",
      "Expanded PEP regimen: Additional third drug (ritonavir/lopinavir, indinavir, nelfinavir or efavirenz). Most common: ritonavir/lopinavir.",
      "Agents not recommended for PEP: Nevirapine, delavirdine, abacavir, zalcitabine. Zidovudine no longer recommended (no clear efficacy advantage over tenofovir, higher side effects).",
      "Preferred HIV-PEP regimen: Raltegravir 400 mg PO BID + tenofovir DF 300 mg + emtricitabine 200 mg Fixed Dose Combination once daily."
    ],
    "Object8": [
      "HIV transmission (0.3% after percutaneous, 0.09% after mucous membrane exposure).",
      "HBV transmission (2-40%).",
      "HCV transmission (1.8%).",
      "Serious side effects from antiretroviral drugs."
    ]
  },
  {
    "Object1": "Postexposure Prophylaxis for Hepatitis B (HBV)",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Management depends on: Source HBsAg status, exposed person's vaccination status, exposed person's immunity."
    ],
    "Object7": [
      "Unvaccinated/nonimmune (source HBsAg positive): HBIG (Hepatitis B immunoglobulin) x1; initiate HB vaccine series.",
      "Unvaccinated/nonimmune (source HBsAg negative/unknown): Initiate HB vaccine series.",
      "Previously vaccinated, known responder: No treatment.",
      "Previously vaccinated, known nonresponder (source HBsAg positive): HBIG x1 and initiate revaccination or HBIG x2. (source HBsAg negative/unknown): No treatment unless high-risk source, then treat as if HBsAg positive.",
      "Previously vaccinated, response unknown (source HBsAg positive): Single vaccine booster dose. (source HBsAg negative/unknown): No treatment unless high-risk source, then treat as if HBsAg positive.",
      "Still undergoing vaccination (source HBsAg positive): HBIG x1; complete series. (source HBsAg negative/unknown): Complete series."
    ],
    "Object8": []
  },
  {
    "Object1": "Postexposure Prophylaxis for Hepatitis C (HCV)",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "No vaccine or treatment will prevent infection.",
      "Immune globulin not recommended.",
      "Early infection effectively treated with Peg-interferon +/- ribavirin."
    ],
    "Object8": []
  },
  {
    "Object1": "Preexposure Prophylaxis (PrEP) for HIV",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Tenofovir/emtricitabine (only medication used in this setting).",
      "Indicated for: Men who have sex with men, Heterosexual men and women, Injection drug users, Sero-discordant couples."
    ],
    "Object8": []
  },
  {
    "Object1": "HIV Vaccine",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Hypercapnic Encephalopathy (Carbon Dioxide (CO2) Narcosis)",
    "Object2": "Encephalopathy (associated with severe hypercapnia)",
    "Object3": [
      "Hypercapnia (raised arterial carbon dioxide (PaCO2) of 45 mm Hg at rest, severe >90 mm Hg)",
      "Central depression of respiratory drive (Brain-stem lesions, Central sleep apnea, Obesity hypoventilation, Sedatives - Morphine)",
      "Neuromuscular (Peripheral neuropathy, Guillain-Barré syndrome, poliomyelitis, Myasthenia gravis, Myopathies)",
      "Reduced alveolar ventilation due to pathology within the lungs (Chronic bronchitis, Emphysema)",
      "Reduced chest wall (including diaphragmatic) movements (Trauma, Kyphoscoliosis, Pectus excavatum, Ankylosing spondylitis)"
    ],
    "Object4": [
      "Severe generalized or bilateral frontal or occipital headache (especially severe on waking up)",
      "Confusion, progressive drowsiness, CO2 narcosis (when PaCO2 exceeds 90 mm Hg)",
      "Mild cases: Intermittent drowsiness, indifference or inattention, reduction of psychomotor activity, forgetfulness."
    ],
    "Object5": [
      "Asterixis",
      "Altered sensorium",
      "Flushed warm extremities",
      "Bounding peripheral pulses",
      "Fasciculations (muscle twitching)",
      "Papilledema",
      "Cyanosis (mixed cyanosis - central and peripheral)"
    ],
    "Object6": [
      "Arterial Blood Gas (ABG) study (for confirmation of hypercapnia)"
    ],
    "Object7": [
      "Mechanical ventilation with intermittent positive-pressure respirator (non-invasive ventilation (NIV) may be sufficient in mild symptoms - BiPAP: 8-12 cm H2O inspiratory, 3-5 cm H2O expiratory).",
      "Maintenance of acid-base and electrolyte balance.",
      "Treatment of the underlying cause.",
      "Respiratory stimulants (Doxapram, Medroxyprogesterone, Acetazolamide) (variable benefits).",
      "Precaution: In chronic hypercapnia (e.g., COPD), oxygen administered in controlled manner (~2 L/minute); morphine and other sedatives avoided."
    ],
    "Object8": [
      "Acute hypercapnic respiratory failure can cause death."
    ]
  },
  {
    "Object1": "Hypoxemia",
    "Object2": "Not specified",
    "Object3": [
      "Arterial oxygen tension (PaO2) of less than 80 mm Hg (10.6 kPa) in young healthy adult (falls gradually with age).",
      "Ventilation-perfusion mismatch in the lung (Chronic bronchitis, Emphysema, Acute asthma, Pulmonary embolism, Interstitial lung diseases)",
      "Hypoventilation (Diminished ventilatory drive - Brainstem lesions, central sleep apnea, stroke, drug overdose, primary alveolar hypoventilation; Impaired neuromuscular transmission - Guillain-Barré syndrome, myasthenia gravis, phrenic nerve injury, spinal cord lesion, amyotrophic lateral sclerosis; Weakness of muscle - myasthenia gravis, muscular dystrophies, electrolyte disturbances; Disorders of chest wall - kyphoscoliosis, ankylosing spondylitis, severe obesity; Disorders of pleura - pneumothorax, pleural effusion; Airway obstruction - COPD, acute severe asthma, foreign body, vocal cord palsy)",
      "Decreased inspired oxygen concentration (High altitudes)",
      "Malfunctioning of mechanical ventilators",
      "Right-to-left shunts (Congenital cyanotic heart diseases, Pulmonary collapse/atelectasis, Consolidation - pneumonia, Pulmonary edema, Pulmonary hemorrhage)",
      "Diffusion abnormality (Interstitial lung disease, ARDS, interstitial pneumonias)"
    ],
    "Object4": [
      "Acute: Impaired judgment, motor incoordination.",
      "Chronic: Fatigue, drowsiness, inattentiveness, apathy, delayed reaction time, reduced work capacity."
    ],
    "Object5": [
      "Acute: Tachypnea, cyanosis, cold peripheries, thready pulses, hypotension.",
      "Chronic: Cyanosis (late stage)."
    ],
    "Object6": [
      "Arterial Blood Gas (ABG) study (for confirmation of hypoxemia).",
      "Calculate the alveolar-arterial O2 (PAO2-PaO2) gradient (to differentiate causes)."
    ],
    "Object7": [
      "Treat the underlying cause or mechanism."
    ],
    "Object8": [
      "Death (due to respiratory failure, affecting brainstem centers)."
    ]
  },
  {
    "Object1": "Clubbing (Hippocrates Fingers)",
    "Object2": [
      "Hereditary",
      "Idiopathic (pachydermoperiostitis or Touraine-Solente-Gole syndrome)",
      "Acquired"
    ],
    "Object3": [
      "Respiratory: Bronchogenic carcinoma (especially squamous cell carcinoma), metastasis to lung, mesothelioma, suppurative lung disease (bronchiectasis, lung abscess, cystic fibrosis, empyema), Asbestosis (with mesothelioma), Sarcoidosis, Cystic fibrosis, Pulmonary AV fistula, Interstitial lung diseases",
      "Cardiovascular: Infective endocarditis, Cyanotic congenital heart diseases, atrial myxoma, Eisenmenger's syndrome",
      "Gastrointestinal: Inflammatory bowel disease (ulcerative colitis, Crohn's disease), Primary biliary cirrhosis, Hepatoma",
      "Miscellaneous: Unidigital clubbing (repeated trauma)",
      "Unilateral Clubbing: Hemiplegia, Vascular disease (aneurysm, pre-subclavian coarctation of aorta), Pancoast tumor, Unilateral erythromelalgia, AV fistula for hemodialysis, Infected arterial graft",
      "Mechanisms: Role of platelets (PDGF, VEGF release), Humoral substances, Persistent hypoxia, Reduced ferritin, Vagal theory, Toxic, Metabolic"
    ],
    "Object4": [],
    "Object5": [
      "Selective bulbous enlargement of distal segment of digit (fingers and toes)",
      "Increase in connective tissue on dorsal aspect, loss of onychonychial angle",
      "Increased fluctuation (softening of nail bed)",
      "Loss of normal Lovibond's profile angle",
      "Thickening of whole distal finger (parrot beak/drumstick)",
      "Hypertrophic osteoarthropathy (pain/tenderness at distal end of long bones due to subperiosteal new bone formation)"
    ],
    "Object6": [
      "Phalangeal depth ratio (>1 indicates clubbing)",
      "Lovibond's profile sign, Curth's modified profile sign, Fluctuation test, Schamroth's window test"
    ],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": [
      "Can develop rapidly (lung abscess, empyema)."
    ]
  },
  {
    "Object1": "Pseudoclubbing",
    "Object2": "Not specified",
    "Object3": [
      "Subungual tumor or cyst",
      "Subperiosteal bone resorption (e.g., scleroderma, thyroid acropachy, vinyl chloride poisoning, acromegaly, hyperparathyroidism, leprosy, chronic renal failure, acrometastasis)"
    ],
    "Object4": [],
    "Object5": [
      "Increase in longitudinal curvature of the nail with loss of nail and nail plate material",
      "Asymmetrical involvement of fingers",
      "Resorption of the terminal tufts (acro-osteolysis) (radiographically)",
      "No over-growth of connective tissue."
    ],
    "Object6": [
      "Radiographically shows resorption of the terminal tufts (acro-osteolysis)."
    ],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Cyanosis",
    "Object2": [
      "Central cyanosis",
      "Peripheral cyanosis",
      "Mixed cyanosis",
      "Differential cyanosis",
      "Reverse differential cyanosis",
      "Intermittent cyanosis",
      "Cyclical cyanosis",
      "Orthocyanosis"
    ],
    "Object3": [
      "Increased concentration of reduced hemoglobin/deoxyhemoglobin (>5 g/dL) or abnormal hemoglobin derivatives (methemoglobin, sulfhemoglobin).",
      "Central: Inadequate oxygenation of systemic arterial blood (hypoxic hypoxia). Cardiac (Congenital cyanotic heart diseases, Acute pulmonary edema), Pulmonary (Acute severe asthma, COPD, cor pulmonale, respiratory failure, pneumonia, tension pneumothorax, acute laryngeal edema, acute pulmonary embolism), High altitude, Polycythemia, Enterogenous/pigment cyanosis (Methemoglobinemia, sulfhemoglobinemia).",
      "Peripheral: Sluggish peripheral circulation (stagnant hypoxia). Low cardiac output (CHF), Local vasoconstriction (Cold, frostbite, Raynaud's phenomenon, shock), Arterial obstruction (Peripheral vascular diseases), Venous obstruction (SVC syndrome), Hyperviscosity syndrome, Cryoglobulinemia, Mitral stenosis.",
      "Mixed: All causes of central cyanosis, cardiogenic shock with pulmonary edema, congestive cardiac failure (left sided), polycythemia.",
      "Differential: PDA with reversal of shunt (lower limbs only).",
      "Reverse differential: Coarctation of aorta (ductal type) with transposition of great arteries (upper limbs only).",
      "Left upper limb and both lower limbs: PDA with reversal of shunt and preductal coarctation of aorta.",
      "Intermittent: Ebstein's anomaly.",
      "Cyclical: Bilateral choanal atresia.",
      "Orthocyanosis: Pulmonary arterio-venous malformation.",
      "Absent despite sufficient reduced hemoglobin: Severe anemia, carbon monoxide poisoning."
    ],
    "Object4": [
      "Dyspnea (central)",
      "Exercise worsens (central)",
      "Dyspnea usually absent (peripheral)",
      "Dyspnea on sitting/standing (platypnea)"
    ],
    "Object5": [
      "Bluish discoloration of skin and mucous membrane (tongue, oral mucosa - central; tip of nose, ear lobules, outer aspect of lips, fingertips, nail bed, extremities - peripheral)",
      "Clubbing, polycythemia (central)",
      "Extremities warm (central), cold (peripheral)",
      "Pulse volume high (central), low (peripheral)",
      "Warming extremities: No change (central), Cyanosis disappears (peripheral)"
    ],
    "Object6": [
      "ABG (PaO2 <85% in central, normal in peripheral)",
      "Hyperoxia test (differentiates cardiac vs pulmonary cyanosis: if PaO2 improves >200 mmHg after 100% O2, cause is respiratory)"
    ],
    "Object7": [
      "Treat underlying cause.",
      "Pseudocyanosis (caused by metals, drugs): discoloration resolves once intake reduced."
    ],
    "Object8": []
  },
  {
    "Object1": "Hypertrophic Osteoarthropathy (HOA) (Hypertrophic Pulmonary Osteoarthropathy)",
    "Object2": [
      "Primary HOA (Pierre-Marie-Bamberger syndrome)",
      "Secondary HOA (associated with underlying disease)"
    ],
    "Object3": [
      "Clubbing of digits (almost always found)",
      "Periosteal new-bone formation and synovial effusions (more advanced stages)",
      "Underlying disease (e.g., lung cancer, bronchiectasis, infective endocarditis)",
      "Primary HOA: Rare hereditary disorder, associated with mutations in 15-hydroxy-prostaglandin dehydrogenase (15-PGDH)"
    ],
    "Object4": [
      "Pain and swelling of wrists and ankles (distal parts of long bones - radius, ulna, tibia, fibula)",
      "Pain aggravated by dependency, relieved by elevation of affected limb"
    ],
    "Object5": [
      "Digital clubbing",
      "Swollen and tender joints",
      "Pitting edema of anterior aspect of shin"
    ],
    "Object6": [
      "X-ray (Fig. 6.35): Periosteal thickening and subperiosteal new bone formation along shaft of distal ends of long bones. Ends of distal phalanges may show osseous resorption.",
      "Radionuclide studies of bones: Pericortical linear uptake along cortical margins of long bones (may be detected before radiographic changes)."
    ],
    "Object7": [
      "Identify and treat associated disease.",
      "Vagotomy or percutaneous blocking of vagus nerve (may give relief).",
      "Analgesics (aspirin or other NSAIDs)."
    ],
    "Object8": []
  },
  {
    "Object1": "Cheyne-Stokes Breathing",
    "Object2": "Cyclical pattern of respiration (hyperpnea alternating with apnea)",
    "Object3": [
      "Impaired responsiveness of respiratory center to carbon dioxide",
      "Physiological: Deep sleep, high altitude, newborn babies",
      "Pathological: Severe heart (left ventricular) failure, uremia, chronic hypoxia, diffuse cerebral atherosclerosis, stroke, head injury and hemorrhage, increased intracranial pressure, severe pneumonia, narcotic drug (barbiturates, opiates) poisoning"
    ],
    "Object4": [],
    "Object5": [
      "Gradual increases and decreases in respiration",
      "Two alternative periods: Rapid deep respiration (hyperpnea) and complete stoppage of respiration (apnea)"
    ],
    "Object6": [],
    "Object7": [
      "Treat underlying cause.",
      "Consequences: Accumulation of carbon dioxide during apnea, stimulation of respiratory centers during hypercapnia, depression of respiratory center during hyperventilation."
    ],
    "Object8": []
  },
  {
    "Object1": "Mitral Stenosis (MS)",
    "Object2": "Not specified",
    "Object3": [
      "Rheumatic fever (most common cause)",
      "Congenital mitral stenosis (parachute mitral valve/Shone complex)",
      "Metastatic carcinoid tumor to the lung, or primary bronchial carcinoid",
      "Severe calcification of mitral valve apparatus (e.g., in elderly)",
      "Systemic lupus erythematosus (extremely rare)",
      "Rheumatoid arthritis (extremely rare)",
      "Endomyocardial fibrosis",
      "Gout",
      "Methysergide treatment",
      "Lutembacher's syndrome (acquired MS + ASD)",
      "Mucopolysaccharidosis-Hurler's syndrome, Hunter's",
      "Whipple's disease",
      "Infective endocarditis with large vegetations",
      "Mimics of MS (Myxoma, Ball valve thrombus, Cor triatriatum)"
    ],
    "Object4": [
      "Dyspnea on exertion (slowly progressive, due to pulmonary hypertension)",
      "Fatigue on exertion (slowly progressive, due to pulmonary hypertension and low cardiac output)",
      "Hemoptysis (rupture of bronchial veins/pulmonary capillaries, pulmonary congestion, embolism/infarction, winter bronchitis, pulmonary hemosiderosis, anticoagulant use)",
      "Chest pain (due to RV enlargement, PAH, coexistent CAD, coronary embolism, angina from decreased cardiac output)",
      "Palpitations (atrial fibrillation, chamber enlargement)",
      "Systemic thromboembolism (stroke, mesenteric/renal/peripheral emboli)",
      "Syncope (PAH, arrhythmias, ball valve thrombus)",
      "Hoarseness of voice (La Ortner’s syndrome - compression of left recurrent laryngeal nerve)",
      "Orthopnea and paroxysmal nocturnal dyspnea (PND) (due to left atrial failure)",
      "Winter bronchitis (susceptibility to recurrent attacks)"
    ],
    "Object5": [
      "Mitral facies (cyanotic lips/face, malar flush, mild jaundice - severe MS with low cardiac output)",
      "Peripheral edema and ascites (right heart failure)",
      "Pulse: Low volume, irregularly irregular and varying volume (AF), peripheral pulse may be absent (embolism)",
      "Blood pressure: Mildly reduced. Mean of 3 readings in AF.",
      "Jugular veins: Raised JVP (CHF). Prominent 'a' waves (vigorous RA systole, PAH without AF). Absent 'a' waves (AF). Prominent 'v' waves and rapid 'y' descent (functional TR).",
      "Apex beat: Not shifted, tapping character of S1 (closing snap). Shifted if coexistent MR/AS/HTN/IHD/myocarditis.",
      "Diastolic thrill at apex.",
      "Palpable pulmonary component of S2 (PAH).",
      "Left parasternal heave (RVH, LA enlargement).",
      "Epigastric pulsations of RV type.",
      "Precordial bulge (juvenile/malignant MS).",
      "Loud S1 (intensity varies in AF; soft if calcified valve, congenital MS, dominant MR/AR).",
      "Loud S2 (sign of PAH, P2 is loud).",
      "Mitral opening snap (OS) (sharp, snappy, early diastole, 0.05-0.12s after A2). Absent OS indicates calcification/immobility. A2-OS interval inversely proportional to severity. Best heard with diaphragm at apex, expiration, left lateral position.",
      "Mid-diastolic/presystolic murmur (low pitched, rumbling, at apex. Longer in severe MS. Presystolic accentuation in sinus rhythm. Absent in AF, mild MS, long PR, bradycardia, LV dysfunction).",
      "Systolic murmur (functional TR, if PAH develops). Pansystolic murmur (if MS coexists with MR). Murmur of pulmonary regurgitation (Graham Steell murmur).",
      "Signs indicating severity: PAH, short A2-OS interval, lengthy MDM."
    ],
    "Object6": [
      "Chest X-ray (Figs. 7.42A-D): Enlargement of left atrial appendage, double atrial shadow, straightening of left heart border, splaying of carina, pushing esophagus backwards, left shift of aorta, 'walking man sign', cephalization of pulmonary vasculature (inverted moustache sign/antler's horn sign), Kerley's lines (A, B, C), peribronchial/perivascular cuffing, batwing opacities, prominent pulmonary outflow tract, enlarged pulmonary arteries, 'pruning' of peripheral pulmonary vessels, RVH, sternal contact sign, right atrial enlargement, calcification of mitral valve/pericardium/MacCallum patch, pulmonary hemosiderosis.",
      "Electrocardiogram: Enlargement of left atrium ('P' mitrale), RVH, tall R waves in V1-V3, atrial fibrillation, AV conduction defects.",
      "Echocardiogram: Thickening of mitral valve area/leaflets, chordae tendineae, fusion of commissures, calcification, diastolic doming. Wilkins score. Transesophageal echocardiography (TEE) for MR severity, LA thrombus. Doppler (definite evaluation, pressure gradient, PA pressure, LV function).",
      "Cardiac catheterization: Assess coexisting CAD, PA pressure, MS and MR (rarely needed)."
    ],
    "Object7": [
      "Medical management (for minor symptoms):",
      "Rheumatic fever prophylaxis (not infective endocarditis prophylaxis).",
      "Anticoagulation (for AF, embolic events, LA thrombus, LA diameter >55 mm, spontaneous echo contrast).",
      "Restrict/decrease sodium intake.",
      "Diuretics (for mild dyspnea).",
      "Beta blockers or non-DHP calcium channel blockers (verapamil/diltiazem) (to reduce heart rate, useful in AF).",
      "Digoxin (if AF with right heart failure).",
      "Surgical management:",
      "Trans-septal balloon mitral valvotomy (BMV/PBV) (treatment of choice for pliable valves, minimal MR). Contraindications: Moderate/severe MR, severe calcification/subvalvular fibrosis, LA thrombus/LV thrombus, recent embolism, bleeding disorders, thick interatrial septum.",
      "Closed mitral valvotomy (CMV) (for mobile, non-calcified valves without regurgitation). Contraindications: LA thrombus, valve calcification, severe subvalvular disease, moderate/severe MR.",
      "Open mitral valvotomy (OMV) (preferred over CMV/MVR).",
      "Mitral valve replacement (MVR) (indications: MS with MR, severely damaged/calcified stenotic valve, moderate/severe MS with LA thrombus). Types: Mechanical (age <65, requires anticoagulation), bioprosthetic (age >65, no anticoagulation)."
    ],
    "Object8": [
      "Atrial fibrillation (commonest complication, worsens symptoms, leads to systemic embolism).",
      "Thrombus formation (left atrial).",
      "Systemic embolization (stroke, mesenteric/renal/peripheral emboli).",
      "Pulmonary hypertension.",
      "Infective endocarditis (infrequently).",
      "Ortner's syndrome (hoarseness of voice due to recurrent laryngeal nerve compression).",
      "Hemoptysis.",
      "Dysphagia.",
      "Lower lobe pneumonia.",
      "Right heart failure.",
      "Pulmonary edema.",
      "Pulmonary infarction.",
      "Cardiac cirrhosis.",
      "Pulmonary hemosiderosis.",
      "Ball valve or free floating thrombus (may produce syncope)."
    ]
  },
  {
    "Object1": "Mitral Regurgitation (MR) (Mitral Insufficiency/Incompetence)",
    "Object2": [
      "Acute mitral regurgitation",
      "Chronic mitral regurgitation"
    ],
    "Object3": [
      "Acute: Infective endocarditis, rupture of a papillary muscle (e.g., acute MI, MVP), chest trauma, cardiac surgery, acute rheumatic carditis, dysfunction of prosthetic valve.",
      "Chronic: Damage to valve leaflets (Rheumatic heart disease, myxomatous degeneration, MVP, IE, SLE), Damage to annulus (abscess (IE), annular calcification, dilated cardiomyopathy), Damage to chordae tendineae (Myxomatous degeneration - MVP, Marfan, Ehlers-Danlos, IE, ARF), Damage to papillary muscles (CAD - ischemia, MI, rupture, dilated cardiomyopathy), Damage to left ventricle (Ischemia, dilated cardiomyopathy).",
      "Mitral valve prolapse (one of the common causes of mild MR)."
    ],
    "Object4": [
      "Acute MR: Dyspnea (due to acute pulmonary edema).",
      "Chronic MR: Asymptomatic for many years (until irreversible LV dysfunction). Palpitations (increased stroke volume, AF). Dyspnea, orthopnea (pulmonary venous hypertension, LV failure). Fatigue and lethargy (reduced cardiac output). Symptoms of right heart failure (late stages). Cardiac cachexia.",
      "Thromboembolism (less common than MS, but subacute IE more common)."
    ],
    "Object5": [
      "Acute MR: Normal apical impulse (no ventricular dilatation). Third and/or fourth heart sound. Early systolic or pansystolic murmur. Normal pulse pressure (near normal SBP/DBP).",
      "Chronic MR: Pulse: High volume, mildly collapsing (severe MR), irregularly irregular and varying volume (AF). Blood pressure: Wide pulse pressure. JVP: Normal (uncomplicated), absent 'a' waves (AF), prominent 'a' waves (PAH), very prominent 'v' waves (functional TR). Hyperdynamic precordium. Apex beat: Shifted left, forceful, diffuse. Systolic thrill at apex (severe MI). Left parasternal heave and palpable P2. Epigastric pulsations of RV type.",
      "Soft S1 (incomplete mitral valve closure). Widely split S2 (early A1, mobile split). Loud P2 (PAH, dilated LA). LV S3 (severe MR). S4 (acute MR). Pulmonary ejection sound (PAH).",
      "Apical pansystolic murmur (high pitched, blowing, holosystolic, loudest at apex, radiates widely to axilla/left interscapular area or base). Murmur character depends on pathology (Table 7.65). Severe MR with soft/no murmur (silent MR) in LV dilation, acute MR, COPD, obesity, dampened MR. Short mid-diastolic flow murmur (severe MR). Ejection systolic/early diastolic murmur at pulmonary area (PAH). Pansystolic murmur at LLSB (functional TR). Opening snap (~10%).",
      "Signs indicating severity: Bisferiens pulse, S3, flow mid diastolic murmur, pulmonary hypertension."
    ],
    "Object6": [
      "Electrocardiogram (ECG): Enlargement/hypertrophy of left atrium, dilatation/hypertrophy of left ventricle, hypertrophy of both ventricles (PAH), atrial fibrillation.",
      "Chest X-ray: Enlargement of left atrium/ventricle (more than MS), pulmonary venous congestion, pulmonary edema (interstitial in acute MR, chronic decompensated MR, coexistent MS). Annular calcium (C-shaped opacity in posterior 1/3 heart in lateral/RAO view).",
      "Echocardiogram: Dilated left atrium/ventricle. Structural abnormalities of mitral valve (prolapsed, chordal/papillary muscle ruptures). Doppler (detects/assesses severity, quantification of regurgitation). Mitral annular calcification. Transesophageal echocardiography (TEE) (identify structural valve abnormalities, helpful pre-surgery, assess efficacy of valve repair). MVP defined as >2mm systolic displacement of mitral leaflet into LA.",
      "Cardiac catheterization: Dilated LA/LV, MR, PAH, coexisting CAD."
    ],
    "Object7": [
      "Asymptomatic mild MR: Conservative management.",
      "Moderate MR: Medical treatment.",
      "Prophylaxis: Rheumatic fever (if rheumatic cause). Infective endocarditis (not required).",
      "Acute severe MR: Surgical intervention usually needed. Medical support: Dobutamine (augment cardiac output, shorten diastole), Sodium nitroprusside (reduce afterload in hypertensive patients).",
      "Chronic severe AR: Medical treatment (vasodilators - ACE inhibitors, nifedipine for hypertension; diuretics). Treatment of AF (digoxin, anticoagulants). Anticoagulation.",
      "Surgery (mitral valve repair or replacement): ESC guidelines for surgical intervention (Table 7.68): Symptomatic severe MR (EF >30%, ESD <55mm), Asymptomatic patients with LV dysfunction (ESD >45mm, EF <60%), new onset AF, or PAH. Mitral valve repair possible in MVP, papillary muscle dysfunction, leaflet perforation (IE), chordal rupture, annular dilation, rheumatic MR in young."
    ],
    "Object8": [
      "Progressive heart failure (most common cause of death).",
      "Less frequent: Sudden death, stroke, fatal endocarditis.",
      "Atrial fibrillation, infective endocarditis, left ventricular failure.",
      "Pulmonary hypertension (late), right ventricular failure (very late).",
      "Rarely systemic embolism."
    ]
  },
  {
    "Object1": "Mitral Valve Prolapse (MVP) (Barlow's Syndrome)",
    "Object2": [
      "MVP (abnormal movement of ≥1 mitral valve leaflet ≥2 mm beyond annular plane into LA)",
      "Barlow's syndrome (posterior leaflet/cusps involvement)",
      "Reads syndrome/floppy valve syndrome (variant of Barlow, affects both mitral cusps and other valves)",
      "Cobb's syndrome (selectively affects anterior mitral cusp)",
      "MVP syndrome (systolic click-murmur syndrome)"
    ],
    "Object3": [
      "Congenital anomalies",
      "Degenerative myxomatous changes (e.g., Marfan's syndrome, cystic medial necrosis) associated with excessive or redundant mitral leaflet tissue.",
      "Familial incidence with autosomal dominant inheritance.",
      "Associated with: Atrial septal defect (20%), polycystic kidney disease, chronic rheumatic heart disease, ischemic heart disease, and cardiomyopathies."
    ],
    "Object4": [
      "Asymptomatic or anxiety neurosis.",
      "Atypical chest pain (precordial stabbing), palpitation, syncope or presyncope, fatigue.",
      "Rarely: LV failure symptoms (exertional dyspnea, orthopnea, PND), sudden death, transient ischemic attacks (TIAs)."
    ],
    "Object5": [
      "Asthenic built, straight back/pectus excavatum.",
      "Mid-systolic click (in mildest forms, valve competent but bulges back into atrium).",
      "Late systolic murmur (when MR present, follows click, apical, rarely 'whooping'/'honking'). Length increases with severity. Increases during standing/Valsalva, decreases during squatting/isometric exercise.",
      "Mitral regurgitation."
    ],
    "Object6": [
      "Electrocardiogram (ECG): Nonspecific ST-T changes or inverted T waves in leads II, III, aVF.",
      "Echocardiography: Confirmation of diagnosis. Color Doppler for degree of regurgitation. Defined as ≥2 mm systolic displacement of mitral leaflet into LA."
    ],
    "Object7": [
      "Medical:",
      "Reassurance for asymptomatic patients.",
      "β-blockers for atypical chest pain.",
      "Antiarrhythmic drugs for arrhythmias.",
      "Aspirin, dipyridamole or anticoagulants for TIAs.",
      "No need for infective endocarditis prophylaxis.",
      "Surgical: Mitral valve repair or replacement in severe mitral regurgitation."
    ],
    "Object8": [
      "Arrhythmias",
      "Sudden rupture of chordate tendineae",
      "Progressive mitral regurgitation",
      "Infective endocarditis",
      "Transient cerebral ischemic attacks, embolism",
      "Acute severe mitral regurgitation",
      "Sudden death"
    ]
  },
  {
    "Object1": "Aortic Stenosis (AS)",
    "Object2": [
      "Valvular aortic stenosis (Acquired: Rheumatic, Calcific aortic valvular disease (CAVD), SLE, Fabry's, CKD, Paget's, RA, IE, senile degenerative, radiation, familial hypercholesterolemia, ochronosis; Congenital: Congenital AS, bicuspid aortic valve (BAV), calcification of congenitally bicuspid aortic valve)",
      "Subvalvular aortic stenosis (Membranous diaphragm, Hypertrophic cardiomyopathy, Congenital subvalvular AS)",
      "Supravalvular aortic stenosis (Hourglass constriction, Congenital supravalvular AS, Williams' syndrome)"
    ],
    "Object3": [
      "Chronic progressive disease, obstruction to left ventricular stroke volume.",
      "Normal aortic valve area 3-4 cm², critical AS <0.8 cm² or gradient >50 mm Hg.",
      "Atherosclerosis of aortic valve (leading cause in elderly)",
      "Rheumatic heart disease",
      "Congenital bicuspid aortic valve",
      "Shone's complex (rare combination of 4 left-sided congenital cardiac anomalies)."
    ],
    "Object4": [
      "Asymptomatic (moderate severity)",
      "Symptomatic triad: Breathlessness (dyspnea) on exertion, Angina (exertional, due to mismatch in O2 demand-supply, or CAD), Syncope (exertional, due to failure of CO to rise, fall in BP).",
      "Exercise intolerance (most common initial presentation).",
      "Heart failure (orthopnea, PND).",
      "Infective endocarditis.",
      "Embolism.",
      "Gastrointestinal bleed (angiodysplasias, Heyde syndrome, acquired von Willebrand syndrome)."
    ],
    "Object5": [
      "Appearance: 'Dresden China' look (asthenic, pale skin - severe AS).",
      "Pulse: Parvus et tardus (slow rising, late peaking, low amplitude). Pulsus bisferens (if AR). Anacrotic pulse, apico-carotid delay (severe AS). Normal pulse if coexistent AR/HTN. Coanda effect (supravalvular AS). Carotid shudder (thrill in carotids).",
      "Blood pressure: Low systolic and pulse pressures (systolic decapitation). Normal BP if coexistent AR/HTN.",
      "JVP: Prominent 'a' waves (Bernheim effect).",
      "Apex beat: Thrusting/heaving LV type, not usually displaced (concentric LVH). Palpable LV S4.",
      "S1 normal (loud if coexistent MS).",
      "S2-A2: Soft (single S2) in rheumatic AS, loud in BAV, normal in sub/supravalvular AS. Paradoxical (reversed) split of A2 (splitting on expiration) in severe AS.",
      "Systolic ejection click (BAV).",
      "Ejection mid-systolic murmur: Harsh/rough, radiates to neck (carotids) and precordium, late peaking in severe AS. Loudest at base of heart (aortic area). Diamond-shaped (crescendo-decrescendo). Musical quality ('mew' of seagull) in elderly. Longer in severe AS. Intensity does not correlate with severity (less intense with reduced CO). May not be audible in severe AS. Gallavardin phenomenon (high frequency radiation to apex)."
    ],
    "Object6": [
      "Chest X-ray: Rounding of apex (concentric LVH), normal/small heart size. Prominent dilation of ascending aorta (post-stenotic dilation). Calcification of aortic valve. LA enlargement (if AF).",
      "Electrocardiogram (ECG): Left ventricular hypertrophy (LVH), atrial fibrillation (10-15%), AV conduction defects (calcific AS).",
      "Echocardiography: Severity and gradient across aortic valve. Dobutamine stress echo (assesses contractile reserve). Doppler (severity of stenosis, associated AR).",
      "Cardiac magnetic resonance and cardiac CT: Aneurysm, dissection, coarctation.",
      "Cardiac catheterization: Assess coexisting CAD, PA pressure, MS/MR (rarely needed). Coronary angiography (before aortic valve surgery, for CAD)."
    ],
    "Object7": [
      "Asymptomatic patients: Conservative management with regular review.",
      "Medical treatment: Avoid vigorous physical activity in severe AS. Diuretics for dyspnea (caution, may reduce CO). ACE inhibitors with caution (only if LV failure). Avoid beta blockers (LV failure). Vasodilators for angina (careful titration). Cardioversion for AF.",
      "Prophylaxis: Infective endocarditis (for valvular replacement). Rheumatic fever.",
      "Surgical treatment:",
      "Indications: Symptomatic patients (dyspnea, angina, syncope). Asymptomatic patients with resting LVEF ≤55%. Asymptomatic patients with LVEF >55% but with LV dilation (LV end diastolic dimension >70 mm or end-systolic dimension >55 mm). Acute severe AR. Undergoing CABG/other cardiac valve surgery.",
      "Balloon dilatation (valvuloplasty): Temporary relief, for unfit/bridge to surgery. Poor results in adults.",
      "Aortic valve replacement (AVR): Usually needed after valvuloplasty. Types: Mechanical (age <65, requires lifelong anticoagulation), Bioprosthetic (age >65, avoid anticoagulation, greater deterioration).",
      "Percutaneous valve replacement (TAVR/TAVI): For patients unsuitable for surgical AVR.",
      "ROSS procedure: Replacement of diseased aortic valve by pulmonic valve and implantation of homograft."
    ],
    "Object8": [
      "Heart failure, syncope, angina (average survival 1.5-5 years after onset).",
      "Infective endocarditis.",
      "Embolism.",
      "Gastrointestinal bleed (angiodysplasias, Heyde syndrome, acquired von Willebrand syndrome).",
      "Sudden death."
    ]
  },
  {
    "Object1": "Aortic Sclerosis",
    "Object2": "Not specified",
    "Object3": [
      "Irregular thickening of the aortic valve leaflets without significant aortic obstruction",
      "Risk factors: Dyslipidemia, diabetes, hypertension, and smoking. Higher prevalence in Paget disease and end stage renal disease (ESRD)."
    ],
    "Object4": [
      "Asymptomatic (may produce a systolic ejection murmur)"
    ],
    "Object5": [
      "Systolic ejection murmur (without symptoms)",
      "Normal pulse, BP."
    ],
    "Object6": [
      "Echocardiography (reveals irregular thickening of aortic valve leaflets)."
    ],
    "Object7": [
      "No medical treatment available.",
      "Rosuvastatin has shown to decrease progression to severe AS.",
      "ACE inhibitors (tried)."
    ],
    "Object8": [
      "Increases cardiovascular death and MI by 50% even without AS."
    ]
  },
  {
    "Object1": "Bicuspid Aortic Valve (BAV) Disease",
    "Object2": "Congenital heart disease",
    "Object3": [
      "Congenital anomaly (1-2% of live births)",
      "Inherited as autosomal dominant (some cases, NOTCH1 gene mutation)",
      "Associated with other congenital cardiac diseases (dilatation of proximal ascending aorta, coarctation of aorta, VSD, ASD)"
    ],
    "Object4": [],
    "Object5": [
      "Ejection click (best heard at apex)",
      "Murmurs of aortic stenosis or aortic regurgitation (may be associated)"
    ],
    "Object6": [
      "Echocardiography (diagnostic, confirms LVH).",
      "CT and MRI (assess dilatation of aorta)."
    ],
    "Object7": [
      "Medical: Control of hypertension, use of β-blockers.",
      "Surgical: Aortic valve replacement, aortic root surgery (if needed)."
    ],
    "Object8": [
      "Aortic regurgitation (20% develop severe AR).",
      "Aortic stenosis (due to calcification, severe AS after 50 years).",
      "Infective endocarditis.",
      "Ascending aortic dilation (due to medial degeneration).",
      "Aortic dissection (risk increased 5-9 times)."
    ]
  },
  {
    "Object1": "Aortic Regurgitation (AR) (Aortic Incompetence)",
    "Object2": [
      "Acute aortic regurgitation",
      "Chronic aortic regurgitation"
    ],
    "Object3": [
      "Acute: Infective endocarditis, aortic dissection, acute rheumatic fever, ruptured sinus of Valsalva aneurysm, failure of prosthetic valve, trauma.",
      "Chronic: Congenital (Bicuspid aortic valve or disproportionate cusps), Acquired (Rheumatic heart disease, Infective endocarditis, Trauma, Aortic dilatation - aneurysm, dissection, Arthritides - ankylosing spondylitis, rheumatoid arthritis, Syphilitic aortitis, Hypertension, Connective tissue disorders - Marfan's syndrome, Ehlers-Danlos syndrome, Osteogenesis imperfecta, methysergide)."
    ],
    "Object4": [
      "Acute AR: Sudden, severe shortness of breath, chest pain (if myocardial perfusion decreased or aortic dissection present), rapidly developing heart failure, pulmonary edema, cardiogenic shock.",
      "Chronic AR: Asymptomatic for 10-15 years. Palpitations (especially on lying down, sinus tachycardia, head pounding). Exertional dyspnea (first symptom of diminished cardiac reserve), orthopnea, PND, excessive diaphoresis. Angina pectoris (even without CAD, at rest/exertion, nocturnal, prolonged, not responding to GTN). Congestive heart failure. Sudden cardiac death. Arrhythmias (not common)."
    ],
    "Object5": [
      "Peripheral signs: Prominent, large-volume (bounding)/'collapsing' peripheral pulses. Low diastolic, increased/wide pulse pressure. Signs of wide pulse pressure (Table 7.72). Prominent neck pulsations, thrill in carotids. Apex beat: Displaced inferiorly/axilla, diffuse/hyperdynamic. Pre-systolic impulse. Diastolic thrill along LSB (thin chest, Erbs maneuver). Prominent systolic thrill in suprasternal notch, transmitted along carotids.",
      "Auscultation: Soft S1. A2 component of S2 soft (rheumatic AR), loud/'tambour' (syphilitic AR). Narrowly split, single or paradoxically split S2. S3 gallop (LV dysfunction). S4 (LVH).",
      "Murmurs: Early diastolic murmur (early-holo diastolic, high pitched blowing, decrescendo, loudest at LSB, end of expiration, sitting/leaning forward). Cole-Cecil murmur (diastolic murmur of AR in left axilla). Musical murmur (cooing dove) signifies eversion/perforation of aortic cusp. Harvey sign (murmur location for valvular vs. aortic root AR). Functional systolic flow murmur (increased stroke volume). Austin-Flint murmur (low-pitched, mid-diastolic rumbling murmur at apex in severe AR). Intensified by strenuous/sustained handgrip. Pulse pressure normal/narrow in severe AR (due to peripheral vasoconstriction in HF)."
    ],
    "Object6": [
      "Chest X-ray: Cardiomegaly (LV enlargement/dilatation). Severely dilated ascending aorta (aortic arch/knob). Left atrial enlargement (only with significant LV dysfunction). Calcification of ascending aortic wall/aortic valve (syphilitic AR). Later, features of left heart failure.",
      "Electrocardiography (ECG): Adaptive changes in LV (volume overload): LVH (tall R waves, deep inverted T waves in left chest leads), left axis deviation, left atrial enlargement. LV volume overload pattern (prominent Q waves in I, aVL, V5-V6). LV conduction defects (late).",
      "Echocardiography: Aortic valve structure/morphology. Vegetations/nodules. Quantification of regurgitant volume/fraction/orifice area. Fluttering anterior mitral leaflet. Associated lesions of aorta. LV structure/function. Doppler echocardiography (severity). TEE (rarely needed).",
      "Cardiac magnetic resonance and cardiac CT: Thoracic aorta for aneurysm, dissection or coarctation (rarely needed). CMR quantifies regurgitant volume.",
      "Cardiac catheterization: Coronary angiography (prior to AVR in CAD risk factors).",
      "Other tests: VDRL and TPHA (if syphilitic). RA factor, ANA, ESR, CRP (exclude CTD)."
    ],
    "Object7": [
      "Underlying cause (dissection, endocarditis, syphillis).",
      "Prophylaxis: Rheumatic fever (if rheumatic). Infective endocarditis (not required).",
      "Acute severe AR: Surgical intervention usually needed. Medical support: Dobutamine (augment cardiac output, shorten diastole), Sodium nitroprusside (reduce afterload in hypertensive patients).",
      "Chronic severe AR:",
      "Medical: Vasodilator therapy (ACE inhibitors, nifedipine) (for hypertension, to reduce afterload). Diuretics. Anticoagulation (if AF).",
      "Surgical: Aortic valve replacement (AVR) (usually required). Valve-sparing repair available (TAVR/TAVI). Indications (Box 7.43): Symptomatic severe AR. Asymptomatic with resting LVEF ≤55%. Asymptomatic with LVEF >55% but LV dilation (LVEDD >70mm or LVESD >55mm). Fractional shortening (FS). Acute severe AR (e.g., endocarditis). If undergoing CABG, ascending aorta surgery or other cardiac valve.",
      "Types of valves: Mechanical (more durable, lifelong warfarin). Bioprosthetic (greater deterioration, no warfarin, preferred in elderly/when anticoagulation contraindicated, contraindicated in children/young adults).",
      "Aortic root dilation causing AR (e.g., Marfan's): Encircling suture, subcommissural annuloplasty, aortic graft with prosthetic valve, or aortic graft alone."
    ],
    "Object8": [
      "Acute AR: Rapidly developing heart failure, pulmonary edema, cardiogenic shock, myocardial ischemia.",
      "Chronic AR: Left ventricular failure, congestive heart failure. Sudden cardiac death. Angina pectoris. Arrhythmias (not common).",
      "Syphilitic AR: Angina, aortic aneurysm.",
      "Marfan's syndrome: Aortic dilatation/dissection."
    ]
  },
  {
    "Object1": "Tricuspid Stenosis (TS)",
    "Object2": "Narrowing of the tricuspid valve opening",
    "Object3": [
      "Rheumatic (frequently associated with mitral and/or aortic valve disease)",
      "Carcinoid syndrome",
      "Congenital",
      "Infective endocarditis",
      "Anorectics (fenfluramine)",
      "Fabry's disease"
    ],
    "Object4": [
      "Usually due to associated left-sided rheumatic valve lesions.",
      "Symptoms of right heart failure: Abdominal pain/hepatic discomfort (hepatomegaly), peripheral edema, ascites.",
      "Little or no dyspnea and fatigue (common)."
    ],
    "Object5": [
      "Jugular venous pressure (JVP): Raised with prominent 'a' waves (giant a waves) and slowly descent.",
      "Mid-diastolic murmur: Loud S1, rumbling mid-diastolic murmur (higher pitched than MS) with presystolic accentuation, best heard at LLSB, increases/louder during inspiration (De-Carvallo's sign).",
      "Tricuspid opening snap (OS): Occasionally heard.",
      "Right heart failure: Hepatomegaly with presystolic pulsation, ascites, peripheral edema."
    ],
    "Object6": [
      "Chest X-ray: May show a prominent right atrial bulge.",
      "ECG: Enlarged right atrium.",
      "Echocardiogram: May reveal thickened and immobile tricuspid valve."
    ],
    "Object7": [
      "Medical: Diuretic therapy, salt and fluid restriction.",
      "Surgical: Tricuspid valve replacement."
    ],
    "Object8": [
      "Right heart failure (hepatomegaly, ascites, dependent edema)."
    ]
  },
  {
    "Object1": "Tricuspid Regurgitation (TR)",
    "Object2": "Tricuspid valve does not close properly, causing backflow of blood into RA",
    "Object3": [
      "Most commonly functional secondary to right ventricular dilatation (e.g., chronic left heart failure, RV infarction, inferior wall MI, pulmonary hypertension, cardiomyopathy).",
      "Primary/organic: Rheumatic heart disease, endocarditis (IV drug abuse), Ebstein's congenital anomaly, carcinoid syndrome."
    ],
    "Object4": [
      "Usually nonspecific. Tiredness due to reduced forward flow.",
      "Symptoms of right heart failure (edema, ascites, hepatomegaly)."
    ],
    "Object5": [
      "JVP: Raised with most prominent 'giant' v wave (a cv wave replaces normal x descent). Earlobe pulsations (Lancisi's sign).",
      "Blowing pansystolic murmur: At LLSB, increases during inspiration, reduced during expiration (De-Carvallo's sign).",
      "P2 may be loud (PAH), RV S3 heard.",
      "Severe TR: Right jugular venous thrill, an RV impulse at LLSB.",
      "Long-standing severe TR may lead to RV dysfunction-induced heart failure and atrial fibrillation (AF)."
    ],
    "Object6": [
      "Echocardiogram: Shows dilated right ventricle and thickened valve."
    ],
    "Object7": [
      "Functional TR: Usually disappears with treatment of underlying cause of RV overload (diuretic and vasodilator treatment for CHF).",
      "Organic TR: Usually well tolerated with normal PA pressure. Severe organic TR may require operative repair (annuloplasty, plication, valve repair) or replacement. Surgical removal of valve for IE in drug addicts."
    ],
    "Object8": [
      "Right heart failure.",
      "Atrial fibrillation."
    ]
  },
  {
    "Object1": "Pulmonary Stenosis (PS)",
    "Object2": [
      "Valvular",
      "Subvalvular (infundibular)",
      "Supravalvular"
    ],
    "Object3": [
      "Congenital: Usually isolated lesion, associated with rubella during pregnancy. May be associated with VSD (Fallot's tetralogy).",
      "Acquired: Rheumatic (uncommon), Carcinoid syndrome."
    ],
    "Object4": [
      "Mild PS may be asymptomatic.",
      "Fatigue, syncope, dyspnea, symptoms of right heart failure. Angina or syncope indicates severe PS."
    ],
    "Object5": [
      "Systolic thrill: Ejection systolic murmur (ESM) often associated with thrill (best felt sitting up, leaning forward, breathing out).",
      "Right ventricular heave (sustained impulse) and epigastric pulsation.",
      "Pulmonary closure sound (P2) is soft and delayed.",
      "Wide splitting of S2 (due to delay in RV ejection).",
      "Ejection systolic murmur: Principal physical sign. Best heard on inspiration at LUS, radiates to left shoulder. Harsh/louder, longer, peaks later in systole with progressive severity. Preceded by ejection sound (click, more prominent in expiration).",
      "High-pitched diastolic murmur after prominent P2 (pulmonary regurgitation secondary to PAH, Graham Steel murmur).",
      "Moderately severe PS: RV S4, prominent jugular venous a wave.",
      "Severe PS: Loud harsh murmur, inaudible P2 (S2 is single loud), increased RV heave, prominent 'a' waves in JVP, RVH in ECG, post-stenotic dilatation of PA on CXR."
    ],
    "Object6": [
      "ECG: Shows RVH and RAE.",
      "Chest X-ray: Prominent pulmonary artery (post-stenotic dilatation).",
      "Doppler echocardiography: Definitive investigation.",
      "Cardiac catheterization."
    ],
    "Object7": [
      "Medical: Mild to moderate PS/PR may require no specific treatment other than prophylaxis for infective endocarditis.",
      "Surgical: Moderately severe and severe PS (>50 mm Hg gradient) treated by percutaneous balloon valvotomy or surgical valvotomy. Postoperatively, pulmonary regurgitation may develop (benign)."
    ],
    "Object8": [
      "Right heart failure (late stage).",
      "Pulmonary regurgitation (post-valvotomy)."
    ]
  },
  {
    "Object1": "Infective Endocarditis (IE)",
    "Object2": [
      "Acute, subacute, chronic (clinical course)",
      "Bacterial, viral, rickettsial, fungal (causative organism)",
      "Native or prosthetic (valve/device)",
      "Left-sided or right-sided (side affected)",
      "Early, intermediate, late (postoperative endocarditis)",
      "Culture Negative Endocarditis"
    ],
    "Object3": [
      "Endovascular infection of cardiovascular structures by microbes (bacterium, fungus, chlamydia, rickettsia). Majority by streptococci or staphylococci.",
      "Predisposing factors: Underlying heart disease (congenital isolated aortic valvular stenosis, VSD, TOF, idiopathic subaortic stenosis, ASD - uncommon), cardiac prosthetic valves, parenteral narcotic drug abuse, impaired host defense (DM, malignancies, cytotoxic therapy, neutropenia).",
      "Transient bacteremia from: Respiratory tract procedures (tonsillectomy, adenoidectomy, surgery involving mucosa), Oral cavity procedures (dental procedures, root canal), Gastrointestinal tract procedures (established GI infection), Genitourinary tract procedures (established GU infection), Skin/musculoskeletal system procedures (infected tissue).",
      "Postoperative: Early (within 60 days): Coagulase-negative Staphylococcus (Staph. epidermidis), fungi. Late (after 1 year): Community-acquired organisms (S. viridans, enterococci). Intermediate (60 days-1 year): Mixture of hospital-acquired and community-acquired. Aortic prosthetic valve > mitral. Mechanical heart valves > bioprosthetic in first 3 months.",
      "Right-sided endocarditis: IV drug users (S. aureus, Candida), affects tricuspid valve.",
      "Culture Negative Endocarditis: Prior antibiotic therapy, inadequate blood culture volume, anaerobic infection, fastidious organisms (Coxiella burnetti, Chlamydia, Bartonella, Legionella), right-sided endocarditis, non-infective endocarditis."
    ],
    "Object4": [
      "Subacute Endocarditis (SBE): Vague (unusual tiredness, fatigue, lassitude, loss of appetite, loss of weight). Persistent or intermittent low-grade/high-grade fever (84%) with night sweats, chills, rigors. Splenic pain (enlargement/infarction).",
      "Acute Endocarditis: Symptoms of acute infection (rapid onset, severe)."
    ],
    "Object5": [
      "Subacute Endocarditis (SBE): Clubbing (10-20%, late sign) (Fig. 7.45A). Splenomegaly (frequently palpable), hepatomegaly. Brownish pigmentation of face/limbs. New/changed heart murmur (particularly diastolic, in ~15% initially, most later). Cutaneous manifestations: Purpura and petechiae (20-40%) (Fig. 7.45B), subconjunctival/splinter/subungual hemorrhages (Fig. 7.45C). Janeway lesions (erythematous, non-tender nodules on palms/soles). Ocular manifestations: Roth spot (Fig. 7.45D) (flame-shaped hemorrhages, cotton wool spots). Osler nodes (Fig. 7.45E) (tender, small, painful, swollen, purplish/erythematous subcutaneous papules/nodules in pulp of distal fingers).",
      "Signs of septic infarcts/abscess: Spleen (painful splenomegaly), kidney (loin pain, hematuria, renal failure), brain (convulsions, hemiplegia, aphasia, loss of vision, cerebellar disturbances), peripheral arteries (claudication, absent pulses, gangrene), lungs (pulmonary infarction, pleurisy, pleural effusion).",
      "Mycotic aneurysms.",
      "Signs of immunological phenomena: Focal segmental glomerulonephritis (flea-bitten kidney, microscopic hematuria)."
    ],
    "Object6": [
      "Microbiological: Blood cultures (crucial, ≥3 sets from different sites over 24h before therapy, aerobic/anaerobic). Serological tests (for culture-negative).",
      "Electrocardiogram (ECG): Conduction abnormalities (AV block), MI (emboli). PR prolongation/heart block (aortic root abscess).",
      "Chest X-ray: Cardiac failure, cardiomegaly, pulmonary edema (left-sided), pulmonary emboli/abscess (right-sided).",
      "Echocardiography: TTE (first-line, 60-75% sensitivity, high specificity for vegetations (Fig. 7.45F), valve dysfunction, abscess, cardiac function, detects vegetations ≥2-4mm). TOE (second-line, >90% sensitivity/specificity, detects smaller vegetations, aortic root abscess, prosthetic valve endocarditis).",
      "Complete blood counts: Normocytic normochromic anemia, increased WBC, increased/reduced platelets.",
      "Urea and Creatinine: Increased (glomerulonephritis).",
      "Liver biochemistry: Serum alkaline phosphatase increased.",
      "Inflammatory markers: Increased ESR, CRP (CRP monitors response).",
      "Urine: Proteinuria, hematuria.",
      "Modified Duke Criteria: Definite IE (2 major, or 1 major + 3 minor, or 5 minor). Possible IE (1 major + 1 minor, or 3 minor). (Major: positive blood cultures for IE organisms/Coxiella, or evidence of endocardial involvement by echo - vegetation, abscess, new partial dehiscence, new valvular regurgitation. Minor: fever ≥38°C, predisposing heart lesion/IVDU, vascular phenomena, immunological phenomena, microbiologic evidence)."
    ],
    "Object7": [
      "Medical treatment:",
      "Blood cultures before empirical antibiotics (do not delay therapy in unstable patients).",
      "Remove source of infection (e.g., tooth extraction).",
      "Empirical antibiotic regimen (penicillins fundamental, depends on presentation, organism, prosthetic valve, allergy) (Table 7.79).",
      "Specific antimicrobial treatment of common causative organisms (Table 7.79).",
      "Surgical treatment (Box 7.46): Debridement of infected material and valve replacement. Antimicrobial therapy before surgery.",
      "Indications for surgery: Prosthetic valve endocarditis, large vegetations (≥10mm), left-sided large vegetation with embolization, very large (≥15mm) mobile vegetation, progressive cardiac failure, active infection persisting despite antibiotics, abscess formation, perivalvular involvement, S. aureus and fungal endocarditis.",
      "Prognosis: Fatal in ~20% (higher in prosthetic valve, antibiotic-resistant organisms)."
    ],
    "Object8": [
      "Cardiac: Valvular dysfunction, heart failure (most common, due to regurgitation), ring abscess, perforation/rupture of valve leaflets/aorta/IVS, myocardial abscess, suppurative pericarditis, prosthetic dehiscence, conduction abnormalities, purulent pericarditis.",
      "Renal: Renal failure (prerenal, microabscesses, immune complex glomerulonephritis, antibiotic-induced).",
      "Embolic events: Septic infarcts (spleen, kidney, brain), mycotic aneurysms, splinter hemorrhages, Janeway lesions, pulmonary abscesses (right-sided IE).",
      "Immunological phenomena: Focal segmental glomerulonephritis, Osler nodes, Roth spots.",
      "Death."
    ]
  },
  {
    "Object1": "Bacterial Endocarditis Prophylaxis",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Not needed for routine local anesthetic injections (noninfected tissue), removable prosthodontic/orthodontic appliances, deciduous teeth shedding, vaginal delivery, hysterectomy, tattooing, bronchoscopy, laryngoscopy, endotracheal intubation, cystoscopy, colonoscopy, skin suturing.",
      "Indications: Cardiac lesions (Box 7.47: high-risk group - prosthetic heart valves, prior IE, complex cyanotic congenital heart disease, surgically constructed systemic-pulmonary shunts, repaired shunts within 6 months, valvulopathy after cardiac transplantation; moderate-risk group - congenital cardiac malformations, acquired valvular dysfunction (rheumatic heart disease), hypertrophic cardiomyopathy, MVP with regurgitation/thickened leaflets), Procedures (dental, respiratory with rigid bronchoscope, GI with established infection, GU with established infection, skin/musculoskeletal with infected tissue).",
      "Antibiotic regimen (adults at moderate/high-risk):",
      "Oral Cavity, Respiratory Tract, or Esophageal Procedures:",
      "Standard: Amoxicillin 2.0 g PO 1 hour before.",
      "Inability to take oral: Ampicillin 2.0 g IV/IM within 30 min before.",
      "Penicillin allergy: Clarithromycin 500 mg PO 1 hour before OR Cephalexin/cefadoxil 2.0 g PO 1 hour before OR Clindamycin 600 mg PO 1 hour before.",
      "Penicillin allergy, unable to take oral: Cefazolin 1.0 g IV/IM 30 min before.",
      "Genitourinary and Gastrointestinal Tract Procedures:",
      "High-risk: Ampicillin 2.0 g IV/IM + gentamicin 1.5 mg/kg IV/IM within 30 min before. Repeat ampicillin 1.0 g IV/IM or amoxicillin 1.0 g PO 6 hours later.",
      "High-risk, penicillin-allergic: Vancomycin 1.0 g IV over 1-2h + gentamicin 1.5 mg/kg IV/IM within 30 min before.",
      "Moderate-risk: Amoxicillin 2.0 g PO 1 hour before OR Ampicillin 2.0 g IV/IM 30 min before.",
      "Moderate-risk, penicillin-allergic: Vancomycin 1.0 g IV over 1-2h completed within 30 min before."
    ],
    "Object8": []
  },
  {
    "Object1": "Noninfective Endocarditis",
    "Object2": [
      "Marantic Endocarditis (Nonbacterial Thrombotic Endocarditis—NBTE)",
      "Libman-Sacks Endocarditis (verrucous endocarditis)"
    ],
    "Object3": [
      "Formation of sterile platelet and fibrin thrombi on cardiac valves and adjacent endocardium.",
      "Response to trauma, circulating immune complexes, vasculitis or a hypercoagulable state.",
      "NBTE: Debilitated patients with cancer or sepsis ('marantic endocarditis'). Concomitant with DVT, PE, systemic hypercoagulable state, advanced malignancy (striking association with mucinous adenocarcinomas). Less common: SLE, antiphospholipid syndrome, rheumatic heart disease, RA, burns.",
      "Libman-Sacks: Autoimmune disease (e.g., SLE). Produced by circulating immune complexes."
    ],
    "Object4": [
      "Systemic arterial embolism."
    ],
    "Object5": [
      "NBTE: Vegetations are small, bland, usually attached to line of closure of valve leaflets.",
      "Libman-Sacks: Small/medium-sized vegetations on either side of valve leaflets (mulberry-like clusters of verrucae)."
    ],
    "Object6": [
      "Echocardiography.",
      "Negative blood cultures."
    ],
    "Object7": [
      "NBTE: Systemic anticoagulant therapy, treatment of underlying malignancy/associated condition."
    ],
    "Object8": [
      "Systemic arterial embolism (NBTE)."
    ]
  },
  {
    "Object1": "Heart Failure (Cardiac Failure, Congestive Cardiac Failure - CHF)",
    "Object2": [
      "Low-output heart failure (Systolic, Diastolic)",
      "High-output heart failure (e.g., hyperthyroidism, anemia, pregnancy, AV fistulae, beriberi, Paget's disease)",
      "Acute heart failure",
      "Chronic heart failure",
      "Compensated heart failure",
      "Left-sided (left ventricular) heart failure",
      "Right-sided (right ventricular) heart failure",
      "Biventricular heart failure",
      "Forward heart failure",
      "Backward heart failure",
      "Refractory Heart Failure"
    ],
    "Object3": [
      "Pathophysiological process: Heart unable to perfuse metabolic requirements of tissue despite normal/increased venous return, or can do so only at elevated filling pressure.",
      "Any structural or functional cardiac disorder.",
      "Common end stage of chronic heart disease (work overload from valve disease/hypertension, ischemic heart disease after MI).",
      "Acute hemodynamic stresses (fluid overload, sudden valvular dysfunction, myocardial infarction).",
      "Ventricular remodeling (changes in size, shape, structure, physiology after myocardial injury).",
      "Systolic dysfunction (ejection fraction <40%): Coronary artery disease, hypertension, valvular heart disease.",
      "Diastolic dysfunction (impaired ventricular relaxation/increased stiffness): Hypertension, coronary artery disease, HOCM, restrictive cardiomyopathy.",
      "Acute heart failure (sudden): Acute MI, rupture of cardiac valve.",
      "Chronic heart failure (gradual): Dilated cardiomyopathy, multivalvular disease.",
      "Left-sided HF: Ischemic heart disease, valvular heart disease, myocarditis, restrictive pericarditis.",
      "Right-sided HF: Cor pulmonale, right-sided valvular heart disease, right-sided myocardial disease, pulmonary hypertension.",
      "Biventricular HF: Dilated cardiomyopathy, ischemic heart disease, left heart disease leading to right heart failure.",
      "Factors precipitating/aggravating HF: Arrhythmias (new onset AF), Infection, Myocardial ischemia/infarction, Uncontrolled hypertension, Fluid overload, Pulmonary embolism, Acute valvular dysfunction, Exacerbation of underlying disease, Anemia, Thyrotoxicosis, Drugs (NSAIDs, COX-2 inhibitors, corticosteroids, non-DHP CCBs), Acute kidney injury, Non-adherence to medication/diet, High output states.",
      "Refractory CHF: Symptoms at rest or repeated exacerbations despite 'optimal triple-drug therapy'."
    ],
    "Object4": [
      "Dyspnea (exertional, orthopnea, paroxysmal nocturnal dyspnea (PND)), Cardiac asthma, Acute pulmonary edema, Cheyne-Stokes respiration.",
      "Nocturia (early HF).",
      "Cerebral symptoms: Confusion, difficulty concentrating, impaired memory, headache, insomnia, anxiety (hypoxia, reduced cerebral perfusion).",
      "Nonspecific: Fatigue (low cardiac output), weakness (decreased muscle perfusion), low-grade fever (reduced cutaneous blood flow). Anorexia, nausea, abdominal fullness/pain (congestion of liver/portal system).",
      "Right ventricular failure: Leg swelling, abdominal pain/hepatic discomfort, oliguria."
    ],
    "Object5": [
      "Pallor (lips, nail beds). Cold, pale extremities (reduced blood flow).",
      "Pulse: Reduced volume, pulsus alternans (severe HF).",
      "Blood pressure: Reduced pulse pressure. Mild elevation of diastolic BP (vasoconstriction). Hypotension (acute HF).",
      "Jugular venous pressure (JVP): Raised (elevated systemic venous pressure). May not be raised at rest (early HF), demonstrable with exercise/hepatojugular reflux. Kussmaul's sign.",
      "Third heart sound (S3) highly suggestive of HF. Triple/quadruple/summation gallop. Fourth heart sound (S4).",
      "Respiratory system: Dull percussion notes over lung bases. Inspiratory crepitations over lung bases. Coarse crepitations and expiratory rhonchi (pulmonary edema). Pleural effusion. Ascites. Pericardial effusion (rare).",
      "Liver: Congestive hepatomegaly. Hypoglycemia (long-standing). Jaundice (late feature, severe in acute hepatic congestion).",
      "Renal: Oliguria, prerenal azotemia. High urine specific gravity, mild proteinuria, low urinary sodium.",
      "Cardiac cachexia (severe anorexia, weight loss, impaired absorption, skeletal muscle atrophy).",
      "Dependent/cardiac edema (symmetrical in pretibial region, ankles; sacral in bedridden). Anasarca (advanced HF).",
      "Cyanosis (lips, nail beds)."
    ],
    "Object6": [
      "Chest X-ray: Cardiomegaly. Phantom tumor (fluid in lung fissures). Bat's wing appearance (hazy opacification from hilar regions). Pleural effusion.",
      "Electrocardiography (ECG): Previous MI, active ischemia, ventricular hypertrophy, atrial/conduction abnormalities, arrhythmias.",
      "Echocardiography: Determine etiology, detect valvular disease, identify patients for drug therapy, assess cardiac chamber dimension, EF, valvular function, cardiomyopathies, wall motion abnormalities. Differentiate systolic/diastolic HF.",
      "Stress echocardiography: Assesses viability in dysfunctional myocardium. Dobutamine stress (contractile reserve).",
      "Nuclear cardiology: Radionucleotide angiography (RNA) for EF. SPECT/PET for myocardial ischemia/viability.",
      "CMR (cardiac MRI): Assesses viability (dobutamine for contractile reserve, gadolinium for delayed enhancement).",
      "Cardiac catheterization: Ischemic HF diagnosis, PA pressure, LA (wedge) pressure, LV end diastolic pressure.",
      "Cardiac biopsy: Cardiomyopathies (e.g., amyloid), transplanted patients (rejection).",
      "Cardiopulmonary exercise testing: Peak oxygen consumption (VO2) predicts hospitalization/death.",
      "Ambulatory 24 hour ECG monitoring (Holter): Suspected arrhythmia, severe HF, inherited cardiomyopathy (for defibrillator decision).",
      "Brain natriuretic peptide (BNP) or N-terminal portion of proBNP (NPproBNP): Elevated in HF. Marker of risk (>100 pg/mL). Differentiates cardiac from respiratory dyspnea. Prognostic, monitors therapy."
    ],
    "Object7": [
      "Aims: Relief of symptoms, prevent/control disease, retard progression, improve quality/length of life.",
      "A. General Lifestyle Advice/Measures:",
      "Education of patients/relatives. Prevent HF: cessation smoking/illicit drugs, control HTN/DM/hypercholesterolemia, pharmacological treatment post-MI. Identify/treat aggravating factors.",
      "Diet: Good general nutrition, ideal weight (BMI), avoid large/salty meals. Low fat, rich in fruit/vegetables/fiber. Fluid restriction (severe HF only). Avoid alcohol. Omega-3 PUFAs reduce mortality/admission.",
      "Physical activity/exercise: Regular low-level endurance exercise (20-30 min walk 3-5x/week). Avoid strenuous isometric activity. Bed rest for exacerbations (brief), avoid prolonged bed rest (DVT prophylaxis).",
      "B. Drug Therapy/Management:",
      "Diuretic therapy: Loop diuretics (furosemide 20-40 mg 1-2x/day), thiazide diuretics (hydrochlorothiazide 25 mg 1-2x/day, metolazone 2.5-5 mg OD) for fluid overload. Combination if severe. Monitor serum electrolytes/renal function. Mineralocorticoid receptor antagonists (spironolactone 12.5-25 mg 1-2x/day) for severe LV systolic dysfunction.",
      "Angiotensin-converting enzyme inhibitors (ACEI): Prevent angiotensin II conversion. Improve survival in all NYHA classes. Start low dose, gradually increase. Captopril (6.25 mg TID to 50 mg TID), enalapril (2.5 mg BID to 10-20 mg BID), lisinopril (2.5-5 mg OD to 20-40 mg OD), ramipril (1.25-2.5 mg OD to 10 mg OD).",
      "Angiotensin II receptor antagonists (ARA)/blockers: Second-line if ACEI intolerant. Losartan (25-50 mg OD to 50-150 mg OD), valsartan, telmisartan, olmesartan. Similar monitoring/titration as ACEI.",
      "Beta-adrenoceptor blocker therapy: For all patients with current/prior HF and LVEF ≤40% (HFrEF). Start low, increase gradually over 12 weeks. Bisoprolol (1.25-2.5 mg OD to 10 mg OD), carvedilol (3.125 BID to 50 mg BID), metoprolol succinate (12.5 OD to 200 mg OD).",
      "Aldosterone receptor antagonists: NYHA II-IV, EF ≤35%. Improve survival. Spironolactone (12.5-25 mg OD to 50 mg daily). Monitor K/creatinine. Side effects: hyperkalemia, gynecomastia.",
      "Digoxin: For AF with HF. Add-on for symptomatic HF patients already on ACEI/BB. No mortality benefit. Usual dose 0.125-0.25 mg daily (low dose for elderly/CKD/low lean body mass). Plasma concentration 0.5-0.9 ng/dL.",
      "Vasodilators and nitrates (Hydralazine Nitrate Combination): Reduce afterload/preload. For African-American origin, NYHA III-IV, low EF on ACEI/BB, or ACEI/ARA intolerant. Dose: 37.5 mg hydralazine + 20 mg isosorbide dinitrate (start 1 tab TID, increase to 2 tabs TID).",
      "Ivabradine: Reduces heart rate by acting on SA node if current. For patients unable to take BBs or high heart rate despite BBs. Not for AF. Reduces hospitalization/mortality.",
      "Anticoagulation therapy: For patients at risk for thromboembolism (AF, valvular heart disease, LV thrombus, embolic stroke). Warfarin (INR 2.0-3.0, 2.5-3.5 for valvular). Newer oral anticoagulants (dabigatran, apixaban, rivaroxaban). Aspirin (alternative if warfarin contraindicated/allergic).",
      "C. Nonpharmacological treatment/Device therapy:",
      "Implantable cardioverter defibrillator (ICD): For symptomatic ventricular arrhythmias with HF (LVEF ≤35%, NYHA II/III, or NYHA I with EF ≤30% on chronic medical therapy).",
      "Cardiac resynchronization therapy (CRT): LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, NYHA II/III/ambulatory IV symptoms. Improves symptoms/survival.",
      "Coronary revascularization (CABG/PCI): For CAD-induced HF. Improves function in hibernating myocardium. Factors: age, symptoms, reversible ischemia.",
      "Heart (Cardiac) transplantation: For younger patients with severe intractable HF, life expectancy <6 months. Most common indications: CAD, dilated cardiomyopathy. Contraindicated in pulmonary vascular disease, complex congenital heart disease, primary pulmonary hypertension.",
      "Ventricular assist devices (VADs): Bridge to transplant, long-term therapy, short-term restoration."
    ],
    "Object8": [
      "Renal failure (Cardiorenal syndrome, worsened by therapy).",
      "Hypokalemia (diuretics, hyperaldosteronism, liver congestion).",
      "Hyperkalemia (ACE inhibitors, ARAs, mineralocorticoid receptor antagonists).",
      "Hyponatremia (severe HF, diuretics, inappropriate ADH, cell membrane ion pump failure).",
      "Hepatic dysfunction (venous congestion, poor arterial perfusion).",
      "Thromboembolism (DVT, PE, systemic emboli in AF/flutter/intracardiac thrombus).",
      "Atrial and ventricular arrhythmias (AF, sudden death, ventricular ectopic beats, non-sustained ventricular tachycardia).",
      "Heart-related death."
    ]
  },
  {
    "Object1": "Brain Natriuretic Peptide (BNP)",
    "Object2": "32-amino acid peptide",
    "Object3": [
      "Predominantly secreted by left ventricles (in response to left ventricular stretching or wall tension)"
    ],
    "Object4": [],
    "Object5": [
      "Elevated in conditions associated with left ventricular systolic dysfunction"
    ],
    "Object6": [
      "Measurement of BNP levels (<50 pg/ml or <50 ng/L is normal).",
      "N-terminal portion of proBNP (NT-proBNP) also elevated."
    ],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Pulmonary Edema",
    "Object2": [
      "Hemodynamic or cardiogenic pulmonary edema (CPE)",
      "Non-cardiogenic pulmonary edema (NCPE) (due to microvascular injury)",
      "Interstitial edema (early stage)",
      "Alveolar edema (later stage)",
      "Neurogenic pulmonary edema",
      "Re-expansion pulmonary edema",
      "High altitude pulmonary edema (HAPE)"
    ],
    "Object3": [
      "Accumulation of excess fluid in interstitium and alveoli of lung due to alteration in Starling forces.",
      "Increased hydrostatic pressure (e.g., left ventricular failure)",
      "Decreased oncotic pressure (e.g., hypoalbuminemia)",
      "Decrease in pleural pressure (e.g., atelectasis)",
      "Increased permeability of microcirculation (e.g., pneumonia)",
      "Impaired lymphatic drainage (e.g., malignancy)",
      "Movement of fluid from abdomen to pleural space (e.g., cirrhosis).",
      "Cardiogenic pulmonary edema: High pulmonary capillary hydrostatic pressure (e.g. MI, HTN, AR, MR, AS, MS, fluid overload, renal artery stenosis, acute glomerulonephritis, fluid retention, cardiomyopathy, myocarditis, cardiac tamponade).",
      "Non-cardiogenic pulmonary edema: Microvascular injury. (e.g. ARDS, aspiration, toxic gas inhalation, blunt chest trauma, near drowning, septicemia, uremia, eclampsia, multiple bone fractures, multiple transfusions, drug overdose, acute pancreatitis, cardiopulmonary bypass, Goodpasture's syndrome, SLE).",
      "Neurogenic pulmonary edema: Central nervous system disorders without apparent pre-existing LV dysfunction.",
      "Re-expansion pulmonary edema: Rapid inflation of lung after prolonged collapse (>3 days) from pleural effusion/pneumothorax.",
      "HAPE: Young individuals quickly ascending to >2700 m, strenuous physical exercise at altitude."
    ],
    "Object4": [
      "Cardiogenic: Extreme breathlessness, shortness of breath, orthopnea, PND, anxiety, feeling of drowning. Cough, pink frothy sputum.",
      "Neurogenic: Dyspnea (without LV dysfunction).",
      "Re-expansion: Chest discomfort, persistent severe cough, dyspnea, frothy sputum.",
      "HAPE: Dyspnea, cough."
    ],
    "Object5": [
      "Cardiogenic: Tachypnea, tachycardia, hypertension, cool extremities (low CO). Fine crepitations, wheezes. S3, accentuated pulmonic component of S2, jugular venous distention. Change in mental status. Hepatomegaly, sustained hepatojugular reflux, peripheral edema (RV failure).",
      "Noncardiogenic: Warm periphery, bounding pulse, no S3 gallop or JVD. PCWP generally >18 mm Hg.",
      "Re-expansion: Tachypnea, tachycardia, crackles on affected side. Features of pulmonary edema on CXR.",
      "HAPE: Crackles, cyanosis."
    ],
    "Object6": [
      "Same as heart/cardiac failure (refer pages 487-8). ARDS discussed on page 369.",
      "Chest X-ray: Diffuse, bilateral alveolar infiltrates (ARDS). Increased heart size, width of vascular pedicle, vascular redistribution to upper lobes, septal lines, perihilar ('bat's wing') distribution (cardiogenic). Lack of these in ARDS.",
      "Arterial blood gas analysis (ABG): PaO2/FIO2 ratio and severity (ARDS). Hypoxemia, respiratory alkalosis initially. Respiratory acidosis later.",
      "Echocardiogram: LV ejection fraction, wall motion, valvular abnormalities (to exclude cardiogenic).",
      "Plasma B-type natriuretic peptide (BNP) value (to exclude cardiogenic).",
      "CT scan (for ARDS): Diffuse consolidation with air bronchograms, bullae, pleural effusions, pneumomediastinum, pneumothorax. Later: lung cysts."
    ],
    "Object7": [
      "Acute cardiogenic pulmonary edema:",
      "Initial: ABCs of resuscitation.",
      "Goals: Reduction of pulmonary venous return (preload reduction), Reduction of systemic vascular resistance (afterload reduction), Inotropic support.",
      "Oxygenation: Administer oxygen to keep saturation >90%. Face mask, noninvasive ventilation (BiPAP, CPAP), intubation/mechanical ventilation. Oxygen corrects hypoxia, positive pressure reduces transudation.",
      "Preload reduction: Nitroglycerin oral or IV (10-100 µg/min).",
      "Diuretics: IV furosemide (venodilator action, reduces venous return, diuresis).",
      "Morphine sulfate: 2-5 mg IV slowly (reduces anxiety, venous return).",
      "Afterload reduction: ACE inhibitors (enalapril 1.25 mg IV, captopril 25 mg sublingually). Angiotensin II receptor blockers. Nitroprusside (3-4 µg/kg/min IV).",
      "Inotropic agents: Dobutamine, dopamine.",
      "Intra-aortic balloon pumping (IABP): Decreases afterload, improves coronary blood flow. For severe/refractory cases.",
      "Ultrafiltration: For renal dysfunction and diuretic resistance.",
      "Correction of precipitating causes (infection, arrhythmias). Treatment of underlying cause.",
      "Re-expansion pulmonary edema: Supportive treatment (oxygen, mechanical ventilation). Patient lies on unaffected side. Controversial: diuretics, bronchodilators, prostaglandin analogues, ibuprofen, steroids. Prevention: Restrict pleural fluid drainage to <1L, low negative pressure during tube thoracostomy, monitor pleural pressures."
    ],
    "Object8": [
      "Acute pulmonary edema can be life-threatening.",
      "Re-expansion pulmonary edema: Hypotension, oliguria, acute respiratory distress, pulmonary edema.",
      "HAPE: Reversible, but can be severe."
    ]
  },
  {
    "Object1": "Cardiac Arrhythmias",
    "Object2": [
      "Bradyarrhythmia (<60/min day, <50/min night)",
      "Tachyarrhythmia (>100/min)",
      "Sinus Arrhythmia (respiratory and non-respiratory forms)",
      "Ectopic Beats (Extrasystoles, Premature Beats: Supraventricular, Junctional, Ventricular)",
      "Supraventricular Tachycardia (SVT) (Sinus Tachycardia, AV Node Re-entry Tachycardia - AVNRT, AV Reciprocating Tachycardia - AVRT, Atrial Fibrillation, Atrial Flutter, Atrial Tachycardia, Multifocal Atrial Tachycardia, Accelerated Junctional Tachycardia)",
      "Ventricular Tachycardia (VT) (Non-sustained, Sustained, Slow, Pulseless, Refractory, VT storm)",
      "Torsades De Pointes",
      "Brugada Syndrome",
      "Ventricular Fibrillation (VF)",
      "Atrioventricular Blocks (First Degree, Second Degree Mobitz type I/Wenckebach, Second Degree Mobitz type II, Third-degree/Complete AV Block)"
    ],
    "Object3": [
      "Structural disease of the heart (most common)",
      "Abnormal conduction or depolarization in healthy heart",
      "Sinus Arrhythmia: Normal physiological phenomenon (cyclic changes in heart rate during breathing, autonomic activity). Non-respiratory form in diseased hearts.",
      "Ectopic Beats: Idiopathic, anxiety, excessive coffee/tea/tobacco, ischemic/valvular heart disease, acute MI, myocardial ischemia, myocarditis, digitalis toxicity, hypokalemia, MVP.",
      "Sinus Tachycardia: Increased sympathetic activity (exercise, emotion, pregnancy), pathological (anemia, thyrotoxicosis, anxiety, fever, heart failure, pheochromocytoma, drugs, embolism, shock).",
      "AVNRT: Re-entry in AV node (slow/fast pathways). Early atrial impulse (atrial premature beat) when fast pathway refractory. Aggravated by exertion, coffee, tea, alcohol.",
      "Atrial Fibrillation: Raised atrial pressure, increased atrial muscle mass, atrial fibrosis, inflammation/infiltration of atrium. Genetic factors. Abnormal automatic firing (pulmonary veins). Multiple interacting re-entry circuits.",
      "Atrial Flutter: Organic heart diseases (ischemic, rheumatic, congenital), pericarditis, post-open heart surgery, acute respiratory failure.",
      "Wolff-Parkinson-White (WPW) Syndrome: Extra electrical (accessory) pathway (Bundle of Kent) between atria/ventricles. Short PR interval, delta wave, wide QRS complex. Re-entry circuit.",
      "Sick-Sinus Syndrome: Sinus node dysfunction (ischemia, fibrosis, drug induced, autonomic dysfunction).",
      "Ventricular Tachycardia (VT): Ischemic heart disease (acute MI, chronic infarction), dilated cardiomyopathy, hypertrophic cardiomyopathy, post CABG/TOF surgery, idiopathic, specific genetic etiology. Reversible causes: Hypoxia, hyperthyroidism, catecholamines, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia, metabolic acidosis), drugs, alcohol, starvation. Re-entry (most common mechanism).",
      "Torsades De Pointes: QT prolongation (electrolyte disturbances, antiarrhythmic drugs - quinidine, phenothiazines, tricyclic agents, bradyarrhythmias), congenital long QT syndrome.",
      "Brugada Syndrome: Genetic abnormality of cardiac sodium channels (SCN5a gene mutation), diminished inward sodium current. Predisposes to local re-entry and life-threatening ventricular arrhythmias. Frequently occurs during sleep.",
      "Ventricular Fibrillation: Very rapid, irregular, uncoordinated ventricular movement.",
      "Atrioventricular Blocks: Block in AV node or His bundle."
    ],
    "Object4": [
      "Bradyarrhythmia: Symptoms of cerebral hypoperfusion (syncope, dizziness), palpitations, worsening of underlying conditions (CHF, angina, CVA).",
      "Ectopic Beats: Extra beats, thumping beats, missed beats.",
      "AVNRT: Rapid, very forceful, regular heart beat, chest discomfort, lightheadedness, breathlessness, polyuria.",
      "Atrial Fibrillation: Palpitations, fatigue, syncope, angina, symptoms of cardiac failure, thromboembolism.",
      "Atrial Flutter: Palpitations, fatigue, syncope, angina, symptoms of cardiac failure.",
      "Wolff-Parkinson-White Syndrome: Tachycardia symptoms, palpitations.",
      "VT: Asymptomatic, palpitations, chest pain (angina), syncope/dizziness, presyncope, cannon a waves, absent pulse, hypotension, variable S1.",
      "Torsades De Pointes: Symptoms related to severe arrhythmias.",
      "Ventricular Fibrillation: Pulseless, rapidly unconscious, respiration ceases (cardiac arrest).",
      "Atrioventricular Blocks: Bradycardia, palpitations, dizziness, syncope, worsening of CHF/angina/CVA. Adams-Stokes Attacks (recurrent episode of sudden loss of consciousness, pallor, deeply unconscious, very slow/absent pulse, rapid recovery, anoxic generalized convulsions)."
    ],
    "Object5": [
      "Sinus Arrhythmia: Predictable irregularities of pulse. Absence of normal variation seen in autonomic neuropathy/cardiac failure.",
      "Ectopic Beats: Irregularity in rhythm, missing beats, post-ectopic bounding beat, cannon waves on JVP.",
      "Sinus Tachycardia: Heart rate >100/minute, normal P waves, PR interval, QRS complexes.",
      "AVNRT: Tachycardia 140-240/minute, normal regular QRS complexes. Occasional bundle branch block.",
      "Atrial Fibrillation: Irregularly irregular pulse, varying volumes of pulse, pulse deficit. Hypotension, mean of three recordings for BP. Absence of 'a' waves on JVP. Varying intensity of S1, disappearance of S4, disappearance of PSA of MS MDM.",
      "Atrial Flutter: Organized, regular, rapid atrial rate (250-350/minute). Ventricles respond every 2nd, 3rd or 4th beat. ECG: Saw-toothed flutter waves ('F' waves).",
      "Wolff-Parkinson-White Syndrome: ECG: Short PR interval (<0.12s), slurred upstroke of QRS complex (Delta wave), wide QRS complex (>0.12s). Tachycardia in SVT indistinguishable from AVNRT.",
      "Sick-Sinus Syndrome: Slow heart rate, fever, left ventricular failure, pulmonary edema.",
      "VT: Heart rate 100-200 bpm. Wide complex tachycardia (QRS >0.12s).",
      "Torsades De Pointes: Polymorphic QRS complexes changing in amplitude/cycle length, oscillations around baseline, associated with QT prolongation.",
      "Brugada Syndrome: ST segment elevation in V1-V3 in sinus rhythm. Ventricular tachycardia, sudden cardiac death (frequently during sleep).",
      "Ventricular Fibrillation: ECG shows shapeless/bizarre, rapid oscillations. Pulseless, unconscious, apneic.",
      "AV Blocks: First Degree: PR interval >0.22s, every P conducted. Mobitz Type I: Progressive PR lengthening, then dropped P. Mobitz Type II: Constant PR, some P's not conducted. Third Degree: Atria/ventricles beat independently (AV dissociation), regular slow pulse (25-50/min), irregular cannon waves on JVP, varying S1 intensity."
    ],
    "Object6": [
      "Electrocardiogram (ECG): For all arrhythmias, characteristic changes for each type (P wave, QRS complex, PR/QT interval, ST segment, T wave, U wave, axis deviation, hypertrophy, infarction/dyselectrolytemia/drug effects).",
      "Holter monitoring (for infrequent arrhythmias, or in VT/VF after MI).",
      "Exercise electrocardiography (if exertion induces arrhythmia).",
      "Echocardiography (for structural heart disease, LV function, complications).",
      "Electrophysiology study (invasive, for conduction system).",
      "Blood tests (Hb, glucose, electrolytes, thyroid function).",
      "2D ECHO (LA size, thrombus, LV function in AF).",
      "Thyroid function tests and serum electrolytes (all AF patients).",
      "Chest X-ray (AF, WPW, Sick Sinus).",
      "Cardiac catheterization (for ablation in AVNRT, WPW).",
      "Serum homocysteine levels (raised in B12/folate deficiency)."
    ],
    "Object7": [
      "General: Identify/treat underlying cause. Eliminate triggers (alcohol, tobacco, stimulants). Mild sedation or beta blocker for symptomatic ectopics.",
      "AVNRT: Carotid sinus pressure, Valsalva maneuver. Adenosine (3-12 mg IV rapid) or Verapamil (5 mg IV over 1 min). IV beta blocker or flecainide. DC cardioversion for severe hemodynamic compromise. Catheter ablation for recurrent SVT.",
      "Atrial Fibrillation:",
      "Acute: Ventricular rate control (AV nodal blockers). Cardioversion (electrical DC shock or pharmacological - flecainide, propafenone, vernakalant, amiodarone). Anticoagulation (if >48h duration).",
      "Long-term: Rhythm control (antiarrhythmic drugs + DC cardioversion + oral anticoagulation). Rate control (AV nodal slowing agents + oral anticoagulation). Drugs: Beta blockers, calcium channel blockers (verapamil, diltiazem), digoxin, amiodarone. Prevention of recurrence (quinidine, amiodarone, dronedarone). Anticoagulation (warfarin, dabigatran, apixaban, rivaroxaban) based on CHA2DS2-VASc score. Aspirin (alternative to warfarin in low-risk). Radiofrequency ablation. Surgical maze procedure.",
      "Atrial Flutter: Direct electrical cardioversion for acute paroxysm. Rate control (digoxin, beta blockers, verapamil/diltiazem), then conversion to sinus rhythm (quinidine, amiodarone, disopyramide, flecainide). Catheter ablation for recurrent. Anticoagulation for stroke prevention.",
      "Wolff-Parkinson-White Syndrome: Carotid sinus pressure or IV adenosine for termination. Acute PSVT similar to PSVT. Life-threatening AF treated with DC cardioversion. Non-life-threatening AF: lidocaine or procainamide IV. Avoid IV verapamil/digitalis in WPW+AF. Catheter ablation (treatment of choice for symptomatic arrhythmias).",
      "Sick-Sinus Syndrome: Permanent pacemaker for recurrent symptomatic bradycardia/prolonged pauses.",
      "Ventricular Tachycardia (VT): Prompt restoration of sinus rhythm. Hemodynamically unstable: synchronized DC cardioversion. Stable: IV procainamide (preserved LV function), IV amiodarone (LV dysfunction). IV lidocaine (caution, may depress LV function). Correct electrolyte/acid-base imbalance. Prevention: Beta blockers, amiodarone. Implantable cardiac defibrillator (ICD) for LVEF <30%. Surgery/catheter ablation for infarct scar VT.",
      "Torsades De Pointes: Correct electrolyte abnormalities. IV magnesium. Avoid Class IA/III antiarrhythmics. Lidocaine. Isoproterenol (bridge before temporary pacemaker). Phenytoin. Temporary pacemaker. Beta blockers (congenital QTc prolongation).",
      "Brugada Syndrome: ICD. (No benefit from beta blockers).",
      "Ventricular Fibrillation: Electrical defibrillation.",
      "AV Blocks: Removal of offending agent. Atropine/isoprenaline (symptomatic). Pacemaker insertion."
    ],
    "Object8": [
      "Arrhythmias may be transient or lead to hemodynamic compromise.",
      "AVNRT: Hypotension, hemodynamic compromise.",
      "Atrial Fibrillation: Thromboembolism (stroke, mesenteric, renal, peripheral embolism), precipitation/worsening of cardiac failure, syncope, hypotension, angina, precipitation of pulmonary edema (mitral stenosis).",
      "Wolff-Parkinson-White Syndrome: Atrial flutter, atrial fibrillation, SVT, VT, VF, death. Increased ventricular response with IV verapamil/digitalis.",
      "Sick-Sinus Syndrome: Syncope, palpitations, dizziness, worsening CHF/angina/CVA.",
      "VT: Major morbidity/mortality in structural heart disease, sudden cardiac death. Recurrence.",
      "Torsades De Pointes: Predisposes to VT, sudden cardiac death. Severe: respiratory depression, altered sensorium, coma, shock, seizures, death.",
      "Brugada Syndrome: Sudden unexpected death syndrome (SUDS), ventricular tachycardia, sudden cardiac death (in young men, often during sleep).",
      "Ventricular Fibrillation: Cardiac arrest, death."
    ]
  },
  {
    "Object1": "Myocarditis",
    "Object2": [
      "Idiopathic",
      "Autoimmune",
      "Infectious (viral, bacterial, fungal, mycobacterial, parasitic)",
      "Fulminant myocarditis",
      "Acute myocarditis",
      "Chronic active myocarditis",
      "Chronic persistent myocarditis"
    ],
    "Object3": [
      "Acute inflammatory disease of the myocardium.",
      "Viruses (Coxsackie, adenoviruses, HIV, parvovirus B19, enterovirus, influenza).",
      "Bacteria (Staphylococcus, Streptococcus, Corynebacterium diphtheriae, Borrelia burgdorferi - Lyme disease, Mycoplasma pneumoniae).",
      "Fungi (Candida, Aspergillus).",
      "Parasites (Trypanosoma cruzi - Chagas disease, Toxoplasma gondii).",
      "Hypersensitivity reactions (drugs - methyldopa, sulfonamides, penicillins).",
      "Toxins (alcohol, cocaine, heavy metals).",
      "Autoimmune diseases (SLE, RA, systemic sclerosis, polymyositis)."
    ],
    "Object4": [
      "Wide range: Mild dyspnea or chest pain (resolves without specific therapy) to cardiogenic shock and death.",
      "Fulminant: Viral prodrome (fever, chills, myalgia, constitutional symptoms) or influenza-like illness, severe acute heart failure or cardiogenic shock.",
      "Acute: Heart failure, acute MI or sudden cardiac death.",
      "Chronic active: Insidious onset, older adults.",
      "Chronic persistent: Chest pain, arrhythmia without ventricular dysfunction.",
      "Fatigue, palpitations, dyspnea."
    ],
    "Object5": [
      "May be normal.",
      "Soft muffled heart sounds, prominent S3, inappropriate tachycardia, arrhythmias (conduction blocks), signs of CHF, pericardial friction rub (associated pericarditis)."
    ],
    "Object6": [
      "Chest X-ray: Mild cardiac enlargement.",
      "ECG: Common but nonspecific changes (ST-T wave abnormalities, arrhythmias). Heart block (diphtheritic, Lyme, Chagas').",
      "Cardiac enzymes (Troponin I/T, CK-MB): May be raised early.",
      "Echocardiography: LV dysfunction, global hypokinesia, pericardial effusion (with/without).",
      "Cardiac magnetic resonance imaging (MRI): Myocardial inflammation/infiltration (increased T2 signal, delayed contrast enhancement after gadolinium-DTPA).",
      "Viral antibody titers: May be increased.",
      "Endomyocardial biopsy: Confirms diagnosis, shows acute inflammation (gold-standard). Considered for giant cell, hypersensitivity/eosinophilic myocarditis, cardiac involvement in systemic disease.",
      "Viral RNA, DNA (PCR, in situ hybridization).",
      "Blood: Leukocytosis, elevated ESR, eosinophilia."
    ],
    "Object7": [
      "Identify, treat, eliminate or avoid underlying cause.",
      "Prolonged bed rest during acute phase, restrict physical activity for 6 months (until ECG normal).",
      "Treatment of heart failure: Diuretics, ACE inhibitors/ARAs, β-blockers, spironolactone ± digoxin (caution with digoxin).",
      "Arrhythmias: Amiodarone, β-blockers.",
      "Antibiotics: Specific antimicrobial therapy if causative organism identified.",
      "NSAIDs avoided in acute phase (may be given in late phase).",
      "Corticosteroids and immunosuppressive agents (controversial).",
      "Immunoglobulin: High-dose IVIG (appears to hasten LV dysfunction resolution, improved survival).",
      "Refractory patients: Rarely need cardiac transplantation or temporary circulatory support (mechanical ventricular assist device)."
    ],
    "Object8": [
      "Major long-term sequelae: Dilated cardiomyopathy (DCM) with chronic heart failure.",
      "Ventricular arrhythmia, heart block, congestive heart failure, acute pericarditis, progression to chronic myocarditis."
    ]
  },
  {
    "Object1": "Cardiomyopathy",
    "Object2": [
      "Primary cardiomyopathy (heart muscle disease predominantly involving myocardium and/or of unknown cause)",
      "Secondary cardiomyopathy (myocardial disease of unknown cause or associated with systemic disease)",
      "Dilated/congestive cardiomyopathy (DCM)",
      "Hypertrophic cardiomyopathy (HCM)",
      "Restrictive/obliterative cardiomyopathy"
    ],
    "Object3": [
      "Heterogeneous group of diseases affecting mechanical or electrical function of heart.",
      "Genetic/inherited, infective, toxic, idiopathic.",
      "Excludes myocardial involvement due to congenital, acquired valvular, hypertensive, coronary arterial or pericardial abnormalities."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Dilated (Congestive) Cardiomyopathy (DCM)",
    "Object2": "Most common of all cardiomyopathies",
    "Object3": [
      "Dilatation/enlargement of ventricular chambers and systolic dysfunction (impaired contraction of LV and/or RV) with preserved wall thickness.",
      "Familial DCM (1/5-1/3 of patients, autosomal dominant, >20 single-gene mutations - cytoskeleton of myocyte, dystrophin, lamin A/C, emerin, metavinculin. X-linked muscular dystrophies - Becker, Duchenne).",
      "Sporadic DCM: Myocarditis (Coxsackie, adenoviruses, HIV, bacteria, fungal, mycobacteria, parasitic - Chagas disease), Toxins (alcohol, chemotherapy - adriamycin, trastuzumab, cyclophosphamide, metals - cobalt, lead, mercury, arsenic), Autoimmune diseases (SLE, systemic sclerosis, dermatomyositis), Endocrine (DM, thyrotoxicosis, hypothyroidism), Neuromuscular (muscular dystrophies, Friedrich's ataxia, myotonic dystrophy).",
      "Idiopathic (significant number)."
    ],
    "Object4": [
      "Gradual onset or sudden cardiac death due to arrhythmias.",
      "Thromboembolism, conduction defects, sporadic chest pain.",
      "Symptoms/signs of heart failure:",
      "Fatigue and weakness.",
      "Pulmonary congestion (LV failure), dyspnea (rest, exertional, nocturnal), orthopnea.",
      "Systemic congestion (RV failure), edema, nausea, abdominal pain, nocturia.",
      "Low cardiac output: Hypotension, tachycardia, tachypnea."
    ],
    "Object5": [
      "LV dilatation with normal or minimally thickened/thinned walls, globed hypokinesia, low EF.",
      "Hypertrophy of RV and/or LV.",
      "Elevated jugular venous pressure (JVP).",
      "Arrhythmia: Atrial fibrillation, conduction delays, complex PVCs, sudden death."
    ],
    "Object6": [
      "Chest X-ray: Generalized enlargement of heart, CHF.",
      "Electrocardiogram: Tachycardia, conduction abnormalities (AV block, LBBB), diffuse nonspecific ST segment and T wave changes, arrhythmias.",
      "24-hour Holter monitor: If lightheadedness, palpitation, syncope.",
      "Echocardiogram, CTI, CMRI: LV dilation with normal/minimally thickened/thinned walls, globed hypokinesia, low EF.",
      "Elevated BNP.",
      "Cardiac catheterization (rule out CAD).",
      "Myocardial biopsy (rarely necessary)."
    ],
    "Object7": [
      "Control and conventional management of heart failure: Salt/fluid restriction. ACE inhibitors, diuretics, digoxin, hydralazine/nitrate combination. L-carnitine, antioxidants, chelating agents (tried).",
      "Anticoagulation prophylaxis.",
      "Implantation of cardiac defibrillator and/or cardiac resynchronization therapy (some patients).",
      "Cardiac transplantation (certain patients)."
    ],
    "Object8": [
      "Heart failure (one in three cases, third most common cause).",
      "Progressive heart failure, ventricular tachycardia.",
      "Sudden cardiac death (SCD).",
      "Thromboembolism, conduction defects."
    ]
  },
  {
    "Object1": "Alcoholic Cardiomyopathy",
    "Object2": "Resembling idiopathic or familial DCM",
    "Object3": [
      "Consumption of >90 g/day of alcohol for many years",
      "Partially genetically predetermined (ALDH2)"
    ],
    "Object4": [],
    "Object5": [
      "Resembles idiopathic or familial DCM."
    ],
    "Object6": [],
    "Object7": [
      "Abstention from alcohol may halt progression or even reverse the condition."
    ],
    "Object8": []
  },
  {
    "Object1": "Peripartum Cardiomyopathy",
    "Object2": "Cardiac dilatation with CHF",
    "Object3": [
      "Develops during last trimester or within 6 months of delivery",
      "Unknown cause",
      "Inflammatory myocarditis, immune activation, multiple gestations (incriminated)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Management is same as IDCM (idiopathic dilated cardiomyopathy).",
      "Further pregnancy should be discouraged."
    ],
    "Object8": []
  },
  {
    "Object1": "Hypertrophic Cardiomyopathy (HCM)",
    "Object2": "Left ventricular hypertrophy",
    "Object3": [
      "Asymmetric myocardial hypertrophy of the left ventricle (greater hypertrophy of the interventricular septum).",
      "Dynamic left ventricular outflow tract pressure gradient (narrowing of the subaortic area, may produce LV outflow tract obstruction).",
      "Familial and transmitted as an autosomal dominant trait."
    ],
    "Object4": [
      "Asymptomatic (echocardiographic finding only, positive family history).",
      "Effort-related: Dyspnea (90%), angina, breathlessness.",
      "Arrhythmia, sudden death."
    ],
    "Object5": [
      "Rapidly rising carotid pulse ('jerky' 'spike and dome')/bisferiens pulse (two systolic peaks).",
      "Double apical impulse.",
      "Reversed pulsus paradoxus on arterial pulse with Bernheim 'a' wave in JVP.",
      "Harsh ejection systolic murmur (lower-left sternal border, apex) due to LV outflow tract obstruction. Increases during standing/Valsalva, decreases during squatting/sustained hand grip/leg rising.",
      "Pansystolic murmur at mitral area (mitral regurgitation)."
    ],
    "Object6": [
      "Electrocardiogram: Abnormal in 85-90% cases. LVH, abnormal ST-Ts, giant T-wave inversions, abnormal Q waves, BBB.",
      "Chest X-ray: Normal or mild-to-moderate cardiac enlargement.",
      "Echocardiography: Diagnostic. Increased LV wall thickness ≥15 mm, systolic anterior motion (SAM) of mitral valve, dynamic LV outflow tract obstruction.",
      "Genetic testing (for family members)."
    ],
    "Object7": [
      "Avoid: Dehydration, digitalis, diuretics, dihydropyridines, vasodilators.",
      "Drug therapy: Beta-adrenergic blockers, calcium-channel blockers (verapamil, diltiazem), disopyramide, anti-arrhythmics (amiodarone).",
      "Implantable cardiac defibrillator (ICD).",
      "Myectomy (partial surgical resection of septum) (improves outflow tract obstruction).",
      "Iatrogenic infarction of basal septum (septal ablation) using catheter-delivered alcohol solution.",
      "Transplantation."
    ],
    "Object8": [
      "Risk of SCD higher in children.",
      "Poor prognosis in males, young age, family history of SCD, syncope, exercise-induced hypotension.",
      "Progression to DCM occurs in 10-15%."
    ]
  },
  {
    "Object1": "Restrictive (Obliterative) Cardiomyopathy",
    "Object2": "Rare condition",
    "Object3": [
      "Ventricular filling is impaired because of the stiff ventricles (abnormal diastolic function).",
      "Resembles constrictive pericarditis.",
      "Idiopathic.",
      "Myocardial: Noninfiltrative (idiopathic, scleroderma), Infiltrative (amyloidosis, sarcoidosis, Gaucher's disease, Hurler disease), Storage disease (hemochromatosis, Fabry disease, glycogen storage diseases).",
      "Endomyocardial: Tropical endomyocardial fibrosis, hypereosinophilic syndrome, carcinoid, metastatic malignancies, radiation, anthracycline drugs."
    ],
    "Object4": [
      "Symptoms of right and left heart failure: Exercise intolerance, dyspnea, peripheral edema, ascites, enlarged tender liver.",
      "Systemic embolism (in ~25% cases)."
    ],
    "Object5": [
      "Jugular venous pressure raised with diastolic collapse and positive Kussmaul's sign.",
      "Mild cardiac enlargement, easily palpable cardiac apex.",
      "Mitral regurgitation murmur (may be heard, not found in constrictive pericarditis).",
      "Heart sounds soft, S3 and S4 may be heard."
    ],
    "Object6": [
      "Electrocardiogram: Nonspecific ST-T wave changes, low voltage, arrhythmias.",
      "Chest X-ray: Mild cardiomegaly.",
      "Doppler echocardiography: Abnormal mitral inflow pattern, symmetrically thickened LV walls, systolic dysfunction, prominent E wave, reduced deceleration time.",
      "Cardiac MRI and CT: Symmetrically thickening of LV wall, normal or slightly reduced ventricular volumes and systolic function (differentiates from constrictive pericarditis).",
      "Cardiac catheterization: Increased ventricular filling pressures with dip-and-plateau pattern."
    ],
    "Object7": [
      "No satisfactory medical therapy.",
      "Drug therapy used with caution.",
      "Diuretics for extremely high-filling pressures.",
      "Chronic anticoagulation often recommended.",
      "Vasodilators may decrease filling pressure.",
      "Calcium-channel blockers to improve diastolic compliance.",
      "Digitalis and other inotropic agents not indicated.",
      "Transplantation may be indicated."
    ],
    "Object8": [
      "Systemic embolism."
    ]
  },
  {
    "Object1": "Persistent Ductus Arteriosus (Patent Ductus Arteriosus, PDA)",
    "Object2": "Congenital anomaly",
    "Object3": [
      "Congenital anomaly in which ductus arteriosus remains open after birth (communication between proximal left pulmonary artery and descending aorta).",
      "Rubella infection during first trimester of pregnancy.",
      "Fetal valproate syndrome.",
      "May occur as isolated anomaly (90%) or associated with VSD, coarctation of aorta, pulmonary/aortic valve stenosis."
    ],
    "Object4": [
      "Small shunt: Asymptomatic for years.",
      "Moderate-to-large shunt: Retardation of growth and development, left heart volume overload. Cardiac failure, dyspnea.",
      "Persistent ductus with reversed shunting (Eisenmenger's syndrome): Cyanosis, differential cyanosis (cyanosis and clubbing of toes, not fingers)."
    ],
    "Object5": [
      "Bounding pulse (increased volume).",
      "Apex beat shifted down and out, hyperdynamic.",
      "Characteristic continuous harsh murmur ('machinery like'/Gibson's murmur), late systolic accentuation, maximal in first left intercostal space below clavicle, often with continuous thrill. Murmur softer with large PDA and pulmonary hypertension.",
      "Loud S1 (due to loud mitral component).",
      "Graham Steell murmur of pulmonary hypertension (will be present).",
      "Differential cyanosis (cyanosis and clubbing of toes, not fingers - due to right-to-left ductal shunting distal to subclavian arteries)."
    ],
    "Object6": [
      "Chest X-ray: Enlargement of pulmonary artery with increased vascular markings (plethoric fields).",
      "ECG: Usually normal with smaller shunts. LA enlargement, LVH, sinus tachycardia or AF (moderate/large shunts).",
      "Echocardiogram and color Doppler: PDA, amount of blood flow.",
      "MRI and CT: Assess calcification.",
      "Cardiac catheterization."
    ],
    "Object7": [
      "Small ductus arteriosus: Ductus closure (unless clinically silent) to prevent endarteritis.",
      "Ductus closure indicated for symptomatic child/adult with significant left-to-right shunting.",
      "Transcatheter-occluding devices (coils, buttons, umbrellas) increasingly used.",
      "Video-assisted thoracoscopic clip closure.",
      "Surgical ligation or division (for very large ductus arteriosus).",
      "Symptomatic patients: Medical regimen of diuretics, digoxin, ACE inhibition, antidysarrhythmia medications with anticoagulation (for AF/flutter).",
      "Neonatal period (first week): Prostaglandin synthetase inhibitor (indomethacin or ibuprofen) to induce closure. Prostaglandin treatment to keep ductus open if impaired lung perfusion (e.g., severe PS)."
    ],
    "Object8": [
      "Cardiac failure, hypertensive pulmonary vascular disease, endarteritis, paradoxical embolism.",
      "Pulmonary hypertension, Eisenmenger's syndrome (with large shunt and increased pulmonary vascular resistance)."
    ]
  },
  {
    "Object1": "Coarctation of Aorta (COA)",
    "Object2": [
      "Infantile (preductal) form",
      "Adult (postductal) form"
    ],
    "Object3": [
      "Congenital heart disease (narrowing of aortic lumen at or just distal to insertion of ductus arteriosus).",
      "Associated with: Bicuspid aortic valve (80%), 'berry' aneurysms in circle of Willis, Turner’s syndrome, patent ductus arteriosus, VSD, mitral stenosis/regurgitation."
    ],
    "Object4": [
      "May present as cardiac failure in newborn.",
      "Asymptomatic for many years (older children/adults).",
      "Headaches and epistaxis/nosebleeds (hypertension proximal to coarctation).",
      "Weakness or cramps/claudication in legs, cold legs (decreased blood flow to lower body)."
    ],
    "Object5": [
      "Femoral pulses and lower limb pulses are weak, delayed (radiofemoral delay) compared to radial pulse. Asynchronous radial pulses if coarctation proximal to left subclavian artery.",
      "BP raised in upper limbs, normal/low in legs (difference >20 mm Hg).",
      "Ejection systolic murmur (ESM) heard posteriorly over spine. Systolic or continuous murmurs over lateral thoracic wall (collaterals). Aortic ejection click, systolic murmur in aortic area (bicuspid AV). Heaving apical impulse.",
      "Aortic narrowing causes formation of collaterals (periscapular, internal mammary, intercostal arteries), may produce localized bruits.",
      "Suzman’s sign (dilated, tortuous, pulsatile arteries around scapulae and intercostals regions in back).",
      "Corkscrew-shaped retinal arteries. Absence of papilledema despite high BP."
    ],
    "Object6": [
      "Chest X-ray: Early childhood normal. Later: Post-stenotic dilatation of aorta, indentation of descending aorta at coarctation site ('figure 3' aorta). Tortuous/dilated collaterals erode undersurfaces of ribs ('rib notching'/‘Dock’ sign - after 6 years).",
      "CT, MRI and CMR scanning: Best imaging to demonstrate coarctation and quantify flow.",
      "ECG: May demonstrate LVH.",
      "Echocardiography: Shows coarctation, associated anomalies, confirms LVH."
    ],
    "Object7": [
      "Treat hypertension and congestive heart failure. Avoid ACE inhibitors and ARAs (risk of renal failure in lower body).",
      "Surgical correction: Indicated if peak-peak gradient across coarctation >20 mm Hg and/or proximal hypertension. Neonates: surgical repair. Older children/adults: balloon dilatation and stenting or surgery.",
      "Balloon dilatation preferred for recoarctation (sometimes stenting)."
    ],
    "Object8": [
      "Hypertension, left ventricular/congestive heart failure, infective endocarditis (at coarctation site, bicuspid AV or collateral channels), cerebral hemorrhage (rupture of Berry aneurysm), rupture or dissection of aorta.",
      "Untreated: Death from complications (LV failure, aortic dissection, cerebral hemorrhage)."
    ]
  },
  {
    "Object1": "Atrial Septal Defect (ASD)",
    "Object2": [
      "Ostium secundum defects (75-85%)",
      "Ostium primum (atrioventricular septal) defects (10-15%)",
      "Sinus venosus defects (Superior - 5-10%, Inferior - 1%)",
      "Coronary sinus septal defect (1%)"
    ],
    "Object3": [
      "Abnormal, fixed opening in atrial septum (due to incomplete formation of atrial septum)."
    ],
    "Object4": [
      "Often asymptomatic till adulthood.",
      "More common in women (2-3 times).",
      "Symptoms include easy fatigability, recurrent chest infection, exertional dyspnea, palpitations (related to arrhythmias, especially AF), platypnea-orthodeoxia (dyspnea with standing, relieved by rest), cardiac failure.",
      "After 40 years: Deterioration due to AF, increased left-to-right shunt (HTN, CAD decreasing LV compliance)."
    ],
    "Object5": [
      "Pulse: No variation in rate/volume with Valsalva, irregularly irregular with AF.",
      "JVP: 'a' and 'v' waves have equal height (reflection of LA waves). 'a' wave taller with PAH/MS. Systolic pulsations in 2nd/3rd LICS (dilated PA).",
      "Characteristic physical signs due to volume overload of RV: Wide, fixed splitting of S2. S2 loud and P2 loud. Systolic flow murmur over pulmonary valve. Diastolic flow murmur over tricuspid valve (large shunt in children). Ventricular heave/parasternal impulse."
    ],
    "Object6": [
      "Chest X-ray (Fig. 7.52): Enlargement of heart (RA, RV), prominent pulmonary arteries ('jug handle appearance') with pulmonary plethora. Hilar dance (fluoroscopy).",
      "ECG: Incomplete RBBB, right axis deviation. Ostium primum defects may show left axis deviation.",
      "Echocardiography: Hypertrophy/dilatation of right heart/pulmonary arteries. Subcostal views with 2D and color Doppler demonstrate ASD and calculate QP:QS ratio. CMR and CT assess anomalous pulmonary venous drainage.",
      "MRI: Size/location of defect, LV outflow, aortic valve involvement. Quantifies RV size, volume, function, systemic/pulmonary venous return.",
      "Cardiac catheterization: In non-restrictive ASD, pressure gradient between atria <3 mm Hg."
    ],
    "Object7": [
      "Prompt treatment of respiratory infections.",
      "Indications for intervention: ASD with significant left-to-right shunting resulting in RA/RV enlargement (irrespective of symptoms). ASD where pulmonary flow is increased 50% above systemic flow (Qp:Qs >1.5:1). Thromboembolic events.",
      "Contraindications to surgery: Severe pulmonary hypertension and shunt reversal.",
      "Surgical options: Median sternotomy with direct closure (small/moderate defects). Larger defects closed with autologous pericardium or synthetic patches. Surgical closure in patients >3 years (if no PAH, Qp:Qs >1.5:1).",
      "Transcatheter septal clamshell device closure (for most secundum ASDs).",
      "Uncorrected ASD does not require antibiotic prophylaxis for endocarditis (unless other high risk conditions)."
    ],
    "Object8": [
      "Congestive heart failure (neonates).",
      "Paradoxical embolism.",
      "Atrial fibrillation.",
      "Pulmonary hypertension (late), Eisenmenger's syndrome (very late).",
      "Rarely infective endocarditis."
    ]
  },
  {
    "Object1": "Patent Foramen Ovale",
    "Object2": "Not specified",
    "Object3": [
      "May be found in >25% of adult population and is hemodynamically insignificant."
    ],
    "Object4": [
      "Usually asymptomatic."
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "May be associated with paradoxical emboli and increased incidence of embolic stroke."
    ]
  },
  {
    "Object1": "Ventricular Septal Defect (VSD)",
    "Object2": [
      "Congenital (most common, 'perimembranous' defects)",
      "Acquired (ventricular septal rupture after acute MI, infective endocarditis, trauma/cardiac catheterization)"
    ],
    "Object3": [
      "Incomplete septation of ventricles (congenital)",
      "May be isolated or associated with other congenital heart disease."
    ],
    "Object4": [
      "Depend on size of defect and severity of shunt.",
      "Large VSD: Dyspnea, repeated pulmonary infection, hepatomegaly, sweating, failure to thrive (soon after birth).",
      "Subpulmonic stenosis (in some children with isolated VSD) - patient not at risk of pulmonary vascular disease."
    ],
    "Object5": [
      "Wide pulse pressure (relatively).",
      "Murmur: Pansystolic murmur (PSM) (high-pressure LV to low-pressure RV flow during systole). Best heard at LLSB (3rd, 4th, 5th IICS), radiates all over precordium. Loud PSM in small defect (maladie de Roger). Softer murmur in large defect (high RV pressure, or Eisenmenger's syndrome). S1 and S2 masked by PSM.",
      "Precordium hyperkinetic, with systolic thrill at LLSB.",
      "Prominent parasternal pulsation, tachypnea, indrawing of lower ribs on inspiration."
    ],
    "Object6": [
      "Chest X-ray: Cardiomegaly (proportional to volume overload, mainly LV, LA, RV). Increased pulmonary blood flow, PAH.",
      "Electrocardiogram: Right/left or combined ventricular hypertrophy. RBBB common. Katz-Wachtel sign (large equiphasic QRS in V2-V3) suggestive of biventricular hypertrophy.",
      "Doppler echocardiography: Location of VSD, morphology of LV outflow, aortic valve involvement.",
      "Cardiac catheterization: Assess pulmonary vascular resistance in complicated VSD."
    ],
    "Object7": [
      "Small VSD: No medication or surgery if asymptomatic. Observe (75-80% close by 2 years).",
      "Cardiac failure in infancy: Digoxin and diuretics initially. Surgical repair if failure persists.",
      "Moderate/large VSD: Repair by intervention.",
      "Large hemodynamically significant VSD (L to R shunting with Qp/Qs ≥ 2:1): Surgical repair, ideally before 1 year, even if asymptomatic.",
      "Growth failure unresponsive to medical therapy is an indication for surgery.",
      "Surgical closure contraindicated in fully developed Eisenmenger's syndrome (may require heart-lung transplantation)."
    ],
    "Object8": [
      "Congestive heart failure.",
      "Pulmonary hypertension.",
      "Eisenmenger's syndrome (reversal of shunt from right to left, cyanosis).",
      "Right ventricular outflow tract obstruction (infundibular stenosis/Gasul's transformation, occurs in 5%, prevents pulmonary vascular obstructive disease).",
      "Infective endocarditis.",
      "Aortic insufficiency (5%, related to prolapse of aortic valve cusp into VSD or lack of support to aortic root)."
    ]
  },
  {
    "Object1": "Eisenmenger's Syndrome",
    "Object2": "Not specified",
    "Object3": [
      "Untreated congenital cardiac defect with intracardiac communication that leads to pulmonary hypertension, reversal of flow, and cyanosis.",
      "Consequence of reversal of a left-to-right shunt to a right-to-left shunt (in VSD, ASD, PDA)."
    ],
    "Object4": [
      "Dyspnea, fatigue, dizziness, syncope."
    ],
    "Object5": [
      "Central cyanosis and clubbing (generalized in ASD/VSD reversal, differential in PDA reversal - toes but not fingers).",
      "Signs of pulmonary hypertension and its sequelae.",
      "Heart sounds: Loud S2 with palpable P2. S2 fixed but narrowly split (ASD reversal). S2 single (VSD reversal). S2 mobile but narrowly split (PDA reversal). RV S4, pulmonary ejection click.",
      "Murmurs: Underlying murmurs (ASD, VSD, PDA) decrease in intensity/duration/disappear. Early diastolic murmur at pulmonary area, pansystolic murmur of TR appear."
    ],
    "Object6": [
      "Clinical diagnosis, supported by imaging."
    ],
    "Object7": [
      "Surgical correction of underlying defect (refer treatment of ASD, VSD, PDA). (Contraindicated in fully developed Eisenmenger's).",
      "Avoid vasodilator therapy using calcium channel blockers (causes systemic vasodilatation, increases right-to-left shunt).",
      "Long-term oxygen inhalation (may relieve symptoms).",
      "Phlebotomy (when hyperviscosity syndrome develops due to polycythemia).",
      "Heart-lung transplantation (only curative treatment).",
      "Relief of symptoms: Prostanoids (epoprostenol, iloprost, treprostinil), endothelin receptor antagonists (bosentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil)."
    ],
    "Object8": [
      "Pulmonary hypertension, reversal of flow, cyanosis.",
      "Right heart failure, infective endocarditis, pulmonary infections, severe hemoptysis, secondary polycythemia, pulmonary thrombosis with infarction, brain abscess, cerebral stroke, ventricular arrhythmias."
    ]
  },
  {
    "Object1": "Tetralogy of Fallot (TOF)",
    "Object2": "Most common congenital cyanotic heart disease in adults",
    "Object3": [
      "Abnormal development of the bulbar septum (separates ascending aorta from pulmonary artery).",
      "Four features: Ventricular septal defect, Pulmonary stenosis (RV outflow tract obstruction), Overriding of dextroposed aorta, Right ventricular hypertrophy.",
      "Presence of ASD along with TOF is pentalogy of Fallot."
    ],
    "Object4": [
      "Depend on severity of pulmonary stenosis.",
      "Paroxysmal attacks of dyspnea, anoxic spells (predominantly after waking up). Child cries, becomes blue (cyanosis), loses consciousness, may develop convulsion. Frequency varies.",
      "Squatting (common, Fallot sign).",
      "Fallot's spell ('tet spell'): Lethal, unpredictable. Child becomes increasingly cyanosed (during feeding, crying, fever, exercise), may become apnoeic, unconscious. Due to spasm of subpulmonary muscle, systemic vasodilatation (increased R-L shunt), acute increase RV outlet obstruction. Can lead to sudden death.",
      "Adults: Growth retardation, fatigue, dyspnea on exertion (cyanotic spells not usual). Secondary polycythemia (thrombotic strokes)."
    ],
    "Object5": [
      "Cyanosis (may not be seen in newborn or mild obstruction - 'acyanotic tetralogy').",
      "Loud ejection systolic murmur in pulmonary area (due to pulmonary stenosis). Intensity/duration inversely proportional to severity of RVOT obstruction. (Shorter murmur with more severe PS).",
      "Second heart sound: P2 soft or inaudible (S2 is single loud). Aortic ejection click (dilated ascending aorta).",
      "Clubbing, parasternal heave, systolic thrill.",
      "X-ray (Fig. 7.53B): Abnormally small pulmonary artery, large right ventricle, 'boot-shaped' heart ('Coeur en Sabot')."
    ],
    "Object6": [
      "Chest X-ray (Fig. 7.53B): Small pulmonary artery, large RV, 'boot-shaped' heart.",
      "ECG: RVH.",
      "Echocardiography: Diagnostic, highly sensitive. Aorta not continuous with anterior ventricular septum.",
      "Cardiac catheterization (rarely required)."
    ],
    "Object7": [
      "Definitive: Total correction by surgical means (relief of PS, closure of VSD) in infants/children prior to 5 years.",
      "Blalock-Taussig shunt (palliative) for babies with severely hypoplastic pulmonary arteries (increases pulmonary blood flow, PA development, facilitates later correction).",
      "Treatment of cyanotic spells: Squatting (knee-to-chest) position. Oxygen. IV fluids. Morphine IV (0.1 mg/kg). Propranolol IV (0.01 mg/kg) then oral (3-5 mg/kg/day).",
      "Antibiotic prophylaxis for endocarditis."
    ],
    "Object8": [
      "Paroxysmal attacks of dyspnea, anoxic spells, Fallot's spell (lethal, can cause sudden death).",
      "Secondary polycythemia (thrombotic strokes, brain abscess).",
      "Infective endocarditis.",
      "Brain abscess.",
      "Cerebrovascular accidents."
    ]
  },
  {
    "Object1": "Ebstein Anomaly",
    "Object2": "Cyanotic congenital heart disease",
    "Object3": [
      "Abnormalities of the tricuspid valve and atrialization of right ventricle",
      "Associated with maternal lithium consumption"
    ],
    "Object4": [
      "Episodic tachyarrhythmia's (associated WPW syndrome)",
      "Cyanosis"
    ],
    "Object5": [
      "Central cyanosis and clubbing",
      "Prominent 'a' waves in JVP",
      "Hepatomegaly",
      "Split S1, split S2, S3 and S4",
      "Pansystolic murmur of TR"
    ],
    "Object6": [
      "ECG: Right axis deviation, 'Himalayan' giant P waves, RBBB, pre-excitation pattern.",
      "CXR: Gross cardiomegaly ('wall to wall heart' or 'box heart').",
      "Doppler echocardiography (diagnostic)."
    ],
    "Object7": [
      "Medical: Treatment of arrhythmias, embolism, nitric oxide.",
      "Surgical repair: Tricuspid replacement, selective plication of atrialized right ventricle, closure of intracardiac shunt (Danielson repair, Carpentier technique)."
    ],
    "Object8": [
      "Paradoxical embolism",
      "Brain abscess",
      "Sudden cardiac death"
    ]
  },
  {
    "Object1": "Acute Pericarditis",
    "Object2": [
      "Acute (<6 weeks)",
      "Subacute (6 weeks to 6 months)",
      "Chronic (>6 months)",
      "Fibrinous",
      "Serous",
      "Hemorrhagic",
      "Purulent"
    ],
    "Object3": [
      "Acute inflammation of the pericardium.",
      "Idiopathic.",
      "Infections: Viral (Coxsackie A and B, Echovirus, HIV), Pyogenic (Pneumococcus, Staphylococcus, Legionella), Tuberculosis (most common in India), Fungal (Histoplasmosis, Candida), Syphilis, parasitic.",
      "Acute myocardial infarction.",
      "Metastatic neoplasm.",
      "Hypothyroidism.",
      "Radiation therapy (up to 20 years earlier).",
      "Chronic renal failure.",
      "Connective tissue disorder (RA, SLE).",
      "Drug reaction (Procainamide, hydralazine).",
      "Autoimmune (following heart surgery and MI - Dressler's syndrome).",
      "Trauma."
    ],
    "Object4": [
      "Pericardial pain (sharp, retrosternal chest pain, radiates to shoulders/neck/trapezius muscle ridges). Aggravated by deep breathing, movement, lying down, coughing, exercise, swallowing. Relieved by sitting up/leaning forward.",
      "Nonspecific: Low-grade fever, malaise.",
      "Dyspnea (large pericardial effusion compressing bronchi/lung - Ewart's sign)."
    ],
    "Object5": [
      "Pericardial Friction Rub (high-pitched, superficial scratching/crunching sound, 'to-and-fro, leathery quality', diagnostic. Best heard with diaphragm at LLSB, end of expiration, sitting/leaning forward. Usually systolic, may be diastolic, mono/biphasic).",
      "Pulsus paradoxus (weakness/disappearance of arterial pulse during inspiration).",
      "Cardiac tamponade (accumulation of pericardial fluid under pressure).",
      "Constrictive pericarditis (scarring, loss of elasticity of pericardial sac, calcification)."
    ],
    "Object6": [
      "Blood: Leukocytosis (bacterial), lymphocytosis (viral), raised ESR. Cardiac enzymes (CPK-MB, troponin T) normal unless myocarditis. Increased white cell count, ESR, CRP.",
      "Electrocardiogram (ECG): Diagnostic. Widespread concave upwards (saddle shaped) ST elevation in multiple leads (I, II, aVL, aVF, V1-V3), reciprocal ST depression in aVR, V1. PR segment depression (characteristic). Changes evolve to T wave flattening/inversion, then normalization. Low voltage QRS/electrical alternans (effusion).",
      "Chest X-ray: Normal if no effusion. Rapid increase in cardiac size (cardiomegaly, 'pear-shaped'/'water-bottle appearance', 'oreo cookie sign'/epicardial fat pad sign) with effusion. Stenciled borders of heart.",
      "Echocardiography: Confirmation of pericardial effusion, monitor size/effect on cardiac function.",
      "CT and cardiac MR: Suspected thickening (>4 mm) or inflammation of pericardium/myocardium.",
      "Pericardial aspiration (pericardiocentesis): Diagnostic (tuberculous, malignant, purulent effusion) or therapeutic (cardiac tamponade). Fluid analysis: cell counts, protein, glucose, LDH, Gram's, AFB, cytology, Mycobacterium culture.",
      "Pericardial biopsy (if TB suspected, pericardiocentesis not diagnostic).",
      "Other tests: Blood cultures, autoantibody screen."
    ],
    "Object7": [
      "Treatment of underlying cause.",
      "Bed rest, avoid physical activity.",
      "Analgesics: Oral NSAIDs (high dose aspirin, indomethacin, ibuprofen) (relieves pain, decreases inflammation in idiopathic/viral). Aspirin 600 mg 4 hourly (post-MI). Ibuprofen 300-800 mg 3 times daily. Indomethacin 25 mg 3 times daily (avoid in elderly). Colchicine 0.5 mg twice daily (with NSAIDs).",
      "Corticosteroids (10-30 mg/day for 2-4 weeks): Reserved for immune cause, or no response to NSAIDs (associated with increased recurrence).",
      "Purulent pericarditis: Antimicrobial therapy, pericardiocentesis, surgical drainage.",
      "Hospitalization indications: Fever (>38°C), leukocytosis, large pericardial effusion, lack of NSAID response (1 week), acute trauma, cardiac tamponade, immunosuppressed state, recurrent pericarditis."
    ],
    "Object8": [
      "Cardiac tamponade (from large/rapid effusion).",
      "Constrictive pericarditis (from scarring/fibrosis).",
      "Effusive-constrictive pericarditis.",
      "Purulent pericarditis.",
      "Damage to myocardium, coronary vessels, air embolism, pneumothorax (from pericardiocentesis).",
      "Increased rate of recurrence (corticosteroids).",
      "Myocarditis (coexisting)."
    ]
  },
  {
    "Object1": "Pericardial Effusion",
    "Object2": [
      "Transudate (hydropericardium)",
      "Exudate (pyopericardium)",
      "Hemopericardium"
    ],
    "Object3": [
      "Accumulation of fluid within pericardial sac (often with acute pericarditis - Box 7.52).",
      "Cardiac tamponade (if large/rapidly developing).",
      "Transudate (hydropericardium): CHF, nephrotic syndrome, cirrhosis, severe malnutrition, hypothyroidism, Meigs' syndrome, peritoneal dialysis.",
      "Exudate (pyopericardium): TB, bacterial pneumonia, malignancy, pulmonary infarction, autoimmune diseases (RA, SLE), acute pancreatitis, Dressler's syndrome, drug-induced, benign asbestos-related, intra-abdominal abscess, ruptured amebic liver abscess, chylous pleural effusion, acute rheumatic fever."
    ],
    "Object4": [
      "Symptoms reflect underlying pericarditis. Retrosternal oppression (sometimes).",
      "Dyspnea (Ewart's sign if large effusion compresses lung)."
    ],
    "Object5": [
      "Normal cardiovascular exam (unless large effusion).",
      "Apex beat/impulse not palpable (sometimes palpable medial to left border of cardiac dullness).",
      "Increased cardiac dullness on percussion.",
      "Faint, soft, distant or muffled heart sounds.",
      "Pericardial friction rub (early, becomes quieter with fluid).",
      "Ewart's sign (dullness, tubular breath sounds in left axilla/base, due to lung compression by large effusion)."
    ],
    "Object6": [
      "Chest X-ray: Increased cardiac silhouette, large globular/pear-shaped heart or 'water-bottle appearance', sharp outlines, lucent pericardial fat lines. Pulmonary veins not distended. 'Oreo cookie sign'/epicardial fat pad sign.",
      "Electrocardiogram: Low voltage QRS complexes (<0.5 mV in limb leads), sinus tachycardia, electrical alternans.",
      "Echocardiography: Most useful. Demonstrates pericardial effusion, monitors size/effect on cardiac function. Small effusions evident over posteriobasal LV. Early diastolic collapse of RV, collapse of RA (sensitive/specific for tamponade).",
      "Cardiac CT or MRI: Suspected loculated effusions (post-cardiac surgery).",
      "Pericardial aspiration (pericardiocentesis): Diagnostic (tuberculous, malignant, purulent) or therapeutic (cardiac tamponade). Fluid analysis (cell counts, protein, glucose, LDH, Gram's, AFB, cytology, Mycobacterium culture).",
      "Pericardial biopsy (if TB suspected, pericardiocentesis not diagnostic).",
      "Other tests: Blood cultures, autoantibody screen (depending on underlying cause)."
    ],
    "Object7": [
      "Treat underlying cause.",
      "Anti-inflammatory drugs (aspirin or indomethacin). Most effusions resolve spontaneously.",
      "Therapeutic pericardiocentesis (for rapid effusion/cardiac tamponade). Pig-tail catheter drain may be left.",
      "Pericardial fenestration (for recurrent effusions, e.g., malignancy) (creating window in pericardium for fluid release).",
      "Intrapericardial instillation of chemotherapeutic agents (malignant effusion)."
    ],
    "Object8": [
      "Cardiac tamponade (if large/rapidly developing).",
      "Ewart's sign (large effusion).",
      "Arrhythmias, myocardial/coronary damage, air embolism, pneumothorax (from pericardiocentesis)."
    ]
  },
  {
    "Object1": "Cardiac Tamponade",
    "Object2": "Acute heart failure",
    "Object3": [
      "Large or rapidly developing pericardial effusion (compresses heart, impairs diastolic filling).",
      "Pericardial effusion (Box 7.52)."
    ],
    "Object4": [
      "Dyspnea, orthopnea, substernal chest discomfort (radiating to neck/jaw).",
      "Pain in right upper quadrant, pedal edema (slowly developing - subacute tamponade)."
    ],
    "Object5": [
      "Friedreich's sign: Markedly raised JVP with sharp rise and 'y' descent.",
      "Pulsus paradoxus (hallmark): Exaggerated reduction in pulse strength during inspiration, drop in systolic BP ≥10 mm Hg.",
      "Kussmaul's sign: Rise in JVP/increased neck vein distension during inspiration.",
      "Reduced cardiac output, hypotension, tachycardia, oliguria.",
      "Beck's triad: Hypotension, muffled heart sounds, elevated JVP (severe tamponade)."
    ],
    "Object6": [
      "Chest X-ray: Discussed under pericarditis.",
      "Electrocardiogram: Sinus tachycardia, reduction in QRS voltage, non-specific ST-T changes, electrical alternans.",
      "Echocardiography: Lucent separation between parietal and visceral pericardium. Early diastolic collapse of RV, collapse of RA (sensitive/specific signs). RV collapse more specific."
    ],
    "Object7": [
      "Emergency pericardiocentesis.",
      "If hypotensive: Temporary expansion of blood volume (saline, blood, plasma, dextran).",
      "Avoid positive pressure mechanical ventilation (reduces cardiac filling).",
      "Treatment of underlying cause."
    ],
    "Object8": [
      "Impaired diastolic filling, embarrassment of circulation."
    ]
  },
  {
    "Object1": "Chronic Constrictive Pericarditis",
    "Object2": "End stage inflammatory process involving pericardium",
    "Object3": [
      "Progressive thickening, fibrosis, and calcification of the pericardium (visceral and parietal pericardium become adherent).",
      "Idiopathic.",
      "Infections: Tuberculosis, Viral (Coxsackie B), Bacterial, Fungal, Parasitic.",
      "Postradiotherapy.",
      "Postcardiac surgery.",
      "Post-traumatic.",
      "Neoplastic.",
      "Connective tissue diseases (e.g., RA, SLE).",
      "Toxic/metabolic: Uremia, chylous pericardium, mesothelioma.",
      "Post myocardial infarction.",
      "Familial."
    ],
    "Object4": [
      "Reduced ventricular filling (similar to cardiac tamponade: Kussmaul's sign, Friedreich's sign, pulsus paradoxus).",
      "Systemic venous congestion (ascites, dependent edema, hepatomegaly, raised JVP).",
      "Reduced cardiac output (fatigue, hypotension, reflex tachycardia).",
      "Rarely: Pulmonary venous congestion (dyspnea, cough, orthopnea)."
    ],
    "Object5": [
      "Kussmaul's sign (rise in JVP/increased neck vein distension during inspiration).",
      "Friedreich's sign (markedly raised JVP with sharp rise and 'y' descent).",
      "Pulsus paradoxus (weakness/disappearance of arterial pulse during inspiration).",
      "Pericardial knock (0.09-0.12s after A2, early diastole, LLSB - due to rapid ventricular filling).",
      "Ascites, dependent edema, hepatomegaly, raised JVP (systemic venous congestion).",
      "Reduced cardiac output (fatigue, hypotension, reflex tachycardia).",
      "Mild cardiac enlargement, easily palpable cardiac apex."
    ],
    "Object6": [
      "ECG: Rarely normal, nonspecific, highly variable. Atrial arrhythmias (frequent, AF late). Low voltage (<50% cases), LA enlargement (19-37%).",
      "Chest X-ray: Pulmonary venous congestion, pleural effusions (late). Calcified pericardium (highly suggestive).",
      "Echocardiography: Pericardial thickening (better with TEE), normal RV/LV chamber size, LA/RA enlargement, abnormal septal/posterior wall motion, paradoxical septal motion, premature opening of pulmonic valve, dilated IVC without respiratory variation.",
      "MRI/CT scan: Confirms pericardial thickening (>4mm helpful, >6mm more specific).",
      "Cardiac catheterization: Ventricular pressure initially decreases rapidly (steep 'y' descent on RA pressure), then increases abruptly to sustained level ('dip-and-plateau waveform' or 'square root sign')."
    ],
    "Object7": [
      "Pericardiectomy (resection of pericardium) is the only definitive treatment.",
      "Pharmacologic therapy: Steroids for subacute (before fibrosis). Diuretics (relieve congestion, optimize volume status). Treatment of causative disease (antituberculosis medication).",
      "Avoid beta-blockers and calcium channel blockers."
    ],
    "Object8": [
      "Restricted diastolic filling, limitation of venous return, reduced ventricular filling, inability to maintain adequate preload.",
      "Systolic function rarely affected until late.",
      "Pulmonary hypertension.",
      "Atrial arrhythmias, atrial fibrillation (late course)."
    ]
  },
  {
    "Object1": "Pulmonary Hypertension (PH)",
    "Object2": [
      "Pulmonary arterial hypertension (PAH) (Idiopathic, Familial, Associated with CTD, Congenital heart disease, Portal hypertension, HIV, Drugs/toxins, HHT, hemoglobinopathies, myeloproliferative disorders, splenectomy)",
      "Associated with venous/capillary involvement (Pulmonary veno-occlusive disease, Pulmonary capillary hemangiomatosis, Persistent PH of newborn)",
      "PH owing to left heart disease (Systolic dysfunction, Diastolic dysfunction, Valvular disease)",
      "PH secondary to chronic hypoxemia (COPD, ILD, sleep disordered breathing, alveolar hypoventilation, high altitude, developmental abnormalities)",
      "Chronic thromboembolic pulmonary hypertension (CTEPH)",
      "Miscellaneous (extrinsic compression of pulmonary arteries - sarcoidosis, histiocytosis X, lymphangiomyomatosis, tumors, fibrosing mediastinitis, thyroid disorders, glycogen storage disease, Gaucher's disease)"
    ],
    "Object3": [
      "Increase in blood pressure in pulmonary circulation (arteries, or arteries and veins).",
      "Hemodynamically defined as mean pulmonary arterial pressure ≥25 mm Hg at rest.",
      "Risk factors: Genetic (BMPR2, ALK1 mutations), Connective tissue disease, Congenital heart disease, Portal hypertension, HIV, Drugs/toxins (aminorex, dexfenfluramine, fenfluramine, cocaine, methamphetamine), Hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy.",
      "Left heart disease, chronic hypoxemia, chronic thromboembolism, extrinsic compression of pulmonary arteries."
    ],
    "Object4": [
      "Insidious onset, usually diagnosed late.",
      "Exertional breathlessness/dyspnea (60%), fatigue (19%), palpitation and near syncope/syncope (13%), chest pain (7%), palpitations (5%), LE edema (3%), hoarseness of voice (2%)."
    ],
    "Object5": [
      "Cold extremities, peripheral edema, cyanosis and rarely clubbing.",
      "Raised jugular venous pulse, prominent v wave (if TR).",
      "Left parasternal lift/heave (RVH).",
      "Accentuated pulmonic component of S2, right sided S3, ejection systolic murmur in pulmonary area. Pansystolic murmur of TR or early-diastolic murmur of pulmonary regurgitation.",
      "Large pulsatile liver.",
      "Signs of underlying cause."
    ],
    "Object6": [
      "Chest X-ray: Enlargement of pulmonary artery/main branches. Peripheral 'pruning' of vascular shadows. Enlarged RA/RV. Findings of underlying lung/cardiac pathology. Westermark sign, Hampton's hump.",
      "Electrocardiogram: Right axis deviation, R/S wave ratio >1 in V1, RBBB, increased P wave amplitude in lead II (RAE). RVH, right precordial T-wave inversions, delayed intrinsicoid deflection of right precordial leads, RVH, S1Q3T3 pattern, QR pattern in V1/V3R.",
      "Echocardiography: Most useful. TR, RVH, flattening of interventricular septum, small LV dimension, dilated PA. Doppler assessment of TR jet (non-invasive PA pressure).",
      "Right heart catheterization: Mean PAP pressure at rest >25 mm Hg, with exercise >30 mm Hg. Wedge pressure, cardiac output, transpulmonary pressure gradient.",
      "Other tests: CBC, PT, PTT, LFTs. Autoantibodies (autoimmune suspected). HIV-ELISA. ABG (exclude hypoxia/acidosis). Sleep studies (sleep apnea suspected). Pulmonary function tests. HRCT chest (exclude occult ILD). Helical CT (pulmonary thromboembolism). Ventilation-perfusion scanning (differentiate CTEPH from primary PH)."
    ],
    "Object7": [
      "Early recognition and treatment of underlying cause.",
      "Medical: Diuretics (edema from RHF), digoxin (atrial tachyarrhythmias), oxygen (keep saturation ≥90%), anticoagulants (IPAH) (INR 2.0-2.5).",
      "PAH specific therapy:",
      "Calcium channel blockers: (for vasodilator responders) Nifedipine (240 mg/day), amlodipine (20 mg/day).",
      "Oral endothelin receptor antagonists (ERAs): Bosentan, sitaxsentan, ambrisentan. (Monitor LFTs).",
      "Phosphodiesterase type 5 inhibitors (PDE 5-I): Sildenafil, tadalafil, vardenafil.",
      "Prostaglandins: Epoprostenol, treprostinil, iloprost, prostacyclin IP receptor antagonist (Selexipag).",
      "Guanylate cyclase stimulant: Riociguat.",
      "Pneumococcal and influenza vaccination.",
      "Surgical therapy: Atrial septostomy. Lung transplantation. Pulmonary thromboendarterectomy (for chronic proximal CTEPH)."
    ],
    "Object8": [
      "Right ventricular failure.",
      "Thromboembolic obstruction.",
      "Hoarseness of voice (rare)."
    ]
  },
  {
    "Object1": "Sudden Cardiac Death (SCD)",
    "Object2": "Unexpected, nontraumatic, natural death due to cardiac causes",
    "Object3": [
      "Coronary artery disease (Coronary atherosclerosis, developmental anomalies, coronary artery embolism, vasculitis, dissection)",
      "Myocardial diseases (Cardiomyopathies, myocarditis, other infiltrative processes, right ventricular dysplasia)",
      "Valvular diseases (Mitral valve prolapse, aortic stenosis and other forms of left ventricular outflow obstruction, endocarditis)",
      "Conduction system abnormalities (Wolff-Parkinson-White (WPW) syndrome, Brugada syndrome, long QT syndromes)"
    ],
    "Object4": [],
    "Object5": [
      "Sudden cessation of cardiac activity with hemodynamic collapse (within 1 hour of symptom onset)"
    ],
    "Object6": [
      "Identifying individuals at high risk of SCD (combination of factors, left ventricular ejection fraction is most important)."
    ],
    "Object7": [
      "Pharmacological agents: Beta blockers, ACEI, amiodarone.",
      "Revascularization.",
      "ICD/CRT (Implantable cardioverter defibrillator/Cardiac resynchronization therapy)."
    ],
    "Object8": []
  },
  {
    "Object1": "Cardiac Arrest",
    "Object2": "Sudden loss of cardiac pump function",
    "Object3": [
      "Hypoxia",
      "Hypotension",
      "Hypothermia",
      "Hypoglycemia",
      "Acidosis (H+)",
      "Hyperkalemia (electrolyte disturbance)",
      "Cardiac Tamponade",
      "Tension pneumothorax",
      "Thromboembolism (pulmonary, coronary)",
      "Toxicity (e.g., digoxin, local anesthetics, insecticides)"
    ],
    "Object4": [],
    "Object5": [
      "Loss of consciousness",
      "Loss of apical and central pulsations (carotid, femoral)",
      "Apnea"
    ],
    "Object6": [
      "ECG: Ventricular tachyarrhythmia (VF/pulseless VT), Ventricular asystole or brady-asystolic rhythm, Pulseless electrical activity (PEA)."
    ],
    "Object7": [
      "Chain of Survival: Immediate identification/activation of ERS, Immediate CPR (chest compressions), Quick defibrillation, Effective ALS, Integrated post-cardiac arrest care.",
      "Cardiopulmonary Resuscitation (CPR): Artificial ventilation/perfusion. BLS (maintain circulation). CAB sequence (Circulation, Airway, Breathing).",
      "Circulation: Chest compressions (at least 5cm in adults, 100-120/min, 30:2 ratio (single rescuer)). Assess adequacy by BP, COP. Complications: rib/sternum fractures, pneumothorax, hemothorax, lacerations.",
      "Airway: Clear airway. Head tilt/chin lift, Jaw thrust. Finger sweep (unconscious, not conscious/convulsing). Heimlich maneuver (conscious).",
      "Breathing: Rescue breathing (mouth-to-mouth/nose). Volume produces visible chest rise. Assessment of restoration: pupil contraction, improved skin color, chest movement, swallowing, struggling.",
      "Advanced life support (ALS): Restore normal cardiac rhythm by defibrillation. Correct reversible causes. Continuous chest compressions (100/min), ventilation (8-10 breaths/min).",
      "Advanced techniques for airway patency: Face mask, oropharyngeal/nasopharyngeal airway, laryngeal mask airway, endotracheal intubation, combitube, cricothyrotomy, tracheostomy.",
      "Advanced breathing: 100% O2, tidal volume 800-1200 mL, 10-12 breaths/min (Ambu bag, Mechanical ventilator).",
      "Advanced circulation: IV access, cardiac monitor/defibrillator, assess rhythm, defibrillation, drugs.",
      "Rhythm in cardiac arrest: Shockable (VT/VF), Nonshockable (asystole, PEA). Rhythm checks after 2 min CPR.",
      "Defibrillation (shockable rhythms): 150-360 J (biphasic), 360 J (monophasic). Immediately resume CPR for 2 min. Repeat shock/CPR cycle.",
      "Drugs (VF/VT): Adrenaline (1 mg IV every 4 min, after 3rd shock). Amiodarone (300 mg IV bolus after 3rd shock, or lidocaine). Vasopressin (40 IU single dose once). Magnesium (VF/VT with hypomagnesemia, Torsade de pointes, Digoxin toxicity). Calcium (PEA with hyperkalemia, hypocalcemia, hypermagnesemia, CCB overdose). Thrombolytics (proven/suspected PE). Sodium bicarbonate (severe metabolic acidosis pH <7.1, life-threatening hyperkalemia, tricyclic antidepressant overdose). Atropine (sinus bradycardia/AV block with hemodynamic instability).",
      "Drugs (PEA/Asystole): Start CPR. 1 mg adrenaline IV immediately, re-check rhythm after 2 min CPR. Continue CPR, adrenaline every 3-5 min. No atropine.",
      "IV fluids: Rapid infusion if hypovolemia. Normal saline/Ringer's solution. Avoid dextrose unless hypoglycemia.",
      "Postresuscitation care: Maintain airway/breathing, cardiac monitoring, vasoactive medications/IV fluids, avoid hyperthermia/hyperglycemia, treat precipitating cause."
    ],
    "Object8": [
      "Death (if not promptly reversed).",
      "Complications of chest compressions: Rib/sternum fractures, pneumothorax, hemothorax, lung contusions, liver lacerations, fat emboli."
    ]
  },
  {
    "Object1": "Syncope",
    "Object2": [
      "Neurocardiogenic syncope ('vasovagal or vasodepressor syncope')",
      "Orthostatic hypotension",
      "Neurovascular syncope",
      "Cardiac syncope"
    ],
    "Object3": [
      "Transient loss of consciousness due to inadequate cerebral blood flow.",
      "Cardiac causes: Arrhythmias (VT, PSVT, long QT syndrome, Brugada syndrome, bradycardia - Mobitz type II/3rd degree heart block), Structural cardiac/cardiopulmonary disease (AS, MS, PS, HOCM, atrial myxoma, acute aortic dissection, pericardial disease/tamponade, PE/PAH, acute MI/ischemia).",
      "Neurocardiogenic: Classical vasovagal, situational, carotid sinus, glossopharyngeal neuralgia, micturition syncope.",
      "Orthostatic hypotension: Autonomic failure (primary - pure autonomic failure, multiple system atrophy, Parkinson's with autonomic failure; secondary - diabetic neuropathy).",
      "Neurovascular syncope: Vascular steal syndromes.",
      "Nonsyncopal attacks (confused with syncope): Seizures, metabolic/toxic abnormalities (hypoglycemia, encephalitis), neurologic syncope (subarachnoid hemorrhage, TIA, complex migraine), psychiatric syncope, drug-induced loss of consciousness."
    ],
    "Object4": [
      "Transient loss of consciousness with loss of postural tone, spontaneous return to baseline neurologic function.",
      "Presyncope: Lightheadedness."
    ],
    "Object5": [
      "Loss of consciousness."
    ],
    "Object6": [
      "Electrocardiogram (ECG): Prolonged intervals (QRS, QTc), severe bradycardia, pre-excitation, evidence of MI. Suggests arrhythmia-induced syncope.",
      "Holter monitoring.",
      "Echocardiography.",
      "Neurological: CT brain and MRI, EEG.",
      "Laboratory evaluation: FBC, hematocrit, RBS, electrolytes, pregnancy test.",
      "Head up tilt table test."
    ],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": [
      "Cardiac syncope has high incidence (~24%) of subsequent cardiac arrest.",
      "Physical injury due to falls."
    ]
  },
  {
    "Object1": "Cor Pulmonale",
    "Object2": [
      "Acute cor pulmonale",
      "Chronic cor pulmonale (hypoxic subtype, vascular obliterans subtype)"
    ],
    "Object3": [
      "Right ventricular hypertrophy and dilation with or without failure secondary to diseases directly affecting lung parenchyma, pulmonary vasculature, chest bellows or central (excludes pulmonary alterations from left-sided heart disease).",
      "Acute: Sudden increase in RV pressure (acute massive pulmonary embolism >60% obstruction of circulation, acute respiratory distress syndrome).",
      "Chronic: Hypoxic subtype (COPD - most common); Obliterans subtype (Pulmonary thromboembolic disease - most common).",
      "Diseases of lung: COPD, pulmonary tuberculosis, ILD, high altitude, cystic fibrosis, pleural fibrosis.",
      "Diseases of pulmonary circulation: Recurrent pulmonary thromboembolism, primary pulmonary hypertension, collagen vascular diseases, chronic liver disease.",
      "Diseases of thorax: Kyphoscoliosis, neuromuscular diseases, sleep apnea syndrome, obesity.",
      "Diseases of respiratory control: Brainstem lesions, central sleep apnea-Ondine's curse."
    ],
    "Object4": [
      "Minimal except in advanced stage.",
      "Similar to right-side heart failure: Fatigability, dyspnea on exertion, syncope, chest pain, palpitation, abdominal distension, edema of lower extremity, exercise-induced peripheral cyanosis, excessive daytime somnolence."
    ],
    "Object5": [
      "Pedal edema.",
      "Accentuated 'a' wave of JVP, prominent jugular 'v' wave (TR).",
      "Palpable left parasternal lift.",
      "Accentuated pulmonic component of S2, right sided S3, ejection systolic murmur in pulmonary area. Pansystolic murmur of TR or early-diastolic murmur of pulmonary regurgitation.",
      "Large pulsatile liver.",
      "Overt right side heart failure: Increasing peripheral edema, raised JVP, positive hepatojugular reflux, tender hepatomegaly, enlargement of heart, right ventricular S3 and gallop rhythm, right sided S4."
    ],
    "Object6": [
      "Chest X-ray: Enlarged pulmonary artery/RV, distended azygous/central vein. Westermark sign, Hampton's hump (PE). Increased AP diameter, flattened diaphragm, honeycombing, hyperlucency (COPD).",
      "Electrocardiogram: Right axis deviation, P pulmonale, RBBB, right precordial T-wave inversions, delayed intrinsicoid deflection of right precordial leads, RVH, S1Q3T3 pattern, QR pattern in V1/V3R.",
      "Arterial blood gas analysis: Hypoxia, hypercapnia.",
      "BNP: Biomarker for pulmonary hypertension in COPD.",
      "Echocardiography: Hypertrophy/dilatation of RV. Right heart catheterization.",
      "Others: CECT/HRCT chest, nuclear scan (PE), right heart catheterization."
    ],
    "Object7": [
      "General measures:",
      "Nonpharmacological: Oxygen therapy, phlebotomy, NIPPV.",
      "Pharmacological: Diuretics, anticoagulation, vasodilators, treatment to decrease pulmonary hypertension (refer page 524).",
      "Treatment of underlying disease.",
      "Oxygen therapy (most important for reducing PAH, start if PaO2 ≤55 mmHg. Retards progression, reduces polycythemia, PA pressures, dyspnea/hypoxemia during sleep, nocturnal arrhythmias).",
      "Treatment of right heart failure: Restriction of salt intake. Digoxin (role not clear). Diuretics.",
      "Chronic anticoagulation with Warfarin (for thrombo-occlusive pulmonary disease).",
      "Surgical: Pulmonary embolectomy (if PE not resolved). Heart lung transplantation (primary PH)."
    ],
    "Object8": [
      "Right ventricular hypertrophy and dilation/failure.",
      "Pulmonary hypertension.",
      "Peripheral edema.",
      "Right-sided heart failure (overt)."
    ]
  },
  {
    "Object1": "Aortic Aneurysms",
    "Object2": [
      "Fusiform aneurysm",
      "Saccular aneurysm",
      "Cylindrical aneurysm",
      "Arterial dissection",
      "Thoracic part of aorta",
      "Ascending aorta",
      "Arch of aorta",
      "Descending aorta",
      "Abdominal aorta (commonest site is infrarenal portion)"
    ],
    "Object3": [
      "Abnormal permanent focal dilatation of a blood vessel/artery to 1.5 times its normal diameter.",
      "Atherosclerosis (commonest cause).",
      "Cystic medial necrosis.",
      "Syphilis (aneurysm of ascending aorta).",
      "Rheumatic aortitis.",
      "Trauma."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Aortic Dissection",
    "Object2": [
      "Stanford anatomical classification (Type A: ascending and/or descending aorta; Type B: limited to descending aorta)",
      "DeBakey classification (Type I: ascending to descending; Type II: limited to ascending/arch; Type III: descending only)",
      "Acute (<2 weeks)",
      "Subacute (2-8 weeks)",
      "Chronic (>8 weeks)"
    ],
    "Object3": [
      "Blood from aortic lumen enters aortic wall through a breach, splitting media into two layers, creating 'false lumen'.",
      "Predisposing factors: Hypertension (most common, 70-80%). Connective tissue disorders (Marfan's syndrome, Ehlers-Danlos syndrome, Turner's syndrome, osteogenesis imperfecta). Pregnancy. Cocaine abuse. Inflammatory vasculitides (giant cell arteritis, Takayasu arteritis). Iatrogenic (cardiac surgery, coronary angiography, intra-aortic balloon pump). Trauma. Congenital bicuspid aortic valve."
    ],
    "Object4": [
      "Sudden (abrupt) onset of severe, tearing, migratory pain (anterior chest, radiating to back between scapulae, moving downward). May be misdiagnosed as MI pain. Anterior chest pain (ascending aorta), intrascapular pain (descending aorta).",
      "Collapse, syncope, dyspnea, weakness, hypertension or hypotension."
    ],
    "Object5": [
      "Asymmetry of pulses and blood pressure (brachial, carotid or femoral pulses and BP).",
      "Signs of aortic regurgitation.",
      "Signs of occlusion of branches of aorta (MI, stroke, paraplegia, mesenteric infarction, renal failure, ischemia of limb).",
      "Pulmonary edema, hemopericardium, cardiac tamponade."
    ],
    "Object6": [
      "Chest X-ray: Widening/broadening of superior mediastinum, distortion of aortic 'knuckle' (absent in 10%). Small left-sided pleural effusion.",
      "Electrocardiogram: LVH (hypertension). Excludes ischemic changes or MI (rarely acute MI evident).",
      "Doppler echocardiography: Aortic regurgitation, dilated aortic root.",
      "Transesophageal echocardiography (TEE): Images of ascending aorta (98-99% sensitivity, 94-95% specificity).",
      "CT and MRI angiography: Highly (98-100%) specific and sensitive. MRI is gold standard."
    ],
    "Object7": [
      "Urgent treatment needed (high mortality if untreated).",
      "Goal: Reduce systolic BP (100-120 mmHg) and diminution of dp/dt (force of LV ejection) via beta blocker. Halt dissection progression.",
      "Initial medical management: Control pain, antihypertensive treatment (IV beta blockers - labetalol, metoprolol; vasodilators - GTN; IV calcium channel blockers - verapamil, diltiazem if BB contra; sodium nitroprusside if other drugs fail).",
      "Type A dissections: Emergency surgery to replace ascending aorta (arch replacement) (high mortality with medical management).",
      "Type B dissections: Initially medical treatment (unless actual/impending external rupture, vital organ/limb ischemia). High morbidity/mortality with surgery.",
      "Surgical therapy: Percutaneous or minimal access endoluminal repair (fenestrating intimal flap, endovascular stent graft)."
    ],
    "Object8": [
      "Mortality rate if untreated is 1-5%/hour and 90% within 3 months.",
      "Acute aortic regurgitation, major branch vessel obstruction, aortic rupture (into pericardium, left pleural cavity, mediastinum).",
      "MI, stroke, paraplegia, mesenteric infarction, renal failure, limb ischemia (occlusion of branches of aorta).",
      "Hemopericardium, cardiac tamponade."
    ]
  },
  {
    "Object1": "Marfan's Syndrome",
    "Object2": "Autosomal dominant disorder of connective tissue",
    "Object3": [
      "Mutations in the fibrillin gene on chromosome 15"
    ],
    "Object4": [],
    "Object5": [
      "Cardiovascular: Weakening of media of aortic root (dilatation, regurgitation, dissection). Mitral valve prolapse, mitral regurgitation.",
      "Skeletal: Tall stature, arachnodactyly, wrist (Fig. 7.55A) and/thumb sign (Fig. 7.55B), joint hypermobility, scoliosis, chest deformity, high arched palate (Fig. 7.55C).",
      "Eyes: Dislocation of lens (superior and temporal)."
    ],
    "Object6": [
      "Chest X-ray (Fig. 7.55D), echocardiography, MRI or CT (detect aortic dilatation)."
    ],
    "Object7": [
      "β-blockers (reduce rate of aortic dilatation and risk of rupture).",
      "Elective replacement of ascending aorta (for progressive aortic dilatation)."
    ],
    "Object8": [
      "Aortic dilatation, regurgitation, dissection.",
      "Mitral valve prolapse, mitral regurgitation."
    ]
  },
  {
    "Object1": "Raynaud's Phenomenon and Raynaud's Disease",
    "Object2": [
      "Raynaud's phenomenon (secondary to underlying disease)",
      "Raynaud's disease (primary or idiopathic Raynaud's phenomenon)"
    ],
    "Object3": [
      "Chronic episodic attacks of digital ischemia due to spasm of digital arteries (precipitated by cold or emotional stress, relieved by heat).",
      "Secondary Raynaud's (Table 7.100): Connective tissue disease/vasculitis (systemic sclerosis, SLE, RA, Sjögren's, MCTD), Obstructive arterial disease (atherosclerosis, TAO/Buerger's), Trauma or vibration (reflex sympathetic dystrophy, vibration exposure, AV fistula), Drugs/toxins (ergot, β-blockers, methysergide), Hematological disease (cryoglobulinemia, cold agglutinins, paroxysmal hemoglobinuria, Waldenström's macroglobulinemia), Neurological disease (thoracic outlet syndrome, carpal tunnel syndrome), Miscellaneous (paraneoplastic syndrome, chronic renal failure, primary pulmonary hypertension)."
    ],
    "Object4": [
      "Pain, erythema, bullae, skin erosions, hirsutism, hyperpigmentation (cutaneous).",
      "Burning sensations in exposed skin (if lipophilic protoporphyrins accumulate)."
    ],
    "Object5": [
      "Sequential color changes: White (pallor from vasospasm) > blue (cyanosis from deoxygenated blood) > red (rubor from reactive hyperemia). Pallor essential for diagnosis.",
      "Usually involves hands, less common in feet. Rarely nose, ear lobe, tongue.",
      "Primary Raynaud's: Bilateral, symmetrical, involves several digits.",
      "Secondary Raynaud's: Involves one/few digits, asymmetry common. Severe cases: Telangiectasias of nail fold, thinning/ridging of nail, atrophy/sclerosis of fingers (sclerodactyly). Skin necrosis (rare in primary, common in secondary, may destroy digits)."
    ],
    "Object6": [
      "Blood tests: CBC, ESR, urinalysis. ANA, specific antigens (Sm, topoisomerase, centromere, DsDNA) to rule out SLE/scleroderma.",
      "Chest X-ray: Cervical rib, evidence of ILD.",
      "Nail fold capillary microscopy: Differentiates primary from secondary (enlarged/deformed capillary loops, avascular areas in CTD)."
    ],
    "Object7": [
      "General measures: Lifestyle modifications (minimize cold exposure). Patient education (recognize/terminate attacks by warming, applying heat). Cessation of smoking. Stress modification, social support. Treatment of underlying cause.",
      "Drugs: Calcium channel blockers (nifedipine, amlodipine), sildenafil, prostaglandin analogues (ilaprost), bosentan, losartan, topical glyceryl trinitrate.",
      "Sympathectomy: For refractory, disabling attacks or acutely ischemic digit unresponsive to other measures."
    ],
    "Object8": [
      "Skin necrosis (severe secondary Raynaud's), destruction of digits."
    ]
  },
  {
    "Object1": "Circulatory Failure: Shock",
    "Object2": [
      "Cardiogenic shock",
      "Obstructive shock",
      "Hypovolemic shock",
      "Distributive shock (Septic, Anaphylactic, Neurogenic)",
      "Preshock (compensatory stage)",
      "Shock (progressive stage)",
      "End organ dysfunction (refractory stage)"
    ],
    "Object3": [
      "Impaired cardiac pump, circulatory system, and/or volume leading to compromised blood flow to tissues.",
      "Cardiogenic: MI, arrhythmia, aortic stenosis, mitral regurgitation, myocarditis, papillary muscle rupture, RV infarction with excessive diuretic therapy. (Heart fails to pump blood out).",
      "Obstructive: Pericardial effusion, tension pneumothorax, tamponade, acute massive pulmonary embolism. (Heart pumps well, but outflow obstructed).",
      "Hypovolemic: Hemorrhage, fluid loss (vomiting, diarrhea, burns). (Heart pumps well, not enough blood volume).",
      "Distributive: Septic, anaphylactic, neurogenic shock. Pancreatitis, burns, multi-trauma (via inflammatory response activation). (Heart pumps well, but peripheral vasodilation).",
      "Neurogenic shock: Loss of sympathetic control of resistance vessels (massive dilatation of arterioles/venules). Most common cause: spinal cord injury above T6."
    ],
    "Object4": [
      "Preshock: MAP = reduced (compensated). Heart rate increased. Extremities cool (vasoconstriction).",
      "Shock: MAP reduced. Tachycardia, dyspnea, restlessness.",
      "End organ dysfunction: Decreased renal function, liver failure, DIC, death.",
      "Hypovolemic shock: Increased heart rate, low JVP, low BP, cold skin, slow capillary refill.",
      "Distributive shock: Increased heart rate (normal in neurogenic), low JVP (low), low BP, warm skin (cold in severe), slow capillary refill.",
      "Cardiogenic shock: Increased/decreased heart rate, high JVP, low BP, cold skin, slow capillary refill.",
      "Obstructive shock: Increased heart rate, high JVP, low BP, cold skin, slow capillary refill."
    ],
    "Object5": [
      "Signs of organ failure (renal, hepatic, DIC, gangrene) (progressive stage).",
      "Tachycardia, cold peripheries, oliguria (early hypovolemic).",
      "Warm skin, bounding pulse (early distributive/septic)."
    ],
    "Object6": [
      "Initial assessment: ABCDE (Airway, Breathing, Circulation, Deficit/Disability, Exposure).",
      "Monitor: Oxygen content (Hb, SaO2 on ABG), Cardiac output (HR, SV - preload, contractility, afterload), Blood Pressure."
    ],
    "Object7": [
      "Goal: Treat reversible causes, protect ischemic myocardium, improve tissue perfusion.",
      "Patient Monitoring: Continuous monitoring.",
      "General Measures: Optimize oxygen content (Hemoglobin, SaO2), Optimize cardiac output (Preload - fluid bolus, CVP. Contractility - history of ischemic disease/CCF, ECHO/ECG, systolic pressure. Afterload - ECHO for obstruction, peripheries temp/vascular resistance. Heart rate - pacing/pharmacological intervention). Optimize Blood Pressure (Vasopressors/inotropes (dopamine, dobutamine, noradrenaline, adrenaline, isoproterenol, phenylephrine), vasopressin, milrinone, steroids in septic shock).",
      "Treatment of Underlying Cause:",
      "Hypovolemic Shock: Rapid replacement of blood, colloid, or crystalloid. Identify/treat source of loss.",
      "Cardiogenic Shock: (Box 7.60) IABP, cardiac angiography, revascularization (angioplasty, CABG), fluid/inotropes with PA catheter (RV infarction), corrective surgery (mechanical abnormality).",
      "Extra-cardiac Obstructive Shock: Pericardial tamponade (pericardiocentesis, surgical drainage). Pulmonary embolism (heparin, lung scan, angiography, thrombolytic therapy, embolectomy).",
      "Septic shock: Identify/drain infection source. Antimicrobial agents. ICU monitoring, fluids, vasopressors, inotropic agents.",
      "Neurogenic shock: Hypovolemia (careful fluid replacement for BP, closely observe for fluid overload). Vasopressors. Hypothermia (warming). Treat hypoxia. Ventilatory support. Alpha agonist (dopamine, ephedrine) to augment tone. Atropine for bradycardia (may need pacing)."
    ],
    "Object8": [
      "Multiple Organ Dysfunction Syndrome (MODS)",
      "Ischemic tissue necrosis with organ dysfunction (progressive stage).",
      "Cell death and organ failure (refractory stage).",
      "Thrombosis (Pulmonary embolism)."
    ]
  },
  {
    "Object1": "Pulmonary Embolism (PE) (Pulmonary Thromboembolism-PTE)",
    "Object2": [
      "Acute massive pulmonary embolism",
      "Pulmonary infarction"
    ],
    "Object3": [
      "Embolism occluding pulmonary arterial tree (pulmonary artery or its branches).",
      "Thromboemboli (more than 95% from deep leg veins - popliteal, femoral, iliac veins; also pelvic/abdominal veins, vena cava; rarely right atrium/ventricle).",
      "Nonthrombotic emboli (rare): Septic emboli (endocarditis), tumor emboli, fat (long bone fractures), air, amniotic fluid emboli, foreign material (IV drug use).",
      "Virchow's triad predisposes to thrombus formation: Endothelial injury, altered blood flow, hypercoagulability. (Table 7.106: stasis, endothelial injury, hypercoagulable states, surgery/trauma, malignancy, pregnancy, oral contraceptives, heart failure, stroke, obesity, inflammatory bowel disease, nephrotic syndrome, central venous catheters, drugs, inherited disorders - Factor V Leiden, Protein C/S deficiency, antithrombin III deficiency, prothrombin gene mutation).",
      "Pulmonary infarction: Embolism to smaller pulmonary arteries, in patients with CHF or chronic lung disease."
    ],
    "Object4": [
      "Dyspnea (75-85%), pleuritic chest pain (57-87%), cough (40-53%), hemoptysis, syncope (similar to obstructive lung disease).",
      "Massive PE: Sudden collapse, hypotension, unexplained hypoxia, engorged neck veins, acute right heart failure (acute cor pulmonale).",
      "Pulmonary infarction: Pleuritic chest pain, cough, dyspnea, hemoptysis (if present).",
      "Symptoms and signs are nonspecific."
    ],
    "Object5": [
      "Patient may be normal.",
      "Tachypnea (>16/min in 96%), rales (58%), accentuated S2 (53%), tachycardia (>100/min), fever (>37.8°C), diaphoresis, S3 or S4 gallop.",
      "Other signs: Lower extremity edema, cardiac murmur, cyanosis, clinical evidence of DVT.",
      "Massive PE: Engorged neck veins, acute right heart failure (acute cor pulmonale).",
      "Wells Scoring System (Box 7.61): Clinically suspected DVT, alternative diagnosis less likely, tachycardia, immobilization/surgery, history of DVT/PE, hemoptysis, malignancy. Score >4 (PE likely), ≤4 (PE unlikely)."
    ],
    "Object6": [
      "Blood tests: Pulmonary infarction (polymorphonuclear leukocytosis, raised ESR, raised LDH). D-dimer assay (best screening test for PE/DVT, >95% sensitive for PE, >80% for DVT, not specific). Normal D-dimer rules out PE/DVT in low-moderate risk patients. Elevated D-dimer in other conditions.",
      "Electrocardiogram (ECG): Often normal. Excludes MI/pericarditis. May show sinus tachycardia, acute pulmonary hypertension/RV strain. S1 Q3T3 sign.",
      "Arterial blood gases: Hypoxemia (reduced PaO2), normal/hypocapnia (low PaCO2), increased alveolar-arterial oxygen gradient (type I respiratory failure).",
      "Noninvasive Imaging: Ultrasound scanning (for clots in deep veins, pelvic/iliofemoral veins). Venous ultrasonography (Color Doppler ultrasound of leg veins, investigation of choice for DVT). Chest X-ray (Pulmonary embolism: Normal/near normal, increased radiolucency, small infiltrative shadows, elevated hemidiaphragm, difference in PA diameter, abrupt cut-off, enlarged RPA - Palla's sign. Pulmonary infarction: Normal early, parenchymal/peripheral/wedge-shaped density - Hampton's hump, translucent underperfused distal zone - Westmark's sign, abrupt cutoff, blunting of costophrenic angle). Chest CT with IV contrast (main imaging test). Lung scanning (second line, perfusion scan defect suggestive, normal rules out). Magnetic resonance (MR) (detects large proximal PE, not reliable for smaller PE). Echocardiography (not for acute PE diagnosis, useful for mimics). Radionuclide ventilation/perfusion scanning (V/Q scan) (good diagnostic tool, less radiation).",
      "Invasive: Pulmonary angiography (replaced by CT with contrast, for interventional procedures, shows filling defect, abrupt blockage, segmental oligemia/avascularity, prolonged arterial phase, tortuous peripheral vessels)."
    ],
    "Object7": [
      "Supportive measures: Prompt recognition/treatment. Bed rest (acute stage). Oxygen for hypoxemic patients (maintain SaO2 >90%). IV saline/noradrenaline for massive embolism (maintain venous pressure). Avoid diuretics/vasodilators. Analgesics (opiates for pain). External cardiac massage (may dislodge/break up embolus).",
      "Anticoagulation: Unfractionated heparin (initial IV bolus 5,000-10,000 units, then continuous IV/intermittent SC/IV maintenance, monitored by aPTT 1.5-2x control). Warfarin (5 mg/day started on day 1, INR 2.0-3.0). Novel oral anticoagulants (rivaroxaban, apixaban). Direct thrombin inhibitors (argatroban, ximelagatran). Indirect factor Xa inhibitors (fondaparinux, idraparinux). Anticoagulation maintained for ≥6 months.",
      "Thrombolytic therapy: Indications: Hemodynamic instability, hypoxia on 100% oxygen, RV dysfunction by echo. Approved thrombolytics: Streptokinase, Urokinase, Recombinant tissue-plasminogen activator (tPA), Tenecteplase, Reteplase. Contraindications: Active internal bleeding, history of cerebrovascular hemorrhage, recent stroke, uncontrolled HTN, aortic dissection, active bleeding. Complications: hemorrhage, allergic reactions, hypotension.",
      "Surgical therapy: Surgical pulmonary embolectomy, inferior vena caval filters (prevent recurrent emboli), venous interruption.",
      "Prophylaxis (Box 7.62): For high-risk patients. Nonpharmacological (Mechanical VTE - antiembolism stockings, foot impulse devices, physiotherapy, intermittent pneumatic compression devices). Pharmacological (Fondaparinux, LMWH, unfractionated heparin before operation/admission, continued until ambulatory. Warfarin for prolonged risk factors)."
    ],
    "Object8": [
      "Pulmonary infarction (develops in <10% of cases, more common with CHF/chronic lung disease).",
      "Pulmonary hemorrhage.",
      "Pulmonary hypertension (recurrent PE).",
      "Right ventricular failure (chronic PAH).",
      "Chronic cor pulmonale.",
      "Death (massive PE, second most common cause of unexpected death)."
    ]
  },
  {
    "Object1": "Venous Thrombosis (Deep Venous Thrombosis - DVT)",
    "Object2": [
      "Deep venous thrombosis (DVT) (lower extremity, popliteal, femoral, iliac veins)",
      "Superficial venous thrombi (varicosities involving saphenous veins)"
    ],
    "Object3": [
      "Formation of thrombus in venous circulation (veins or right side of heart).",
      "Virchow's triad (endothelial injury, altered blood flow, hypercoagulability). (Refer Table 7.106 for specific risk factors).",
      "DVT: Associated with venous stasis and hypercoagulable states. Lower extremity DVTs found with venous stasis/hypercoagulability. Right atrium/ventricle (AF, CHF).",
      "Superficial venous thrombi: Develop in varicosities involving saphenous veins."
    ],
    "Object4": [
      "Often asymptomatic (50% of DVT).",
      "Pain in calf or tenderness, or both. Swelling (ankle edema), redness, increased temperature (affected calf is warmer), dilatation or engorgement of superficial veins (DVT).",
      "Thrombosis in iliofemoral region: Severe pain, swelling of thigh and/or ankle edema.",
      "Complete occlusion of large vein: Cyanosis of limb, severe edema."
    ],
    "Object5": [
      "Unilateral (one leg) or bilateral DVT. Thrombus may extend proximally into IVC.",
      "Homan's sign (pain in posterior calf on forced dorsiflexion of foot with extended knee - not diagnostic, should not be done).",
      "Moses test (tenderness over calf muscles on squeezing - not done).",
      "Cyanosis of limb, severe edema (complete occlusion of large vein)."
    ],
    "Object6": [
      "Wells clinical prediction guide for DVT (Table 7.107): Incorporates risk factors, clinical signs, alternative diagnoses. Quantifies pretest probability (high, moderate, low). Score >3: high probability; 1-2: moderate; 0: low.",
      "D-Dimer: Raised (>500 ng/mL) but not specific. Negative D-dimer rules out DVT in low-to-moderate risk. Positive D-dimer (moderate-to-high risk) needs diagnostic investigation (Doppler ultrasonography).",
      "B mode venous compression, ultrasonography or Doppler (duplex) ultrasonography: Compression ultrasound is imaging of choice (99.5% sensitivity for proximal DVT). Failure to compress vascular lumen is sign of thrombosis.",
      "Contrast venography (phlebography): Reliably detects below knee thromboses (rarely used).",
      "Impedance plethysmography (IPG): Detects above knee thrombi.",
      "Radiofibrinogen scanning: Accurate in calf vein and lower thigh thrombi."
    ],
    "Object7": [
      "Bed rest until fully anticoagulated.",
      "Legs: Elevation by 15° and physiotherapy.",
      "Anticoagulation: Initial heparin, then oral warfarin (INR 2.0-3.0). Duration at least 6 months.",
      "Prophylaxis: For DVT and pulmonary embolism in high-risk patients (Box 7.62). Nonpharmacological (Mechanical VTE - antiembolism stockings, foot impulse devices, physiotherapy, intermittent pneumatic compression devices). Pharmacological (Fondaparinux, LMWH, unfractionated heparin before operation/admission, continued until ambulatory. Warfarin for prolonged risk factors)."
    ],
    "Object8": [
      "Pulmonary embolism.",
      "Post-thrombotic syndrome (edema, skin pigmentation, venous eczema/dermatitis, ulceration around medial malleolus, venous claudication, nocturnal cramping, lifelong pain).",
      "Venous gangrene (due to complete obstruction of large veins)."
    ]
  },
  {
    "Object1": "Disorders of Blood Lipids and Lipoproteins",
    "Object2": [
      "Hyperlipidemia (Primary, Secondary)",
      "Lipodystrophy (Total - congenital/acquired; Partial - Kobberling-Dunnigan syndrome/progressive partial/centrifugal/semicircular/annular atrophic panniculitis/lipoatrophia annularis; Localized; HIV associated)"
    ],
    "Object3": [
      "Hyperlipidemia: Abnormal lipid profile (raised total cholesterol, LDL or TG, or lower HDL).",
      "Primary hyperlipidemia: Genetic disorder of lipid metabolism (familial hypercholesterolemia - impaired clearance of LDL due to absence of LDL receptors).",
      "Secondary hyperlipidemia (Table 7.108): Diabetes mellitus, Hypothyroidism, Nephrotic syndrome, Obstructive liver disease, Drugs (anabolic steroids, progestins, beta-adrenergic blockers, thiazides, bile acid binding resins, estrogens, ticlopidine), Alcoholism, Obesity, Renal insufficiency, Cigarette smoking, Hypertriglyceridemia, Menopause, Uremia.",
      "Lipodystrophy: Changes in body fat distribution. Lipoatrophy (partial/complete decrease of fat).",
      "HIV associated lipodystrophy: Effective ART with reverse transcriptase inhibitors and protease inhibitors. Fat redistribution from face, buccal, buttocks, limbs to neck, upper back, intra-abdominal areas."
    ],
    "Object4": [
      "Familial hypercholesterolemia: Xanthomas.",
      "Hypertriglyceridemia: Pancreatitis.",
      "Lipodystrophy: Centrifugal (spreading loss of abdominal fat). Semicircular (asymptomatic depressions of anterolateral thigh). Annular atrophic panniculitis (band of atrophy around ankles). Lipoatrophia annularis (bracelet-like constrictions, arthralgias, pain). HIV lipodystrophy (peripheral lipodystrophy, central fat accumulation, lipomatosis)."
    ],
    "Object5": [
      "Hyperlipidemia: Xanthelasma, tendon xanthoma.",
      "Lipodystrophy: Visible changes in fat distribution."
    ],
    "Object6": [
      "Lipid profile (total cholesterol, LDL, TG, HDL).",
      "Coronary heart disease (CHD) risk assessment (Framingham Risk Score, emerging risk factors - apolipoprotein B, lipoprotein (a), C-reactive protein, hyperhomocysteinemia, small dense LDL particles).",
      "LDL cholesterol goals in different categories (Table 7.109).",
      "Genetic testing (familial hypercholesterolemia)."
    ],
    "Object7": [
      "Hyperlipidemia:",
      "Therapeutic lifestyle changes (healthy eating, regular exercise, weight reduction). Increase soluble fiber. Limit salt/alcohol. Avoid simple carbohydrates. Aerobic exercise.",
      "Drug classes (Table 7.110): Bile acid binding resins, Nicotinic acid, Fibric acid analogs, HMG-CoA reductase inhibitors (Statins).",
      "Statins: First-line. Reduce LDL 20-60%. Side effects: myositis, myalgia, elevated LFTs.",
      "Ezetimibe: Inhibits cholesterol absorption from diet.",
      "Omega-3 fatty acids: Reduce TG levels.",
      "Newer agents: Torcetrapib (CETP inhibitor).",
      "Lipodystrophy: Treatment of HIV-associated lipodystrophy (manage ART, cosmetic surgery)."
    ],
    "Object8": [
      "Hyperlipidemia: Atherosclerosis (major risk factor for CAD).",
      "Hypertriglyceridemia: Pancreatitis.",
      "Lipoatrophia annularis: Arthralgias and pain.",
      "HIV associated lipodystrophy."
    ]
  },
  {
    "Object1": "Straight Back Syndrome (SBS)",
    "Object2": "Loss of normal curvature upper thoracic spinal",
    "Object3": [
      "Loss of normal curvature upper thoracic spinal which reduces anteroposterior diameter of chest."
    ],
    "Object4": [
      "Chest pain",
      "Tracheal compression",
      "Mitral valve prolapse (MVP)"
    ],
    "Object5": [
      "Displacement of heart towards left, resulting in cardiac murmurs."
    ],
    "Object6": [
      "Chest X-ray (lateral): Significant reduction of distance from middle of anterior border T8 to vertical line connecting T4 and T12 (<1.2 cm is diagnostic).",
      "ECG: Often shows right bundle branch block."
    ],
    "Object7": [
      "Symptomatic management for chest pain, MVP."
    ],
    "Object8": [
      "Cardiac murmurs",
      "MVP"
    ]
  },
  {
    "Object1": "Cardiac Tumors",
    "Object2": [
      "Myxoma (most common primary cardiac tumor in adults)",
      "Rhabdomyomas (commonest cardiac tumor in children)"
    ],
    "Object3": [
      "Myxoma: Most are sporadic, some familial (autosomal dominant - 10%). Solitary, in left atrium from interatrial septum near fossa ovalis. Most common in females.",
      "Rhabdomyomas: Commonest cardiac tumor in children."
    ],
    "Object4": [
      "Myxoma: Symptoms mimic mitral valve disease. Fever, weight loss, cachexia, malaise, arthralgia, rash, clubbing, Raynaud's phenomenon. Peripheral or pulmonary embolization."
    ],
    "Object5": [
      "Myxoma: 'Tumor plop' (low-pitched early/mid diastolic sound).",
      "Rhabdomyomas: Signs of heart failure or arrhythmia (depend on location)."
    ],
    "Object6": [
      "Myxoma: Anemia, polycythemia, elevated ESR, thrombocytopenia or thrombocytosis. 2-D echocardiography (screening). CT and MRI (investigations of choice)."
    ],
    "Object7": [
      "Myxoma: Surgical excision using cardiopulmonary bypass."
    ],
    "Object8": [
      "Myxoma: Peripheral or pulmonary embolization. Arrhythmia, heart failure."
    ]
  },
  {
    "Object1": "Digoxin Toxicity",
    "Object2": "Not specified",
    "Object3": [
      "Digoxin (purified glycoside from Digitalis lanata, cardiac inotropic property)",
      "High toxicity, low margin of safety.",
      "Serum digoxin concentration (SDC) >2.0 ng/mL helpful.",
      "Contributing factors: Hypokalemia, hypomagnesemia, renal impairment, drug interactions (amiodarone, verapamil, quinidine, macrolides, antifungals)."
    ],
    "Object4": [
      "Extracardiac (nonspecific, common): Gastrointestinal (nausea/vomiting, anorexia, abdominal pain, diarrhea - 60-80%), Malaise (30-40%), lethargy, fatigue, Neurological (20-30%): Dizziness, confusion, headache, visual changes (flashing lights, halos, color disturbances, green-yellow spectrum, blurred vision)."
    ],
    "Object5": [
      "Cardiac (more specific, less common): Almost any permutations/combinations of heart block (partial to complete), brady and tachydysrhythmias.",
      "Classical: Paroxysmal atrial tachycardia, ventricular bigeminy, bidirectional ventricular tachycardia, nodal and ventricular extra systoles.",
      "ECG changes: Inverse check mark with proximal ST segment depressed, T wave not rising above baseline (inverted T), shortened QTc."
    ],
    "Object6": [
      "Blood test: Urea, electrolytes and plasma digoxin concentration."
    ],
    "Object7": [
      "Stop digoxin.",
      "Correction of hypokalemia: IV potassium (≤20 mmol/h).",
      "Heart blocks: Atropine, temporary cardiac pacing.",
      "Malignant ventricular arrhythmias: Phenytoin (100 mg IV, repeated), ultrashort acting beta blockers (esmolol). Avoid cardioversion (risk of asystole).",
      "Digoxin-specific antibody fragments (Digibind): Most effective (for serious toxicity, malignant cardiac dysrhythmias)."
    ],
    "Object8": [
      "Heart block, brady- and tachy-dysrhythmias (potentially fatal).",
      "Asystole (with rapid potassium infusion or cardioversion)."
    ]
  },
  {
    "Object1": "Valsalva Maneuver",
    "Object2": "Forceful attempted exhalation against a closed glottis",
    "Object3": [],
    "Object4": [
      "Headache at back of head (Chiari malformation)."
    ],
    "Object5": [
      "Physiological effects on blood pressure and heart rate (Fig. 7.58, Table 7.112).",
      "Phase 1 (onset of blowing): Increased BP, decreased HR, increased parasympathetic activity, decreased venous return.",
      "Phase 2 (sustained strain): Decreased venous return, decreased CO, decreased MAP. Activates baroreflex, decreased parasympathetic activity, increased HR, increased sympathetic activity (vasoconstriction), slight BP rise (2b).",
      "Phase 3 (relaxation): Decreased intrathoracic pressure, brief BP drop, venous blood fills heart.",
      "Phase 4 (blood pressure overshoot): Heart ejects blood against increased peripheral resistance, BP rises, activates baroreflex, decreased HR."
    ],
    "Object6": [
      "Used as provocative test for: Neurogenic orthostatic hypotension, Chiari malformation.",
      "Diagnosis of inguinal hernia, prolapse of uterus/bladder/vagina, varicocele, intrinsic sphincter deficiency."
    ],
    "Object7": [
      "Modified Valsalva maneuver (blowing against closed glottis, then lying down face up, raising legs): Used to terminate SVT (19-54% effective).",
      "Müller's maneuver (forced exhalation then attempted forceful inhalation with closed mouth/nose/glottis): Evaluates soft palate/throat wall weakness in OSA."
    ],
    "Object8": [
      "Abnormal BP response (absence of BP rise in phase 4) suggests sympathetic system abnormality.",
      "Abnormal HR response suggests parasympathetic system abnormality."
    ]
  },
  {
    "Object1": "HIV Infection and AIDS",
    "Object2": [
      "HIV-1 (most common, subtypes A-D, F-H, J, K; Group M, O, N, P)",
      "HIV-2 (common in West Africa and India)",
      "Acute retroviral syndrome",
      "Asymptomatic chronic HIV infection",
      "Symptomatic HIV infection/AIDS"
    ],
    "Object3": [
      "Retrovirus human immunodeficiency virus (HIV)",
      "HIV-1 and HIV-2 genetic forms",
      "Spread through exchange of blood or body fluids containing virus or virus-infected cells",
      "Sexual transmission (>75% of cases): Homosexual, heterosexual (major route worldwide); increased risk with STDs (genital ulceration), vaginal/rectal laceration, menstruation, uncircumcised male partner",
      "Parenteral transmission: Intravenous drug abusers (sharing needles/syringes), hemophiliacs (before 1985), transfusion of blood/blood components (before screening), splash of body fluids on mucosa, organs from HIV-infected donors, accidental needle-stick/nonintact skin exposure in healthcare workers",
      "Perinatal transmission: In utero (transplacental), perinatal/peripartum (during delivery), after birth (breastfeeding)",
      "High viral load is a high-risk factor for all modes of transmission"
    ],
    "Object4": [
      "Acute retroviral syndrome (2-3 weeks post-infection): Sore throat, mucosal ulcers, arthralgia, myalgias, fever, weight loss, lethargy, lymphadenopathy, fatigue, transient faint pink maculopapular rash, diarrhea, vomiting, neurological symptoms (myelopathy, neuropathy, headache, photophobia)",
      "Middle Chronic Phase (Clinical Latency): Minimal/no symptoms. Minor opportunistic infections (oral candidiasis, vaginal candidiasis, herpes zoster, mycobacterial tuberculosis)",
      "Final Crisis Phase/AIDS: Fever, weight loss, diarrhea, generalized lymphadenopathy, multiple opportunistic infections, neurologic disease, secondary neoplasms"
    ],
    "Object5": [
      "CD4 T-cell depletion",
      "Inversion of CD4+/CD8+ ratio (normal 2:1, in AIDS ≤0.5)",
      "Persistent generalized lymphadenopathy (PGL) (>1 cm at ≥2 extrainguinal sites for >3 months, symmetrical, firm, mobile, non-tender nodes)",
      "Oral candidiasis (thrush)",
      "Oral hairy leukoplakia",
      "Papular pruritic eruptions",
      "Seborrheic dermatitis",
      "Fungal nail infections",
      "Kaposi's sarcoma (vascular neoplasm, erythematous/violaceous macules, plaques or nodules)",
      "Neurological signs (confusion, visual disturbances, headache, seizures, ataxia, focal deficits, altered consciousness, papilledema, cranial nerve palsies)",
      "Ocular signs (retinal hemorrhages, exudates, vitritis, retinitis, corneal opacification)",
      "Cardiovascular signs (coronary heart disease, dilated cardiomyopathy, pericardial effusions)",
      "Renal signs (proteinuria, enlarged/hyperechoic kidneys in HIVAN)",
      "Hematological signs (anemia, leukopenia, lymphopenia, thrombocytopenia, pancytopenia)"
    ],
    "Object6": [
      "Detection of virus specific antibodies (anti-HIV): ELISA (screening, detects antibodies against viral proteins), Western blot (confirmatory test). IgG antibody to envelope components (most common marker, detectable 3-12 weeks post-infection). IgG antibody to p24 (earliest weeks, lost as disease progresses)",
      "Direct Detection of Viral Material/Infection: p24 antigen capture assay (detectable shortly after infection, disappears by 8-10 weeks), Reverse transcriptase polymerase chain reaction (RT-PCR), DNA-PCR (viral load, HIV-RNA), Isolation of virus in culture (research tool)",
      "Hematological abnormalities: Complete blood count (normochromic, normocytic anemia, lymphopenia, leucopenia, thrombocytopenia, decreased CD4+ T-cells)",
      "CD4 cell count and CD4+ T-cell percentage (for staging)",
      "Chest X-ray (for pulmonary complications, e.g., bilateral interstitial infiltrate in PJP)",
      "High-resolution CT scan (for PJP: 'ground-glass' interstitial infiltrates)",
      "Arterial blood gas (ABG) (for PJP: hypoxemia, increased alveolar-arterial oxygen gradient, respiratory alkalosis)",
      "Serum LDH (elevated in PJP)",
      "Examination of induced sputum, bronchoalveolar lavage, transbronchial biopsy (for PJP: silver stains for cyst wall, Giemsa for trophozoites/sporozoites)",
      "CT scan or MRI (for CNS involvement, e.g., PML: non-enhancing, focal hypodense lesions; cerebral toxoplasmosis: multiple contrast-enhancing lesions with ring enhancement)",
      "Detection of JC virus DNA in CSF by PCR (for PML)",
      "CSF examination (for cryptococcal meningitis: high opening pressure, mild/absent pleocytosis, variable protein/glucose, cryptococcal antigen tests, culture positive; Indian ink staining for Cryptococcus neoformans)",
      "Toxoplasma serology (IgG antibodies for previous exposure)",
      "Fundoscopy (for CMV retinitis: hemorrhages and exudates following vasculature, 'pizza pie' appearances)",
      "Renal biopsy (for HIVAN)"
    ],
    "Object7": [
      "General Measures: Balanced diet, quitting smoking/alcohol, adequate rest, safer sex, counseling, education.",
      "Antiretroviral Drugs (cART/HAART): Suppress viral replication, reduce viral load, improve CD4 count, improve quality/length of life, reduce transmission. Initiated in all adults regardless of WHO clinical stage/CD4 count (priority for severe/advanced disease, CD4 <350, active TB, HBV co-infection, serodiscordant couples, children <5, infants <1 year).",
      "Categories of Antiretroviral Drugs:",
      "Reverse transcriptase inhibitors (NRTIs/NtRTIs): Zidovudine (AZT), Stavudine (d4T), Zalcitabine (ddC), Lamivudine (3TC), Didanosine (ddI), Emtricitabine (FTC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF).",
      "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine, Rilpivirine.",
      "Protease inhibitors (PIs): Indinavir (IDV), Ritonavir (RTV), Saquinavir (SQV), Nelfinavir (NFV), Amprenavir (APV), Lopinavir/ritonavir (LPV/RTV), Atazanavir (ATV), Darunavir (TMC114), Fosamprenavir (FOSAPV), Tipranavir (TPV).",
      "Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir, Elvitegravir, Dolutegravir, Cabotegravir.",
      "Viral entry inhibitors: Fusion inhibitors (Enfuvirtide), Coreceptor blockers (Maraviroc).",
      "Pharmacokinetic enhancers: Cobicistat.",
      "Antiretroviral Regimens: Fixed-dose combinations and once-daily regimens preferred. First-line preferred: TDF + 3TC (or FTC) + EFV. EFV preferred for HIV+TB, HIV+HBV, pregnant women. TDF/FTC or TDF/3TC preferred NRTI backbone for HIV+HBV, HIV+TB, pregnant women. Infants at high risk: dual prophylaxis AZT + NVP for 6 weeks.",
      "Treatment of Opportunistic Infections:",
      "PJP: Trimethoprim 160mg + sulphamethoxazole 800mg/day (or IV for moderate-to-severe). Adjunctive steroids if hypoxic. Primary prophylaxis if CD4 <200 cells/µl. (TMP-SMX, aerosolized pentamidine, dapsone).",
      "MAC: Azithromycin/clarithromycin +/- ethambutol/rifabutin for ≥12 months. Prophylaxis if CD4 <50 cells/µl.",
      "Esophageal Candidiasis: Systemic azole therapy (fluconazole 200mg daily for 14 days).",
      "Diarrhea (protozoal): Nitazoxanide (Cryptosporidium), Co-trimaxazole (Isosporiasis). ART is indicated for immune restoration.",
      "CMV Retinitis: Oral valganciclovir (900mg BID), IV ganciclovir (5mg/kg BID) for ≥3 weeks or until quiescent. Foscarnet (nephrotoxic).",
      "Cryptococcal Meningitis: Amphotericin B (0.7mg/kg/day) (+flucytosine) for 2 weeks, then fluconazole (400mg/day) for 8-10 weeks. Continuous fluconazole (200mg/day) for relapse prevention.",
      "Cerebral Toxoplasmosis: Sulfadiazine (1000-1500mg QID) + pyrimethamine (200mg loading, then 50mg daily) + folinic acid. Co-trimoxazole (effective, less toxic). Clindamycin if sulfa-allergic. Prophylaxis if toxoplasma-seropositive and CD4 <100 cells/µL (TMP-SMX).",
      "Kaposi's sarcoma: Radiation, cryotherapy, intralesional vinblastine for cutaneous lesions. Interferon-alpha with liposomal doxarubucin and paclitaxel for extensive disease.",
      "TB in HIV: Start ART in all HIV+TB patients (TB treatment first, then ART within 8 weeks). Recommended ART regimen: AZT + 3TC + EFV or TDF + 3TC/FTC + EFV. Rifampicin can be used with NNRTI efavirenz. Rifabutin in PI-based regimens.",
      "Management of HIV/AIDS during Pregnancy: ART in 2nd trimester (severe disease in 1st trimester). EFV generally avoided in 1st trimester. Zidovudine monotherapy or single-dose nevirapine at delivery. C-section to lower transmission risk.",
      "Immune Reconstitution Inflammatory Syndrome (IRIS): Continue HAART (unless life-threatening). Corticosteroids/NSAIDs to decrease inflammation. Treat infection/malignancy.",
      "Postexposure Prophylaxis (PEP) for HCW: Within 72 hours. 2-3 drug regimen for 28 days. Decontamination (soap/water). HIV-PEP regimens: Basic (NRTI + NNRTI or 2 NRTIs), Expanded (additional 3rd drug). Preferred: Raltegravir + TDF/emtricitabine. For Hepatitis B (HBIG + vaccine series). For Hepatitis C (early infection with Peg-interferon +/- ribavirin). Preexposure prophylaxis (PrEP) with tenofovir/emtricitabine for high-risk populations."
    ],
    "Object8": [
      "Severe immunosuppression leads to opportunistic infections, secondary neoplasms, and neurologic manifestations (AIDS-defining conditions).",
      "T-cell depletion: Opportunistic infections (PJP, MAC, cryptococcal meningitis, cerebral toxoplasmosis), Kaposi's sarcoma, Lymphoma, Invasive cervical carcinoma.",
      "B-cell dysfunction: Disseminated infections by capsulated bacteria (S. pneumoniae, H. influenzae).",
      "Neurological: HIV encephalopathy (HAND), PML, Herpes simplex encephalitis, CMV encephalitis, Primary CNS lymphoma.",
      "Ocular: CMV retinitis (blindness), ocular toxoplasmosis.",
      "Cardiovascular: Coronary heart disease, dilated cardiomyopathy, pericardial effusions.",
      "Renal/Genitourinary: HIVAN, drug-induced toxicity.",
      "Hematological: Anemia, leucopenia, lymphopenia, thrombocytopenia, pancytopenia.",
      "TB in HIV: Accelerated HIV course, higher MDR-TB, IRIS.",
      "Pregnancy: Mother-to-child transmission of HIV.",
      "IRIS: Clinical worsening, atypical infection presentation, autoimmune disorders (Graves' disease), life-threatening, fatal.",
      "PEP: Bleeding, thrombocytopenia (Glycoprotein IIb/IIIa receptor antagonists), mitochondrial toxicity (NRTIs), rash, hepatotoxicity (NNRTIs), lipodystrophy, hyperglycemia (PIs)."
    ]
  },
  {
    "Object1": "Acute Bronchitis and Sinusitis in HIV",
    "Object2": [
      "Acute Bronchitis",
      "Sinusitis"
    ],
    "Object3": [
      "Prevalent during all stages of HIV infection",
      "Microorganisms: Encapsulated organisms (H. influenzae, Streptococcus pneumoniae)",
      "Mucormycosis infections of the sinuses (in patients with low CD4+ T-cell counts)"
    ],
    "Object4": [
      "Sinusitis: Fever, nasal congestion, headache"
    ],
    "Object5": [
      "Maxillary sinuses most commonly involved, ethmoid, sphenoid, frontal also frequent"
    ],
    "Object6": [],
    "Object7": [
      "Antibiotics for bacterial infections (guided by culture). Antifungal for mucormycosis."
    ],
    "Object8": []
  },
  {
    "Object1": "Pneumocystis jirovecii Infection (PJP) (Pneumocystis Pneumonia)",
    "Object2": "Fungal pneumonia (officially classified)",
    "Object3": [
      "Pneumocystis jirovecii (formerly Pneumocystis carinii)",
      "Single most common cause of pneumonia in patients with HIV",
      "Life cycle: Cysts, trophozoites, sporozoites"
    ],
    "Object4": [
      "Progressive dyspnea (key presenting feature)",
      "Fever",
      "Dry (non-productive) cough or productive cough with scant white sputum",
      "Sharp or burning, retrosternal chest pain (worse on inspiration)"
    ],
    "Object5": [
      "Crepitations",
      "Unusual consolidation",
      "Fall in oxygen saturation after exercise (classical)"
    ],
    "Object6": [
      "Chest X-ray: Bilateral interstitial infiltrate spreading from hilar regions (Fig. 5.6). Pneumatoceles (may rupture, resulting in pneumothorax).",
      "High-resolution CT scan: Typical 'ground-glass' interstitial infiltrates.",
      "Arterial blood gas: Hypoxemia, increased alveolar-arterial oxygen gradient, respiratory alkalosis (mild/moderate cases). Respiratory acidosis (severe cases).",
      "Serum LDH: Elevated.",
      "Diagnosis by examination of induced sputum (hypertonic saline nebulization) stained with silver stains, PCR or immunofluorescence of bronchoalveolar lavage, or transbronchial biopsy. Methenamine silver stains cyst wall; Giemsa stains trophozoites/sporozoites."
    ],
    "Object7": [
      "Mild cases: Trimethoprim 5 mg/kg 6 hourly + sulphamethoxazole 25 mg/kg 6 hourly orally. OR Trimethoprim 5 mg/kg 6 hourly + dapsone 2 mg/day.",
      "Moderate-to-severe cases: Trimethoprim 5 mg/kg 6 hourly + sulphamethoxazole 25 mg/kg 6 hourly IV. OR Pentamidine 4 mg/kg/day IV. OR Clindamycin (600 mg qid) + primaquine (30 mg od).",
      "All cases: Add prednisolone 40 mg BID for 5 days, then 40 mg/day for 5 days, then 20 mg/day for 11 days (if hypoxic).",
      "Prophylaxis: Primary prophylaxis if CD4 count <200 cells/µl (Trimethoprim 160 mg + sulphamethoxazole 800 mg/day daily, OR Aerosolized pentamidine 300 mg once a month, OR Dapsone 50 mg BID)."
    ],
    "Object8": [
      "Pneumothorax (rupture of pneumatoceles)",
      "Extrapulmonary involvement (skin, meninges, brain, eyes, heart, liver, spleen, kidneys)"
    ]
  },
  {
    "Object1": "Atypical Mycobacterial Infections in HIV (Mycobacterium avium complex - MAC)",
    "Object2": "Disseminated disease (common), Pulmonary MAC (may develop)",
    "Object3": [
      "Mycobacterium avium complex (MAC) infection (M. avium or M. intracellulare species)",
      "Occurs predominantly in patients with CD4+ T-cell counts of <50-100 cells/µl",
      "Arise from ubiquitous environmental organisms (soil, water)",
      "Person-to-person transmission"
    ],
    "Object4": [
      "Disseminated disease: Fever, weight loss, night sweats, abdominal pain, diarrhea",
      "Pulmonary: Cough with expectoration"
    ],
    "Object5": [
      "Massive splenomegaly",
      "Lymphadenopathy",
      "Bilateral, lower lobe infiltrate (suggestive of miliary spread)",
      "Alveolar or nodular infiltrates",
      "Hilar and/or mediastinal adenopathy",
      "Anemia",
      "Elevated liver alkaline phosphatase"
    ],
    "Object6": [
      "Blood: Anemia, elevated liver alkaline phosphatase."
    ],
    "Object7": [
      "Azithromycin (600 mg daily) or clarithromycin (500 mg twice daily) +/- ethambutol (15 mg/kg PO once daily)/rifabutin for minimum 12 months.",
      "Chemoprophylaxis against disseminated MAC disease if CD4+ count <50 cells/µL."
    ],
    "Object8": []
  },
  {
    "Object1": "Rhodococcus equi Infection in HIV",
    "Object2": "Pulmonary and disseminated infection",
    "Object3": [
      "Rhodococcus equi (gram-positive, pleomorphic, acid-fast non-spore forming bacillus)"
    ],
    "Object4": [
      "Fever and cough with expectoration (common presenting complaints)"
    ],
    "Object5": [
      "Cavitary lesions and consolidation (X-ray)"
    ],
    "Object6": [
      "X-ray chest"
    ],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Coccidioides Immitis Infection in HIV",
    "Object2": "Reactivation pulmonary syndrome",
    "Object3": [
      "Coccidioides Immitis (mould, endemic in southwest US)",
      "Patients with CD4+ T-cell counts < 250/µl"
    ],
    "Object4": [
      "Fever, weight loss, cough"
    ],
    "Object5": [
      "Extensive, diffuse reticulonodular infiltrates on chest X-ray",
      "Nodules, cavities, pleural effusions, and hilar adenopathy"
    ],
    "Object6": [
      "Chest X-ray"
    ],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Invasive Aspergillosis in HIV",
    "Object2": "Not an AIDS-defining illness",
    "Object3": [
      "Generally not seen in patients with AIDS in absence of neutropenia or glucocorticoid administration"
    ],
    "Object4": [],
    "Object5": [
      "Pseudomembranous tracheobronchitis"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Primary Pulmonary Histoplasmosis in HIV",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Primary pulmonary infection of the lung"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Idiopathic Interstitial Pneumonia in HIV",
    "Object2": "Benign infiltrate of the lung",
    "Object3": [
      "Polyclonal activation of lymphocytes"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Esophageal Diseases in HIV",
    "Object2": [
      "Esophagitis"
    ],
    "Object3": [
      "Candida (most common), CMV, Herpes simplex virus"
    ],
    "Object4": [
      "Pain on swallowing (odynophagia)",
      "Dysphagia",
      "Regurgitation"
    ],
    "Object5": [
      "Esophageal candidiasis (Fig. 5.7A) (white patches in esophagus)"
    ],
    "Object6": [],
    "Object7": [
      "Systemic azole therapy (e.g., fluconazole 200 mg daily for 14 days) (usually curative)"
    ],
    "Object8": []
  },
  {
    "Object1": "Chronic Diarrhea in HIV",
    "Object2": "Not specified",
    "Object3": [
      "Very common in patients with advanced HIV, major cause of wasting",
      "Infections: Bacterial (Salmonella, Shigella, Campylobacter, Escherichia coli, Clostridium difficile), Fungal (Histoplasmosis, Coccidioidomycosis, Penicilliosis), Protozoa (Cryptosporidia, Microsporidia, Isospora belli, Giardia, Entameba histolytica, Enterocytozoon bieneusi, Septata intestinalis), Viral (Cytomegalovirus (CMV), herpes, adenovirus, astrovirus, Calicivirida), Mycobacterium avium complex, Mycobacterium tuberculosis",
      "HIV related: HIV invading gut epithelium (AIDS enteropathy)",
      "GI malignancies: Lymphoma, Kaposi's sarcoma"
    ],
    "Object4": [
      "Protracted diarrhea",
      "Fluid and electrolyte imbalance"
    ],
    "Object5": [],
    "Object6": [
      "Stool culture and examination (for various pathogens)"
    ],
    "Object7": [
      "Protozoal infections: Nitazoxanide (Cryptosporidium), Co-trimaxazole (TMP-SMX) (isosporiasis).",
      "ART (Antiretroviral therapy) is indicated in all patients with opportunistic infections (immune restoration often leads to eradication)."
    ],
    "Object8": [
      "Wasting"
    ]
  },
  {
    "Object1": "Mucocutaneous Diseases in HIV",
    "Object2": "Extremely common manifestations",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Warts (Fig. 5.8A)",
      "Molluscum contagiosum (Fig. 5.8B)",
      "Herpes simplex (Fig. 5.8C and D)",
      "Herpes varicella zoster (Fig. 5.8E)",
      "Bacillary angiomatosis (Bartonella infection)",
      "Oral candidiasis (Fig. 5.7B)",
      "Anogenital warts",
      "Kaposi's sarcoma (Fig. 5.8F)"
    ],
    "Object6": [],
    "Object7": [
      "Specific treatment for each manifestation (e.g. fluconazole for oral candidiasis, acyclovir for herpes simplex)."
    ],
    "Object8": []
  },
  {
    "Object1": "Neurological Disease in HIV",
    "Object2": [
      "Meningitis (acute/aseptic)",
      "HIV associated neurocognitive disorders (HAND) (AIDS dementia complex - ADC)",
      "Sensory polyneuropathy",
      "Vacuolar myelopathy",
      "Autonomic neuropathy",
      "Progressive multifocal leucoencephalopathy (PML)",
      "Herpes simplex encephalitis",
      "Herpes zoster (myelitis or radiculitis)",
      "CMV encephalitis",
      "Cryptococcal meningitis",
      "Tuberculosis meningitis",
      "Syphilis (neurosyphilis)",
      "Cerebral toxoplasmosis",
      "Primary CNS lymphoma (PCNSL)"
    ],
    "Object3": [
      "Directly due to HIV: Release of neurotoxic products by HIV itself, cytokine abnormalities secondary to immune dysregulation.",
      "Unmask autoimmune diseases: Polymyositis, Myasthenia gravis, Acute inflammatory demyelinating neuropathy (GBS), Multiple sclerosis.",
      "Opportunistic infections (viral, fungal, bacterial, protozoan).",
      "Complications of ART.",
      "Immune reconstitution syndrome (IRIS)."
    ],
    "Object4": [
      "Acute meningitis: Silent CSF pleocytosis, aseptic meningitis, infectious mononucleosis-like syndrome, multiple cranial nerve palsies, acute encephalopathy.",
      "HAND: Executive dysfunction, memory impairment, motor dysfunction (bradykinesia, loss of coordination, gait imbalance), attention/multitasking/impulse control/judgment impairment.",
      "Sensory polyneuropathy: Intense pain (usually feet), disrupts sleep, impairs mobility, reduces quality of life.",
      "Autonomic neuropathy: Postural hypotension, diarrhea.",
      "PML: Stroke-like episodes, cognitive impairment, focal neurological abnormalities (vision impairment, aphasia, hemiparesis, ataxia), altered sensorium, death.",
      "Herpes simplex encephalitis: Insidious onset.",
      "CMV encephalitis: Slowly progressive behavioral disturbance, cognitive impairment, reduced consciousness.",
      "Cryptococcal meningitis: Headache, vomiting, mild confusion.",
      "Cerebral toxoplasmosis: Headache, confusion, seizures, ataxia, focal deficits.",
      "PCNSL: Encephalopathy, focal deficits, seizures, lymphomatous meningitis."
    ],
    "Object5": [
      "Acute meningitis: Lymphocytosis in CSF, raised proteins (<200 mg/dL).",
      "PML: CT scan (non-enhancing, focal hypodense lesions). MRI (distinct white matter lesions) (Fig. 5.9).",
      "Cryptococcal meningitis: High lumbar puncture opening pressure. CSF pleocytosis (mild/absent), variable protein/glucose. Indian ink staining on CSF (Cryptococcus neoformans) (Fig. 5.10).",
      "Tuberculosis meningitis: Elevated cell counts (lymphocytes), protein; low glucose in CSF. CT scan (multiple ring lesions suggestive of tuberculomas).",
      "Cerebral toxoplasmosis: Contrast CT scan (multiple contrast-enhancing lesions with ring enhancement, surrounding edema) (Fig. 5.11).",
      "PCNSL: CT scan (single, homogeneously enhancing, periventricular lesion with surrounding edema)."
    ],
    "Object6": [
      "CSF examination (for meningitis, PML, CMV encephalitis, TB meningitis, PCNSL).",
      "CT/MRI brain (for HAND, PML, cerebral toxoplasmosis, PCNSL).",
      "PCR for JC virus DNA in CSF (PML).",
      "Toxoplasma serology (IgG antibodies for cerebral toxoplasmosis).",
      "Brain biopsy (for cerebral toxoplasmosis - usually not necessary; for PCNSL - definitive but carries risk).",
      "PCR for EBV DNA in CSF (PCNSL)."
    ],
    "Object7": [
      "PML: Main treatment is ART (prognosis remains poor).",
      "Herpes simplex encephalitis: Acyclovir (prognosis poor despite treatment).",
      "CMV encephalitis: Anti-CMV therapy (response poor).",
      "Cryptococcal meningitis: Amphotericin B (0.7 mg/kg/day) (+flucytosine) for 2 weeks, then fluconazole (400 mg/day) for 8-10 weeks. Continuous fluconazole (200 mg/day) for relapse prevention.",
      "Cerebral toxoplasmosis: Sulfadiazine (1000-1500 mg QID) + pyrimethamine (200 mg loading, then 50 mg daily) + folinic acid. Co-trimoxazole (effective, less toxic). Clindamycin if sulfa-allergic.",
      "PCNSL: Radiotherapy and/or chemotherapy."
    ],
    "Object8": [
      "PML: Death within 6 months.",
      "CMV encephalitis: Myelitis, retinitis (retinal hemorrhage, blindness).",
      "Cryptococcal meningitis: High relapse rates.",
      "PCNSL: Very poor prognosis."
    ]
  },
  {
    "Object1": "Ocular Diseases in HIV",
    "Object2": [
      "Retinopathy (Ocular toxoplasmosis, HIV retinopathy, Herpes zoster, Varicella zoster virus, CMV Retinitis)",
      "Ocular pain",
      "Conjunctival infection",
      "Corneal opacification"
    ],
    "Object3": [
      "Ocular toxoplasmosis",
      "HIV infection (microangiopathy)",
      "Herpes zoster",
      "Varicella zoster virus",
      "CMV Retinitis (CD4 count below 100 cells/µl)"
    ],
    "Object4": [
      "Painless, progressive loss of vision (CMV retinitis, with macular involvement)"
    ],
    "Object5": [
      "Ocular toxoplasmosis: Vitritis and retinitis (without retinal hemorrhages).",
      "HIV retinopathy: Cotton-wool spots (benign).",
      "CMV Retinitis (Fig. 5.13): Hemorrhages and exudates in retina following vasculature ('pizza pie' appearances/'frosted branch angiitis')."
    ],
    "Object6": [
      "Fundoscopy (for CMV retinitis).",
      "Demonstration of CMV DNA by PCR of vitreous fluid (diagnostic for CMV retinitis)."
    ],
    "Object7": [
      "CMV Retinitis: Oral valganciclovir (900 mg BID), IV ganciclovir (5 mg/kg BID) for at least 3 weeks or until retinitis is quiescent. Stops progression, but vision does not recover."
    ],
    "Object8": [
      "Blindness (CMV retinitis, if untreated)."
    ]
  },
  {
    "Object1": "Cardiovascular Diseases in HIV",
    "Object2": [
      "Coronary heart disease",
      "Dilated cardiomyopathy (HIV-associated cardiomyopathy)",
      "Pericardial effusions"
    ],
    "Object3": [
      "Classical risk factors",
      "Direct consequence of HIV infection",
      "Result of ART (antiretroviral therapy)",
      "Pericardial effusions: TB, CHF, mycobacterial infection, cryptococcal infection, pulmonary infection, lymphoma, Kaposi's sarcoma (KS)"
    ],
    "Object4": [
      "Congestive heart failure (with dilated cardiomyopathy)"
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Psychiatric Diseases in HIV",
    "Object2": "Not specified",
    "Object3": [
      "Pre-test issues (worries about infection, disclosure, positive result)",
      "Mild cognitive dysfunction (later-stage disease)",
      "Drugs directly (e.g., depression with efavirenz) or indirectly"
    ],
    "Object4": [
      "Anxiety",
      "Mood disturbance",
      "Depression (with efavirenz)",
      "Mild cognitive dysfunction"
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "HAART (for mild cognitive dysfunction)."
    ],
    "Object8": []
  },
  {
    "Object1": "Diseases of Kidney and Genitourinary System in HIV",
    "Object2": [
      "HIV-associated nephropathy (HIVAN)"
    ],
    "Object3": [
      "Direct consequence of HIV infection",
      "Opportunistic infection",
      "Neoplasms",
      "Drug toxicity (nephrotoxic drugs: pentamidine, amphotericin B, adefovir, tenofovir, foscarnet, sulfadiazine; cotrimoxazole increases creatinine by tubular secretion)"
    ],
    "Object4": [],
    "Object5": [
      "HIVAN: Proteinuria. Edema and hypertension are rare. Enlarged and hyperechoic kidneys (ultrasound).",
      "Nephrotic syndrome (focal segmental glomerulosclerosis, mesangial proliferation)."
    ],
    "Object6": [
      "Ultrasound (enlarged/hyperechoic kidneys for HIVAN)",
      "Renal biopsy (definitive for HIVAN)"
    ],
    "Object7": [
      "Treatment depends on specific cause (e.g., stopping nephrotoxic drugs)."
    ],
    "Object8": [
      "Renal failure (from various causes)"
    ]
  },
  {
    "Object1": "Hematological Conditions in HIV",
    "Object2": [
      "Anemia",
      "Leucopenia",
      "Lymphopenia",
      "Thrombocytopenia",
      "Pancytopenia"
    ],
    "Object3": [
      "Anemia: Bone marrow infiltration (opportunistic infections, neoplasms), bone marrow suppression (drugs), direct effect of HIV, blood loss (Kaposi's sarcoma), malabsorption (GI infection)",
      "Leucopenia: Bone marrow infiltration, drug toxicity",
      "Thrombocytopenia: Very early, direct effect of HIV, may be first indicator",
      "Pancytopenia: Opportunistic infection, malignancies, Mycobacterium avium intracellulare infection, disseminated cytomegalovirus, lymphoma"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Treatment of underlying cause (e.g., appropriate antibiotics, chemotherapy)."
    ],
    "Object8": []
  },
  {
    "Object1": "Cancers in HIV",
    "Object2": [
      "AIDS-Defining (Kaposi's sarcoma, Non-Hodgkin's lymphoma, Invasive cervical carcinoma)",
      "Non-AIDS Defining (Anal cancer, Hodgkin's disease, Leiomyosarcoma (pediatric), Squamous carcinoma (oral), Merkel cell carcinoma, Hepatocellular carcinoma)"
    ],
    "Object3": [
      "Kaposi's sarcoma (KS herpes virus - KSHV/HHV8)",
      "Non-Hodgkin's lymphoma (Epstein-Barr virus - EBV, HHV8)",
      "Invasive cervical carcinoma (Human papilloma virus - HPV)",
      "Anal cancer (HPV)",
      "Hodgkin's disease (EBV)",
      "Leiomyosarcoma (pediatric, EBV)",
      "Squamous carcinoma (oral, HPV)",
      "Merkel cell carcinoma (Merkel cell polyoma virus - MCV)",
      "Hepatocellular carcinoma (Hepatitis B virus - HBV, Hepatitis C virus - HCV)"
    ],
    "Object4": [],
    "Object5": [
      "Kaposi's sarcoma (Fig. 5.8F): Skin, mucus membrane and viscera (lymph nodes, GIT, lungs) involvement. Erythematous/violaceous macules, plaques or nodules."
    ],
    "Object6": [],
    "Object7": [
      "Kaposi's sarcoma: Cutaneous lesions treated with radiation, cryotherapy, intralesional vinblastine. Extensive disease needs interferon-alpha with liposomal doxorubicin and paclitaxel."
    ],
    "Object8": []
  },
  {
    "Object1": "Chikungunya",
    "Object2": "Viral fever",
    "Object3": [
      "Alphavirus",
      "Bites from Aedes aegypti mosquitoes"
    ],
    "Object4": [
      "Fever (often severe, usually lasts 2-5 days, may be saddleback pattern)",
      "Arthralgia or arthritis (migratory polyarthritis, early morning pain/swelling in small joints of ankles, feet, hands, wrists, larger joints can be affected)",
      "Constitutional symptoms (abdominal pain, headache, anorexia, nausea, conjunctival injection, slight photophobia)",
      "Bleeding from skin (petechiae) and epistaxis (occasionally)"
    ],
    "Object5": [
      "Maculopapular rash (skin involvement common in children, 40-50% cases, appears at beginning or day 2-3 of illness, pruritic, predominating on trunk/limbs)",
      "Arthritis (may persist for months, become chronic, associated with HLA-B27)",
      "Skin pigmentation (may persist for months to years)"
    ],
    "Object6": [
      "Blood: Leucopenia and thrombocytopenia (may occur but uncommon)",
      "Raised asparate amino transferases and C-reactive protein (may be found)",
      "ELISA (for demonstrating antibodies)",
      "RT-PCR (to detect structural genes of virus in blood sample)"
    ],
    "Object7": [
      "Symptomatic: No specific treatment available.",
      "NSAIDs (ibuprofen, diclofenac or naproxen) for arthralgias and arthritis.",
      "Rest is important.",
      "Hydroxychloroquine (200 mg once or twice a day) for prolonged joint pains."
    ],
    "Object8": [
      "CNS involvement (rare, reported in outbreaks)",
      "Fulminant hepatitis (rare, reported in outbreaks)",
      "Chronic arthritis (can persist for months to years, especially if HLA-B27 positive)"
    ]
  },
  {
    "Object1": "Japanese Encephalitis",
    "Object2": "Mosquito-borne encephalitis",
    "Object3": [
      "Flavivirus",
      "Transmitted by infected Culex tritaeniorhynchus mosquitoes"
    ],
    "Object4": [
      "Prodromal (1-6 days): Fever, severe rigors, headache, malaise, nausea, diarrhea, vomiting, cough, myalgia, weight loss.",
      "Acute encephalitic stage: High fever, neck rigidity, neurological signs (irritability, altered consciousness/behavior, hemiparesis, convulsions). Mental deterioration over 3-4 days, may terminate in coma."
    ],
    "Object5": [
      "Residual neurological defects: Cognitive and speech impairment, emotional liability, cranial nerve palsies (e.g., ocular palsies, deafness), hemiplegia, quadriplegia, Parkinsonian presentation (extrapyramidal signs: rigidity, dystonia, choreoathetosis, coarse tremors)."
    ],
    "Object6": [
      "Blood: Leukocytosis with neutrophilia.",
      "Cerebrospinal fluid (CSF): Raised pressure and cell count (neutrophils early, then lymphocytic pleocytosis). Protein levels moderately raised (~50%), glucose normal.",
      "Virus isolation from CSF.",
      "Detection of viral antigens in CSF by IFA.",
      "Serological tests: Virus neutralization test, hemagglutination inhibition, complement fixation. IgM capture ELISA (rapid diagnostic test for serum and CSF).",
      "EEG: Persistent abnormalities (common in children).",
      "Imaging: CT scan (low-density areas in temporal lobes). MRI scan (more sensitive for early abnormalities)."
    ],
    "Object7": [
      "Supportive/symptomatic: Management of fever, raised intracranial tension, convulsions.",
      "Prevention: Control mosquito vectors, interruption of human-vector contact, Vaccines (purified formalin-inactivated virus from mouse brain; cell-culture derived live attenuated)."
    ],
    "Object8": [
      "Residual neurological defects (in ~70% of patients with CNS involvement)",
      "Mortality ranges from 7% to 40% (higher in children)"
    ]
  },
  {
    "Object1": "Smallpox (Variola)",
    "Object2": [
      "Severe disease",
      "Hemorrhagic smallpox"
    ],
    "Object3": [
      "Variola virus (Orthopoxvirus genus)",
      "Virus spread through respiratory or oropharyngeal mucosa (contaminated aerosols, lesional tissue, body fluids, fomites)",
      "Direct contact with lesions"
    ],
    "Object4": [
      "Prodromal (abrupt onset): High fever, headache, backache, prostration, malaise.",
      "Hemorrhagic smallpox: Widespread hemorrhages into skin and mucous membranes."
    ],
    "Object5": [
      "Skin lesions (macules, papules, vesicles, pustules, scabs - all rashes of same stage)",
      "Involvement of palms and soles",
      "Rash prominent on extensor surfaces and bony prominences (centrifugal distribution)",
      "Flat, confluent or semiconfluent lesions (smallpox)",
      "Bleeding (hemorrhagic smallpox)"
    ],
    "Object6": [
      "Clinical diagnosis (based on characteristic rash presentation)"
    ],
    "Object7": [
      "Symptomatic and no effective postexposure therapy.",
      "Prophylaxis by Vaccine: Live attenuated vaccinia vaccine (can prevent or reduce severity if given within 4 days of exposure)."
    ],
    "Object8": [
      "High mortality",
      "DIC, hypotension, multiorgan failure (cause of death)",
      "Scar formation or hypopigmentation (after lesions detach)"
    ]
  },
  {
    "Object1": "Rabies",
    "Object2": [
      "Furious rabies (classic variety)",
      "Dumb rabies (paralytic variety)"
    ],
    "Object3": [
      "Rhabdovirus (genotype 1, single stranded RNA virus of Lyssavirus genus)",
      "By saliva, usually through bites or licks of an infected animal on abrasions or intact mucous membranes",
      "Rarely: aerosolized exposure in bat-infested caves, post-organ transplant",
      "Source: Dogs/fox (rarely cats) and bats"
    ],
    "Object4": [
      "Prodromal (1-10 days): Pain and tingling (paraesthesia) at bite site. Fever, malaise, headache.",
      "Furious: Marked anxiety, agitation/depressive features, hallucinations, paralysis. Spitting, biting, mania, with lucid intervals (patient anxious). Hyperexcitability (precipitated by auditory/visual stimuli). Hydrophobia (violent contractions of diaphragm/pharyngeal muscles on attempting to drink/eat). Aerophobia.",
      "Dumb: Symmetrical ascending paralysis (similar to Guillain-Barré syndrome)."
    ],
    "Object5": [
      "Furious: Hyperreflexia, spasticity. Pupillary dilatation and diaphoresis (sympathetic overactivity). Convulsions, respiratory paralysis, cardiac arrhythmias. Death within 10-14 days.",
      "Dumb: Commonly develops after bites from rabid bats."
    ],
    "Object6": [
      "Diagnosis usually clinical.",
      "Skin punch biopsy: Detect antigen with immunofluorescent antibody test on frozen section.",
      "Reverse transcription polymerase chain reaction (RTPCR): Isolation of viral RNA.",
      "Isolation of viruses: From saliva or presence of antibodies in blood/CSF.",
      "Classic Negri bodies: Postmortem (90%): eosinophilic, cytoplasmic, ovoid bodies in hippocampus/cerebellum neurons.",
      "Diagnosis on biting animal: RTPCR, immunofluorescence assay (IFA), tissue culture of brain."
    ],
    "Object7": [
      "Established disease: Symptomatic, death is virtually inevitable. Intensive care (control cardiac/respiratory failure, nutritional support). Heavy sedation (diazepam/morphine, chlorpromazine).",
      "Milwaukee Protocol (antivirals: Ribavirin, Amantadine + ketamine, midazolam infusion) (tried).",
      "Prevention:",
      "Preexposure prophylaxis (high-risk individuals): Three 1.0 mL doses of human diploid (HDCV) or chick embryo cell vaccine (days 0, 7, 28) IM/SC. Reinforcing dose after 12 months, then every 3-5 years.",
      "Postexposure prophylaxis (PEP):",
      "Wound treatment: Thoroughly clean with quaternary ammonium detergent/soap and water. Excise damaged tissues, leave wound unsutured.",
      "Human rabies immunoglobulin: 20 IU/kg body weight. Half infiltrated around bite, half IM (different site from vaccine).",
      "Vaccine: HDCV 1.0 mL doses IM on days 0, 3, 7, 14, 30, 90."
    ],
    "Object8": [
      "Established infection is invariably fatal.",
      "Death (convulsions, respiratory paralysis, cardiac arrhythmias)."
    ]
  },
  {
    "Object1": "Ebola Virus Disease (EVD) (Ebola Hemorrhagic Fever)",
    "Object2": "Severe, often fatal illness in humans",
    "Object3": [
      "Ebola virus",
      "Close contact with blood, secretions, organs or other bodily fluids of infected animals (fruit bats - natural host)",
      "Human-to-human transmission (direct contact through broken skin/mucous membranes, indirect contact with contaminated environments)",
      "Transmission through semen for up to 7 weeks after recovery"
    ],
    "Object4": [
      "Acute EVD: Sudden onset of high-grade fever, severe weakness, muscle pain, headache, vomiting, diarrhea, skin rash."
    ],
    "Object5": [
      "Skin rash"
    ],
    "Object6": [
      "Diagnosis is clinical and serological tests available."
    ],
    "Object7": [
      "Symptomatic and supportive.",
      "Isolation of patient.",
      "Emphasis on handling dead bodies, animal carcasses."
    ],
    "Object8": [
      "Very high fatality rate (around 90%)",
      "Acute renal failure",
      "Hemorrhagic manifestations",
      "DIC (disseminated intravascular coagulation)",
      "Hepatitis",
      "MODS (multiple organ dysfunction syndrome)"
    ]
  },
  {
    "Object1": "Swine Flu (Influenza A (H1N1) Viruses)",
    "Object2": "Respiratory disease",
    "Object3": [
      "Orthomyxovirus (Influenza type A H1N1 virus, reassortant mix of genes from swine, bird, human flu viruses)",
      "Droplets from cough or sneeze of an infected individual",
      "Object contaminated by cough or touch of infected person"
    ],
    "Object4": [
      "Fever",
      "Cough",
      "Myalgias"
    ],
    "Object5": [
      "Influenza-like illness (CDC criteria)"
    ],
    "Object6": [
      "Confirmed case by laboratory confirmed novel influenza A (H1N1) virus infection by one or more of:",
      "Real-time RT-PCR",
      "Viral culture from swabs (nasal, oral, respiratory secretions)"
    ],
    "Object7": [
      "Mainly supportive: Bed rest, increased fluid consumption, cough suppressants, antipyretics and analgesics (acetaminophen, nonsteroidal anti-inflammatory drugs) for fever and myalgias.",
      "Severe cases: Intravenous hydration and other supportive measures.",
      "Antiviral Agents (may be considered for treatment/prophylaxis):",
      "Neuraminidase inhibitors (inhibit viral neuraminidase, decrease virus release): Oseltamivir (Tamiflu) (75 mg PO BID for 5 days, prophylaxis 75 mg PO qd). Zanamivir (Relenza) (10 mg inhaled orally BID for 5 days, prophylaxis 10 mg inhaled orally qd for 10 days for household contacts, 28 days for community outbreak).",
      "Other antiviral agents (amantadine, rimantadine) not recommended due to resistance.",
      "Vaccination: Yearly vaccination with season specific strain vaccine before annual flu season (intranasal, intramuscular monovalent/trivalent vaccines)."
    ],
    "Object8": [
      "Acute Respiratory Distress Syndrome (ARDS)",
      "Multiple Organ Dysfunction Syndrome (MODS)",
      "High risk of serious complications in: >65 years, <5 years, pregnant women (especially 3rd trimester), underlying medical conditions (asthma, diabetes, obesity, heart disease), weakened immune system (immunosuppressive medications, HIV)."
    ]
  },
  {
    "Object1": "Zika Virus (ZIKV)",
    "Object2": "Arbovirus (Flavivirus family)",
    "Object3": [
      "Zika virus (ZIKV)",
      "Transmitted by Aedes mosquito species (e.g., A. aegypti)",
      "Rarely: mother to child transmission, sexual transmission"
    ],
    "Object4": [
      "Similar to mild form of dengue fever: Mild headaches, maculopapular rash, malaise, conjunctivitis, arthralgia.",
      "Rash starts fading, fever resolves within 2-4 days."
    ],
    "Object5": [
      "Maculopapular rash",
      "Conjunctivitis"
    ],
    "Object6": [
      "Sample to be tested: Blood, saliva, urine.",
      "PCR: Useful in first 3-5 days after symptom onset (directly detects virus or specific viral antigens).",
      "Serology test: Detects presence of antibodies (useful only after 5 days)."
    ],
    "Object7": [
      "Only symptomatic.",
      "No specific antiviral drugs or vaccines available."
    ],
    "Object8": [
      "Neurological complications: Guillain-Barré syndrome and other neurologic complications.",
      "Congenital infection (if acquired during pregnancy): Microcephaly, chorioretinal atrophy, hydranencephaly, IUGR, hydrops fetalis (most dangerous during first trimester, damage to fetal brain)."
    ]
  },
  {
    "Object1": "Molluscum Contagiosum",
    "Object2": "Skin infection",
    "Object3": [
      "DNA poxvirus (Molluscum contagiosum virus - MCV, only infects humans, no nonhuman-animal reservoir)",
      "Spread from person to person by touching affected skin",
      "Touching a surface with the virus on it (towel, clothing, toys)"
    ],
    "Object4": [],
    "Object5": [
      "Lesions begin as small (3-6 mm) papules that are smooth, flesh-colored domes with a central dimple (umbilication).",
      "Inside the papule is a white, curd-like core (easily expressed).",
      "Can occur anywhere on skin and mucous membranes, usually grouped in one or two areas (Head, eyelids, trunk, genitalia - predominant in adults).",
      "May be widely disseminated."
    ],
    "Object6": [
      "Clinical diagnosis based on appearance."
    ],
    "Object7": [
      "Imiquimod and Retinoids have been used.",
      "Cryosurgery, curettage also used."
    ],
    "Object8": [
      "May be complicated by secondary bacterial infections."
    ]
  },
  {
    "Object1": "Candidiasis (Moniliasis)",
    "Object2": [
      "Superficial (non-invasive) candidiasis",
      "Invasive (disseminated) candidiasis"
    ],
    "Object3": [
      "Candida species (usually C. albicans, small asexual fungi, most common cause of human fungal infections).",
      "Occurs when normal commensal flora breach skin or mucosal barriers.",
      "Predisposing conditions for oral candida: Broad-spectrum antibiotics, xerostomia, immune dysfunction (diabetes, immunosuppressive therapy, HIV), removable prostheses, lichen planus."
    ],
    "Object4": [
      "Vulvovaginal candidiasis: Pruritus, pain, vaginal discharge.",
      "Deeply Invasive: Esophageal candidiasis (dysphagia, retrosternal pain)."
    ],
    "Object5": [
      "Oral thrush: White adherent, painless, discrete or confluent patches in mouth.",
      "Vulvovaginal candidiasis: Vaginal discharge (usually thin, may appear as whitish 'curds').",
      "Cutaneous candidiasis: Intertriginous infection (skin folds), paronychia (painful swelling at nail-skin interface), balanitis (glans penis), pruritus ani, vulval candidiasis, scrotal candidiasis.",
      "Chronic mucocutaneous candidiasis: Infection of hair, nails, skin, mucous membranes (persists despite therapy, mild/limited or severe/Candida granuloma).",
      "Hematogenous dissemination (invasive candidiasis/candidemia): Retinal abscesses (extending into vitreous), pulmonary candidiasis, endocarditis, chronic meningitis, arthritis."
    ],
    "Object6": [
      "Visualization of hyphae or pseudohyphae on wet mount (saline and 10% KOH) preparation or in scrapings under microscope.",
      "Tissue secretions stained with Gram's, periodic acid-Schiff, or methenamine silver stain (may show candida with inflammation).",
      "Blood cultures (in invasive disease)."
    ],
    "Object7": [
      "Cutaneous: Topical azole or topical nystatin.",
      "Vulvovaginal: Oral fluconazole (150 mg) or azole cream/suppository or nystatin suppository.",
      "Thrush: Clotrimazole troches or Nystatin or fluconazole.",
      "Esophageal: Fluconazole tablets (100-200 mg/day) or itraconazole solution (200 mg/day) or caspofungin, micafungin, or amphotericin B (therapy for 3 weeks or 2 weeks after symptoms subside).",
      "Disseminated candidiasis: Ketoconazole (200-400 mg/day), fluconazole (200 mg/day) or itraconazole (100 mg/day) for 2 weeks.",
      "Severe disseminated candidiasis: IV fluconazole (6 mg/kg/day) or amphotericin B. Echinocandins (caspofungin, micafungin, anidulafungin)."
    ],
    "Object8": [
      "Invasive candidiasis can be due to non-albicans candida species (e.g., C. glabrata) which may be resistant to fluconazole."
    ]
  },
  {
    "Object1": "Superficial Mycoses",
    "Object2": [
      "Pityriasis versicolor",
      "Black piedra",
      "White piedra",
      "Tinea nigra",
      "Tinea capitis",
      "Tinea favosa",
      "Tinea corporis",
      "Tinea cruris",
      "Tinea unguium",
      "Tinea barbae",
      "Tinea manuum",
      "Tinea pedis"
    ],
    "Object3": [
      "Fungal infections of the outermost keratinized layers of skin or hair shaft.",
      "Pityriasis versicolor: Malassezia furfur (lipophilic yeast). Predisposing factors: malnutrition, burns, corticosteroid therapy, immunosuppression, depressed cellular immunity, excess heat/humidity, increased sweating.",
      "Dermatophytes (keratinophilic fungi): Trichophyton, Epidermophyton, and Microsporum species (degrade keratin).",
      "Kerion: Microsporum canis or Trichophyton mentagrophyte.",
      "Favus: Trichophyton schoenleinii."
    ],
    "Object4": [
      "Pityriasis versicolor: Asymptomatic, pruritus (rarely).",
      "Kerion: Fever, pain (extensive lesions).",
      "Favus: Distinctive mousy odor."
    ],
    "Object5": [
      "Pityriasis versicolor: Multiple small, asymptomatic, red to fawn-colored, circular, macules, patches, or follicular papules (hypopigmented or tan to dark brown).",
      "Dermatophytes: Characteristic circular pattern lesions ('ringworm').",
      "Kerion: Boggy indurated swellings with crusting and loose hairs. Hair follicles may discharge pus. Regional lymphadenopathy (extensive lesions).",
      "Favus: Yellowish, cup-shaped crusts ('scutula') around a hair.",
      "Cicatricial alopecia (favus, long-standing cases)."
    ],
    "Object6": [
      "Microscopy of skin scrapings (Pityriasis versicolor: 'spaghetti and meatballs' hyphae).",
      "Wood's light (Pityriasis versicolor: lesions fluoresce greenish yellow)."
    ],
    "Object7": [
      "Pityriasis versicolor: Topical selenium sulphide or 2% ketoconazole shampoo, topical imidazole cream. Oral ketoconazole or oral itraconazole (resistant cases).",
      "Dermatophytes: Topical (miconazole, clotrimazole, econazole, terbinafine). Oral (griseofulvin, ketaconazole, itraconazole, terbinafine).",
      "Kerion: Requires systemic antifungal treatment and possibly corticosteroids."
    ],
    "Object8": [
      "Kerion: Scarring and alopecia.",
      "Pityriasis versicolor: Altered pigmentation persists for months after treatment."
    ]
  },
  {
    "Object1": "Opportunistic Mycoses",
    "Object2": "Fungal infections in immunocompromised individuals",
    "Object3": [
      "Normal resident flora becoming pathogenic when host's immune defenses are altered (immunosuppressive therapy, chronic disease like diabetes, steroid/antibacterial therapy).",
      "Causative agents: Candida species, Cryptococcus neoformans, Aspergillus species, Zygomycosis (Rhizopus, mucor, absidia), Penicillium species, Fusarium species, Alternaria species."
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Aspergillosis",
    "Object2": [
      "Pulmonary aspergillosis (allergic asthma, bronchopulmonary aspergillosis, aspergilloma)",
      "Invasive aspergillosis",
      "Superficial infections (sinusitis, mycotic keratitis, otomycosis)"
    ],
    "Object3": [
      "Aspergillus species (ubiquitous saprophytes, e.g., A. fumigatus, A. niger, A. flavus, A. terreus, A. nidulans)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Invasive aspergillosis: Intravenous amphotericin B, voriconazoles."
    ],
    "Object8": []
  },
  {
    "Object1": "Mucormycosis",
    "Object2": [
      "Rhinocerebral (most common in diabetics)",
      "Pulmonary (in HSCT patients)",
      "Cutaneous",
      "Gastrointestinal",
      "Disseminated",
      "Miscellaneous"
    ],
    "Object3": [
      "Fungi of the order Mucorales (Rhizopus oryzae is most common).",
      "Risk factors: Impaired immune system (diabetes, defects in phagocytic function, prolonged neutropenia, glucocorticoid treatment, solid organ/HSCT, malignancy). Elevated levels of free iron (deferoxamine treatment in iron-overloaded ESRD patients)."
    ],
    "Object4": [
      "Rhinocerebral: Nonspecific (eye/facial pain, facial numbness). Fever may be absent.",
      "Pulmonary: Fever, cough with expectoration."
    ],
    "Object5": [
      "Rhinocerebral: Conjunctival suffusion, blurring of vision, soft tissue swelling. Compromise of extraocular muscle function, proptosis, chemosis. Infected tissue may appear normal, then erythematous, then violaceous, finally black necrotic eschar. Contralateral eye involvement (bilateral proptosis, chemosis, vision loss, ophthalmoplegia) suggests cavernous sinus thrombosis.",
      "Pulmonary: Cavitation, consolidation (X-ray)."
    ],
    "Object6": [
      "Definitive Diagnosis: Positive culture from a sterile site (needle aspirate, tissue biopsy, pleural fluid). Probable diagnosis: culture from nonsterile site (sputum, BAL).",
      "Biopsy with histopathologic evidence (most sensitive/specific): Characteristic wide (6-30 µm), thick-walled, ribbon-like, aseptate hyphal elements branching at right angles."
    ],
    "Object7": [
      "Surgical debridement plus:",
      "Amphotericin B deoxycholate (1 mg/kg/day).",
      "Liposomal AmB (LAmB) (5-10 mg/kg/day, dose escalation to 10 mg/kg/day for CNS mucormycosis).",
      "Amphotericin B lipid complex (ABLC) (5-7.5 mg/kg).",
      "Echinocandin-lipid polyene combinations (for diabetic rhino-orbital cerebral mucormycosis)."
    ],
    "Object8": [
      "Progress to fatal disseminated mucormycosis (with deferoxamine in iron-overloaded patients).",
      "Cavernous sinus thrombosis (rhinocerebral)."
    ]
  },
  {
    "Object1": "Mycetoma",
    "Object2": [
      "Actinomycetoma (60%, caused by bacteria like Actinomadura, Nocardia, Streptomyces spp.)",
      "Eumycetoma (40%, caused by true fungi like Madurella mycetomatis, M. grisea, Leptosphaeria senegalensis, Scedosporium apiospermum)"
    ],
    "Object3": [
      "Inoculation (e.g., from a thorn)",
      "Most commonly affects the foot ('Madura foot')"
    ],
    "Object4": [
      "Painless swelling at implantation site (progressively grows, spreads within soft tissues, extends into bone)",
      "Little pain without fever or lymphadenopathy"
    ],
    "Object5": [
      "Discharging sinuses (nodules rupture, produce sinuses through which colored grains/fungal colonies are discharged).",
      "Sinuses heal with scarring, fresh sinuses appear."
    ],
    "Object6": [
      "Demonstration of fungal grains in pus.",
      "Causative agent by histopathological examination of tissue.",
      "Culture and sensitivity for identification of species and susceptibility testing."
    ],
    "Object7": [
      "Actinomycetoma: Prolonged antibiotic combinations (streptomycin and dapsone; or co-trimoxazole with amikacin, rifampicin added for refractory cases).",
      "Eumycetoma: Combination of surgery and antifungal therapy (itraconazole and ketoconazole 200–400 mg/day; terbinafine monotherapy, voriconazole, posaconazole). Amphotericin B usually not effective. Therapy for 6–12 months or longer. Amputation for extensive/severe cases."
    ],
    "Object8": [
      "Progressive disability."
    ]
  },
  {
    "Object1": "Nocardiosis",
    "Object2": [
      "Localized cutaneous infection",
      "Systemic Nocardia infection"
    ],
    "Object3": [
      "Aerobic actinomycetes of the genus Nocardia (gram-positive bacteria found in soil)",
      "Direct traumatic inoculation",
      "Inhalation or ingestion"
    ],
    "Object4": [
      "Localized cutaneous: Localized cutaneous ulcers or nodules (most frequently in lower limbs).",
      "Systemic: Suppurative disease with lung and brain abscesses (immunocompromised individuals)."
    ],
    "Object5": [
      "Nocardia spp. appear as long, filamentous, branching gram-positive rods (weakly acid-fast)."
    ],
    "Object6": [
      "Microscopic appearance (Nocardia spp. are weakly acid-fast).",
      "Culture (needs prolonged incubation)."
    ],
    "Object7": [
      "Systemic infection: Combinations of ceftriaxone, meropenem, amikacin and co-trimoxazole (for 6-12 months or longer). Surgical drainage of abscesses.",
      "Localized cutaneous infection: Single drug for 1-3 months.",
      "Actinomycetoma (chronic destructive infection in tropical countries, refer above on page 172)."
    ],
    "Object8": []
  },
  {
    "Object1": "Actinomyces israelii Infection",
    "Object2": "Deep infection",
    "Object3": [
      "Actinomyces israelii (anaerobic organism, oral cavity commensal, causes disease when local defenses impaired)"
    ],
    "Object4": [],
    "Object5": [
      "Oral-cervicofacial actinomycosis: Soft tissue swelling, abscess, discharging sinuses.",
      "Abdominal actinomycosis: Discharging sinuses, abdominal mass or abscess.",
      "Pulmonary actinomycosis: Widespread suppurative pneumonia, empyema (often bilateral), persistent discharging chest wall sinuses.",
      "Pus shows 'sulfur grains'."
    ],
    "Object6": [],
    "Object7": [
      "Penicillin or doxycycline."
    ],
    "Object8": []
  },
  {
    "Object1": "Malaria",
    "Object2": [
      "P. falciparum malaria (malignant tertian or subtertian malaria)",
      "P. vivax malaria",
      "P. ovale malaria",
      "P. malariae malaria",
      "P. knowlesi malaria"
    ],
    "Object3": [
      "Plasmodium species (P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi - protozoan disease)",
      "Bite of female anopheline mosquitoes",
      "Contaminated blood transfusions"
    ],
    "Object4": [
      "Nonspecific first symptoms.",
      "P. vivax/P. ovale: Headache, fatigue, abdominal discomfort, muscle aches (prodromal). Paroxysms of fever (tertian, every third day).",
      "P. malariae: Prodromal symptoms may be more severe than P. vivax. Quartan fever (every fourth day).",
      "P. falciparum: Insidious onset, malaise, headache, myalgia, anorexia, vomiting (prodromal). Mild fever with no particular pattern, or high irregularly spiking unremitting fever, or daily (quotidian) paroxysm. Acute headache, irritability, agitation, seizures, psychosis, impaired consciousness (neurological complications).",
      "Severe falciparum malaria (complicated malaria): Unarousable coma (cerebral malaria), severe anemia, renal failure, metabolic (lactic) acidosis, pulmonary edema/ARDS, hypoglycemia, hypotension and shock (algid malaria), abnormal bleeding/DIC, repeated generalized convulsions, hemoglobinuria (blackwater fever), impaired consciousness, prostration, hyperparasitemia, hyperpyrexia, jaundice, severe thrombocytopenia, fluid/electrolyte disturbances, vomiting of oral drugs, complicating/associated infections, malarial retinopathy."
    ],
    "Object5": [
      "P. vivax/P. ovale: Anemia, thrombocytopenia, mild jaundice, tender hepatosplenomegaly. Splenic rupture (more common).",
      "P. malariae: Gross splenomegaly. Anemia (less severe).",
      "P. falciparum: Anemic, jaundiced (moderate tender hepatosplenomegaly).",
      "Cerebral malaria: Diffuse symmetric encephalopathy. Convulsions (generalized, repeated). Symmetrical upper motor neuron lesion signs. Abdominal/cremasteric reflexes absent. Mild neck stiffness (no rigidity/photophobia/raised intracranial tension). Retinal hemorrhages (~15%). Motor abnormalities (decerebrate/decorticate rigidity, opisthotonus). Fixed jaw closure, tooth grinding. Neuropsychiatric, cerebellar signs, extrapyramidal syndromes, multiple cranial nerve involvement. Eyes may be divergent, pout reflex. Corneal reflexes preserved (except deep coma). Transient eye movement abnormalities. Ophthalmoscopy: Retinal hemorrhages (poor prognosis).",
      "Algid malaria: Systolic BP <50 mmHg (children), <70 mmHg (adults); cold, clammy, cyanotic skin; constricted peripheral veins; rapid feeble pulse.",
      "Malarial hemoglobinuria (blackwater fever): Head ache, nausea, vomiting, severe pain in loins, prostration. Fever up to 39.4°C with rigor. Urine dark red to almost black."
    ],
    "Object6": [
      "Microscopic demonstration of parasite: Peripheral smear examination (thick and thin blood smears, stained with Romanowsky stains) for asexual forms (ring, trophozoite, schizont, merozoites) and sexual forms (gametocytes). Bone marrow aspirate (if peripheral smear negative). Quantitative buffy coat analysis (QBC) with acridine orange staining.",
      "Immunodiagnosis: Serological techniques for malarial antibodies (IFA, ELISA). Rapid diagnostic tests for malaria antigens (PfHRP2, PfHRP2 and pLDH, pLDH tests).",
      "PCR testing: Molecular diagnosis by PCR amplification of parasite nucleic acid (more sensitive).",
      "Other laboratory findings: Normochromic normocytic anemia, thrombocytopenia, low/normal WBC count (neutrophil leukocytosis in severe). High ESR, CRP. Coagulation study (prolonged PT/PTT, decreased ATIII). Metabolic acidosis (complicated malaria). Low plasma glucose, sodium, bicarbonate, calcium, magnesium, albumin. Elevated lactate, BUN, creatinine, muscle/liver enzymes, bilirubin, gamma globulin.",
      "Neuroimaging (cerebral malaria): Brain swelling, cortical infarcts, hyperintense areas in white matter."
    ],
    "Object7": [
      "Aims: Alleviate symptoms (blood schizontocidal drugs), prevent relapses (tissue schizontocidal drugs), prevent spread (gametocytocidal drugs).",
      "Uncomplicated falciparum malaria: Artemisinin-based Combination Therapy (ACT) is recommended. Artesunate + sulfadoxine + pyrimethamine (200 mg artesunate + 1500 mg sulfadoxine + 75 mg pyrimethamine on day 1; 200 mg artesunate on days 2 and 3). Quinine 600 mg salt TID for 5 days orally + single dose sulfadoxine 1.5 g + pyrimethamine 75 mg.",
      "Chloroquine-resistant P. falciparum: Mefloquine (15 mg/kg then 10 mg/kg after 8h), halofantrine. Dihydroartemisinin + Piperaquine for 3 days.",
      "Radical cure (P. vivax, P. ovale): Primaquine 15 mg daily for 14 days (destroys hypnozoites).",
      "Severe malaria: Artesunate 2.4 mg/kg IV/IM on admission, then 12h, 24h, then daily (for ≥24h), then full ACT. OR Artemether 3.2 mg/kg IM on admission, then 1.6 mg/kg daily (for ≥24h), then full ACT. OR Quinine 20 mg salt/kg on admission IV infusion/IM, then 10 mg/kg every 8h. Follow-on treatment: Full course of any ACT (e.g., artesunate + SP, artesunate + amodiaquine, artesunate + clindamycin/doxycycline, artemether + lumefantrine, dihydroartemisinin + piperaquine). Doxycycline or clindamycin for 7 days (pregnancy).",
      "Management of severe complications:",
      "Coma (cerebral malaria): Maintain airway, lateral position, exclude other causes, avoid harmful ancillary treatment (corticosteroids, heparin, adrenaline), intubate if needed.",
      "Hyperpyrexia: Tepid sponging, fanning, cooling blanket, antipyretics.",
      "Convulsions: Maintain airway, IV/rectal diazepam, IM paraldehyde.",
      "Hypoglycemia: Check blood glucose, correct, maintain with glucose infusion.",
      "Severe anemia: Transfuse screened fresh whole blood.",
      "Acute pulmonary edema: Prop patient up, oxygen, diuretic, stop IV fluids, intubate/PEEP/CPAP.",
      "Acute renal failure: Exclude prerenal causes, check fluid balance/urinary sodium. Hemofiltration/hemodialysis/peritoneal dialysis for established failure. Benefits of diuretics/dopamine not proven.",
      "Spontaneous bleeding/coagulopathy: Transfuse screened fresh whole blood (cryoprecipitate, FFP, platelets if available), give vitamin K.",
      "Metabolic acidosis: Exclude/treat hypoglycemia, hypovolemia, septicemia. Hemofiltration/hemodialysis for severe.",
      "Shock (algid malaria): Suspect septicemia, blood cultures, parenteral antimicrobials, correct hemodynamic disturbances.",
      "Hyperparasitemia: Artemisinins IV or orally.",
      "Uncomplicated P. falciparum in pregnancy: 1st trimester: Quinine + clindamycin for 7 days (ACT if only effective treatment). 2nd/3rd trimesters: Effective ACT or artesunate + clindamycin for 7 days or quinine + clindamycin for 7 days.",
      "Chemoprophylaxis: Doxycycline (100 mg daily for <6 weeks, start 2 days before, continue 4 weeks after). Mefloquine (5 mg/kg weekly for >6 weeks, start 2 weeks before, during, and 4 weeks after)."
    ],
    "Object8": [
      "Cerebral malaria (20% mortality in adults, 15% in children. Residual neurological sequelae in 5% adults, 10% children).",
      "Anemia (hemolysis, dyserythropoiesis, splenomegaly, hemodilution, folate depletion, hemorrhage, iron deficiency).",
      "Renal failure (acute kidney injury common in adults, progressive oliguria to anuria, usually reversible).",
      "Hypoglycemia (children with severe disease, quinine/quinidine treated, pregnant women).",
      "Fluid, electrolyte, acid-base disturbances (hypovolemia, acidotic breathing, lactic acidosis).",
      "Noncardiogenic pulmonary edema (serious in adults, high mortality >80%. May develop in vivax malaria, usually reversible).",
      "Circulatory collapse ('Algid malaria').",
      "Malarial hemoglobinuria (Blackwater fever) (uncommon, hyperparasitemia/severe disease, G6PD deficiency, can lead to renal failure).",
      "Chronic complications: Tropical splenomegaly syndrome, Quartan malarial nephropathy, Burkitt's lymphoma."
    ]
  },
  {
    "Object1": "Tropical Splenomegaly Syndrome (TSS) (Big Spleen Disease, Hyper-reactive Malarial Splenomegaly)",
    "Object2": "Massive enlargement of the spleen (chronic complication of malaria)",
    "Object3": [
      "Abnormal immune response to repeated attacks of malaria (in residents of endemic areas)"
    ],
    "Object4": [
      "Anemia",
      "Increased vulnerability to respiratory and skin infections (overwhelming sepsis)",
      "Low-grade fever (occasionally)"
    ],
    "Object5": [
      "Massive splenomegaly",
      "Hepatomegaly"
    ],
    "Object6": [
      "Antimalarial antibodies: High levels. IgM levels markedly elevated (up to 20 times).",
      "Increased serum levels of polyclonal IgM with cryoglobulinemia, reduced C3, positive rheumatoid factor (may be).",
      "Liver biopsy: Sinusoidal lymphocytosis, Kupffer cell hyperplasia. Immunofluorescence microscopy shows IgM aggregates phagocytosed by RE cells.",
      "Peripheral blood: Normocytic normochromic anemia with increased reticulocyte count. Leukopenia, thrombocytopenia (hypersplenism). Malarial parasites not found.",
      "Pancytopenia (due to hypersplenism)."
    ],
    "Object7": [
      "Chloroquine weekly or proguanil daily (may need to be continued for long periods/life).",
      "Blood transfusion for severe anemia.",
      "Splenectomy only for splenic lymphoma (may do more harm than good for TSS).",
      "Splenic irradiation or antimitotic therapy not beneficial/dangerous."
    ],
    "Object8": [
      "Overwhelming sepsis (due to increased vulnerability to infections)",
      "Portal hypertension (does not develop)",
      "Malignant lymphoproliferative disorder (e.g., CLL) (some may evolve into)"
    ]
  },
  {
    "Object1": "Leishmaniasis",
    "Object2": [
      "Visceral Leishmaniasis (Kala-azar)",
      "Post-Kala-azar Dermal Leishmaniasis (PKDL)",
      "Cutaneous Leishmaniasis"
    ],
    "Object3": [
      "Unicellular, flagellate, intracellular protozoa of the genus Leishmania",
      "Transmitted by the bite of the female phlebotomine sandfly",
      "Visceral Leishmaniasis: Leishmania donovani complex (L. donovani, L. infantum, L. chagasi)",
      "PKDL: Local parasitic infection concurrent with or after apparent recovery/cure of visceral leishmaniasis"
    ],
    "Object4": [
      "Kala-azar: Insidious onset (most asymptomatic). Fever (first sign, low-grade or high-grade with rigor/chills, intermittent, 'camel hump fever'). Anemia (moderate to severe). Bleeding manifestations (from retina, GI tract, nose).",
      "PKDL: Skin lesions (hypopigmented macules, papules, or nodules, erythematous patches, yellowish pink nodules)."
    ],
    "Object5": [
      "Kala-azar: Massive splenomegaly and hepatomegaly. Lymphadenopathy (Africa, Mediterranean, South America; West Bengal, India). Blackish discoloration of skin ('kala-azar' means black fever) (prominent over face in advanced stage, rare now).",
      "PKDL: Hypopigmented macules (earliest, trunk/extremities). Erythematous patches (butterfly distribution on face). Yellowish pink nodules (skin, rarely tongue/eye)."
    ],
    "Object6": [
      "Direct evidences:",
      "Demonstration of amastigotes (Leishman-Donovan bodies): In stained smears of aspirates (bone marrow 50-70%, spleen 70-90%, liver, lymph nodes, buffy coat). Spleen is most useful (98% sensitivity) but high hemorrhage risk. Gold standard for VL.",
      "Culture: Aspirated material cultured in NNN medium.",
      "Indirect evidences:",
      "Blood: Pancytopenia (anemia, granulocytopenia, thrombocytopenia).",
      "Biochemical: Low serum albumin, polyclonal hypergammaglobulinemia (high serum globulin, IgG then IgM). Mildly elevated bilirubin, AST/ALT, alkaline phosphatase.",
      "Serological/immunodiagnostic tests: Leishmanin (Montenegro) skin test (positive only in cured kala-azar). Napier's aldehyde (formal gel) test and Chopra's antimony test (non-specific, for increased immunoglobulins). Detection of specific antibody (complement fixation, indirect hemagglutination, IFA, countercurrent immunoglobulins - poor sensitivity/specificity). Antigen detection (reverse western blotting, dot-EIA, latex agglutination). PCR (detect DNA, identify species).",
      "PKDL: Demonstration of parasite in slit smear or culture of dermal tissue."
    ],
    "Object7": [
      "General: Blood transfusions for severe anemia, antibiotics for intercurrent bacterial infections.",
      "Pentavalent antimonial compounds (sodium stibogluconate, meglumine antimoniate): 20 mg/kg IV/IM for 40 days (risk of parasitic resistance). Side effects: arthralgias, myalgias, abdominal pain, raised LFTs, pancreatitis, ECG changes (T wave inversion, reduced amplitude), cardiotoxicity (rarely fatal). PKDL treatment for 3-4 months.",
      "Amphotericin B deoxycholate: Primary drug of choice in Bihar, India; 0.75-1.00 mg/kg daily or alternate days for 15-20 infusions (~100% cure rate). Side effects: infusion-related (fever, chills, thrombophlebitis, diarrhea, vomiting), hypokalemia, renal/hepatic toxicity, thrombocytopenia. Lipid formulations (liposomal amphotericin B, amphotericin B lipid complex, amphotericin B colloidal dispersion) reduce side effects.",
      "Miltefosine: First highly effective oral drug for VL. 50 mg once a day (if weight ≥25 kg) for 28 days. Side effects: vomiting, diarrhea, reversible hepatotoxicity/nephrotoxicity.",
      "Pentamidine isethionate (abandoned due to reduced effectiveness and serious side effects - hypoglycemia, hypotension, diabetes mellitus).",
      "Other drugs: Paromomycin (aminosidine) 11 mg/kg IM daily for 21 days. Azoles (ketoconazole, fluconazole, itraconazole) - variable efficacy."
    ],
    "Object8": [
      "Kala-azar: Hypoalbuminemia (pedal edema, ascites, anasarca). Immunosuppression (secondary infections: tuberculosis, pneumonia, malaria, severe amebic/bacillary dysentery, gastroenteritis, herpes zoster, chickenpox, skin infections). Death (within a year) due to bacterial infection or uncontrolled bleeding."
    ]
  },
  {
    "Object1": "Toxoplasmosis",
    "Object2": [
      "Infection in immunocompetent host",
      "Infection in immunocompromised host",
      "Congenital toxoplasmosis",
      "Ocular infection"
    ],
    "Object3": [
      "Intracellular protozoan parasite Toxoplasma gondii",
      "Ingestion of oocyst discharged in feces of infected cat, contaminated salads, vegetables, water",
      "Ingestion of raw or undercooked meats containing tissue cysts (bradyzoites - sheep, pigs, rabbits)",
      "Transplacental infection from mother to fetus"
    ],
    "Object4": [
      "Immunocompetent: Most acute cases subclinical. Symptomatic: Painless lymphadenopathy (most common, local/generalized, cervical). Systemic symptoms (fever, malaise, fatigue, myalgias, sore throat, headache) (uncommon). Skin rash, confusion (rarely). Myocarditis, encephalitis, pneumonia, hepatitis, polymyositis (rarely).",
      "Immunocompromised: Reactivation of latent infection. CNS (encephalopathy, meningoencephalitis, seizures, headache, focal neurological deficits). Pneumonia, ocular involvement.",
      "Congenital: Asymptomatic or serious disease. CNS (hydrocephalus, microcephaly, encephalitis, convulsions, tremors, paralysis, mental retardation). Ophthalmic (microphthalmus, nystagmus, chorioretinitis - common, blindness). Other (hepatomegaly, jaundice, thrombocytopenia, purpura)."
    ],
    "Object5": [
      "Immunocompetent: Painless lymphadenopathy (local/generalized, cervical most common).",
      "Congenital: Skull radiograph may show patches of calcification in brain. Cerebrospinal fluid may be xanthochromic with raised protein and mononuclear cells. Ocular: Gray white foci of retinal necrosis with adjacent choroiditis, vasculitis, hemorrhage, vitreitis. Anterior uveitis.",
      "Immunocompromised: Cerebral toxoplasmosis (headache, confusion, seizures, ataxia, focal deficits). Contrast CT scan: multiple contrast-enhancing lesions, space-occupying lesions with ring enhancement, surrounding edema (Fig. 5.11).",
      "Toxoplasma choroioretinitis (Fig. 5.12)."
    ],
    "Object6": [
      "Blood: Mild lymphocytosis, raised ESR, mild increase in liver enzymes.",
      "Serodiagnosis: Significant levels of Toxoplasma specific IgM antibody (acute infection). IgG antibodies (presumptive diagnosis in immunocompromised). Sabin-Feldman methylene blue dye test (titer 1:128 is diagnostic). Indirect fluorescent antibody test. Fluorescent stain for toxoplasma (Goldman's test) for parasites in smears/biopsies. ELISA test.",
      "PCR for toxoplasma DNA in ocular secretions and amniotic fluid.",
      "Microscopic examination of smear or biopsy material (lymph node/muscle) shows parasite.",
      "Inoculation of suspected material into laboratory-bred mice/guinea pigs.",
      "Toxoplasma encephalitis: CSF (normal or mild increase in cells/protein). Serum IgG antibodies. CT scan (multiple contrast-enhancing lesions). MRI (more sensitive). SPECT (differentiates from CNS lymphoma)."
    ],
    "Object7": [
      "Acquired uncomplicated in immunocompetent: Self-limiting, no treatment required.",
      "Severe/progressive disease or in immunocompromised patients: Combination of sulfadiazine (2-4 g daily) and pyrimethamine (25 mg daily loading, then 50 mg daily) for 4-6 weeks, with folinic acid/leucovorin. Steroids for ocular toxoplasmosis. Clindamycin or azithromycin if sulfa-allergic.",
      "Pregnant women (seroconversion/acute infection): Aim to reduce fetal complications. Spiramycin (3 g daily in divided doses) until term. Infected infants treated from birth."
    ],
    "Object8": [
      "Immunocompromised: Neurologic problems (encephalopathy, meningoencephalitis, seizures, headache, focal deficits). Pneumonia, ocular involvement. Primary CNS lymphoma (PCNSL).",
      "Congenital: Miscarriage, fetal death, severe birth defects.",
      "Severe toxoplasmosis can lead to fatal outcomes in immunocompromised individuals."
    ]
  },
  {
    "Object1": "Cestodes (Tapeworms) - Taenia solium",
    "Object2": [
      "Intestinal infection",
      "Cysticercosis (systemic infection from larval migration)"
    ],
    "Object3": [
      "Taenia solium (pork tapeworm)",
      "Intestinal infection: Ingestion of cysticercosis in undercooked pork",
      "Cysticercosis: Ingestion of ova/eggs of Taenia solium in contaminated water/vegetables. Feco-oral autoinfection. Reversal of peristaltic movements of intestine."
    ],
    "Object4": [
      "Intestinal infection: Usually asymptomatic (discovered by proglottids in feces/underclothing).",
      "Cysticercosis: Superficial cysts (subcutaneous/muscles) cause few/no symptoms (palpable/visible nodule). Dead larvae: muscular pain, weakness, fever, eosinophilia. Neurocysticercosis: Meningoencephalitis, epilepsy, personality changes, staggering gait, space-occupying lesion, stroke, hydrocephalus (occurs 5-20 years after larvae die)."
    ],
    "Object5": [
      "Superficial cysts: palpable or visible nodule (pea-like ovoid bodies) under skin or mucosa."
    ],
    "Object6": [
      "Stool examination: Eggs and proglottids in stool (intestinal infection).",
      "Radiological: X-rays of soft tissue (buttocks/thigh) may show calcified cysts ('cigar-shaped'/rice grain calcification). CT brain (calcified cysticerci, small hypodense lesions with/without ring enhancement, central bright spot - more sensitive than MRI for calcified cysts). MRI (better for cystic lesions, enhancement, ventricular cysticercosis).",
      "Serological test: Specific EITB (highly sensitive/specific). IFA and ELISA useful.",
      "Histological examination: Excised subcutaneous nodule or lesion shows cysticerci."
    ],
    "Object7": [
      "Intestinal infection (adult worm): Niclosamide (2 g single dose), praziquantel (5 mg/kg), or albendazole.",
      "Neurocysticercosis: Albendazole (15 mg/kg/day for 2-4 weeks). Alternative: Praziquantel (PZQ) (50 mg/kg in 3 divided doses daily for 10 days). Corticosteroids (prednisolone 10 mg 8 hourly for 14 days, starting 1 day before/during/after anthelminthic). Antiepileptic drugs for epilepsy. Operative intervention for internal hydrocephalus."
    ],
    "Object8": [
      "Neurocysticercosis: Epilepsy, personality changes, stroke, hydrocephalus, neurological deficits from spinal cord/nerve compression."
    ]
  },
  {
    "Object1": "Echinococcus granulosus (Taenia echinococcus) and Hydatid Disease",
    "Object2": "Hydatid cyst (larval stage of E. granulosus)",
    "Object3": [
      "Ingestion of eggs (by handling a dog or drinking contaminated water). Canines (dogs) are definitive hosts."
    ],
    "Object4": [
      "Usually acquired in childhood, diagnosed after 5-20 year latent period.",
      "Pressure symptoms depend on site (organ/tissue).",
      "Liver: Palpable masses or abdominal pain. Obstructive jaundice (bile duct obstruction).",
      "Rupture of hydatid cysts (into bile duct, peritoneal cavity, lung, pleura, bronchus): Fever, pruritus, urticarial rash, anaphylactoid reaction.",
      "Pulmonary hydatid cyst rupture: Cough, chest pain, hemoptysis.",
      "CNS: Epilepsy or blindness."
    ],
    "Object5": [],
    "Object6": [
      "Radiological: X-ray chest (lung: round, irregular masses. 'Meniscus sign' or 'crescent sign' (air between pericyst and laminated membrane). 'Water lily sign' (endocyst floating in fluid-filled cyst). Chest X-ray may show calcified hepatic cyst). CT scan (Fig. 4.25B), ultrasonography, MRI (identify scolices and daughter cysts).",
      "Casoni's skin test (intradermal injection of hydatid fluid, positive: immediate hypersensitivity reaction - not routinely available).",
      "Serological test: Precipitin reaction, complement fixation, immunofluorescent tests, ELISA (positive in 70-90%). IHAT, ELISA using specific echinococcal antigens."
    ],
    "Object7": [
      "Surgical excision of cysts (treatment of choice, avoid spillage of fluid, sterilize cavities with 0.5% silver nitrate or 2.7% sodium chloride).",
      "Inoperable cases: High-dose albendazole (7.5 mg/kg twice daily or 400 mg twice daily for 1-3 months). May combine with PAIR (percutaneous puncture, aspiration, injection of scolicidal agent and reaspiration).",
      "Praziquantel (20 mg/kg twice daily for 14 days) (kills protoscolices, useful perioperatively)."
    ],
    "Object8": [
      "Rupture of cysts (fatal anaphylactoid reaction).",
      "Obstructive jaundice.",
      "Recurrent cholecystitis (intrabiliary extrusion of calcified hepatic cysts)."
    ]
  },
  {
    "Object1": "Enterobius vermicularis (Threadworm/Pinworm) (Enterobiasis)",
    "Object2": "Intestinal infection",
    "Object3": [
      "Ingestion of eggs (direct transfer from anus to mouth by contaminated fingers, contaminated food or water)",
      "Retroinfection (eggs hatch in perianal region, larvae migrate back into bowel lumen)"
    ],
    "Object4": [
      "Perianal itching (Pruritus ani), especially at night (most common).",
      "Vaginal discharge, salpingitis, endometritis (migration into female genitalia).",
      "Irritability, insomnia, enuresis."
    ],
    "Object5": [
      "Adult worms may be seen moving on buttocks or in stool."
    ],
    "Object6": [
      "Direct visualizing the worms in perineal and perianal region.",
      "Stool examination for eggs (positive in only 5-10% cases).",
      "Cellophane tape test (touch adhesive tape to perianal area, examine for eggs under microscope, ~90% sensitivity)."
    ],
    "Object7": [
      "Pyrantel pamoate (single oral dose of 11 mg/kg) (treatment of choice).",
      "Other drugs: Mebendazole (100 mg single oral dose), albendazole (400 mg single oral dose), piperazine (4 g single oral dose).",
      "Recurring infections (in family): Mebendazole (100 mg twice daily for 3 days, repeated after 2 weeks). Launder night clothes/bed linens, trim fingernails, wash hands before meals."
    ],
    "Object8": [
      "Vaginal discharge, salpingitis, endometritis (female genital migration)."
    ]
  },
  {
    "Object1": "Ascaris lumbricoides (Roundworm) (Ascariasis)",
    "Object2": "Intestinal infection",
    "Object3": [
      "Nematode Ascaris lumbricoides"
    ],
    "Object4": [
      "Usually asymptomatic.",
      "Heavy infections: Nausea, vomiting, abdominal discomfort, anorexia, malnutrition (especially in children).",
      "Pulmonary: Pulmonary eosinophilia, ascaris bronchopneumonia (fever, cough, dyspnea, wheeze, eosinophilic leukocytosis, migratory pulmonary infiltrates), eosinophilic granulomas, bronchial asthma, urticaria (larval migration through lungs)."
    ],
    "Object5": [
      "Adult worm may be vomited or passed in stool."
    ],
    "Object6": [
      "Stool examination: Microscopically shows typical ova in feces. Occasionally adult worms expelled.",
      "Radiographic study: Barium examination may demonstrate worms.",
      "Blood: Eosinophilia."
    ],
    "Object7": [
      "Intestinal ascariasis: Single dose of albendazole (400 mg), pyrantel pamoate (11 mg/kg, max 1 g), ivermectin (150-200 µg/kg) or mebendazole (100 mg twice daily for 3 days).",
      "Obstruction (bolus of worms): Nasogastric suction, piperazine citrate, IV fluids. Rarely, surgical/endoscopic intervention.",
      "Ascaris bronchopneumonia: Treated symptomatically."
    ],
    "Object8": [
      "Serious morbidity and mortality (rare).",
      "Mechanical effects: Volvulus, intussusception, obstruction of small intestine (most common terminal ileum), hemorrhagic infarction, perforation (due to bolus of adult worms).",
      "Ectopic Ascariasis: Invasion of appendix (acute appendicitis), bile duct (biliary obstruction, suppurative cholangitis, liver abscess), pancreatic ducts (pancreatitis)."
    ]
  },
  {
    "Object1": "Trichuris trichiura (Whipworm) (Trichuriasis)",
    "Object2": "Intestinal infection",
    "Object3": [
      "Trichuris trichiura (whipworm)"
    ],
    "Object4": [
      "Usually asymptomatic.",
      "Mucosal damage at worm attachment: Petechiae, loss of 0.005 ml blood/worm/day (anemia).",
      "Intense infections (children): Severe mucosal damage leading to colonic ulceration, persistent diarrhea/dysentery, growth retardation, rectal prolapse."
    ],
    "Object5": [],
    "Object6": [
      "Stool examination: Microscopic examination of stool shows characteristic eggs/ova."
    ],
    "Object7": [
      "Mebendazole (100 mg twice daily for 3 days) or albendazole (400 mg once daily for 3 days) (treatment of choice). Heavy infections may need repeated doses."
    ],
    "Object8": [
      "Anemia.",
      "Colonic ulceration, persistent diarrhea/dysentery, growth retardation, rectal prolapse (intense infections in children)."
    ]
  },
  {
    "Object1": "Ancylostomiasis (Hookworm)",
    "Object2": "Symptomatic infection",
    "Object3": [
      "Parasitization with human hookworms Ancylostoma duodenale or Necator americanus",
      "Entry through skin by filariform larvae (walking bare-foot on focally contaminated soil)"
    ],
    "Object4": [
      "Skin: Allergic dermatitis/itching dermatitis ('ground itch dermatitis') at entry site (usually feet, between toes).",
      "Pulmonary: Cough with blood-stained sputum, fever, bronchitis, patchy pulmonary consolidation/bronchopneumonia, eosinophilia (larval migration through lungs).",
      "Gastrointestinal: Light infections often asymptomatic. Heavier worm loads: epigastric pain, nausea, vomiting (resembling peptic ulcer disease). Abdominal distension, pica, small frequent loose stools.",
      "Chronic heavy infection (malnourished): Iron deficiency anemia, hypoproteinemia/hypoalbuminemia, retarded physical/mental/sexual development (older children)."
    ],
    "Object5": [
      "Microcytic hypochromic anemia (peripheral blood smear)",
      "Eosinophilia (up to 70-80% in some cases)",
      "Hypoalbuminemia (severe disease)"
    ],
    "Object6": [
      "Stool examination: Microscopic examination of stool shows characteristic eggs/ovum. Tests for occult blood usually positive.",
      "Blood: Peripheral blood smear shows microcytic hypochromic anemia. Eosinophilia. Hemoglobin level low. Hypoalbuminemia.",
      "Diagnosis can be made by microscopic examination of stools for eggs."
    ],
    "Object7": [
      "Drugs: Single dose of albendazole (400 mg) (treatment of choice). Mebendazole (100 mg twice daily for 3 days), pyrantel pamoate (single oral dose of 11 mg/kg).",
      "Improvement of nutrition with high-protein diet.",
      "Anemia: Oral iron therapy for mild anemia. Blood transfusions for severe anemia (with anasarca and heart failure).",
      "Eradication confirmed by follow-up stool examination 2 weeks after treatment."
    ],
    "Object8": [
      "Iron deficiency anemia (due to chronic intestinal blood loss).",
      "Hypoproteinemia/hypoalbuminemia.",
      "Retarded physical, mental and sexual development (children with heavy infection).",
      "Heart failure (severe anemia)."
    ]
  },
  {
    "Object1": "Cutaneous Larva Migrans (Creeping Eruption)",
    "Object2": "Creeping eruptions in the skin",
    "Object3": [
      "Filariform larvae (Ancylostoma braziliense, A. caninum - non-human hookworms)",
      "Strongyloides stercoralis (larva currens, rapid movement)"
    ],
    "Object4": [
      "Intensely pruritic (itching) papule along path of larval travel."
    ],
    "Object5": [
      "Multiple, clearly defined, intensely pruritic, linear and serpiginous tracts (usually on dorsum/sole of feet, buttocks, pelvic waist, legs, shoulders).",
      "Usually no systemic symptoms."
    ],
    "Object6": [
      "Diagnosis purely clinical."
    ],
    "Object7": [
      "Ivermectin (single dose of 150-200 µg/kg) (drug of choice).",
      "Alternative: Albendazole (200 mg twice a day for 5-7 days).",
      "Antihistamines for intense itching."
    ],
    "Object8": [
      "Loeffler's syndrome (transient migratory pulmonary infiltrates, peripheral blood eosinophilia and sputum eosinophilia) (in many cases)."
    ]
  },
  {
    "Object1": "Strongyloidiasis",
    "Object2": "Intestinal infection",
    "Object3": [
      "Strongyloides stercoralis (nematode, adult worm lives in small intestine - upper jejunum)"
    ],
    "Object4": [
      "Skin: Itchy rashes at site of entry (larval migration). Migratory linear weal around buttocks/lower abdomen (cutaneous larva currens, autoinfection).",
      "Pulmonary: Cough, dyspnea, hemoptysis, bronchospasm (larval migration through lungs).",
      "Intestinal: Abdominal pain, bloating, diarrhea, steatorrhea (malabsorption), weight loss (adult worms).",
      "Systemic (Strongyloides hyperinfection syndrome): Diarrhea, severe generalized abdominal pain, abdominal distension, pneumonia, meningoencephalitis, shock, death (in immunocompromised states).",
      "Classic triad: Abdominal pain, diarrhea, urticaria."
    ],
    "Object5": [],
    "Object6": [
      "Stool examination: Motile larvae observed on microscopic examination (at least three samples), especially after incubation. Larvae may be cultured.",
      "Blood: Eosinophilia (in some patients).",
      "Duodenal/jejunal aspirate may show larvae.",
      "Serological tests: ELISA for antibody to S. stercoralis.",
      "Disseminated infection: Stool examination, ELISA, sputum and blood examination for larvae."
    ],
    "Object7": [
      "Ivermectin (200 µg/kg/day for 2 days) (drug of choice).",
      "Albendazole (alternative, less effective): 400 mg twice daily for 7 days. (Repeated if disseminated).",
      "Disseminated systemic infections: Ivermectin and albendazole (continued for 7 days or till parasites cleared)."
    ],
    "Object8": [
      "Damage to small intestinal mucosa (heavy infections) can cause perforation.",
      "Systemic strongyloidiasis (hyperinfection syndrome) can lead to death. Gram-negative sepsis."
    ]
  },
  {
    "Object1": "Filariasis",
    "Object2": [
      "Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi)",
      "Onchocerciasis (river blindness) (Onchocerca volvulus)",
      "Loiasis (Loa loa)"
    ],
    "Object3": [
      "Tissue-dwelling human nematodes (microfilariae)",
      "Lymphatic filariasis: Wuchereria bancrofti and Brugia malayi (mosquito-borne)",
      "Onchocerciasis: Onchocerca volvulus (blackfly-borne)",
      "Loiasis: Loa loa (deerfly-borne)"
    ],
    "Object4": [
      "Acute filarial lymphangitis: Fever with chills and sweats, headache, muscle pain.",
      "Chronic stage: Permanent lymphedema, scrotal edema, chylous ascites, chylous pleural effusion, chyluria. Pruritus, nocturnal bronchospasm (Tropical pulmonary eosinophilia - TPE).",
      "TPE: Paroxysmal dry cough, fever, malaise, anorexia, weight loss, dyspnea or wheeze (asthma-like symptoms)."
    ],
    "Object5": [
      "Acute filarial lymphangitis: Pain, tenderness, erythema along inflamed lymphatic vessels. Enlarged, painful, tender regional lymph nodes (inguinal). Inflammation of spermatic cord (funiculitis), epididymis (epididymitis), testis (orchitis).",
      "Chronic stage: Elephantiasis of legs (Fig. 4.28), scrotal edema, milky/opalescent chyluria/chylous effusions.",
      "TPE: Miliary pulmonary infiltrates (Weingarten syndrome). Coarse crackles and rhonchi (chest exam). Generalized lymphadenopathy and hepatosplenomegaly (may be present)."
    ],
    "Object6": [
      "Early lymphangitis: Clinical diagnosis, peripheral blood eosinophilia. Microfilariae not seen in early stages.",
      "Peripheral blood: Eosinophilia (massive). Demonstration of microfilariae (at night).",
      "Microfilariae in other fluids: Hydrocele fluid (occasionally adult worm).",
      "Diethylcarbamazine (DEC) provocation test: 100 mg DEC produces positive blood specimens within 30-60 min.",
      "Radiology: Calcified filariae (by radiography).",
      "Serological tests: Antigen detection, antibody detection (ELISA, immunochromatic method). PCR for DNA detection.",
      "Radionuclide lymphoscintigraphy: Detects widespread lymphatic abnormalities.",
      "Tropical pulmonary eosinophilia: Strongly positive serology, markedly raised IgE (>1000 units/mL). Chest X-ray (miliary changes or mottled opacities). Lung function tests (restrictive picture)."
    ],
    "Object7": [
      "Lymphatic filariasis:",
      "Diethylcarbamazine (DEC): 6 mg/kg in 3 divided doses for 12-21 days (kills microfilariae and adult worms). Adverse effects: host response to dying microfilariae (fever, headache, nausea, vomiting, arthralgia, prostration - treated with antihistamines/corticosteroids).",
      "Ivermectin: Kills only microfilariae, not adult worms.",
      "Combined albendazole (400 mg) and ivermectin (200 µg/kg) in single dose, with/without DEC (300 mg) (highly effective).",
      "Doxycycline (200 mg/day for 4 weeks) + ivermectin (single dose 200 µg/kg) (eliminates bacteria, interrupts embryogenesis).",
      "Surgery for established elephantiasis (excision of bronchiectatic areas).",
      "Chronic lymphatic pathology:",
      "Prevention of secondary infection: Meticulous skin care in lymphedematous limbs.",
      "Control of lymphedema: Tight bandaging, massage, bed rest with elevation of limb.",
      "Prevention of further damage: Prompt diagnosis/antibiotic therapy of bacterial cellulitis.",
      "Plastic surgery for established elephantiasis. Hydroceles and chyluria repaired surgically."
    ],
    "Object8": [
      "Lymphatic filariasis: Irreversible 'elephantiasis', massive hydrocele, chyluria, chylous ascites, chylous pleural effusions.",
      "Tropical pulmonary eosinophilia: Chronic interstitial lung disease (if untreated).",
      "Adverse effects of DEC: Allergic reactions (fever, headache, nausea, vomiting, arthralgia, prostration, due to host response to dying microfilariae)."
    ]
  },
  {
    "Object1": "Scabies",
    "Object2": [
      "Uncomplicated scabies",
      "Crusted or Norwegian Scabies"
    ],
    "Object3": [
      "Ectoparasitic mite, Sarcoptes scabiei var hominis",
      "Person-to-person contact (prolonged close/intimate personal contact, sexual contact)",
      "Through contaminated clothes (hats, clothes, pillow covers)",
      "Crusted scabies: Impaired immune response, lack of pruritus, neurological disorders with physical inability to scratch (hyperinfestation)"
    ],
    "Object4": [
      "Intensely itchy red papules (or occasionally vesicles and pustules)",
      "Itching/pruritus worse at night and after hot shower.",
      "Itching may produce sleep disturbances and difficulties in concentration.",
      "Crusted scabies: No/reduced pruritus (due to impaired immune response)."
    ],
    "Object5": [
      "Itchy red papules, vesicles, pustules (on web spaces of fingers/toes, palms/soles, wrists/axillae, male genitalia, nipples/umbilicus). Rare on face/scalp except infants.",
      "Generalized rash of scabies (tiny red intensely itchy bumps on limbs/trunk - allergic reaction).",
      "Itchy lumps or nodules in armpits/groins/penis shaft (highly suggestive).",
      "Acropustulosis (blisters/pustules on palms/soles of infants).",
      "Pathognomonic sign: Linear or curved skin burrows (not always seen, dark wavy lines in epidermis, up to 15mm).",
      "Crusted scabies: Marked thickening and crusting of skin (hyperkeratotic crusted lesions) on hands, may involve entire body (face/scalp). Nails often show hyperkeratosis."
    ],
    "Object6": [
      "Clinical grounds (itching, symmetrical skin lesions in characteristic distribution, history of contact).",
      "Confirmation: Identify scabietic burrow, visualize mite. Skin scrapings (microscopically for mite, eggs, fecal pellets). Clear adhesive tape from lesions. Skin biopsy."
    ],
    "Object7": [
      "Principles: Topical treatment for patient and all asymptomatic close contacts simultaneously. Wash/clean recently worn clothes/bed linen (60°C). Avoid unnecessary retreatment.",
      "Topical treatment: Scabicides applied thinly/thoroughly all over skin below neck. Reapply to hands if washed. Duration: Usually 1 day for noninfectious. Pruritus/rash may remain 4 weeks after successful treatment.",
      "Topical scabicides: Precipitated sulfur (2-10%), benzyl benzoate (10-25%), crotamiton (10%), Lindane (gamma benzene hexachloride 1%), permethrin (5%), malathion (0.5%).",
      "Oral therapy: Ivermectin (single oral dose 200 µg/kg for healthy. Two doses 2 weeks apart for Crusted/Norwegian scabies).",
      "Oral antihistamines for hypersensitivity response.",
      "Emergency treatment: Platelet transfusion, IV methylprednisolone, IV immunoglobulin for life-threatening hemorrhage."
    ],
    "Object8": [
      "Excoriations and secondary bacterial infection (from scratching).",
      "Secondary infection by nephritogenic streptococci (leading to poststreptococcal glomerulonephritis).",
      "Crusted scabies: Highly infectious, transmission through fomites.",
      "Bleeding due to severe thrombocytopenia (if ITP is also present)."
    ]
  },
  {
    "Object1": "Lice Infection (Pediculosis)",
    "Object2": [
      "Head lice (Pediculosis capitis)",
      "Body lice (Pediculosis corporis)",
      "Pubic lice (Crab lice, Phthiriasis pubis)"
    ],
    "Object3": [
      "Blood-sucking ectoparasites (lice)",
      "Head lice: Direct head-to-head contact, overcrowding. Indirectly through hats, clothes, pillow covers.",
      "Body lice: Poor hygiene, poverty, neglect, overcrowded conditions. Direct contact or sharing infested clothing.",
      "Pubic lice: Sexually acquired (direct contact)."
    ],
    "Object4": [
      "Head lice: Scalp itch, scratching, sleep disturbances, difficulties in concentration (poor school performance).",
      "Body lice: Itch, excoriations.",
      "Pubic lice: Asymptomatic or severe itching (especially at night)."
    ],
    "Object5": [
      "Head lice: Scalp excoriations, secondary infection (impetigo), cervical lymphadenopathy. Living louse, nymph, empty egg cases ('nits' on hair shaft).",
      "Body lice: Secondary infection. Post-inflammatory hyperpigmentation of skin. Lice and eggs on clothing (rarely on skin).",
      "Pubic lice: Lice seen near hair base with eggs."
    ],
    "Object6": [
      "Diagnosis by identifying live lice, nymphs, or nits."
    ],
    "Object7": [
      "Head lice: Malathion or permethrin or carbaryl or phenothrin lotion/aqueous (twice at 7-10 day interval, 12h contact time). Rotational treatments. Regular 'wet-combing'. Vaseline to eyelashes/brows. Oral ivermectin (400 µg/kg as 2 doses 1 week apart) for resistant cases. Treat secondary bacterial infection.",
      "Body lice: Malathion or permethrin. Dry cleaning/high-temperature washing/insecticide treatment for clothes.",
      "Pubic lice: Malathion or carbaryl in aqueous base (applied twice to whole body). All sexual contacts treated. Screen for other STDs."
    ],
    "Object8": [
      "Head lice: Secondary infection (impetigo).",
      "Body lice: Secondary infection.",
      "Can cause other STDs (Pubic lice)."
    ]
  },
  {
    "Object1": "Gonorrhea",
    "Object2": "Sexually transmitted infection (STI)",
    "Object3": [
      "Neisseria gonorrhea (gram-negative diplococcus)",
      "Genital-genital, genital-anorectal, or oro-genital or oro-anal contact",
      "Mother-to-child transmission during delivery"
    ],
    "Object4": [
      "Men (acute urethritis): Urethral discharge, dysuria (without urinary frequency/urgency).",
      "Women (gonococcal cervicitis/vaginitis): Scant vaginal discharge, dysuria. (Often asymptomatic, up to 80%).",
      "Anorectal and pharyngeal gonorrhea: Usually asymptomatic.",
      "Ocular gonorrhea: Purulent discharge from eye(s).",
      "Disseminated gonococcal infection (DGI): Arthritis (asymmetric and migratory), pustular skin lesions, fever, tenosynovitis.",
      "Acute perihepatitis (Fitz-Hugh-Curits syndrome): Sharp, pleuritic right upper quadrant pain."
    ],
    "Object5": [
      "Men: Urethra shows mucopurulent discharge, erythema of urethral meatus.",
      "DGI: Pustular skin lesions.",
      "Ocular: Purulent conjunctivitis, edema of eyelids."
    ],
    "Object6": [
      "Gram's staining and culture: Urethral exudates, genital, rectal, pharyngeal or ocular secretions show gram-negative intracellular monococci and diplococci.",
      "Sterile pyuria: Polymorphonuclear leukocytes with negative urine culture.",
      "Nucleic acid amplification tests (NAATs): More sensitive than culture, on urine samples, swabs (endocervix, urethra, rectum, pharynx).",
      "Direct antigen detection by fluorescein-conjugated monoclonal antibodies and direct fluorescence microscopy.",
      "Enzyme-linked immunoassays for gonococcal antigen.",
      "Blood cultures (disseminated disease)."
    ],
    "Object7": [
      "Cefixime 400 mg orally (single dose) OR Ceftriaxone 250 mg intramuscularly (single dose) OR Spectinomycin 2 g intramuscularly (single dose).",
      "If quinolone and azithromycin resistance not a problem: Ciprofloxacin 500 mg orally (single dose) OR Ofloxacin 400 mg orally (single dose) OR Levofloxacin 250 mg orally (single dose) OR Azithromycin 2 g orally (single dose).",
      "Epididymo-orchitis: Doxycycline 100 mg twice daily for 14 days + one dose of ceftriaxone or ciprofloxacin.",
      "General: All sex partners in last 60 days evaluated/treated. Sexual abstinence till completion. Review patient 2-3 weeks post-treatment. Check for other STIs (syphilis, HIV)."
    ],
    "Object8": [
      "Females: Pelvic inflammatory disease (PID), endometritis, salpingitis, tubo-ovarian abscess, bartholinitis, peritonitis, perihepatitis.",
      "Males: Periurethritis, epididymitis epididymo-orchitis, prostatitis.",
      "Newborns: Ophthalmia neonatorum.",
      "Disseminated gonococcal infection: Gonococcal bacteremia, endocarditis, meningitis (rarely)."
    ]
  },
  {
    "Object1": "Nongonococcal Urethritis",
    "Object2": "Urethritis",
    "Object3": [
      "Chlamydia trachomatis (15-40%)",
      "Mycoplasma genitalium (15-25%)",
      "Others (20-50%): Trichomonas vaginalis, Ureaplasma urealiticum, Herpes simplex virus (in absence of skin lesions), Adenovirus, Hemophilus",
      "Miscellaneous: Urinary tract infection, bacterial prostatitis, urethral stricture, phimosis, secondary to instrumentation of the urethra, congenital abnormalities, chemical imitation, tumors"
    ],
    "Object4": [
      "Similar to gonococcal urethritis but differ in severity."
    ],
    "Object5": [],
    "Object6": [
      "Gram staining of discharge or sediment of first voided urine.",
      "Direct fluorescence assay.",
      "Enzyme immunoassay.",
      "Hybridization assay.",
      "Nucleic acid amplification tests."
    ],
    "Object7": [
      "Doxycycline 100 mg twice daily for 7 days OR Azithromycin 1 g orally.",
      "Alternatives: Erythromycin base 500 mg four times for 7 days OR Ofloxacin 300 mg twice daily for 7 days OR Levofloxacin 500 mg once daily for 7 days.",
      "General: All sex partners in last 60 days should be evaluated and treated. Sexual abstinence till completion of treatment. Patients reviewed 2-3 weeks after treatment. Check for other STIs including syphilis and HIV."
    ],
    "Object8": []
  },
  {
    "Object1": "Chancroid (Soft Chancre)",
    "Object2": "Acute sexually transmitted infection",
    "Object3": [
      "Haemophilus ducreyi"
    ],
    "Object4": [
      "Painful genital ulcerations",
      "Inguinal adenitis"
    ],
    "Object5": [
      "Initial erythematous papule (at inoculation site) appears then breaks down into classic chancroidal ulcer (superficial, circumscribed, painful, ragged/undermined edges, necrotic base, bleeds easily, generally not indurated. May be single or merge to giant serpiginous ulcer).",
      "Enlarged, painful, tender inguinal lymph nodes (usually unilateral) (buboes). May become matted, fluctuant, rupture (multiple draining fistulae)."
    ],
    "Object6": [
      "Microscopic identification and culture isolation of Hemophilus ducreyi (scrapings from ulcer or pus from bubo).",
      "Polymerase chain reaction (PCR) technique (not commercially available).",
      "Detection of antibody to H. ducreyi using EIA (may be useful)."
    ],
    "Object7": [
      "Azithromycin, 1 g orally, single dose OR Ceftriaxone, 250 mg IM single dose OR Ciprofloxacin, 500 mg orally, twice daily for 3 days OR Erythromycin base, 500 mg orally 4 times daily for 7 days.",
      "Early treatment is necessary. Fluctuant buboes should be aspirated. Surgical drainage or reconstructive surgery may be needed.",
      "Sex partners treated."
    ],
    "Object8": [
      "Genital ulceration increases efficiency of HIV transmission and susceptibility to HIV infection.",
      "Coinfection with Treponema pallidum and herpes simplex (10% cases)."
    ]
  },
  {
    "Object1": "Chlamydial Infections",
    "Object2": "Not specified",
    "Object3": [
      "Chlamydia trachomatis"
    ],
    "Object4": [
      "Males: Urethritis, epididymitis, prostatitis.",
      "Females: Cervicitis, salpingitis (most asymptomatic)."
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Treatment with antibiotics (e.g., doxycycline, azithromycin)."
    ],
    "Object8": [
      "Males: Infertility, reactive arthritis (if untreated).",
      "Females: Pelvic inflammatory disease (PID), infertility, ectopic pregnancy (if untreated)."
    ]
  },
  {
    "Object1": "Lymphogranuloma Venereum (LGV)",
    "Object2": "Sexually transmitted disease",
    "Object3": [
      "Chlamydia trachomatis (types LGV 1, 2 and 3)"
    ],
    "Object4": [
      "Primary genital lesion: Asymptomatic small painless papule at inoculation site, tends to ulcerate.",
      "Acute LGV: Proctitis with perirectal abscesses (may resemble Crohn's disease).",
      "Constitutional symptoms: Fever, chills, headache, anorexia, meningismus, myalgias, arthralgias."
    ],
    "Object5": [
      "Regional lymphadenopathy (usually unilateral, initially discrete painful and fixed, overlying skin dusky/erythematous).",
      "Buboes (lymph nodes become matted, fluctuant, rupture, multiple draining fistulae).",
      "Extensive enlargement of inguinal lymph nodes ('groove sign').",
      "Chronic phase: Extensive scarring, abscess, sinus formation. Lymphedema of genitalia."
    ],
    "Object6": [
      "Detection of nucleic acid (DNA): Direct immunofluorescent antibody, NAATs, real time PCR for LGV specific DNA.",
      "Isolation of LGV (L1-3 serotypes) strain of Chlamydia: Tissue culture from swab (ulcer, bubo pus, rectum, urethra, endocervix - 75-85% sensitivity).",
      "Serological tests: Microimmunofluorescence (micro IF) test, complement fixation test (CF) for antibodies.",
      "Frei skin test (not useful)."
    ],
    "Object7": [
      "Doxycycline, 100 mg orally, twice daily for 14 days OR Erythromycin, 500 mg orally, 4 times daily for 14 days OR Tetracycline, 500 mg orally, 4 times daily for 14 days.",
      "Early treatment is necessary to prevent chronic phase.",
      "Fluctuant buboes aspirated. Surgical drainage or reconstructive surgery needed sometimes."
    ],
    "Object8": [
      "Chronic phase: Extensive scarring, abscess, sinus formation. Destruction of local lymph nodes can produce lymphedema of the genitalia."
    ]
  },
  {
    "Object1": "Granuloma Inguinale (Donovanosis)",
    "Object2": "Genital ulcerative disease",
    "Object3": [
      "Intracellular gram-negative bacterium Klebsiella granulomatis (Donovan bodies)"
    ],
    "Object4": [],
    "Object5": [
      "Painless, progressive ulcerative lesions without regional lymphadenopathy.",
      "Genital lesions highly vascular ('beefy red appearance'), bleed easily on touch. Can produce hypertrophic granulomatous, necrotic or sclerotic lesions."
    ],
    "Object6": [
      "Microscopy examination of material from lesion (tissue crush preparation or biopsy) shows dark staining intracellular bipolar-staining Donovan bodies.",
      "Causative organism difficult to culture."
    ],
    "Object7": [
      "Azithromycin, 1 g orally on first day, then 500 mg orally, once a day, OR Doxycycline, 100 mg orally, twice daily, OR Erythromycin, 500 mg orally, 4 times daily, OR Tetracycline, 500 mg orally, 4 times daily, OR Trimethoprim 80 mg/sulfamethoxazole 400 mg, 2 tablets orally, twice daily.",
      "Treatment continued until all lesions completely epithelialized (at least 3 weeks)."
    ],
    "Object8": []
  },
  {
    "Object1": "Syphilis (Lues)",
    "Object2": [
      "Acquired Syphilis (Primary, Secondary, Latent, Late/Tertiary)",
      "Congenital Syphilis (Intrauterine death, perinatal death, Early (infantile), Late (tardive))"
    ],
    "Object3": [
      "Spirochete Treponema pallidum (gram-negative, slender corkscrew-shaped)",
      "Sexual contact (usual mode of spread)",
      "Transplacental transmission (mother to fetus) → congenital syphilis",
      "Blood transfusion",
      "Direct contact with open infectious lesion (chancre, mucous patch, skin rash, condylomata lata)"
    ],
    "Object4": [
      "Primary: Chancre (painless), Regional lymphadenitis (painless).",
      "Secondary: Malaise, sore throat, headache, low-grade fever, arthralgia (systemic). Meningitis, cranial nerve palsies, anterior/posterior uveitis, hepatitis, gastritis, glomerulonephritis, arthritis, periostitis (less common).",
      "Latent: No clinical disease, positive serology (early latent - sexually transmissible; late latent - not sexually transmissible).",
      "Late (Tertiary): Benign tertiary (gummatous): Localized bone pain or pathological fracture (vertebral lesions). Neurologic symptoms (spinal cord/root compression). Cardiovascular: Angina (syphilitic aortitis), aortic incompetence, aortic aneurysm. Neurosyphilis (pages 976-7).",
      "Congenital (Early/infantile): Nasal discharge/congestion ('snuffles'). Desquamating/bullous eruption/rash (hands, feet, mouth, anus). Condyloma lata. Skeletal abnormalities (syphilitic osteochondritis/periostitis, saddle nose, saber shin).",
      "Congenital (Late/tardive): Interstitial keratitis, Hutchinson's teeth, eighth-nerve deafness (Hutchinson's triad). Clutton's joints, neurosyphilis, gummatous periostitis, destruction of palate/nasal septum."
    ],
    "Object5": [
      "Primary chancre (Fig. 4.31): Single, firm, non-tender (painless), slightly raised, red papule. Rapidly eroded to clean-based shallow ulcer ('hard chancre'). Regional lymphadenitis (firm, rubbery, mobile, non-suppurative, painless, non-tender).",
      "Secondary: Mucocutaneous lesions (painless, superficial, infectious): Skin rashes (macules to scaly/pustular/annular/necrotic ulcers, often on palms/soles). Condylomata lata (Fig. 4.32B) (broad-based, moist, pink/gray-white, elevated plaques). Mucosal lesions (silvery-gray erosions, 'snail track' ulcers in mouth). Generalized painless lymphadenopathy ('shotty'). Mild fever, malaise, weight loss.",
      "Late (Tertiary): Gumma (chronic granulomatous lesion, single/multiple, may ulcerate).",
      "Congenital (Early): Desquamating/bullous eruption/rash. Condyloma lata. Saddle nose. Saber shin.",
      "Congenital (Late): Stigmata of congenital syphilis (Hutchinson's incisors, Mulberry molars, High arched palate, Saddle nose, Rhagades, Salt and pepper scars on retina, Corneal scars, Sabre tibia, Bossing of frontal/parietal bones)."
    ],
    "Object6": [
      "Demonstration of Treponema pallidum: Dark-field microscopy (most sensitive/specific, from primary chancres/mucous lesions). Direct fluorescent antibody T. pallidum (DFA-TP) test (fixed smears). Microscopic demonstration in stained tissues. PCR.",
      "Serological Tests: Non-treponemal antibody tests (nonspecific, measure antibody to cardiolipin): VDRL, RPR. Treponemal (specific) antibody tests (measure antibodies reacting with T. pallidum): Treponemal antigen-based EIA (IgG/IgM), TPHA, TPPA, FTA-ABS. (Remain positive for life regardless of treatment, usually. 15-25% primary stage treated become nonreactive).",
      "CSF examination (in benign tertiary, cardiovascular, neurosyphilis, congenital syphilis).",
      "Chest X-ray, ECG, Echocardiogram (cardiovascular syphilis).",
      "Biopsy (for gumma)."
    ],
    "Object7": [
      "Penicillin is drug of choice.",
      "Primary, Secondary, Early Latent Syphilis:",
      "Benzathine penicillin G: 2.4 million units IM single dose (1.2 million units in each buttock).",
      "Procaine penicillin: 6,00,000 units IM/day for 12 days.",
      "Penicillin allergic: Tetracycline or doxycycline for 2 weeks. Ceftriaxone (1 g once a day for 10-14 days). Azithromycin (2 g single dose, except homosexual men/pregnancy).",
      "Late Latent/Tertiary and Cardiovascular Syphilis:",
      "Benzathine penicillin: 2.4 million units IM weekly for 3 weeks.",
      "Neurosyphilis:",
      "Crystalline penicillin: 18-24 million units/day for 10-14 days.",
      "Procaine penicillin: 2.4 million units/day IM for 10-14 days + probenecid 500 mg QID for 10-14 days.",
      "Treatment response: Four-fold decrease in non-treponemal titers at 3-6 months. Neurosyphilis: Lumbar puncture every 6 months until cell count normal; retreatment if not decreased.",
      "Treatment reactions:",
      "Anaphylaxis (penicillin).",
      "Jarisch-Herxheimer reaction: Acute febrile reaction (headache, myalgia, malaise, mild fever, rigors) 8 hours after first dose (due to endotoxin/cytokine release). Common in early syphilis, rare in late. May induce fetal distress/premature labor. Prednisolone (10-20 mg orally TID for 3 days, starting 24h prior) may prevent reaction."
    ],
    "Object8": [
      "Untreated: Progression to secondary, latent, or late syphilis. Congenital syphilis.",
      "Secondary: Meningitis, cranial nerve palsies, uveitis, hepatitis, gastritis, glomerulonephritis, arthritis, periostitis.",
      "Late (Tertiary): Organ damage (skin, mucous membranes, bone, viscera). Cardiovascular syphilis (aortic aneurysm, aortic incompetence). Neurosyphilis.",
      "Congenital: Intrauterine death, perinatal death. Blindness, deafness, mental retardation, skeletal deformities."
    ]
  },
  {
    "Object1": "Nosocomial Infections (Hospital Infections) / Health Care-Associated Infection (HAI)",
    "Object2": [
      "Reactivation of latent infection",
      "Endogenous infections (autogenous infections)",
      "Exogenous infections (cross infections)",
      "Intravascular Catheter-Related Infections (localized: thrombophlebitis, abscess; systemic: bacteremia, sepsis, endocarditis, metastatic infection)",
      "Hospital-Acquired Pneumonia (HAP)",
      "Other Respiratory Tract Infections (Tracheobronchitis, Sinusitis)",
      "Urinary Tract Infections (UTI) - Urinary Catheter-Related Infections",
      "Surgical Site Infections (SSI) (Superficial, Deep, Organ)",
      "Gastrointestinal Infections (Antibiotic-associated colitis)",
      "Central Nervous System Infections (CSF shunt-related)"
    ],
    "Object3": [
      "Pathogens acquired in hospital (e.g., Staphylococcus aureus, enterobacteria, Pseudomonas aeruginosa, Acinetobacter spp., coagulase-negative Staphylococci, Enterococci, Candida)",
      "Reactivation of latent infection (TB, herpes viruses)",
      "Endogenous: Altered normal flora, transfer of microorganisms within body cavities.",
      "Exogenous: Hospital personnel, other individuals, objects, hospital environment (Aspergillus from construction, Legionella from water).",
      "Predisposing factors: Pre-existing condition, invasive devices, surgery (skin wound, tissue trauma, colonized viscus opening, immobilization, foreign material implants), antibiotic treatment (colonization by resistant bacteria/fungi), immunosuppressive treatment, exposure to health care workers/patients/pathogens in hospital environment.",
      "HAP: Severe underlying disease, immunosuppression, prolonged antibiotic therapy, mechanical ventilation (VAP), invasive access devices. Early onset HAP/VAP: antibiotic sensitive bacteria. Late onset HAP/VAP: multidrug resistant (MDR) pathogens (P. aeruginosa).",
      "UTI: Endogenous (patient's own enteric flora - E. coli), Exogenous (cross contamination of drainage systems). Risk factors: Length of catheterization, opened drainage system, diabetes, female sex, age >50."
    ],
    "Object4": [
      "Catheter-Related: Local signs of inflammation (redness, tenderness, swelling, purulent exudate), systemic signs (fever, rigors, no other source).",
      "Antibiotic-associated colitis: Diarrhea, fever, abdominal pains, vomiting (related to antibiotic treatment).",
      "HAP: Purulent sputum/endotracheal secretions, new infiltrate on chest X-ray, unexplained increase in oxygen requirement, core temperature >38.3°C, leukocytosis/leukopenia."
    ],
    "Object5": [
      "Local signs of inflammation at catheter entry site.",
      "Purulent sputum/endotracheal secretions.",
      "New infiltrate on chest X-ray."
    ],
    "Object6": [
      "Catheter-Related: Two blood cultures (one from catheter, one peripheral), catheter tip culture (>15 CFU = infection).",
      "HAP: Blood cultures, microbiological confirmation from respiratory secretions (bronchoscopy-directed brush specimens, BAL, endotracheal aspirates). FBC, U&E, ESR, CRP, ABG, Chest X-ray.",
      "UTI: Pyuria (>5 leukocytes/HPF), Urine culture (significant bacteriuria ≥10^5 CFU/mL).",
      "Antibiotic-associated colitis: Cl. difficile toxin detection (ELISA), antigen detection (latex agglutination). Colonoscopy (pseudomembranes, histology).",
      "General: Microbial cultures, imaging studies (X-ray, CT)."
    ],
    "Object7": [
      "Catheter-Related: Catheter removal, culture of tip. Antibiotics (if symptoms persist after removal, guided by culture). Long-time catheters: catheter treatment, antibiotic locks.",
      "HAP: Prompt initiation of antibiotic therapy. Empirical choice based on likely pathogens, penetration to source, susceptibility patterns. Source control (drainage, debridement, device removal, definitive control).",
      "UTI: Catheter removal/change. Antibiotics in symptomatic UTI.",
      "Antibiotic-associated colitis: Stop precipitating antibiotic. Rehydration, diet. Antibiotic (oral metronidazol or vancomycin for ≥7 days). Probiotic drugs, colestipol, rifaximin. Colectomy for toxic megacolon.",
      "Prevention: Rigorous handwashing (single most important measure). Aseptic technique. Proper patient isolation. Modify host risk factors (difficult). Reduce patient exposure. Reduce number/virulence of pathogens.",
      "HAP Prevention: Pulmonary toilet (change position, elevate head, deep breathing, incentive spirometry, frequent suctioning, bronchoscopy). Tracheobronchitis/Sinusitis prevention in ventilated patients.",
      "UTI Prevention: Avoid/discontinue catheter ASAP. Aseptic insertion. Maintain closed drainage. Dependent drainage. Minimize manipulation. Silver-coated catheters. Good patient hygiene. Regular catheter replacement. ICU screening.",
      "SSI Prevention: Preoperative (minimize hospital stay, cutting vs shaving, antibiotic prophylaxis, surgical team hygiene, skin decolonization - chlorhexidine, mupirocin). Intraoperative (tissue-saving technique, bleeding control, foreign body/devitalized tissue excision, incised bowel isolation, minimize staff/movement). Postoperative (aseptic site care, sterile covering)."
    ],
    "Object8": [
      "Catheter-Related: Pneumothorax, brachial plexus/subclavian artery injury, local infection/septicemia, pericarditis.",
      "HAP: Serious and life-threatening. VAP (highest risk in mechanically ventilated patients). Tracheobronchitis, sinusitis.",
      "UTI: Ascending infection (pyelonephritis, bacteremia, sepsis).",
      "Antibiotic-associated colitis: Pseudomembranous colitis, toxic megacolon.",
      "SSI: Surgical site infections and related bacteremias.",
      "CNS: CSF shunt-related infections (serious course, high mortality).",
      "Multidrug-resistant pathogens."
    ]
  },
  {
    "Object1": "Sepsis",
    "Object2": [
      "Systemic inflammatory response syndrome (SIRS)",
      "Sepsis (SIRS + suspected/confirmed infection)",
      "Severe sepsis (Sepsis + organ hypoperfusion/dysfunction - removed in 2016 guidelines)",
      "Septic shock (Severe sepsis + hypotension/pressors/lactate >2 mmol/L)",
      "Multiple organ dysfunction syndrome (MODS)"
    ],
    "Object3": [
      "Clinical insult (e.g., infection, inflammation, stress, trauma, burns)",
      "Gram-positive (most common) or gram-negative bacteria, fungi, protozoa, Rickettsiae (septic shock)",
      "Common gram-positive: Staphylococcus aureus, enterococci, Streptococcus pneumoniae",
      "Gram-negative bacilli: Resistant to usual antibiotics",
      "Risk factors: Genetic polymorphism (cytokine, coagulation, mannose binding proteins), Procedures (urinary catheters, IV cannula, wound dressings, surgery), Wounds, Emergency vs elective surgery, Dirty vs clean wounds, Prosthetic material, Intrinsic factors (age, nutrition, comorbidities, vaccination, immunosuppression), Community factors (contacts, disease outbreaks, specific exposure), Hospital factors (duration of stay, ICU, outbreaks, local antimicrobial resistance rates)"
    ],
    "Object4": [
      "SIRS: Temperature >38.5°C or <36°C, Heart rate >90 bpm, Respiratory rate >20 breaths/min or PaCO2 <32 mmHg, WBC >12,000 cells/mm3 or <4,000 cells/mm3 or >10% immature forms.",
      "Sepsis: Organ dysfunction (Hypotension, Tachypnea, Altered mentation (qSOFA ≥2)).",
      "Septic shock: Hypotension (not responding to fluid), need for pressors, lactate >2 mmol/L."
    ],
    "Object5": [
      "SIRS signs",
      "Signs of organ dysfunction (cardiovascular: tachycardia, hypotension; respiratory: tachypnea, low PaO2/SaO2/PaO2/FiO2; CNS: altered consciousness, confusion, psychosis; renal: oliguria, anuria, increased creatinine; hematological: low platelets, increased PT/APTT, low protein C, increased D-dimer; liver: jaundice, increased LFTs, low albumin, increased PT)"
    ],
    "Object6": [
      "Blood culture (at least two sets before antibiotics, one percutaneous, one from each vascular access device if >48h)",
      "Other cultures (urine, CSF, wounds, respiratory secretions, other body fluids) as per clinical situation.",
      "Other diagnostic studies (imaging, sampling) to determine source/organism.",
      "Lactate level (septic shock)."
    ],
    "Object7": [
      "Surviving sepsis campaign: Identify, categorize, initiate treatment.",
      "Initial resuscitation: Volume resuscitation with normal saline 30 mL/kg over first 30 min. If MAP <70 mmHg, start inotropes.",
      "Antibiotic therapy: IV within first hour of severe sepsis, after cultures. Empirical choice (broad-spectrum, cover likely pathogens, penetrate source, guided by susceptibility). Continue broad-spectrum until organism/susceptibilities defined.",
      "Source control: Drainage (intra-abdominal abscess, empyema, septic arthritis, pyelonephritis, cholangitis), Debridement (necrotizing fasciitis, infected pancreatic necrosis, mediastinitis, intestinal infarction), Device removal (infected vascular catheter, urinary catheter, colonized endotracheal tube), Definitive control (sigmoid resection for diverticulitis, amputation for clostridial myonecrosis, cholecystectomy for gangrenous cholecystitis).",
      "Fluid therapy: Crystalloids first. Colloids (FFP for coagulopathy, RBCs for HCT <7g/dL).",
      "Vasopressors: If fluid challenge fails. Norepinephrine or dopamine (first-line).",
      "Inotropic therapy: Dobutamine for low cardiac output despite fluids (combine with vasopressor if hypotensive).",
      "Steroids: IV hydrocortisone 200-300 mg/day for 7 days (for septic shock requiring vasopressors).",
      "Recombinant Human Activated Protein C (rhAPC) (drotrecogin alfa): For high risk of death (APACHE II ≥25, MOF, septic shock, ARDS) (Removed from guidelines).",
      "Blood product administration: RBC transfusion only when Hb <7 g/dL (target 7-9 g/dL).",
      "Mechanical ventilation: For ALI/ARDS. Lung-protective (low tidal volumes, low plateau pressures, PEEP).",
      "Sedation, analgesia, neuromuscular blockade: Protocols and daily interruption.",
      "Glucose control: <150 mg/dL after initial stabilization. Nutrition protocol (preferential enteral route).",
      "Renal replacement: CVVH and intermittent hemodialysis equivalent for AKI. CVVH for unstable septic patients.",
      "Bicarbonate therapy: Not recommended for improving hemodynamics/reducing vasopressors/lactic academia with pH >7.15.",
      "Deep vein thrombosis prophylaxis: Low-dose unfractionated heparin or LMWH.",
      "Stress ulcer prophylaxis: H2 receptor blockers (preferred).",
      "Early goal directed therapy (EGDT): Obtain lactate, early blood culture/antibiotics, fluid bolus, vasopressors, CVP/ScvO2 monitoring, PRBCs, inotropes, glucose control, rhAPC, steroids, lung protection, DVT/stress ulcer prophylaxis, early enteral nutrition."
    ],
    "Object8": [
      "MODS (multiple organ dysfunction syndrome)",
      "Organ hypoperfusion or dysfunction (severe sepsis)",
      "Hypotension (septic shock)",
      "Lactate elevation (septic shock)",
      "Coagulopathy",
      "ALI/ARDS",
      "Thrombosis (due to rhAPC)"
    ]
  },
  {
    "Object1": "Antimicrobial Combination Therapy",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Limit combination therapy to special situations: Synergistic killing (B-lactam + aminoglycoside for endocarditis), Mixed infections/severe unknown cause (limb infections in diabetics), Prevent emergence of resistance (M. tuberculosis).",
      "Initial empiric therapy (for acute sepsis): Broad-spectrum antibiotics.",
      "Multidrug Therapy: Tuberculosis, infective endocarditis, malaria, HIV, leprosy."
    ],
    "Object8": []
  },
  {
    "Object1": "Antibiotic Chemoprophylaxis",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Infective endocarditis: Amoxicillin + Gentamicin",
      "Splenectomy: Penicillin",
      "Rheumatic fever: Penicillin",
      "Tuberculosis: INH",
      "Meningitis (Meningococcal and H. influenzae): Rifampicin"
    ],
    "Object8": []
  },
  {
    "Object1": "Beta-lactam Antibiotics Adverse Effects",
    "Object2": "Adverse effects",
    "Object3": [
      "Use of Beta-lactam antibiotics"
    ],
    "Object4": [],
    "Object5": [
      "Generalized allergy to penicillin",
      "Gastrointestinal upset and diarrhea",
      "Mild reversible hepatitis",
      "Leucopenia, thrombocytopenia and coagulation deficiencies",
      "Interstitial nephritis",
      "Potentiation of aminoglycoside-mediated renal damage",
      "Thrombophlebitis with parenteral ẞ-lactams"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Beta-Lactamases (Drug Resistance)",
    "Object2": [
      "Extended-Spectrum B-Lactamases (ESBL)",
      "Carbapenem-Resistant Enterobacteriaceae (KPC, NDM-1)"
    ],
    "Object3": [
      "Bacterial enzymes that inactivate B-lactam antibacterials by hydrolysis of B-lactam ring structure.",
      "ESBL: Plasmid-mediated cephamycinases, amino acid substitutions in native B-lactamases (TEM-1, TEM-2, SHV-1). Commonly produced by Klebsiella spp., E. coli, Enterobacter, Proteus, Salmonella, Citrobacter spp., Morganella amorganii, Shigella dysenteriae, Serratia marcescens, Pseudomonas aeruginosa, Burkholderia cepacia.",
      "Risk factors for ESBL: Critically ill/severely debilitated patients, prolonged hospital/ICU stay, invasive procedures, long-term care facility stay, decubitus ulcer, total dependence on healthcare workers, prior antibiotic use (2nd/3rd cephalosporins, aztreonam, penicillin, quinolones), delay in appropriate antibiotic therapy.",
      "NDM-1: Novel metallo-B-lactamase (MBL) coded by gene blaNDM-1 in Enterobacteriaceae."
    ],
    "Object4": [],
    "Object5": [
      "ESBL: Resistance to all penicillins, cephalosporins (except cephamycins), monobactams. Associated with multidrug resistance (fluoroquinolones, co-trimoxazole, aminoglycosides).",
      "NDM-1: Multidrug resistance, susceptible only to tigecycline and colistin."
    ],
    "Object6": [
      "Culture and sensitivity testing to identify resistance."
    ],
    "Object7": [
      "ESBL producers (infection):",
      "Imipenem or meropenem (bloodstream infection, VAP, reduced susceptibility to ertapenem).",
      "Ertapenem or doripenem (complicated UTI, diabetic foot infections, intra-abdominal infections).",
      "Quinolones (for carbapenem allergy, if susceptible).",
      "Nitrofurantoin or fosfomycin (uncomplicated lower UTI).",
      "Tigecycline, colistin, or polymyxin B (for isolates resistant to all other antibiotics, or beta-lactam allergy).",
      "No treatment for colonization with ESBL producers.",
      "NDM-1: Tigecycline and colistin (only susceptible agents)."
    ],
    "Object8": [
      "Multidrug resistance.",
      "Increased morbidity and mortality (ESBL).",
      "Hospital epidemics (Clostridium difficile toxin A/B)."
    ]
  },
  {
    "Object1": "Amikacin",
    "Object2": "Semisynthetic derivative of kanamycin (aminoglycoside)",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Ototoxicity (more hearing loss than vestibular disturbance), cochlear and vestibular damage, deafness, neuromuscular blockage.",
      "Nephrotoxicity (non-oliguric renal failure).",
      "Rare: Hemolytic anemia, aplastic anemia, agranulocytosis, thrombocytopenia, lupoid reactions."
    ]
  },
  {
    "Object1": "Doxycycline",
    "Object2": "Tetracycline antibiotic",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Cephalosporins",
    "Object2": [
      "First generation (Cephalexin, Cephradine, Cefadroxil)",
      "Second generation (Cefuroxime, Cefuroxime axetil, Cefaclor)",
      "Third generation (Cefotaxime, Ceftizoxime, Ceftriaxone, Ceftazidime, Cefoperazone, Cefixime, Cefpodoxime, Cefdinir, Ceftibuten, Ceftamet pivoxil)",
      "Fourth generation (Cefepime, Cefpirome)",
      "Fifth generation (Ceftobiprole, Ceftaroline)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Tetracycline Adverse Effects",
    "Object2": "Adverse Effects",
    "Object3": [
      "Use of Tetracycline"
    ],
    "Object4": [
      "Epigastric pain, nausea, vomiting, diarrhea",
      "Phototoxicity",
      "Increased intracranial pressure"
    ],
    "Object5": [
      "Fatty liver",
      "Renal damage",
      "Brown discoloration of teeth",
      "Antianabolic effect",
      "Vestibular toxicity",
      "Superinfection",
      "Hypersensitivity"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Chloramphenicol Adverse Effects",
    "Object2": "Adverse Effects",
    "Object3": [
      "Use of Chloramphenicol"
    ],
    "Object4": [],
    "Object5": [
      "Bone marrow depression",
      "Hypersensitivity reactions",
      "Nausea, vomiting, diarrhea",
      "Superinfection",
      "Gray baby syndrome"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Quinolones/Fluoroquinolones Adverse Effects",
    "Object2": "Adverse Effects",
    "Object3": [
      "Use of Quinolones/Fluoroquinolones"
    ],
    "Object4": [
      "Nausea, anorexia, vomiting, bad taste",
      "Dizziness, headache, restlessness, anxiety, insomnia, tremor"
    ],
    "Object5": [
      "Hypersensitivity, rash, pruritus",
      "Tendonitis and tendon rupture"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Sulfonamides Adverse Effects",
    "Object2": "Adverse Effects",
    "Object3": [
      "Use of Sulfonamides"
    ],
    "Object4": [
      "Nausea, vomiting, epigastric pain"
    ],
    "Object5": [
      "Crystalluria",
      "Hypersensitivity reactions",
      "Hepatitis",
      "Contact sensitization with topical use",
      "Hemolysis in persons with G6PD deficiency",
      "Precipitation of kernicterus in premature newborn"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Ketoconazole",
    "Object2": "Antifungal drug (azole group)",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Severe hepatitis (with oral administration, discontinued in many countries)"
    ]
  },
  {
    "Object1": "Antiviral Agents",
    "Object2": [
      "Anti-influenza agents (Amantadine, Oseltamir, Permivir, Rimantadine, Zanamivir)",
      "Antiherpes virus agents (Aciclovir, Cidofovir, Docosanol, Famciclovir, Foscarnet, Fomivirsen, Ganciclovir, Idoxuridine, Penciclovir, Trifluridine, Tromantadine, Valaciclovir, Valganciclovir, Vidarabine)",
      "Antiretroviral agents (NRTIs: Zidovudine, Didanosine, Stavudine, Zalcitabine, Lamivudine, Abacavir, Tenofovir; NNRTIs: Nevirapine, Efavirenz, Delaviridine; PIs: Saquinavir, Indinavir, Atazanavir, Ritonavir, Nefinavir, Amprenavir, Lopinavir, Tipranavir; New ART: Maraviroc, Enfluvitide)",
      "Other antiviral agents (Fomivirsen, Enfuvirtide, Imiquimod, Interferon, Ribavirin, Viramidine)"
    ],
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Ivermectin",
    "Object2": "Extremely potent semisynthetic derivative (from Streptomyces avermitilis)",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Intravenous Gamma Globulin (IVIG)",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Infections Associated with Skin Rash",
    "Object2": [
      "Macular/maculopapular",
      "Erythematous",
      "Vesicular",
      "Petechial/hemorrhagic",
      "Urticarial",
      "Others (Tick typhus (eschar), primary syphilis (chancre), anthrax (ulcerating papule), ulcers associated with other STD's)"
    ],
    "Object3": [
      "Macular/maculopapular: Measles, rubella, enterovirus, Epstein-Barr virus, cytomegalovirus, human immunodeficiency virus (HIV), dengue, typhoid, secondary syphilis, Rickettsiae spotted fevers",
      "Erythematous: Scarlet fever, Lyme disease. Toxic shock syndrome (Staphylococcus, Streptococcus), Human parvovirus B19",
      "Vesicular: Chickenpox (varicella zoster virus), Shingles (varicella zoster virus), herpes simplex virus",
      "Petechial/hemorrhagic: Meningococcal septicemia, any septicemia with DIC, Rickettsiae and viruses (Flavivirus, Bunyavirus, Arenavirus, Filovirus)",
      "Urticarial: Strongyloides, Schistosoma, Cutaneous larva migrans"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Vitamin A Deficiency",
    "Object2": "Not specified, generally one condition with varying severity.",
    "Object3": [
      "Prolonged dietary deprivation (vegetarians, refugees, chronic alcoholics, toddlers, preschool children)",
      "Sprue",
      "Cystic fibrosis",
      "Pancreatic insufficiency",
      "Duodenal bypass",
      "Chronic diarrhea",
      "Bile duct obstruction",
      "Giardiasis",
      "Cirrhosis"
    ],
    "Object4": [
      "Poor adaptation to darkness (nyctalopia)",
      "Increased susceptibility to infections (e.g., respiratory infections)",
      "Fatigue",
      "Anemia",
      "Diarrhea",
      "Decreased growth rate",
      "Decreased bone development",
      "Infertility"
    ],
    "Object5": [
      "Bitot's spots",
      "Xerophthalmia (dry eye)",
      "Keratomalacia",
      "Keratinization of mucous membranes",
      "Xerosis of skin"
    ],
    "Object6": [
      "Serum retinol level (decreased, normal range 28-86 µg/dL; deficiency <20 µg/dL)",
      "Albumin levels (indirect measure)",
      "Complete blood count (CBC) with differential count (for anemia, infection, sepsis)"
    ],
    "Object7": [
      "For xerophthalmia: 60 mg Vitamin A in oily solution, 3 doses (day 0, day 1, day 14)",
      "For measles: two 60 mg capsules for two consecutive days",
      "Prophylactic Vitamin A: 60 mg every 6 months for high-risk individuals",
      "Vitamin A supplements for malabsorption syndrome"
    ],
    "Object8": [
      "Blindness due to retinal injury"
    ]
  },
  {
    "Object1": "Vitamin A Toxicity (Hypervitaminosis A)",
    "Object2": [
      "Acute (usually due to accidental ingestion by children)",
      "Chronic"
    ],
    "Object3": [
      "Accidental ingestion (children)",
      "Single doses of 300 mg in adults or 100 mg in children (can be harmful)",
      "Vitamin A intakes of >3 mg/day during pregnancy"
    ],
    "Object4": [
      "Headache",
      "Increased intracranial pressure (pseudotumor cerebri)",
      "Nausea (acute)",
      "Vomiting (acute, chronic)",
      "Changes in skin, hair (loss), nails (chronic)",
      "Liver and bone damage (chronic)",
      "Double vision (chronic)",
      "Ataxia (chronic)",
      "Hyperlipidemia (chronic)"
    ],
    "Object5": [
      "Skin changes",
      "Hair loss",
      "Nail changes"
    ],
    "Object6": [
      "Diagnosis is usually clinical"
    ],
    "Object7": [
      "Adjusting the dose almost always leads to complete recovery"
    ],
    "Object8": [
      "Incidence of birth defects in infants (if intake >3 mg/day during pregnancy)"
    ]
  },
  {
    "Object1": "Thiamine (B1) Deficiency (Beriberi)",
    "Object2": [
      "Wet (cardiovascular) beriberi",
      "Infantile beriberi",
      "Shoshin beriberi (acute fulminant cardiovascular beriberi)",
      "Dry beriberi"
    ],
    "Object3": [
      "Lack of thiamine intake (milled rice, raw freshwater fish, raw shellfish, ferns with high thiaminase, foods high in antithiamine factor like tea, coffee, betel nuts)",
      "Alcoholic state",
      "Starvation state",
      "Increased consumption (diets high in carbohydrate or saturated fat, pregnancy and lactation, hyperthyroidism, fever-severe infection, increased physical exercise)",
      "Increased depletion (diarrhea, peritoneal dialysis, hemodialysis, diuretic therapies, hyperemesis gravidarum)",
      "Decreased absorption (chronic intestinal disease, alcoholism, malnutrition, gastric bypass surgery, malabsorption syndrome like celiac and tropical sprue)"
    ],
    "Object4": [
      "Wet: Orthopnea (later stage)",
      "Dry: Bilateral and roughly symmetrical heaviness and stiffness of the legs (early), weakness, numbness, pins and needles (stocking-glove distribution) (later), paresthesias in the toes, burning in the feet (severe at night), muscle cramps in the calves, pains in the legs, plantar dysesthesias"
    ],
    "Object5": [
      "Wet: Vasodilatation, tachycardia, wide pulse pressure, sweating, warm skin, lactic acidosis, congestive heart failure, marked cardiomegaly",
      "Infantile: Edema, aphonia, tachycardia, tachypnea, absent deep tendon reflexes",
      "Dry: Calf muscle tenderness, difficulty rising from a squatting position, decreased vibratory sensation in the toes, lost ankle jerk reflexes"
    ],
    "Object6": [
      "Measurement of thiamine, pyruvate and lactate levels in blood or urine",
      "Erythrocyte thiamine transketolase activity"
    ],
    "Object7": [
      "Complete bed rest",
      "Thiamine 100 mg IM/IV for the first 7 days, then 10 mg/day orally for several months",
      "Severe cases may need 400-600 mg/day",
      "Parenteral thiamine produces marked diuresis (in wet beriberi)"
    ],
    "Object8": [
      "Infantile: Death if prompt treatment is not given",
      "Dry: Degeneration of thalamus, mammillary bodies, and cerebellum"
    ]
  },
  {
    "Object1": "Wernicke's Encephalopathy",
    "Object2": "Acute neuropsychiatric condition",
    "Object3": [
      "As listed for Thiamine (B1) Deficiency",
      "May be precipitated by administration of intravenous glucose solutions to individuals with thiamine deficiency"
    ],
    "Object4": [
      "Global confusion",
      "Impairment in the synthesis of one of the important enzymes of the pentose phosphate pathway (erythrocyte transketolase)",
      "Impaired memory and learning"
    ],
    "Object5": [
      "Ophthalmoplegia (nystagmus, lateral rectus palsy, conjugate gaze palsy)",
      "Ataxia (mainly involves stance and gait, due to polyneuropathy, cerebellar involvement, vestibular dysfunction)",
      "Severe disorientation",
      "Indifference",
      "Inattentiveness",
      "Progresses through stupor and coma to death if untreated"
    ],
    "Object6": [
      "Circulating thiamine concentration",
      "Transketolase activity in red cells (fresh heparinized blood)"
    ],
    "Object7": [
      "Medical emergency, immediate administration of thiamine",
      "Thiamine 500 mg intravenously, infused over 30 minutes, three times daily for two consecutive days",
      "Then 250 mg intravenously or intramuscularly once daily for an additional five days, in combination with other B vitamins",
      "Magnesium is often needed (cofactor for thiamine-dependent enzymes)",
      "Glucose administration should be preceded or accompanied by thiamine 100 mg IV in susceptible individuals"
    ],
    "Object8": [
      "Progress to stupor, coma, and death if untreated"
    ]
  },
  {
    "Object1": "Korsakoff's Psychosis/Syndrome",
    "Object2": "Central nervous system involvement in thiamine deficiency",
    "Object3": [
      "Deficiency of thiamine with involvement of central nervous system",
      "Common in chronic alcoholics",
      "May also be seen with thiamine deficiency due to gastric disorders (e.g., carcinoma, chronic gastritis, or persistent vomiting)"
    ],
    "Object4": [
      "Defect in retentive memory (severe defect in storing new information and learning)",
      "Disturbances of short-term memory",
      "Marked deficits in anterograde and retrograde memory",
      "Apathy",
      "Confabulation (fabricated, distorted or misinterpreted memories without conscious intention to deceive)"
    ],
    "Object5": [
      "Intact sensorium",
      "Relative preservation of long-term memory and other cognitive skills",
      "Attention and social behavior are relatively maintained"
    ],
    "Object6": [],
    "Object7": [
      "Parenteral thiamine (100 mg IM daily for 7 days)"
    ],
    "Object8": []
  },
  {
    "Object1": "Riboflavin (B2) Deficiency",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Cheilitis",
      "Stomatitis",
      "Glossitis",
      "Normochromic anemia",
      "Seborrheic dermatitis"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Niacin Deficiency (Pellagra)",
    "Object2": "Metabolic encephalopathy",
    "Object3": [
      "Inadequate intake (Maize or jowar (sorghum) diet, malnutrition, chronic alcoholism, anorexia nervosa)",
      "Generalized malabsorption (rare)",
      "Drug-induced (prolonged isoniazid therapy, pyrazinamide, 6-mercaptopurine, 5-fluouracil, azathioprine, ethionamide, carbamazepine, phenytoin, and phenobarbitone)",
      "Other disorders (Hartnup's disease, Carcinoid syndrome, Pheochromocytoma – tryptophan metabolism diverted)"
    ],
    "Object4": [
      "Diarrhea (proctitis, malabsorption, anorexia, nausea, glossitis, dysphagia)",
      "Dementia (depression, apathy, sometimes thought disorders, insomnia, anxiety, disorientation, tremor, delusions, encephalopathy)",
      "Burning dysesthesias",
      "Vaginitis",
      "Esophagitis",
      "Vertigo"
    ],
    "Object5": [
      "Casal's necklace or collar rash (hyperpigmented and scaling, sun-exposed areas, forms ring around neck)",
      "Dermatitis (may progress to vesiculation, cracking (ulceration), exudation and secondary infection)",
      "Symmetrical chronic thickening, dryness and pigmentation on dorsal surfaces of the hands",
      "Raw, painful, bright red tongue (glossitis)",
      "Angular stomatitis"
    ],
    "Object6": [],
    "Object7": [
      "Nicotinamide: 100 mg 3 times daily orally (approximately 300 mg daily) with a maintenance dose of 50 mg daily",
      "High-protein diet with adequate nutrients and treatment of malnutrition",
      "Supplementation of other vitamin B complex with iron and folic acid"
    ],
    "Object8": [
      "Death (in severe, untreated cases)"
    ]
  },
  {
    "Object1": "Vitamin C Deficiency (Scurvy)",
    "Object2": [
      "Adult scurvy",
      "Infantile scurvy (Barlow's disease)"
    ],
    "Object3": [
      "Infants fed only on boiled cow's milk during the first year of life",
      "Individuals who do not eat vegetables (elderly, people who live alone, chronic alcoholics)",
      "Pregnant and lactating women (increased utilization)",
      "Those with thyrotoxicosis (increased utilization)",
      "Anorexia nervosa or anorexia from other diseases (such as AIDS or cancer)",
      "Type 1 diabetes (increased requirement)",
      "Patients undergoing peritoneal dialysis and hemodialysis",
      "Diseases of small intestine (such as Crohn's, Whipple, and celiac disease)"
    ],
    "Object4": [
      "Nonspecific malaise, weakness, lethargy, muscle pain (myalgias, due to reduced carnitine production) (early)",
      "Bone pain (more common in children)",
      "Fractures, dislocations, and tenderness of bones (children)",
      "Hemorrhaging (hallmark, can occur in any organ)",
      "Easy bruising, petechiae, ecchymosis, perifollicular hemorrhages",
      "Bleeding into muscles, joints and underneath peritoneum (may be spontaneous)",
      "Delayed/poor wound healing and breakdown of old scars",
      "Anemia (may cause high-output heart failure)",
      "Emotional changes",
      "Shortness of breath",
      "Painful limbs ('pseudoparalysis' in infants)"
    ],
    "Object5": [
      "Hair follicles: common site of cutaneous bleeding",
      "Inflamed spongy gums (gum swelling), friability, bleeding and infection with loosening of teeth",
      "Mucosal petechiae",
      "Roughness, keratosis of hair follicles with 'corkscrew' hair",
      "Perifollicular hemorrhages",
      "Nails: Splinter hemorrhages",
      "Infantile: Subperiosteal hemorrhage into shafts of long bones",
      "Infantile: Scorbutic rosary (enlargement of costochondral junctions, tender)",
      "Infantile: Retrobulbar, subarachnoid and intracerebral hemorrhages"
    ],
    "Object6": [
      "Diagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C deficiency",
      "Response to replacement therapy is the best way for the diagnosis",
      "Serum vitamin C level of <11 μmol/L (0.2 mg/100 mL)",
      "Anemia (may be normochromic, normocytic due to bleeding; megaloblastic due to reduced erythropoiesis; microcytic hypochromic anemia due to impaired iron absorption and impaired heme synthesis)",
      "Capillary fragility test (looking for petechiae on forearm after inflating blood pressure cuff)",
      "Bleeding time, clotting time and Prothrombin time (to rule out other bleeding disorders)",
      "Imaging Studies (loss of trabeculae (ground-glass appearance), thinning of cortex, white line of Frankel (calcified, irregular cartilage at metaphysis), Wimberger ring sign (circular calcification surrounding epiphyseal center of ossification))"
    ],
    "Object7": [
      "Ascorbic acid at 100 mg 3-5 times a day until total of 4 g is reached, then reduce to 100 mg daily",
      "Encourage consumption of foods with high vitamin C (citrus fruits, broccoli, green peppers, tomatoes, potatoes, cabbage)",
      "Recommended dose for adults: 120 mg daily (60 mg daily prevents scurvy)"
    ],
    "Object8": [
      "High-output heart failure (due to anemia in adult scurvy)"
    ]
  },
  {
    "Object1": "Vitamin D Deficiency",
    "Object2": [
      "In children (Rickets)",
      "In adults (Osteomalacia, Osteoporosis)"
    ],
    "Object3": [
      "Impaired cutaneous production due to limited exposure to sunlight",
      "Dietary absence (diets deficient in calcium and vitamin D)",
      "Malabsorption"
    ],
    "Object4": [
      "Rickets (children): Retardation of growth",
      "Osteomalacia (adults): Proximal muscle weakness and bone fragility",
      "Osteoporosis: Decrease of bone mineralization and increased bone fragility",
      "Osteomalacia: Bone pains, muscle weakness, fractures of bones with minor trauma, pain in the hip (antalgic gait), waddling gait, collapse of vertebrae (local pain and deformity)"
    ],
    "Object5": [
      "Rickets (children): Expansion of the growth plate, Craniotabes (skull square/box-like, delayed closure anterior fontanelle, frontal/parietal bossing), Frontal bossing, Delayed eruption primary teeth, enamel defects/caries, Rachitic rosary (overgrowth cartilage/osteoid at costochondral junction), Pigeon breast/chest deformity (pectus carinatum), Harrison's sulcus/groove, Bowing of the legs, Seizures and tetany (hypocalcemia), Hypotonia and delayed motor development, Protuberant abdomen, bone pain, waddling gait, fatigue (may be asymptomatic)",
      "Osteomalacia (adults): Softening of skeleton (kyphosis, coxa vara, pigeon chest, triradiate pelvis with narrow pubic arch)"
    ],
    "Object6": [
      "Rickets/Osteomalacia: Wrist radiograph (splayed lower ends radius/ulna, fuzzy/ill-defined epiphyseal surfaces, widened unossified zone - 'saucer' deformity, bow legs)",
      "Blood: Serum calcium (low), Serum phosphate (low due to secondary hyperparathyroidism), Serum alkaline phosphatase (increased), Plasma 25-hydroxyvitamin D3 level (low)",
      "Osteomalacia: Urinary excretion of calcium (reduced)",
      "Radiological findings (osteomalacia): Bone density (reduced - osteopenia), Epiphyseal growth plate (increased thickness, cupped/hazy at metaphyseal border), Cortical thinning (secondary hyperparathyroidism), Nontraumatic fractures, radiolucent bands (pseudofractures/Looser's zones), Bone scan (normal or discrete foci of increased radionuclide uptake), Bone mineral density by DEXA (reduced at spine, hip, forearm)"
    ],
    "Object7": [
      "Rickets: Treat underlying cause, supplementation diet with calcium and vitamin D, Ergocalciferol (1,50,000-6,00,000 IU orally or IM single dose; or 2000 IU daily)",
      "Osteomalacia: Treat underlying cause",
      "Dietary deficiency: Ergocalciferol or cholecalciferol (1000-4000 IU for 3 months, then lower maintenance doses, with fatty diet)",
      "Malabsorption: 50,000-100,000 IU of vitamin D + calcium supplementation, small doses of calcitriol (0.5-1.0 µg daily)",
      "Chronic renal failure: Calcitriol with weekly monitoring of calcium level"
    ],
    "Object8": [
      "Rickets: Seizures and tetany, respiratory infections and atelectasis (chest deformities)",
      "Osteomalacia: Fractures of bones with minor trauma"
    ]
  },
  {
    "Object1": "Hypervitaminosis D",
    "Object2": "Not specified",
    "Object3": [
      "Excessive intake of Vitamin D"
    ],
    "Object4": [
      "Nausea",
      "Vomiting",
      "Excessive thirst",
      "Polyuria",
      "Severe itching",
      "Joint and muscle pains",
      "Disorientation",
      "Coma"
    ],
    "Object5": [
      "Metastatic calcifications"
    ],
    "Object6": [
      "Diagnosis is usually clinical"
    ],
    "Object7": [
      "Hydration and treatment of hypercalcemia"
    ],
    "Object8": [
      "Hypercalcemia"
    ]
  },
  {
    "Object1": "Iron Poisoning (Acute)",
    "Object2": "Acute",
    "Object3": [
      "When iron level exceed 60 mg/kg elemental iron"
    ],
    "Object4": [
      "Vomiting",
      "Abdominal pain",
      "Bloody diarrhea",
      "Shock",
      "Dehydration",
      "Cyanosis",
      "Acidosis",
      "Coma"
    ],
    "Object5": [
      "Cyanosis"
    ],
    "Object6": [
      "Blood iron levels"
    ],
    "Object7": [
      "Gastric lavage with sodium bicarbonate solution",
      "Desferrioxamine 15 mg/kg/hour IV, increased to maximum dose of 35 mg/kg/hour",
      "Correction of acidosis and shock",
      "Extracorporeal removal with exchange transfusion or continuous venovenous hemofiltration"
    ],
    "Object8": [
      "Hepatotoxicity",
      "Bowel obstruction"
    ]
  },
  {
    "Object1": "Fluorosis",
    "Object2": [
      "Acute ingestion toxicity",
      "Dental fluorosis",
      "Skeletal fluorosis"
    ],
    "Object3": [
      "Fluoride content in water is high (>3 to 5 ppm)",
      "Acute ingestion of >30 mg/kg body weight"
    ],
    "Object4": [
      "Gastrointestinal symptoms (diarrhea, vomiting) (acute ingestion)",
      "Severe pain and stiffness in joints, stiffness in neck and backbone, bow legs (skeletal)",
      "Weakness, anemia and weight loss (skeletal)"
    ],
    "Object5": [
      "Dental fluorosis (mottling of teeth, enamel loses luster, teeth appear chalky white with transverse yellow bands, rough, pigmented, pitted and brittle)",
      "Skeletal fluorosis (sclerosis of bones, calcification of ligaments, interosseous membrane and tendinous insertions, osteoporosis with brittle bones)"
    ],
    "Object6": [
      "Diagnosis is clinical and radiological."
    ],
    "Object7": [
      "Reduce fluoride intake.",
      "No specific treatment for skeletal changes."
    ],
    "Object8": [
      "Renal failure (acute ingestion)",
      "Death (acute ingestion)"
    ]
  },
  {
    "Object1": "Angular Stomatitis",
    "Object2": "Not specified",
    "Object3": [
      "Iron deficiency anemia",
      "Secondary infection of Candida albicans, Staphylococcus",
      "Vitamin deficiency (Riboflavin (B2), Pyridoxine (B6), Niacin deficiency (pellagra))",
      "Herpes labialis at the angle of mouth"
    ],
    "Object4": [
      "Pain"
    ],
    "Object5": [
      "Cracking of the epithelium at the edge of the lips",
      "Erythema, maceration, scaling, and fissuring at the corners of the mouth (most commonly bilateral)"
    ],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Refeeding Syndrome",
    "Object2": "Metabolic disturbances",
    "Object3": [
      "Reinstitution of nutrition to patients who are starved or severely malnourished"
    ],
    "Object4": [
      "Nonspecific (initial)",
      "Rhabdomyolysis",
      "Leucocyte dysfunction",
      "Respiratory and cardiac failure",
      "Hypotension",
      "Arrhythmias",
      "Seizures",
      "Coma",
      "Sudden death"
    ],
    "Object5": [
      "Electrolyte imbalance (cellular uptake of phosphate, potassium, magnesium, leading to significant falls in serum levels)"
    ],
    "Object6": [
      "Monitor fluid balance and clinical status",
      "Monitor PO4, K, Mg levels."
    ],
    "Object7": [
      "Start nutrition at 5-10 kcal/kg/day and increase gradually",
      "Provide thiamine, multivitamins and trace elements",
      "Restore circulatory volume",
      "Replace PO4, K and Mg",
      "Prevent Wernicke's encephalopathy by providing thiamin before starting nutritional support in thiamin-deficient patients"
    ],
    "Object8": [
      "Serious consequences due to electrolyte imbalance (e.g., cardiac arrhythmias)",
      "Wernicke's encephalopathy (if thiamin deficient and refeed with carbohydrates)"
    ]
  },
  {
    "Object1": "Protein-Energy Malnutrition (PEM)",
    "Object2": [
      "Marasmus",
      "Kwashiorkor",
      "Intermediate states of marasmus-kwashiorkor"
    ],
    "Object3": [
      "Marasmus: Inadequate intake of protein and calories",
      "Kwashiorkor: Inadequate protein intake with reasonable caloric (energy) intake",
      "Kwashiorkor: May be precipitated by infections (e.g., measles, malaria, diarrheal illnesses)"
    ],
    "Object4": [
      "Marasmus: No edema, does not appear as apathetic or anorexic as with kwashiorkor, diarrhea is frequent, signs of infection",
      "Kwashiorkor: Child appears apathetic and lethargic with severe anorexia, likely presence of vitamin deficiencies, defects in immunity and secondary infections"
    ],
    "Object5": [
      "Marasmus: Emaciation with apparent muscle wasting and loss of body fat, thin and dry hair",
      "Kwashiorkor: Marked protein deprivation causes hypoalbuminemia leading to generalized or dependent edema, characteristic skin lesions (alternating zones of hyperpigmentation and hypopigmentation, producing 'flaky paint' appearance), hair is dry and sparse, loss of color or alternating bands of pale and darker hair (Flag sign), abdomen is distended due to hepatomegaly (enlarged, fatty liver) and/or ascites"
    ],
    "Object6": [],
    "Object7": [
      "Provision of protein and energy supplements",
      "Control of infection"
    ],
    "Object8": [
      "Secondary infections (Kwashiorkor)"
    ]
  },
  {
    "Object1": "Obesity",
    "Object2": [
      "Central ('abdominal', 'visceral', 'android' or 'apple-shaped')",
      "Generalized ('gynoid' or 'pear-shaped')"
    ],
    "Object3": [
      "Genetic aspects: Polygenic disorder, single-gene (monogenic forms) disorders (mutations in leptin gene, leptin receptor gene, POMC, Mc4R genes), genetic conditions (Prader-Willi and Laurence-Moon-Biedl syndromes)",
      "Environmental contributors: Increased consumption of energy-dense foods, larger food portion size, increased variety of food, increased availability, reduced cost, increased caloric beverages, increased sedentary behavior, reduced activities of daily living and decreased physical activity",
      "Reversible causes: Hypothyroidism, Cushing's syndrome, Insulinoma, Stein-Leventhal syndrome, Hypothalamic damage (e.g., due to trauma, tumor), Drug Induced (Psychiatric and neurologic medications, Steroid hormones, Antidiabetes agents, Antihypertensive agents)"
    ],
    "Object4": [
      "Weight gain"
    ],
    "Object5": [
      "Appearance of morbid obesity (Figure 1.13)"
    ],
    "Object6": [
      "Evaluate severity using BMI (refer Table 1.9)",
      "Exclude underlying cause",
      "Identify complications",
      "Prepare management plan"
    ],
    "Object7": [
      "Goal: Initially reduce weight by about 10% from baseline, reduce weight of about 0.5 to 1 kg/week for 6 months",
      "Lifestyle Modification: Diet (low calorie, low in saturated fats, low density foods, normal protein intake, increased fibers), Regular physical activity (30-45 minutes, 3-5 days/week), Behavioral modification",
      "Drug therapy (Pharmacotherapy):",
      "Centrally acting: Sibutramine (monoamine reuptake inhibitor, reduces appetite, prevents decrease in BMR), Rimonabant (endocannabinoid (CB1) receptor blocker, reduces weight - BANNED)",
      "Peripherally acting: Orlistat (nonsystemic reversible inhibitor of gastric and pancreatic lipases), Olestra (synthesized using sucrose molecule, not absorbed)",
      "Others: Phentermine (amphetamine-like, reduces appetite), Metformin (decreases appetite), Tesofensine (norepinephrine, dopamine, and serotonin reuptake inhibitor), Betahistine (stimulates histamine-1 receptor, reduces craving for fatty foods), Amylin (pramlintide), Liraglutide (GLP-1 agonist), Lorcaserin (serotonin agonist)",
      "Combination therapy: Phentermine-topiramate, Bupropion-naltrexone",
      "Bariatric surgical techniques: Malabsorptive procedures (biliopancreatic diversion, Roux-en-Y gastric bypass), Restrictive procedures (adjustable gastric banding, vertical banded gastroplasty, sleeve gastroplasty), Restrictive plus malabsorptive procedures (duodenal switch, Roux-en-Y gastric bypass, intragastric balloon), Liposuction (removal of fat by suction)"
    ],
    "Object8": [
      "Morbidity and mortality: Increased risk of early death (mainly from diabetes, coronary heart disease, cerebrovascular disease)",
      "Metabolic: Insulin resistance and type 2 diabetes mellitus, Dyslipidemia (Increased triglycerides, increased LDL cholesterol with VLDL, decreased HDL cholesterol, decreased adiponectin), Atherosclerosis, Cardiomyopathy",
      "Endocrine: Reproductive disorders (reduced plasma testosterone and SHBG in men, increased estrogen, gynecomastia; increased androgen, decreased SHBG, PCOS, reduced IVF success in women)",
      "Mechanical: Osteoarthritis, Gout, Venous stasis/varicose veins, Acanthosis nigricans, Increased friability of skin (especially in skinfolds, increasing risk of fungal/yeast infections), Urinary incontinence",
      "Pulmonary: Reduced chest wall compliance, Increased work of breathing, Increased minute ventilation, Decreased functional residual capacity and expiratory reserve volume, Obstructive sleep apnea, Obesity hypoventilation syndrome (Pickwickian syndrome), Asthma (reduced TLC, RV, FRC)",
      "Cancer: Biggest preventable cause of cancer after smoking (esophagus, gallbladder, colon, bile ducts, rectum, breasts, endometrium, liver, cervix, prostate, ovaries)",
      "Gastrointestinal: Gastroesophageal reflux disease, Gallstones, Fatty liver (steatosis) and nonalcoholic steatohepatitis (NAFLD), progressing to hepatic cirrhosis and hepatocellular carcinoma",
      "Retinal: Overweight diabetics are twice more likely to develop retinopathy",
      "Psychological: Lack self-confidence, depression, physical and sexual abuse, lack of attention, low education, low self-esteem",
      "Others: Accident proneness, socioeconomic disadvantage, postoperative problems, skin infections (groin and submammary candidiasis; hidradenitis)"
    ]
  },
  {
    "Object1": "Radiation Exposure",
    "Object2": [
      "Ionizing radiation (X-rays, CT, radionuclide scans, radiotherapy)",
      "Non-ionizing radiations (UV rays, visible light, laser, infrared, microwave)"
    ],
    "Object3": [
      "Accidental exposure (industries, nuclear power plants, hospitals)",
      "Deliberate nuclear explosions",
      "Poisoning (e.g., with polonium)"
    ],
    "Object4": [
      "Mild acute radiation sickness: Nausea, vomiting, malaise",
      "CNS syndrome: Nausea, vomiting, disorientation, coma"
    ],
    "Object5": [
      "Hemopoietic system: Lymphocyte depletion (most sensitive indicator of bone marrow injury), aplasia of bone marrow",
      "Gastrointestinal mucosal toxicity: Severe diarrhea, vomiting, dehydration, sepsis",
      "Gonads: Temporary or permanent sterility",
      "Eye: Cataracts",
      "Skin: Radiation dermatitis (burns) (erythema, purpura, blistering, secondary infection), complete loss of body hair (>5 Gy)",
      "Lung: Acute inflammatory reactions, pulmonary fibrosis",
      "CNS syndrome: Cerebral edema",
      "Bone necrosis and lymphatic fibrosis",
      "Thyroid gland damage"
    ],
    "Object6": [],
    "Object7": [
      "Large-dose exposures: Maintain adequate hydration, control of sepsis, management of marrow aplasia, treatment of associated thermal burns",
      "Internal exposure to radioisotopes: Chelating agents (such as Prussian blue for 137-cesium)",
      "White cell colony stimulation and hematopoietic stem cell transplantation for marrow aplasia",
      "Reduction of X-ray exposures whenever possible"
    ],
    "Object8": [
      "Death: Due to aplasia of bone marrow, due to severe diarrhea, vomiting, dehydration and sepsis, due to cerebral edema",
      "Stochastic effects: Carcinogenesis (leukemias, solid tumors), teratogenic effects"
    ]
  },
  {
    "Object1": "Illnesses at High Altitude",
    "Object2": [
      "Acute mountain sickness (AMS)",
      "Chronic mountain sickness (Monge's disease)",
      "High-altitude cerebral edema (HACE)",
      "High-altitude pulmonary edema (HAPE)",
      "High-altitude retinal hemorrhage",
      "Venous thrombosis",
      "Refractory cough"
    ],
    "Object3": [
      "Ascent to altitudes above 2,500 m (develops in healthy individuals)",
      "Sudden ascent to altitudes above 6,000 m (decompression sickness)",
      "AMS: Probably hypoxemia increases cerebral blood flow and intracranial pressure",
      "Chronic mountain sickness: Long exposure to high altitude",
      "Venous thrombosis: Dehydration, inactivity, cold, use of oral contraceptive pill at high altitude",
      "Refractory cough: Breathing dry, cold air and increased mouth breathing"
    ],
    "Object4": [
      "AMS: Headache, fatigue, anorexia, nausea and vomiting, difficulty sleeping or dizziness. Ataxia and peripheral edema may be present.",
      "Chronic mountain sickness: Headache, poor concentration, signs of polycythemia.",
      "HACE: Ataxia and altered consciousness, confusion, disorientation, visual disturbance, lethargy, loss of consciousness (in addition to AMS symptoms).",
      "HAPE: Initially dry cough, exertional dyspnea, extreme fatigue. Later wet cough, may be blood-stained sputum. Tachycardia and tachypnea at rest.",
      "High-altitude retinal hemorrhage: Usually asymptomatic. Visual defects if macula involved.",
      "Venous thrombosis: Symptoms of thrombosis.",
      "Refractory cough: Persistent cough."
    ],
    "Object5": [
      "Chronic mountain sickness: Cyanosis and clubbing of fingers.",
      "HACE: Papilledema and retinal hemorrhages are common. Focal neurological signs may be detected.",
      "HAPE: Crepitations may be heard in both lung fields. Severe hypoxemia, pulmonary hypertension."
    ],
    "Object6": [
      "HAPE: Radiologically show diffuse alveolar edema. Decreased arterial oxygen saturation."
    ],
    "Object7": [
      "AMS: Mild cases: rest and simple analgesics. If symptoms persist: descend. Acetazolamide (carbonic anhydrase inhibitor) as prophylaxis for rapid ascent.",
      "HACE: Improve oxygenation. Descent is needed. Oxygen therapy in portable pressurized bag. Dexamethasone: 8 mg immediately and 4 mg 4 times daily.",
      "HAPE: Reversal of hypoxia with immediate descent and oxygen administration. Nifedipine (20 mg 4 times daily) to reduce pulmonary arterial pressure. Oxygen therapy in a portable pressurized bag if descent delayed.",
      "High-altitude retinal hemorrhage: No specific treatment.",
      "Venous thrombosis: Standard thrombosis treatment."
    ],
    "Object8": [
      "AMS: May progress to cerebral edema.",
      "HACE: Can lead to loss of consciousness.",
      "HAPE: May lead to severe hypoxemia, pulmonary hypertension."
    ]
  },
  {
    "Object1": "Heatstroke",
    "Object2": [
      "Classic/Nonexertional",
      "Exertional"
    ],
    "Object3": [
      "Increased heat production: Hyperthyroidism, exercise, sepsis.",
      "Impaired heat loss (impaired sweating): Drugs (anticholinergics, anti-Parkinsonian, antihistamines, butyrophenones, phenothiazines, tricyclics), abnormal sweat glands (sweat gland injury after heatstroke/barbiturate poisoning, cystic fibrosis, healed thermal burn), salt and water depletion (diuretic induced), hypokalemia",
      "Impaired voluntary mechanisms: Coma, physical disability, mental illness",
      "Impaired delivery of blood to peripheral circulation: Cardiovascular disease, hypokalemia (decreased muscle blood flow), dehydration",
      "Others: Elderly, high ambient temperature and humidity, poor ventilation, lack of acclimatization, obesity, fatigue, diabetes mellitus, malnutrition, alcoholism"
    ],
    "Object4": [
      "May develop without any warning prodrome",
      "Rapid deterioration from apparent baseline health to coma or mentally dull state",
      "CNS: Irritability or irrational behavior (precedes), confusion, aggressive behavior, delirium, convulsions, pupillary abnormalities (rapid progression to coma), decorticate posturing, fecal incontinence, flaccidity or hemiplegia (unusual focal signs), cerebellar signs (ataxia, dysarthria)",
      "Metabolic: Sweating results in low levels of Na, Mg, K (early), hyperkalemia, hypocalcemia (from rhabdomyolysis), metabolic acidosis, respiratory alkalosis",
      "Splanchnic: Ischemic intestinal ulceration (may lead to hemorrhage)",
      "Hematological: Anemia and bleeding"
    ],
    "Object5": [
      "Three cardinal signs: CNS dysfunction, Hyperpyrexia (core temperature >40 °C), Hot dry skin (pink or ashen, may be clammy and sweat)",
      "Cardiovascular: Tachycardia, dysrhythmias, hypotension or normotensive with wide pulse pressure, hyperdynamic-hemodynamic profile, myocardial pump failure",
      "Respiratory: Extreme tachypnea (up to 60/minute), crackles and cyanosis (signs of pulmonary edema)"
    ],
    "Object6": [
      "Temperature recording",
      "Electrolytes, urea, creatinine, calcium",
      "Liver function tests",
      "Creatine phosphokinase (CPK)",
      "Arterial blood gas (ABG)",
      "ECG monitoring",
      "Urine output",
      "Full blood count (FBC), clotting, fibrinogen, FDP, D-dimer (anemia, low/normal platelets, lymphocytosis)",
      "Test urine for myoglobin"
    ],
    "Object7": [
      "First Aid: Remove to cooler location, out of sun. Loosen/remove clothing. Immerse in cool water or wrap in wet sheets and fan. Use cold compresses on head, neck, armpits, groin. Seek medical attention immediately. DO NOT administer fever medication or alcohol rub. DO NOT give anything by mouth until stabilized.",
      "In Hospital Care: Treat in critical care unit. Cooling methods: Evaporative, Immersion, Strategic ice packs, Ice cold IV fluids, Ice packing, Cooling blankets, Gastric lavage, Peritoneal lavage, Cardiac bypass, Endovascular cooling catheters.",
      "Supportive: IV volume replacement. Dobutamine if inotrope needed. Urgent treatment of hyperkalemia. Calcium only if ECG changes of severe hyperkalemia. Small dose of mannitol for rhabdomyolysis. IV lorazepam for shivering.",
      "Avoid: ASA (increases temperature), Paracetamol (increases hepatic dysfunction), Dantrolene (not effective for heatstroke)."
    ],
    "Object8": [
      "Rhabdomyolysis",
      "Acute renal failure (ARF) (common in exertional heatstroke)",
      "Myocardial damage and frank infarction",
      "Cor pulmonale or acute respiratory distress syndrome (ARDS)",
      "Hepatic damage (hepatic necrosis, may cause death)",
      "Disseminated intravascular coagulation (DIC)",
      "Cerebral edema (CNS), permanent neurological deficit",
      "Death"
    ]
  },
  {
    "Object1": "Hypothermia (HT)",
    "Object2": [
      "Mild (32-35°C)",
      "Moderate (28-32°C)",
      "Severe (<28°C)",
      "Death (HT V, 13.7-24°C)"
    ],
    "Object3": [
      "Primary: Overwhelming cold exposure (normal heat production)",
      "Secondary: Hypothyroidism, Addison's disease, malnutrition, burns, hypothalamic abnormalities, sepsis, thiamine deficiency, alcohol intoxication, hypoglycemia"
    ],
    "Object4": [
      "Mild: Normal mental status with shivering, amnesia/dysarthria/ataxia, loss of coordination",
      "Moderate: Altered mental status without shivering, stupor, no shivering",
      "Severe: Unconscious, coma, apparent death"
    ],
    "Object5": [
      "Mild: Tachycardic, tachypneic",
      "Moderate: Bradycardic/atrial fibrillation, decreased BP and RR, pupils dilated",
      "Severe: No corneal or oculocephalic reflexes, decreased BP, ventricular fibrillation (max risk: 22°C), apnea, asystole, areflexia/fixed pupils, flat EEG (19°C)"
    ],
    "Object6": [
      "Blood glucose, renal function tests, electrolytes (including calcium), CPK, TSH, ABG, complete hemogram, X-ray chest, ECG",
      "ECG changes: Prolongation of all ECG intervals (RR, PR, QRS, QT), elevation of the J point (Osborn wave - roughly proportional to degree of hypothermia)"
    ],
    "Object7": [
      "Evaluation and support of airway, breathing, circulation",
      "Prevention of further heat loss (remove from cold, wet clothes, provide blanket)",
      "Initiation of rewarming appropriate to degree of hypothermia:",
      "Passive rewarming: Endogenous heat production (shivering, metabolic rate, TSH, sympathetic activity). Decreasing heat loss.",
      "Active external rewarming: Heating blankets, air blankets, radiant warmers, immersion in hot bath, water bottles/heating pads. Rewarming rates: 1-2.5°C/hour.",
      "Active internal (core) rewarming: Warm IV fluids, warm humid oxygen, peritoneal lavage, gastric/esophageal lavage, bladder/rectal lavage, pleural/mediastinal lavage, microwaves (diathermy), extracorporeal circulatory rewarming.",
      "Treatment of complications (hypotension, arrhythmias, hyperkalemia, hypoglycemia, rhabdomyolysis, bladder atony, bleeding diathesis)"
    ],
    "Object8": [
      "Hypotension during active rewarming",
      "Arrhythmias",
      "Hyperkalemia",
      "Hypoglycemia",
      "Rhabdomyolysis",
      "Bladder atony",
      "Bleeding diathesis"
    ]
  },
  {
    "Object1": "Drowning (Submersion Injuries)",
    "Object2": [
      "Wet drowning (aspiration of water into airways and lungs - 85%)",
      "Dry drowning (severe parasympathetically mediated laryngospasm - 15%)"
    ],
    "Object3": [
      "Drug and alcohol intoxication",
      "Cardiac arrest",
      "Hypoglycemia",
      "Seizure",
      "Suicidal or homicidal behavior",
      "Child abuse"
    ],
    "Object4": [
      "About 70% develop signs within 7 hours",
      "Alertness agitation coma",
      "Cyanosis",
      "Coughing and pink frothy sputum (pulmonary edema)",
      "Tachypnea",
      "Tachycardia",
      "Low-grade fever",
      "Rales, rhonchi and less often wheezes"
    ],
    "Object5": [
      "Cyanosis",
      "Pink frothy sputum",
      "Tachypnea",
      "Tachycardia",
      "Rales, rhonchi, wheezes",
      "Signs of associated trauma to head and neck"
    ],
    "Object6": [
      "Arterial blood gas (ABG) (metabolic and/or respiratory acidosis)"
    ],
    "Object7": [
      "Prehospital care, emergency department (ED) care, inpatient care",
      "Ventilation is most important initial treatment",
      "Standard CPR protocol",
      "Identify spine injuries and other major organ injuries and manage accordingly",
      "Supportive care (renal failure, shock, infections)"
    ],
    "Object8": [
      "Pulmonary: Hypoxemia, noncardiogenic pulmonary edema-acute respiratory distress syndrome (ARDS)",
      "Neurologic: Neuronal damage, cerebral edema, elevations in intracranial pressure, hypoxic ischemic encephalopathy",
      "Cardiovascular: Arrhythmias (secondary to hypothermia and hypoxemia like sinus tachycardia, sinus bradycardia, and atrial fibrillation)",
      "Acid-base and electrolytes: Metabolic and/or respiratory acidosis, life-threatening hypernatremia, hypermagnesemia, hypercalcemia (drowning in concentrated seawater)",
      "Renal: Renal failure due to acute tubular necrosis"
    ]
  },
  {
    "Object1": "Hypopituitarism/Panhypopituitarism",
    "Object2": [
      "Combined deficiency (partial or complete) of any of the anterior pituitary hormones",
      "Panhypopituitarism (deficiency of all anterior pituitary hormones)",
      "Selective or multiple deficiencies of pituitary hormones"
    ],
    "Object3": [
      "Isolated hormone deficiencies",
      "Invasive tumors: Pituitary adenomas, hypothalamic tumors",
      "Injury: Surgery, irradiation, stalk section, head trauma",
      "Infarction: Sheehan's syndrome (post-partum pituitary necrosis), diabetic antepartum necrosis, carotid aneurysm",
      "Inflammatory diseases: Granulomatous disease, autoimmune (lymphocytic) hypophysitis",
      "Infiltrative diseases: Hemochromatosis, amyloidosis",
      "Immunologic: Lymphocytic hypophysitis",
      "Infections: Tuberculosis, syphilis, fungal infection",
      "Idiopathic",
      "Developmental defects (Kallmann syndrome)"
    ],
    "Object4": [
      "Highly variable, depends on underlying cause/lesion and degree of deficiencies",
      "Mild deficiencies may be asymptomatic",
      "GH deficiency: Decreased growth in children, decreased sense of well-being, lethargy, muscle weakness, increased fat mass (adults)",
      "LH and FSH deficiency: Loss of libido, impotence (males), oligomenorrhea or amenorrhea (females), infertility, osteoporosis",
      "ACTH deficiency: Weakness, nausea, vomiting, anorexia, weight loss, fever, hypotension",
      "TSH deficiency: Cold intolerance, dry skin, mental dullness, bradycardia, constipation, weight gain, hoarseness, anemia",
      "PRL deficiency: Failure of lactation (postpartum)"
    ],
    "Object5": [
      "Pituitary tumors (mass effects): Headache, visual impairment, electrolyte alterations, disorders of autonomic nervous system (hypothalamic involvement)",
      "Sequential loss of hormone secretion (GH>FSH>LH>TSH>ACTH)",
      "Longstanding panhypopituitarism: pallor with hairlessness ('alabaster skin')",
      "LH and FSH deficiency: Sparse axillary and pubic hair, fine and wrinkled skin, gynecomastia and decreased frequency of shaving (males)",
      "ACTH deficiency: Normal plasma electrolytes (mineralocorticoid preservation), depigmentation and diminished tanning (versus hyperpigmentation in excess ACTH)",
      "TSH deficiency: Goiter is absent"
    ],
    "Object6": [
      "Demonstration of low levels of trophic pituitary hormones in setting of low levels of target hormones",
      "Low free thyroxine (T4) with low or inappropriately normal TSH (secondary hypothyroidism)",
      "Low early morning cortisol with low or inappropriately normal ACTH",
      "Low testosterone level without elevated gonadotrophins (LH and FSH) (hypogonadotropic hypogonadism)",
      "Low IGF-1 (insulin-like growth factor-1) (GH deficiency)",
      "Provocation tests (for pituitary reserve): Insulin-induced hypoglycemia (gold standard for GH reserve), L-dopa, arginine, GHRH, growth hormone-releasing peptides (GH reserve), TRH reserve (prolactin fails to rise), CRH administration (ACTH release), synthetic ACTH (cosyntropin) (adrenal cortisol release - indirect ACTH reserve), ACTH and cortisol levels during insulin-induced hypoglycemia (ACTH reserve), TSH response to TRH (TSH reserve)",
      "Surgical biopsy of tumor (for type: chromophobe, acidophil, basophil)",
      "Immunohistochemistry (confirm secretory capacity)"
    ],
    "Object7": [
      "Replacement of deficient hormones",
      "Adrenocorticotropic hormone: Hydrocortisone 15-25 mg daily in divided doses. Mineralocorticoid replacement not needed.",
      "LH and FSH (Female): Conjugated estrogen 0.65 mg/day, Micronized estradiol 1 mg/day, Ethinyl estradiol 0.02-0.05 mg/day, Estradiol skin patch 4-8 mg twice weekly, Estradiol plus testosterone",
      "LH and FSH (Male): Testosterone enanthate 200 mg IM every 2-3 weeks, Testosterone skin patch 2.5-5.0 mg/day (can increase to 7.5 mg/day), Testosterone gel 3-6 g daily",
      "Growth hormone: Adults: Somatotropin 0.2-1.0 mg SC daily, Children: Somatotropin 0.02-0.05 mg/kg/day",
      "Thyroid-stimulating hormone: L (levo)-Thyroxine 0.05-0.2 mg daily according to T4 levels",
      "Vasopressin: Intranasal desmopressin-rhinal tube 5-20 µg twice daily, Oral DDAVP (Desmopressin) 300-600 µg daily, usually in divided doses"
    ],
    "Object8": [
      "Mass effects (headache, visual impairment)",
      "Electrolyte alterations",
      "Disorders of autonomic nervous system"
    ]
  },
  {
    "Object1": "Sheehan's Syndrome",
    "Object2": "Potentially life-threatening complication",
    "Object3": [
      "Infarction of pituitary gland following postpartum hemorrhage",
      "Consequent systemic hypotension"
    ],
    "Object4": [
      "Failure to lactate (earliest)",
      "Failure to regain menstruation after delivery",
      "Other symptoms of hypopituitarism (appear over months or years)",
      "Hypotension, hyponatremia, hypothyroidism (acute presentation)"
    ],
    "Object5": [],
    "Object6": [
      "Laboratory findings of hypopituitarism",
      "MRI: hypertrophied pituitary (early), atrophic pituitary and empty sella (later stages)"
    ],
    "Object7": [
      "Control of hemorrhage and volume replacement",
      "Administration of deficient hormones"
    ],
    "Object8": [
      "Coma and death can occur in severe cases"
    ]
  },
  {
    "Object1": "Empty Sella Syndrome",
    "Object2": [
      "Primary congenital weakness of the diaphragm",
      "Secondary (subsequent to infarction of a pituitary adenoma or to surgical or radiation-induced damage to the sellar diaphragm)"
    ],
    "Object3": [
      "Herniation of arachnoid diverticulum through an incomplete diaphragm sellae results in symmetrically ballooned sella, filled with CSF",
      "Infarction of a pituitary adenoma",
      "Surgical or radiation-induced damage to the sellar diaphragm"
    ],
    "Object4": [
      "Usually normal pituitary function",
      "Hypopituitarism may develop insidiously",
      "Chronic headache"
    ],
    "Object5": [
      "Incidental MRI finding"
    ],
    "Object6": [
      "MRI"
    ],
    "Object7": [
      "Treatment of hypopituitarism if developed"
    ],
    "Object8": [
      "Hypopituitarism"
    ]
  },
  {
    "Object1": "Kallmann Syndrome",
    "Object2": "Not specified",
    "Object3": [
      "Defective hypothalamic gonadotropin-releasing hormone synthesis",
      "Olfactory bulb agenesis or hypoplasia"
    ],
    "Object4": [
      "Anosmia or hyposmia",
      "Delayed puberty and hypogonadism (males)",
      "Primary amenorrhea and failure of secondary sexual development (females)"
    ],
    "Object5": [
      "Micropenis (males)"
    ],
    "Object6": [],
    "Object7": [
      "Males: Replacement by human chorionic gonadotropin (hCG) or testosterone for long term",
      "Females: Long-term treatment with estrogen and progestin"
    ],
    "Object8": [
      "Color blindness, optic atrophy, cleft palate, renal abnormalities, cryptorchidism, neurologic abnormalities like synkinesis or mirror movements"
    ]
  },
  {
    "Object1": "Pituitary Apoplexy",
    "Object2": "Rare life-threatening endocrine emergency",
    "Object3": [
      "Sudden hemorrhage into the pituitary gland",
      "Sudden infarction of the gland"
    ],
    "Object4": [
      "Sudden severe headache, double vision, sudden severe visual loss",
      "Cardiovascular collapse, change in consciousness, neck stiffness, sometimes hypoglycemia",
      "Acute life-threatening hypopituitarism"
    ],
    "Object5": [],
    "Object6": [
      "CT/MRI (without contrast): intra-pituitary or intra-adenoma hemorrhage, stalk deviation, compression of normal pituitary tissue, parasellar subarachnoid hemorrhage (severe cases)"
    ],
    "Object7": [
      "Initial: Conservative with careful monitoring of fluid and electrolyte balance, immediate replacement of deficient hormones (corticosteroids). Close monitoring of vision. High dose corticosteroids and supportive treatment.",
      "Surgical decompression: If rapid deterioration in visual acuity and fields (optic chiasm compression)."
    ],
    "Object8": [
      "Acute adrenal insufficiency (due to loss of ACTH)",
      "GnRH deficiency (most common)",
      "TSH deficiency (half of patients)"
    ]
  },
  {
    "Object1": "Pituitary Tumors",
    "Object2": [
      "Microadenomas (<1 cm)",
      "Macroadenomas (>1 cm)",
      "Functional (hormone excess)",
      "Nonfunctional (no hormone excess)",
      "Pituitary incidentalomas (nonfunctional, incidentally detected)"
    ],
    "Object3": [
      "Most common cause of pituitary disease, most are benign pituitary adenomas"
    ],
    "Object4": [
      "Mass effects: Headache (common, non-specific), visual field abnormalities (loss of acuity, optic atrophy, superior temporal quadrantanopsia, temporal hemianopsia), diplopia and strabismus (cranial nerve III, IV, VI palsies), facial numbness, obesity, disturbances of sleep, thirst, appetite, temperature regulation, diabetes insipidus (DI), anosmia (frontal lobe), vomiting, papilledema (raised intracranial tension)",
      "Symptoms due to hormone secretion (e.g. hypopituitarism)"
    ],
    "Object5": [
      "Specific signs depending on hormone excess (Table 2.4)"
    ],
    "Object6": [
      "Plain radiograph of skull: Enlargement of sella tursica, calcification of suprasellar region, erosion of clinoid process, double floor of sella",
      "CT scan with contrast: More sensitive for bony erosions and calcification",
      "MRI (before and after gadolinium): Superior to CT, shows pituitary mass. Detects small microadenomas (incidentalomas).",
      "Visual field plotting (automated computer perimetry or Goldmann perimetry)",
      "Functional assessment (hormonal assays): PRL, IGF-1, 24-hours urinary cortisol, FSH, LH, thyroid function tests"
    ],
    "Object7": [
      "Surgery: Primary mode for tumors warranting intervention (except prolactinomas). Trans-sphenoidal adenomectomy or hypophysectomy (treatment of choice). Open transcranial (transfrontal) route for very large tumors. Endoscopic or endonasal approach.",
      "Medical therapy: Somatostatin analogues (Octreotide, Pasireotide, Lanreotide) and/or dopamine agonists (bromocriptine, cabergoline) (for prolactinomas to reduce PRL levels and tumor size).",
      "Radiation therapy: Adjunctive after surgery, or if surgery impracticable/incomplete, or with medical therapy. External radiotherapy, Yttrium implantation, gamma knife (stereotactic radiosurgery)."
    ],
    "Object8": [
      "Pituitary apoplexy (infarction or bleeding into tumor)"
    ]
  },
  {
    "Object1": "Acromegaly",
    "Object2": [
      "Pituitary gigantism (GH excess prior to epiphyseal closure)",
      "Acromegaly (GH excess after puberty)"
    ],
    "Object3": [
      "Pituitary tumor (somatotrope pituitary adenoma) (most common)",
      "Few adenomas secrete both GH and prolactin",
      "Other tumors of pancreas, lungs, adrenal glands (produce GH or GHRH)"
    ],
    "Object4": [
      "Visual-field defects, cranial nerve palsy, headache",
      "Arthralgias and arthritis",
      "Carpal tunnel syndrome",
      "Acroparesthesia",
      "Proximal myopathy",
      "Sleep disturbances",
      "Sleep apnea (central and obstructive)",
      "Narcolepsy",
      "Menstrual abnormalities",
      "Decreased libido",
      "Impotence",
      "Impaired glucose tolerance, insulin resistance, hyperinsulinemia, diabetes mellitus",
      "Hypertriglyceridemia",
      "Hypercalciuria",
      "Low renin levels",
      "Increased aldosterone levels",
      "Hypothyroidism"
    ],
    "Object5": [
      "Acral enlargement (soft tissue of hands and feet)",
      "Gigantism (children)",
      "Prognathism, jaw malocclusion, widely spaced teeth",
      "Hypertrophy of frontal bones",
      "Osteoporosis",
      "Skin tags, acanthosis nigricans, increased sweat and sebum (moist/oily skin)",
      "Enlargement of lips, nose, tongue",
      "Increased heel pad thickness",
      "Macroglossia",
      "Colonic polyps",
      "Visceromegaly (tongue, thyroid, salivary glands, liver, spleen, kidney, prostate)",
      "Left ventricular hypertrophy, asymmetric septal hypertrophy, cardiomyopathy, hypertension, congestive heart failure, coronary artery disease",
      "Galactorrhea (if prolactin co-secretion)",
      "Goiter"
    ],
    "Object6": [
      "Biochemical: Basal fasting GH levels (>10 ng/mL, normal 1-5 ng/mL)",
      "Glucose tolerance test (failure to suppress GH below 0.3 µg/L, paradoxical rise)",
      "IGF-1 levels (single best test, almost always elevated)",
      "Serum IGFBP-3 concentrations (elevated)",
      "Postprandial plasma glucose (elevated)",
      "Serum insulin (increased in 70%)",
      "Prolactin (mild to moderate elevation in 30%)",
      "Serum phosphorus (elevated)",
      "Radiological: Plain films of skull (sellar enlargement in 90%, thickening of calvarium, enlarged frontal/maxillary sinuses, enlarged jaw)",
      "Radiographs of hand ('arrowhead' tufting of distal phalanges, increased width of intra-articular cartilages, cystic changes of carpal bones)",
      "Radiographs of feet (similar to hand, increased heel pad thickness >22 mm)",
      "X-ray spine (scoliosis, calcification of spinal ligaments)",
      "MRI scan of pituitary (reveals/localizes adenoma. If normal, image abdomen/chest for ectopic source.)",
      "Pituitary function: Partial or complete anterior hypopituitarism",
      "Visual field examination: Defects (e.g., bitemporal hemianopia)"
    ],
    "Object7": [
      "Aim: Achieve mean growth hormone level below 2.5 µg/L or normal IGF-1",
      "Surgery: Trans-sphenoidal surgical removal of pituitary adenoma (first-line therapy)",
      "Medical therapy: For patients without visual impairment risk, unfit for surgery, decline surgery, unlikely controlled by surgery, persistent acromegaly after surgery, or needing pituitary function preservation (fertility).",
      "Somatostatin receptor ligands (SRL): Octreotide, Pasireotide, Lanreotide (inhibit GH/IGF-I)",
      "GH receptor antagonist: Pegvisomant (blocks peripheral IGF-1 action)",
      "Dopamine receptor agonists: Bromocriptine or cabergoline (useful for mildly elevated IGF-1)",
      "Radiotherapy: Second-line after surgery, unfit for surgery, or medical therapy failure. External radiotherapy, Yttrium implantation, stereotactic radiosurgery (gamma knife, cyber knife).",
      "Others: Treatment of associated conditions (diabetes, hypertension, hyperlipidemia)"
    ],
    "Object8": [
      "Reduced survival (heart failure, coronary artery disease, hypertension)",
      "Increased neoplasia (carcinoma colon)",
      "Pituitary apoplexy",
      "Hypopituitarism",
      "Galactorrhea",
      "Multiple endocrine neoplasia type 1 (hyperparathyroidism, pancreatic islet cell tumors)"
    ]
  },
  {
    "Object1": "Prolactinoma",
    "Object2": [
      "Pituitary tumor (most common functional pituitary tumor, most are microadenomas)"
    ],
    "Object3": [
      "Pituitary tumor (lactotroph, somatotroph-lactotroph)",
      "Hypothalamic and stalk disease (craniopharyngiomas, irradiation, granulomas, stalk section/compression)",
      "Primary hypothyroidism",
      "Miscellaneous (cirrhosis, chronic renal failure, seizures)"
    ],
    "Object4": [
      "Hypogonadism, decreased libido, infertility, galactorrhea (spontaneous or expressible) (both sexes)",
      "Females: Amenorrhea, oligomenorrhea, osteoporosis",
      "Males: Loss of libido, impotence, gynecomastia, rarely galactorrhea"
    ],
    "Object5": [
      "Visual field defects and headache (if sufficiently large macroadenoma)"
    ],
    "Object6": [
      "Same as for other pituitary tumors",
      "Serum prolactin: >150 µg/L (nonpregnant, suggests adenoma); >300 µg/L (almost diagnostic of tumor)",
      "Visual fields checked",
      "Primary hypothyroidism excluded",
      "Anterior pituitary function assessed if hypopituitarism or radiological evidence of tumor",
      "MRI or contrast-enhanced CT scan of pituitary (delineates macroprolactinoma, microprolactinoma harder)"
    ],
    "Object7": [
      "Medical: Dopamine agonists (bromocriptine 2.5 mg thrice daily, cabergoline 0.25-0.5 mg twice a week) (reduce prolactin secretion and tumor size)",
      "Surgical: Trans-sphenoidal removal (if dopamine agonists fail, or large invasive tumor)",
      "Radiation: External radiotherapy (rarely necessary)",
      "Asymptomatic patients not requiring pregnancy: estrogens to prevent bone loss, regular monitoring"
    ],
    "Object8": [
      "Estrogen deficiency or testosterone deficiency (long-term effects)",
      "Bone loss"
    ]
  },
  {
    "Object1": "Diabetes Insipidus (DI)",
    "Object2": [
      "Primary deficiency (neurogenic, pituitary, hypothalamic, cranial or central DI)",
      "Secondary deficiency (due to inhibition of ADH secretion - primary polydipsia)",
      "Deficient action of ADH (nephrogenic DI)",
      "Transient DI of pregnancy (gestogenic DI)"
    ],
    "Object3": [
      "Central DI: Idiopathic (30%), neoplastic or infiltrative lesions of hypothalamus (pituitary tumors with suprasellar extension, metastases, leukemia, histiocytosis-X, sarcoidosis, germinomas, pinealomas), pituitary or hypothalamic surgery, severe head injury (skull fracture), ruptured cerebral aneurysms, infections (e.g., encephalitis, TB), autoimmune (associated with thyroiditis), familial (AD and X-linked inheritance), Wolfram syndrome (DIDMOAD syndrome), septo-optic dysplasia",
      "Nephrogenic DI: Primary/congenital or familial (X-linked recessive vasopressin receptor mutation), acquired (chronic pyelonephritis, hypokalemia, hypercalcemia, sickle cell disease, protein deprivation, drug-induced (lithium, demeclocycline, amphotericin B, aminoglycosides, cisplatin, rifampicin, colchicine), amyloidosis, other renal diseases (chronic renal failure, obstructive uropathy, polycystic disease), Sjögren's syndrome)"
    ],
    "Object4": [
      "Polyuria (4-18 L/day), polydipsia (compensatory excessive thirst), nocturia",
      "Change in mentation, insomnia, weight loss"
    ],
    "Object5": [
      "Skin, mucous membranes cool",
      "Hypernatremia, restlessness, agitation, diminished deep tendon reflexes, seizures (if untreated)",
      "Hypotension (shock-like symptoms, but urine output increased)"
    ],
    "Object6": [
      "Careful history, examination",
      "Document presence of polyuria (usually 4-15 L/24h)",
      "Measurement of osmolality of plasma and urine (plasma >295 mOsml/kg, urine 50-150 mOsml/kg in DI; plasma low in primary polydipsia)",
      "Urine: high 24h volumes, clear and low specific gravity, low urine osmolality",
      "Serum sodium: high or high normal (hypernatremia)",
      "MRI of pituitary and hypothalamus",
      "Water deprivation test: Indication: Diagnosis/exclusion of DI, differentiate DI from primary polydipsia. Procedure: 8h fasting, hourly plasma/urine osmolality, urine volume, weight. Administer ADH (vasopressin) if plasma osmolality >300 mOsm/kg or urine osmolality <600 mOsm/kg. Interpretation: Normal response (urine osmolality >600, increases minimally after ADH). Primary polydipsia (urine/plasma osmolality ratio >2 after dehydration). Central DI (plasma osmolality >300, no urine osmolality rise after restriction, urine osmolality increases 50-100% after ADH). Nephrogenic DI (urine osmolality < plasma osmolality, urine osmolality increases <50% after ADH). Alternative: Infuse hypertonic saline, measure ADH response."
    ],
    "Object7": [
      "Goals: Balance fluid intake with output (rapid replacement in acute, slow in chronic to prevent cerebral edema), daily weights, accurate in/out, urine specific gravity and osmolality",
      "Drugs:",
      "Desmopressin (DDAVP): 10 µg intranasal at bedtime, titrated up. Typical maintenance 10-20 µg once/twice daily. Oral DDAVP 300-600 µg daily.",
      "Chlorpropamide: Increases renal responsiveness to vasopressin (risk of hypoglycemia).",
      "Carbamazepine: Enhances ADH release and increases collecting duct sensitivity.",
      "Clofibrate: Stimulates residual ADH production.",
      "Thiazide diuretics (e.g., bendrofluazide): Only effective drugs for nephrogenic DI.",
      "NSAIDs: Inhibit renal prostaglandin synthesis, decrease GFR.",
      "Nephrogenic DI: Adequate fluids, calorie and low sodium diet. Correct underlying cause. Diuretics, high dose DDAVP, indomethacin, chlorpropamide, clofibrate, carbamazepine."
    ],
    "Object8": [
      "Hypernatremia, dehydration and its neurological sequelae",
      "Growth retardation",
      "Hydronephrosis (due to excessive urine output)"
    ]
  },
  {
    "Object1": "Thyrotoxicosis (Hyperthyroidism)",
    "Object2": [
      "Primary hyperthyroidism",
      "Thyrotoxicosis without hyperthyroidism",
      "Secondary hyperthyroidism"
    ],
    "Object3": [
      "Primary hyperthyroidism: Graves disease, Toxic multinodular goiter, Toxic adenoma (Plummer's disease), Iodine excess (Jod Basedow), Activating mutation of TSH receptor",
      "Thyrotoxicosis without hyperthyroidism: Subacute thyroiditis, Hashitoxicosis, Amiodarone induced (Type I: pre-existing Graves/MNG; Type II: direct cytotoxicity), Radiation induced, Thyrotoxicosis factitia, Struma ovarii, Infarction of thyroid gland",
      "Secondary hyperthyroidism: TSH secreting pituitary adenoma, Human chorionic gonadotropin-mediated hyperthyroidism (hyperemesis gravidarum, trophoblastic disease), Gestational thyrotoxicosis",
      "Graves' disease: Autoimmune disorder with autoantibodies (TSI or TSH-receptor antibodies - IgG type, stimulate hormone production/enlargement). Ophthalmopathy/dermatopathy due to immunologically mediated activation of fibroblasts. Genetic factors (HLA-DR3). Triggered by viral/bacterial infections (molecular mimicry)."
    ],
    "Object4": [
      "Weight loss, increased appetite, vomiting, increased frequency of stool, diarrhea",
      "Exertional dyspnea, palpitations, angina",
      "Nervousness, irritability, psychosis, emotional lability",
      "Pruritus",
      "Menstrual disturbances (amenorrhea or oligomenorrhea), repeated abortions, infertility, loss of libido, impotence",
      "Heat intolerance, fatigue, apathy, thirst",
      "Diminution of visual acuity, diplopia (ophthalmopathy)",
      "Shortness of breath (elderly)",
      "Behavioral problems (hyperactivity) (children)",
      "Non-specific symptoms (elderly: anorexia, apathy, fatigue, weight loss)"
    ],
    "Object5": [
      "Diffuse or nodular enlargement of thyroid, warmth and bruit (increased vascularity)",
      "Sinus tachycardia, atrial fibrillation, wide pulse pressure, cardiac failure, cardiomyopathy, ‘scratchy’ midsystolic murmur (Means-Lerman scratch)",
      "Fine tremors, hyperreflexia, proximal myopathy, bulbar myopathy, ill-sustained clonus",
      "Soft, warm and moist skin. Increased sweating, palmar erythema, spider naevi, onycholysis, pretibial myxedema (Graves’), pigmentation, alopecia, clubbing (thyroid acropachy)",
      "Gynecomastia",
      "Eyes (Ophthalmopathy): Lid lag, exophthalmos, proptosis, extraocular diplopia, exposure keratitis, lagophthalmos (Graves’ disease). Dalrymple sign (rim of sclera all around cornea), Rosenbach's sign (fine tremor of upper eyelids), Joffroy's sign (lack of forehead wrinkling on upward gaze), Möblus sign (lack of convergence), Von Graefe's sign (lid lag on downward gaze), Stellwag's sign (staring look with infrequent blinking), Vigouroux sign (eyelid fullness), Grove sign (resistance to pulling down retracted upper lid), Ballet sign (restriction of extraocular muscles), Kocher sign (staring look), Naffziger's sign (eyeball seen beyond superior orbital margin).",
      "Pretibial Myxedema (Dermopathy): Scaly thickening and induration (raised pinkish or purplish plaques) of dermis on shins, dorsum of foot (rarely face/arms). Peau d'orange appearance with coarse hair.",
      "Subclinical Thyrotoxicosis: Atrial fibrillation (in >60 years), bone loss (postmenopausal women).",
      "Younger patients: Excessive height or excessive growth rate."
    ],
    "Object6": [
      "TSH levels: Very low or undetectable (primary thyrotoxicosis). Primary test, normal level excludes thyrotoxicosis. (Normal range 0.4-5.0 mU/L).",
      "Serum free T3 (fT3) and free T4 (fT4): Elevated (primary thyrotoxicosis). fT4 normal, fT3 elevated in T3-thyrotoxicosis. fT4 elevated, fT3 normal on T4 therapy.",
      "Total serum thyroxine (tT4): Increased in hyperthyroidism, pregnancy, estrogen therapy, tamoxifen use, congenital anomaly. Decreased in hypothyroidism, nephrotic syndrome, androgen therapy, liver failure, drugs (salicylate, sulfonylureas, phenytoin).",
      "Total serum triiodothyronine (tT3): Increased in hyperthyroidism, T3-thyrotoxicosis.",
      "Reverse T3 (rT3): Raised in high TBG. Normal in hypothyroid on thyroxine.",
      "Thyroglobulin (Tg): Increased in well-differentiated thyroid carcinoma, hyperthyroidism.",
      "Radioactive iodine uptake (RAIU) or technetium: Increased in hyperthyroidism (Graves' disease, toxic multinodular goiter, adenoma, early thyroiditis). Decreased in hypothyroidism, late thyroiditis. Contraindicated in children/pregnancy/lactation.",
      "Ultrasound of thyroid gland: Look for nodularity, vascularity, lymph nodes, for guided FNAC.",
      "Thyroid autoantibody tests: Antithyroid peroxidase (TPO) antibody (TPOAb) (tissue destructive process), Antithyroglobulin (Tg) antibody, TSH receptor (TR) antibody (TRAb) (formerly TSI/LATS, driving force for thyrotoxicosis).",
      "Calcitonin: Increased in medullary carcinoma of thyroid.",
      "Fine-needle aspiration cytology/excision biopsy: Helps in diagnosis.",
      "Other: Minor LFT abnormalities, mild hypercalcemia, glycosuria."
    ],
    "Object7": [
      "Antithyroid drugs (ATD): Primary therapy in pregnancy, children/adolescents, severe Graves’ with eye changes.",
      "Thionamides (propylthiouracil, carbimazole, methimazole): Inhibit TPO, prevent iodine binding. Propylthiouracil (100-600 mg/day) inhibits peripheral T4-T3 conversion (preferred in pregnancy/severe thyrotoxicosis). Carbimazole (5-15 mg thrice daily, then 10 mg thrice daily, maintenance 5-20 mg daily for 18-24 months). Side effects: Rashes, urticaria, fever, arthralgia, agranulocytosis, hepatotoxicity, aplasia cutis.",
      "Potassium perchlorate: Reduces iodine uptake (temporary, iodine-induced thyrotoxicosis).",
      "Potassium iodide: Decreases T3/T4 synthesis and release (preparation for thyroidectomy, thyrotoxic crisis).",
      "Beta adrenergic blockers: Non-selective, for immediate symptom control (anxiety, palpitation, tremors). Propranolol (20-40 mg 6 hourly).",
      "Lithium (rarely used)",
      "Surgical treatment: Subtotal thyroidectomy (treatment of choice for MNG with severe hyperthyroidism in children, pregnant women intolerant to ATD, large goiters with severe ophthalmopathy/pressure, patients needing quick normalization).",
      "Radioactive iodine (RAI): 131I (concentrated in thyroid, destroys cells). Indications: >40 years, young parents with short lifespan, young individuals sterilized. Contraindications: Children, pregnant/lactating women, severe ophthalmopathy, chronic smokers.",
      "Thyrotoxicosis factitia: Stop thyroxine, give symptom relief drugs.",
      "Amiodarone-induced hyperthyroidism (AIT): Type I: ATD. Type II: corticosteroids."
    ],
    "Object8": [
      "Cardiac: Atrial fibrillation, cardiac failure, cardiomyopathy, angina.",
      "Ophthalmopathy: Corneal ulcers, visual field defects, papilledema.",
      "Dermatopathy: Pretibial myxedema.",
      "Thyroid Storm/Crisis: Rare, life-threatening medical emergency (10% mortality).",
      "Others: Hypokalemic periodic paralysis, Mitral valve prolapse, Secondary cancers (RAI therapy)"
    ]
  },
  {
    "Object1": "Hyperthyroid Crisis/Thyrotoxic Crisis/Thyroid Storm",
    "Object2": "Life-threatening medical emergency",
    "Object3": [
      "Severe infections in previously undetected or inadequately treated hyperthyroidism/thyrotoxicosis",
      "Following surgery (subtotal thyroidectomy in ill-prepared patient, or other surgery in undetected hyperthyroidism)",
      "Following radiotherapy (131I therapy, due to transient rise in serum thyroid hormone)",
      "Other precipitating factors: Cerebrovascular accidents, diabetic ketoacidosis, acute coronary syndrome, iodine contrast agent use, sudden withdrawal of antithyroid medications, stress, major trauma"
    ],
    "Object4": [
      "Marked hypermetabolism and excessive adrenergic response",
      "Hyperpyrexia (104-106°F) with flushing and sweating",
      "Marked tachycardia, often with atrial fibrillation",
      "Heart failure",
      "Marked agitation, restlessness, delirium, coma",
      "Nausea, vomiting, diarrhea, jaundice"
    ],
    "Object5": [
      "Flushing and sweating",
      "Tachycardia (with AF)",
      "High pulse pressure",
      "Heart failure and shock (fatal outcome)"
    ],
    "Object6": [
      "Clinical diagnosis with supporting lab if available."
    ],
    "Object7": [
      "Rehydration and antibiotics (if infection)",
      "Control hyperthermia: External cooling (DO NOT administer salicylates, converts T4 to T3).",
      "Propranolol: Oral (80 mg 4 times daily) or IV (1-5 mg 4 times daily) (blocks peripheral T4-T3 conversion).",
      "Propylthiouracil (800-1200 mg orally every 4 hours) or carbimazole (15-30 mg stat, then 15 mg TID) (inhibit new thyroid hormone synthesis). Carbimazole rectally in unconscious/uncooperative.",
      "Lugol's iodine: 10 drops TID (1 hour after PTU/carbimazole).",
      "Sodium iopodate: 500 mg/day orally (inhibits hormone release and T4-T3 conversion).",
      "Benzodiazepines: For agitation.",
      "Corticosteroids: IV hydrocortisone 100-200 mg every 6 hours (suppresses manifestations).",
      "Bile acid sequestrants (cholestyramine 4g orally 4 times daily): Decreases thyroid hormone levels by interfering with enterohepatic circulation.",
      "Digoxin: To control cardiac failure and atrial fibrillation (AF)."
    ],
    "Object8": [
      "Heart failure and shock (fatal outcome)"
    ]
  },
  {
    "Object1": "Hypothyroidism",
    "Object2": [
      "Primary hypothyroidism (intrinsic disorder of thyroid gland)",
      "Secondary hypothyroidism (failure of TSH production due to pituitary/hypothalamic disease)"
    ],
    "Object3": [
      "Primary: Hashimoto's thyroiditis (most common), Radioactive iodine therapy for Graves' disease, Subtotal thyroidectomy for Graves' disease, nodular goiter, or thyroid cancer, Excessive iodide intake (radiocontrast dyes), Subacute thyroiditis (usually transient), Postpartum thyroiditis, Iodide deficiency, Drugs (lithium, interferon-alfa, amiodarone), Dyshormonogenesis-Pendred syndrome",
      "Secondary: Hypopituitarism (pituitary adenoma, pituitary ablative therapy, or pituitary destruction)",
      "Tertiary: Hypothalamic dysfunction (rare)",
      "Rarely peripheral resistance to action of thyroid hormone"
    ],
    "Object4": [
      "Lethargy, somnolence, weight gain, cold intolerance, hoarse voice",
      "Reduced appetite, constipation",
      "Angina, bradycardia",
      "Aches and pains, muscle stiffness, depression, psychosis",
      "Menorrhagia, infertility, impotence"
    ],
    "Object5": [
      "Pallor",
      "Goiter (primary, absent in secondary)",
      "Myxedema (non-pitting edema of skin of hands, feet, eyelids - due to mucopolysaccharide accumulation)",
      "Myxedema facies (periorbital puffiness, scanty eyebrows, facial pallor/lemon-yellow tint, purplish lips, malar flush)",
      "Dry flaky skin and hair, alopecia, vitiligo, carotenemia, erythema abigne, xanthelasmas, madarosis (thinning of lateral 1/3 of eyebrows)",
      "Delayed relaxation of tendon reflexes (Woltman's sign)",
      "Carpal tunnel syndrome",
      "Cerebellar ataxia, deafness, myotonia, proximal myopathy, pseudohypertrophy of muscles, Hashimoto encephalopathy",
      "Pericardial effusion, pleural effusion",
      "OSA (obstructive sleep apnea)",
      "Hyponatremia"
    ],
    "Object6": [
      "Serum TSH: Investigation of choice. High level confirms primary hypothyroidism.",
      "Serum T4 levels: Low level confirms hypothyroid state.",
      "Thyroid and other organ-specific antibodies may be found.",
      "Increased serum aspartate transferase, lactate dehydrogenase (LDH), creatine kinase (CK) (with myopathy).",
      "Hypercholesterolemia and hypertriglyceridemia.",
      "Hyponatremia (due to increased ADH and impaired free water clearance).",
      "Anemia: Usually normochromic and normocytic.",
      "ECG: Sinus bradycardia, low voltage QRS, ST segment and T wave abnormalities.",
      "Chest radiograph: Enlarged cardiac shadow."
    ],
    "Object7": [
      "Levothyroxine sodium (thyroxine, T4) for life (1.6-1.8 µg/kg/day).",
      "Starting dose: <50 years: 1.0 µg/kg/day. >50 years: <50 µg/day (increase by 25 µg at 6-8 week intervals). Heart disease: 12.5-25 µg/day (increase slowly).",
      "Administration: Empty stomach with water, 1 hour before breakfast.",
      "Dosage adjustments: Age, severity/duration, weight, malabsorption, concomitant drugs, pregnancy (25-50% increase), cardiac disease (low dose/alternate day).",
      "Monitoring: Normalize TSH level (avoid complete suppression), restore T4. Assessed clinically and by TFTs after 6 weeks.",
      "Hashimoto's thyroiditis: Levothyroxine (150-200 μg/day) (may shrink goiter)."
    ],
    "Object8": [
      "Untreated: Mental retardation (infancy), myxedema.",
      "Thyroxine therapy: Angina or worsening angina (ischemic heart disease patients).",
      "Hashimoto's: Increased risk for thyroid lymphoma."
    ]
  },
  {
    "Object1": "Myxedema Coma",
    "Object2": "Very rare, life-threatening medical emergency",
    "Object3": [
      "Long-standing, severe untreated hypothyroidism (or undiagnosed) in elderly patient where adaptive mechanisms fail.",
      "Precipitating factors: Infections, drugs (amiodarone, B-blockers, diuretics, anesthetic agents, barbiturates, lithium, narcotics, phenothiazines), cardiac failure, hypoxia, hyponatremia, hypercapnia."
    ],
    "Object4": [
      "Hypothermia (body temperature as low as 25°C)",
      "Depressed level of consciousness, convulsions, coma",
      "Severe cardiac failure, hypoventilation",
      "Metabolic abnormalities (hypoglycemia, hyponatremia)"
    ],
    "Object5": [
      "Cool pale skin",
      "Absence of mild diastolic hypertension",
      "Reduced ECG voltage",
      "Respiratory acidosis, hypoxia, hypercapnia"
    ],
    "Object6": [
      "Serum free T4: low",
      "Serum TSH: usually high, sometimes slightly elevated",
      "Serum creatine phosphokinase: mostly markedly raised",
      "Hypoglycemia and hyponatremia, increased CO2, decreased WBC count and Hct",
      "Blood gases: respiratory acidosis, hypoxia, hypercapnia"
    ],
    "Object7": [
      "Treatment started before biochemical confirmation.",
      "Hypothyroidism: Large initial IV dose of 300-500 µg T4; add T3 if no response in 48h.",
      "Hypocortisolemia: IV hydrocortisone 200-400 mg daily.",
      "Hypoventilation: Intubation and mechanical ventilation.",
      "Hypothermia: Gentle warming with blankets, no active rewarming.",
      "Hyponatremia: Mild fluid restriction, 3% saline.",
      "Hypotension: Cautious volume expansion with crystalloid or whole blood.",
      "Hypoglycemia: Glucose administration.",
      "Precipitating event: Identification and elimination (liberal antibiotics).",
      "Monitor cardiac output and pressures. Cautious IV fluids, high-flow oxygen, assisted ventilation."
    ],
    "Object8": [
      "Coma, death",
      "Severe cardiac failure",
      "Pericardial effusions",
      "Hypoventilation"
    ]
  },
  {
    "Object1": "Myxedema Madness",
    "Object2": "Neuropsychiatric manifestation",
    "Object3": [
      "Severe hypothyroidism (rarely in elderly patients)"
    ],
    "Object4": [
      "Depression",
      "Dementia or psychotic symptoms (delusions, hallucinations)",
      "Develops shortly after starting T4 replacement (rarely)"
    ],
    "Object5": [
      "Hypothermia"
    ],
    "Object6": [],
    "Object7": [
      "Treatment of hypothyroidism."
    ],
    "Object8": []
  },
  {
    "Object1": "Sick Euthyroid Syndrome/Nonthyroid Illness State (NTIS)",
    "Object2": [
      "Nonthyroidal illness syndrome",
      "low-T3 syndrome"
    ],
    "Object3": [
      "Systemic illness, surgery, or fasting (not primary thyroid/pituitary dysfunction)",
      "Malnutrition, HIV, anorexia nervosa, trauma, myocardial infarction, chronic renal failure, diabetic ketoacidosis, cirrhosis, sepsis"
    ],
    "Object4": [],
    "Object5": [
      "Changes in thyroid function (influences H-P-T axis, hormone transport/metabolism)"
    ],
    "Object6": [
      "Serum levels of free T4 and triiodothyronine (within normal)",
      "Serum TSH (usually normal, can be influenced)"
    ],
    "Object7": [
      "Treatment with thyroxine is not recommended."
    ],
    "Object8": []
  },
  {
    "Object1": "Subclinical Hypothyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Iatrogenic",
      "Hashimoto's thyroiditis",
      "Postpartum thyroiditis",
      "Medications (amiodarone, lithium, interferon, sorafenib)",
      "Partial thyroidectomy",
      "Head and neck radiation"
    ],
    "Object4": [
      "Symptoms or signs of hypothyroidism (may be present)"
    ],
    "Object5": [
      "Increased serum TSH in presence of normal serum FT4 and T3 concentration"
    ],
    "Object6": [
      "Serum TSH",
      "Serum FT4 and T3",
      "Antibodies"
    ],
    "Object7": [
      "Levothyroxine for: pregnant or planning pregnancy, serum TSH > 10.0 mU/L, symptomatic, age <70 years, TSH >7.0 mU/L with positive antibodies, goiter, high vascular risk (ischemic heart disease, diabetes, dyslipidemia)."
    ],
    "Object8": [
      "Progression to overt hypothyroidism (2-5% yearly)",
      "Risk of CV disease (diastolic dysfunction, hypertension, increased LDL-C, hsCRP, coagulation alterations, endothelial dysfunction)",
      "Infertility",
      "Neuropsychiatric manifestations"
    ]
  },
  {
    "Object1": "Subclinical Hyperthyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Iatrogenic",
      "Autonomous nodules (solitary and in MNG)",
      "Graves' disease",
      "Thyroiditis",
      "Graves' disease in remission",
      "High hCG"
    ],
    "Object4": [],
    "Object5": [
      "Serum levels of free T4 and triiodothyronine are within normal. Serum TSH levels is subnormal."
    ],
    "Object6": [
      "Serum TSH",
      "Serum FT4 and FT3"
    ],
    "Object7": [
      "No evidence to treat with antithyroid drugs."
    ],
    "Object8": [
      "Functional cardiac effects (resting tachycardia, atrial fibrillation, LV hypertrophy, increased LV mass index, increased cardiac workload, diastolic dysfunction, increased systolic function at rest, impaired systolic response to exercise)",
      "Noncardiac effects (osteoporosis, decreased BMD, increased fracture risk, muscle weakness, dementia)"
    ]
  },
  {
    "Object1": "Thyroiditis",
    "Object2": [
      "Acute",
      "Subacute",
      "Chronic"
    ],
    "Object3": [
      "Acute: Bacterial infections (Staphylococcus, Streptococcus, Enterobacter), Fungal infections (Aspergillus, Candida, Histoplasma), Radiation, Drugs (Amiodarone)",
      "Subacute: Viral or granulomatous (de Quervain's) thyroiditis, Silent thyroiditis (includes post-partum thyroiditis), Mycobacterial infection, Drug induced (Interferon, Amiodarone)",
      "Chronic: Autoimmune (Hashimoto's thyroiditis, Riedel's thyroiditis), Parasitic thyroiditis (Echinococcosis, Strongyloidiasis, Cysticercosis), Traumatic (Palpation thyroiditis)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Subacute Thyroiditis (De Quervain's Thyroiditis/Granulomatous Thyroiditis)",
    "Object2": "Spontaneously remitting, painful, subacute inflammatory disease",
    "Object3": [
      "Often preceded by a viral infection (e.g., Coxsackie, mumps, adenovirus) of upper respiratory tract"
    ],
    "Object4": [
      "Prodromal viral symptoms (fever, malaise, pain in neck with tachycardia, local thyroid tenderness)",
      "Anterior neck pain (abrupt onset, sometimes unilateral, may radiate to ear, mandible, occiput)",
      "Pain may shift to contralateral lobe (creeping thyroiditis)",
      "Pain aggravated by moving head, swallowing, coughing"
    ],
    "Object5": [
      "Enlarged and tender thyroid gland",
      "Initially hyperthyroidism, then hypothyroidism, then full recovery (4-6 months)"
    ],
    "Object6": [
      "Erythrocyte sedimentation rate (ESR): Elevated (>55 mm/h)",
      "Leukocyte counts: Normal or slightly elevated",
      "Serum IL-6 and Tg concentrations: Increased during thyrotoxic phase",
      "Thyroid radionuclide uptake: Reduced or absent",
      "Thyroid antibodies: Transiently detectable at low titers"
    ],
    "Object7": [
      "Mild cases: Salicylates or non-steroidal anti-inflammatory drugs (NSAIDs)",
      "Severe cases: Corticosteroids (prednisone 40-60 mg/day)",
      "Thyrotoxicosis symptoms: Beta-adrenergic blocking agents (propranolol 20-40 mg 3-4 times daily)",
      "Hypothyroidism: L-T4 replacement needed"
    ],
    "Object8": [
      "Hypothyroidism may persist in about 5% of cases."
    ]
  },
  {
    "Object1": "Hashimoto's Thyroiditis (Autoimmune Thyroiditis)",
    "Object2": "Autoimmune condition",
    "Object3": [
      "Autoimmune disorder with destructive lymphoid infiltration of thyroid"
    ],
    "Object4": [
      "Most patients asymptomatic",
      "Feeling of tightness or fullness in the neck (some)",
      "Neck pain and tenderness (rare)"
    ],
    "Object5": [
      "Diffuse enlargement of thyroid with firm or rubbery consistency",
      "Hypothyroidism (commonest cause of goitrous hypothyroidism)",
      "Hashitoxicosis (acute phase)",
      "Associated with other autoimmune disorders (Type 1 DM, pernicious anemia, Addison's disease)"
    ],
    "Object6": [
      "Thyroid function tests: Features of hypothyroidism",
      "Antithyroid peroxidase (TPO) antibody (TPOAb) in 95% patients",
      "Antithyroglobulin (Tg) antibody in 60-80% patients",
      "Antinuclear factor (ANF) (in <20 years)",
      "Ultrasound of thyroid: Reduced echogenicity",
      "Fine-needle aspiration cytology (FNAC) of thyroid"
    ],
    "Object7": [
      "Levothyroxine/thyroxine (150-200 μg/day) (for hypothyroidism, may shrink goiter). Dose sufficient to suppress serum TSH to low but detectable levels."
    ],
    "Object8": [
      "Increased risk for thyroid lymphoma (rare)."
    ]
  },
  {
    "Object1": "Riedel's Thyroiditis (Sclerosing Thyroiditis/Ligneous Thyroiditis/Invasive Fibrous Thyroiditis)",
    "Object2": "Rare, chronic inflammatory disorder of unknown etiology",
    "Object3": [
      "Unknown, associated with dense fibrosis of thyroid and adjacent/extracervical tissues (fibrous mediastinitis, retroperitoneal fibrosis, retro-orbital fibrosis, sclerosing cholangitis, pancreatitis)."
    ],
    "Object4": [
      "Painless, progressively increasing anterior neck mass (long history)",
      "Dysphagia, cough, hoarseness, stridor, attacks of suffocation (pressure symptoms)",
      "Most patients are euthyroid"
    ],
    "Object5": [
      "Stony-hard or woody thyroid mass (varies in size, fixed to surrounding structures, may involve one or both lobes)"
    ],
    "Object6": [
      "Thyroid antibodies: May be found in ~45%.",
      "Serum calcium: May be low (parathyroid invasion).",
      "Open biopsy (to differentiate from thyroid carcinoma or lymphoma, FNAB difficult to interpret)."
    ],
    "Object7": [
      "Surgical treatment: To relieve pressure on trachea and establish diagnosis.",
      "Corticosteroids: Little or no value."
    ],
    "Object8": [
      "Pressure on trachea"
    ]
  },
  {
    "Object1": "Simple (Nontoxic) Goiter",
    "Object2": [
      "Diffuse nontoxic (simple) goiter (simple hyperplastic (colloid) goiter, endemic goiter, sporadic goiter)"
    ],
    "Object3": [
      "Simple hyperplastic goiter: Physiological (pregnancy, puberty), iodine deficiency",
      "Endemic goiter: Deficiency of iodine (low iodine in soil, water, food), Goitrogens (vegetables from Brassicaceae family, Cassava root)",
      "Sporadic goiter: In most cases, cause is not known"
    ],
    "Object4": [
      "Endemic goiter: Later develop hypothyroidism, hypothyroidism and mental retardation (children/adults)"
    ],
    "Object5": [
      "Diffuse enlargement of the thyroid without any nodularity",
      "Large, smooth firm, non-tender goiter",
      "Euthyroid state (initial)",
      "Cretinism (iodine deficiency): Stunting, deaf-mutism, malformed limbs, spastic motor disorders, goiter, mental impairment"
    ],
    "Object6": [
      "Serum inorganic iodide: Reduced",
      "Urinary iodide excretion: Low < 50 µg/day",
      "Serum T4: Normal",
      "Serum T3: May be normal or raised",
      "TSH: May be normal or mildly raised"
    ],
    "Object7": [
      "Early stages: Replacement with iodine.",
      "Later: May need suppressive therapy with T4."
    ],
    "Object8": [
      "Hypothyroidism",
      "Cretinism",
      "Malignancy (risk factors: solitary thyroid nodules in >60 or <30, neck/face irradiation, pain/pressure, male sex, large nodules, nodule growth)"
    ]
  },
  {
    "Object1": "Hyperparathyroidism",
    "Object2": [
      "Primary",
      "Secondary",
      "Tertiary"
    ],
    "Object3": [
      "Primary: Autonomous secretion of PTH by parathyroid (single adenoma - 90%, multiple adenomata, nodular hyperplasia, carcinoma of parathyroid)",
      "Secondary: Parathyroid hyperplasia with increased PTH secretion to compensate for prolonged hypocalcemia (chronic renal failure, malabsorption, osteomalacia, rickets)",
      "Tertiary: Adenoma formation and autonomous PTH secretion (occurring in cases of secondary hyperparathyroidism, post renal transplantation)"
    ],
    "Object4": [
      "Classical symptoms: 'moans, bones, stones, abdominal groans'",
      "Moans (psychiatric): lethargy, fatigue, depression, memory loss, psychoses, neuroses, paranoia, confusion, stupor, coma",
      "Stones (renal): renal stones, uremia, polydipsia, polyuria",
      "Groans (abdominal): constipation, nausea, vomiting, peptic ulcers, indigestion, pancreatitis",
      "Nonspecific: Anorexia, lassitude, tiredness, generalized aches, weight loss, pain, drowsiness, poor concentration",
      "Renal: Recurrent renal calculi (calcium oxalate/phosphate), polyuria and polydipsia, loss of renal function with uremia, hypokalemia, hyperuricemia, hyperchloremic acidosis, dilute urine",
      "Skeletal: Bone pain, osteoporosis, fractures, deformity due to osteitis fibrosa cystica, localized bone swelling/brown tumor"
    ],
    "Object5": [
      "Often diagnosed by incidental hypercalcemia (more than 70%)",
      "Hypertension (common)",
      "Calcification of cornea, arterial walls, soft tissues of hand",
      "Myopathy"
    ],
    "Object6": [
      "Biochemical: Estimation of fasting serum calcium and phosphate. Hallmark: Hypercalcemia and hypophosphatemia with detectable or elevated intact PTH levels.",
      "Correction of serum calcium concentrations for albumin levels.",
      "Mild hyperchloremic acidosis (may be associated).",
      "Renal function tests.",
      "Urine: Hypercalciuria (>300 mg/24 hours in ~30%), Increased markers of bone resorption (urinary pyridinoline, deoxypyridinoline, N-telopeptide of collagen).",
      "ECG: Shortened QT interval, Rarely cardiac arrhythmias.",
      "Radiological: Most sensitive/specific for osteitis fibrosa cystica: subperiosteal resorption of cortical bone (phalanges). 'Salt-and-pepper' appearance (skull). Bone cysts or brown tumors (osteolytic lesions). Osteoporosis (preferential loss of cortical bone). Loss of lamina dura of teeth (non-specific). Nephrocalcinosis. Soft tissue calcification. DEXA/CT scan (reduced bone density).",
      "Localization of tumor: High-resolution ultrasonography, CT scanning, subtraction imaging, scintigraphy (technetium 99 sestamibi), Selective neck vein catheterization with PTH estimation (for re-operations)."
    ],
    "Object7": [
      "Hypercalcemia: Adequate rehydration (4-6 L 0.9% saline day 1, then 3-4 L). IV bisphosphonate (pamidronate 15-60 mg). Calcitonin (200 units IV 6-hourly). Prednisolone (30-60 mg daily for myeloma, sarcoidosis, vitamin D excess). Oral phosphate. Diuretics (furosemide). Mithramycin. Hemodialysis.",
      "Primary hyperparathyroidism: Adenoma: Surgical removal. Hyperplasia: Removal of all four parathyroid glands, transplantation of excised tissue to forearm.",
      "Secondary disease: Calcium supplements, Vitamin D.",
      "Tertiary disease: Phosphate binders (Amphojel, Basaljel, Tums)."
    ],
    "Object8": [
      "Renal: Nephrocalcinosis, Uremia",
      "Skeletal: Osteoporosis, Fractures",
      "Cardiovascular: Hypertension"
    ]
  },
  {
    "Object1": "Hypercalcemia",
    "Object2": [
      "Mild (10.5-12 mg/dl)",
      "Severe (>14 mg/dl)"
    ],
    "Object3": [
      "Parathyroid hormone related (normal or elevated PTH): Primary hyperparathyroidism, Tertiary hyperparathyroidism, Lithium therapy-induced hyperparathyroidism, Familial hypercalciuric hypercalcemia",
      "Malignancy related (low PTH): Multiple myeloma, PTH related protein secretion (tumors of lung and kidney), Secondary deposits in bone (breast carcinoma), Production of osteoclastic factors by tumors",
      "Associated with renal failure: Secondary hyperparathyroidism, Aluminum intoxication"
    ],
    "Object4": [
      "Nausea",
      "Vomiting",
      "Excessive thirst",
      "Polyuria",
      "Severe itching",
      "Joint and muscle pains",
      "Disorientation",
      "Coma"
    ],
    "Object5": [
      "Metastatic calcifications"
    ],
    "Object6": [
      "Serum calcium levels",
      "Serum PTH levels",
      "Renal function tests"
    ],
    "Object7": [
      "Adequate rehydration (4-6 L 0.9% saline day 1, then 3-4 L)",
      "IV bisphosphonate (pamidronate 15-60 mg)",
      "Calcitonin (200 units IV 6-hourly)",
      "Prednisolone (30-60 mg daily for myeloma, sarcoidosis, vitamin D excess)",
      "Oral phosphate",
      "Diuretics (furosemide)",
      "Mithramycin",
      "Hemodialysis"
    ],
    "Object8": [
      "Renal failure",
      "Coma",
      "Cardiac arrhythmias"
    ]
  },
  {
    "Object1": "Hypoparathyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Surgical hypoparathyroidism (commonest: removal of glands, interruption of blood supply)",
      "Idiopathic hypoparathyroidism (genetic origin, autosomal recessive, 'multiple endocrine deficiency-autoimmune-candidiasis (MEDAC) syndrome', 'juvenile familial endocrinopathy-HAM syndrome')",
      "Functional hypoparathyroidism (chronic hypomagnesemia)",
      "DiGeorge syndrome"
    ],
    "Object4": [
      "Hypocalcemia",
      "Neuromuscular hyperactivity (tetany)",
      "Lethargy, weakness, fatigue, thin and patchy hair, brittle nails, dry and scaly skin, personality changes, cataracts, permanent brain damage (chronic)",
      "Steatorrhea (long-standing untreated disease)"
    ],
    "Object5": [
      "Hypocalcemia",
      "Hyperphosphatemia",
      "Diminished or absent circulating iPTH",
      "Abnormal enamel formation with delayed/absent dental eruption, defective dental root formation",
      "Posterior lenticular cataract"
    ],
    "Object6": [
      "Serum calcium (low)",
      "Serum phosphate (high)",
      "Circulating iPTH (diminished or absent)"
    ],
    "Object7": [
      "Acute phase (tetany): Calcium gluconate IV (20 mL of 10% solution slowly over 10 min), Magnesium (if calcium ineffective).",
      "Substitution therapy: 1-α-hydroxycholecalciferol (alfacalcidol) or 1,25 dihydroxycholecalciferol (calcitriol) at 0.25-2 μg/day."
    ],
    "Object8": [
      "Permanent brain damage",
      "Steatorrhea"
    ]
  },
  {
    "Object1": "Tetany",
    "Object2": "Not specified.",
    "Object3": [
      "Hypocalcemia",
      "Alkalosis",
      "Hypomagnesemia",
      "Due to hypocalcemia: Increased phosphate levels (chronic renal failure, phosphate therapy), Hypoparathyroidism (surgical, congenital, idiopathic), Severe hypomagnesemia, Resistance to PTH (pseudohypoparathyroidism), Vitamin D deficiency (osteomalacia/rickets, vitamin D resistance), Acute pancreatitis, Citrated blood in massive transfusion, Low plasma albumin, Malabsorption, Drugs (calcitonin, bisphosphonates)",
      "Due to alkalosis: Repeated vomiting of gastric juice, Excessive intake of oral alkali, Hyperventilation (hysteria)",
      "Due to hypomagnesemia",
      "Primary hyperaldosteronism"
    ],
    "Object4": [
      "Muscle spasms",
      "Tingling in hands, feet, around mouth (circumoral paresthesia) (adults)"
    ],
    "Object5": [
      "Children: Characteristic triad of carpopedal spasm, stridor and convulsions. Carpal spasm (flexion of MCP joints, extension of IP joints, opposition of thumb - 'main d'accoucheur').",
      "Latent tetany: Chvostek's sign (ipsilateral facial muscle contraction on tapping facial nerve). Trousseau's sign (carpopedal spasm on inflating BP cuff for 3-5 min).",
      "Cardiac: Prolonged QT interval on ECG, Resistance to digitalis, hypotension, refractory heart failure with cardiomegaly."
    ],
    "Object6": [
      "ECG (prolonged QT interval)"
    ],
    "Object7": [
      "Control of tetany: Calcium gluconate (20 mL of 10% solution IV slowly over 10 min). Magnesium (if calcium ineffective).",
      "Correction of alkalosis: IV isotonic saline and potassium (for vomiting). Withdraw alkali excess. Ammonium chloride (2g 4 hourly orally) for alkali excess. Rebreathing expired air or 5% CO2 in O2 (for hysterical hyperventilation)."
    ],
    "Object8": [
      "Refractory heart failure with cardiomegaly."
    ]
  },
  {
    "Object1": "Pseudohypoparathyroidism (PHP)",
    "Object2": [
      "PHP type IB",
      "PHP type IA (with Albright's hereditary osteodystrophy - AHO)"
    ],
    "Object3": [
      "Inherited disorder of target-organ unresponsiveness to PTH"
    ],
    "Object4": [
      "Hypocalcemia",
      "Hyperphosphatemia"
    ],
    "Object5": [
      "PHP type IB: Secondary hyperparathyroidism (biochemical features).",
      "PHP type IA: Characteristic somatic phenotype (AHO): short stature, round face, short neck, brachydactyly, shortened metatarsals, subcutaneous ossifications, mental retardation. Dimple instead of knuckle on affected digits."
    ],
    "Object6": [
      "Biochemical features: Hypocalcemia, hyperphosphatemia, elevated PTH level."
    ],
    "Object7": [
      "Treatment of hypocalcemia."
    ],
    "Object8": [
      "Mental retardation"
    ]
  },
  {
    "Object1": "Cushing's Syndrome",
    "Object2": [
      "ACTH-dependent causes (ACTH-secreting pituitary tumor - Cushing's disease, pituitary CRH-secreting neoplasm, nonpituitary ACTH-secreting neoplasm)",
      "ACTH-independent causes (adrenal adenoma, adrenal carcinoma, micronodular adrenal disease, McCune-Albright syndrome, massive macronodular adrenal disease)",
      "Iatrogenic (use of corticosteroids)"
    ],
    "Object3": [
      "Pituitary-dependent bilateral adrenal hyperplasia (Cushing's disease)",
      "Ectopic ACTH secretion (Small cell carcinoma of lung, Endocrine tumors of foregut origin, Thymic carcinoid, Pancreatic islet cell tumor, Medullary carcinoma thyroid, Bronchial carcinoid, Pheochromocytoma, Ovarian tumors)",
      "Excess alcohol consumption (pseudo-Cushing's syndrome)"
    ],
    "Object4": [
      "Weight gain/obesity (90%)",
      "Back pain (80%)",
      "Muscle weakness (65%)",
      "Menstrual disorders (oligomenorrhea, amenorrhea), decreased libido, impotence (70-85%)",
      "Emotional lability, depression, euphoria, psychosis, irritability (85%)",
      "Polyuria (30%)",
      "Kidney stones (15%)"
    ],
    "Object5": [
      "Central obesity ('lemon on match-stick')",
      "Buffalo hump",
      "Moon face",
      "Hypertension (85%)",
      "Plethoric appearance",
      "Hirsutism (70-75%)",
      "Purplish striae over abdomen, buttocks and thighs",
      "Bruising",
      "Thin skin",
      "Osteopenia, osteoporosis and vertebral compression fractures",
      "Proximal myopathy",
      "Hypokalemia",
      "Skin pigmentation (only with ACTH-dependent causes)",
      "Impaired glucose tolerance or frank diabetes (common, especially ectopic ACTH)",
      "Hypokalemic alkalosis (ectopic ACTH)"
    ],
    "Object6": [
      "Confirmation of presence: 48-hour low-dose dexamethasone test (normal: plasma cortisol <50 nmol/L, Cushing's: fails to suppress)",
      "24-hour urinary free cortisol (repeatedly normal values render diagnosis unlikely)",
      "Plasma cortisol (loss of circadian rhythm, midnight level <1.8 µg/dL normal)",
      "Overnight dexamethasone suppression test",
      "Late-night salivary cortisol (screening test)",
      "Establish cause: Plasma ACTH level at 8 AM (normal 10-80 ng/L - pituitary; intermediate 80-300 ng/L - pituitary/ectopic; very high >300 ng/L - ectopic; low <10 ng/L - adrenal/exogenous steroid), High-dose dexamethasone suppression test (plasma cortisol on day +2 <50% of day 0 suggests pituitary), Plasma potassium levels (normal in pituitary/adrenal, low in ectopic ACTH), ACTH/cortisol response to CRH (increased in pituitary, unchanged in ectopic/adrenal), Bilateral inferior petrosal sinus sampling for ACTH (before/after CRH)",
      "Other: Blood glucose, cholesterol, LDL (may be raised), Radiological (Plain skull/chest X-ray, CT/MRI head/abdomen, CT mediastinum, upper abdomen, pancreas), Investigations in oncology for tumors"
    ],
    "Object7": [
      "Adrenal tumors: Surgical resection. Postoperatively, prednisolone replacement.",
      "Adrenal carcinomas: Surgical resection, irradiation, adrenolytic drug (mitotane).",
      "Medical adrenalectomy: Ketoconazole, metyrapone, mitotane, aminoglutethimide, octreotide.",
      "Cushing's disease: Trans-sphenoidal removal of tumor (treatment of choice).",
      "Radiotherapy and radiosurgery for recurrent/residual ACTH-secreting tumors.",
      "Bilateral adrenalectomy (if diagnosis uncertain, followed by pituitary irradiation to prevent Nelson's syndrome). Postoperatively, prednisolone and fludrocortisones.",
      "Medical therapy to reduce ACTH (bromocriptine - rarely effective).",
      "Ectopic ACTH syndrome: Surgical removal of benign tumors (bronchial carcinoid).",
      "Radiotherapy and chemotherapy for malignant tumors.",
      "Recurrent tumors: metyrapone or aminoglutethimide."
    ],
    "Object8": [
      "Systemic fungal infections and tinea versicolor",
      "Higher risk of coronary artery disease and venous thrombosis",
      "Impaired glucose tolerance or frank diabetes",
      "Nelson's syndrome (increased pigmentation with enlarging pituitary tumor post-bilateral adrenalectomy)",
      "Osteoporosis",
      "Vertebral compression fractures"
    ]
  },
  {
    "Object1": "Nelson's Syndrome",
    "Object2": "Increased pigmentation associated with an enlarging pituitary tumor post-bilateral adrenalectomy",
    "Object3": [
      "Occurs after bilateral adrenalectomy for Cushing's disease (about 20% of cases)"
    ],
    "Object4": [],
    "Object5": [
      "Increased pigmentation"
    ],
    "Object6": [
      "Diagnosis is clinical."
    ],
    "Object7": [
      "Pituitary surgery and/or radiotherapy."
    ],
    "Object8": []
  },
  {
    "Object1": "Hyperaldosteronism",
    "Object2": [
      "Primary hyperaldosteronism",
      "Secondary hyperaldosteronism"
    ],
    "Object3": [
      "Primary: Adrenal adenoma (Conn's syndrome), Bilateral hyperplasia of zona glomerulosa, Idiopathic, ACTH dependent (glucocorticoid-responsive or dexamethasone-suppressible)",
      "Secondary: Physiological (salt depletion, pregnancy), Pathological (inadequate renal perfusion: excessive diuretic therapy, nephrotic syndrome, liver failure, congestive cardiac failure, Bartter's syndrome, accelerated/malignant hypertension, severe renal artery stenosis; renin-secreting renal tumor)"
    ],
    "Object4": [
      "Hypertension (most important)",
      "Tetany (due to metabolic alkalosis)",
      "Muscle weakness (due to hypokalemia)",
      "Polyuria and polydipsia (due to nephrogenic DI)"
    ],
    "Object5": [
      "Hypokalemia (may be absent)",
      "Metabolic alkalosis"
    ],
    "Object6": [
      "Diagnosis: Hypokalemia (normal serum K+ does not exclude), Urinary potassium loss (>30 mEq/day during hypokalemia is inappropriate), Plasma aldosterone concentration (PAC) elevated (>15 ng/dL), not suppressed by saline/flurocortisone, Suppressed plasma renin activity (PRA) or immunoreactivity, PAC:PRA ratio (>20 suggests primary), Confirmatory aldosterone suppression test, Oral salt loading test, Saline infusion test, Oral captopril test (no significant decrease in PAC in primary)",
      "Differential diagnosis: CT/MRI scanning (detect adenoma/hyperplasia), Adrenal vein catheterization (detect hypersecretion), Dexamethasone suppression (lowers PAC transiently in adenoma, prolonged suppression in glucocorticoid-sensitive), Measurement of 18-OH-cortisol levels (very high in adenomas/glucocorticoid-responsive hyperplasia, slightly raised in idiopathic hyperplasia)"
    ],
    "Object7": [
      "Potassium (K+) supplementation",
      "Definitive treatment: Adrenalectomy (bilateral if multiple tumors)",
      "Aldosterone antagonists: Spironolactone, eplerenone (for inoperable). Amiloride also tried.",
      "Glucocorticoids (for ACTH dependent type)"
    ],
    "Object8": [
      "Hypertension",
      "Tetany",
      "Muscle weakness",
      "Nephrogenic DI"
    ]
  },
  {
    "Object1": "Adrenocortical Insufficiency",
    "Object2": [
      "Primary adrenocortical insufficiency (adrenal causes)",
      "Secondary adrenocortical insufficiency (inadequate ACTH)"
    ],
    "Object3": [
      "Primary: Autoimmune adrenal insufficiency (most common), Metastatic malignancy, Adrenal hemorrhage (Waterhouse-Friderichsen syndrome), Anticoagulation therapy, Infectious (Tuberculosis, CMV, fungi, HIV), Adrenal infarction (APLA, SLE), Adrenoleukodystrophy, Infiltrative disorders (Amyloidosis, Hemochromatosis, Sarcoidosis), Bilateral adrenalectomy, Congenital adrenal hyperplasia, Familial glucocorticoid deficiency and hypoplasia, Drugs (Ketoconazole, Metyrapone, Aminoglutethimide, Trilostane, Mitotane, Etomidate, Rifampin, Cyproterone acetate), Autoimmune polyglandular syndrome 1 and 2, Kearns-Sayre syndrome",
      "Secondary: Exogenous glucocorticoid therapy, Hypopituitarism (selective removal, pituitary apoplexy, granulomatous disease, secondary tumor deposits, postpartum pituitary infarction - Sheehan's syndrome, pituitary irradiation)"
    ],
    "Object4": [
      "Glucocorticoid deficiency: Fasting hypoglycemia, increased insulin sensitivity, morning headache, weight loss, anorexia, nausea, vomiting, diarrhea or constipation",
      "Mineralocorticoid deficiency: Dizziness, salt craving",
      "Adrenal androgen deficiency: Decreased axillary/pubic hair in females, loss of libido in females, asymptomatic during prepuberty"
    ],
    "Object5": [
      "ACTH excess (Primary only): Pigmentation of exposed areas, pressure areas (elbows, knees, knuckles), palmar creases, mucous membranes, conjunctiva, recently acquired scars, perineum, axillae, areolae of breasts (due to increased POMC/MSH), Hypotension, Electrolyte anomalies (hyponatremia, hyperkalemia, metabolic acidosis), Fatigue, malaise, weakness, Postural hypotension"
    ],
    "Object6": [
      "Confirm adrenal insufficiency: 08:00 AM cortisol level (<3 µg/dl suggestive, >11 µg/dl excludes), Random cortisol in ill patient (≥20 µg/dL reassuring), Plasma ACTH level (elevated in primary), ACTH stimulation test (failure of plasma cortisol rise after 250 µg synthetic ACTH. Low dose 1µg useful in central AI and for recovery after chronic steroid. High dose 250µg for baseline and 30/60 minute levels)",
      "Determine cause: PRA (high in primary), plasma aldosterone (low/normal in primary), Radiograph (chest for TB, plain abdomen/CT/MRI for adrenal calcification), Adrenal autoantibodies (ACA, anti-21-OH-hydroxylase antibody), Elevated blood urea, hyponatremia, hyperkalemia, Blood sugar (low), Peripheral blood (mild anemia, mild eosinophilia), Central AI (evaluate other pituitary hormones)"
    ],
    "Object7": [
      "Primary adrenal insufficiency (Acute): Normal saline for volume resuscitation, 25% dextrose for hypoglycemia, Steroids (hydrocortisone 50-100 mg/m² IV/IM loading, then 50-100 mg/m²/day divided), Stress conditions: double or triple glucocorticoid dose, 100-150 mg hydrocortisone for major surgery.",
      "Primary adrenal insufficiency (Long-term): Daily glucocorticoid replacement (hydrocortisone 10-15 mg/m²/day divided), Daily mineralocorticoid replacement (fludrocortisone 0.05-0.2 mg daily)",
      "Tuberculous adrenalitis: Antituberculous chemotherapy."
    ],
    "Object8": [
      "Adrenal crisis (acute adrenocortical insufficiency)"
    ]
  },
  {
    "Object1": "Acute Adrenal Crisis",
    "Object2": "Acute adrenocortical insufficiency",
    "Object3": [
      "Addison's disease patients exposed to stress (infection, trauma, surgery, dehydration from salt deprivation, vomiting, diarrhea)",
      "Bilateral adrenal infarction",
      "Bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome)"
    ],
    "Object4": [
      "Shock (major manifestation)",
      "Non-specific (weakness, fatigue, lethargy, anorexia, nausea, vomiting, abdominal pain, confusion or coma)",
      "Abdominal tenderness, fever",
      "Features of chronic adrenal insufficiency (hyperpigmentation, weight loss, serum electrolyte abnormalities) (in long-standing cases)"
    ],
    "Object5": [
      "Shock",
      "Abdominal tenderness, fever",
      "Hyperpigmentation (chronic), weight loss (chronic)"
    ],
    "Object6": [
      "Hyponatremia, hyperkalemia, lymphocytosis, eosinophilia, hypoglycemia"
    ],
    "Object7": [
      "Start therapy as soon as suspected",
      "Correction of hypovolemia and sodium depletion with normal saline",
      "5% dextrose for hypoglycemia",
      "Hydrocortisone (100 mg IV bolus) OR dexamethasone (4 mg bolus)",
      "Hydrocortisone 100 mg 6 hourly, tapered over 26-48 hours to maintenance",
      "Treat precipitating cause"
    ],
    "Object8": [
      "Cardiac and/or respiratory failure (in Waterhouse-Friderichsen syndrome)"
    ]
  },
  {
    "Object1": "Waterhouse-Friderichsen Syndrome",
    "Object2": "Acute hemorrhagic infarction of both adrenal glands",
    "Object3": [
      "Usually associated with fulminant meningococcal septicemia"
    ],
    "Object4": [],
    "Object5": [
      "Cutaneous petechiae, vasomotor collapse, shock",
      "Abrupt onset, profound prostration within hours",
      "Purpuric lesion, hemorrhage into skin"
    ],
    "Object6": [
      "Clinical diagnosis with supporting lab from septicemia."
    ],
    "Object7": [
      "Intravenous fluids, high dose antibiotics (Penicillin, cephalosporins, sulfonamides), vasopressors, inotropes, plasma transfusion, steroids immediately."
    ],
    "Object8": [
      "Death within hours to days due to cardiac and/or respiratory failure."
    ]
  },
  {
    "Object1": "Pheochromocytoma",
    "Object2": [
      "Very rare tumor of sympathetic nervous system",
      "Paraganglioma (extra-adrenal pheochromocytoma)"
    ],
    "Object3": [
      "Tumor of chromaffin cells that secretes catecholamines (noradrenaline, adrenaline)",
      "Neurofibromatosis type 1 (Von Recklinghausen's disease) is associated",
      "Familial pheochromocytoma (MEN 2a, MEN 2b, Von Hippel-Landau, NF1, Familial paraganglioma, Familial pheochromocytoma and islet cell tumor, Tuberous sclerosis, Sturge-Weber, ataxia-telangiectasia, Carney's Triad)"
    ],
    "Object4": [
      "Paroxysmal hypertension: Episodes of pallor or flushing, headache, sweating, palpitations, anxiety (fear of death). Paroxysms last 10-60 min, daily to monthly. Precipitated by: diagnostic procedures, intra-arterial contrast, drugs (opioids, unopposed beta-blockade, anesthesia induction, histamine, ACTH, glucagon, metoclopramide), strenuous exercise, movement increasing intra-abdominal pressure, micturition (bladder paraganglioma).",
      "Abdominal pain, vomiting, constipation, weight loss (gastrointestinal)",
      "Mild glucose intolerance",
      "Lipolysis and weight-loss"
    ],
    "Object5": [
      "Sustained hypertension (more common than paroxysmal)",
      "5 Ps: Pressure (Hypertension - 90%), Pain (Headache - 80%), Perspiration (70%), Palpitation (65%), Pallor (42%)",
      "Hypercalcemia (associated MEN2 hyperparathyroidism)"
    ],
    "Object6": [
      "Plasma metanephrine: Most sensitive test (raised)",
      "24-hour urine Vanillylmandelic acid (VMA) (raised 63% sensitivity, 94% specificity)",
      "24-hour urine metanephrines and normetanephrines (raised 76% sensitivity, 94% specificity)",
      "24-hour urine free catecholamines (raised 83% sensitivity, 88% specificity)",
      "24-hour urine free catecholamines + metanephrines (raised 90% sensitivity, 98% specificity)",
      "Plasma catecholamines (raised 85% sensitivity, 80% specificity)",
      "Chromogranin A (elevated)",
      "Provocative (glucagon provocative test) and adrenolytic (clonidine, phentolamine test) tests (rarely necessary)",
      "CT scan (localize tumor)",
      "Scintigraphy (MIBG, 111Indium-labeled diethylenetriamine pentaacetic acid octreotide scan, 18F flurodihydroxyphenylalanine (DOPA) PET scan)",
      "Plasma noradrenaline: Selective venous sampling with PTH estimation"
    ],
    "Object7": [
      "Excision of the tumor (main treatment)",
      "Preoperative preparation (at least 2 weeks): Combined α + β-blockade (phenoxybenzamine, prazosin, terazosin, doxazosin, propranolol), High sodium diet (>5000 mg daily), If uncontrolled: Metyrosine, Calcium channel blocker (Nicardipine), Avoid diuretics.",
      "Intraoperative: Careful monitoring and control of blood pressure.",
      "Postoperative: Adequate fluid replacement (avoid hypotension), Glucose infusion (prevent hypoglycemia).",
      "If tumor cannot be excised: Long-term α- and β-adrenoreceptors blocking drugs (phenoxybenzamine and propranolol, or labetalol). β-blockers never alone.",
      "Nuclear medicine treatment."
    ],
    "Object8": [
      "Complications of hypertension (stroke, myocardial infarction, cardiomyopathy, left ventricular failure)",
      "Hypotension (postoperative)",
      "Hypoglycemia (postoperative)"
    ]
  },
  {
    "Object1": "Male Hypogonadism",
    "Object2": [
      "Hypothalamic-pituitary disorders",
      "Gonadal abnormalities",
      "Secondary hypogonadism",
      "Defects in androgen action"
    ],
    "Object3": [
      "Hypothalamic-pituitary disorders: Panhypopituitarism, LH and FSH deficiency (with normal sense of smell, hyposmia/anosmia (Kallmann's syndrome), complex neurologic syndromes (Prader-Willi, Laurence-Moon, Bardet-Biedl, Möbius', Lowe's syndrome))",
      "Gonadal abnormalities: Klinefelter's syndrome, Other chromosomal defects (AX male, XY/XXY, XX/XXY, XXXY, XYY), Bilateral anorchia (vanishing testes syndrome), Cryptorchidism, Noonan's syndrome, Myotonic dystrophy, Adult seminiferous tubule failure, Adult Leydig cell failure, Malignant tumors of testes, Infiltrative diseases (hemochromatosis), Chronic orchitis (TB, leprosy, syphillis), Pituitary apoplexy, Trauma, Idiopathic",
      "Secondary hypogonadism: Hyperprolactinemia, Glucocorticoid treatments, Chronic systemic illness, Anorexia nervosa, Diabetes mellitus, Obesity",
      "Defects in androgen action: Complete androgen insensitivity (testicular feminization), Incomplete androgen insensitivity"
    ],
    "Object4": [
      "Musculoskeletal: Decreased vigour and physical energy, diminished muscle strength",
      "Sexuality: Decreased interest in sex, reduction in frequency of sexual activity, poor erectile function/arousal, loss of nocturnal erections, reduced quality of orgasm, reduced volume of ejaculate",
      "Mood disorder and cognitive function: Irritability and lethargy, decreased sense of well-being, lack of motivation, low mental energy, difficulty with short-term memory, depression, low self-esteem, insomnia, nervousness",
      "Vasomotor and nervous: Hot flushes, sweating",
      "Prepubertal onset: Eunuchoidism (lack of adult male hair distribution, sparse axillary/pubic hair, lack of temporal hair recession, high-pitched voice, infantile genitalia, small penis/testes/scrotum, increased fat deposition in pectoral/hip/thigh/lower abdomen, eunuchoidal proportion (arm span > height > 5 cm, upper/lower segment ratio < 1))"
    ],
    "Object5": [
      "Diminished muscle mass",
      "Loss of body hair",
      "Abdominal obesity",
      "Gynecomastia",
      "Testes frequently normal, occasionally small"
    ],
    "Object6": [
      "Serum testosterone (8.00 AM)",
      "Serum FSH, LH",
      "Semen analysis",
      "Others: Peripheral leukocyte karyotype, other pituitary hormones, serum prolactin, iron saturation, MRI brain"
    ],
    "Object7": [
      "Treatment of primary hypogonadism: Testosterone replacement",
      "Treatment of the underlying disease",
      "Testosterone replacement: Intramuscular preparations (testosterone enanthate 200-300 mg IM q 3 wk), Transdermal patch/gel, Oral agent (testosterone undecanoate 40-80 mg po 2-3 times daily)",
      "Treatment of secondary hypogonadism: GnRH pulsatile infusion, HCG"
    ],
    "Object8": [
      "Testosterone replacement: BPH, prostatic cancer, dyslipidemia, polycythemia, transaminitis"
    ]
  },
  {
    "Object1": "Impotence (Male Sexual Dysfunction)",
    "Object2": "Male sexual dysfunction",
    "Object3": [
      "Loss of desire",
      "Inability to obtain and maintain erection",
      "Premature ejaculation",
      "Absence of emission",
      "Inability to achieve orgasm",
      "Endocrine: Hypothalamic-pituitary disorders, Testicular disorders, Defects of androgen action, Hyperthyroidism, Hypothyroidism, Adrenal insufficiency, Congenital adrenal hyperplasia",
      "Systemic illness",
      "Defects in spermatogenesis: Immotile cilia syndrome",
      "Drug-induced",
      "Ductal obstruction (congenital, acquired)",
      "Seminal vesicle disease",
      "Prostatic disease",
      "Varicocele",
      "Retrograde ejaculation",
      "Antibodies to sperm or seminal plasma",
      "Anatomic defects of the penis",
      "Poor coital technique",
      "Sexual dysfunction",
      "Idiopathic",
      "Erectile Dysfunction (Organic causes): Neurologic (Anterior temporal lobe lesions, Spinal cord lesions, Autonomic neuropathy), Vascular (Leriche's syndrome, Pelvic vascular insufficiency, Sickle cell disease), Endocrine (Diabetes mellitus, Hypogonadism, Hyperprolactinemia, Adrenal insufficiency, Feminizing tumors, Hypothyroidism, Hyperthyroidism), Urogenital (Trauma, Castration, Priapism, Peyronie's disease), Systemic Illness (Cardiac insufficiency, Cirrhosis, Uremia, Respiratory insufficiency, Lead poisoning), Postoperative (Aortoiliac/aortofemoral reconstruction, Lumbar sympathectomy, Perineal prostatectomy, Retroperitoneal dissection), Drugs (Antiandrogens, Estrogens, 5 alfa-reductase inhibitors, GnRH agonists, Antihypertensives, Diuretics, Psychotropic agents, Tranquilizers, Monoamine oxidase inhibitors, Tricyclic antidepressants), Tobacco, Alcohol, Cocaine"
    ],
    "Object4": [
      "Loss of desire",
      "Inability to obtain and maintain erection",
      "Premature ejaculation",
      "Absence of emission",
      "Inability to achieve orgasm"
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Psychological counselling; psychosexual therapy",
      "Phosphodiesterase type 5 inhibitors (oral: sildenafil, vardenafil, tadalafil)",
      "Dopamine agonist (apomorphine) through sublingual route",
      "Prostaglandin E1 (alprostadil): Injected into corpus cavernosum or intraurethral administration of pellets",
      "Vacuum tumescence devices",
      "Implanted penile prosthesis"
    ],
    "Object8": []
  },
  {
    "Object1": "Gynecomastia",
    "Object2": "Clinically defined as the presence of a rubbery or firm mass concentrically extending from the nipples in a male secondary to proliferation of both stromal and epithelial component of the glands.",
    "Object3": [
      "Physiologic: Neonatal, pubertal, involutional",
      "Endocrine: Primary hypogonadism with Leydig cell damage, hyperprolactinemia, hyperthyroidism, androgen receptor disorders, excessive aromatase activity",
      "Drug-induced: Androgens and anabolic steroids, chorionic gonadotropin, estrogens and estrogen agonists, growth hormone, cyproterone, flutamide. isoniazid, ketoconazole, metronidazole, cimetidine, omeprazole, ranitidine, cancer chemotherapeutic agents (especially alkylating agents), amiodarone, captopril, reserpine, spironolactone, verapamil psychotropic agents, diazepam, haloperidol, phenothiazines, tricyclic antidepressants, alcohol, amphetamines, heroin, marijuana, highly active antiretroviral therapy (HAART), phenytoin, penicillamine",
      "Systemic diseases: Hepatic cirrhosis, uremia",
      "Neoplasms: Testicular germ cell or Leydig cell tumors, HCG-secreting nontrophoblastic neoplasms",
      "Idiopathic"
    ],
    "Object4": [
      "Principal complaint is unilateral or bilateral concentric enlargement of breast glandular tissue",
      "Breast pain (present in one-fourth of patients)",
      "Nipple discharge (can be elicited in 4% of cases)"
    ],
    "Object5": [
      "Objective tenderness (about 40%)"
    ],
    "Object6": [],
    "Object7": [
      "Medical: Correct underlying disease, discontinue offending drugs. Antiestrogens or selective estrogen receptor modulators (tamoxifen or raloxifene) for pain relief and reversal. Aromatase inhibitors (less beneficial).",
      "Surgical: Reduction mammoplasty for cosmetic reasons.",
      "Radiotherapy: Low-dose radiation therapy (900 cGy or less) to breasts before estrogen therapy for prostatic carcinoma patients (prevents/diminishes gynecomastia). Not for other patients."
    ],
    "Object8": [
      "Slightly increased risk of development of breast carcinoma"
    ]
  },
  {
    "Object1": "Short Stature",
    "Object2": "Not specified",
    "Object3": [
      "Nonendocrine causes: Constitutional short stature, familial short stature, genetic short stature, intrauterine growth retardation and SGA syndromes of short stature, Turner's syndrome and its variants, Noonan's syndrome, Prader-Willi syndrome, Laurence-Moon and Bardet-Biedl syndromes, Chronic disease (Cardiac disorders, Pulmonary disorders, Gastrointestinal disorders), Hematologic disorders (Sickle cell anemia, Thalassemia), Renal disorders (Renal tubular acidosis, Chronic uremia), Immunologic disorders (Connective tissue disease, Juvenile rheumatoid arthritis, Chronic infection (TB)), Malnutrition (Voluntary dieting, Anorexia nervosa, Cancer chemotherapy)",
      "Endocrine disorders: GH deficiency and variants (Congenital GH deficiency, With midline defects, With other pituitary hormone deficiencies, Isolated GH deficiency, Pituitary agenesis, Acquired GH deficiency), Hypothalamic-pituitary tumors, Histiocytosis X, Central nervous system infections, Head injuries, GH deficiency following cranial irradiation, Central nervous system vascular accidents, Hydrocephalus, Empty sella syndrome, Abnormalities of GH action (GH insensitivity (Laron's dwarfism), Pygmies), Psychosocial dwarfism, Hypothyroidism, Glucocorticoid excess (Cushing's syndrome), Pseudohypoparathyroidism, Disorders of vitamin D metabolism, Diabetes mellitus (uncontrolled), Diabetes insipidus (untreated)"
    ],
    "Object4": [],
    "Object5": [
      "Height that is below the 2.5th percentile OR two or more standard deviations below the mean for age and gender",
      "Growth velocity that is below the 5th percentile for age and gender (growth deceleration)"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Diabetes Mellitus (DM)",
    "Object2": [
      "Type 1 diabetes (absolute deficiency of insulin)",
      "Type 2 diabetes (insulin resistance, impaired insulin secretion, increased glucose production)",
      "Other specific types of diabetes",
      "Gestational diabetes mellitus (GDM)",
      "Latent autoimmune diabetes in adults (LADA)",
      "Maturity onset diabetes of the young (MODY)"
    ],
    "Object3": [
      "Type 1 DM: Absolute (complete or near total) deficiency of insulin (Type 1 A: autoimmune destruction of β-cells; Type 1 B: unknown cause of β-cell destruction)",
      "Type 2 DM: Variable degrees of insulin resistance, impaired insulin secretion and increased glucose production (associated with several genetic and metabolic syndromes)",
      "Other specific types: Genetic defects of β-cell development/function (mutations in HNF 4 α, Glucokinase, HNF-1 α), Genetic defects in insulin action (Type A insulin resistance, leprechaunism, Rabson-Mendenhall syndrome, lipodystrophy syndromes), Exocrine pancreatic defects (Pancreatitis, pancreatectomy, hemochromatosis, pancreatic neoplasm, cystic fibrosis, fibrocalculous pancreatopathy), Endocrinopathies (Acromegaly, Cushing syndrome, hyperthyroidism, pheochromocytoma, glucagonoma), Infections (Cytomegalovirus, coxsackie B virus, congenital rubella), Drugs or chemical induced (Glucocorticoids, pentamidine, nicotinic acid, thyroid hormone, diazoxide, β-adrenergic agonists, thiazides, phenytoin, α-interferon), Genetic syndromes (Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram's syndrome, DIDMOAD, Friedreich's ataxia, Huntington's disease, Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome), Uncommon forms of immune-mediated diabetes ('Stiff-man' syndrome, anti-insulin receptor antibodies)",
      "GDM: Glucose intolerance develops/first recognized during pregnancy",
      "LADA: Autoimmune type 1 diabetes diagnosed in older individuals",
      "MODY: Noninsulin-dependent monogenic form of diabetes diagnosed at young age (mutations in transcription factors or glucokinase, resulting in insufficient insulin release)"
    ],
    "Object4": [
      "Classic triad: Polyuria, polydipsia, polyphagia (Type 1, abrupt onset)",
      "Weight loss (Type 1, over days/weeks; Type 2, unexplained)",
      "Nonspecific weakness (Type 2, gradual onset)",
      "Blurring of vision (due to glucose-induced changes in refraction)",
      "Pruritus vulvae or balanitis (caused by Candida infection)",
      "Lack of energy (Type 2)",
      "Symptoms of end-organ involvement (retinopathy, nephropathy, neuropathy) (Type 2)",
      "Staphylococcal skin infections (Type 2)",
      "Erectile dysfunction (Type 2)",
      "Arterial disease (myocardial infarction or peripheral gangrene) (Type 2)"
    ],
    "Object5": [
      "Normal to lean (wasted) weight (Type 1)",
      "Obese (Type 2, frequently)",
      "Hypoglycemia (Type 1, due to exogenous insulin)",
      "Hyperglycemic hyperosmolar state (Type 2, in decompensated state)"
    ],
    "Object6": [
      "Fasting plasma glucose (FPG) level (diagnosis: >126 mg/dL on more than one occasion. Pre-diabetes: 100-125 mg/dL)",
      "2-hour oral glucose tolerance test (OGTT) (diagnosis: >200 mg/dL. Pre-diabetes: >140 mg/dL but <200 mg/dL)",
      "HbA1c (diagnosis: ≥6.5% (48 mmol/mol). Pre-diabetes: 5.7-6.4% (39-46 mmol/mol))",
      "Random plasma glucose (diagnosis: ≥200 mg/dL with classical symptoms)",
      "Plasma insulin and C peptide levels (Type 1: low/unmeasurable; Type 2: normal to high)",
      "Glucagon levels (Type 1: raised, suppressible with insulin; Type 2: raised, resistant to insulin)",
      "Islet cell autoantibodies, glutamic acid decarboxylase (GAD65), zinc transporter ZnT8, tyrosine phosphatase IA-2 and IA-2β (immunologic markers for Type 1 DM)"
    ],
    "Object7": [
      "Lifestyle Management: Medical nutrition therapy (MNT) (achieve good glycemic control, reduce hyperglycemia/hypoglycemia, reduce complications, weight management, adequate nutrition, avoid atherogenic diets), Regular pattern of meals/snacks, Mediterranean Diet, Caloric content adjusted, Protein (0.9 g/kg/day, 10-15% total calories, <0.8 g/kg/day in nephropathy), Fat (≤30% total calories, 10% each saturated/monounsaturated/polyunsaturated), Carbohydrate (50-55% total calories, high fiber, restrict mono/disaccharides), Alcohol (avoid/limit)",
      "Exercise (improves insulin sensitivity, reduces glucose, metabolic/cardiovascular/psychological benefits)",
      "Treatment goals: HbA1c <7.0%, Preprandial glucose 70-130 mg/dL, Postprandial glucose <180 mg/dL, BP <130/80, Lipids (LDL <100 mg/dL, HDL >40/50 mg/dL, Triglycerides <150 mg/dL)",
      "Oral Hypoglycemic (Glucose-Lowering) Drugs:",
      "Biguanides (Metformin): Reduces hepatic glucose production (1-2% HbA1c reduction). Weight neutral/loss, no hypoglycemia. Side effects: Diarrhea, nausea, lactic acidosis, B12 deficiency. Contraindicated in malabsorption, low BMI, organ failure (creatinine >1.4, liver/cardiac failure, hypotension/sepsis), active B12 deficiency.",
      "Insulin Secretagogues (Sulfonylureas, Meglitinides): Stimulate insulin secretion (1-2% HbA1c reduction). Inexpensive. Side effects: Hypoglycemia, weight gain, sulfonamide allergies. Meglitinides (repaglinide, nateglinide) are short-acting, lower postprandial glucose.",
      "GLP-1 Receptor Agonists (Exenatide, Liraglutide): Prolong endogenous GLP-1 action (0.5-1.0% HbA1c reduction). Weight loss, no hypoglycemia. Side effects: Injection, nausea, pancreatitis, renal failure.",
      "Dipeptidyl Peptidase 4 (DPP-4) Inhibitors (Gliptins: Linagliptin, Saxagliptin, Alogliptin, Sitagliptin, Vildagliptin, Teneligliptin): Inhibit DPP-4 to conserve GLP-1 (0.5-0.8% HbA1c reduction). No hypoglycemia. Side effects: Nasopharyngitis, headache, myalgia, pancreatitis.",
      "α-Glucosidase Inhibitors (Acarbose, Miglitol, Voglibose): Reduce glucose absorption (0.5-0.8% HbA1c reduction). Reduce postprandial glycemia. Side effects: GI flatulence, liver function abnormalities. Contraindicated in kidney disease, IBD.",
      "Thiazolidinediones (Pioglitazone, Rosiglitazone (withdrawn), Troglitazone (withdrawn)): Reduce insulin resistance, increase glucose utilization (0.5-1.4% HbA1c reduction). Side effects: Weight gain, fluid retention, CHF, fractures, macular edema, bladder carcinoma. Contraindicated in CHF, liver disease.",
      "Sodium-glucose co-transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Help eliminate glucose in urine (0.4-1.1% HbA1c reduction). No hypoglycemia, weight loss. Side effects: Genital/urinary infections, hypotension, AKI, bone fracture, auto-amputations.",
      "Amylin Agonist (Pramlintide): Synthetic pancreatic hormone, injected before meals. Reduces postprandial glycemia, weight loss. Side effects: Injection, nausea, hypoglycemia.",
      "Bile Acid-Binding Resins (Colesevelam): Reduces glucose absorption. Side effects: Constipation, nausea, dyspepsia.",
      "Dopamine Agonist (Bromocriptine): Minimally effective, side effects: nausea, vomiting, dizziness, headache.",
      "Insulin Treatment: Necessary for Type 1 DM, many Type 2 DM. Goals: Eliminate symptoms, prevent DKA/HHS, restore lean body mass, improve physical/well-being, reduce infections, decrease fetal malformation/morbidity in pregnancy, delay/arrest/prevent macro/microvascular complications. Various insulin preparations (rapid, short, intermediate, long-acting, analogs). Regimens: Once/twice daily, premixed/split-mix, basal-bolus, CSII. Delivery systems: Syringes, pens, pumps.",
      "Pancreatic Transplantation/Islet Cell Transplantation: Can restore normoglycemia without exogenous insulin therapy in Type 1 DM."
    ],
    "Object8": [
      "Diabetic Ketoacidosis (DKA)",
      "Hyperglycemic Hyperosmolar State (HHS)",
      "Lactic acidosis",
      "Hypoglycemia",
      "Chronic (Long-Term) Complications:",
      "Microvascular: Diabetic retinopathy (non-proliferative, proliferative), Cataract, Glaucoma, Peripheral neuropathy (sensory, motor, sensory motor), Autonomic neuropathy, Nephropathy (microalbuminuria, macroalbuminuria, chronic kidney disease), Foot disease",
      "Macrovascular: Coronary artery disease, Peripheral vascular disease, Cerebrovascular disease",
      "Nonvascular: Gastroparesis, Infections, Skin changes (dermatological complications), Hearing loss",
      "Type 1 DM: Ketoacidosis (severe cases)",
      "Type 2 DM: Hyperosmolar hyperglycemic state",
      "LADA: High risk of progression to insulin dependency",
      "MODY: Macrovascular complications (in earlier generation)"
    ]
  },
  {
    "Object1": "Pyrexia (Fever) of Unknown Origin (PUO)",
    "Object2": [
      "Classic pyrexia of unknown origin",
      "Nosocomial PUO",
      "Neutropenic PUO",
      "HIV-associated PUO"
    ],
    "Object3": [
      "Infections (40%): Bacterial (Abscesses, Tuberculosis, Urinary tract infections, Infective endocarditis, Hepatobiliary infections, Osteomyelitis, Brucellosis, Borrelia recurrentis (tick borne relapsing fever), Spirillum minor (Rat-bite fever), Borrelia burgdorferi (Lyme disease), Treponema pallidum (syphilis)), Viral (Herpes viruses - cytomegalovirus, Epstein-Barr virus; HIV), Fungi (disseminated fungal infections), Parasites (Malaria, Toxoplasmosis, Trypanosoma, Leishmania, Amoeba), Rickettsial organisms (Coxiella burnetii - Q fever), Psittacosis",
      "Neoplasms (20%): Hematological (Lymphoma, Chronic leukemia), Non-hematological (Renal cell cancer, Hepatocellular carcinoma, Pancreatic cancer, Colon cancer, Myelodysplastic syndrome, Sarcomas, Atrial myxoma, Malignant histiocytosis)",
      "Collagen Vascular Disease/Autoimmune Disease (20%): Adult onset Still's disease, Macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH), Polymyalgia rheumatica, Temporal arteritis, Rheumatoid arthritis, Rheumatic fever, Inflammatory bowel disease, Reiter's syndrome, Systemic lupus erythematosus, Vasculitides (Polyarteritis nodosa, Giant cell arteritis, Kawasaki disease)",
      "Psychogenic Fevers: Habitual hyperthermia, Afebrile PUO, Exaggerated circadian rhythm, Hysterical fever, Malignant hyperthermia, Neuroleptic malignant syndrome (NMS)",
      "Periodic Fevers: Familial Mediterranean fever",
      "Miscellaneous (10%): Drugs (penicillin, phenytoin, captopril, allopurinol, erythromycin, cimetidine), Hyperthyroidism, Pheochromocytoma, Addison's disease, Alcoholic hepatitis, Sarcoidosis, Inflammatory bowel disease, Deep venous thrombosis/pulmonary thromboembolism, Hemolytic anemia, Thyroiditis, Granulomatous hepatitis, Cyclic neutropenia, Kikuchi-Fujimoto disease, Cerebrovascular accidents (CVA) (Intracranial bleeds)",
      "Undiagnosed (10-15%)"
    ],
    "Object4": [
      "General constitutional symptoms (in infections like tuberculosis)",
      "Headache (temporal arteritis, typhoid fever, sinusitis, meningitis, drug fever)",
      "Joint pain (rheumatoid arthritis, SLE, vasculitis, adult onset Still's disease)",
      "Abdominal pain (cholangitis, biliary obstruction, perinephric abscess, Crohn's disease, dissecting aneurysm, gynecological infection)",
      "Bone pain (osteomyelitis, lymphoma)",
      "Sore throat (infectious mononucleosis, retropharyngeal abscess, streptococcal infection)",
      "Dysuria, rectal pain (prostatic abscess, UTI)",
      "Altered bowel habit (IBD, typhoid fever, schistosomiasis, amebiasis)",
      "Night sweats (TB, Hodgkin's lymphoma)",
      "Loss of weight (malignancy, TB)",
      "Cough and dyspnea (miliary TB, multiple pulmonary emboli, AIDS patient with PCP, CMV)"
    ],
    "Object5": [
      "Fever (>101°F/38.3°C persistently)",
      "Skin rash (gonococcal infection, PAN, NHL, dengue fever, CTD)",
      "Splenomegaly (hemopoietic malignancy, endocarditis, malaria)",
      "Lymphadenopathy (lymphoma, sarcoidosis, focal infection)",
      "Jaundice (ascending cholangitis)",
      "Choroidal tubercle (miliary TB)",
      "Roth's spot (infective endocarditis)",
      "Retinal hemorrhage (leukemia)",
      "Hepatomegaly (abscess, hepatoma, metastasis)",
      "Renal enlargement (renal cell carcinoma)",
      "Testicular enlargement (seminoma)",
      "Perirectal/pelvic mass (abscess, carcinoma, prostatitis)",
      "Erythema, maceration, scaling, fissuring at corners of mouth (angular stomatitis)",
      "Petechiae, purpura (NMS)"
    ],
    "Object6": [
      "Stage 1: Screening tests: Full blood count with peripheral smear, ESR and CRP, Renal function tests, Liver function tests, Blood culture, Serum virology for HIV, dengue, leptospira, Widal test, Urinalysis and culture, Sputum culture and sensitivity, Stool routine and occult blood, Chest X-ray, Mantoux test, Ultrasound abdomen, pelvis, neck (if adenopathy, thyroid), Malarial smear in endemic areas",
      "Stage 2: Laboratory investigations: Repeat blood counts, chemistry, Protein electrophoresis, CT (chest, brain, abdomen, pelvis), Autoantibody screen (ANA, RF, ANCA, anti-ds DNA), ECG, Thyroid function tests, Bone marrow examination with culture, Lumbar puncture, Coagulation workup, Serum ferritin (adult onset Still's disease), PSA, CEA, LDH, Temporal artery biopsy, Paul Bunnell test, brucella agglutination test, Weil Felix reaction",
      "Stage 3: Echocardiography, PET scan (Indium-labelled WBC scan), IVU (intravenous urogram), Liver biopsy, Exploratory laparotomy, Bronchoscopy"
    ],
    "Object7": [
      "Treat underlying cause identified.",
      "Empirical broad-spectrum antibiotics.",
      "Therapeutic trial of aspirin/steroids.",
      "Naprosyn challenge for malignancy/lymphoma.",
      "Empirical antitubercular treatment."
    ],
    "Object8": []
  },
  {
    "Object1": "Streptococcal Infections",
    "Object2": [
      "Streptococcal Pharyngitis",
      "Scarlet Fever",
      "Erysipelas",
      "Streptococcal Impetigo",
      "Cellulitis",
      "Lymphangitis",
      "Streptococcal Bacteremia",
      "Necrotizing Fasciitis (Streptococcal Gangrene)",
      "Streptococcal Myositis",
      "Pneumonia and Empyema",
      "Streptococcal Toxic Shock Syndrome"
    ],
    "Object3": [
      "Gram-positive cocci (Streptococci)"
    ],
    "Object4": [
      "Pharyngitis: Abrupt onset of sore throat, dysphagia, headache, malaise, anorexia, fever",
      "Scarlet Fever: Malaise, chills, headache, vomiting",
      "Erysipelas: Malaise, chills, headache, vomiting",
      "Necrotizing Fasciitis: Severe prostration, toxemia, mental clouding, delirium",
      "Myositis: Severe pain and swelling of muscles",
      "Toxic Shock Syndrome: Vascular collapse, organ failure"
    ],
    "Object5": [
      "Pharyngitis: Red and edematous posterior pharyngeal wall, enlarged/red tonsils with yellowish exudate, enlarged/tender anterior cervical lymph nodes",
      "Scarlet Fever: Erythematous rash (neck, trunk, spares palms/soles, blanches on pressure), subsides with desquamation after 4-5 days",
      "Erysipelas: Erythematous skin lesions with clear advancing margin, may show vesicles, tender part, local lymph node enlargement",
      "Impetigo: Isolated pustules becoming crusted (around mouth/nostrils), may ulcerate to ecthyma (pigmentation/scarring)",
      "Cellulitis: Pain, tenderness, erythema, fever, regional lymphadenopathy",
      "Lymphangitis: Linear red streaks radiating from entry site to draining lymph nodes",
      "Necrotizing Fasciitis: Part hot, swollen, tender, edematous, edema/violaceous hue spreads, bullae develop, progress to gangrene within 4-5 days, gangrenous area demarcated",
      "Myositis: Muscle compartment syndromes"
    ],
    "Object6": [
      "Diagnosis is mainly clinical. Sputum for sensitivity tests (pneumonia).",
      "Toxic Shock Syndrome: M-protein analysis"
    ],
    "Object7": [
      "Pharyngitis: Penicillin, erythromycin, cephalosporins (first generation orally), or clindamycin (600-900 mg 8th hourly)",
      "Scarlet Fever: Single IM injection of benzathine penicillin G (600,000 units for <25 kg, 1.2 million units for others) or phenoxymethylpenicillin (250 mg orally 4 times daily for 7-10 days). Erythromycin (250 mg 6 hourly for 7-10 days) for penicillin allergy. Surgical drainage if suppuration.",
      "Necrotizing Fasciitis: Broad-spectrum antibiotics, early surgical debridement",
      "Myositis: Broad-spectrum antibiotics, early surgical debridement",
      "Pneumonia: Benzyl penicillin (drug of choice), or vancomycin, cefotaxime, ceftazidime, levofloxacin for multiple-drug-resistant pneumococci"
    ],
    "Object8": [
      "Pharyngitis: Rheumatic fever, poststreptococcal glomerulonephritis",
      "Bacteremia: Suppurative arthritis, osteomyelitis, peritonitis, endocarditis, meningitis, visceral abscesses",
      "Pneumonia: Empyema",
      "Myositis: Mortality over 80% if unrecognized"
    ]
  },
  {
    "Object1": "Staphylococcal Infections",
    "Object2": [
      "Superficial Lesions (Furuncle, carbuncle, impetigo, ecthyma, sycosis barbae, Follicular Impetigo of Bockhart, Scalded skin syndrome)",
      "Staphylococcal pneumonia",
      "Osteomyelitis/septic arthritis",
      "Staphylococcal bacteremia",
      "Staphylococcal food poisoning",
      "Endocarditis",
      "Toxic shock syndrome",
      "Tropical pyomyositis"
    ],
    "Object3": [
      "Staphylococcus aureus (pyogenic lesions)",
      "Coagulase negative staphylococci (Staphylococcus epidermidis - infection of cardiac/vascular prostheses, endocarditis, ventriculitis, peritonitis in CAPD, septicemia, cystitis)"
    ],
    "Object4": [],
    "Object5": [
      "Scalded skin syndrome (Fig. 4.3)"
    ],
    "Object6": [],
    "Object7": [
      "First choice: Oxacillin (methicillin), Cephalosporins of first generation (cefazolin, cephalothin)",
      "Second choice (for MRSA/VRSA): Lincosamides (clindamycin), Glycopeptides (vancomycin, teicoplanin), Quinupristin/dalfopristin, Chloramphenicol, Minocycline, Rifampin, Trimethoprim sulfamethoxazole, Fosfomycin, Linezolid, Daptomycin, Tigecycline, Dalbavancin, Oritavancin, Telithromycin, Ceftobiprole medocaril (anti-MRSA cephalosporin)"
    ],
    "Object8": []
  },
  {
    "Object1": "Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA)",
    "Object2": "Type of staphylococcal bacteria resistant to certain antibiotics (methicillin, oxacillin, penicillin, amoxicillin)",
    "Object3": [
      "Crowding",
      "Compromised skin (abrasions, cuts)",
      "Contaminated surfaces",
      "Frequent, skin-to-skin Contact",
      "Lack of Cleanliness"
    ],
    "Object4": [],
    "Object5": [
      "Tends to cause more aggressive skin and soft tissue infections, necrotizing pneumonia, septic shock and bacteremia"
    ],
    "Object6": [
      "Diagnosis by culture and sensitivity for MRSA"
    ],
    "Object7": [
      "Doxycycline (mild cases oral): 100 mg IV or PO 12 hourly",
      "Trimethoprim sulfamethoxazole (mild cases oral): 160 mg PO 12 hourly, 2.5 mg/kg IV 12 hourly",
      "Clindamycin: 300-400 mg PO 6 hourly, 600-900 mg IV 8 hourly",
      "Daptomycin: 4 mg/kg IV per day, 6 mg/kg IV per day",
      "Linezolid: 600 mg PO or IV 12 hourly",
      "Minocycline: 100 mg IV or PO 12 hourly",
      "Quinupristin/dalfopristin: 7.5 mg/kg IV 12 hourly",
      "Telavancin: 10 mg/kg IV per day",
      "Tigecycline: 100 mg IV (initial) then 50 mg IV 12 hourly",
      "Vancomycin: 1 g IV 12 hourly"
    ],
    "Object8": [
      "Necrotizing pneumonia",
      "Septic shock",
      "Bacteremia"
    ]
  },
  {
    "Object1": "Pneumococcal Infections",
    "Object2": [
      "Pneumococcal pneumonia",
      "Extrapulmonary pneumococcal lesions",
      "Pneumococcal meningitis",
      "Pneumococcal peritonitis"
    ],
    "Object3": [
      "Pneumococci (Streptococcus pneumoniae)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [
      "Sputum for sensitivity tests"
    ],
    "Object7": [
      "Benzyl penicillin (drug of choice for uncomplicated)",
      "Vancomycin, cefotaxime or ceftazidime (for multiple-drug-resistant)",
      "Levofloxacin (effective)"
    ],
    "Object8": []
  },
  {
    "Object1": "Meningococcal Infections",
    "Object2": [
      "Meningococcal Meningitis (Cerebrospinal Fever)",
      "Fulminant meningococcemia",
      "Chronic meningococcemia"
    ],
    "Object3": [
      "Neisseria meningitidis"
    ],
    "Object4": [
      "Fulminant meningococcemia: Abrupt onset, severe constitutional disturbances"
    ],
    "Object5": [
      "Fulminant meningococcemia: Peripheral vascular collapse, shock, sometimes myocarditis",
      "Waterhouse-Friderichsen syndrome: Hemorrhage into the adrenal glands resulting in acute adrenal failure, toxic vasculitis aggravating hypotension"
    ],
    "Object6": [],
    "Object7": [
      "Penicillin G (antibiotic of choice): 24 million units daily IV in divided doses",
      "Glucocorticoids (early in treatment): Favors prompt recovery and prevents complications",
      "Ampicillin: 200-400 mg/kg body weight daily",
      "Third generation cephalosporins (cefotaxime, ceftriaxone): Equally effective"
    ],
    "Object8": [
      "Waterhouse-Friderichsen syndrome",
      "Endocarditis",
      "Allergic polyarthritis",
      "Pneumonia",
      "Osteomyelitis"
    ]
  },
  {
    "Object1": "Diphtheria",
    "Object2": [
      "Nasopharyngeal (respiratory diphtheria)",
      "Skin infection (cutaneous diphtheria)"
    ],
    "Object3": [
      "Corynebacterium diphtheriae (gram-positive bacillus, releases powerful soluble exotoxin)"
    ],
    "Object4": [
      "Insidious onset with sore throat and fever (moderate, but marked tachycardia)",
      "Pharyngeal: Marked tonsillar and pharyngeal inflammation",
      "Laryngeal: Husky voice, brassy cough, later dyspnea and cyanosis",
      "Nasal: Unilateral, serosanguineous nasal discharge",
      "Cutaneous: Constitutional symptoms not common"
    ],
    "Object5": [
      "Pseudomembrane (well-defined edge, 'wash-leather', elevated, firm, grayish-green/black, adherent, surrounded by inflammation)",
      "Pharyngeal: Regional lymphadenopathy (cervical), marked edema of submandibular areas ('bull-neck' appearance)",
      "Cutaneous: Round, deep, 'punched-out' skin ulcers with undermined edges, covered by gray-yellow/gray-brown adherent membrane (more on extremities, head, trunk)"
    ],
    "Object6": [
      "Clinical diagnosis",
      "Demonstration of Corynebacterium diphtheriae on methylene blue-stained preparations",
      "Bacterial culture of Corynebacterium diphtheriae on Loeffler's medium and toxin studies (Elek test)"
    ],
    "Object7": [
      "Hospitalization with close monitoring of cardiac and respiratory function",
      "Patient isolation, strict bed rest",
      "Diphtheria antitoxin (only specific treatment): IM, given as early as possible without culture result. Dose 20,000-120,000 units IV over 60 min after test dose (risk of anaphylaxis/serum sickness).",
      "Antibiotics (to eliminate C. diphtheriae): Benzylpenicillin (1200 mg 4 times daily IV) or amoxicillin (500 mg 3 times daily) for 2 weeks. Erythromycin (500 mg 4 times daily for 14 days) for penicillin allergy.",
      "Tracheostomy or intubation (for respiratory distress)",
      "Immunization (following recovery, all sufferers with diphtheria toxoid; close contacts with erythromycin prophylaxis and immunization)",
      "Contact prophylaxis: Single dose of penicillin G benzathine (600,000 units IM) or oral erythromycin (500 mg 4 times daily for 7-10 days)"
    ],
    "Object8": [
      "Airway (laryngeal) obstruction (fatal airway obstruction)",
      "Cardiac complications (myocarditis with arrhythmias, cardiac failure, ECG changes - usually reversible)",
      "Neurological complications (palatal palsy, polyneuropathy with weakness/paraesthesia, paralysis of accommodation, encephalitis)",
      "Other: Pneumonia, renal failure, cerebral infarction, pulmonary embolism"
    ]
  },
  {
    "Object1": "Tetanus",
    "Object2": [
      "Generalized tetanus",
      "Local tetanus",
      "Cephalic tetanus",
      "Neonatal tetanus"
    ],
    "Object3": [
      "Infection by toxin-secreting Clostridium tetani (found in soil)",
      "Contaminated wound (injury may be trivial)",
      "Intravenous drug misusers",
      "Neonatal tetanus: Contamination of umbilical stump (unhygienic practices), site of circumcision"
    ],
    "Object4": [
      "Generalized: General malaise (rapidly followed by trismus), painful violent exhausting reflex spasms (convulsions) (spontaneous or induced by stimuli). Laryngeal spasm (impaired respiration), esophageal/urethral spasm (dysphagia, urinary retention). Cardiovascular complications (tachycardia, labile BP, sweating, cardiac arrhythmias).",
      "Local: Pain, stiffness, increased tone or spasms of muscles near infected wound.",
      "Cephalic: Cranial nerve abnormalities (e.g., seventh nerve).",
      "Neonatal: Failure to thrive, poor sucking, grimacing, irritability, intense rigidity and spasms."
    ],
    "Object5": [
      "Generalized: Trismus (spasm of masseter muscles, difficulty opening mouth/masticating), Risus sardonicus (contraction of frontalis and mouth muscles, grinning expression), Opisthotonus (tonic rigidity of neck/trunk muscles, arched back, board-like abdominal wall). Patients are mentally alert. Hyperexcitability (precipitated by auditory/visual stimuli). Hydrophobia, Aerophobia. Hyperreflexia, spasticity. Pupillary dilatation and diaphoresis (sympathetic overactivity). Convulsions, respiratory paralysis, cardiac arrhythmias.",
      "Neonatal: Intense rigidity and spasms."
    ],
    "Object6": [
      "Diagnosis usually clinical.",
      "C. tetani rarely isolated from wounds."
    ],
    "Object7": [
      "Suspected Tetanus: Care of wound (clean, debride). Human tetanus immunoglobulin (250 units) + IM tetanus toxoid. Booster for immunized, full course for unimmunized.",
      "Established Tetanus: Prevent further toxin production (wound debridement, antibiotics - IV metronidazole, penicillin, cephalosporins). General supportive care (isolation in quiet, dark room; hydration, nutrition, treat secondary infections). Control of spasm (benzodiazepines/IV diazepam; if continues, paralyze/ventilate; baclofen). Intubation and mechanical ventilation (if airway compromised). Magnesium sulfate infusion. Neutralization of absorbed toxin (HTIG 3000-6000 IU IM; if unavailable, immune equine tetanus immunoglobulin 10,000 IU IM). Active immunization after recovery."
    ],
    "Object8": [
      "Generalized: Death (exhaustion, hypoxia, cardiac arrest, asphyxia, respiratory failure, aspiration pneumonia), physical injury from falls.",
      "Neonatal: Mortality almost 100%."
    ]
  },
  {
    "Object1": "Anthrax",
    "Object2": [
      "Cutaneous anthrax",
      "Inhalational anthrax (Woolsorter's disease)",
      "Gastrointestinal anthrax"
    ],
    "Object3": [
      "Bacillus anthracis (gram-positive bacillus with central spore, produces toxins)"
    ],
    "Object4": [
      "Cutaneous: Small, itching, erythematous, maculopapule on edematous hemorrhage, vesicle filled with sero-sanguinous, pain infrequent",
      "Inhalational: Fever, non-productive cough, dyspnea, headache, retrosternal discomfort. Symptoms of septicemia (3-14 days after exposure).",
      "Gastrointestinal: Nausea, vomiting, anorexia, fever, followed by severe abdominal pain and bloody diarrhea (2-3 days later)."
    ],
    "Object5": [
      "Cutaneous: Maculopapule progressing to vesicle, then ulcerates and dries to form central depressed thick black 'eschar' surrounded by blebs ('malignant pustule'). Perivascular edema and regional lymphadenopathy (occasionally).",
      "Inhalational: Bronchopneumonia. Pleural effusions (hemorrhagic). Meningitis (may occur). Chest X-ray shows broncho-pneumonia, widening of mediastinum, pleural effusions.",
      "Gastrointestinal: Toxemia, shock."
    ],
    "Object6": [
      "Demonstration of organism: Stained smear of fluid from skin lesion, stools, laryngeal secretions, sputum, CSF. Culture of blood and other body fluids (Bacillus anthracis can be cultured in mice, rabbits, guinea pigs).",
      "Serological examination: ELISAs for antibodies to organism and toxin.",
      "Chest X-ray: Mediastinal widening, bronchopneumonia, pleural effusion (inhalational)."
    ],
    "Object7": [
      "Systemic anthrax with meningitis: Ciprofloxacin (400mg TDS) PLUS meropenum plus linezolid/clindamycin.",
      "Bioterrorism-related anthrax: Ciprofloxacin (drug of choice): 400 mg IV BID, then 500 mg PO BID for 60 days.",
      "Raxibacumab, Obiltoxaximab (human monoclonal antibody against protective antigen).",
      "Anthrax Immunoglobulin (for inhalational anthrax)."
    ],
    "Object8": [
      "Inhalational: Meningitis. Mortality 50-90% without rapid treatment.",
      "Gastrointestinal: Toxemia, shock, death."
    ]
  },
  {
    "Object1": "Plague ('Black Death')",
    "Object2": [
      "Bubonic plague",
      "Septicemic plague (primary, secondary)",
      "Pneumonic plague (primary, secondary)",
      "Cutaneous plague"
    ],
    "Object3": [
      "Yersinia pestis (small gram-negative, non-motile bacillus)"
    ],
    "Object4": [
      "Bubonic: Acute/sudden onset, high fever, rigor, chills, severe headache, dry skin, myalgia, nausea, vomiting, prostration. Painful lymphadenopathy. Apathy, confusion, fright, anxiety, oliguria or anuria, tachycardia, toxemia, hypotension.",
      "Septicemic: Acute fulminant infection, high fever, chills, malaise (without lymphadenopathy in primary). Nausea, vomiting, abdominal pain, diarrhea (gastrointestinal).",
      "Pneumonic: Sudden onset, malaise, high fever, vomiting, abdominal pain, diarrhea, marked prostration. Cough, dyspnea, copious blood-stained, frothy, highly infective sputum. Marked respiratory distress/failure, cyanosis, septic shock."
    ],
    "Object5": [
      "Bubonic: Swollen, tender, suppurating lymph nodes ('bubo'). Spleen usually palpable.",
      "Septicemic: Hypotension, septic shock, renal failure, ARDS, DIC. Gangrene of acral regions (tip of nose, fingers, toes).",
      "Pneumonic: Chest X-ray shows bilateral infiltrates (nodular, progressing to ARDS-like picture).",
      "Cutaneous: Pustule, eschar, papule, or extensive purpura. Necrosis and gangrene."
    ],
    "Object6": [
      "Demonstration of organism: Smears from blood, sputum, bubo aspirate, CSF (Gram, Giemsa, Wayson's stains - bipolar staining coccobacilli, 'safety pin' appearance).",
      "Culture of organism: From blood, sputum, bubo aspirates.",
      "Serological diagnosis: Rapid antigen detection test (immunofluorescence, Y. pestis F1 antigen-specific antibodies).",
      "Septicemic: Lab findings of DIC.",
      "Chest X-ray (pneumonic): Multilobar consolidation, cavities or bronchopneumonia.",
      "Blood: WBC count 20,000/mm², thrombocytopenia (~50%)."
    ],
    "Object7": [
      "Urgent treatment, even before culture results.",
      "First choices: Streptomycin (30 mg/kg/day IM in two divided doses for 10 days), Gentamicin (effective OD dosing, less toxic).",
      "Second choices: Tetracyclines (Doxycycline), Fluoroquinolones (Ciprofloxacin, Levofloxacin, Ofloxacin, Moxifloxacin), Chloramphenicol (1st choice for meningitis +/- aminoglycoside).",
      "Supportive treatment of ARDS, DIC, shock.",
      "Prophylaxis: Control of rats and fleas. Avoid handling wild animals. Isolation of patients with plague pneumonia. Chemoprophylaxis (doxycycline 100 mg or ciprofloxacin 500 mg twice daily for 7 days for close contacts). Vaccine (partially effective, formalin-killed)."
    ],
    "Object8": [
      "Bubonic: Secondary septicemia, secondary pneumonia, meningitis. Mortality 60% if untreated.",
      "Septicemic: Hypotension, septic shock, renal failure, ARDS, DIC. Gangrene of acral regions ('Black Death'). Mortality approaches 100% if untreated.",
      "Pneumonic: Death in almost all patients within 2-3 days without antibiotics."
    ]
  },
  {
    "Object1": "Botulism",
    "Object2": [
      "Food-borne botulism (most common)",
      "Infantile botulism",
      "Wound botulism",
      "Inhalational botulism",
      "Iatrogenic botulism"
    ],
    "Object3": [
      "Neurotoxin (botulinum) produced by Clostridium botulinum",
      "Ingestion (contaminated food like canned/bottled food, fish; honey in infants)",
      "Inoculation (wound botulism in injection drug-users, contaminated heroin injection)"
    ],
    "Object4": [
      "Food-borne: Initial GI symptoms (nausea, diarrhea), rapidly followed by neurotoxic effects (bulbar/ocular palsies - difficulty swallowing, blurred/double vision, ptosis), progressing to symmetrical descending limb weakness, diaphragmatic paralysis, respiratory paralysis, death. No sensory deficits except blurring of vision. Parasympathetic dysfunction (dry mouth, paralytic ileus, dilated/nonreactive pupils).",
      "Infantile: Onset of constipation, followed by weakness in sucking, crying or swallowing. Progressive bulbar and muscle weakness of extremities.",
      "Wound: Similar to food-borne except no GI upset."
    ],
    "Object5": [
      "Absence of fever, patients are alert (mild drowsiness possible).",
      "Heart rate normal or slow, blood pressure normal."
    ],
    "Object6": [
      "Diagnosis usually clinical.",
      "Detection of toxin: In blood (foodborne), stools (infant), or contaminated food.",
      "Culture of organism from wound."
    ],
    "Object7": [
      "Mainly general supportive care (mechanical ventilation, prevention of secondary infection).",
      "Administration of antitoxin (Equine serum heptavalent botulism antitoxin, human-derived botulism immune globulin).",
      "Antibiotics (penicillin G and metronidazole) (of limited use)."
    ],
    "Object8": [
      "Respiratory paralysis and death."
    ]
  },
  {
    "Object1": "Whooping Cough (Pertussis)",
    "Object2": "Acute infection of the respiratory tract",
    "Object3": [
      "Bordetella pertussis (gram-negative coccobacillus)"
    ],
    "Object4": [
      "Catarrhal phase: Upper respiratory catarrh with rhinitis, lacrimation (conjunctivitis), low-grade fever, unproductive cough",
      "Paroxysmal phase: Spasmodic, frequent, severe cough with repetitive bouts of 5-10 coughs. Inspiratory audible whoop. Usually terminate in vomiting. Conjunctival suffusion and petechiae, ulceration of frenulum of tongue.",
      "Convalescence phase: Slow resolution of whoop, cough may persist for weeks/months"
    ],
    "Object5": [
      "Whoop (classic inspiratory audible whoop in younger patients)",
      "Conjunctival suffusion and petechiae",
      "Ulceration of frenulum of tongue",
      "Lymphocytosis"
    ],
    "Object6": [
      "Clinical diagnosis (classic symptoms, whoop, history of contact)",
      "Blood: Lymphocytosis (peripheral blood)",
      "Culture of nasopharyngeal secretions (gold standard)",
      "B. pertussis DNA detection by PCR assay",
      "Direct fluorescent antibody test"
    ],
    "Object7": [
      "Antibiotics: Erythromycin for 7-14 days (recommended). Azithromycin (500 mg day 1, then 250 mg day 2-5) or clarithromycin (500 mg twice daily for days). Trimethoprim/sulfamethoxazole (alternative for macrolide allergy).",
      "Cough suppressants are not effective.",
      "Steroids, antihistamines, ẞ-agonists, immunoglobulins are not beneficial."
    ],
    "Object8": [
      "Respiratory: Apnea (children), Bronchopneumonia, Atelectasis, Bronchiectasis (sequelae), Rib fractures, Pneumothorax",
      "Other: Encephalitis, Convulsions (due to cerebral anoxia), Conjunctival hemorrhage, Subdural hematoma, Direct inguinal hernia, Rectal prolapse, Weight loss"
    ]
  },
  {
    "Object1": "Enteric Fever (Typhoid and Paratyphoid Fever)",
    "Object2": "Acute systemic illness",
    "Object3": [
      "Salmonella typhi (typhoid fever)",
      "Salmonella paratyphi (paratyphoid fever) (A, B, or C)"
    ],
    "Object4": [
      "Gradual and nonspecific onset",
      "Fever (rises in step-ladder fashion to 40-41°C, continuous, persistent for 4-8 weeks in untreated)",
      "Anorexia, headache, abdominal pain, bloating, nausea, vomiting",
      "Early intestinal: Constipation (adults) or mild diarrhea (children)",
      "Late intestinal (3rd/4th week): Diarrhea (loose, greenish, 'pea-soup'), abdominal distension, tenderness in right iliac fossa",
      "Neurological: Delirium ('muttering delirium'), psychosis, seizures, coma vigil, catatonia, meningitis, encephalopathy, GB syndrome, peripheral neuritis, deafness"
    ],
    "Object5": [
      "Abdominal tenderness (early stages)",
      "Hepatosplenomegaly (mild)",
      "Lymphadenopathy (early stages)",
      "Scanty maculopapular rash ('rose spots') (2-4 mm, pale-red maculopapular lesions on chest/abdomen, fade on pressure, occur first week, last 2-3 days)",
      "Relative bradycardia (pulse slower than expected for fever height)",
      "Toxemia (3rd week, patient may develop coma and die)"
    ],
    "Object6": [
      "Total leukocyte count: Leukopenia with relative lymphocytosis. Eosinophils usually absent.",
      "Isolation of Bacilli: Blood culture ('Gold Standard', maximum positivity first week - 90%), Bone marrow culture aspirate (more sensitive than blood culture), Stool cultures (positive in third week), Urine culture (~25% positive by third week).",
      "Widal test/reaction: Measures agglutinating antibodies against O, H, Vi antigens of S. typhi and H antigens of S. paratyphi A/B. Positive from end of first week to fourth week. High false-positive/negative rates. Not recommended as sole diagnostic test.",
      "Other serologic tests: Rapid diagnosis with higher sensitivity.",
      "Molecular methods: PCR detects flagellin, somatic gene, Vi gene."
    ],
    "Object7": [
      "General management: Bed rest, isolation, maintenance of nutrition and fluid intake.",
      "Antibiotic therapy: Guided by culture and sensitivity. Ceftriaxone (75 mg/kg/day for 7-14 days), Chloramphenicol (3-4 g/day till fever subsides, then 2 g/day for 14 days), Amoxicillin (4-6 g/day in four divided doses for 14 days), Cotrimoxazole (TMP 640 mg + SMX 3200 mg daily for 14 days), Ciprofloxacin (500-750 mg twice daily for 14 days), Ofloxacin (400-800 mg/day for 14 days), Cefotaxime (50-75 mg/kg/day for 7-14 days), Cefixime (20 mg/kg/day for 10-14 days), Azithromycin (1 g once a day for 7 days), Aztreonam (50-100 mg/kg/day for 14 days).",
      "Multidrug resistant (MDR) strains: Ciprofloxacin (if resistant to chloramphenicol, amoxicillin, cotrimoxazole). NARST strains (nalidixic acid resistant): Longer duration ciprofloxacin or ceftriaxone.",
      "Corticosteroids: Indicated in severe toxemia, CNS manifestations, DIC. IV dexamethasone (3 mg/kg loading, then 1 mg/kg every 6 hourly for 24 hours).",
      "Treatment of complications: Intestinal perforation and hemorrhage (3rd/4th week) managed accordingly.",
      "Carrier state: Ciprofloxacin/ampicillin for 4 weeks. Cholecystectomy may be needed."
    ],
    "Object8": [
      "General: Toxemia, dehydration, peripheral circulatory failure, DIC.",
      "Intestinal: Ileus (most common), perforation of typhoid ulcer, hemorrhage from ulcer (end of 2nd/3rd week).",
      "Extraintestinal: Neurological (Delirium, psychosis, seizures, coma vigil, catatonia, meningitis, encephalopathy, GB syndrome, peripheral neuritis, deafness), Miscellaneous (Myocarditis, endocarditis, pericarditis, pneumonia, cholecystitis, pyelonephritis, glomerulonephritis, osteomyelitis, arthritis, periostitis, hepatitis, thrombophlebitis).",
      "Carrier state: Persistence of bacilli in gallbladder or urinary tract (source of infection)."
    ]
  },
  {
    "Object1": "Food Poisoning",
    "Object2": [
      "Infective (bacteria or their toxins)",
      "Noninfective (allergic, non-allergic, chemicals)"
    ],
    "Object3": [
      "Infective:",
      "Due to toxin: Preformed toxins (Staphylococcus aureus, Bacillus cereus), Enterotoxins released in intestine (Vibrio cholerae, E. coli, Clostridium perfringens, Clostridium difficile)",
      "Due to intestinal mucosal damage: Invasion of mucosa (rotavirus), Invasion and destruction of mucosa (Shigella, Yersinia enterocolitica, Salmonella, Entamoeba histolytica, Bacillus anthracis)",
      "Noninfective: Allergic type (shellfish), Non-allergic type (scombrotoxin - fish, fungi - Amanita Phalloides), Chemicals (detergents, pesticides)",
      "Specific organisms (Incubation, Symptoms, Foods):",
      "Campylobacter jejuni (2-5 days, diarrhea, vomiting, headache, fever, muscle pain; Poultry, dairy, water)",
      "Salmonella enteriditis (12-36 hours, abdominal cramps, headache, fever, nausea, diarrhea; Poultry, meat, eggs, melons)",
      "Escherichia coli (3-4 days, diarrhea, vomiting, mild fever; Undercooked ground beef, unpasteurized cider)",
      "Listeria monocytogenes (3-70 days, flu-like, meningitis, encephalitis, spontaneous abortion; Unpasteurized milk, ice cream, lunch meats)",
      "Clostridium perfringens (10-12 hours, abdominal pain, nausea, diarrhea; Stews, gravies, beans)",
      "Clostridium botulinum (intoxication) (4 hours-8 days, vomiting, constipation, diplopia, dysphagia, dysarthria, paralysis, death; Baked potatoes, fish, garlic/oil, canned foods)",
      "Staphylococcus aureus (intoxication) (1-7 hours, nausea, retching, abdominal cramps, diarrhea; Ready-to-eat, reheated foods, dairy, protein foods)",
      "Bacillus cereus (intoxication) (30 min-6 hours (emetic) or 6-15 hours (diarrheal), nausea, vomiting, watery diarrhea; Rice products, starchy foods, casseroles, puddings, soups)",
      "Hepatitis A (10-50 days, sudden fever, vomiting, jaundice; Water (ice), shellfish, ready-to-eat, fruit juices, vegetables)",
      "Norwalk virus (10-50 hours, nausea, diarrhea, headache, mild fever; Water, shellfish, raw vegetables, fruits)",
      "Rotavirus (1-3 days, vomiting, diarrhea, mild fever; Ready-to-eat, water and ice)",
      "Giardia lamblia (3-25 days, fatigue, nausea, weight loss, abdominal cramps; Water, ice, raw vegetables)",
      "Cryptosporidium parvum (1-12 days, severe diarrhea, may have no symptoms; Water, raw foods, unpasteurized cider, ready-to-eat)"
    ],
    "Object4": [
      "Severe vomiting",
      "Diarrhea",
      "Headache",
      "Fever",
      "Abdominal pain",
      "Tiredness"
    ],
    "Object5": [],
    "Object6": [
      "Diagnosis is mainly clinical. Stool culture for identification of organism."
    ],
    "Object7": [
      "Symptoms subside in 2-3 days.",
      "Replace fluids and electrolytes lost (oral rehydration therapy, IV saline for severe dehydration).",
      "Supportive treatment (antiemetics, antipyretics, probiotics, antimotility agents).",
      "Antibiotics used sparingly, only in infective cases."
    ],
    "Object8": []
  },
  {
    "Object1": "Bacillary Dysentery (Shigellosis)",
    "Object2": "Acute necrotizing infection of distal small bowel and colon",
    "Object3": [
      "Shigella species (dysenteriae - most virulent, flexneri, boydii, sonnei)",
      "E. coli O157:H7, Salmonella, Campylobacter",
      "Shigella produces toxin (endotoxin, exotoxin) with cytotoxic, neurotoxic, enterotoxic effects"
    ],
    "Object4": [
      "Frequent small quantity of stools containing blood, mucus, purulent exudate (dysentery) (starts 24-48 hours after ingestion)",
      "Fever",
      "Colicky abdominal pain",
      "Tenesmus",
      "Systemic toxicity, dehydration, electrolyte disturbances (severe cases)"
    ],
    "Object5": [
      "Tenderness over the colon in the left iliac fossa",
      "Hyperactive bowel sounds"
    ],
    "Object6": [
      "Stool culture (for Shigella infection)",
      "Sigmoidoscopy (red/swollen mucosa covered by mucopus, obscured submucous veins)",
      "Enzyme immunoassay for Shiga toxins in stools",
      "PCR for Shigella DNA in stools"
    ],
    "Object7": [
      "Fluid and electrolyte deficits corrected (oral rehydration therapy, IV replacement for severe diarrhea)",
      "Antibiotic therapy: Ciprofloxacin (500 mg twice daily for 3 days) for S. dysenteriae and S. flexneri. Second-line: Azithromycin and ceftriaxone.",
      "Antidiarrheal medication should be avoided (codeine or loperamide may be given in adults without dysentery)."
    ],
    "Object8": [
      "Intestinal: Rectal prolapse, Toxic megacolon, Colonic perforation",
      "Extraintestinal: Bacteremia, Meningismus, seizures, Transient peripheral neuropathy, Reiter syndrome, Hemolytic-uremic syndrome (HUS), Thrombotic thrombocytopenic purpura"
    ]
  },
  {
    "Object1": "Amebiasis",
    "Object2": [
      "Intestinal Amebiasis (Amebic Colitis - Amebic Dysentery, Non-dysenteric Amebic Colitis)",
      "Extraintestinal Amebiasis (e.g. Amebic Liver Abscess)"
    ],
    "Object3": [
      "Protozoan Entamoeba histolytica (trophozoite, precyst, cyst stages)"
    ],
    "Object4": [
      "Intestinal Amebiasis (Amebic Dysentery): Intermittent diarrhea (foul smelling, loose, watery, with mucus/blood), sometimes alternating with constipation. Abdominal pain/cramp (especially right lower quadrant), flatulence, weight loss. Systemic symptoms (headache, fever, nausea, anorexia) (less commonly).",
      "Non-dysenteric Amebic Colitis: Recurrent bouts of diarrhea with or without mucus, but without visible blood."
    ],
    "Object5": [
      "Tenderness over the cecum (amebic typhlitis), ascending colon and over the left iliac fossa (amebic point or Manson-Barr point)",
      "Tender hepatomegaly"
    ],
    "Object6": [
      "Microscopic examination of stool: Motile trophozoites containing red blood cells (hematophagous trophozoites) in fresh sample (confirms diagnosis). Amebic cysts alone do not imply disease.",
      "Sigmoidoscopy and barium enema: Characteristic 'flask-shaped' ulcers with normal surrounding mucosa. Aspirated material/scrapings/biopsy may show trophozoites.",
      "Serologic tests: Indirect hemagglutination test, ELISA or counter immunoelectrophoresis (detect antibodies, more useful in extraintestinal amebiasis). Amebic fluorescent antibody test positive in ~90% with liver abscess and 60-70% with active colitis.",
      "Detection of E. histolytica antigen or DNA in stool sample.",
      "Diagnosis of amebic liver abscess (suspected on clinical grounds, discussed on pages 848-9)."
    ],
    "Object7": [
      "Invasive intestinal amebiasis: Metronidazole (500-750 mg 3 times daily for 7-10 days) or long-acting nitroimidazoles (tinidazole or ornidazole - 2 g daily for 3 days), secnidazole or nitazoxanide (500 mg twice daily for 3 days). After invasive disease, luminal amebicide (diloxanide furoate, diiodohydroxyquin or paromomycin) to clear luminal cysts/parasite. Alternative: iodoquinol, nitazoxanide.",
      "Hepatic amebiasis (refer pages 848-9)."
    ],
    "Object8": [
      "Intestinal: Massive hemorrhage, Ameboma, Perforation and peritonitis, Toxic megacolon (fulminant cases), Postdysenteric colitis, Rectovaginal fistula, Chronic infection with stricture formation",
      "Extraintestinal: Amebic liver abscess, Pleuropulmonary amebiasis, Hepaticobronchial fistula, Amebic pericarditis, Cutaneous amebiasis"
    ]
  },
  {
    "Object1": "Brucellosis (Abortus Fever; Malta Fever; Undulant Fever; Mediterranean Fever)",
    "Object2": [
      "Acute brucellosis",
      "Subacute brucellosis",
      "Chronic brucellosis"
    ],
    "Object3": [
      "Brucella species (Brucella melitensis, Brucella abortus, Brucella suis, Brucella canis - gram-negative organism, natural reservoir is animals)",
      "Ingestion (contaminated dairy products like unpasteurized raw milk, uncooked meat)",
      "Direct infection (animal urine, feces, vaginal discharge, uterine products enter through abraded skin)",
      "Inhalation of infectious aerosols (pens, tables, slaughter houses)",
      "Conjunctival splashes, injection"
    ],
    "Object4": [
      "Insidious onset with varying clinical signs. Most common: intermittent/irregular fever ('undulant fever').",
      "Acute: Fever, malaise, headache, chills, fatigue, weakness, backache, generalized myalgia, night sweats, anorexia, weight loss, cough, arthralgias.",
      "Subacute: Similar to acute, but less severe.",
      "Chronic: Low-grade fever, easy fatigability, myalgia, arthralgia, occasional bouts of fever, neuropsychiatric manifestations (e.g., depression)."
    ],
    "Object5": [
      "Acute: Splenomegaly (20%), lymphadenopathy (15%), hepatomegaly (10%), sacroiliitis and arthritis.",
      "Chronic: Splenomegaly usually observed.",
      "Localized brucellosis: Osteomyelitis, splenic abscess, epididymo-orchitis, pneumonia, meningoencephalitis, pleural effusion, endocarditis."
    ],
    "Object6": [
      "Culture: Definitive diagnosis depends on isolation of Brucella.",
      "Serological tests: Brucella agglutination test (four-fold or greater rise in titer of agglutination antibody (IgM)), Raised serum IgG level (current or recent infection).",
      "Other tests: Ultrasound and CT, bone radiographs, radionuclide scans and species-specific PCR tests."
    ],
    "Object7": [
      "Regimen A: Doxycycline 100 mg PO BID for 6 weeks + streptomycin 1 g IM qd for first 14-21 days.",
      "Regimen B: Doxycycline 100 mg PO BID + rifampin 600 to 900 mg (15 mg/kg) PO qd for 6 weeks."
    ],
    "Object8": [
      "Chronic: Bone and joint complications (uveitis, sacroiliitis, spondylitis, peripheral arthritis, osteomyelitis, bursitis)."
    ]
  },
  {
    "Object1": "Cholera",
    "Object2": "Acute illness",
    "Object3": [
      "Vibrio cholerae (curved, flagellated, halophilic gram-negative bacillus, colonizes small intestine, produces powerful exotoxin)",
      "Exotoxin causes massive secretion of isotonic fluid into intestinal lumen",
      "Cholera toxin releases serotonin (5HT) from enterochromaffin cells, activating neural secretory reflex",
      "V. cholerae also produces zona occludens toxin (ZOT) and accessory cholera toxin (ACT)"
    ],
    "Object4": [
      "Mild illness (cannot be distinguished from other diarrheas)",
      "Severe cases: Abrupt onset of severe, painless, watery diarrhea (without pain/colic), followed by vomiting (may be absent)",
      "Intense dehydration with muscular cramps",
      "Cholera sicca: Fluid accumulation into dilated bowel, kills patient before typical GI symptoms"
    ],
    "Object5": [
      "Rice-water stool (clear fluid with flecks of mucus)",
      "Hypovolemic shock (cold, clammy, wrinkled 'washer women' skin, loss of skin turgor, tachycardia, hypotension, peripheral cyanosis)",
      "Sunken eyes, hollow cheeks",
      "Diminished urine output",
      "Rapid, thready pulse"
    ],
    "Object6": [
      "Clinical diagnosis (during epidemic)",
      "Stool examination: 'Hanging drop' preparation shows rapidly motile (shooting star motility) V. cholerae",
      "Culture of stool or rectal swab (isolate and identify V. cholerae, antibiotic sensitivity)"
    ],
    "Object7": [
      "Appropriate and effective rehydration therapy (mainstay)",
      "IV therapy (severe dehydration): Ringer-Lactate (Dhaka solution: NaCl 5g/L, KCl 1g/L, NaHCO3 4g/L). Initial fluid deficit replaced in 3-4 hours. 200-300 ml/kg in initial 24 hours. Continue until hemodynamically stable and vomiting subsides.",
      "Oral rehydration: Once vomiting stops and stable, 500 mL hourly. Oral rehydration solutions (ORS) with resistant starch (rice/cereal) shorten diarrhea, improve prognosis.",
      "Antibiotics: 3 days treatment. Tetracycline (500 mg 6 hourly), single dose doxycycline (300 mg) or ciprofloxacin (1 g), or cotrimoxazole (one tablet daily) reduce duration/excretion of V. cholerae. Alternative: erythromycin, furazolidone.",
      "Children: Zinc supplementation may reduce severity of diarrhea."
    ],
    "Object8": [
      "Severe depletion of extracellular fluid leads to hypotension, metabolic acidosis, hypokalemia",
      "Massive fluid loss may lead to hypovolemic shock, acute tubular necrosis, renal failure",
      "Death from acute circulatory failure (if fluids not promptly replaced)"
    ]
  },
  {
    "Object1": "Leprosy (Hansen's Disease)",
    "Object2": [
      "Tuberculoid leprosy (TT)",
      "Borderline tuberculoid (BT)",
      "Borderline leprosy (BB)",
      "Borderline lepromatous (BL)",
      "Lepromatous leprosy (LL)",
      "Indeterminate type",
      "Paucibacillary (WHO classification)",
      "Multibacillary (WHO classification)"
    ],
    "Object3": [
      "Mycobacterium leprae (acid and alcohol fast, intracellular bacillus, survives and grows better at ~30°C)"
    ],
    "Object4": [
      "Tuberculoid: Hypoesthetic skin lesions (loss of sweat glands/hair follicles). Sensory nerve involvement (glove/stocking anesthesia, chronic non-healing plantar ulcers, repeated injuries). Motor nerve involvement (muscle weakness, wasting, paralysis, contractures). Facial nerve (facial paralysis, lagophthalmos, exposure keratitis, corneal ulcerations). Trigeminal nerve (loss of corneal reflex).",
      "Lepromatous: Anosmia, nasal stuffiness, crust formation, blood-stained nasal discharge (early nasal symptoms). Painless lymphadenopathy (inguinal, axillary).",
      "Reactions: Type I (erythema and swelling of existing skin lesions, new lesions, neuritis causing pain/tenderness of nerves). Type II (painful, tender inflamed, red, subcutaneous papules/plaques, low-grade fever, malaise, lymphadenopathy, neuritis, arthralgia, uveitis, iritis, orchitis, myositis, glomerulonephritis, edema, anemia, leukocytosis, abnormal LFTs)."
    ],
    "Object5": [
      "Tuberculoid: Single or few, localized, sharply demarcated, dry, elevated, hypoesthetic, red or hypopigmented macules (later larger, elevated/circinate margins). Thickened and palpable involved nerves (ulnar, peroneal, greater auricular). Claw hand, ape hand, foot drop, claw toes/hammer toes. Anhidrosis or hyperhidrosis. Lagophthalmos, corneal ulcerations.",
      "Lepromatous: Multiple, symmetric, macules, papules, plaques or nodules (hypopigmented, ill-defined borders, indurated/raised/convex centers - 'inverted saucer'). Diffuse infiltration. Nodular lesions on face (cheeks, nose, eyebrows), ears, wrists, elbows, buttocks, knees. Coalescing nodular lesions in face/ear lobes ('leonine facies'). Loss of eyebrows/eyelashes. Bilateral edema of legs/ankles. Saddle nose. Loosening/loss of upper incisor teeth. Keratitis, iridocyclitis. Laryngitis, palatal perforation, hoarseness. Testicular atrophy, impotence, infertility, gynecomastia. Renal lesions (glomerulonephritis, interstitial nephritis, pyelonephritis, amyloidosis).",
      "Reactions: Type I (inflammation of existing/new skin lesions, nerve pain/tenderness). Type II (erythema nodosum leprosum: painful, tender inflamed, red, subcutaneous papules/plaques on face/limbs).",
      "PKDL: Hypopigmented macules, erythematous patches (butterfly on face), yellowish pink nodules."
    ],
    "Object6": [
      "Clinical diagnosis (hypopigmented/reddish patches with loss of sensation and thickening of peripheral nerves).",
      "Slit-skin smears (earlobes, finger) for AFB (useful in BL, LL).",
      "Nasal secretions for AFB (LL).",
      "Lepromin test (not diagnostic, for immune response classification: LL negative, TT positive, Borderline negative/weakly positive).",
      "Skin biopsy (pathognomonic: peripheral nerve involvement, with/without AFB. Fite-Ferraco stain for LL, BL).",
      "Serological test (not sensitive/specific for diagnosis). Hypergammaglobulinemia in LL (false-positive VDRL, RF, ANA). IgM antibodies to PGI-1 (95% LL, 60% TT).",
      "PCR for M. leprae DNA (possible, not sensitive/specific enough for diagnosis)."
    ],
    "Object7": [
      "Drugs: Dapsone (100 mg), rifampicin (600 mg), clofazimine (100 mg), ethionamide (500 mg), thiacetazone (150 mg). Others: ofloxacin, minocycline, clarithromycin.",
      "Multibacillary leprosy (MB): 1 year treatment. Regimen 1: Dapsone 2 mg/kg daily (max 100 mg), Clofazimine 50 mg daily or 100 mg 3x/week, Rifampicin 450 mg (for patients <50kg) daily for 6 months. Regimen 2: Dapsone 100 mg daily, Clofazimine 50 mg daily + 300 mg once/month (supervised), Rifampicin 600 mg once/month (supervised).",
      "Paucibacillary leprosy (PB): 6 months treatment. Dapsone 100 mg daily, Rifampicin 600 mg once/month (supervised). Follow-up for 5 years.",
      "Dapsone resistance: Clofazimine alone, or clofazimine + ethionamide (500 mg daily) + rifampicin (first 2 days of month).",
      "Type 1 lepra reaction: Mild: Aspirin 600 mg 6 hourly. Severe: Prednisone 40-80 mg daily, reduce gradually over 3-9 months. Maintain leprosy chemotherapy.",
      "Type 2 lepra reaction: Mild: Aspirin 600 mg 6 hourly. Severe: Prednisone 1 mg/kg/day. If no response, add clofazimine (300 mg/day) or thalidomide (100 mg 4 times daily). Doses slowly reduced. If eye involvement: 1% hydrocortisone drops/ointment, 1% atropine drops. Maintain leprosy chemotherapy."
    ],
    "Object8": [
      "Tuberculoid: Irreversible nerve damage (if reaction untreated). Autoamputation of fingers/toes. Blindness.",
      "Lepromatous: Permanent nerve damage (sensory loss, glove/stocking anesthesia, mononeuritis multiplex), skin ulcers, disfiguration ('leonine facies'), eye damage (keratitis, iridocyclitis, blindness), upper airways damage (anosmia, nasal discharge/stuffiness, laryngitis, palatal perforation, hoarseness), muscle weakness (claw hands, inability to flex feet), bone involvement (shortening of fingers, nasal collapse, atrophy maxillary alveolar process - 'facies leprosa'), testicular atrophy, impotence, infertility, gynecomastia, renal lesions (glomerulonephritis, interstitial nephritis, pyelonephritis, amyloidosis).",
      "PKDL: Chronic interstitial lung disease (if untreated).",
      "Reactions: Irreversible nerve damage (Type I). Organ damage (Type II: uveitis, orchitis, glomerulonephritis)."
    ]
  },
  {
    "Object1": "Leptospirosis",
    "Object2": [
      "Leptospiremic (initial/first) phase",
      "Immune (second) phase",
      "Weil's Syndrome (severe leptospirosis)"
    ],
    "Object3": [
      "Spirochaete Leptospira interrogans (pathogenic)",
      "Direct contact with urine or tissue of an infected animal (rodents, foxes, skunks, dogs, livestock)",
      "Prolonged immersion in contaminated water",
      "Ingestion of contaminated water, soil or vegetation"
    ],
    "Object4": [
      "Leptospiremic phase (up to 1 week): Nonspecific illness. High-grade fever with chills and rigors, malaise, weakness, severe headache (retro-orbital/occipital), severe myalgia (thighs, lumbar areas, calf, back) with cutaneous hyperesthesia (causalgia). Less common: anorexia, nausea, vomiting, abdominal pain, cough, pharyngitis, uveitis.",
      "Immune phase (2-5 days after recovery from first phase): Symptoms worsen. Headache, fever, neck stiffness (meningitis). Change in consciousness, encephalitis, cranial nerve palsies, acute dilatation of gallbladder with cholecystitis (less frequent).",
      "Weil's Syndrome (severe leptospirosis): Jaundice, Renal failure (oliguria or anuria), Hemorrhagic manifestations (purpura, petechiae on oral/vaginal/conjunctival mucosa, bruising, epistaxis, hemoptysis, hematemesis, melena, hemorrhage into adrenal glands/pleural/pericardial/subarachnoid spaces). Pulmonary syndrome (ARDS, hemorrhage, pneumonia, effusion). CNS (meningoencephalitis, subarachnoid hemorrhage, seizures). DIC, hemolytic anemia, myocarditis, arrhythmias, MODS."
    ],
    "Object5": [
      "Leptospiremic phase: Conjunctival suffusion/congestion (pericorneal reddening/hyperemia without exudate).",
      "Weil's Syndrome: Deep jaundice. Oliguria or anuria. Purpura, petechiae, bruising, epistaxis, hemoptysis, hematemesis, melena. Thrombocytopenia. Crepitations (chest X-ray). Bradycardia, low voltage ECG, non-specific ST-T changes. Pleural effusion.",
      "Meningitis: Abnormalities in CSF (lymphocytic pleocytosis, normal glucose, raised protein)."
    ],
    "Object6": [
      "Urine examination: Microscopic hematuria, pyuria, proteinuria (early illness). Visualization of tightly coiled spirochete (phase contrast/dark-field microscopy).",
      "Blood: Polymorphonuclear leukocytosis (>70% neutrophils) with shift to left. Anemia (intravascular hemolysis, azotemia, blood loss). Thrombocytopenia (severe infection). Elevated ESR, C-reactive protein. Raised BUN, hyperkalemia (renal failure). Prolonged prothrombin time (reversible with vitamin K). CPK elevated (50% patients in first week, differentiates from viral hepatitis). LFTs (raised AST/ALT, conjugated hyperbilirubinemia, raised alkaline phosphatase).",
      "Chest radiograph: Patchy bronchopneumonia, small pleural effusion.",
      "ECG: Bradycardia, low voltage, non-specific ST-T wave changes.",
      "CSF: Abnormal in up to 90%. Increased cell counts (<500/mm³) with neutrophils predominance. Protein levels normal/raised, glucose normal. Xanthochromia in severe jaundice.",
      "Serological tests: IgM antibodies by MAT. IgM ELISA and immunofluorescent techniques. Rapid immunochromatographic tests. Detection of leptospiral antigen by RIA or ELISA.",
      "Culture: Of blood/CSF (first week), urine (from second week). May take weeks.",
      "PCR: Detect leptospiral DNA in blood (early), urine (from 8th day)."
    ],
    "Object7": [
      "Antibiotic therapy (early therapy prevents major organ failure):",
      "Mild disease (oral for 7 days, within 4 days of onset): Doxycycline (100 mg twice daily) or Ampicillin (750 mg 4 times daily) or Amoxicillin (500 mg 4 times daily) or Azithromycin (500 mg once daily).",
      "Severe leptospirosis (IV): Penicillin (1.5 million units IV 6 hourly) or Ceftriaxone (1 g twice daily IV) or Cefotaxime (1 g IV 4 times daily).",
      "Treatment of complications/general care: Blood product transfusion (hemorrhage, anemia, thrombocytopenia). Mechanical ventilation (ARDS). Dialysis (Renal failure). IV corticosteroids (vasculitic nature, severe leptospirosis, pulmonary hemorrhage)."
    ],
    "Object8": [
      "Weil's Syndrome: Jaundice, renal failure, hemorrhagic manifestations, pulmonary syndrome, CNS involvement (meningoencephalitis, subarachnoid hemorrhage, seizures), DIC, hemolytic anemia, myocarditis, arrhythmias, MODS.",
      "Meningitis, iridocyclitis.",
      "Fulminant hepatic dysfunction."
    ]
  },
  {
    "Object1": "Melioidosis (Whitmore Disease)",
    "Object2": [
      "Acute pulmonary infection",
      "Focal infection",
      "Severe systemic form (non-disseminated or disseminated)",
      "Encephalomyelitis (rarely)"
    ],
    "Object3": [
      "Burkholderia pseudomallei (aerobic, gram-negative motile bacillus, 'safety pin' appearance, opportunistic pathogen, produces exotoxin)",
      "Contact with contaminated soil or water (most common)",
      "Aspiration or ingestion of contaminated water",
      "Inhalation of dust from soil",
      "Person-to-person transmission (very rare, sexual contact with prostatic infection)",
      "Risk factors: Immunosuppressive events or chronic diseases (diabetes, chronic alcohol use, chronic renal disease, chronic lung disease)"
    ],
    "Object4": [
      "Most infections are asymptomatic",
      "Acute pulmonary: Lobar/multilobar pneumonia, necrotizing lesions, pleural effusions, fever, cough with expectoration.",
      "Focal infection: Localized lesions on skin (infected wounds) or internal organs.",
      "Severe systemic: Severe septicemic form."
    ],
    "Object5": [
      "Acute pulmonary: Resembles tuberculosis (cavitary lesions, consolidation).",
      "Focal infection: Lymphadenopathy, parotitis, cystitis, osteomyelitis, prostatitis, spondylitis, septic arthritis.",
      "Lesions have no distinguishing characteristics (great imitator)."
    ],
    "Object6": [
      "Isolation of the organism from blood, sputum, tissues or wound exudates by culture.",
      "Serological tests for titers (agglutination tests, indirect hemagglutination, complement fixation, immunofluorescence, enzyme assays)."
    ],
    "Object7": [
      "Initial intensive therapy with one of:",
      "Ceftazidime (2 g IV every 6 hours)",
      "Meropenem (1 g IV every 8 hours)",
      "Imipenem (1 g IV every 6 hours)",
      "Addition of TMP-SMX (trimethoprim sulfamethoxazole) twice daily during intensive phase, continued for 2-3 months.",
      "Surgical drainage for localized infection.",
      "Long-term treatment with multiple drugs for chronic/severe cases."
    ],
    "Object8": [
      "Relapses are common."
    ]
  },
  {
    "Object1": "Rickettsial Diseases",
    "Object2": [
      "Typhus Group (Epidemic typhus, Murine typhus - Endemic typhus, Scrub typhus)",
      "Spotted Fever Group (Indian tick typhus, Rocky mountain spotted fever, Rickettsial pox)",
      "Others (Q fever, Trench fever)"
    ],
    "Object3": [
      "Rickettsiae (obligate intracellular gram negative parasites). Replicate within cytoplasm of endothelial cells and smooth muscle cells of capillaries, arterioles, small arteries causing necrotizing vasculitis.",
      "Typhus Group: R. prowazekii (louse, human); R. typhi (flea, rodents); R. tsutsugamushi (mite, rodents)",
      "Spotted Fever Group: R. conorii (tick, rodent/dog); R. rickettsii (tick, rodents/dogs); R. akari (mite, mice)",
      "Others: C. burnetii (nil vector, cattle/sheep/goats); R. quintana (louse, human)"
    ],
    "Object4": [
      "Most are febrile infections with characteristic rash.",
      "Typhus Group: Fever/chills, myalgia, headache. R. typhi (milder form of illness).",
      "Scrub typhus: Fever, headache, rash.",
      "Spotted Fever Group: Fever, headache, rash. R. rickettsii (systemic complications - respiratory, cardiovascular, CNS, renal, hepatic).",
      "Rickettsial pox: Mild illness, fever, headache.",
      "Q fever: Fever, headache, fatigue, pneumonia, endocarditis.",
      "Trench fever: Fever, splenomegaly, bone pains."
    ],
    "Object5": [
      "Eschar (characteristic lesion at inoculation site, except in typhus group and Rocky Mountain Spotted Fever).",
      "Typhus Group: Rash (all over body except palm, sole, face - Epidemic; trunk, extremities - Murine; with eschar - Scrub).",
      "Scrub typhus: Eschar ('cigarette burn sign'). Lymphadenopathy.",
      "Spotted Fever Group: Rash (with eschar - Indian tick typhus; no eschar, first appear on wrist/ankle, palms/soles involved - Rocky mountain).",
      "Rickettsial pox: Vesicular rash with eschar, lymphadenopathy (resemblance to chicken pox).",
      "Q fever: No rash.",
      "Trench fever: Maculopapular rash."
    ],
    "Object6": [
      "Polymerase chain reaction (PCR)",
      "Serological tests: Indirect fluorescent antibody (IFA) test (Titer ≥ 1:200), Complement fixation test, Weil Felix Test, IgM ELISA test (highly specific)."
    ],
    "Object7": [
      "Tetracycline is the drug of choice.",
      "Doxycycline: 100 mg BID PO x 7–15 days.",
      "Chloramphenicol: 500 mg qid PO x 7–15 days."
    ],
    "Object8": [
      "Rocky mountain spotted fever: Systemic complications."
    ]
  },
  {
    "Object1": "Measles (Rubeola)",
    "Object2": [
      "Uncomplicated measles",
      "Hemorrhagic measles (black measles)",
      "Modified measles (rare)"
    ],
    "Object3": [
      "Measles virus (RNA virus of Morbillivirus genus, Paramyxoviridae family)"
    ],
    "Object4": [
      "Prodromal (3-5 days): Low-grade to moderate fever, dry cough, coryza, conjunctivitis.",
      "Exanthematous: High fever, maculopapular rash (starts on neck/behind ears/hairline/cheek, spreads to face/neck/upper arms/chest (first 24h), then back/abdomen/arms/thighs (next 24h), fades on face as it reaches feet).",
      "Hemorrhagic measles: Bleeding from mouth, nose, or bowel.",
      "Modified measles: Complete absence of rash (rare, in Ig recipients, HIV, infants <9 months with maternal antibody)."
    ],
    "Object5": [
      "Prodromal: Koplik spots (pathognomonic: grayish white dots with reddish areolae, on buccal mucosa, opposite lower molars, appear 12-18h, disappear rapidly). Conjunctival inflammation and photophobia (transverse line of inflammation along eyelid margin).",
      "Exanthematous: Maculopapular rash. Lymphadenopathy, conjunctivitis, pharyngitis.",
      "Hemorrhagic measles: Widespread bleeding.",
      "Modified measles: Milder rash, lower mortality (if vaccinated)."
    ],
    "Object6": [
      "Clinical diagnosis (rarely lab confirmation).",
      "Measles IgM antibodies (detectable for 1 month after illness; limited sensitivity first 72h of rash)."
    ],
    "Object7": [
      "No specific antiviral therapy, entirely supportive.",
      "Antipyretics (acetaminophen or ibuprofen) for fever.",
      "Bed rest.",
      "Adequate fluid intake.",
      "Vitamin A supplementation (for children 6 months-2 years hospitalized with complications, or >6 months with immunodeficiency). Regimen: 100,000 IU orally (6 months-1 year), 200,000 IU (≥1 year). Additional doses if ophthalmologic deficiency.",
      "Treatment of secondary bacterial infections (with appropriate antibiotics).",
      "Measles encephalitis: Aerosolized and IV ribavirin (may be useful)."
    ],
    "Object8": [
      "Due to virus replication: Acute laryngotracheobronchitis (croup), Giant-cell pneumonitis (immunocompromised).",
      "Due to secondary bacterial infections: Otitis media, Bronchitis, Bronchopneumonia, Gastroenteritis, Noma/cancrum oris, Gangrenous stomatitis, Diarrhea (undernutrition).",
      "Less common: Transient hepatitis, Myocarditis, Conjunctivitis, Keratitis, Corneal ulcers.",
      "Postinfectious (rare CNS): Postmeasles encephalomyelitis, Measles inclusion body encephalitis (MIBE), Subacute sclerosing panencephalitis (SSPE).",
      "Others: Guillain-Barré syndrome, Hemiplegia, Cerebral thrombophlebitis, Retrobulbar neuritis, Exacerbation of Mycobacterium tuberculosis, Measles pneumonia (HIV-infected, often fatal)."
    ]
  },
  {
    "Object1": "Rubella (German Measles)",
    "Object2": [
      "Acquired rubella",
      "Congenital rubella syndrome (CRS)",
      "Expanded rubella syndrome"
    ],
    "Object3": [
      "Rubella virus (enveloped RNA virus, Togaviridae family)",
      "Spread via respiratory droplet infection",
      "Transplacental transmission (mother to fetus) for congenital rubella"
    ],
    "Object4": [
      "Acquired (prodromal): Malaise, fever, headache, mild conjunctivitis. Forschhelmer spots (small petechial lesions on soft palate) (suggestive).",
      "Acquired (eruptive): Pinkish red, macular rashes (appear behind ears/forehead, spread to trunk/limbs, last 2-3 days). Polyarthritis and generalized lymphadenopathy (may persist 2 weeks).",
      "Congenital rubella syndrome: Depends on gestational age of infection, can be mild/severe. Classical triad: Cataract, Cardiac abnormalities, Deafness.",
      "Expanded rubella syndrome: Additionally hepatosplenomegaly, thrombocytopenic purpura, intrauterine growth retardation, myocarditis, interstitial pneumonia, humoral and cellular immunodeficiency."
    ],
    "Object5": [
      "Acquired: Rash (exanthema) on face spreading to trunk and limbs (fades after 3 days), 'blueberry muffin lesions' (skin manifestations). Lymphadenopathy (suboccipital, postauricular, posterior cervical lymph nodes) (may be observed 2nd week). Splenomegaly (may be found).",
      "Congenital: Eye diseases (Corneal clouding, cataracts, chorioretinitis, microphthalmia, blindness), Congenital heart diseases (Patent ductus arteriosus, ventricular septal defect, pulmonary stenosis), CNS (Mental retardation, microcephaly), Deafness, Hepatosplenomegaly, Interstitial pneumonia, Metaphyseal bone lesions."
    ],
    "Object6": [
      "Clinical diagnosis. Laboratory diagnosis needed in pregnancy.",
      "Detection of rubella specific IgM by ELISA in serum (diagnostic).",
      "Demonstration of IgG seroconversion (or rising IgG titer) in serum (14 days later).",
      "Detection of viral genome in throat swabs (or oral fluid), urine, products of conception."
    ],
    "Object7": [
      "No specific therapy, symptom-based treatment for fever/arthralgia.",
      "Prevention: Passive immunization (human immunoglobulin, reduces symptoms but not teratogenic effects). Active immunization (live attenuated rubella vaccine - MMR vaccine at 15 months, second dose 11-13 years, seronegative females of child-bearing age).",
      "Contraindications for vaccination: Pregnancy (or likelihood within 3 months), immune deficiency, immunosuppressive drugs."
    ],
    "Object8": [
      "Acquired: Rare. Secondary bacterial infection of lung, arthralgia (commoner in females), hemorrhagic manifestations (thrombocytopenia), postinfectious encephalitis.",
      "Congenital rubella syndrome: Miscarriage, fetal death, premature delivery, severe birth defects (eyes, ears, heart, CNS, hepatosplenomegaly, purpura, IUGR, myocarditis, pneumonia, bone lesions)."
    ]
  },
  {
    "Object1": "Mumps",
    "Object2": "Acute systemic viral infection",
    "Object3": [
      "Paramyxovirus (RNA virus)",
      "Transmitted by respiratory route (droplet infection), direct contact, or through saliva and fomites"
    ],
    "Object4": [
      "Prodromal: Malaise, low-grade fever, myalgia, anorexia, headache, tenderness at angle of jaw.",
      "Parotid gland enlargement: Severe pain over parotid glands. Difficulty eating, swallowing, talking. Submandibular gland involvement (less frequent)."
    ],
    "Object5": [
      "Parotid swelling (unilateral or bilateral in 75% cases)",
      "Obliteration of space between earlobe and angle of mandible"
    ],
    "Object6": [
      "Clinical diagnosis. In atypical cases:",
      "Serological test: Mumps-specific IgM response in blood or oral fluid (diagnostic).",
      "Demonstration virus: Culture of virus or identification by genome (PCR) or antigen detection assays (saliva, throat swab, urine, CSF)."
    ],
    "Object7": [
      "Generally benign, self-resolving illness.",
      "Symptom-based and supportive: Adequate nutrition, mouth care, analgesics for pain.",
      "Prevention: MMR vaccine (at 15 months)."
    ],
    "Object8": [
      "CNS: Aseptic meningitis (10-30%, most common), Encephalitis, Myelitis, Cranial nerve palsies, Sensorineural deafness (rare, unilateral)",
      "Glands: Orchitis (20-30% postpubertal males, often unilateral, can cause testicular atrophy/infertility), Epididymitis, Oophoritis (5% postpubertal females, less severe), Pancreatitis (acute, mild), Thyroiditis",
      "Other: Myocarditis (ECG changes), Nephritis (rare), Arthritis (rare)"
    ]
  },
  {
    "Object1": "Herpes Simplex Virus (HSV) Infections",
    "Object2": [
      "Herpes labialis (herpes febrilis/cold sore)",
      "Keratoconjunctivitis",
      "Dendritic corneal ulcer",
      "Pulp space infections (whitlows)",
      "Encephalitis (temporal lobe involvement)",
      "Genital herpes",
      "Pneumonitis",
      "Tracheobronchitis",
      "Ulcerative stomatitis",
      "Esophagitis"
    ],
    "Object3": [
      "Herpes simplex virus (HSV) Type 1",
      "Herpes simplex virus (HSV) Type 2"
    ],
    "Object4": [],
    "Object5": [
      "Herpes labialis/febrilis (Fig. 4.13A)"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Cytomegalovirus (CMV) Infections",
    "Object2": "Not specified",
    "Object3": [
      "Cytomegalovirus (human beta herpesvirus)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Congenital infections (intrauterine growth retardation)",
      "Perinatal infections",
      "Infections in immunocompromised patients (pneumonitis, retinitis)"
    ]
  },
  {
    "Object1": "Epstein-Barr Virus (EBV) Infections",
    "Object2": "Not specified",
    "Object3": [
      "Epstein-Barr virus (EBV, human herpesvirus)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Infectious mononucleosis",
      "Burkitt's lymphoma",
      "Nasopharyngeal carcinoma",
      "Hairy leukoplakia (in AIDS patients)"
    ]
  },
  {
    "Object1": "Varicella-Zoster Virus (VZV) Infections",
    "Object2": [
      "Chickenpox (Varicella)",
      "Herpes-zoster (Shingles)"
    ],
    "Object3": [
      "Varicella-zoster virus (human herpesvirus 3)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Human Herpes Virus 6 (HHV-6) Infections",
    "Object2": "Not specified",
    "Object3": [
      "Human herpes virus 6"
    ],
    "Object4": [],
    "Object5": [
      "Exanthem subitum (sixth disease)",
      "Roseola subitum-slapped cheek appearance (Fig. 4.13B)"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Human Herpes Virus 7 (HHV-7) Infections",
    "Object2": "Not specified",
    "Object3": [
      "Human herpes virus 7"
    ],
    "Object4": [],
    "Object5": [
      "Exanthem subitum (sixth disease)"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Human Herpes Virus 8 (HHV-8) Infections",
    "Object2": "Not specified",
    "Object3": [
      "Human herpes virus 8"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": [
      "Kaposi's sarcoma",
      "Multicentric Castleman's disease"
    ]
  },
  {
    "Object1": "Infectious Mononucleosis (Glandular Fever)",
    "Object2": "Not specified",
    "Object3": [
      "Epstein-Barr virus (EBV, herpes virus, infects B lymphocytes)"
    ],
    "Object4": [
      "Nonspecific prodromal symptoms",
      "Fever",
      "Severe pharyngitis and tonsillitis",
      "Petechial rashes on palate",
      "Maculopapular skin rash (after ampicillin/amoxicillin)",
      "Glanotti-Crosti syndrome (symmetrical rash on cheeks, erythematous papules coalescing to plaques, persists 15-50 days)"
    ],
    "Object5": [
      "Generalized lymphadenopathy (particularly posterior cervical lymph node enlargement)",
      "Hepatosplenomegaly"
    ],
    "Object6": [
      "Peripheral blood smear: 20-40% atypical lymphocytes (large, eccentric/folded nuclei, low nuclear-to-cytoplasm ratio)",
      "Liver function tests: Raised liver enzymes",
      "Serological Tests: Demonstration of heterophile antibodies (Paul Bunnell test positive - sheep RBC agglutination; Monospot test sensitive - horse red cells agglutinate). Demonstration specific antibodies against EBV antigens (anti-VCA - IgM/IgG; Antibodies to Epstein-Barr nuclear antigen (EBNA) by PCR)."
    ],
    "Object7": [
      "Usually self-limiting, no specific treatment, rapid recovery.",
      "Symptomatic treatment: Rest, acetaminophen.",
      "Corticosteroids: Indicated for neurological complications (meningitis, encephalitis), severe hemolysis, marked thrombocytopenia, marked tonsillar enlargement causing respiratory obstruction."
    ],
    "Object8": [
      "Chronic fatigue syndrome",
      "Hematological: Hemolytic anemia, thrombocytopenia, aplastic anemia, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, DIC",
      "Glomerulonephritis, interstitial nephritis, hepatitis, myocarditis, pericarditis",
      "Splenic rupture",
      "Cardiac: Myocarditis, pericarditis",
      "Hepatic: Reyes syndrome",
      "Skin: Ampicillin associated rash (Jarisch-Herxheimer reaction), oral hairy leukoplakia",
      "Neurologic: Meningitis, encephalitis, transverse myelitis, Guillain-Barré (GB) syndrome",
      "Airway obstruction (marked tonsil enlargement/pharyngeal edema)",
      "EBV Associated Oncogenesis: Burkitt Lymphoma, Hodgkin Lymphoma, Nasopharyngeal Carcinoma, Lymphoproliferative Disorders"
    ]
  },
  {
    "Object1": "Chickenpox (Varicella)",
    "Object2": "Primary infection with varicella-zoster virus",
    "Object3": [
      "Varicella-zoster virus (VZV, human herpes virus 3)",
      "Highly contagious, spread by droplet infection from upper respiratory tract",
      "Direct contact with discharge from ruptured skin lesions"
    ],
    "Object4": [],
    "Object5": [
      "Characteristic rash (appears on 2nd day, first on trunk, then face, then limbs; maximal on trunk, minimum on periphery - centripetal distribution)",
      "Rash appears as small pink macules, progresses to papules, vesicles (Fig. 4.14B), and pustules within 24 hours. Lesions dry up and form scabs.",
      "New lesions develop in crops every 2-4 days, each crop associated with fever (lesions at all stages seen simultaneously).",
      "Immunocompromised patients: Hemorrhagic and numerous skin lesions, dissemination to other organs common.",
      "Enanthem (rash/small spots on mucous membranes) (Fig. 4.14C)."
    ],
    "Object6": [
      "Mainly clinical.",
      "Detection of antigen (direct immunofluorescence) or DNA (PCR) of fluid aspirated from vesicles.",
      "Serology (identify seronegative individuals at risk).",
      "Isolation of virus by culture of vesicular fluid.",
      "Tzanck smear (scraping of vesicular lesion base: multinucleated giant cells and epithelial cells with eosinophilic intranuclear inclusion bodies, 60% sensitivity)."
    ],
    "Object7": [
      "No treatment needed in majority of patients.",
      "Medical management (immunologically normal): Prevention of complications. Good hygiene (daily bathing), meticulous skin care (avoid secondary bacterial infection).",
      "Avoid aspirin (in children, to prevent Reye's syndrome).",
      "Symptomatic treatment for itching/pruritus: Antihistamines, local calamine lotion.",
      "Secondary bacterial infection: Local antiseptic or systemic antibiotics (e.g., cloxacillin).",
      "Antiviral Therapy (acyclovir, valacyclovir, famciclovir): Not required for uncomplicated in children, but may reduce duration if given within 24h. Indicated for: uncomplicated within 24-48h, all patients with complications, immunocompromised patients, pregnant women (regardless of vesicle duration). Severe in immunocompromised: initial parenteral therapy. Prolonged treatment if prolonged viral shedding."
    ],
    "Object8": [
      "Skin: Secondary bacterial infection (impetigo), Cellulitis, Abscess, Gangrene (severe infection)",
      "Pulmonary: Viral pneumonia, Bacterial pneumonia, Pneumonitis (severe, in immunocompromised/pregnant/adults)",
      "Neurological: Cerebellar ataxia (most common in children), Encephalitis, Transverse myelitis, Reye's syndrome (with aspirin in children), Optic neuritis, Guillain-Barré syndrome",
      "Other: Carditis, Nephritis, Hepatitis, Orchitis, Keratitis (corneal scarring), Disseminated varicella (in immunocompromised), Hemorrhagic varicella"
    ]
  },
  {
    "Object1": "Shingles (Herpes Zoster)",
    "Object2": "Reactivation of latent VZV",
    "Object3": [
      "Reactivation of latent varicella-zoster virus (VZV) in dorsal root ganglion of sensory nerves or cranial nerve ganglia"
    ],
    "Object4": [
      "Severe pain (burning discomfort) in affected dermatome (3-4 days before rash)",
      "Paresthesia without rash ('zoster sine herpete') (occasionally)",
      "Postherpetic neuralgia (persistent pain for 1-6 months or longer after rash healing, common in elderly)"
    ],
    "Object5": [
      "Rash (similar to chickenpox, unilateral, restricted to sensory nerve/dermatomal distribution) (Fig. 4.15A). Distant satellite 'chickenpox' lesions possible.",
      "Dermatome involved: Most commonly thoracic or ophthalmic division of trigeminal nerve (vesicles on cornea, corneal ulceration, blindness). Bowel/bladder dysfunction with sacral nerve root involvement. Cranial nerve palsy, myelitis or encephalitis (occasionally).",
      "Ramsay Hunt syndrome (geniculate ganglion involvement): Triad of (1) ipsilateral facial paralysis/palsy, (2) ear pain, (3) vesicles/rashes in external auditory canal and auricle."
    ],
    "Object6": [
      "Clinical diagnosis."
    ],
    "Object7": [
      "Early therapy with aciclovir or related agents (valacyclovir, famciclovir) (reduces early/late pain, especially in >65 years).",
      "Postherpetic neuralgia: Analgesics, amitriptyline (25-100 mg daily) or gabapentin (300 mg daily, increasing to 300 mg twice daily or more). Capsaicin cream (0.075%) (may help)."
    ],
    "Object8": [
      "Herpes zoster ophthalmicus (leading to loss of vision)",
      "Ramsay Hunt syndrome (facial paralysis/palsy, ear pain, vesicles in ear canal/auricle)",
      "Postherpetic neuralgia",
      "Granulomatous cerebral angiitis (cerebrovascular complication, stroke-like syndrome, especially with ophthalmic distribution)",
      "Myelitis or radiculitis (occasionally)"
    ]
  },
  {
    "Object1": "Human Papillomaviruses (HPV) Infections",
    "Object2": [
      "High-risk types (HPV-16, HPV-18 - dysplastic lesions and invasive carcinoma in cervix)",
      "Low-risk types (HPV-6, HPV-11 - condylomata acuminata, low-grade cervical lesions)",
      "Verrucae plantaris (hands/feet)",
      "Verrucae plana (face, hands, distal forearms)",
      "Condyloma acuminatum (genital wart)",
      "Anogenital malignancies",
      "Intraepithelial neoplasms (cervix, vulva, vagina, anus, penis)",
      "Penile carcinoma",
      "Cervical carcinoma (squamous cell carcinoma)",
      "Oral lesions (papilloma)",
      "Head and neck cancers (oropharynx, tonsils, base of tongue, soft palate)",
      "Periungual warts",
      "Skin cancers (squamous cell carcinoma, basal cell carcinoma)"
    ],
    "Object3": [
      "Human papillomavirus (HPV) (non-enveloped, double-stranded DNA virus)",
      "Direct contact with skin or mucous membrane lesion",
      "Autoinoculation"
    ],
    "Object4": [
      "Majority asymptomatic.",
      "Periungual warts (often painful).",
      "Oral lesions (asymptomatic)."
    ],
    "Object5": [
      "Verrucae plantaris: Skin colored, flat or dome-shaped papules, rough/hyperkeratotic surface.",
      "Verrucae plana: Flat, reddish or skin-colored papules.",
      "Condyloma acuminatum (Fig. 4.16): Multiple, flat or raised exophytic papillomas, with pedicle or broad based.",
      "HPV-positive lesions appear white with 3-5% acetic acid test."
    ],
    "Object6": [
      "Clinical presentation and appearance.",
      "Biopsy (necessary to confirm dysplasia or carcinoma).",
      "Acetic acid test (HPV-positive lesions appear white within 5 minutes).",
      "Endoscopic examination (colposcopy, proctoscopy) (visualize condyloma, dysplasia, carcinomas).",
      "Molecular methods (HPV viral DNA detection, e.g., hybrid capture 2 DNA test, PCR)."
    ],
    "Object7": [
      "No specific antiviral treatment.",
      "Verrucae: Keratolysis (mechanical removal with salicylic acid:lactic acid:collodion 1:1:4), Cryotherapy (liquid nitrogen).",
      "Anogenital warts: Podophyllotoxin (application causes cell death, contraindicated in pregnancy, systemic side effects if large areas), Imiquimod (induces antiviral cytokines, 5% cream 3x/week for up to 4 months), Ablation (surgery, laser, electrocauterisation), Cryotherapy, Trichloroacetic acid (50-90% topical), 5-Flurouracil cream.",
      "HPV vaccines: Quadrivalent and bivalent vaccines (prevent ~70% of cervical dysplasias)."
    ],
    "Object8": [
      "Dysplastic lesions and invasive carcinoma in the cervix (high-risk types)",
      "Anogenital malignancies, intraepithelial neoplasms, penile carcinoma, cervical carcinoma, oral lesions, head and neck cancers, periungual warts, skin cancers."
    ]
  },
  {
    "Object1": "Dengue",
    "Object2": [
      "Non-severe dengue (with and without warning signs)",
      "Severe dengue",
      "Classic dengue (break bone fever)",
      "Dengue hemorrhagic fever (DHF)",
      "Dengue shock syndrome (DSS)",
      "Expanded Dengue syndrome"
    ],
    "Object3": [
      "Flavivirus, transmitted by daytime Aedes mosquito (Aedes aegypti breeds in stagnant water)",
      "Humans are main amplifying host (infective during first 3 days of illness - viremic stage)",
      "Mosquitoes become infective ~2 weeks after feeding on infected individual, remain infective for life.",
      "Severe dengue: Plasma leakage (endothelial cell activation/dysfunction mediated by infected monocytes, T cells, complement, mediators, monokines, cytokines, soluble receptors). Bleeding (thrombocytopenia, platelet dysfunction, DIC)."
    ],
    "Object4": [
      "Febrile phase (2-7 days): Abrupt onset of high-grade fever (continuous or saddle-back). Facial flushing, skin erythema, generalized body ache ('break-bone fever'), myalgia, arthralgia, malaise, headache (retrobulbar pain worsens on eye movements), severe backache, anorexia, nausea, vomiting. Some: sore throat (pharyngitis), upper respiratory symptoms, conjunctival suffusion. Children: febrile convulsions/seizures.",
      "Critical phase (around defervescence, days 3-7): Increased capillary permeability, increase of hematocrit. Shock (if critical plasma leakage), often with subnormal body temperature. Hypoperfusion of organs, metabolic acidosis, DIC (if prolonged shock). Severe hemorrhage, severe organ impairment (severe hepatitis, encephalitis, myocarditis).",
      "Recovery phase (48-72 hours after critical phase): Improvement in general well-being, return of appetite, disappearance of GI symptoms, hemodynamic stabilization, diuresis. Some: rash of 'isles of white in the sea of red', generalized pruritus (hands/feet)."
    ],
    "Object5": [
      "Febrile phase: High-grade fever. Facial flushing, skin erythema. Liver often enlarged and tender. Mild hemorrhagic manifestations (petechiae, mucosal bleeding - nose/gums).",
      "Critical phase: Increased hematocrit levels. Pleural effusion, ascites (from plasma leakage). Shock (weak pulse, narrow pulse pressure, hypotension, restlessness).",
      "Recovery phase: Bradycardia and electrocardiographic changes. Hematocrit stabilizes/low. WBC count rises. Platelet count recovers later. Massive pleural effusion/ascites leading to respiratory distress (if excessive IV fluids)."
    ],
    "Object6": [
      "Blood: Progressive decrease in total white cell count (earliest, high probability). Increasing hemoglobin and hematocrit (after initial fall), leucopenia, thrombocytopenia, raised liver enzymes (AST or ALT).",
      "Tourniquet test (Hess test): Positive (≥20 petechiae in 5cm circle after 5 min at 80 mmHg).",
      "Isolation of dengue virus from blood (within first 5 days) by tissue culture.",
      "Detection of dengue virus RNA by RT-PCR or NASBA (first few days) (diagnostic).",
      "Detection of serum NS1 antigen by ELISA (early, highly specific, less sensitive than PCR).",
      "Detection of virus specific IgM antibodies or rising IgG titers (after 5 days).",
      "Severe dengue: Chest radiograph for pleural effusion, ultrasound abdomen for ascites."
    ],
    "Object7": [
      "Step I: Overall assessment (History, Physical examination, Investigations: CBC, Hematocrit, LFT, Blood glucose, Serum electrolytes, Urea, Creatinine, Bicarbonate, Lactate, Cardiac enzymes, ECG, Urine specific gravity, Serum albumin, Ferritin, CRP).",
      "Step II: Diagnosis, assessment of disease phase and severity (Dengue likely, phase, warning signs, hydration/hemodynamic status, need for admission).",
      "Step III: Management:",
      "Group A (Home): Tolerates oral fluids/urine. No warning signs. Daily review. Oral rehydration solution (ORS), fruit juice. Paracetamol for high fever, tepid sponge. Avoid NSAIDs/aspirin. Hospitalize if no improvement/bleeding.",
      "Group B (In-hospital for observation): Warning signs, coexisting conditions (pregnancy, infancy, elderly, obesity, DM, renal failure, chronic hemolytic diseases), social circumstances. Obtain baseline hematocrit. IV fluids: Isotonic crystalloid (0.9% saline/Ringer's lactate). Start 5-7 mL/kg/hour for 1-2h, then reduce to 3-5 mL/kg/hour for 2-4h, then 2-3 mL/kg/hour. Reassess, repeat hematocrit. Increase rate if worsening vitals/rising hematocrit. Monitor hematocrit, platelet, creatinine, electrolytes, LFT.",
      "Group C (Emergency/Urgent Referral - Severe Dengue): Severe plasma leakage (shock/fluid accumulation/respiratory distress), severe hemorrhages, severe organ impairment. Admit to ICU with blood transfusion. Judicious IV fluid resuscitation (isotonic crystalloid or colloid for hypotensive shock).",
      "Treatment of shock: IV fluid resuscitation (isotonic crystalloid 5-10 mL/kg/hour for 1h). Reassess. If no improvement, increase fluid rate. Vasopressors and inotropes if needed.",
      "Treatment of hemorrhagic complications: Avoid IM injections. Withhold NSAIDs/antiplatelet/anticoagulants. Platelet transfusion if platelet count <10,000/mm³ or bleeding. Plasma for coagulopathy. Packed red cells if Hb <8 gm%. Steroids if hemophagocytosis.",
      "Prevention: Control mosquito vectors (Aedes aegypti). Interruption of human-vector contact. No vaccine/antiviral drug currently available."
    ],
    "Object8": [
      "Dengue hemorrhagic fever (DHF)",
      "Disseminated intravascular coagulation (DIC)",
      "Hemophagocytic lymphohistiocytosis (HLH)",
      "Dengue shock syndrome (DSS)",
      "Polyserositis",
      "Acalculous cholecystitis",
      "Acute pancreatitis",
      "Cerebral hemorrhage or edema",
      "Cranial nerve palsies",
      "Rhabdomyolysis",
      "Hemolytic uremic syndrome",
      "Hepatitis",
      "Encephalitis",
      "Myocarditis",
      "Aseptic meningitis",
      "Guillain-Barré syndrome",
      "Cortical venous thrombosis",
      "Pericarditis",
      "Atrial fibrillation",
      "Heart blocks",
      "Cardiomyopathy",
      "Vertical transmission (if infection within 5 weeks of delivery)"
    ]
  },
  {
    "Object1": "Vitamin A Deficiency",
    "Object2": "Not specified, generally one condition with varying severity.",
    "Object3": [
      "Prolonged dietary deprivation (vegetarians, refugees, chronic alcoholics, toddlers, preschool children)",
      "Sprue",
      "Cystic fibrosis",
      "Pancreatic insufficiency",
      "Duodenal bypass",
      "Chronic diarrhea",
      "Bile duct obstruction",
      "Giardiasis",
      "Cirrhosis"
    ],
    "Object4": [
      "Poor adaptation to darkness (nyctalopia)",
      "Increased susceptibility to infections (e.g., respiratory infections)",
      "Fatigue",
      "Anemia",
      "Diarrhea",
      "Decreased growth rate",
      "Decreased bone development",
      "Infertility"
    ],
    "Object5": [
      "Bitot's spots",
      "Xerophthalmia (dry eye)",
      "Keratomalacia",
      "Keratinization of mucous membranes",
      "Xerosis of skin"
    ],
    "Object6": [
      "Serum retinol level (decreased, normal range 28-86 µg/dL; deficiency <20 µg/dL)",
      "Albumin levels (indirect measure)",
      "Complete blood count (CBC) with differential count (for anemia, infection, sepsis)"
    ],
    "Object7": [
      "For xerophthalmia: 60 mg Vitamin A in oily solution, 3 doses (day 0, day 1, day 14)",
      "For measles: two 60 mg capsules for two consecutive days",
      "Prophylactic Vitamin A: 60 mg every 6 months for high-risk individuals",
      "Vitamin A supplements for malabsorption syndrome"
    ],
    "Object8": [
      "Blindness due to retinal injury"
    ]
  },
  {
    "Object1": "Vitamin A Toxicity (Hypervitaminosis A)",
    "Object2": [
      "Acute (usually due to accidental ingestion by children)",
      "Chronic"
    ],
    "Object3": [
      "Accidental ingestion (children)",
      "Single doses of 300 mg in adults or 100 mg in children (can be harmful)",
      "Vitamin A intakes of >3 mg/day during pregnancy"
    ],
    "Object4": [
      "Headache",
      "Increased intracranial pressure (pseudotumor cerebri)",
      "Nausea (acute)",
      "Vomiting (acute, chronic)",
      "Changes in skin, hair (loss), nails (chronic)",
      "Liver and bone damage (chronic)",
      "Double vision (chronic)",
      "Ataxia (chronic)",
      "Hyperlipidemia (chronic)"
    ],
    "Object5": [
      "Skin changes",
      "Hair loss",
      "Nail changes"
    ],
    "Object6": [
      "Diagnosis is usually clinical"
    ],
    "Object7": [
      "Adjusting the dose almost always leads to complete recovery"
    ],
    "Object8": [
      "Incidence of birth defects in infants (if intake >3 mg/day during pregnancy)"
    ]
  },
  {
    "Object1": "Thiamine (B1) Deficiency (Beriberi)",
    "Object2": [
      "Wet (cardiovascular) beriberi",
      "Infantile beriberi",
      "Shoshin beriberi (acute fulminant cardiovascular beriberi)",
      "Dry beriberi"
    ],
    "Object3": [
      "Lack of thiamine intake (milled rice, raw freshwater fish, raw shellfish, ferns with high thiaminase, foods high in antithiamine factor like tea, coffee, betel nuts)",
      "Alcoholic state",
      "Starvation state",
      "Increased consumption (diets high in carbohydrate or saturated fat, pregnancy and lactation, hyperthyroidism, fever-severe infection, increased physical exercise)",
      "Increased depletion (diarrhea, peritoneal dialysis, hemodialysis, diuretic therapies, hyperemesis gravidarum)",
      "Decreased absorption (chronic intestinal disease, alcoholism, malnutrition, gastric bypass surgery, malabsorption syndrome like celiac and tropical sprue)"
    ],
    "Object4": [
      "Wet: Orthopnea (later stage)",
      "Dry: Bilateral and roughly symmetrical heaviness and stiffness of the legs (early), weakness, numbness, pins and needles (stocking-glove distribution) (later), paresthesias in the toes, burning in the feet (severe at night), muscle cramps in the calves, pains in the legs, plantar dysesthesias"
    ],
    "Object5": [
      "Wet: Vasodilatation, tachycardia, wide pulse pressure, sweating, warm skin, lactic acidosis, congestive heart failure, marked cardiomegaly",
      "Infantile: Edema, aphonia, tachycardia, tachypnea, absent deep tendon reflexes",
      "Dry: Calf muscle tenderness, difficulty rising from a squatting position, decreased vibratory sensation in the toes, lost ankle jerk reflexes"
    ],
    "Object6": [
      "Measurement of thiamine, pyruvate and lactate levels in blood or urine",
      "Erythrocyte thiamine transketolase activity"
    ],
    "Object7": [
      "Complete bed rest",
      "Thiamine 100 mg IM/IV for the first 7 days, then 10 mg/day orally for several months",
      "Severe cases may need 400-600 mg/day",
      "Parenteral thiamine produces marked diuresis (in wet beriberi)"
    ],
    "Object8": [
      "Infantile: Death if prompt treatment is not given",
      "Dry: Degeneration of thalamus, mammillary bodies, and cerebellum"
    ]
  },
  {
    "Object1": "Wernicke's Encephalopathy",
    "Object2": "Acute neuropsychiatric condition",
    "Object3": [
      "As listed for Thiamine (B1) Deficiency",
      "May be precipitated by administration of intravenous glucose solutions to individuals with thiamine deficiency"
    ],
    "Object4": [
      "Global confusion",
      "Impairment in the synthesis of one of the important enzymes of the pentose phosphate pathway (erythrocyte transketolase)",
      "Impaired memory and learning"
    ],
    "Object5": [
      "Ophthalmoplegia (nystagmus, lateral rectus palsy, conjugate gaze palsy)",
      "Ataxia (mainly involves stance and gait, due to polyneuropathy, cerebellar involvement, vestibular dysfunction)",
      "Severe disorientation",
      "Indifference",
      "Inattentiveness",
      "Progresses through stupor and coma to death if untreated"
    ],
    "Object6": [
      "Circulating thiamine concentration",
      "Transketolase activity in red cells (fresh heparinized blood)"
    ],
    "Object7": [
      "Medical emergency, immediate administration of thiamine",
      "Thiamine 500 mg intravenously, infused over 30 minutes, three times daily for two consecutive days",
      "Then 250 mg intravenously or intramuscularly once daily for an additional five days, in combination with other B vitamins",
      "Magnesium is often needed (cofactor for thiamine-dependent enzymes)",
      "Glucose administration should be preceded or accompanied by thiamine 100 mg IV in susceptible individuals"
    ],
    "Object8": [
      "Progress to stupor, coma, and death if untreated"
    ]
  },
  {
    "Object1": "Korsakoff's Psychosis/Syndrome",
    "Object2": "Central nervous system involvement in thiamine deficiency",
    "Object3": [
      "Deficiency of thiamine with involvement of central nervous system",
      "Common in chronic alcoholics",
      "May also be seen with thiamine deficiency due to gastric disorders (e.g., carcinoma, chronic gastritis, or persistent vomiting)"
    ],
    "Object4": [
      "Defect in retentive memory (severe defect in storing new information and learning)",
      "Disturbances of short-term memory",
      "Marked deficits in anterograde and retrograde memory",
      "Apathy",
      "Confabulation (fabricated, distorted or misinterpreted memories without conscious intention to deceive)"
    ],
    "Object5": [
      "Intact sensorium",
      "Relative preservation of long-term memory and other cognitive skills",
      "Attention and social behavior are relatively maintained"
    ],
    "Object6": [],
    "Object7": [
      "Parenteral thiamine (100 mg IM daily for 7 days)"
    ],
    "Object8": []
  },
  {
    "Object1": "Riboflavin (B2) Deficiency",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Cheilitis",
      "Stomatitis",
      "Glossitis",
      "Normochromic anemia",
      "Seborrheic dermatitis"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Niacin Deficiency (Pellagra)",
    "Object2": "Metabolic encephalopathy",
    "Object3": [
      "Inadequate intake (Maize or jowar (sorghum) diet, malnutrition, chronic alcoholism, anorexia nervosa)",
      "Generalized malabsorption (rare)",
      "Drug-induced (prolonged isoniazid therapy, pyrazinamide, 6-mercaptopurine, 5-fluouracil, azathioprine, ethionamide, carbamazepine, phenytoin, and phenobarbitone)",
      "Other disorders (Hartnup's disease, Carcinoid syndrome, Pheochromocytoma – tryptophan metabolism diverted)"
    ],
    "Object4": [
      "Diarrhea (proctitis, malabsorption, anorexia, nausea, glossitis, dysphagia)",
      "Dementia (depression, apathy, sometimes thought disorders, insomnia, anxiety, disorientation, tremor, delusions, encephalopathy)",
      "Burning dysesthesias",
      "Vaginitis",
      "Esophagitis",
      "Vertigo"
    ],
    "Object5": [
      "Casal's necklace or collar rash (hyperpigmented and scaling, sun-exposed areas, forms ring around neck)",
      "Dermatitis (may progress to vesiculation, cracking (ulceration), exudation and secondary infection)",
      "Symmetrical chronic thickening, dryness and pigmentation on dorsal surfaces of the hands",
      "Raw, painful, bright red tongue (glossitis)",
      "Angular stomatitis"
    ],
    "Object6": [],
    "Object7": [
      "Nicotinamide: 100 mg 3 times daily orally (approximately 300 mg daily) with a maintenance dose of 50 mg daily",
      "High-protein diet with adequate nutrients and treatment of malnutrition",
      "Supplementation of other vitamin B complex with iron and folic acid"
    ],
    "Object8": [
      "Death (in severe, untreated cases)"
    ]
  },
  {
    "Object1": "Vitamin C Deficiency (Scurvy)",
    "Object2": [
      "Adult scurvy",
      "Infantile scurvy (Barlow's disease)"
    ],
    "Object3": [
      "Infants fed only on boiled cow's milk during the first year of life",
      "Individuals who do not eat vegetables (elderly, people who live alone, chronic alcoholics)",
      "Pregnant and lactating women (increased utilization)",
      "Those with thyrotoxicosis (increased utilization)",
      "Anorexia nervosa or anorexia from other diseases (such as AIDS or cancer)",
      "Type 1 diabetes (increased requirement)",
      "Patients undergoing peritoneal dialysis and hemodialysis",
      "Diseases of small intestine (such as Crohn's, Whipple, and celiac disease)"
    ],
    "Object4": [
      "Nonspecific malaise, weakness, lethargy, muscle pain (myalgias, due to reduced carnitine production) (early)",
      "Bone pain (more common in children)",
      "Fractures, dislocations, and tenderness of bones (children)",
      "Hemorrhaging (hallmark, can occur in any organ)",
      "Easy bruising, petechiae, ecchymosis, perifollicular hemorrhages",
      "Bleeding into muscles, joints and underneath peritoneum (may be spontaneous)",
      "Delayed/poor wound healing and breakdown of old scars",
      "Anemia (may cause high-output heart failure)",
      "Emotional changes",
      "Shortness of breath",
      "Painful limbs ('pseudoparalysis' in infants)"
    ],
    "Object5": [
      "Hair follicles: common site of cutaneous bleeding",
      "Inflamed spongy gums (gum swelling), friability, bleeding and infection with loosening of teeth",
      "Mucosal petechiae",
      "Roughness, keratosis of hair follicles with 'corkscrew' hair",
      "Perifollicular hemorrhages",
      "Nails: Splinter hemorrhages",
      "Infantile: Subperiosteal hemorrhage into shafts of long bones",
      "Infantile: Scorbutic rosary (enlargement of costochondral junctions, tender)",
      "Infantile: Retrobulbar, subarachnoid and intracerebral hemorrhages"
    ],
    "Object6": [
      "Diagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C deficiency",
      "Response to replacement therapy is the best way for the diagnosis",
      "Serum vitamin C level of <11 μmol/L (0.2 mg/100 mL)",
      "Anemia (may be normochromic, normocytic due to bleeding; megaloblastic due to reduced erythropoiesis; microcytic hypochromic anemia due to impaired iron absorption and impaired heme synthesis)",
      "Capillary fragility test (looking for petechiae on forearm after inflating blood pressure cuff)",
      "Bleeding time, clotting time and Prothrombin time (to rule out other bleeding disorders)",
      "Imaging Studies (loss of trabeculae (ground-glass appearance), thinning of cortex, white line of Frankel (calcified, irregular cartilage at metaphysis), Wimberger ring sign (circular calcification surrounding epiphyseal center of ossification))"
    ],
    "Object7": [
      "Ascorbic acid at 100 mg 3-5 times a day until total of 4 g is reached, then reduce to 100 mg daily",
      "Encourage consumption of foods with high vitamin C (citrus fruits, broccoli, green peppers, tomatoes, potatoes, cabbage)",
      "Recommended dose for adults: 120 mg daily (60 mg daily prevents scurvy)"
    ],
    "Object8": [
      "High-output heart failure (due to anemia in adult scurvy)"
    ]
  },
  {
    "Object1": "Vitamin D Deficiency",
    "Object2": [
      "In children (Rickets)",
      "In adults (Osteomalacia, Osteoporosis)"
    ],
    "Object3": [
      "Impaired cutaneous production due to limited exposure to sunlight",
      "Dietary absence (diets deficient in calcium and vitamin D)",
      "Malabsorption"
    ],
    "Object4": [
      "Rickets (children): Retardation of growth",
      "Osteomalacia (adults): Proximal muscle weakness and bone fragility",
      "Osteoporosis: Decrease of bone mineralization and increased bone fragility",
      "Osteomalacia: Bone pains, muscle weakness, fractures of bones with minor trauma, pain in the hip (antalgic gait), waddling gait, collapse of vertebrae (local pain and deformity)"
    ],
    "Object5": [
      "Rickets (children): Expansion of the growth plate, Craniotabes (skull square/box-like, delayed closure anterior fontanelle, frontal/parietal bossing), Frontal bossing, Delayed eruption primary teeth, enamel defects/caries, Rachitic rosary (overgrowth cartilage/osteoid at costochondral junction), Pigeon breast/chest deformity (pectus carinatum), Harrison's sulcus/groove, Bowing of the legs, Seizures and tetany (hypocalcemia), Hypotonia and delayed motor development, Protuberant abdomen, bone pain, waddling gait, fatigue (may be asymptomatic)",
      "Osteomalacia (adults): Softening of skeleton (kyphosis, coxa vara, pigeon chest, triradiate pelvis with narrow pubic arch)"
    ],
    "Object6": [
      "Rickets/Osteomalacia: Wrist radiograph (splayed lower ends radius/ulna, fuzzy/ill-defined epiphyseal surfaces, widened unossified zone - 'saucer' deformity, bow legs)",
      "Blood: Serum calcium (low), Serum phosphate (low due to secondary hyperparathyroidism), Serum alkaline phosphatase (increased), Plasma 25-hydroxyvitamin D3 level (low)",
      "Osteomalacia: Urinary excretion of calcium (reduced)",
      "Radiological findings (osteomalacia): Bone density (reduced - osteopenia), Epiphyseal growth plate (increased thickness, cupped/hazy at metaphyseal border), Cortical thinning (secondary hyperparathyroidism), Nontraumatic fractures, radiolucent bands (pseudofractures/Looser's zones), Bone scan (normal or discrete foci of increased radionuclide uptake), Bone mineral density by DEXA (reduced at spine, hip, forearm)"
    ],
    "Object7": [
      "Rickets: Treat underlying cause, supplementation diet with calcium and vitamin D, Ergocalciferol (1,50,000-6,00,000 IU orally or IM single dose; or 2000 IU daily)",
      "Osteomalacia: Treat underlying cause",
      "Dietary deficiency: Ergocalciferol or cholecalciferol (1000-4000 IU for 3 months, then lower maintenance doses, with fatty diet)",
      "Malabsorption: 50,000-100,000 IU of vitamin D + calcium supplementation, small doses of calcitriol (0.5-1.0 µg daily)",
      "Chronic renal failure: Calcitriol with weekly monitoring of calcium level"
    ],
    "Object8": [
      "Rickets: Seizures and tetany, respiratory infections and atelectasis (chest deformities)",
      "Osteomalacia: Fractures of bones with minor trauma"
    ]
  },
  {
    "Object1": "Hypervitaminosis D",
    "Object2": "Not specified",
    "Object3": [
      "Excessive intake of Vitamin D"
    ],
    "Object4": [
      "Nausea",
      "Vomiting",
      "Excessive thirst",
      "Polyuria",
      "Severe itching",
      "Joint and muscle pains",
      "Disorientation",
      "Coma"
    ],
    "Object5": [
      "Metastatic calcifications"
    ],
    "Object6": [
      "Diagnosis is usually clinical"
    ],
    "Object7": [
      "Hydration and treatment of hypercalcemia"
    ],
    "Object8": [
      "Hypercalcemia"
    ]
  },
  {
    "Object1": "Iron Poisoning (Acute)",
    "Object2": "Acute",
    "Object3": [
      "When iron level exceed 60 mg/kg elemental iron"
    ],
    "Object4": [
      "Vomiting",
      "Abdominal pain",
      "Bloody diarrhea",
      "Shock",
      "Dehydration",
      "Cyanosis",
      "Acidosis",
      "Coma"
    ],
    "Object5": [
      "Cyanosis"
    ],
    "Object6": [
      "Blood iron levels"
    ],
    "Object7": [
      "Gastric lavage with sodium bicarbonate solution",
      "Desferrioxamine 15 mg/kg/hour IV, increased to maximum dose of 35 mg/kg/hour",
      "Correction of acidosis and shock",
      "Extracorporeal removal with exchange transfusion or continuous venovenous hemofiltration"
    ],
    "Object8": [
      "Hepatotoxicity",
      "Bowel obstruction"
    ]
  },
  {
    "Object1": "Fluorosis",
    "Object2": [
      "Acute ingestion toxicity",
      "Dental fluorosis",
      "Skeletal fluorosis"
    ],
    "Object3": [
      "Fluoride content in water is high (>3 to 5 ppm)",
      "Acute ingestion of >30 mg/kg body weight"
    ],
    "Object4": [
      "Gastrointestinal symptoms (diarrhea, vomiting) (acute ingestion)",
      "Severe pain and stiffness in joints, stiffness in neck and backbone, bow legs (skeletal)",
      "Weakness, anemia and weight loss (skeletal)"
    ],
    "Object5": [
      "Dental fluorosis (mottling of teeth, enamel loses luster, teeth appear chalky white with transverse yellow bands, rough, pigmented, pitted and brittle)",
      "Skeletal fluorosis (sclerosis of bones, calcification of ligaments, interosseous membrane and tendinous insertions, osteoporosis with brittle bones)"
    ],
    "Object6": [
      "Diagnosis is clinical and radiological."
    ],
    "Object7": [
      "Reduce fluoride intake.",
      "No specific treatment for skeletal changes."
    ],
    "Object8": [
      "Renal failure (acute ingestion)",
      "Death (acute ingestion)"
    ]
  },
  {
    "Object1": "Angular Stomatitis",
    "Object2": "Not specified",
    "Object3": [
      "Iron deficiency anemia",
      "Secondary infection of Candida albicans, Staphylococcus",
      "Vitamin deficiency (Riboflavin (B2), Pyridoxine (B6), Niacin deficiency (pellagra))",
      "Herpes labialis at the angle of mouth"
    ],
    "Object4": [
      "Pain"
    ],
    "Object5": [
      "Cracking of the epithelium at the edge of the lips",
      "Erythema, maceration, scaling, and fissuring at the corners of the mouth (most commonly bilateral)"
    ],
    "Object6": [],
    "Object7": [
      "Treat underlying cause."
    ],
    "Object8": []
  },
  {
    "Object1": "Refeeding Syndrome",
    "Object2": "Metabolic disturbances",
    "Object3": [
      "Reinstitution of nutrition to patients who are starved or severely malnourished"
    ],
    "Object4": [
      "Nonspecific (initial)",
      "Rhabdomyolysis",
      "Leucocyte dysfunction",
      "Respiratory and cardiac failure",
      "Hypotension",
      "Arrhythmias",
      "Seizures",
      "Coma",
      "Sudden death"
    ],
    "Object5": [
      "Electrolyte imbalance (cellular uptake of phosphate, potassium, magnesium, leading to significant falls in serum levels)"
    ],
    "Object6": [
      "Monitor fluid balance and clinical status",
      "Monitor PO4, K, Mg levels."
    ],
    "Object7": [
      "Start nutrition at 5-10 kcal/kg/day and increase gradually",
      "Provide thiamine, multivitamins and trace elements",
      "Restore circulatory volume",
      "Replace PO4, K and Mg",
      "Prevent Wernicke's encephalopathy by providing thiamin before starting nutritional support in thiamin-deficient patients"
    ],
    "Object8": [
      "Serious consequences due to electrolyte imbalance (e.g., cardiac arrhythmias)",
      "Wernicke's encephalopathy (if thiamin deficient and refeed with carbohydrates)"
    ]
  },
  {
    "Object1": "Protein-Energy Malnutrition (PEM)",
    "Object2": [
      "Marasmus",
      "Kwashiorkor",
      "Intermediate states of marasmus-kwashiorkor"
    ],
    "Object3": [
      "Marasmus: Inadequate intake of protein and calories",
      "Kwashiorkor: Inadequate protein intake with reasonable caloric (energy) intake",
      "Kwashiorkor: May be precipitated by infections (e.g., measles, malaria, diarrheal illnesses)"
    ],
    "Object4": [
      "Marasmus: No edema, does not appear as apathetic or anorexic as with kwashiorkor, diarrhea is frequent, signs of infection",
      "Kwashiorkor: Child appears apathetic and lethargic with severe anorexia, likely presence of vitamin deficiencies, defects in immunity and secondary infections"
    ],
    "Object5": [
      "Marasmus: Emaciation with apparent muscle wasting and loss of body fat, thin and dry hair",
      "Kwashiorkor: Marked protein deprivation causes hypoalbuminemia leading to generalized or dependent edema, characteristic skin lesions (alternating zones of hyperpigmentation and hypopigmentation, producing 'flaky paint' appearance), hair is dry and sparse, loss of color or alternating bands of pale and darker hair (Flag sign), abdomen is distended due to hepatomegaly (enlarged, fatty liver) and/or ascites"
    ],
    "Object6": [],
    "Object7": [
      "Provision of protein and energy supplements",
      "Control of infection"
    ],
    "Object8": [
      "Secondary infections (Kwashiorkor)"
    ]
  },
  {
    "Object1": "Obesity",
    "Object2": [
      "Central ('abdominal', 'visceral', 'android' or 'apple-shaped')",
      "Generalized ('gynoid' or 'pear-shaped')"
    ],
    "Object3": [
      "Genetic aspects: Polygenic disorder, single-gene (monogenic forms) disorders (mutations in leptin gene, leptin receptor gene, POMC, Mc4R genes), genetic conditions (Prader-Willi and Laurence-Moon-Biedl syndromes)",
      "Environmental contributors: Increased consumption of energy-dense foods, larger food portion size, increased variety of food, increased availability, reduced cost, increased caloric beverages, increased sedentary behavior, reduced activities of daily living and decreased physical activity",
      "Reversible causes: Hypothyroidism, Cushing's syndrome, Insulinoma, Stein-Leventhal syndrome, Hypothalamic damage (e.g., due to trauma, tumor), Drug Induced (Psychiatric and neurologic medications, Steroid hormones, Antidiabetes agents, Antihypertensive agents)"
    ],
    "Object4": [
      "Weight gain"
    ],
    "Object5": [
      "Appearance of morbid obesity (Figure 1.13)"
    ],
    "Object6": [
      "Evaluate severity using BMI (refer Table 1.9)",
      "Exclude underlying cause",
      "Identify complications",
      "Prepare management plan"
    ],
    "Object7": [
      "Goal: Initially reduce weight by about 10% from baseline, reduce weight of about 0.5 to 1 kg/week for 6 months",
      "Lifestyle Modification: Diet (low calorie, low in saturated fats, low density foods, normal protein intake, increased fibers), Regular physical activity (30-45 minutes, 3-5 days/week), Behavioral modification",
      "Drug therapy (Pharmacotherapy):",
      "Centrally acting: Sibutramine (monoamine reuptake inhibitor, reduces appetite, prevents decrease in BMR), Rimonabant (endocannabinoid (CB1) receptor blocker, reduces weight - BANNED)",
      "Peripherally acting: Orlistat (nonsystemic reversible inhibitor of gastric and pancreatic lipases), Olestra (synthesized using sucrose molecule, not absorbed)",
      "Others: Phentermine (amphetamine-like, reduces appetite), Metformin (decreases appetite), Tesofensine (norepinephrine, dopamine, and serotonin reuptake inhibitor), Betahistine (stimulates histamine-1 receptor, reduces craving for fatty foods), Amylin (pramlintide), Liraglutide (GLP-1 agonist), Lorcaserin (serotonin agonist)",
      "Combination therapy: Phentermine-topiramate, Bupropion-naltrexone",
      "Bariatric surgical techniques: Malabsorptive procedures (biliopancreatic diversion, Roux-en-Y gastric bypass), Restrictive procedures (adjustable gastric banding, vertical banded gastroplasty, sleeve gastroplasty), Restrictive plus malabsorptive procedures (duodenal switch, Roux-en-Y gastric bypass, intragastric balloon), Liposuction (removal of fat by suction)"
    ],
    "Object8": [
      "Morbidity and mortality: Increased risk of early death (mainly from diabetes, coronary heart disease, cerebrovascular disease)",
      "Metabolic: Insulin resistance and type 2 diabetes mellitus, Dyslipidemia (Increased triglycerides, increased LDL cholesterol with VLDL, decreased HDL cholesterol, decreased adiponectin), Atherosclerosis, Cardiomyopathy",
      "Endocrine: Reproductive disorders (reduced plasma testosterone and SHBG in men, increased estrogen, gynecomastia; increased androgen, decreased SHBG, PCOS, reduced IVF success in women)",
      "Mechanical: Osteoarthritis, Gout, Venous stasis/varicose veins, Acanthosis nigricans, Increased friability of skin (especially in skinfolds, increasing risk of fungal/yeast infections), Urinary incontinence",
      "Pulmonary: Reduced chest wall compliance, Increased work of breathing, Increased minute ventilation, Decreased functional residual capacity and expiratory reserve volume, Obstructive sleep apnea, Obesity hypoventilation syndrome (Pickwickian syndrome), Asthma (reduced TLC, RV, FRC)",
      "Cancer: Biggest preventable cause of cancer after smoking (esophagus, gallbladder, colon, bile ducts, rectum, breasts, pancreas, endometrium, liver, cervix, prostate, ovaries)",
      "Gastrointestinal: Gastroesophageal reflux disease, Gallstones, Fatty liver (steatosis) and nonalcoholic steatohepatitis (NAFLD), progressing to hepatic cirrhosis and hepatocellular carcinoma",
      "Retinal: Overweight diabetics are twice more likely to develop retinopathy",
      "Psychological: Lack self-confidence, depression, physical and sexual abuse, lack of attention, low education, low self-esteem",
      "Others: Accident proneness, socioeconomic disadvantage, postoperative problems, skin infections (groin and submammary candidiasis; hidradenitis)"
    ]
  },
  {
    "Object1": "Radiation Exposure",
    "Object2": [
      "Ionizing radiation (X-rays, CT, radionuclide scans, radiotherapy)",
      "Non-ionizing radiations (UV rays, visible light, laser, infrared, microwave)"
    ],
    "Object3": [
      "Accidental exposure (industries, nuclear power plants, hospitals)",
      "Deliberate nuclear explosions",
      "Poisoning (e.g., with polonium)"
    ],
    "Object4": [
      "Mild acute radiation sickness: Nausea, vomiting, malaise",
      "CNS syndrome: Nausea, vomiting, disorientation, coma"
    ],
    "Object5": [
      "Hemopoietic system: Lymphocyte depletion (most sensitive indicator of bone marrow injury), aplasia of bone marrow",
      "Gastrointestinal mucosal toxicity: Severe diarrhea, vomiting, dehydration, sepsis",
      "Gonads: Temporary or permanent sterility",
      "Eye: Cataracts",
      "Skin: Radiation dermatitis (burns) (erythema, purpura, blistering, secondary infection), complete loss of body hair (>5 Gy)",
      "Lung: Acute inflammatory reactions, pulmonary fibrosis",
      "CNS syndrome: Cerebral edema",
      "Bone necrosis and lymphatic fibrosis",
      "Thyroid gland damage"
    ],
    "Object6": [],
    "Object7": [
      "Large-dose exposures: Maintain adequate hydration, control of sepsis, management of marrow aplasia, treatment of associated thermal burns",
      "Internal exposure to radioisotopes: Chelating agents (such as Prussian blue for 137-cesium)",
      "White cell colony stimulation and hematopoietic stem cell transplantation for marrow aplasia",
      "Reduction of X-ray exposures whenever possible"
    ],
    "Object8": [
      "Death: Due to aplasia of bone marrow, due to severe diarrhea, vomiting, dehydration and sepsis, due to cerebral edema",
      "Stochastic effects: Carcinogenesis (leukemias, solid tumors), teratogenic effects"
    ]
  },
  {
    "Object1": "Illnesses at High Altitude",
    "Object2": [
      "Acute mountain sickness (AMS)",
      "Chronic mountain sickness (Monge's disease)",
      "High-altitude cerebral edema (HACE)",
      "High-altitude pulmonary edema (HAPE)",
      "High-altitude retinal hemorrhage",
      "Venous thrombosis",
      "Refractory cough"
    ],
    "Object3": [
      "Ascent to altitudes above 2,500 m (develops in healthy individuals)",
      "Sudden ascent to altitudes above 6,000 m (decompression sickness)",
      "AMS: Probably hypoxemia increases cerebral blood flow and intracranial pressure",
      "Chronic mountain sickness: Long exposure to high altitude",
      "Venous thrombosis: Dehydration, inactivity, cold, use of oral contraceptive pill at high altitude",
      "Refractory cough: Breathing dry, cold air and increased mouth breathing"
    ],
    "Object4": [
      "AMS: Headache, fatigue, anorexia, nausea and vomiting, difficulty sleeping or dizziness. Ataxia and peripheral edema may be present.",
      "Chronic mountain sickness: Headache, poor concentration, signs of polycythemia.",
      "HACE: Ataxia and altered consciousness, confusion, disorientation, visual disturbance, lethargy, loss of consciousness (in addition to AMS symptoms).",
      "HAPE: Initially dry cough, exertional dyspnea, extreme fatigue. Later wet cough, may be blood-stained sputum. Tachycardia and tachypnea at rest.",
      "High-altitude retinal hemorrhage: Usually asymptomatic. Visual defects if macula involved.",
      "Venous thrombosis: Symptoms of thrombosis.",
      "Refractory cough: Persistent cough."
    ],
    "Object5": [
      "Chronic mountain sickness: Cyanosis and clubbing of fingers.",
      "HACE: Papilledema and retinal hemorrhages are common. Focal neurological signs may be detected.",
      "HAPE: Crepitations may be heard in both lung fields. Severe hypoxemia, pulmonary hypertension."
    ],
    "Object6": [
      "HAPE: Radiologically show diffuse alveolar edema. Decreased arterial oxygen saturation."
    ],
    "Object7": [
      "AMS: Mild cases: rest and simple analgesics. If symptoms persist: descend. Acetazolamide (carbonic anhydrase inhibitor) as prophylaxis for rapid ascent.",
      "HACE: Improve oxygenation. Descent is needed. Oxygen therapy in portable pressurized bag. Dexamethasone: 8 mg immediately and 4 mg 4 times daily.",
      "HAPE: Reversal of hypoxia with immediate descent and oxygen administration. Nifedipine (20 mg 4 times daily) to reduce pulmonary arterial pressure. Oxygen therapy in a portable pressurized bag if descent delayed.",
      "High-altitude retinal hemorrhage: No specific treatment.",
      "Venous thrombosis: Standard thrombosis treatment."
    ],
    "Object8": [
      "AMS: May progress to cerebral edema.",
      "HACE: Can lead to loss of consciousness.",
      "HAPE: May lead to severe hypoxemia, pulmonary hypertension."
    ]
  },
  {
    "Object1": "Heatstroke",
    "Object2": [
      "Classic/Nonexertional",
      "Exertional"
    ],
    "Object3": [
      "Increased heat production: Hyperthyroidism, exercise, sepsis.",
      "Impaired heat loss (impaired sweating): Drugs (anticholinergics, anti-Parkinsonian, antihistamines, butyrophenones, phenothiazines, tricyclics), abnormal sweat glands (sweat gland injury after heatstroke/barbiturate poisoning, cystic fibrosis, healed thermal burn), salt and water depletion (diuretic induced), hypokalemia",
      "Impaired voluntary mechanisms: Coma, physical disability, mental illness",
      "Impaired delivery of blood to peripheral circulation: Cardiovascular disease, hypokalemia (decreased muscle blood flow), dehydration",
      "Others: Elderly, high ambient temperature and humidity, poor ventilation, lack of acclimatization, obesity, fatigue, diabetes mellitus, malnutrition, alcoholism"
    ],
    "Object4": [
      "May develop without any warning prodrome",
      "Rapid deterioration from apparent baseline health to coma or mentally dull state",
      "CNS: Irritability or irrational behavior (precedes), confusion, aggressive behavior, delirium, convulsions, pupillary abnormalities (rapid progression to coma), decorticate posturing, fecal incontinence, flaccidity or hemiplegia (unusual focal signs), cerebellar signs (ataxia, dysarthria)",
      "Metabolic: Sweating results in low levels of Na, Mg, K (early), hyperkalemia, hypocalcemia (from rhabdomyolysis), metabolic acidosis, respiratory alkalosis",
      "Splanchnic: Ischemic intestinal ulceration (may lead to hemorrhage)",
      "Hematological: Anemia and bleeding"
    ],
    "Object5": [
      "Three cardinal signs: CNS dysfunction, Hyperpyrexia (core temperature >40 °C), Hot dry skin (pink or ashen, may be clammy and sweat)",
      "Cardiovascular: Tachycardia, dysrhythmias, hypotension or normotensive with wide pulse pressure, hyperdynamic-hemodynamic profile, myocardial pump failure",
      "Respiratory: Extreme tachypnea (up to 60/minute), crackles and cyanosis (signs of pulmonary edema)"
    ],
    "Object6": [
      "Temperature recording",
      "Electrolytes, urea, creatinine, calcium",
      "Liver function tests",
      "Creatine phosphokinase (CPK)",
      "Arterial blood gas (ABG)",
      "ECG monitoring",
      "Urine output",
      "Full blood count (FBC), clotting, fibrinogen, FDP, D-dimer (anemia, low/normal platelets, lymphocytosis)",
      "Test urine for myoglobin"
    ],
    "Object7": [
      "First Aid: Remove to cooler location, out of sun. Loosen/remove clothing. Immerse in cool water or wrap in wet sheets and fan. Use cold compresses on head, neck, armpits, groin. Seek medical attention immediately. DO NOT administer fever medication or alcohol rub. DO NOT give anything by mouth until stabilized.",
      "In Hospital Care: Treat in critical care unit. Cooling methods: Evaporative, Immersion, Strategic ice packs, Ice cold IV fluids, Ice packing, Cooling blankets, Gastric lavage, Peritoneal lavage, Cardiac bypass, Endovascular cooling catheters.",
      "Supportive: IV volume replacement. Dobutamine if inotrope needed. Urgent treatment of hyperkalemia. Calcium only if ECG changes of severe hyperkalemia. Small dose of mannitol for rhabdomyolysis. IV lorazepam for shivering.",
      "Avoid: ASA (increases temperature), Paracetamol (increases hepatic dysfunction), Dantrolene (not effective for heatstroke)."
    ],
    "Object8": [
      "Rhabdomyolysis",
      "Acute renal failure (ARF) (common in exertional heatstroke)",
      "Myocardial damage and frank infarction",
      "Cor pulmonale or acute respiratory distress syndrome (ARDS)",
      "Hepatic damage (hepatic necrosis, may cause death)",
      "Disseminated intravascular coagulation (DIC)",
      "Cerebral edema (CNS), permanent neurological deficit",
      "Death"
    ]
  },
  {
    "Object1": "Hypothermia (HT)",
    "Object2": [
      "Mild (32-35°C)",
      "Moderate (28-32°C)",
      "Severe (<28°C)",
      "Death (HT V, 13.7-24°C)"
    ],
    "Object3": [
      "Primary: Overwhelming cold exposure (normal heat production)",
      "Secondary: Hypothyroidism, Addison's disease, malnutrition, burns, hypothalamic abnormalities, sepsis, thiamine deficiency, alcohol intoxication, hypoglycemia"
    ],
    "Object4": [
      "Mild: Normal mental status with shivering, amnesia/dysarthria/ataxia, loss of coordination",
      "Moderate: Altered mental status without shivering, stupor, no shivering",
      "Severe: Unconscious, coma, apparent death"
    ],
    "Object5": [
      "Mild: Tachycardic, tachypneic",
      "Moderate: Bradycardic/atrial fibrillation, decreased BP and RR, pupils dilated",
      "Severe: No corneal or oculocephalic reflexes, decreased BP, ventricular fibrillation (max risk: 22°C), apnea, asystole, areflexia/fixed pupils, flat EEG (19°C)"
    ],
    "Object6": [
      "Blood glucose, renal function tests, electrolytes (including calcium), CPK, TSH, ABG, complete hemogram, X-ray chest, ECG",
      "ECG changes: Prolongation of all ECG intervals (RR, PR, QRS, QT), elevation of the J point (Osborn wave - roughly proportional to degree of hypothermia)"
    ],
    "Object7": [
      "Evaluation and support of airway, breathing, circulation",
      "Prevention of further heat loss (remove from cold, wet clothes, provide blanket)",
      "Initiation of rewarming appropriate to degree of hypothermia:",
      "Passive rewarming: Endogenous heat production (shivering, metabolic rate, TSH, sympathetic activity). Decreasing heat loss.",
      "Active external rewarming: Heating blankets, air blankets, radiant warmers, immersion in hot bath, water bottles/heating pads. Rewarming rates: 1-2.5°C/hour.",
      "Active internal (core) rewarming: Warm IV fluids, warm humid oxygen, peritoneal lavage, gastric/esophageal lavage, bladder/rectal lavage, pleural/mediastinal lavage, microwaves (diathermy), extracorporeal circulatory rewarming.",
      "Treatment of complications (hypotension, arrhythmias, hyperkalemia, hypoglycemia, rhabdomyolysis, bladder atony, bleeding diathesis)"
    ],
    "Object8": [
      "Hypotension during active rewarming",
      "Arrhythmias",
      "Hyperkalemia",
      "Hypoglycemia",
      "Rhabdomyolysis",
      "Bladder atony",
      "Bleeding diathesis"
    ]
  },
  {
    "Object1": "Drowning (Submersion Injuries)",
    "Object2": [
      "Wet drowning (aspiration of water into airways and lungs - 85%)",
      "Dry drowning (severe parasympathetically mediated laryngospasm - 15%)"
    ],
    "Object3": [
      "Drug and alcohol intoxication",
      "Cardiac arrest",
      "Hypoglycemia",
      "Seizure",
      "Suicidal or homicidal behavior",
      "Child abuse"
    ],
    "Object4": [
      "About 70% develop signs within 7 hours",
      "Alertness agitation coma",
      "Cyanosis",
      "Coughing and pink frothy sputum (pulmonary edema)",
      "Tachypnea",
      "Tachycardia",
      "Low-grade fever",
      "Rales, rhonchi and less often wheezes"
    ],
    "Object5": [
      "Cyanosis",
      "Pink frothy sputum",
      "Tachypnea",
      "Tachycardia",
      "Rales, rhonchi, wheezes",
      "Signs of associated trauma to head and neck"
    ],
    "Object6": [
      "Arterial blood gas (ABG) (metabolic and/or respiratory acidosis)"
    ],
    "Object7": [
      "Prehospital care, emergency department (ED) care, inpatient care",
      "Ventilation is most important initial treatment",
      "Standard CPR protocol",
      "Identify spine injuries and other major organ injuries and manage accordingly",
      "Supportive care (renal failure, shock, infections)"
    ],
    "Object8": [
      "Pulmonary: Hypoxemia, noncardiogenic pulmonary edema-acute respiratory distress syndrome (ARDS)",
      "Neurologic: Neuronal damage, cerebral edema, elevations in intracranial pressure, hypoxic ischemic encephalopathy",
      "Cardiovascular: Arrhythmias (secondary to hypothermia and hypoxemia like sinus tachycardia, sinus bradycardia, and atrial fibrillation)",
      "Acid-base and electrolytes: Metabolic and/or respiratory acidosis, life-threatening hypernatremia, hypermagnesemia, hypercalcemia (drowning in concentrated seawater)",
      "Renal: Renal failure due to acute tubular necrosis"
    ]
  },
  {
    "Object1": "Hypopituitarism/Panhypopituitarism",
    "Object2": [
      "Combined deficiency (partial or complete) of any of the anterior pituitary hormones",
      "Panhypopituitarism (deficiency of all anterior pituitary hormones)",
      "Selective or multiple deficiencies of pituitary hormones"
    ],
    "Object3": [
      "Isolated hormone deficiencies",
      "Invasive tumors: Pituitary adenomas, hypothalamic tumors",
      "Injury: Surgery, irradiation, stalk section, head trauma",
      "Infarction: Sheehan's syndrome (post-partum pituitary necrosis), diabetic antepartum necrosis, carotid aneurysm",
      "Inflammatory diseases: Granulomatous disease, autoimmune (lymphocytic) hypophysitis",
      "Infiltrative diseases: Hemochromatosis, amyloidosis",
      "Immunologic: Lymphocytic hypophysitis",
      "Infections: Tuberculosis, syphilis, fungal infection",
      "Idiopathic",
      "Developmental defects (Kallmann syndrome)"
    ],
    "Object4": [
      "Highly variable, depends on underlying cause/lesion and degree of deficiencies",
      "Mild deficiencies may be asymptomatic",
      "GH deficiency: Decreased growth in children, decreased sense of well-being, lethargy, muscle weakness, increased fat mass (adults)",
      "LH and FSH deficiency: Loss of libido, impotence (males), oligomenorrhea or amenorrhea (females), infertility, osteoporosis",
      "ACTH deficiency: Weakness, nausea, vomiting, anorexia, weight loss, fever, hypotension",
      "TSH deficiency: Cold intolerance, dry skin, mental dullness, bradycardia, constipation, weight gain, hoarseness, anemia",
      "PRL deficiency: Failure of lactation (postpartum)"
    ],
    "Object5": [
      "Pituitary tumors (mass effects): Headache, visual impairment, electrolyte alterations, disorders of autonomic nervous system (hypothalamic involvement)",
      "Sequential loss of hormone secretion (GH>FSH>LH>TSH>ACTH)",
      "Longstanding panhypopituitarism: pallor with hairlessness ('alabaster skin')",
      "LH and FSH deficiency: Sparse axillary and pubic hair, fine and wrinkled skin, gynecomastia and decreased frequency of shaving (males)",
      "ACTH deficiency: Normal plasma electrolytes (mineralocorticoid preservation), depigmentation and diminished tanning (versus hyperpigmentation in excess ACTH)",
      "TSH deficiency: Goiter is absent"
    ],
    "Object6": [
      "Demonstration of low levels of trophic pituitary hormones in setting of low levels of target hormones",
      "Low free thyroxine (T4) with low or inappropriately normal TSH (secondary hypothyroidism)",
      "Low early morning cortisol with low or inappropriately normal ACTH",
      "Low testosterone level without elevated gonadotrophins (LH and FSH) (hypogonadotropic hypogonadism)",
      "Low IGF-1 (insulin-like growth factor-1) (GH deficiency)",
      "Provocation tests (for pituitary reserve): Insulin-induced hypoglycemia (gold standard for GH reserve), L-dopa, arginine, GHRH, growth hormone-releasing peptides (GH reserve), TRH reserve (prolactin fails to rise), CRH administration (ACTH release), synthetic ACTH (cosyntropin) (adrenal cortisol release - indirect ACTH reserve), ACTH and cortisol levels during insulin-induced hypoglycemia (ACTH reserve), TSH response to TRH (TSH reserve)",
      "Surgical biopsy of tumor (for type: chromophobe, acidophil, basophil)",
      "Immunohistochemistry (confirm secretory capacity)"
    ],
    "Object7": [
      "Replacement of deficient hormones",
      "Adrenocorticotropic hormone: Hydrocortisone 15-25 mg daily in divided doses. Mineralocorticoid replacement not needed.",
      "LH and FSH (Female): Conjugated estrogen 0.65 mg/day, Micronized estradiol 1 mg/day, Ethinyl estradiol 0.02-0.05 mg/day, Estradiol skin patch 4-8 mg twice weekly, Estradiol plus testosterone",
      "LH and FSH (Male): Testosterone enanthate 200 mg IM every 2-3 weeks, Testosterone skin patch 2.5-5.0 mg/day (can increase to 7.5 mg/day), Testosterone gel 3-6 g daily",
      "Growth hormone: Adults: Somatotropin 0.2-1.0 mg SC daily, Children: Somatotropin 0.02-0.05 mg/kg/day",
      "Thyroid-stimulating hormone: L (levo)-Thyroxine 0.05-0.2 mg daily according to T4 levels",
      "Vasopressin: Intranasal desmopressin-rhinal tube 5-20 µg twice daily, Oral DDAVP (Desmopressin) 300-600 µg daily, usually in divided doses"
    ],
    "Object8": [
      "Mass effects (headache, visual impairment)",
      "Electrolyte alterations",
      "Disorders of autonomic nervous system"
    ]
  },
  {
    "Object1": "Sheehan's Syndrome",
    "Object2": "Potentially life-threatening complication",
    "Object3": [
      "Infarction of pituitary gland following postpartum hemorrhage",
      "Consequent systemic hypotension"
    ],
    "Object4": [
      "Failure to lactate (earliest)",
      "Failure to regain menstruation after delivery",
      "Other symptoms of hypopituitarism (appear over months or years)",
      "Hypotension, hyponatremia, hypothyroidism (acute presentation)"
    ],
    "Object5": [],
    "Object6": [
      "Laboratory findings of hypopituitarism",
      "MRI: hypertrophied pituitary (early), atrophic pituitary and empty sella (later stages)"
    ],
    "Object7": [
      "Control of hemorrhage and volume replacement",
      "Administration of deficient hormones"
    ],
    "Object8": [
      "Coma and death can occur in severe cases"
    ]
  },
  {
    "Object1": "Empty Sella Syndrome",
    "Object2": [
      "Primary congenital weakness of the diaphragm",
      "Secondary (subsequent to infarction of a pituitary adenoma or to surgical or radiation-induced damage to the sellar diaphragm)"
    ],
    "Object3": [
      "Herniation of arachnoid diverticulum through an incomplete diaphragm sellae results in symmetrically ballooned sella, filled with CSF",
      "Infarction of a pituitary adenoma",
      "Surgical or radiation-induced damage to the sellar diaphragm"
    ],
    "Object4": [
      "Usually normal pituitary function",
      "Hypopituitarism may develop insidiously",
      "Chronic headache"
    ],
    "Object5": [
      "Incidental MRI finding"
    ],
    "Object6": [
      "MRI"
    ],
    "Object7": [
      "Treatment of hypopituitarism if developed"
    ],
    "Object8": [
      "Hypopituitarism"
    ]
  },
  {
    "Object1": "Kallmann Syndrome",
    "Object2": "Not specified",
    "Object3": [
      "Defective hypothalamic gonadotropin-releasing hormone synthesis",
      "Olfactory bulb agenesis or hypoplasia"
    ],
    "Object4": [
      "Anosmia or hyposmia",
      "Delayed puberty and hypogonadism (males)",
      "Primary amenorrhea and failure of secondary sexual development (females)"
    ],
    "Object5": [
      "Micropenis (males)"
    ],
    "Object6": [],
    "Object7": [
      "Males: Replacement by human chorionic gonadotropin (hCG) or testosterone for long term",
      "Females: Long-term treatment with estrogen and progestin"
    ],
    "Object8": [
      "Color blindness, optic atrophy, cleft palate, renal abnormalities, cryptorchidism, neurologic abnormalities like synkinesis or mirror movements"
    ]
  },
  {
    "Object1": "Pituitary Apoplexy",
    "Object2": "Rare life-threatening endocrine emergency",
    "Object3": [
      "Sudden hemorrhage into the pituitary gland",
      "Sudden infarction of the gland"
    ],
    "Object4": [
      "Sudden severe headache, double vision, sudden severe visual loss",
      "Cardiovascular collapse, change in consciousness, neck stiffness, sometimes hypoglycemia",
      "Acute life-threatening hypopituitarism"
    ],
    "Object5": [],
    "Object6": [
      "CT/MRI (without contrast): intra-pituitary or intra-adenoma hemorrhage, stalk deviation, compression of normal pituitary tissue, parasellar subarachnoid hemorrhage (severe cases)"
    ],
    "Object7": [
      "Initial: Conservative with careful monitoring of fluid and electrolyte balance, immediate replacement of deficient hormones (corticosteroids). Close monitoring of vision. High dose corticosteroids and supportive treatment.",
      "Surgical decompression: If rapid deterioration in visual acuity and fields (optic chiasm compression)."
    ],
    "Object8": [
      "Acute adrenal insufficiency (due to loss of ACTH)",
      "GnRH deficiency (most common)",
      "TSH deficiency (half of patients)"
    ]
  },
  {
    "Object1": "Pituitary Tumors",
    "Object2": [
      "Microadenomas (<1 cm)",
      "Macroadenomas (>1 cm)",
      "Functional (hormone excess)",
      "Nonfunctional (no hormone excess)",
      "Pituitary incidentalomas (nonfunctional, incidentally detected)"
    ],
    "Object3": [
      "Most common cause of pituitary disease, most are benign pituitary adenomas"
    ],
    "Object4": [
      "Mass effects: Headache (common, non-specific), visual field abnormalities (loss of acuity, optic atrophy, superior temporal quadrantanopsia, temporal hemianopsia), diplopia and strabismus (cranial nerve III, IV, VI palsies), facial numbness, obesity, disturbances of sleep, thirst, appetite, temperature regulation, diabetes insipidus (DI), anosmia (frontal lobe), vomiting, papilledema (raised intracranial tension)",
      "Symptoms due to hormone secretion (e.g. hypopituitarism)"
    ],
    "Object5": [
      "Specific signs depending on hormone excess (Table 2.4)"
    ],
    "Object6": [
      "Plain radiograph of skull: Enlargement of sella tursica, calcification of suprasellar region, erosion of clinoid process, double floor of sella",
      "CT scan with contrast: More sensitive for bony erosions and calcification",
      "MRI (before and after gadolinium): Superior to CT, shows pituitary mass. Detects small microadenomas (incidentalomas).",
      "Visual field plotting (automated computer perimetry or Goldmann perimetry)",
      "Functional assessment (hormonal assays): PRL, IGF-1, 24-hours urinary cortisol, FSH, LH, thyroid function tests"
    ],
    "Object7": [
      "Surgery: Primary mode for tumors warranting intervention (except prolactinomas). Trans-sphenoidal adenomectomy or hypophysectomy (treatment of choice). Open transcranial (transfrontal) route for very large tumors. Endoscopic or endonasal approach.",
      "Medical therapy: Somatostatin analogues (Octreotide, Pasireotide, Lanreotide) and/or dopamine agonists (bromocriptine, cabergoline) (for prolactinomas to reduce PRL levels and tumor size).",
      "Radiation therapy: Adjunctive after surgery, or if surgery impracticable/incomplete, or with medical therapy. External radiotherapy, Yttrium implantation, gamma knife (stereotactic radiosurgery)."
    ],
    "Object8": [
      "Pituitary apoplexy (infarction or bleeding into tumor)"
    ]
  },
  {
    "Object1": "Acromegaly",
    "Object2": [
      "Pituitary gigantism (GH excess prior to epiphyseal closure)",
      "Acromegaly (GH excess after puberty)"
    ],
    "Object3": [
      "Pituitary tumor (somatotrope pituitary adenoma) (most common)",
      "Few adenomas secrete both GH and prolactin",
      "Other tumors of pancreas, lungs, adrenal glands (produce GH or GHRH)"
    ],
    "Object4": [
      "Visual-field defects, cranial nerve palsy, headache",
      "Arthralgias and arthritis",
      "Carpal tunnel syndrome",
      "Acroparesthesia",
      "Proximal myopathy",
      "Sleep disturbances",
      "Sleep apnea (central and obstructive)",
      "Narcolepsy",
      "Menstrual abnormalities",
      "Decreased libido",
      "Impotence",
      "Impaired glucose tolerance, insulin resistance, hyperinsulinemia, diabetes mellitus",
      "Hypertriglyceridemia",
      "Hypercalciuria",
      "Low renin levels",
      "Increased aldosterone levels",
      "Hypothyroidism"
    ],
    "Object5": [
      "Acral enlargement (soft tissue of hands and feet)",
      "Gigantism (children)",
      "Prognathism, jaw malocclusion, widely spaced teeth",
      "Hypertrophy of frontal bones",
      "Osteoporosis",
      "Skin tags, acanthosis nigricans, increased sweat and sebum (moist/oily skin)",
      "Enlargement of lips, nose, tongue",
      "Increased heel pad thickness",
      "Macroglossia",
      "Colonic polyps",
      "Visceromegaly (tongue, thyroid, salivary glands, liver, spleen, kidney, prostate)",
      "Left ventricular hypertrophy, asymmetric septal hypertrophy, cardiomyopathy, hypertension, congestive heart failure, coronary artery disease",
      "Galactorrhea (if prolactin co-secretion)",
      "Goiter"
    ],
    "Object6": [
      "Biochemical: Basal fasting GH levels (>10 ng/mL, normal 1-5 ng/mL)",
      "Glucose tolerance test (failure to suppress GH below 0.3 µg/L, paradoxical rise)",
      "IGF-1 levels (single best test, almost always elevated)",
      "Serum IGFBP-3 concentrations (elevated)",
      "Postprandial plasma glucose (elevated)",
      "Serum insulin (increased in 70%)",
      "Prolactin (mild to moderate elevation in 30%)",
      "Serum phosphorus (elevated)",
      "Radiological: Plain films of skull (sellar enlargement in 90%, thickening of calvarium, enlarged frontal/maxillary sinuses, enlarged jaw)",
      "Radiographs of hand ('arrowhead' tufting of distal phalanges, increased width of intra-articular cartilages, cystic changes of carpal bones)",
      "Radiographs of feet (similar to hand, increased heel pad thickness >22 mm)",
      "X-ray spine (scoliosis, calcification of spinal ligaments)",
      "MRI scan of pituitary (reveals/localizes adenoma. If normal, image abdomen/chest for ectopic source.)",
      "Pituitary function: Partial or complete anterior hypopituitarism",
      "Visual field examination: Defects (e.g., bitemporal hemianopia)"
    ],
    "Object7": [
      "Aim: Achieve mean growth hormone level below 2.5 µg/L or normal IGF-1",
      "Surgery: Trans-sphenoidal surgical removal of pituitary adenoma (first-line therapy)",
      "Medical therapy: For patients without visual impairment risk, unfit for surgery, decline surgery, unlikely controlled by surgery, persistent acromegaly after surgery, or needing pituitary function preservation (fertility).",
      "Somatostatin receptor ligands (SRL): Octreotide, Pasireotide, Lanreotide (inhibit GH/IGF-I)",
      "GH receptor antagonist: Pegvisomant (blocks peripheral IGF-1 action)",
      "Dopamine receptor agonists: Bromocriptine or cabergoline (useful for mildly elevated IGF-1)",
      "Radiotherapy: Second-line after surgery, unfit for surgery, or medical therapy failure. External radiotherapy, Yttrium implantation, stereotactic radiosurgery (gamma knife, cyber knife).",
      "Others: Treatment of associated conditions (diabetes, hypertension, hyperlipidemia)"
    ],
    "Object8": [
      "Reduced survival (heart failure, coronary artery disease, hypertension)",
      "Increased neoplasia (carcinoma colon)",
      "Pituitary apoplexy",
      "Hypopituitarism",
      "Galactorrhea",
      "Multiple endocrine neoplasia type 1 (hyperparathyroidism, pancreatic islet cell tumors)"
    ]
  },
  {
    "Object1": "Prolactinoma",
    "Object2": [
      "Pituitary tumor (most common functional pituitary tumor, most are microadenomas)"
    ],
    "Object3": [
      "Pituitary tumor (lactotroph, somatotroph-lactotroph)",
      "Hypothalamic and stalk disease (craniopharyngiomas, irradiation, granulomas, stalk section/compression)",
      "Primary hypothyroidism",
      "Miscellaneous (cirrhosis, chronic renal failure, seizures)"
    ],
    "Object4": [
      "Hypogonadism, decreased libido, infertility, galactorrhea (spontaneous or expressible) (both sexes)",
      "Females: Amenorrhea, oligomenorrhea, osteoporosis",
      "Males: Loss of libido, impotence, gynecomastia, rarely galactorrhea"
    ],
    "Object5": [
      "Visual field defects and headache (if sufficiently large macroadenoma)"
    ],
    "Object6": [
      "Same as for other pituitary tumors",
      "Serum prolactin: >150 µg/L (nonpregnant, suggests adenoma); >300 µg/L (almost diagnostic of tumor)",
      "Visual fields checked",
      "Primary hypothyroidism excluded",
      "Anterior pituitary function assessed if hypopituitarism or radiological evidence of tumor",
      "MRI or contrast-enhanced CT scan of pituitary (delineates macroprolactinoma, microprolactinoma harder)"
    ],
    "Object7": [
      "Medical: Dopamine agonists (bromocriptine 2.5 mg thrice daily, cabergoline 0.25-0.5 mg twice a week) (reduce prolactin secretion and tumor size)",
      "Surgical: Trans-sphenoidal removal (if dopamine agonists fail, or large invasive tumor)",
      "Radiation: External radiotherapy (rarely necessary)",
      "Asymptomatic patients not requiring pregnancy: estrogens to prevent bone loss, regular monitoring"
    ],
    "Object8": [
      "Estrogen deficiency or testosterone deficiency (long-term effects)",
      "Bone loss"
    ]
  },
  {
    "Object1": "Diabetes Insipidus (DI)",
    "Object2": [
      "Primary deficiency (neurogenic, pituitary, hypothalamic, cranial or central DI)",
      "Secondary deficiency (due to inhibition of ADH secretion - primary polydipsia)",
      "Deficient action of ADH (nephrogenic DI)",
      "Transient DI of pregnancy (gestogenic DI)"
    ],
    "Object3": [
      "Central DI: Idiopathic (30%), neoplastic or infiltrative lesions of hypothalamus (pituitary tumors with suprasellar extension, metastases, leukemia, histiocytosis-X, sarcoidosis, germinomas, pinealomas), pituitary or hypothalamic surgery, severe head injury (skull fracture), ruptured cerebral aneurysms, infections (e.g., encephalitis, TB), autoimmune (associated with thyroiditis), familial (AD and X-linked inheritance), Wolfram syndrome (DIDMOAD syndrome), septo-optic dysplasia",
      "Nephrogenic DI: Primary/congenital or familial (X-linked recessive vasopressin receptor mutation), acquired (chronic pyelonephritis, hypokalemia, hypercalcemia, sickle cell disease, protein deprivation, drug-induced (lithium, demeclocycline, amphotericin B, aminoglycosides, cisplatin, rifampicin, colchicine), amyloidosis, other renal diseases (chronic renal failure, obstructive uropathy, polycystic disease), Sjögren's syndrome)"
    ],
    "Object4": [
      "Polyuria (4-18 L/day), polydipsia (compensatory excessive thirst), nocturia",
      "Change in mentation, insomnia, weight loss"
    ],
    "Object5": [
      "Skin, mucous membranes cool",
      "Hypernatremia, restlessness, agitation, diminished deep tendon reflexes, seizures (if untreated)",
      "Hypotension (shock-like symptoms, but urine output increased)"
    ],
    "Object6": [
      "Careful history, examination",
      "Document presence of polyuria (usually 4-15 L/24h)",
      "Measurement of osmolality of plasma and urine (plasma >295 mOsml/kg, urine 50-150 mOsml/kg in DI; plasma low in primary polydipsia)",
      "Urine: high 24h volumes, clear and low specific gravity, low urine osmolality",
      "Serum sodium: high or high normal (hypernatremia)",
      "MRI of pituitary and hypothalamus",
      "Water deprivation test: Indication: Diagnosis/exclusion of DI, differentiate DI from primary polydipsia. Procedure: 8h fasting, hourly plasma/urine osmolality, urine volume, weight. Administer ADH (vasopressin) if plasma osmolality >300 mOsm/kg or urine osmolality <600 mOsm/kg. Interpretation: Normal response (urine osmolality >600, increases minimally after ADH). Primary polydipsia (urine/plasma osmolality ratio >2 after dehydration). Central DI (plasma osmolality >300, no urine osmolality rise after restriction, urine osmolality increases 50-100% after ADH). Nephrogenic DI (urine osmolality < plasma osmolality, urine osmolality increases <50% after ADH). Alternative: Infuse hypertonic saline, measure ADH response."
    ],
    "Object7": [
      "Goals: Balance fluid intake with output (rapid replacement in acute, slow in chronic to prevent cerebral edema), daily weights, accurate in/out, urine specific gravity and osmolality",
      "Drugs:",
      "Desmopressin (DDAVP): 10 µg intranasal at bedtime, titrated up. Typical maintenance 10-20 µg once/twice daily. Oral DDAVP 300-600 µg daily.",
      "Chlorpropamide: Increases renal responsiveness to vasopressin (risk of hypoglycemia).",
      "Carbamazepine: Enhances ADH release and increases collecting duct sensitivity.",
      "Clofibrate: Stimulates residual ADH production.",
      "Thiazide diuretics (e.g., bendrofluazide): Only effective drugs for nephrogenic DI.",
      "NSAIDs: Inhibit renal prostaglandin synthesis, decrease GFR.",
      "Nephrogenic DI: Adequate fluids, calorie and low sodium diet. Correct underlying cause. Diuretics, high dose DDAVP, indomethacin, chlorpropamide, clofibrate, carbamazepine."
    ],
    "Object8": [
      "Hypernatremia, dehydration and its neurological sequelae",
      "Growth retardation",
      "Hydronephrosis (due to excessive urine output)"
    ]
  },
  {
    "Object1": "Thyrotoxicosis (Hyperthyroidism)",
    "Object2": [
      "Primary hyperthyroidism",
      "Thyrotoxicosis without hyperthyroidism",
      "Secondary hyperthyroidism"
    ],
    "Object3": [
      "Primary hyperthyroidism: Graves disease, Toxic multinodular goiter, Toxic adenoma (Plummer's disease), Iodine excess (Jod Basedow), Activating mutation of TSH receptor",
      "Thyrotoxicosis without hyperthyroidism: Subacute thyroiditis, Hashitoxicosis, Amiodarone induced (Type I: pre-existing Graves/MNG; Type II: direct cytotoxicity), Radiation induced, Thyrotoxicosis factitia, Struma ovarii, Infarction of thyroid gland",
      "Secondary hyperthyroidism: TSH secreting pituitary adenoma, Human chorionic gonadotropin-mediated hyperthyroidism (hyperemesis gravidarum, trophoblastic disease), Gestational thyrotoxicosis",
      "Graves' disease: Autoimmune disorder with autoantibodies (TSI or TSH-receptor antibodies - IgG type, stimulate hormone production/enlargement). Ophthalmopathy/dermatopathy due to immunologically mediated activation of fibroblasts. Genetic factors (HLA-DR3). Triggered by viral/bacterial infections (molecular mimicry)."
    ],
    "Object4": [
      "Weight loss, increased appetite, vomiting, increased frequency of stool, diarrhea",
      "Exertional dyspnea, palpitations, angina",
      "Nervousness, irritability, psychosis, emotional lability",
      "Pruritus",
      "Menstrual disturbances (amenorrhea or oligomenorrhea), repeated abortions, infertility, loss of libido, impotence",
      "Heat intolerance, fatigue, apathy, thirst",
      "Diminution of visual acuity, diplopia (ophthalmopathy)",
      "Shortness of breath (elderly)",
      "Behavioral problems (hyperactivity) (children)",
      "Non-specific symptoms (elderly: anorexia, apathy, fatigue, weight loss)"
    ],
    "Object5": [
      "Diffuse or nodular enlargement of thyroid, warmth and bruit (increased vascularity)",
      "Sinus tachycardia, atrial fibrillation, wide pulse pressure, cardiac failure, cardiomyopathy, ‘scratchy’ midsystolic murmur (Means-Lerman scratch)",
      "Fine tremors, hyperreflexia, proximal myopathy, bulbar myopathy, ill-sustained clonus",
      "Soft, warm and moist skin. Increased sweating, palmar erythema, spider naevi, onycholysis, pretibial myxedema (Graves’), pigmentation, alopecia, clubbing (thyroid acropachy)",
      "Gynecomastia",
      "Eyes (Ophthalmopathy): Lid lag, exophthalmos, proptosis, extraocular diplopia, exposure keratitis, lagophthalmos (Graves’ disease). Dalrymple sign (rim of sclera all around cornea), Rosenbach's sign (fine tremor of upper eyelids), Joffroy's sign (lack of forehead wrinkling on upward gaze), Möblus sign (lack of convergence), Von Graefe's sign (lid lag on downward gaze), Stellwag's sign (staring look with infrequent blinking), Vigouroux sign (eyelid fullness), Grove sign (resistance to pulling down retracted upper lid), Ballet sign (restriction of extraocular muscles), Kocher sign (staring look), Naffziger's sign (eyeball seen beyond superior orbital margin).",
      "Pretibial Myxedema (Dermopathy): Scaly thickening and induration (raised pinkish or purplish plaques) of dermis on shins, dorsum of foot (rarely face/arms). Peau d'orange appearance with coarse hair.",
      "Subclinical Thyrotoxicosis: Atrial fibrillation (in >60 years), bone loss (postmenopausal women).",
      "Younger patients: Excessive height or excessive growth rate."
    ],
    "Object6": [
      "TSH levels: Very low or undetectable (primary thyrotoxicosis). Primary test, normal level excludes thyrotoxicosis. (Normal range 0.4-5.0 mU/L).",
      "Serum free T3 (fT3) and free T4 (fT4): Elevated (primary thyrotoxicosis). fT4 normal, fT3 elevated in T3-thyrotoxicosis. fT4 elevated, fT3 normal on T4 therapy.",
      "Total serum thyroxine (tT4): Increased in hyperthyroidism, pregnancy, estrogen therapy, tamoxifen use, congenital anomaly. Decreased in hypothyroidism, nephrotic syndrome, androgen therapy, liver failure, drugs (salicylate, sulfonylureas, phenytoin).",
      "Total serum triiodothyronine (tT3): Increased in hyperthyroidism, T3-thyrotoxicosis.",
      "Reverse T3 (rT3): Raised in high TBG. Normal in hypothyroid on thyroxine.",
      "Thyroglobulin (Tg): Increased in well-differentiated thyroid carcinoma, hyperthyroidism.",
      "Radioactive iodine uptake (RAIU) or technetium: Increased in hyperthyroidism (Graves' disease, toxic multinodular goiter, adenoma, early thyroiditis). Decreased in hypothyroidism, late thyroiditis. Contraindicated in children/pregnancy/lactation.",
      "Ultrasound of thyroid gland: Look for nodularity, vascularity, lymph nodes, for guided FNAC.",
      "Thyroid autoantibody tests: Antithyroid peroxidase (TPO) antibody (TPOAb) (tissue destructive process), Antithyroglobulin (Tg) antibody, TSH receptor (TR) antibody (TRAb) (formerly TSI/LATS, driving force for thyrotoxicosis).",
      "Calcitonin: Increased in medullary carcinoma of thyroid.",
      "Fine-needle aspiration cytology/excision biopsy: Helps in diagnosis.",
      "Other: Minor LFT abnormalities, mild hypercalcemia, glycosuria."
    ],
    "Object7": [
      "Antithyroid drugs (ATD): Primary therapy in pregnancy, children/adolescents, severe Graves’ with eye changes.",
      "Thionamides (propylthiouracil, carbimazole, methimazole): Inhibit TPO, prevent iodine binding. Propylthiouracil (100-600 mg/day) inhibits peripheral T4-T3 conversion (preferred in pregnancy/severe thyrotoxicosis). Carbimazole (5-15 mg thrice daily, then 10 mg thrice daily, maintenance 5-20 mg daily for 18-24 months). Side effects: Rashes, urticaria, fever, arthralgia, agranulocytosis, hepatotoxicity, aplasia cutis.",
      "Potassium perchlorate: Reduces iodine uptake (temporary, iodine-induced thyrotoxicosis).",
      "Potassium iodide: Decreases T3/T4 synthesis and release (preparation for thyroidectomy, thyrotoxic crisis).",
      "Beta adrenergic blockers: Non-selective, for immediate symptom control (anxiety, palpitation, tremors). Propranolol (20-40 mg 6 hourly).",
      "Lithium (rarely used)",
      "Surgical treatment: Subtotal thyroidectomy (treatment of choice for MNG with severe hyperthyroidism in children, pregnant women intolerant to ATD, large goiters with severe ophthalmopathy/pressure, patients needing quick normalization).",
      "Radioactive iodine (RAI): 131I (concentrated in thyroid, destroys cells). Indications: >40 years, young parents with short lifespan, young individuals sterilized. Contraindications: Children, pregnant/lactating women, severe ophthalmopathy, chronic smokers.",
      "Thyrotoxicosis factitia: Stop thyroxine, give symptom relief drugs.",
      "Amiodarone-induced hyperthyroidism (AIT): Type I: ATD. Type II: corticosteroids."
    ],
    "Object8": [
      "Cardiac: Atrial fibrillation, cardiac failure, cardiomyopathy, angina.",
      "Ophthalmopathy: Corneal ulcers, visual field defects, papilledema.",
      "Dermatopathy: Pretibial myxedema.",
      "Thyroid Storm/Crisis: Rare, life-threatening medical emergency (10% mortality).",
      "Others: Hypokalemic periodic paralysis, Mitral valve prolapse, Secondary cancers (RAI therapy)"
    ]
  },
  {
    "Object1": "Hyperthyroid Crisis/Thyrotoxic Crisis/Thyroid Storm",
    "Object2": "Life-threatening medical emergency",
    "Object3": [
      "Severe infections in previously undetected or inadequately treated hyperthyroidism/thyrotoxicosis",
      "Following surgery (subtotal thyroidectomy in ill-prepared patient, or other surgery in undetected hyperthyroidism)",
      "Following radiotherapy (131I therapy, due to transient rise in serum thyroid hormone)",
      "Other precipitating factors: Cerebrovascular accidents, diabetic ketoacidosis, acute coronary syndrome, iodine contrast agent use, sudden withdrawal of antithyroid medications, stress, major trauma"
    ],
    "Object4": [
      "Marked hypermetabolism and excessive adrenergic response",
      "Hyperpyrexia (104-106°F) with flushing and sweating",
      "Marked tachycardia, often with atrial fibrillation",
      "Heart failure",
      "Marked agitation, restlessness, delirium, coma",
      "Nausea, vomiting, diarrhea, jaundice"
    ],
    "Object5": [
      "Flushing and sweating",
      "Tachycardia (with AF)",
      "High pulse pressure",
      "Heart failure and shock (fatal outcome)"
    ],
    "Object6": [
      "Clinical diagnosis with supporting lab if available."
    ],
    "Object7": [
      "Rehydration and antibiotics (if infection)",
      "Control hyperthermia: External cooling (DO NOT administer salicylates, converts T4 to T3).",
      "Propranolol: Oral (80 mg 4 times daily) or IV (1-5 mg 4 times daily) (blocks peripheral T4-T3 conversion).",
      "Propylthiouracil (800-1200 mg orally every 4 hours) or carbimazole (15-30 mg stat, then 15 mg TID) (inhibit new thyroid hormone synthesis). Carbimazole rectally in unconscious/uncooperative.",
      "Lugol's iodine: 10 drops TID (1 hour after PTU/carbimazole).",
      "Sodium iopodate: 500 mg/day orally (inhibits hormone release and T4-T3 conversion).",
      "Benzodiazepines: For agitation.",
      "Corticosteroids: IV hydrocortisone 100-200 mg every 6 hours (suppresses manifestations).",
      "Bile acid sequestrants (cholestyramine 4g orally 4 times daily): Decreases thyroid hormone levels by interfering with enterohepatic circulation.",
      "Digoxin: To control cardiac failure and atrial fibrillation (AF)."
    ],
    "Object8": [
      "Heart failure and shock (fatal outcome)"
    ]
  },
  {
    "Object1": "Hypothyroidism",
    "Object2": [
      "Primary hypothyroidism (intrinsic disorder of thyroid gland)",
      "Secondary hypothyroidism (failure of TSH production due to pituitary/hypothalamic disease)"
    ],
    "Object3": [
      "Primary: Hashimoto's thyroiditis (most common), Radioactive iodine therapy for Graves' disease, Subtotal thyroidectomy for Graves' disease, nodular goiter, or thyroid cancer, Excessive iodide intake (radiocontrast dyes), Subacute thyroiditis (usually transient), Postpartum thyroiditis, Iodide deficiency, Drugs (lithium, interferon-alfa, amiodarone), Dyshormonogenesis-Pendred syndrome",
      "Secondary: Hypopituitarism (pituitary adenoma, pituitary ablative therapy, or pituitary destruction)",
      "Tertiary: Hypothalamic dysfunction (rare)",
      "Rarely peripheral resistance to action of thyroid hormone"
    ],
    "Object4": [
      "Lethargy, somnolence, weight gain, cold intolerance, hoarse voice",
      "Reduced appetite, constipation",
      "Angina, bradycardia",
      "Aches and pains, muscle stiffness, depression, psychosis",
      "Menorrhagia, infertility, impotence"
    ],
    "Object5": [
      "Pallor",
      "Goiter (primary, absent in secondary)",
      "Myxedema (non-pitting edema of skin of hands, feet, eyelids - due to mucopolysaccharide accumulation)",
      "Myxedema facies (periorbital puffiness, scanty eyebrows, facial pallor/lemon-yellow tint, purplish lips, malar flush)",
      "Dry flaky skin and hair, alopecia, vitiligo, carotenemia, erythema abigne, xanthelasmas, madarosis (thinning of lateral 1/3 of eyebrows)",
      "Delayed relaxation of tendon reflexes (Woltman's sign)",
      "Carpal tunnel syndrome",
      "Cerebellar ataxia, deafness, myotonia, proximal myopathy, pseudohypertrophy of muscles, Hashimoto encephalopathy",
      "Pericardial effusion, pleural effusion",
      "OSA (obstructive sleep apnea)",
      "Hyponatremia"
    ],
    "Object6": [
      "Serum TSH: Investigation of choice. High level confirms primary hypothyroidism.",
      "Serum T4 levels: Low level confirms hypothyroid state.",
      "Thyroid and other organ-specific antibodies may be found.",
      "Increased serum aspartate transferase, lactate dehydrogenase (LDH), creatine kinase (CK) (with myopathy).",
      "Hypercholesterolemia and hypertriglyceridemia.",
      "Hyponatremia (due to increased ADH and impaired free water clearance).",
      "Anemia: Usually normochromic and normocytic.",
      "ECG: Sinus bradycardia, low voltage QRS, ST segment and T wave abnormalities.",
      "Chest radiograph: Enlarged cardiac shadow."
    ],
    "Object7": [
      "Levothyroxine sodium (thyroxine, T4) for life (1.6-1.8 µg/kg/day).",
      "Starting dose: <50 years: 1.0 µg/kg/day. >50 years: <50 µg/day (increase by 25 µg at 6-8 week intervals). Heart disease: 12.5-25 µg/day (increase slowly).",
      "Administration: Empty stomach with water, 1 hour before breakfast.",
      "Dosage adjustments: Age, severity/duration, weight, malabsorption, concomitant drugs, pregnancy (25-50% increase), cardiac disease (low dose/alternate day).",
      "Monitoring: Normalize TSH level (avoid complete suppression), restore T4. Assessed clinically and by TFTs after 6 weeks.",
      "Hashimoto's thyroiditis: Levothyroxine (150-200 μg/day) (may shrink goiter)."
    ],
    "Object8": [
      "Untreated: Mental retardation (infancy), myxedema.",
      "Thyroxine therapy: Angina or worsening angina (ischemic heart disease patients).",
      "Hashimoto's: Increased risk for thyroid lymphoma."
    ]
  },
  {
    "Object1": "Myxedema Coma",
    "Object2": "Very rare, life-threatening medical emergency",
    "Object3": [
      "Long-standing, severe untreated hypothyroidism (or undiagnosed) in elderly patient where adaptive mechanisms fail.",
      "Precipitating factors: Infections, drugs (amiodarone, B-blockers, diuretics, anesthetic agents, barbiturates, lithium, narcotics, phenothiazines), cardiac failure, hypoxia, hyponatremia, hypercapnia."
    ],
    "Object4": [
      "Hypothermia (body temperature as low as 25°C)",
      "Depressed level of consciousness, convulsions, coma",
      "Severe cardiac failure, hypoventilation",
      "Metabolic abnormalities (hypoglycemia, hyponatremia)"
    ],
    "Object5": [
      "Cool pale skin",
      "Absence of mild diastolic hypertension",
      "Reduced ECG voltage",
      "Respiratory acidosis, hypoxia, hypercapnia"
    ],
    "Object6": [
      "Serum free T4: low",
      "Serum TSH: usually high, sometimes slightly elevated",
      "Serum creatine phosphokinase: mostly markedly raised",
      "Hypoglycemia and hyponatremia, increased CO2, decreased WBC count and Hct",
      "Blood gases: respiratory acidosis, hypoxia, hypercapnia"
    ],
    "Object7": [
      "Treatment started before biochemical confirmation.",
      "Hypothyroidism: Large initial IV dose of 300-500 µg T4; add T3 if no response in 48h.",
      "Hypocortisolemia: IV hydrocortisone 200-400 mg daily.",
      "Hypoventilation: Intubation and mechanical ventilation.",
      "Hypothermia: Gentle warming with blankets, no active rewarming.",
      "Hyponatremia: Mild fluid restriction, 3% saline.",
      "Hypotension: Cautious volume expansion with crystalloid or whole blood.",
      "Hypoglycemia: Glucose administration.",
      "Precipitating event: Identification and elimination (liberal antibiotics).",
      "Monitor cardiac output and pressures. Cautious IV fluids, high-flow oxygen, assisted ventilation."
    ],
    "Object8": [
      "Coma, death",
      "Severe cardiac failure",
      "Pericardial effusions",
      "Hypoventilation"
    ]
  },
  {
    "Object1": "Myxedema Madness",
    "Object2": "Neuropsychiatric manifestation",
    "Object3": [
      "Severe hypothyroidism (rarely in elderly patients)"
    ],
    "Object4": [
      "Depression",
      "Dementia or psychotic symptoms (delusions, hallucinations)",
      "Develops shortly after starting T4 replacement (rarely)"
    ],
    "Object5": [
      "Hypothermia"
    ],
    "Object6": [],
    "Object7": [
      "Treatment of hypothyroidism."
    ],
    "Object8": []
  },
  {
    "Object1": "Sick Euthyroid Syndrome/Nonthyroid Illness State (NTIS)",
    "Object2": [
      "Nonthyroidal illness syndrome",
      "low-T3 syndrome"
    ],
    "Object3": [
      "Systemic illness, surgery, or fasting (not primary thyroid/pituitary dysfunction)",
      "Malnutrition, HIV, anorexia nervosa, trauma, myocardial infarction, chronic renal failure, diabetic ketoacidosis, cirrhosis, sepsis"
    ],
    "Object4": [],
    "Object5": [
      "Changes in thyroid function (influences H-P-T axis, hormone transport/metabolism)"
    ],
    "Object6": [
      "Serum levels of free T4 and triiodothyronine (within normal)",
      "Serum TSH (usually normal, can be influenced)"
    ],
    "Object7": [
      "Treatment with thyroxine is not recommended."
    ],
    "Object8": []
  },
  {
    "Object1": "Subclinical Hypothyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Iatrogenic",
      "Hashimoto's thyroiditis",
      "Postpartum thyroiditis",
      "Medications (amiodarone, lithium, interferon, sorafenib)",
      "Partial thyroidectomy",
      "Head and neck radiation"
    ],
    "Object4": [
      "Symptoms or signs of hypothyroidism (may be present)"
    ],
    "Object5": [
      "Increased serum TSH in presence of normal serum FT4 and T3 concentration"
    ],
    "Object6": [
      "Serum TSH",
      "Serum FT4 and T3",
      "Antibodies"
    ],
    "Object7": [
      "Levothyroxine for: pregnant or planning pregnancy, serum TSH > 10.0 mU/L, symptomatic, age <70 years, TSH >7.0 mU/L with positive antibodies, goiter, high vascular risk (ischemic heart disease, diabetes, dyslipidemia)."
    ],
    "Object8": [
      "Progression to overt hypothyroidism (2-5% yearly)",
      "Risk of CV disease (diastolic dysfunction, hypertension, increased LDL-C, hsCRP, coagulation alterations, endothelial dysfunction)",
      "Infertility",
      "Neuropsychiatric manifestations"
    ]
  },
  {
    "Object1": "Subclinical Hyperthyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Iatrogenic",
      "Autonomous nodules (solitary and in MNG)",
      "Graves' disease",
      "Thyroiditis",
      "Graves' disease in remission",
      "High hCG"
    ],
    "Object4": [],
    "Object5": [
      "Serum levels of free T4 and triiodothyronine are within normal. Serum TSH levels is subnormal."
    ],
    "Object6": [
      "Serum TSH",
      "Serum FT4 and FT3"
    ],
    "Object7": [
      "No evidence to treat with antithyroid drugs."
    ],
    "Object8": [
      "Functional cardiac effects (resting tachycardia, atrial fibrillation, LV hypertrophy, increased LV mass index, increased cardiac workload, diastolic dysfunction, increased systolic function at rest, impaired systolic response to exercise)",
      "Noncardiac effects (osteoporosis, decreased BMD, increased fracture risk, muscle weakness, dementia)"
    ]
  },
  {
    "Object1": "Thyroiditis",
    "Object2": [
      "Acute",
      "Subacute",
      "Chronic"
    ],
    "Object3": [
      "Acute: Bacterial infections (Staphylococcus, Streptococcus, Enterobacter), Fungal infections (Aspergillus, Candida, Histoplasma), Radiation, Drugs (Amiodarone)",
      "Subacute: Viral or granulomatous (de Quervain's) thyroiditis, Silent thyroiditis (includes post-partum thyroiditis), Mycobacterial infection, Drug induced (Interferon, Amiodarone)",
      "Chronic: Autoimmune (Hashimoto's thyroiditis, Riedel's thyroiditis), Parasitic thyroiditis (Echinococcosis, Strongyloidiasis, Cysticercosis), Traumatic (Palpation thyroiditis)"
    ],
    "Object4": [],
    "Object5": [],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Subacute Thyroiditis (De Quervain's Thyroiditis/Granulomatous Thyroiditis)",
    "Object2": "Spontaneously remitting, painful, subacute inflammatory disease",
    "Object3": [
      "Often preceded by a viral infection (e.g., Coxsackie, mumps, adenovirus) of upper respiratory tract"
    ],
    "Object4": [
      "Prodromal viral symptoms (fever, malaise, pain in neck with tachycardia, local thyroid tenderness)",
      "Anterior neck pain (abrupt onset, sometimes unilateral, may radiate to ear, mandible, occiput)",
      "Pain may shift to contralateral lobe (creeping thyroiditis)",
      "Pain aggravated by moving head, swallowing, coughing"
    ],
    "Object5": [
      "Enlarged and tender thyroid gland",
      "Initially hyperthyroidism, then hypothyroidism, then full recovery (4-6 months)"
    ],
    "Object6": [
      "Erythrocyte sedimentation rate (ESR): Elevated (>55 mm/h)",
      "Leukocyte counts: Normal or slightly elevated",
      "Serum IL-6 and Tg concentrations: Increased during thyrotoxic phase",
      "Thyroid radionuclide uptake: Reduced or absent",
      "Thyroid antibodies: Transiently detectable at low titers"
    ],
    "Object7": [
      "Mild cases: Salicylates or non-steroidal anti-inflammatory drugs (NSAIDs)",
      "Severe cases: Corticosteroids (prednisone 40-60 mg/day)",
      "Thyrotoxicosis symptoms: Beta-adrenergic blocking agents (propranolol 20-40 mg 3-4 times daily)",
      "Hypothyroidism: L-T4 replacement needed"
    ],
    "Object8": [
      "Hypothyroidism may persist in about 5% of cases."
    ]
  },
  {
    "Object1": "Hashimoto's Thyroiditis (Autoimmune Thyroiditis)",
    "Object2": "Autoimmune condition",
    "Object3": [
      "Autoimmune disorder with destructive lymphoid infiltration of thyroid"
    ],
    "Object4": [
      "Most patients asymptomatic",
      "Feeling of tightness or fullness in the neck (some)",
      "Neck pain and tenderness (rare)"
    ],
    "Object5": [
      "Diffuse enlargement of thyroid with firm or rubbery consistency",
      "Hypothyroidism (commonest cause of goitrous hypothyroidism)",
      "Hashitoxicosis (acute phase)",
      "Associated with other autoimmune disorders (Type 1 DM, pernicious anemia, Addison's disease)"
    ],
    "Object6": [
      "Thyroid function tests: Features of hypothyroidism",
      "Antithyroid peroxidase (TPO) antibody (TPOAb) in 95% patients",
      "Antithyroglobulin (Tg) antibody in 60-80% patients",
      "Antinuclear factor (ANF) (in <20 years)",
      "Ultrasound of thyroid: Reduced echogenicity",
      "Fine-needle aspiration cytology (FNAC) of thyroid"
    ],
    "Object7": [
      "Levothyroxine/thyroxine (150-200 μg/day) (for hypothyroidism, may shrink goiter). Dose sufficient to suppress serum TSH to low but detectable levels."
    ],
    "Object8": [
      "Increased risk for thyroid lymphoma (rare)."
    ]
  },
  {
    "Object1": "Riedel's Thyroiditis (Sclerosing Thyroiditis/Ligneous Thyroiditis/Invasive Fibrous Thyroiditis)",
    "Object2": "Rare, chronic inflammatory disorder of unknown etiology",
    "Object3": [
      "Unknown, associated with dense fibrosis of thyroid and adjacent/extracervical tissues (fibrous mediastinitis, retroperitoneal fibrosis, retro-orbital fibrosis, sclerosing cholangitis, pancreatitis)."
    ],
    "Object4": [
      "Painless, progressively increasing anterior neck mass (long history)",
      "Dysphagia, cough, hoarseness, stridor, attacks of suffocation (pressure symptoms)",
      "Most patients are euthyroid"
    ],
    "Object5": [
      "Stony-hard or woody thyroid mass (varies in size, fixed to surrounding structures, may involve one or both lobes)"
    ],
    "Object6": [
      "Thyroid antibodies: May be found in ~45%.",
      "Serum calcium: May be low (parathyroid invasion).",
      "Open biopsy (to differentiate from thyroid carcinoma or lymphoma, FNAB difficult to interpret)."
    ],
    "Object7": [
      "Surgical treatment: To relieve pressure on trachea and establish diagnosis.",
      "Corticosteroids: Little or no value."
    ],
    "Object8": [
      "Pressure on trachea"
    ]
  },
  {
    "Object1": "Simple (Nontoxic) Goiter",
    "Object2": [
      "Diffuse nontoxic (simple) goiter (simple hyperplastic (colloid) goiter, endemic goiter, sporadic goiter)"
    ],
    "Object3": [
      "Simple hyperplastic goiter: Physiological (pregnancy, puberty), iodine deficiency",
      "Endemic goiter: Deficiency of iodine (low iodine in soil, water, food), Goitrogens (vegetables from Brassicaceae family, Cassava root)",
      "Sporadic goiter: In most cases, cause is not known"
    ],
    "Object4": [
      "Endemic goiter: Later develop hypothyroidism, hypothyroidism and mental retardation (children/adults)"
    ],
    "Object5": [
      "Diffuse enlargement of the thyroid without any nodularity",
      "Large, smooth firm, non-tender goiter",
      "Euthyroid state (initial)",
      "Cretinism (iodine deficiency): Stunting, deaf-mutism, malformed limbs, spastic motor disorders, goiter, mental impairment"
    ],
    "Object6": [
      "Serum inorganic iodide: Reduced",
      "Urinary iodide excretion: Low < 50 µg/day",
      "Serum T4: Normal",
      "Serum T3: May be normal or raised",
      "TSH: May be normal or mildly raised"
    ],
    "Object7": [
      "Early stages: Replacement with iodine.",
      "Later: May need suppressive therapy with T4."
    ],
    "Object8": [
      "Hypothyroidism",
      "Cretinism",
      "Malignancy (risk factors: solitary thyroid nodules in >60 or <30, neck/face irradiation, pain/pressure, male sex, large nodules, nodule growth)"
    ]
  },
  {
    "Object1": "Hyperparathyroidism",
    "Object2": [
      "Primary",
      "Secondary",
      "Tertiary"
    ],
    "Object3": [
      "Primary: Autonomous secretion of PTH by parathyroid (single adenoma - 90%, multiple adenomata, nodular hyperplasia, carcinoma of parathyroid)",
      "Secondary: Parathyroid hyperplasia with increased PTH secretion to compensate for prolonged hypocalcemia (chronic renal failure, malabsorption, osteomalacia, rickets)",
      "Tertiary: Adenoma formation and autonomous PTH secretion (occurring in cases of secondary hyperparathyroidism, post renal transplantation)"
    ],
    "Object4": [
      "Classical symptoms: 'moans, bones, stones, abdominal groans'",
      "Moans (psychiatric): lethargy, fatigue, depression, memory loss, psychoses, neuroses, paranoia, confusion, stupor, coma",
      "Stones (renal): renal stones, uremia, polydipsia, polyuria",
      "Groans (abdominal): constipation, nausea, vomiting, peptic ulcers, indigestion, pancreatitis",
      "Nonspecific: Anorexia, lassitude, tiredness, generalized aches, weight loss, pain, drowsiness, poor concentration",
      "Renal: Recurrent renal calculi (calcium oxalate/phosphate), polyuria and polydipsia, loss of renal function with uremia, hypokalemia, hyperuricemia, hyperchloremic acidosis, dilute urine",
      "Skeletal: Bone pain, osteoporosis, fractures, deformity due to osteitis fibrosa cystica, localized bone swelling/brown tumor"
    ],
    "Object5": [
      "Often diagnosed by incidental hypercalcemia (more than 70%)",
      "Hypertension (common)",
      "Calcification of cornea, arterial walls, soft tissues of hand",
      "Myopathy"
    ],
    "Object6": [
      "Biochemical: Estimation of fasting serum calcium and phosphate. Hallmark: Hypercalcemia and hypophosphatemia with detectable or elevated intact PTH levels.",
      "Correction of serum calcium concentrations for albumin levels.",
      "Mild hyperchloremic acidosis (may be associated).",
      "Renal function tests.",
      "Urine: Hypercalciuria (>300 mg/24 hours in ~30%), Increased markers of bone resorption (urinary pyridinoline, deoxypyridinoline, N-telopeptide of collagen).",
      "ECG: Shortened QT interval, Rarely cardiac arrhythmias.",
      "Radiological: Most sensitive/specific for osteitis fibrosa cystica: subperiosteal resorption of cortical bone (phalanges). 'Salt-and-pepper' appearance (skull). Bone cysts or brown tumors (osteolytic lesions). Osteoporosis (preferential loss of cortical bone). Loss of lamina dura of teeth (non-specific). Nephrocalcinosis. Soft tissue calcification. DEXA/CT scan (reduced bone density).",
      "Localization of tumor: High-resolution ultrasonography, CT scanning, subtraction imaging, scintigraphy (technetium 99 sestamibi), Selective neck vein catheterization with PTH estimation (for re-operations)."
    ],
    "Object7": [
      "Hypercalcemia: Adequate rehydration (4-6 L 0.9% saline day 1, then 3-4 L). IV bisphosphonate (pamidronate 15-60 mg). Calcitonin (200 units IV 6-hourly). Prednisolone (30-60 mg daily for myeloma, sarcoidosis, vitamin D excess). Oral phosphate. Diuretics (furosemide). Mithramycin. Hemodialysis.",
      "Primary hyperparathyroidism: Adenoma: Surgical removal. Hyperplasia: Removal of all four parathyroid glands, transplantation of excised tissue to forearm.",
      "Secondary disease: Calcium supplements, Vitamin D.",
      "Tertiary disease: Phosphate binders (Amphojel, Basaljel, Tums)."
    ],
    "Object8": [
      "Renal: Nephrocalcinosis, Uremia",
      "Skeletal: Osteoporosis, Fractures",
      "Cardiovascular: Hypertension"
    ]
  },
  {
    "Object1": "Hypercalcemia",
    "Object2": [
      "Mild (10.5-12 mg/dl)",
      "Severe (>14 mg/dl)"
    ],
    "Object3": [
      "Parathyroid hormone related (normal or elevated PTH): Primary hyperparathyroidism, Tertiary hyperparathyroidism, Lithium therapy-induced hyperparathyroidism, Familial hypercalciuric hypercalcemia",
      "Malignancy related (low PTH): Multiple myeloma, PTH related protein secretion (tumors of lung and kidney), Secondary deposits in bone (breast carcinoma), Production of osteoclastic factors by tumors",
      "Associated with renal failure: Secondary hyperparathyroidism, Aluminum intoxication"
    ],
    "Object4": [
      "Nausea",
      "Vomiting",
      "Excessive thirst",
      "Polyuria",
      "Severe itching",
      "Joint and muscle pains",
      "Disorientation",
      "Coma"
    ],
    "Object5": [
      "Metastatic calcifications"
    ],
    "Object6": [
      "Serum calcium levels",
      "Serum PTH levels",
      "Renal function tests"
    ],
    "Object7": [
      "Adequate rehydration (4-6 L 0.9% saline day 1, then 3-4 L)",
      "IV bisphosphonate (pamidronate 15-60 mg)",
      "Calcitonin (200 units IV 6-hourly)",
      "Prednisolone (30-60 mg daily for myeloma, sarcoidosis, vitamin D excess)",
      "Oral phosphate",
      "Diuretics (furosemide)",
      "Mithramycin",
      "Hemodialysis"
    ],
    "Object8": [
      "Renal failure",
      "Coma",
      "Cardiac arrhythmias"
    ]
  },
  {
    "Object1": "Hypoparathyroidism",
    "Object2": "Not specified",
    "Object3": [
      "Surgical hypoparathyroidism (commonest: removal of glands, interruption of blood supply)",
      "Idiopathic hypoparathyroidism (genetic origin, autosomal recessive, 'multiple endocrine deficiency-autoimmune-candidiasis (MEDAC) syndrome', 'juvenile familial endocrinopathy-HAM syndrome')",
      "Functional hypoparathyroidism (chronic hypomagnesemia)",
      "DiGeorge syndrome"
    ],
    "Object4": [
      "Hypocalcemia",
      "Neuromuscular hyperactivity (tetany)",
      "Lethargy, weakness, fatigue, thin and patchy hair, brittle nails, dry and scaly skin, personality changes, cataracts, permanent brain damage (chronic)",
      "Steatorrhea (long-standing untreated disease)"
    ],
    "Object5": [
      "Hypocalcemia",
      "Hyperphosphatemia",
      "Diminished or absent circulating iPTH",
      "Abnormal enamel formation with delayed/absent dental eruption, defective dental root formation",
      "Posterior lenticular cataract"
    ],
    "Object6": [
      "Serum calcium (low)",
      "Serum phosphate (high)",
      "Circulating iPTH (diminished or absent)"
    ],
    "Object7": [
      "Acute phase (tetany): Calcium gluconate IV (20 mL of 10% solution slowly over 10 min), Magnesium (if calcium ineffective).",
      "Substitution therapy: 1-α-hydroxycholecalciferol (alfacalcidol) or 1,25 dihydroxycholecalciferol (calcitriol) at 0.25-2 μg/day."
    ],
    "Object8": [
      "Permanent brain damage",
      "Steatorrhea"
    ]
  },
  {
    "Object1": "Tetany",
    "Object2": "Not specified.",
    "Object3": [
      "Hypocalcemia",
      "Alkalosis",
      "Hypomagnesemia",
      "Due to hypocalcemia: Increased phosphate levels (chronic renal failure, phosphate therapy), Hypoparathyroidism (surgical, congenital, idiopathic), Severe hypomagnesemia, Resistance to PTH (pseudohypoparathyroidism), Vitamin D deficiency (osteomalacia/rickets, vitamin D resistance), Acute pancreatitis, Citrated blood in massive transfusion, Low plasma albumin, Malabsorption, Drugs (calcitonin, bisphosphonates)",
      "Due to alkalosis: Repeated vomiting of gastric juice, Excessive intake of oral alkali, Hyperventilation (hysteria)",
      "Due to hypomagnesemia",
      "Primary hyperaldosteronism"
    ],
    "Object4": [
      "Muscle spasms",
      "Tingling in hands, feet, around mouth (circumoral paresthesia) (adults)"
    ],
    "Object5": [
      "Children: Characteristic triad of carpopedal spasm, stridor and convulsions. Carpal spasm (flexion of MCP joints, extension of IP joints, opposition of thumb - 'main d'accoucheur').",
      "Latent tetany: Chvostek's sign (ipsilateral facial muscle contraction on tapping facial nerve). Trousseau's sign (carpopedal spasm on inflating BP cuff for 3-5 min).",
      "Cardiac: Prolonged QT interval on ECG, Resistance to digitalis, hypotension, refractory heart failure with cardiomegaly."
    ],
    "Object6": [
      "ECG (prolonged QT interval)"
    ],
    "Object7": [
      "Control of tetany: Calcium gluconate (20 mL of 10% solution IV slowly over 10 min). Magnesium (if calcium ineffective).",
      "Correction of alkalosis: IV isotonic saline and potassium (for vomiting). Withdraw alkali excess. Ammonium chloride (2g 4 hourly orally) for alkali excess. Rebreathing expired air or 5% CO2 in O2 (for hysterical hyperventilation)."
    ],
    "Object8": [
      "Refractory heart failure with cardiomegaly."
    ]
  },
  {
    "Object1": "Pseudohypoparathyroidism (PHP)",
    "Object2": [
      "PHP type IB",
      "PHP type IA (with Albright's hereditary osteodystrophy - AHO)"
    ],
    "Object3": [
      "Inherited disorder of target-organ unresponsiveness to PTH"
    ],
    "Object4": [
      "Hypocalcemia",
      "Hyperphosphatemia"
    ],
    "Object5": [
      "PHP type IB: Secondary hyperparathyroidism (biochemical features).",
      "PHP type IA: Characteristic somatic phenotype (AHO): short stature, round face, short neck, brachydactyly, shortened metatarsals, subcutaneous ossifications, mental retardation. Dimple instead of knuckle on affected digits."
    ],
    "Object6": [
      "Biochemical features: Hypocalcemia, hyperphosphatemia, elevated PTH level."
    ],
    "Object7": [
      "Treatment of hypocalcemia."
    ],
    "Object8": [
      "Mental retardation"
    ]
  },
  {
    "Object1": "Cushing's Syndrome",
    "Object2": [
      "ACTH-dependent causes (ACTH-secreting pituitary tumor - Cushing's disease, pituitary CRH-secreting neoplasm, nonpituitary ACTH-secreting neoplasm)",
      "ACTH-independent causes (adrenal adenoma, adrenal carcinoma, micronodular adrenal disease, McCune-Albright syndrome, massive macronodular adrenal disease)",
      "Iatrogenic (use of corticosteroids)"
    ],
    "Object3": [
      "Pituitary-dependent bilateral adrenal hyperplasia (Cushing's disease)",
      "Ectopic ACTH secretion (Small cell carcinoma of lung, Endocrine tumors of foregut origin, Thymic carcinoid, Pancreatic islet cell tumor, Medullary carcinoma thyroid, Bronchial carcinoid, Pheochromocytoma, Ovarian tumors)",
      "Excess alcohol consumption (pseudo-Cushing's syndrome)"
    ],
    "Object4": [
      "Weight gain/obesity (90%)",
      "Back pain (80%)",
      "Muscle weakness (65%)",
      "Menstrual disorders (oligomenorrhea, amenorrhea), decreased libido, impotence (70-85%)",
      "Emotional lability, depression, euphoria, psychosis, irritability (85%)",
      "Polyuria (30%)",
      "Kidney stones (15%)"
    ],
    "Object5": [
      "Central obesity ('lemon on match-stick')",
      "Buffalo hump",
      "Moon face",
      "Hypertension (85%)",
      "Plethoric appearance",
      "Hirsutism (70-75%)",
      "Purplish striae over abdomen, buttocks and thighs",
      "Bruising",
      "Thin skin",
      "Osteopenia, osteoporosis and vertebral compression fractures",
      "Proximal myopathy",
      "Hypokalemia",
      "Skin pigmentation (only with ACTH-dependent causes)",
      "Impaired glucose tolerance or frank diabetes (common, especially ectopic ACTH)",
      "Hypokalemic alkalosis (ectopic ACTH)"
    ],
    "Object6": [
      "Confirmation of presence: 48-hour low-dose dexamethasone test (normal: plasma cortisol <50 nmol/L, Cushing's: fails to suppress)",
      "24-hour urinary free cortisol (repeatedly normal values render diagnosis unlikely)",
      "Plasma cortisol (loss of circadian rhythm, midnight level <1.8 µg/dL normal)",
      "Overnight dexamethasone suppression test",
      "Late-night salivary cortisol (screening test)",
      "Establish cause: Plasma ACTH level at 8 AM (normal 10-80 ng/L - pituitary; intermediate 80-300 ng/L - pituitary/ectopic; very high >300 ng/L - ectopic; low <10 ng/L - adrenal/exogenous steroid), High-dose dexamethasone suppression test (plasma cortisol on day +2 <50% of day 0 suggests pituitary), Plasma potassium levels (normal in pituitary/adrenal, low in ectopic ACTH), ACTH/cortisol response to CRH (increased in pituitary, unchanged in ectopic/adrenal), Bilateral inferior petrosal sinus sampling for ACTH (before/after CRH)",
      "Other: Blood glucose, cholesterol, LDL (may be raised), Radiological (Plain skull/chest X-ray, CT/MRI head/abdomen, CT mediastinum, upper abdomen, pancreas), Investigations in oncology for tumors"
    ],
    "Object7": [
      "Adrenal tumors: Surgical resection. Postoperatively, prednisolone replacement.",
      "Adrenal carcinomas: Surgical resection, irradiation, adrenolytic drug (mitotane).",
      "Medical adrenalectomy: Ketoconazole, metyrapone, mitotane, aminoglutethimide, octreotide.",
      "Cushing's disease: Trans-sphenoidal removal of tumor (treatment of choice).",
      "Radiotherapy and radiosurgery for recurrent/residual ACTH-secreting tumors.",
      "Bilateral adrenalectomy (if diagnosis uncertain, followed by pituitary irradiation to prevent Nelson's syndrome). Postoperatively, prednisolone and fludrocortisones.",
      "Medical therapy to reduce ACTH (bromocriptine - rarely effective).",
      "Ectopic ACTH syndrome: Surgical removal of benign tumors (bronchial carcinoid).",
      "Radiotherapy and chemotherapy for malignant tumors.",
      "Recurrent tumors: metyrapone or aminoglutethimide."
    ],
    "Object8": [
      "Systemic fungal infections and tinea versicolor",
      "Higher risk of coronary artery disease and venous thrombosis",
      "Impaired glucose tolerance or frank diabetes",
      "Nelson's syndrome (increased pigmentation with enlarging pituitary tumor post-bilateral adrenalectomy)",
      "Osteoporosis",
      "Vertebral compression fractures"
    ]
  },
  {
    "Object1": "Nelson's Syndrome",
    "Object2": "Increased pigmentation associated with an enlarging pituitary tumor post-bilateral adrenalectomy",
    "Object3": [
      "Occurs after bilateral adrenalectomy for Cushing's disease (about 20% of cases)"
    ],
    "Object4": [],
    "Object5": [
      "Increased pigmentation"
    ],
    "Object6": [
      "Diagnosis is clinical."
    ],
    "Object7": [
      "Pituitary surgery and/or radiotherapy."
    ],
    "Object8": []
  },
  {
    "Object1": "Hyperaldosteronism",
    "Object2": [
      "Primary hyperaldosteronism",
      "Secondary hyperaldosteronism"
    ],
    "Object3": [
      "Primary: Adrenal adenoma (Conn's syndrome), Bilateral hyperplasia of zona glomerulosa, Idiopathic, ACTH dependent (glucocorticoid-responsive or dexamethasone-suppressible)",
      "Secondary: Physiological (salt depletion, pregnancy), Pathological (inadequate renal perfusion: excessive diuretic therapy, nephrotic syndrome, liver failure, congestive cardiac failure, Bartter's syndrome, accelerated/malignant hypertension, severe renal artery stenosis; renin-secreting renal tumor)"
    ],
    "Object4": [
      "Hypertension (most important)",
      "Tetany (due to metabolic alkalosis)",
      "Muscle weakness (due to hypokalemia)",
      "Polyuria and polydipsia (due to nephrogenic DI)"
    ],
    "Object5": [
      "Hypokalemia (may be absent)",
      "Metabolic alkalosis"
    ],
    "Object6": [
      "Diagnosis: Hypokalemia (normal serum K+ does not exclude), Urinary potassium loss (>30 mEq/day during hypokalemia is inappropriate), Plasma aldosterone concentration (PAC) elevated (>15 ng/dL), not suppressed by saline/flurocortisone, Suppressed plasma renin activity (PRA) or immunoreactivity, PAC:PRA ratio (>20 suggests primary), Confirmatory aldosterone suppression test, Oral salt loading test, Saline infusion test, Oral captopril test (no significant decrease in PAC in primary)",
      "Differential diagnosis: CT/MRI scanning (detect adenoma/hyperplasia), Adrenal vein catheterization (detect hypersecretion), Dexamethasone suppression (lowers PAC transiently in adenoma, prolonged suppression in glucocorticoid-sensitive), Measurement of 18-OH-cortisol levels (very high in adenomas/glucocorticoid-responsive hyperplasia, slightly raised in idiopathic hyperplasia)"
    ],
    "Object7": [
      "Potassium (K+) supplementation",
      "Definitive treatment: Adrenalectomy (bilateral if multiple tumors)",
      "Aldosterone antagonists: Spironolactone, eplerenone (for inoperable). Amiloride also tried.",
      "Glucocorticoids (for ACTH dependent type)"
    ],
    "Object8": [
      "Hypertension",
      "Tetany",
      "Muscle weakness",
      "Nephrogenic DI"
    ]
  },
  {
    "Object1": "Adrenocortical Insufficiency",
    "Object2": [
      "Primary adrenocortical insufficiency (adrenal causes)",
      "Secondary adrenocortical insufficiency (inadequate ACTH)"
    ],
    "Object3": [
      "Primary: Autoimmune adrenal insufficiency (most common), Metastatic malignancy, Adrenal hemorrhage (Waterhouse-Friderichsen syndrome), Anticoagulation therapy, Infectious (Tuberculosis, CMV, fungi, HIV), Adrenal infarction (APLA, SLE), Adrenoleukodystrophy, Infiltrative disorders (Amyloidosis, Hemochromatosis, Sarcoidosis), Bilateral adrenalectomy, Congenital adrenal hyperplasia, Familial glucocorticoid deficiency and hypoplasia, Drugs (Ketoconazole, Metyrapone, Aminoglutethimide, Trilostane, Mitotane, Etomidate, Rifampin, Cyproterone acetate), Autoimmune polyglandular syndrome 1 and 2, Kearns-Sayre syndrome",
      "Secondary: Exogenous glucocorticoid therapy, Hypopituitarism (selective removal, pituitary apoplexy, granulomatous disease, secondary tumor deposits, postpartum pituitary infarction - Sheehan's syndrome, pituitary irradiation)"
    ],
    "Object4": [
      "Glucocorticoid deficiency: Fasting hypoglycemia, increased insulin sensitivity, morning headache, weight loss, anorexia, nausea, vomiting, diarrhea or constipation",
      "Mineralocorticoid deficiency: Dizziness, salt craving",
      "Adrenal androgen deficiency: Decreased axillary/pubic hair in females, loss of libido in females, asymptomatic during prepuberty"
    ],
    "Object5": [
      "ACTH excess (Primary only): Pigmentation of exposed areas, pressure areas (elbows, knees, knuckles), palmar creases, mucous membranes, conjunctiva, recently acquired scars, perineum, axillae, areolae of breasts (due to increased POMC/MSH), Hypotension, Electrolyte anomalies (hyponatremia, hyperkalemia, metabolic acidosis), Fatigue, malaise, weakness, Postural hypotension"
    ],
    "Object6": [
      "Confirm adrenal insufficiency: 08:00 AM cortisol level (<3 µg/dl suggestive, >11 µg/dl excludes), Random cortisol in ill patient (≥20 µg/dL reassuring), Plasma ACTH level (elevated in primary), ACTH stimulation test (failure of plasma cortisol rise after 250 µg synthetic ACTH. Low dose 1µg useful in central AI and for recovery after chronic steroid. High dose 250µg for baseline and 30/60 minute levels)",
      "Determine cause: PRA (high in primary), plasma aldosterone (low/normal in primary), Radiograph (chest for TB, plain abdomen/CT/MRI for adrenal calcification), Adrenal autoantibodies (ACA, anti-21-OH-hydroxylase antibody), Elevated blood urea, hyponatremia, hyperkalemia, Blood sugar (low), Peripheral blood (mild anemia, mild eosinophilia), Central AI (evaluate other pituitary hormones)"
    ],
    "Object7": [
      "Primary adrenal insufficiency (Acute): Normal saline for volume resuscitation, 25% dextrose for hypoglycemia, Steroids (hydrocortisone 50-100 mg/m² IV/IM loading, then 50-100 mg/m²/day divided), Stress conditions: double or triple glucocorticoid dose, 100-150 mg hydrocortisone for major surgery.",
      "Primary adrenal insufficiency (Long-term): Daily glucocorticoid replacement (hydrocortisone 10-15 mg/m²/day divided), Daily mineralocorticoid replacement (fludrocortisone 0.05-0.2 mg daily)",
      "Tuberculous adrenalitis: Antituberculous chemotherapy."
    ],
    "Object8": [
      "Adrenal crisis (acute adrenocortical insufficiency)"
    ]
  },
  {
    "Object1": "Acute Adrenal Crisis",
    "Object2": "Acute adrenocortical insufficiency",
    "Object3": [
      "Addison's disease patients exposed to stress (infection, trauma, surgery, dehydration from salt deprivation, vomiting, diarrhea)",
      "Bilateral adrenal infarction",
      "Bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome)"
    ],
    "Object4": [
      "Shock (major manifestation)",
      "Non-specific (weakness, fatigue, lethargy, anorexia, nausea, vomiting, abdominal pain, confusion or coma)",
      "Abdominal tenderness, fever",
      "Features of chronic adrenal insufficiency (hyperpigmentation, weight loss, serum electrolyte abnormalities) (in long-standing cases)"
    ],
    "Object5": [
      "Shock",
      "Abdominal tenderness, fever",
      "Hyperpigmentation (chronic), weight loss (chronic)"
    ],
    "Object6": [
      "Hyponatremia, hyperkalemia, lymphocytosis, eosinophilia, hypoglycemia"
    ],
    "Object7": [
      "Start therapy as soon as suspected",
      "Correction of hypovolemia and sodium depletion with normal saline",
      "5% dextrose for hypoglycemia",
      "Hydrocortisone (100 mg IV bolus) OR dexamethasone (4 mg bolus)",
      "Hydrocortisone 100 mg 6 hourly, tapered over 26-48 hours to maintenance",
      "Treat precipitating cause"
    ],
    "Object8": [
      "Cardiac and/or respiratory failure (in Waterhouse-Friderichsen syndrome)"
    ]
  },
  {
    "Object1": "Waterhouse-Friderichsen Syndrome",
    "Object2": "Acute hemorrhagic infarction of both adrenal glands",
    "Object3": [
      "Usually associated with fulminant meningococcal septicemia"
    ],
    "Object4": [],
    "Object5": [
      "Cutaneous petechiae, vasomotor collapse, shock",
      "Abrupt onset, profound prostration within hours",
      "Purpuric lesion, hemorrhage into skin"
    ],
    "Object6": [
      "Clinical diagnosis with supporting lab from septicemia."
    ],
    "Object7": [
      "Intravenous fluids, high dose antibiotics (Penicillin, cephalosporins, sulfonamides), vasopressors, inotropes, plasma transfusion, steroids immediately."
    ],
    "Object8": [
      "Death within hours to days due to cardiac and/or respiratory failure."
    ]
  },
  {
    "Object1": "Pheochromocytoma",
    "Object2": [
      "Very rare tumor of sympathetic nervous system",
      "Paraganglioma (extra-adrenal pheochromocytoma)"
    ],
    "Object3": [
      "Tumor of chromaffin cells that secretes catecholamines (noradrenaline, adrenaline)",
      "Neurofibromatosis type 1 (Von Recklinghausen's disease) is associated",
      "Familial pheochromocytoma (MEN 2a, MEN 2b, Von Hippel-Landau, NF1, Familial paraganglioma, Familial pheochromocytoma and islet cell tumor, Tuberous sclerosis, Sturge-Weber, ataxia-telangiectasia, Carney's Triad)"
    ],
    "Object4": [
      "Paroxysmal hypertension: Episodes of pallor or flushing, headache, sweating, palpitations, anxiety (fear of death). Paroxysms last 10-60 min, daily to monthly. Precipitated by: diagnostic procedures, intra-arterial contrast, drugs (opioids, unopposed beta-blockade, anesthesia induction, histamine, ACTH, glucagon, metoclopramide), strenuous exercise, movement increasing intra-abdominal pressure, micturition (bladder paraganglioma).",
      "Abdominal pain, vomiting, constipation, weight loss (gastrointestinal)",
      "Mild glucose intolerance",
      "Lipolysis and weight-loss"
    ],
    "Object5": [
      "Sustained hypertension (more common than paroxysmal)",
      "5 Ps: Pressure (Hypertension - 90%), Pain (Headache - 80%), Perspiration (70%), Palpitation (65%), Pallor (42%)",
      "Hypercalcemia (associated MEN2 hyperparathyroidism)"
    ],
    "Object6": [
      "Plasma metanephrine: Most sensitive test (raised)",
      "24-hour urine Vanillylmandelic acid (VMA) (raised 63% sensitivity, 94% specificity)",
      "24-hour urine metanephrines and normetanephrines (raised 76% sensitivity, 94% specificity)",
      "24-hour urine free catecholamines (raised 83% sensitivity, 88% specificity)",
      "24-hour urine free catecholamines + metanephrines (raised 90% sensitivity, 98% specificity)",
      "Plasma catecholamines (raised 85% sensitivity, 80% specificity)",
      "Chromogranin A (elevated)",
      "Provocative (glucagon provocative test) and adrenolytic (clonidine, phentolamine test) tests (rarely necessary)",
      "CT scan (localize tumor)",
      "Scintigraphy (MIBG, 111Indium-labeled diethylenetriamine pentaacetic acid octreotide scan, 18F flurodihydroxyphenylalanine (DOPA) PET scan)",
      "Plasma noradrenaline: Selective venous sampling with PTH estimation"
    ],
    "Object7": [
      "Excision of the tumor (main treatment)",
      "Preoperative preparation (at least 2 weeks): Combined α + β-blockade (phenoxybenzamine, prazosin, terazosin, doxazosin, propranolol), High sodium diet (>5000 mg daily), If uncontrolled: Metyrosine, Calcium channel blocker (Nicardipine), Avoid diuretics.",
      "Intraoperative: Careful monitoring and control of blood pressure.",
      "Postoperative: Adequate fluid replacement (avoid hypotension), Glucose infusion (prevent hypoglycemia).",
      "If tumor cannot be excised: Long-term α- and β-adrenoreceptors blocking drugs (phenoxybenzamine and propranolol, or labetalol). β-blockers never alone.",
      "Nuclear medicine treatment."
    ],
    "Object8": [
      "Complications of hypertension (stroke, myocardial infarction, cardiomyopathy, left ventricular failure)",
      "Hypotension (postoperative)",
      "Hypoglycemia (postoperative)"
    ]
  },
  {
    "Object1": "Male Hypogonadism",
    "Object2": [
      "Hypothalamic-pituitary disorders",
      "Gonadal abnormalities",
      "Secondary hypogonadism",
      "Defects in androgen action"
    ],
    "Object3": [
      "Hypothalamic-pituitary disorders: Panhypopituitarism, LH and FSH deficiency (with normal sense of smell, hyposmia/anosmia (Kallmann's syndrome), complex neurologic syndromes (Prader-Willi, Laurence-Moon, Bardet-Biedl, Möbius', Lowe's syndrome))",
      "Gonadal abnormalities: Klinefelter's syndrome, Other chromosomal defects (AX male, XY/XXY, XX/XXY, XXXY, XYY), Bilateral anorchia (vanishing testes syndrome), Cryptorchidism, Noonan's syndrome, Myotonic dystrophy, Adult seminiferous tubule failure, Adult Leydig cell failure, Malignant tumors of testes, Infiltrative diseases (hemochromatosis), Chronic orchitis (TB, leprosy, syphillis), Pituitary apoplexy, Trauma, Idiopathic",
      "Secondary hypogonadism: Hyperprolactinemia, Glucocorticoid treatments, Chronic systemic illness, Anorexia nervosa, Diabetes mellitus, Obesity",
      "Defects in androgen action: Complete androgen insensitivity (testicular feminization), Incomplete androgen insensitivity"
    ],
    "Object4": [
      "Musculoskeletal: Decreased vigour and physical energy, diminished muscle strength",
      "Sexuality: Decreased interest in sex, reduction in frequency of sexual activity, poor erectile function/arousal, loss of nocturnal erections, reduced quality of orgasm, reduced volume of ejaculate",
      "Mood disorder and cognitive function: Irritability and lethargy, decreased sense of well-being, lack of motivation, low mental energy, difficulty with short-term memory, depression, low self-esteem, insomnia, nervousness",
      "Vasomotor and nervous: Hot flushes, sweating",
      "Prepubertal onset: Eunuchoidism (lack of adult male hair distribution, sparse axillary/pubic hair, lack of temporal hair recession, high-pitched voice, infantile genitalia, small penis/testes/scrotum, increased fat deposition in pectoral/hip/thigh/lower abdomen, eunuchoidal proportion (arm span > height > 5 cm, upper/lower segment ratio < 1))"
    ],
    "Object5": [
      "Diminished muscle mass",
      "Loss of body hair",
      "Abdominal obesity",
      "Gynecomastia",
      "Testes frequently normal, occasionally small"
    ],
    "Object6": [
      "Serum testosterone (8.00 AM)",
      "Serum FSH, LH",
      "Semen analysis",
      "Others: Peripheral leukocyte karyotype, other pituitary hormones, serum prolactin, iron saturation, MRI brain"
    ],
    "Object7": [
      "Treatment of primary hypogonadism: Testosterone replacement",
      "Treatment of the underlying disease",
      "Testosterone replacement: Intramuscular preparations (testosterone enanthate 200-300 mg IM q 3 wk), Transdermal patch/gel, Oral agent (testosterone undecanoate 40-80 mg po 2-3 times daily)",
      "Treatment of secondary hypogonadism: GnRH pulsatile infusion, HCG"
    ],
    "Object8": [
      "Testosterone replacement: BPH, prostatic cancer, dyslipidemia, polycythemia, transaminitis"
    ]
  },
  {
    "Object1": "Impotence (Male Sexual Dysfunction)",
    "Object2": "Male sexual dysfunction",
    "Object3": [
      "Loss of desire",
      "Inability to obtain and maintain erection",
      "Premature ejaculation",
      "Absence of emission",
      "Inability to achieve orgasm",
      "Endocrine: Hypothalamic-pituitary disorders, Testicular disorders, Defects of androgen action, Hyperthyroidism, Hypothyroidism, Adrenal insufficiency, Congenital adrenal hyperplasia",
      "Systemic illness",
      "Defects in spermatogenesis: Immotile cilia syndrome",
      "Drug-induced",
      "Ductal obstruction (congenital, acquired)",
      "Seminal vesicle disease",
      "Prostatic disease",
      "Varicocele",
      "Retrograde ejaculation",
      "Antibodies to sperm or seminal plasma",
      "Anatomic defects of the penis",
      "Poor coital technique",
      "Sexual dysfunction",
      "Idiopathic",
      "Erectile Dysfunction (Organic causes): Neurologic (Anterior temporal lobe lesions, Spinal cord lesions, Autonomic neuropathy), Vascular (Leriche's syndrome, Pelvic vascular insufficiency, Sickle cell disease), Endocrine (Diabetes mellitus, Hypogonadism, Hyperprolactinemia, Adrenal insufficiency, Feminizing tumors, Hypothyroidism, Hyperthyroidism), Urogenital (Trauma, Castration, Priapism, Peyronie's disease), Systemic Illness (Cardiac insufficiency, Cirrhosis, Uremia, Respiratory insufficiency, Lead poisoning), Postoperative (Aortoiliac/aortofemoral reconstruction, Lumbar sympathectomy, Perineal prostatectomy, Retroperitoneal dissection), Drugs (Antiandrogens, Estrogens, 5 alfa-reductase inhibitors, GnRH agonists, Antihypertensives, Diuretics, Psychotropic agents, Tranquilizers, Monoamine oxidase inhibitors, Tricyclic antidepressants), Tobacco, Alcohol, Cocaine"
    ],
    "Object4": [
      "Loss of desire",
      "Inability to obtain and maintain erection",
      "Premature ejaculation",
      "Absence of emission",
      "Inability to achieve orgasm"
    ],
    "Object5": [],
    "Object6": [],
    "Object7": [
      "Psychological counselling; psychosexual therapy",
      "Phosphodiesterase type 5 inhibitors (oral: sildenafil, vardenafil, tadalafil)",
      "Dopamine agonist (apomorphine) through sublingual route",
      "Prostaglandin E1 (alprostadil): Injected into corpus cavernosum or intraurethral administration of pellets",
      "Vacuum tumescence devices",
      "Implanted penile prosthesis"
    ],
    "Object8": []
  },
  {
    "Object1": "Gynecomastia",
    "Object2": "Clinically defined as the presence of a rubbery or firm mass concentrically extending from the nipples in a male secondary to proliferation of both stromal and epithelial component of the glands.",
    "Object3": [
      "Physiologic: Neonatal, pubertal, involutional",
      "Endocrine: Primary hypogonadism with Leydig cell damage, hyperprolactinemia, hyperthyroidism, androgen receptor disorders, excessive aromatase activity",
      "Drug-induced: Androgens and anabolic steroids, chorionic gonadotropin, estrogens and estrogen agonists, growth hormone, cyproterone, flutamide. isoniazid, ketoconazole, metronidazole, cimetidine, omeprazole, ranitidine, cancer chemotherapeutic agents (especially alkylating agents), amiodarone, captopril, reserpine, spironolactone, verapamil psychotropic agents, diazepam, haloperidol, phenothiazines, tricyclic antidepressants, alcohol, amphetamines, heroin, marijuana, highly active antiretroviral therapy (HAART), phenytoin, penicillamine",
      "Systemic diseases: Hepatic cirrhosis, uremia",
      "Neoplasms: Testicular germ cell or Leydig cell tumors, HCG-secreting nontrophoblastic neoplasms",
      "Idiopathic"
    ],
    "Object4": [
      "Principal complaint is unilateral or bilateral concentric enlargement of breast glandular tissue",
      "Breast pain (present in one-fourth of patients)",
      "Nipple discharge (can be elicited in 4% of cases)"
    ],
    "Object5": [
      "Objective tenderness (about 40%)"
    ],
    "Object6": [],
    "Object7": [
      "Medical: Correct underlying disease, discontinue offending drugs. Antiestrogens or selective estrogen receptor modulators (tamoxifen or raloxifene) for pain relief and reversal. Aromatase inhibitors (less beneficial).",
      "Surgical: Reduction mammoplasty for cosmetic reasons.",
      "Radiotherapy: Low-dose radiation therapy (900 cGy or less) to breasts before estrogen therapy for prostatic carcinoma patients (prevents/diminishes gynecomastia). Not for other patients."
    ],
    "Object8": [
      "Slightly increased risk of development of breast carcinoma"
    ]
  },
  {
    "Object1": "Short Stature",
    "Object2": "Not specified",
    "Object3": [
      "Nonendocrine causes: Constitutional short stature, familial short stature, genetic short stature, intrauterine growth retardation and SGA syndromes of short stature, Turner's syndrome and its variants, Noonan's syndrome, Prader-Willi syndrome, Laurence-Moon and Bardet-Biedl syndromes, Chronic disease (Cardiac disorders, Pulmonary disorders, Gastrointestinal disorders), Hematologic disorders (Sickle cell anemia, Thalassemia), Renal disorders (Renal tubular acidosis, Chronic uremia), Immunologic disorders (Connective tissue disease, Juvenile rheumatoid arthritis, Chronic infection (TB)), Malnutrition (Voluntary dieting, Anorexia nervosa, Cancer chemotherapy)",
      "Endocrine disorders: GH deficiency and variants (Congenital GH deficiency, With midline defects, With other pituitary hormone deficiencies, Isolated GH deficiency, Pituitary agenesis, Acquired GH deficiency), Hypothalamic-pituitary tumors, Histiocytosis X, Central nervous system infections, Head injuries, GH deficiency following cranial irradiation, Central nervous system vascular accidents, Hydrocephalus, Empty sella syndrome, Abnormalities of GH action (GH insensitivity (Laron's dwarfism), Pygmies), Psychosocial dwarfism, Hypothyroidism, Glucocorticoid excess (Cushing's syndrome), Pseudohypoparathyroidism, Disorders of vitamin D metabolism, Diabetes mellitus (uncontrolled), Diabetes insipidus (untreated)"
    ],
    "Object4": [],
    "Object5": [
      "Height that is below the 2.5th percentile OR two or more standard deviations below the mean for age and gender",
      "Growth velocity that is below the 5th percentile for age and gender (growth deceleration)"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Diabetes Mellitus (DM)",
    "Object2": [
      "Type 1 diabetes (absolute deficiency of insulin)",
      "Type 2 diabetes (insulin resistance, impaired insulin secretion, increased glucose production)",
      "Other specific types of diabetes",
      "Gestational diabetes mellitus (GDM)",
      "Latent autoimmune diabetes in adults (LADA)",
      "Maturity onset diabetes of the young (MODY)"
    ],
    "Object3": [
      "Type 1 DM: Absolute (complete or near total) deficiency of insulin (Type 1 A: autoimmune destruction of β-cells; Type 1 B: unknown cause of β-cell destruction)",
      "Type 2 DM: Variable degrees of insulin resistance, impaired insulin secretion and increased glucose production (associated with several genetic and metabolic syndromes)",
      "Other specific types: Genetic defects of β-cell development/function (mutations in HNF 4 α, Glucokinase, HNF-1 α), Genetic defects in insulin action (Type A insulin resistance, leprechaunism, Rabson-Mendenhall syndrome, lipodystrophy syndromes), Exocrine pancreatic defects (Pancreatitis, pancreatectomy, hemochromatosis, pancreatic neoplasm, cystic fibrosis, fibrocalculous pancreatopathy), Endocrinopathies (Acromegaly, Cushing syndrome, hyperthyroidism, pheochromocytoma, glucagonoma), Infections (Cytomegalovirus, coxsackie B virus, congenital rubella), Drugs or chemical induced (Glucocorticoids, pentamidine, nicotinic acid, thyroid hormone, diazoxide, β-adrenergic agonists, thiazides, phenytoin, α-interferon), Genetic syndromes (Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram's syndrome, DIDMOAD, Friedreich's ataxia, Huntington's disease, Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome), Uncommon forms of immune-mediated diabetes ('Stiff-man' syndrome, anti-insulin receptor antibodies)",
      "GDM: Glucose intolerance develops/first recognized during pregnancy",
      "LADA: Autoimmune type 1 diabetes diagnosed in older individuals",
      "MODY: Noninsulin-dependent monogenic form of diabetes diagnosed at young age (mutations in transcription factors or glucokinase, resulting in insufficient insulin release)"
    ],
    "Object4": [
      "Classic triad: Polyuria, polydipsia, polyphagia (Type 1, abrupt onset)",
      "Weight loss (Type 1, over days/weeks; Type 2, unexplained)",
      "Nonspecific weakness (Type 2, gradual onset)",
      "Blurring of vision (due to glucose-induced changes in refraction)",
      "Pruritus vulvae or balanitis (caused by Candida infection)",
      "Lack of energy (Type 2)",
      "Symptoms of end-organ involvement (retinopathy, nephropathy, neuropathy) (Type 2)",
      "Staphylococcal skin infections (Type 2)",
      "Erectile dysfunction (Type 2)",
      "Arterial disease (myocardial infarction or peripheral gangrene) (Type 2)"
    ],
    "Object5": [
      "Normal to lean (wasted) weight (Type 1)",
      "Obese (Type 2, frequently)",
      "Hypoglycemia (Type 1, due to exogenous insulin)",
      "Hyperglycemic hyperosmolar state (Type 2, in decompensated state)"
    ],
    "Object6": [
      "Fasting plasma glucose (FPG) level (diagnosis: >126 mg/dL on more than one occasion. Pre-diabetes: 100-125 mg/dL)",
      "2-hour oral glucose tolerance test (OGTT) (diagnosis: >200 mg/dL. Pre-diabetes: >140 mg/dL but <200 mg/dL)",
      "HbA1c (diagnosis: ≥6.5% (48 mmol/mol). Pre-diabetes: 5.7-6.4% (39-46 mmol/mol))",
      "Random plasma glucose (diagnosis: ≥200 mg/dL with classical symptoms)",
      "Plasma insulin and C peptide levels (Type 1: low/unmeasurable; Type 2: normal to high)",
      "Glucagon levels (Type 1: raised, suppressible with insulin; Type 2: raised, resistant to insulin)",
      "Islet cell autoantibodies, glutamic acid decarboxylase (GAD65), zinc transporter ZnT8, tyrosine phosphatase IA-2 and IA-2β (immunologic markers for Type 1 DM)"
    ],
    "Object7": [
      "Lifestyle Management: Medical nutrition therapy (MNT) (achieve good glycemic control, reduce hyperglycemia/hypoglycemia, reduce complications, weight management, adequate nutrition, avoid atherogenic diets), Regular pattern of meals/snacks, Mediterranean Diet, Caloric content adjusted, Protein (0.9 g/kg/day, 10-15% total calories, <0.8 g/kg/day in nephropathy), Fat (≤30% total calories, 10% each saturated/monounsaturated/polyunsaturated), Carbohydrate (50-55% total calories, high fiber, restrict mono/disaccharides), Alcohol (avoid/limit)",
      "Exercise (improves insulin sensitivity, reduces glucose, metabolic/cardiovascular/psychological benefits)",
      "Treatment goals: HbA1c <7.0%, Preprandial glucose 70-130 mg/dL, Postprandial glucose <180 mg/dL, BP <130/80, Lipids (LDL <100 mg/dL, HDL >40/50 mg/dL, Triglycerides <150 mg/dL)",
      "Oral Hypoglycemic (Glucose-Lowering) Drugs:",
      "Biguanides (Metformin): Reduces hepatic glucose production (1-2% HbA1c reduction). Weight neutral/loss, no hypoglycemia. Side effects: Diarrhea, nausea, lactic acidosis, B12 deficiency. Contraindicated in malabsorption, low BMI, organ failure (creatinine >1.4, liver/cardiac failure, hypotension/sepsis), active B12 deficiency.",
      "Insulin Secretagogues (Sulfonylureas, Meglitinides): Stimulate insulin secretion (1-2% HbA1c reduction). Inexpensive. Side effects: Hypoglycemia, weight gain, sulfonamide allergies. Meglitinides (repaglinide, nateglinide) are short-acting, lower postprandial glucose.",
      "GLP-1 Receptor Agonists (Exenatide, Liraglutide): Prolong endogenous GLP-1 action (0.5-1.0% HbA1c reduction). Weight loss, no hypoglycemia. Side effects: Injection, nausea, pancreatitis, renal failure.",
      "Dipeptidyl Peptidase 4 (DPP-4) Inhibitors (Gliptins: Linagliptin, Saxagliptin, Alogliptin, Sitagliptin, Vildagliptin, Teneligliptin): Inhibit DPP-4 to conserve GLP-1 (0.5-0.8% HbA1c reduction). No hypoglycemia. Side effects: Nasopharyngitis, headache, myalgia, pancreatitis.",
      "α-Glucosidase Inhibitors (Acarbose, Miglitol, Voglibose): Reduce glucose absorption (0.5-0.8% HbA1c reduction). Reduce postprandial glycemia. Side effects: GI flatulence, liver function abnormalities. Contraindicated in kidney disease, IBD.",
      "Thiazolidinediones (Pioglitazone, Rosiglitazone (withdrawn), Troglitazone (withdrawn)): Reduce insulin resistance, increase glucose utilization (0.5-1.4% HbA1c reduction). Side effects: Weight gain, fluid retention, CHF, fractures, macular edema, bladder carcinoma. Contraindicated in CHF, liver disease.",
      "Sodium-glucose co-transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Help eliminate glucose in urine (0.4-1.1% HbA1c reduction). No hypoglycemia, weight loss. Side effects: Genital/urinary infections, hypotension, AKI, bone fracture, auto-amputations.",
      "Amylin Agonist (Pramlintide): Synthetic pancreatic hormone, injected before meals. Reduces postprandial glycemia, weight loss. Side effects: Injection, nausea, hypoglycemia.",
      "Bile Acid-Binding Resins (Colesevelam): Reduces glucose absorption. Side effects: Constipation, nausea, dyspepsia.",
      "Dopamine Agonist (Bromocriptine): Minimally effective, side effects: nausea, vomiting, dizziness, headache.",
      "Insulin Treatment: Necessary for Type 1 DM, many Type 2 DM. Goals: Eliminate symptoms, prevent DKA/HHS, restore lean body mass, improve physical/well-being, reduce infections, decrease fetal malformation/morbidity in pregnancy, delay/arrest/prevent macro/microvascular complications. Various insulin preparations (rapid, short, intermediate, long-acting, analogs). Regimens: Once/twice daily, premixed/split-mix, basal-bolus, CSII. Delivery systems: Syringes, pens, pumps.",
      "Pancreatic Transplantation/Islet Cell Transplantation: Can restore normoglycemia without exogenous insulin therapy in Type 1 DM."
    ],
    "Object8": [
      "Diabetic Ketoacidosis (DKA)",
      "Hyperglycemic Hyperosmolar State (HHS)",
      "Lactic acidosis",
      "Hypoglycemia",
      "Chronic (Long-Term) Complications:",
      "Microvascular: Diabetic retinopathy (non-proliferative, proliferative), Cataract, Glaucoma, Peripheral neuropathy (sensory, motor, sensory motor), Autonomic neuropathy, Nephropathy (microalbuminuria, macroalbuminuria, chronic kidney disease), Foot disease",
      "Macrovascular: Coronary artery disease, Peripheral vascular disease, Cerebrovascular disease",
      "Nonvascular: Gastroparesis, Infections, Skin changes (dermatological complications), Hearing loss",
      "Type 1 DM: Ketoacidosis (severe cases)",
      "Type 2 DM: Hyperosmolar hyperglycemic state",
      "LADA: High risk of progression to insulin dependency",
      "MODY: Macrovascular complications (in earlier generation)"
    ]
  },
  {
    "Object1": "Vitamin A Deficiency",
    "Object2": "Not specified, generally one condition with varying severity.",
    "Object3": [
      "Prolonged dietary deprivation (vegetarians, refugees, chronic alcoholics, toddlers, preschool children)",
      "Sprue",
      "Cystic fibrosis",
      "Pancreatic insufficiency",
      "Duodenal bypass",
      "Chronic diarrhea",
      "Bile duct obstruction",
      "Giardiasis",
      "Cirrhosis"
    ],
    "Object4": [
      "Poor adaptation to darkness (nyctalopia)",
      "Increased susceptibility to infections (e.g., respiratory infections)",
      "Fatigue",
      "Anemia",
      "Diarrhea",
      "Decreased growth rate",
      "Decreased bone development",
      "Infertility"
    ],
    "Object5": [
      "Bitot's spots",
      "Xerophthalmia (dry eye)",
      "Keratomalacia",
      "Keratinization of mucous membranes",
      "Xerosis of skin"
    ],
    "Object6": [
      "Serum retinol level (decreased, normal range 28-86 µg/dL; deficiency <20 µg/dL)",
      "Albumin levels (indirect measure)",
      "Complete blood count (CBC) with differential count (for anemia, infection, sepsis)"
    ],
    "Object7": [
      "For xerophthalmia: 60 mg Vitamin A in oily solution, 3 doses (day 0, day 1, day 14)",
      "For measles: two 60 mg capsules for two consecutive days",
      "Prophylactic Vitamin A: 60 mg every 6 months for high-risk individuals",
      "Vitamin A supplements for malabsorption syndrome"
    ],
    "Object8": [
      "Blindness due to retinal injury"
    ]
  },
  {
    "Object1": "Vitamin A Toxicity (Hypervitaminosis A)",
    "Object2": [
      "Acute (usually due to accidental ingestion by children)",
      "Chronic"
    ],
    "Object3": [
      "Accidental ingestion (children)",
      "Single doses of 300 mg in adults or 100 mg in children (can be harmful)",
      "Vitamin A intakes of >3 mg/day during pregnancy"
    ],
    "Object4": [
      "Headache",
      "Increased intracranial pressure (pseudotumor cerebri)",
      "Nausea (acute)",
      "Vomiting (acute, chronic)",
      "Changes in skin, hair (loss), nails (chronic)",
      "Liver and bone damage (chronic)",
      "Double vision (chronic)",
      "Ataxia (chronic)",
      "Hyperlipidemia (chronic)"
    ],
    "Object5": [
      "Skin changes",
      "Hair loss",
      "Nail changes"
    ],
    "Object6": [
      "Diagnosis is usually clinical"
    ],
    "Object7": [
      "Adjusting the dose almost always leads to complete recovery"
    ],
    "Object8": [
      "Incidence of birth defects in infants (if intake >3 mg/day during pregnancy)"
    ]
  },
  {
    "Object1": "Thiamine (B1) Deficiency (Beriberi)",
    "Object2": [
      "Wet (cardiovascular) beriberi",
      "Infantile beriberi",
      "Shoshin beriberi (acute fulminant cardiovascular beriberi)",
      "Dry beriberi"
    ],
    "Object3": [
      "Lack of thiamine intake (milled rice, raw freshwater fish, raw shellfish, ferns with high thiaminase, foods high in antithiamine factor like tea, coffee, betel nuts)",
      "Alcoholic state",
      "Starvation state",
      "Increased consumption (diets high in carbohydrate or saturated fat, pregnancy and lactation, hyperthyroidism, fever-severe infection, increased physical exercise)",
      "Increased depletion (diarrhea, peritoneal dialysis, hemodialysis, diuretic therapies, hyperemesis gravidarum)",
      "Decreased absorption (chronic intestinal disease, alcoholism, malnutrition, gastric bypass surgery, malabsorption syndrome like celiac and tropical sprue)"
    ],
    "Object4": [
      "Wet: Orthopnea (later stage)",
      "Dry: Bilateral and roughly symmetrical heaviness and stiffness of the legs (early), weakness, numbness, pins and needles (stocking-glove distribution) (later), paresthesias in the toes, burning in the feet (severe at night), muscle cramps in the calves, pains in the legs, plantar dysesthesias"
    ],
    "Object5": [
      "Wet: Vasodilatation, tachycardia, wide pulse pressure, sweating, warm skin, lactic acidosis, congestive heart failure, marked cardiomegaly",
      "Infantile: Edema, aphonia, tachycardia, tachypnea, absent deep tendon reflexes",
      "Dry: Calf muscle tenderness, difficulty rising from a squatting position, decreased vibratory sensation in the toes, lost ankle jerk reflexes"
    ],
    "Object6": [
      "Measurement of thiamine, pyruvate and lactate levels in blood or urine",
      "Erythrocyte thiamine transketolase activity"
    ],
    "Object7": [
      "Complete bed rest",
      "Thiamine 100 mg IM/IV for 7 days, then 10 mg/day orally for several months",
      "Severe cases may need 400-600 mg/day",
      "Parenteral thiamine produces marked diuresis (in wet beriberi)"
    ],
    "Object8": [
      "Infantile: Death if prompt treatment is not given",
      "Dry: Degeneration of thalamus, mammillary bodies, and cerebellum"
    ]
  },
  {
    "Object1": "Wernicke's Encephalopathy",
    "Object2": "Acute neuropsychiatric condition",
    "Object3": [
      "As listed for Thiamine (B1) Deficiency",
      "May be precipitated by administration of intravenous glucose solutions to individuals with thiamine deficiency"
    ],
    "Object4": [
      "Global confusion",
      "Impaired memory and learning"
    ],
    "Object5": [
      "Ophthalmoplegia (nystagmus, lateral rectus palsy, conjugate gaze palsy)",
      "Ataxia (mainly involves stance and gait, due to polyneuropathy, cerebellar involvement, vestibular dysfunction)",
      "Severe disorientation",
      "Indifference",
      "Inattentiveness",
      "Progresses through stupor and coma to death if untreated"
    ],
    "Object6": [
      "Circulating thiamine concentration",
      "Transketolase activity in red cells (fresh heparinized blood)"
    ],
    "Object7": [
      "Medical emergency, immediate administration of thiamine",
      "Thiamine 500 mg intravenously, infused over 30 minutes, three times daily for two consecutive days",
      "Then 250 mg intravenously or intramuscularly once daily for an additional five days, in combination with other B vitamins",
      "Magnesium is often needed (cofactor for thiamine-dependent enzymes)",
      "Glucose administration should be preceded or accompanied by thiamine 100 mg IV in susceptible individuals"
    ],
    "Object8": [
      "Progress to stupor, coma, and death if untreated"
    ]
  },
  {
    "Object1": "Korsakoff's Psychosis/Syndrome",
    "Object2": "Central nervous system involvement in thiamine deficiency",
    "Object3": [
      "Deficiency of thiamine with involvement of central nervous system",
      "Common in chronic alcoholics",
      "May also be seen with thiamine deficiency due to gastric disorders (e.g., carcinoma, chronic gastritis, or persistent vomiting)"
    ],
    "Object4": [
      "Defect in retentive memory (severe defect in storing new information and learning)",
      "Disturbances of short-term memory",
      "Marked deficits in anterograde and retrograde memory",
      "Apathy",
      "Confabulation (fabricated, distorted or misinterpreted memories without conscious intention to deceive)",
      "Relatively preserved long-term memory and other cognitive skills"
    ],
    "Object5": [
      "Intact sensorium",
      "Attention and social behavior are relatively maintained"
    ],
    "Object6": [],
    "Object7": [
      "Parenteral thiamine (100 mg IM daily for 7 days)"
    ],
    "Object8": []
  },
  {
    "Object1": "Riboflavin (B2) Deficiency",
    "Object2": "Not specified",
    "Object3": [],
    "Object4": [],
    "Object5": [
      "Cheilitis",
      "Stomatitis",
      "Glossitis",
      "Normochromic anemia",
      "Seborrheic dermatitis"
    ],
    "Object6": [],
    "Object7": [],
    "Object8": []
  },
  {
    "Object1": "Niacin Deficiency (Pellagra)",
    "Object2": "Metabolic encephalopathy",
    "Object3": [
      "Inadequate intake (Maize or jowar (sorghum) diet, malnutrition, chronic alcoholism, anorexia nervosa)",
      "Generalized malabsorption (rare)",
      "Drug-induced (prolonged isoniazid therapy, pyrazinamide, 6-mercaptopurine, 5-fluouracil, azathioprine, ethionamide, carbamazepine, phenytoin, and phenobarbitone)",
      "Other disorders (Hartnup's disease, Carcinoid syndrome, Pheochromocytoma – tryptophan metabolism diverted)"
    ],
    "Object4": [
      "Dermatitis",
      "Diarrhea (proctitis, malabsorption, anorexia, nausea, glossitis, dysphagia)",
      "Dementia (depression, apathy, sometimes thought disorders, insomnia, anxiety, disorientation, tremor, delusions, encephalopathy)",
      "Burning dysesthesias",
      "Vaginitis",
      "Esophagitis",
      "Vertigo"
    ],
    "Object5": [
      "Casal's necklace or collar rash (hyperpigmented and scaling, sun-exposed areas, forms ring around neck)",
      "Dermatitis (may progress to vesiculation, cracking (ulceration), exudation and secondary infection)",
      "Symmetrical chronic thickening, dryness and pigmentation on dorsal surfaces of the hands",
      "Raw, painful, bright red tongue (glossitis)",
      "Angular stomatitis"
    ],
    "Object6": [],
    "Object7": [
      "Nicotinamide: 100 mg 3 times daily orally (approximately 300 mg daily) with a maintenance dose of 50 mg daily",
      "High-protein diet with adequate nutrients and treatment of malnutrition",
      "Supplementation of other vitamin B complex with iron and folic acid"
    ],
    "Object8": [
      "Death (in severe, untreated cases)"
    ]
  },
  {
    "Object1": "Hypercapnic Encephalopathy (Carbon Dioxide Narcosis)",
    "Object2": "A neurological condition resulting from severe hypercapnia (raised arterial carbon dioxide) leading to central nervous system depression.",
    "Object3": [
      "Alveolar hypoventilation (most common)",
      "Central depression of respiratory drive (brain-stem lesions, central sleep apnea, sedatives like morphine)",
      "Neuromuscular disorders (peripheral neuropathy, Guillain-Barré syndrome, poliomyelitis, myasthenia gravis, myopathies)",
      "Reduced alveolar ventilation due to pathology within the lungs (chronic bronchitis, emphysema)",
      "Reduced chest wall movements (trauma, kyphoscoliosis, pectus excavatum, ankylosing spondylitis)"
    ],
    "Object4": [
      "Headache (severe, generalized, frontal/occipital, worse on waking)",
      "Depressed level of consciousness (drowsiness, indifference, inattention, forgetfulness, confusion, stupor, coma)",
      "Asterixis (flapping tremor)",
      "Flushed warm extremities",
      "Bounding peripheral pulses",
      "Fasciculations (muscle twitching)",
      "Papilledema (swelling of the optic disc)",
      "Mixed cyanosis"
    ],
    "Object5": [
      "Arterial Blood Gas (ABG) study (for confirmation of hypercapnia: PaCO₂ >45 mm Hg)",
      "Investigations for underlying cause"
    ],
    "Object6": [
      "Mechanical ventilation (intermittent positive-pressure respirator, non-invasive ventilation (NIV) for mild symptoms)",
      "Maintenance of acid-base and electrolyte balance",
      "Treatment of the underlying cause",
      "Respiratory stimulants (doxapram, medroxyprogesterone, acetazolamide) (variable benefits)",
      "Precaution: In chronic hypercapnia (e.g., COPD), oxygen should be administered in a controlled manner (about 2 L/minute); avoid morphine and other sedatives."
    ],
    "Object7": [
      "Respiratory failure",
      "Death (if untreated)"
    ]
  },
  {
    "Object1": "Hypoxemia",
    "Object2": "Defined as arterial oxygen tension (PaO₂) of less than 80 mm Hg in a young healthy adult, indicating inadequate oxygenation of the blood.",
    "Object3": [
      "Ventilation-perfusion (V/Q) mismatch (chronic bronchitis, emphysema, acute asthma, pulmonary embolism, interstitial lung diseases)",
      "Hypoventilation (diminished ventilatory drive, impaired neuromuscular transmission, muscle weakness, chest wall disorders, pleural disorders)",
      "Decreased inspired oxygen concentration (high altitudes, malfunctioning mechanical ventilators)",
      "Right-to-left shunts (congenital cyanotic heart diseases, intrapulmonary shunts from alveolar collapse/pneumonia/pulmonary edema/hemorrhage)",
      "Diffusion abnormality (interstitial lung disease, ARDS)"
    ],
    "Object4": [
      "Acute hypoxemia: Impaired judgment, motor incoordination, tachypnea, cyanosis, cold peripheries, thready pulses, hypotension",
      "Chronic hypoxemia: Fatigue, drowsiness, inattentiveness, apathy, delayed reaction time, reduced work capacity"
    ],
    "Object5": [
      "Arterial Blood Gas (ABG) study (for confirmation of hypoxemia)",
      "Calculate alveolar-arterial O₂ (PAO₂-PaO₂) gradient (to differentiate causes)"
    ],
    "Object6": [
      "Treat the underlying cause or mechanism",
      "Oxygen therapy"
    ],
    "Object7": [
      "Respiratory failure",
      "Death (due to brainstem effects)"
    ]
  },
  {
    "Object1": "Clubbing (Hippocrates Fingers)",
    "Object2": "Selective bulbous enlargement of the distal segment of a digit due to an increase in connective tissue, resulting in loss of the onychonychial angle.",
    "Object3": [
      "Grade 1: Increased fluctuation (softening) of nail bed",
      "Grade 2: Loss of normal onychonychial angle",
      "Grade 3: Thickening of the whole distal finger (parrot beak/drumstick)",
      "Grade 4: Hypertrophic osteoarthropathy (pain/tenderness at distal long bones)"
    ],
    "Object4": [
      "Respiratory: Bronchogenic carcinoma, suppurative lung disease (bronchiectasis, lung abscess, cystic fibrosis, empyema), asbestosis, sarcoidosis, pulmonary AV fistula, interstitial lung diseases",
      "Cardiovascular: Infective endocarditis, cyanotic congenital heart diseases (tetralogy of Fallot, Eisenmenger's syndrome), atrial myxoma",
      "Gastrointestinal: Inflammatory bowel disease (UC, Crohn's), primary biliary cirrhosis, hepatoma",
      "Miscellaneous: Hereditary/idiopathic (pachydermoperiostitis), unidigital (repeated trauma), unilateral (hemiplegia, vascular disease, Pancoast tumor, pre-subclavian coarctation, AV fistula for hemodialysis, infected arterial graft)"
    ],
    "Object5": [
      "Platelets: Megakaryocytes bypass pulmonary capillaries, lodge in digits, release PDGF and VEGF, increasing endothelial permeability and fibroblast proliferation.",
      "Humoral: Unknown substances dilate fingertip vessels.",
      "Persistent hypoxia: Opening of deep arteriovenous fistula in fingers.",
      "Reduced ferritin in systemic circulation: Dilation of arteriovenous anastomoses.",
      "Vagal theory: Persistent vagal stimulation causes vasodilation.",
      "Toxic: Subacute bacterial endocarditis.",
      "Metabolic: Thyrotoxicosis."
    ],
    "Object6": [
      "Phalangeal depth ratio (>1 indicates clubbing)",
      "Schamroth's window test (absence of diamond-shaped window)",
      "Lovibond's profile sign, Curth's modified profile sign"
    ],
    "Object7": [
      "Associated with various underlying systemic diseases"
    ]
  },
  {
    "Object1": "Cyanosis",
    "Object2": "Bluish discoloration of the skin and mucous membranes due to increased concentration of reduced hemoglobin (>5 g/dL) or abnormal hemoglobin derivatives (methemoglobin, sulfhemoglobin). Detected when oxygen saturation (SaO₂) is <85%.",
    "Object3": [
      "Central cyanosis (inadequate oxygenation of systemic arterial blood, hypoxic hypoxia)",
      "Peripheral cyanosis (sluggish peripheral circulation, stagnant hypoxia)",
      "Differential cyanosis (e.g., lower limbs in PDA with shunt reversal)",
      "Orthocyanosis (cyanosis only in upright position)",
      "Pseudocyanosis (caused by metals, drugs)"
    ],
    "Object4": [
      "Central: Cardiac (cyanotic congenital heart diseases, acute pulmonary edema), Pulmonary (acute severe asthma, COPD, cor pulmonale, respiratory failure, pneumonia, tension pneumothorax, laryngeal edema), High altitude, Polycythemia, Enterogenous/pigment cyanosis (methemoglobinemia, sulfhemoglobinemia)",
      "Peripheral: Low cardiac output (CHF), local vasoconstriction (cold, frostbite, Raynaud's, shock), arterial obstruction (PVD, Buerger's), venous obstruction (SVC syndrome), hyperviscosity (myeloma, polycythemia, macroglobulinemia), cryoglobulinemia, mitral stenosis"
    ],
    "Object5": [
      "Bluish discoloration of tongue, oral mucosa (central); fingertips, nail beds, earlobes (peripheral)",
      "Dyspnea (central), increased respiratory rate",
      "Clubbing (central), warm extremities (central), cold extremities (peripheral)"
    ],
    "Object6": [
      "Arterial Blood Gas (ABG) (PaO₂ low in central, normal in peripheral)",
      "Hyperoxia test (differentiates cardiac vs. pulmonary cyanosis)"
    ],
    "Object7": [
      "Treat underlying cause",
      "Oxygen therapy"
    ],
    "Object8": [
      "Tissue hypoxia, organ damage"
    ]
  },
  {
    "Object1": "Respiratory (Pulmonary) Function Tests (PFT)",
    "Object2": "A group of diagnostic tests that measure lung volumes, capacities, and airflow rates to assess lung function and diagnose respiratory disorders. Spirometry is a key component.",
    "Object3": [
      "Forced Vital Capacity (FVC): Volume of air expired with maximal effort after deep inspiration.",
      "Forced Expiratory Volume in one second (FEV1): Volume of air expired in the first second of FVC.",
      "FEV1/FVC ratio: Important for distinguishing obstructive from restrictive defects.",
      "Peak Expiratory Flow (PEF): Volume of forcibly expired air during the first 10 seconds after deep inspiration.",
      "Total Lung Capacity (TLC): Volume of air in lungs after maximum inspiration.",
      "Residual Volume (RV): Air remaining in lungs after maximum exhalation.",
      "Inspiratory Capacity (IC), Expiratory Capacity (EC), Inspiratory Reserve Volume (IRV), Expiratory Reserve Volume (ERV), Tidal Volume (TV)",
      "Diffusing Capacity of Lung for Carbon Monoxide (DLCO): Measures gas transfer from alveoli to blood."
    ],
    "Object4": [
      "Obstructive ventilatory defect (e.g., asthma, COPD): Reduced FEV1, reduced FEV1/FVC ratio (<70%), normal/increased TLC/RV. (Airway narrowing, difficulty exhaling)",
      "Restrictive ventilatory defect (e.g., pulmonary fibrosis): Reduced FVC, reduced FEV1, normal/elevated FEV1/FVC ratio, reduced TLC/RV. (Reduced lung volumes/compliance)"
    ],
    "Object5": [
      "Diagnosis and classification of lung diseases (asthma, COPD, ILD)",
      "Monitoring disease progression and response to treatment",
      "Assessing surgical risk",
      "Differentiation of dyspnea causes"
    ],
    "Object6": [
      "Flow-volume loops (visualize airflow limitation site)",
      "Arterial Blood Gases (ABG) and oximetry (assess gas exchange, acid-base)",
      "Alveolar-arterial O2 tension gradient (V/Q inequality)",
      "Dyspnea differentiation index (DDI) (respiratory vs. cardiac dyspnea)",
      "Exercise tests (6-minute walk test, VO2 Max for cardiopulmonary reserve)",
      "Exhaled Nitric Oxide (FeNO) (biomarker for airway inflammation, steroid responsiveness)"
    ]
  },
  {
    "Object1": "Bronchoscopy",
    "Object2": "An endoscopic procedure that allows visualization of the tracheobronchial tree using a flexible or rigid bronchoscope. It is used for both diagnostic and therapeutic purposes.",
    "Object3": [
      "Diagnostic:",
      "Diagnosis of lung cancer (visualization, biopsy, washings, brushings)",
      "Evaluation of hemoptysis (identify bleeding source)",
      "Evaluation of persistent or recurrent cough",
      "Diagnosis of diffuse lung disease (transbronchial biopsy, BAL)",
      "Identification of infecting agents (BAL for pneumonia, TB, PCP)",
      "Staging of lung cancer",
      "Evaluation of vocal cord paralysis",
      "To obtain positive sputum cytology",
      "Therapeutic:",
      "Removal of foreign bodies",
      "Aspiration of secretions (e.g., mucus plugs in atelectasis)",
      "Relief of tracheobronchial narrowing (laser treatment, stent placement)",
      "Delivery of endobronchial radiotherapy (brachytherapy)",
      "Tamponade of endobronchial bleeding"
    ],
    "Object4": [
      "Bleeding, pneumothorax, infection, bronchospasm, hypoxia, arrhythmias"
    ]
  },
  {
    "Object1": "Breath Sounds",
    "Object2": "Sounds generated by airflow through the respiratory tract, assessed during auscultation of the chest. Abnormal breath sounds indicate various underlying lung pathologies.",
    "Object3": [
      "Vesicular breath sounds: Soft, low-pitched, rustling, inspiration longer than expiration, no gap (normal). Diminished in asthma, emphysema, pleural effusion, atelectasis.",
      "Bronchial breath sounds: Loud, high-pitched, inspiration and expiration equal duration, gap between them (normal over trachea/large bronchi, abnormal over lung parenchyma).",
      "Tubular bronchial breathing: High-pitched, heard in consolidation, partially collapsed lung, above pleural effusion.",
      "Cavernous bronchial breathing: Low-pitched, heard over thick-walled cavity with communicating bronchus.",
      "Amphoric bronchial breathing: Low-pitched, high-tone, metallic quality, heard in bronchopleural fistula, superficial cavity, tension pneumothorax.",
      "Bronchovesicular breath sound: Prolonged expiration, no gap (obstructive lung disease)."
    ],
    "Object4": [
      "Crackles (rales): Discontinuous, popping sounds (fine/coarse), heard in pneumonia, pulmonary edema, fibrosis, bronchiectasis.",
      "Wheezes (rhonchi): Continuous, musical, high-pitched (sibilant) or low-pitched (sonorous), heard in asthma, COPD, bronchial obstruction.",
      "Pleural friction rub: Creaking, leathery sound, heard in pleurisy, pleural effusion.",
      "Stridor: Harsh inspiratory noise, heard in upper airway obstruction (laryngeal edema, tracheal stenosis)."
    ],
    "Object5": [
      "Aids in localizing and characterizing lung pathology, guiding diagnosis and management."
    ]
  },
  {
    "Object1": "Occupational Asthma",
    "Object2": [
      "Specific occupational sensitizers (proteins, glycopeptides) that trigger an allergic response.",
      "Examples: Fumes (epoxy resins, plastics), organic/chemical dusts (wood, cotton, platinum), gases (toluene diisocyanate), animal allergens, plants/plant products (flours, cereals), other chemicals (formaldehyde, penicillin products)."
    ],
    "Object3": [
      "Asthma symptoms (wheeze, cough, dyspnea, chest tightness) developing or worsening at work, improving away from work.",
      "Often associated with allergic rhinitis/conjunctivitis.",
      "Latency period between exposure and symptom onset can range from weeks to years.",
      "Work-exacerbated asthma: Preexisting asthma subjectively worsening at workplace."
    ],
    "Object4": [
      "Detailed occupational history (identify specific exposures, timing of symptoms)",
      "Spirometry (pre/post-shift FEV1 measurements showing work-related decline, or serial PEF monitoring)",
      "Bronchial provocation tests with suspected occupational agents (diagnostic, performed under medical supervision)",
      "Skin prick tests or specific IgE to occupational allergens."
    ],
    "Object5": [
      "Primary prevention: Avoid sensitizer agent (most important).",
      "Secondary prevention: Medical surveillance programs.",
      "Tertiary prevention: Treatment as per asthma severity (bronchodilators, inhaled corticosteroids).",
      "Removal from exposure is crucial, ideally with job transfer if sensitizer cannot be avoided."
    ],
    "Object6": [
      "Chronic asthma if exposure continues",
      "Permanent lung function impairment"
    ]
  },
  {
    "Object1": "Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)",
    "Object2": [
      "Immune-mediated lung disease due to inhalational exposure to a variety of antigens, leading to diffuse inflammatory reaction in alveoli and small airways.",
      "Involves TH1 and TH17 lymphocyte subsets.",
      "Examples:",
      "Farming/Food processing: Farmer's lung (moldy hay, thermophilic actinomycetes), Bagassosis (sugarcane), Mushroom worker's lung, Coffee worker's lung, Malt worker's lung, Miller's lung, Tobacco grower's lung.",
      "Birds and other animals: Bird fancier's lung (avian droppings/feathers).",
      "Other: Humidifier/air-conditioner lung (contaminated water/microbes), Woodworker's lung."
    ],
    "Object3": [
      "Acute form: Onset 4-8 hours post-exposure: fevers, chills, cough, malaise, dyspnea. Resolves in hours-days with no further exposure.",
      "Subacute form: Gradual onset over weeks-months: cough, dyspnea, cyanosis, systemic symptoms.",
      "Chronic form: Most common. More gradual onset over months-years: progressive dyspnea, cough, fatigue, weight loss, clubbing. Clinically resembles pulmonary fibrosis.",
      "Most patients (80-95%) are non-smokers."
    ],
    "Object4": [
      "Chest X-ray: Diffuse micronodular shadowing, streaky shadows, honeycomb lung (late).",
      "HRCT: Reticular/nodular changes, ground-glass opacity.",
      "Blood: Elevated ESR, neutrophilia (acute), normal eosinophils/IgE. Precipitating antibodies (evidence of exposure, not disease).",
      "Lung function tests: Restrictive ventilatory defect (reduced FVC/FEV1, normal FEV1/FVC), impaired DLCO (chronic).",
      "Bronchoscopy with BAL: Increased T-lymphocytes (often CD4:CD8 ratio <1 in HP, vs >2 in sarcoidosis).",
      "Lung biopsy: Chronic inflammatory cells, ill-defined non-caseating granulomas, fibrosis (late).",
      "Provocation test (controlled exposure to antigen): Respiratory/systemic findings, reduced DLCO/VC, increased radiographic abnormalities, worsening A-a gradient."
    ],
    "Object5": [
      "Prevention: Identification and avoidance of offending antigen (most important).",
      "Corticosteroids: Prednisolone (acute/subacute/chronic, high doses initially, then tapering). Effective in early stages, not for established fibrosis.",
      "Oxygen therapy (for hypoxemia).",
      "Symptomatic bronchodilator therapy."
    ],
    "Object6": [
      "Diffuse pulmonary interstitial fibrosis",
      "Pulmonary hypertension, cor pulmonale"
    ]
  },
  {
    "Object1": "Drug-induced Asthma",
    "Object2": [
      "Aspirin (aspirin-induced asthma, AIA) (most common, especially in Samter's triad)",
      "NSAIDs (ibuprofen, indomethacin, naproxen)",
      "Beta-blockers",
      "Adenosine, prostaglandin analogues",
      "Cholinergic drugs",
      "Streptomycin, pentazocine, penicillin",
      "Non-pharmaceutical agents: Tartrazine (coloring agent), sulfating agents (preservatives in food/medicines)"
    ],
    "Object3": [
      "AIA: Decreased production of prostaglandin E₂ (PGE₂) and enhanced production of leukotriene B₄ (LTB₄).",
      "Beta-blockers: Block beta-2 adrenergic receptors in airways, causing bronchoconstriction."
    ],
    "Object4": [
      "Bronchospasm, wheezing, dyspnea, cough triggered by specific drugs.",
      "AIA: Cutaneous form (urticaria, angioedema), respiratory form (rhinoconjunctivitis, bronchospasm). Often associated with nasal polyps, vasomotor rhinitis, hyperplastic rhinosinusitis (Samter's triad)."
    ],
    "Object5": [
      "Clinical history of drug exposure and correlation with asthma symptoms.",
      "Bronchial challenge with suspected drug (e.g., aspirin) (diagnostic, under supervision)."
    ],
    "Object6": [
      "Treat underlying asthma (bronchodilators, corticosteroids).",
      "Strict avoidance of offending drug and cross-reacting agents.",
      "Aspirin-sensitive patients: Use acetaminophen, selective COX2 inhibitors.",
      "Leukotriene receptor antagonists may be beneficial in AIA."
    ],
    "Object7": [
      "Acute severe asthma, anaphylaxis (rare with asthma-inducing drugs)."
    ]
  },
  {
    "Object1": "Chronic Bronchitis",
    "Object2": "A clinical diagnosis of chronic productive cough for three months in each of two successive years, after excluding other causes of chronic cough. It is a component of COPD.",
    "Object3": [
      "Smoking (most important)",
      "Air pollution",
      "Respiratory infections"
    ],
    "Object4": [
      "Hypertrophy and hyperplasia of submucosal mucus-secreting glands (Reid index increased)",
      "Increased goblet cells in small airways, leading to mucus plugging",
      "Chronic inflammation and fibrosis of bronchial walls",
      "Narrowing of bronchioles"
    ],
    "Object5": [
      "Chronic productive cough ('winter cough', 'morning cough'), often purulent sputum",
      "Dyspnea (develops later than cough)",
      "Wheezing and chest tightness",
      "Physical signs: Overweight, cyanosis ('blue bloaters'), rhonchi, prolonged expiration"
    ],
    "Object6": [
      "Spirometry: Obstructive pattern (reduced FEV1, FEV1/FVC)",
      "Chest X-ray: Increased bronchovascular markings, cardiomegaly (in 'blue bloaters')",
      "ABG: Hypoxemia, hypercapnia (in severe cases)"
    ],
    "Object7": "Refer to COPD management, with emphasis on smoking cessation and antibiotics for exacerbations."
  },
  {
    "Object1": "Emphysema (Pulmonary)",
    "Object2": "An anatomical diagnosis of irreversible enlargement of airspaces distal to terminal bronchioles, with destruction of alveolar walls without obvious fibrosis. It is a component of COPD.",
    "Object3": [
      "Centriacinar (centrilobular): Affects central parts of acini (respiratory bronchioles), common in upper lobes, heavy smokers.",
      "Panacinar (panlobular): Uniform dilation of all airspaces, common in lower lobes, associated with α1-antitrypsin deficiency.",
      "Distal acinar (paraseptal): Affects distal airspaces, near pleura, causes bullae, risk of pneumothorax.",
      "Irregular (scar/cicatricial): Irregular involvement, common near scars, often asymptomatic."
    ],
    "Object4": [
      "Protease-antiprotease imbalance (e.g., α1-antitrypsin deficiency - leading to early, severe panacinar emphysema)",
      "Oxidant-antioxidant imbalance",
      "Cigarette smoke (induces inflammation, protease release from macrophages/neutrophils, oxidative stress)",
      "Cell death (apoptosis/necrosis) of epithelial cells",
      "Insufficient repair of damaged alveolar parenchyma"
    ],
    "Object5": [
      "Progressive dyspnea (most striking, insidious onset), often presenting with minimal cough ('pink puffers')",
      "Scanty mucoid sputum",
      "Weight loss, weakness, anorexia (in advanced disease)",
      "Physical signs: Asthenic build, barrel chest, pursed-lip breathing, use of accessory muscles, diminished breath sounds, prolonged expiration, reduced cardiac/liver dullness."
    ],
    "Object6": [
      "Spirometry: Obstructive pattern (reduced FEV1, FVC, FEV1/FVC), increased TLC, RV.",
      "Chest X-ray: Hyperlucency, flattened diaphragm, paucity of vascular markings, bullae, tubular heart.",
      "HRCT: Confirms and quantifies emphysema.",
      "DLCO: Reduced (due to alveolar destruction).",
      "ABG: Normal PaCO2 (early), hypoxemia."
    ],
    "Object7": "Refer to COPD management. No specific treatment for established emphysema; focus on preventing progression (smoking cessation), treating complications."
  },
  {
    "Object1": "Emphysema predominance",
    "Object2": [
      "Thin and non-cyanotic at rest ('pink')",
      "Marked dyspnea ('puffer'), often with pursed-lip breathing",
      "Minimal cough and sputum production",
      "Late and mild pulmonary hypertension and right ventricular failure",
      "Normal PaCO₂ (early), hypoxemia"
    ]
  },
  {
    "Object1": "Asthma COPD Overlap Syndrome (ACOS)",
    "Object2": "A condition characterized by persistent airflow limitation with features of both asthma and COPD.",
    "Object3": [
      "Persistent airflow limitation (FEV1/FVC <0.70)",
      "Features of both asthma (history of atopy, allergic rhinitis, positive bronchodilator response) and COPD (age >40, smoking history >10 pack-years)",
      "Significant bronchodilator response (≥15% or ≥200 mL increase in FEV1 post-bronchodilator)"
    ],
    "Object4": [
      "Often involves a combination of treatments for both asthma and COPD, including inhaled corticosteroids (ICS) and long-acting bronchodilators (LABA/LAMA)."
    ],
    "Object5": [
      "Worse prognosis than either asthma or COPD alone"
    ]
  },
  {
    "Object1": "Atypical Mycobacterial Infections (NTM/MOTT)",
    "Object2": "Ubiquitous environmental mycobacteria that usually cause infection in immunocompromised individuals or those with underlying lung disease. Their isolation from non-sterile sites does not automatically indicate disease.",
    "Object3": [
      "Slow growing:",
      "Group I Photochromogens (pigment in light): Mycobacterium kansasii (lung disease, skin), M. marinum (skin, swimming pool granuloma)",
      "Group II Scotochromogens (pigment in dark): M. scrofulaceum (lymphadenitis)",
      "Group III Non-photochromogens (no pigment): M. avium complex (MAC, most common in HIV, pulmonary/disseminated disease), M. xenopi, M. malmoense",
      "Fast growing (3-5 days): M. fortuitum, M. chelonae (skin/soft tissue, post-surgical), M. abscessus"
    ],
    "Object4": [
      "Pulmonary MAC: Chronic cough, dyspnea, weight loss, often cavitary or nodular lesions on imaging.",
      "Disseminated MAC (HIV): Fever, weight loss, night sweats, abdominal pain, diarrhea, hepatosplenomegaly, lymphadenopathy, anemia.",
      "Skin infections: Nodules, ulcers, granulomas (M. marinum, M. ulcerans)."
    ],
    "Object5": [
      "Culture of organism from sterile sites (sputum, BAL, biopsy)",
      "PCR for species identification",
      "Chest CT (for pulmonary disease)",
      "Biopsy (for skin lesions)"
    ],
    "Object6": [
      "Combination antibiotic therapy, often prolonged (6-18 months), specific to species and susceptibility.",
      "MAC: Clarithromycin/azithromycin + ethambutol +/- rifabutin (for >12 months).",
      "M. kansasii: Rifampin + ethambutol + isoniazid (for >18 months).",
      "Rapid growers: Doxycycline, amikacin, imipenem, quinolones, sulfonamides.",
      "Surgery for localized lesions."
    ],
    "Object7": [
      "Chronic lung disease, respiratory failure",
      "Disseminated infection, sepsis",
      "Drug resistance, treatment failure"
    ]
  },
  {
    "Object1": [
      "Sputum examination: Direct microscopic examination for Acid-Fast Bacilli (AFB) (Ziehl-Neelsen or rhodamine-auramine stain) (first step). 2 positive smears diagnostic.",
      "Culture of sputum/BAL/gastric washings: Gold standard, identifies species, drug sensitivity (Löwenstein-Jensen, liquid media like MGIT).",
      "Nucleic Acid Amplification (NAA) tests (e.g., GeneXpert MTB/RIF): Rapid detection of M. tuberculosis DNA and rifampicin resistance.",
      "Tuberculin Skin Test (Mantoux test): Positive (induration ≥10mm, or ≥5mm in high-risk groups) indicates exposure/infection, not active disease. False negatives/positives occur.",
      "Interferon Gamma Release Assays (IGRAs): Detect T-cell response to M. tuberculosis specific antigens (ESAT-6, CFP10). Differentiates latent from active TB, but not always. Not affected by BCG vaccination.",
      "Chest X-ray (CXR): Infiltrates (upper zone in secondary TB), cavitation, calcified lesions, pleural effusion, miliary mottling (miliary TB), hilar lymphadenopathy (primary TB).",
      "CT chest: Better delineation of lesions, 'tree-in-bud' appearance, nodal involvement.",
      "Biopsy (lymph node, pleural, liver, bone marrow): Histology (caseating granulomas), AFB stain, culture.",
      "CSF analysis (for TB meningitis): Lymphocytic pleocytosis, low glucose, high protein, AFB stain/culture/PCR.",
      "Blood: Anemia, leukocytosis/leukopenia, elevated ESR/CRP.",
      "Serology (ELISA) (low specificity)."
    ],
    "Object2": [
      "Drug Susceptibility Testing (DST): On culture isolates (phenotypic) or by molecular methods (GenXpert, Line Probe Assay for genotypic resistance)."
    ]
  },
  {
    "Object1": [
      "Multi-drug regimens (to kill dividing, persisting bacilli, prevent resistance).",
      "Initial Intensive Phase (2-3 months): Rapidly kill most bacilli, render non-infectious. (HRZE daily: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol).",
      "Continuation Phase (4-7 months): Eliminate remaining bacilli, prevent relapse. (HR daily: Isoniazid, Rifampicin).",
      "Regimens for new cases (Category 1): 2HRZE/4HR (6 months total).",
      "Regimens for previously treated cases (Category 2): Longer, more intensive regimens (e.g., 2HRZES/1HRZE/5HRE - 8 months total).",
      "Directly Observed Treatment, Short Course (DOTS): Intermittent regimens (thrice-weekly) with direct supervision (now mostly daily regimens in many programs).",
      "Corticosteroids (adjunctive): For severe TB (meningitis, pericarditis, extensive pulmonary TB, severe hypersensitivity reactions, hypoadrenalism, large effusions)."
    ],
    "Object2": [
      "MDR-TB (resistant to INH + Rifampicin): Longer regimens (9-24 months) with second-line drugs (fluoroquinolones, aminoglycosides/capreomycin, ethionamide, cycloserine, bedaquiline, delamanid, pretomanid).",
      "XDR-TB (MDR + resistance to fluoroquinolones + one injectable second-line drug): Even more complex regimens.",
      "Management in specialized centers."
    ],
    "Object3": [
      "ART should be started in all HIV-TB co-infected patients, usually 2-8 weeks after starting TB treatment.",
      "Regimen choice: Consider drug-drug interactions (Rifampicin and PIs/NNRTIs), co-formulations (e.g., TDF/3TC/EFV)."
    ],
    "Object4": [
      "For latent TB infection (LTBI) to prevent progression to active disease.",
      "Indications: Close contacts of active TB cases (especially children <5 years, HIV-infected, recent converters), newly infected, immunosuppressed patients.",
      "Regimen: INH (6-12 months) or INH+Rifampicin (3 months)."
    ]
  },
  {
    "Object1": [
      "Cavitation, massive hemoptysis (Rasmussen's aneurysm, aspergilloma), pulmonary fibrosis, bronchiectasis, pneumothorax, empyema, obstructive airways disease, lung cancer, broncholithiasis."
    ],
    "Object2": [
      "TB meningitis, Pott's disease (spinal TB with cord compression), psoas abscess, renal TB, bladder TB (contracture), GI TB (strictures, obstruction), pericarditis (constrictive pericarditis), Addison's disease (adrenal TB), infertility, amyloidosis."
    ],
    "Object3": [
      "Miliary TB, sepsis, cachexia, drug resistance, immune reconstitution inflammatory syndrome (IRIS) in HIV patients."
    ]
  },
  {
    "Object1": "Atelectasis (Lung Collapse)",
    "Object2": "Incomplete expansion of lungs or complete collapse of previously inflated lung parenchyma, leading to airless pulmonary parenchyma.",
    "Object3": [
      "Obstructive (absorption) atelectasis: Due to complete airway obstruction (mucus plugs, foreign body, tumors). Air distal to obstruction absorbed. Mediastinum shifts TOWARDS collapsed lung.",
      "Nonobstructive atelectasis:",
      "Compression atelectasis: Lung compressed by space-occupying lesion (tumors, cysts, large effusion/pneumothorax). Mediastinum shifts AWAY from collapsed lung.",
      "Relaxation (passive) atelectasis: Contact lost between visceral/parietal pleura due to fluid/air in pleural cavity.",
      "Fibrotic (cicatrisation/contraction) atelectasis: Pulmonary/pleural fibrosis prevents lung expansion.",
      "Surfactant deficiency/dysfunction: Increased alveolar surface tension (ARDS, preterm neonates)."
    ],
    "Object4": [
      "Intrabronchial obstruction (mucus plugs, foreign body, bronchial tumors)",
      "Extrabronchial compression (tumors, enlarged lymph nodes, cardiomegaly, chest wall defects)",
      "Pleural fluid/air accumulation (effusion, pneumothorax)",
      "Fibrosis (pulmonary, pleural)",
      "Surfactant deficiency (ARDS, meconium aspiration)"
    ],
    "Object5": [
      "Often asymptomatic if slow onset/small area.",
      "Chronic atelectasis: Nidus for chronic infection, bronchiectasis.",
      "Physical signs: Reduced chest movement, tracheal deviation towards affected side (obstructive/fibrotic), dullness to percussion, absent breath sounds."
    ],
    "Object6": [
      "Chest X-ray: Homogenous opacification, displacement of fissure, volume loss, mediastinal shift.",
      "CT chest: Confirms findings.",
      "Bronchoscopy (identifies/removes obstructive lesions).",
      "ABG (hypoxemia, hypocapnia initially)."
    ],
    "Object7": [
      "Treat underlying cause.",
      "Emergency bronchoscopy (for mucus plug, foreign body removal).",
      "Physiotherapy (chest percussion, deep breathing)."
    ],
    "Object8": [
      "Infection, bronchiectasis, respiratory failure."
    ]
  },
  {
    "Object1": "Ciliary Dysfunction Syndromes (Primary Ciliary Dyskinesia - PCD)",
    "Object2": "Genetic disorders with dysfunction of cilia (respiratory tract, sperm) leading to impaired mucociliary clearance, left-right body asymmetry, and male infertility.",
    "Object3": [
      "Kartagener's syndrome (most classical): Recurrent sinusitis, bronchiectasis, situs inversus (dextrocardia), male infertility (due to dynein arm defects).",
      "Young's syndrome: Bronchiectasis, sinusitis, obstructive azoospermia."
    ],
    "Object4": [
      "Recurrent respiratory infections and bronchiectasis (from infancy/childhood)",
      "Chronic sinusitis, rhinorrhea, nasal polyps",
      "Otitis media, cholesteatoma, hearing loss",
      "Male infertility",
      "Situs inversus totalis (in ~50% of PCD), complex congenital heart disease",
      "Respiratory distress in neonates"
    ],
    "Object5": [
      "Exhaled nasal nitric oxide (low).",
      "Mucociliary clearance test (saccharin test: prolonged clearance time).",
      "Electron microscopy of ciliary biopsies (detects structural abnormalities like dynein arm defects).",
      "Genetic testing (PCD genes)."
    ],
    "Object6": [
      "No definite cure.",
      "Manage bronchiectasis (secretion clearance, antibiotics) - refer to bronchiectasis treatment.",
      "Avoid cough suppressants.",
      "Hearing aids for hearing loss.",
      "Assisted reproductive technologies for infertility."
    ],
    "Object7": [
      "Chronic respiratory infections, progressive bronchiectasis, respiratory failure",
      "Hearing loss",
      "Male infertility"
    ]
  },
  {
    "Object1": "Suppurative Pneumonias (Necrotizing Pneumonias)",
    "Object2": "Pneumonic consolidation characterized by destruction of lung parenchyma by inflammation, leading to microabscess formation or localized collections of pus (lung abscess).",
    "Object3": [
      "Infectious causes: Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus pyogenes, anaerobes (mouth flora, in aspiration), M. tuberculosis, fungi (Aspergillus), parasites (Entamoeba histolytica, Paragonimus).",
      "Noninfectious causes: Neoplasms (primary lung cancer, metastases), pulmonary infarction, septic embolism, vasculitis (Wegener's), developmental (sequestration)."
    ],
    "Object4": "Refer to Lung Abscess."
  },
  {
    "Object1": "Lung Abscess",
    "Object2": [
      "Primary cryptogenic lung abscesses (most common, due to aspiration of infected material): Aspiration pneumonia (anaerobes, streptococci, H. influenzae) in patients with depressed cough reflex (alcoholics, neurological disease, anesthesia). Often single, right lung (dependent segments).",
      "Secondary lung abscesses (complication of other conditions):",
      "Necrotizing pneumonia (S. aureus, K. pneumoniae, type 3 Pneumococcus).",
      "Pulmonary tuberculosis (cavitary TB).",
      "Septic embolism (from endocarditis, thrombophlebitis).",
      "Bronchial obstruction (by tumor, foreign body, stricture) with secondary infection.",
      "Direct penetrating trauma, spread from neighboring organs (subphrenic abscess, esophageal perforation).",
      "Amebic liver abscess (direct extension through diaphragm, typically right lower lobe).",
      "Infected cavitary malignancy, pulmonary infarct."
    ],
    "Object3": [
      "Acute (symptoms <1 month): Dry cough, high-grade fever, chills, rigors, pleuritic chest pain. Later, expectoration of large quantities of foul-smelling, purulent/sanguineous sputum (when abscess ruptures into bronchus).",
      "Chronic (symptoms >1 month): Insidious onset low-grade fever, malaise, weight loss, anorexia, deep-seated chest pain.",
      "Physical signs: Anemia, fever, clubbing (may develop rapidly), halitosis, oronasal sepsis. Signs of consolidation/cavitation (dullness, bronchial breathing, coarse post-tussive crepitations)."
    ],
    "Object4": [
      "Blood: Anemia, leukocytosis, elevated ESR/CRP.",
      "Sputum: Gram stain, Z-N stain, culture/sensitivity (aerobic/anaerobic), cytology (malignancy). Foul-smelling sputum suggestive of anaerobes.",
      "Chest X-ray: Radiolucency within an opaque area of consolidation, often with air-fluid level.",
      "CT scan chest: Diagnostic, better delineation of abscess.",
      "Bronchoscopy: To exclude malignancy, obtain specimens, remove secretions (therapeutic)."
    ],
    "Object5": [
      "Postural drainage and chest physiotherapy.",
      "Antibiotic therapy: Prolonged course (4-6 weeks) based on culture/sensitivity. Oral (ampicillin, co-trimoxazole, clindamycin, metronidazole for anaerobes) or parenteral (beta-lactamase inhibitors, carbapenems).",
      "Percutaneous catheter drainage (for large abscesses).",
      "Resectional surgery (lobectomy/pneumonectomy): For massive hemoptysis, associated symptomatic bronchiectasis, localized malignancy, persistent cavity, large cavities (>8cm), resistant organisms."
    ],
    "Object6": [
      "Empyema, pneumothorax, pyopneumothorax, bronchopleural fistula, pleural effusion, pleurocutaneous fistula (rupture into pleural cavity).",
      "Hemorrhage, massive hemoptysis.",
      "Septic emboli (brain abscesses, meningitis).",
      "Secondary amyloidosis, aspergilloma.",
      "Residual fibrosis and bronchiectasis."
    ]
  },
  {
    "Object1": "Cystic Fibrosis (CF)",
    "Object2": [
      "Autosomal recessive genetic disorder (mutation in CFTR gene on chromosome 7).",
      "Defect in chloride channel (CFTR protein) leads to inability to adequately hydrate mucus."
    ],
    "Object3": [
      "Multisystem disease, presentation varies by age, severity.",
      "Respiratory tract: Chronic sinusitis, nasal polyps. Earliest is small airways disease (cough), progressing to bronchiectasis, recurrent infections (Pseudomonas aeruginosa), respiratory failure, hemoptysis, pneumothorax, clubbing, cor pulmonale.",
      "Gastrointestinal tract: Meconium ileus (neonatal), pancreatic exocrine insufficiency (steatorrhea, weight loss, fat-soluble vitamin deficiencies, diabetes mellitus), intestinal obstruction, appendicitis, liver disease (focal biliary cirrhosis, cholelithiasis).",
      "Genitourinary tract: Late puberty, male infertility (obstructive azoospermia), subfertility in women.",
      "Other: Aquagenic wrinkling of palms, heat stroke, growth retardation."
    ],
    "Object4": [
      "Newborn screening (immunoreactive trypsinogen - IRT, followed by genetic testing).",
      "Sweat chloride test (diagnostic, chloride >60 mEq/L).",
      "Genetic testing (CFTR gene mutations).",
      "Nasal bioelectrical response (trans-epithelial potential difference - TEPD).",
      "Sputum culture (Pseudomonas, S. aureus).",
      "Pulmonary function tests (obstructive pattern).",
      "Chest CT (bronchiectasis, mucus plugging)."
    ],
    "Object5": [
      "Clear secretions (breathing exercises, flutter valves, chest percussion, recombinant human DNAse - dornase alpha, hypertonic saline).",
      "Infection control (long courses of antibiotics, oral/IV/aerosolized, tailored to sputum cultures; antipseudomonal agents).",
      "Pancreatic enzyme replacement therapy (PERT) (for exocrine insufficiency).",
      "Nutritional support (high-calorie diet, fat-soluble vitamin supplementation).",
      "CFTR modulators (ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor, elexacaftor/tezacaftor/ivacaftor) (for specific CFTR mutations).",
      "Management of complications (bronchodilators for obstruction, surgery for complications, lung transplantation for ESRD)."
    ],
    "Object6": [
      "Respiratory failure (major cause of morbidity/mortality)",
      "Bronchiectasis, recurrent infections, hemoptysis, pneumothorax",
      "Cor pulmonale",
      "Diabetes mellitus",
      "Liver disease (cirrhosis, portal hypertension)",
      "Male infertility",
      "Malabsorption, malnutrition, fat-soluble vitamin deficiencies"
    ]
  },
  {
    "Object1": "Re-expansion Pulmonary Edema",
    "Object2": "Non-cardiogenic pulmonary edema occurring after rapid inflation of a collapsed lung (e.g., after drainage of large pleural effusion or pneumothorax, especially if prolonged collapse).",
    "Object3": [
      "Rapid, large volume drainage of pleural fluid (>1-1.5 L)",
      "Prolonged lung collapse (>3 days)",
      "High negative intrapleural pressure during drainage"
    ],
    "Object4": [
      "Inflammatory response, generation of reactive oxygen species.",
      "Increased capillary permeability, increased pulmonary hydrostatic pressure.",
      "Mechanical disruption of alveolar capillaries, reduced surfactant function."
    ],
    "Object5": [
      "Develops within 24 hours (majority 1-2 hours) post-re-expansion.",
      "Chest discomfort, persistent severe cough, dyspnea, frothy sputum.",
      "Tachypnea, tachycardia, crackles on affected side.",
      "Chest X-ray: Features of pulmonary edema."
    ],
    "Object6": [
      "Supportive care (oxygen, mechanical ventilation for severe cases).",
      "Position patient on unaffected side.",
      "Diuretics, bronchodilators, steroids (controversial)."
    ],
    "Object7": [
      "Restrict fluid drainage to <1-1.5 L at a time.",
      "Avoid high negative pressure during drainage.",
      "Monitor pleural pressures, stop drainage if chest pressure/pain occurs."
    ],
    "Object8": [
      "Respiratory failure, death (mortality ~20%)."
    ]
  },
  {
    "Object1": "Subpulmonic Effusion",
    "Object2": "A small pleural effusion located beneath the lung, often difficult to detect on standard CXR.",
    "Object3": [
      "Clinical: Obliteration of Traube's space (left-sided), abnormal tidal percussion (right-sided).",
      "Chest X-ray (PA erect): Mild elevation of hemidiaphragm, lateral displacement/flattening of diaphragm dome, wide density between gastric air shadow and diaphragm (left-sided).",
      "Lateral decubitus X-ray: Fluid layering along lateral chest wall.",
      "Ultrasonography: Confirms effusion."
    ]
  },
  {
    "Object1": "Hemorrhagic Pleural Effusion (Hemothorax)",
    "Object2": "Accumulation of blood within the pleural cavity (hemothorax) or bloody pleural fluid (hemorrhagic effusion).",
    "Object3": [
      "Hemothorax (pleural fluid hematocrit >50% of peripheral blood): Trauma (most common), rupture of blood vessel, rupture of tumor.",
      "Hemorrhagic pleural effusion (pleural fluid hematocrit <50% of peripheral blood): Malignancy, pulmonary infarction, asbestos-related, tuberculosis (rare), post-cardiac injury."
    ],
    "Object4": [
      "Dyspnea, chest pain, symptoms of hypovolemia/anemia (if significant blood loss).",
      "Signs of pleural effusion."
    ],
    "Object5": [
      "Pleural fluid analysis: Bloody fluid. Hematocrit (differentiates hemothorax from hemorrhagic effusion).",
      "CT chest: Identifies source of bleeding, underlying pathology."
    ],
    "Object6": [
      "Treat underlying cause.",
      "Chest tube drainage (for hemothorax, large hemorrhagic effusions).",
      "Surgical intervention (for persistent bleeding)."
    ]
  },
  {
    "Object1": "Malignant Pleural Effusion",
    "Object2": "Pleural effusion due to malignancy, either primary (mesothelioma) or secondary (metastasis from other cancers).",
    "Object3": [
      "Metastatic cancer (most common): Lung cancer (35%), breast cancer (25%), lymphomas (10%).",
      "Primary pleural malignancy: Malignant mesothelioma."
    ],
    "Object4": [
      "Tumor invasion of pleura, lymphatic obstruction, bronchial obstruction with pneumonia/atelectasis, systemic effects of tumor."
    ],
    "Object5": [
      "Dyspnea (most common), chest pain.",
      "Usually unilateral, massive, recurrent effusion.",
      "Symptoms of underlying malignancy (weight loss, fatigue)."
    ],
    "Object6": [
      "Pleural fluid analysis: Often hemorrhagic, exudative (high protein, high LDH, low glucose), lymphocytic predominance. Cytological examination for malignant cells (positive in ~60%).",
      "Closed pleural biopsy (may reveal malignancy, ~40% yield).",
      "Thoracoscopy with biopsy (higher diagnostic yield).",
      "CT chest: Identifies primary tumor, pleural nodules/thickening."
    ],
    "Object7": [
      "Treat underlying malignancy.",
      "Therapeutic aspiration (for symptomatic relief).",
      "Pleurodesis (for recurrent symptomatic effusions: talc slurry, tetracycline) to prevent fluid re-accumulation.",
      "Indwelling pleural catheter (for refractory cases).",
      "Chemotherapy (intrapericardial for malignant effusion, systemic for underlying cancer)."
    ],
    "Object8": [
      "Recurrence, dyspnea, pain.",
      "Trapped lung, empyema (rare)."
    ]
  },
  {
    "Object1": "Parapneumonic Effusion (Synpneumonic/Postpneumonic Effusion)",
    "Object2": "Pleural effusion developing as a complication of pneumonia, lung abscess, or bronchiectasis. Empyema is a grossly purulent parapneumonic effusion.",
    "Object3": [
      "Bacterial pneumonia (most common, especially gram-negative, pneumococcal)",
      "Lung abscess, bronchiectasis",
      "Less frequent with viral pneumonias."
    ],
    "Object4": [
      "Symptoms of pneumonia (fever, chest pain, cough, sputum)",
      "Symptoms/signs of pleural effusion."
    ],
    "Object5": [
      "Nonsignificant (<1 cm on decubitus view): Antibiotics.",
      "Typical (>1 cm, glucose >40, pH >7.20, negative Gram/culture): Antibiotics +/- therapeutic thoracentesis.",
      "Borderline complicated (pH 7-7.20 or LDH >1000, neg Gram/culture): Antibiotics + drainage tube +/- fibrinolytics.",
      "Simple complicated (pH <7.0, positive Gram/culture, no loculation/pus): Antibiotics + drainage tube + fibrinolytics.",
      "Complex complicated (pH <7.0, positive Gram/culture, multiloculated): Antibiotics + drainage tube + fibrinolytics + VATS +/- surgery.",
      "Simple empyema (frank pus, single loculation): Antibiotics + drainage tube + fibrinolytics +/- VATS.",
      "Complex empyema (frank pus, multiple loculations): Antibiotics + drainage tube + fibrinolytics + VATS +/- decortication."
    ],
    "Object6": [
      "Urgent pleural aspiration (for fluid analysis - cell count, pH, glucose, LDH, Gram stain, culture)",
      "Imaging (ultrasound, CT chest) for loculation, fluid size."
    ],
    "Object7": [
      "Antibiotics (for underlying infection).",
      "Pleural drainage (intercostal tube) for complicated effusions/empyema (pH <7.2, glucose <60 mg/dL, positive Gram stain/culture, gross pus).",
      "Intrapleural fibrinolytic agents (streptokinase, tPA) + deoxyribonuclease for loculated effusions.",
      "Video-assisted thoracoscopy (VATS) or decortication (for complex/refractory empyema)."
    ],
    "Object8": [
      "Empyema, fibrothorax, trapped lung",
      "Sepsis",
      "Acute respiratory failure"
    ]
  },
  {
    "Object1": "Chylous Pleural Effusion (Chylothorax)",
    "Object2": "Accumulation of chyle (lymph fluid rich in triglycerides) in the pleural cavity.",
    "Object3": [
      "Trauma (most common, especially thoracic surgery)",
      "Malignancy (lymphoma, lung cancer with mediastinal spread)",
      "Mediastinal fibrosis",
      "Obstruction of central veins, amyloidosis, lymphangiomyomatosis"
    ],
    "Object4": [
      "Dyspnea, signs of pleural effusion.",
      "Milky appearance of pleural fluid (on aspiration).",
      "Weight loss, malnutrition."
    ],
    "Object5": [
      "Pleural fluid analysis: Milky appearance, total triglyceride level >110 mg/dL, very low cholesterol, Sudan III stain positive for fat globules.",
      "CT chest/mediastinum, lymphangiogram (to identify source of leakage)."
    ],
    "Object6": [
      "Treat underlying cause.",
      "Chest tube drainage.",
      "Octreotide (reduces lymph flow).",
      "Dietary modifications (low-fat, high-protein, MCT-rich diet).",
      "Total parenteral nutrition (TPN) (to reduce chyle production).",
      "Surgical ligation of thoracic duct or pleuroperitoneal shunt (for refractory cases)."
    ],
    "Object7": [
      "Hypoproteinemia, malnutrition, immunodeficiency",
      "Respiratory distress",
      "Fluid and electrolyte imbalance"
    ]
  },
  {
    "Object1": "Pseudochylous Pleural Effusion (Pseudochylothorax)",
    "Object2": "Rare condition where pleural fluid appears milky due to high cholesterol, but is not chyle.",
    "Object3": [
      "Long-standing benign pleural effusions (e.g., tuberculous effusion, rheumatoid effusion)."
    ],
    "Object4": [
      "Milky appearance.",
      "High cholesterol level (>200 mg/dL).",
      "Sudan III staining negative for fat globules.",
      "Triglyceride levels usually <50 mg/dL."
    ]
  },
  {
    "Object1": "Empyema Thoracis",
    "Object2": "Collection of frank pus in the pleural space. Often a complication of pneumonia or lung abscess.",
    "Object3": [
      "Spread of infection from neighboring structures (bacterial pneumonias, lung abscess, bronchiectasis, subphrenic abscess, esophageal perforation, infected hemothorax).",
      "Distant source (bacteremia).",
      "Direct infection (penetrating chest injury, chest tube placement, thoracic surgery).",
      "Common organisms: Pneumococcus, Streptococcus, Staphylococcus, Pseudomonas, M. tuberculosis, H. influenzae, anaerobes."
    ],
    "Object4": [
      "Systemic: High-grade, remittent fever, chills, rigors, sweating, malaise, weight loss.",
      "Respiratory: Pleuritic chest pain, breathlessness, dry cough (purulent sputum if bronchopleural fistula).",
      "Physical signs: Clinical signs of pleural effusion PLUS intercostal tenderness, digital clubbing (in chronic), edema of chest wall."
    ],
    "Object5": [
      "Blood: Polymorphonuclear leukocytosis, high CRP.",
      "Chest X-ray: Similar to pleural effusion, 'D'-shaped shadow if loculated, air-fluid level if pyopneumothorax.",
      "Ultrasound/CT chest: Loculation, pleural thickening, underlying lung pathology.",
      "Aspiration of pus (diagnostic and therapeutic): Very thick to thin fluid, numerous PMNs, Gram stain/culture (to identify causative organism), AFB stain/culture for TB."
    ],
    "Object6": [
      "Antibiotics (based on culture/sensitivity).",
      "Drainage of pus:",
      "Aspiration (daily for early/small/thin fluid).",
      "Chest tube drainage (most cases).",
      "Limited thoracotomy (if tube drainage fails, thick/loculated pus).",
      "Intrapleural fibrinolytic agents (streptokinase, tPA) (for loculated empyema).",
      "Surgical decortication (for chronic empyema with thick visceral pleura preventing lung re-expansion)."
    ],
    "Object7": [
      "Empyema necessitans (subcutaneous abscess/sinus through chest wall).",
      "Bronchopleural fistula, pyopneumothorax.",
      "Fibrothorax (chronic).",
      "Secondary amyloidosis, metastatic brain abscess."
    ]
  },
  {
    "Object1": [
      "Lobar pneumonia (contiguous alveoli, e.g., pneumococcal)",
      "Bronchopneumonia (patchy, centered on bronchioles, e.g., staphylococcal)",
      "Interstitial pneumonia (inflammation in interalveolar septa, e.g., Mycoplasma, viral)"
    ],
    "Object2": [
      "Community-acquired pneumonia (CAP)",
      "Hospital-acquired pneumonia (HAP) / Nosocomial pneumonia",
      "Ventilator-associated pneumonia (VAP)",
      "Health-care associated pneumonia (HCAP)",
      "Pneumonia in immunocompromised host"
    ]
  },
  {
    "Object1": "Noninfective Pneumonias",
    "Object2": [
      "Lipid/Lipoid Pneumonia: Due to aspiration of fatty/oily material (mineral oil, liquid paraffin). Can cause chronic fibrosis (paraffinomas).",
      "Radiation Pneumonitis: Inflammation due to radiation therapy (>25 Gy). Acute phase (cough, fever, infiltrate), late phase (dyspnea, fibrosis).",
      "Recall Pneumonitis: Pneumonitis due to chemotherapy in a previous radiation field.",
      "Chemical Pneumonitis: Due to aspiration of toxic substances, especially gastric acid (Mendelson's syndrome). Can cause ARDS, secondary bacterial infection."
    ]
  },
  {
    "Object1": "Community-Acquired Pneumonia (CAP)",
    "Object2": "Acute pulmonary infection in a non-hospitalized patient. Affects all ages, common at extremes of age, spread by droplet infection.",
    "Object3": [
      "Extremes of age, URTI, comorbidities (CHF, diabetes, CKD, influenza, malnutrition), smoking, alcohol, corticosteroid therapy, immunodeficiencies, asplenia, other respiratory conditions, indoor air pollution."
    ],
    "Object4": [
      "Streptococcus pneumoniae (most common), Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae, various viruses."
    ],
    "Object5": [
      "Classical: Sudden onset, high fever, shaking chills, pleuritic chest pain, productive/rusty sputum, poor general condition, higher mortality (e.g., S. pneumoniae).",
      "Atypical: Gradual onset, low-grade fever, dry cough, prominent extrapulmonary symptoms (myalgia, headache, GI symptoms), lower mortality (e.g., Mycoplasma, Chlamydia, Legionella, viruses)."
    ],
    "Object6": "Refer to general Pneumonia discussion."
  },
  {
    "Object1": "Hospital-Acquired Pneumonia (HAP) / Nosocomial Pneumonia",
    "Object2": "Pneumonia acquired >48 hours after hospital admission. Second most common HAI, leading cause of HAI-associated death. Ventilator-associated pneumonia (VAP) is a subcategory.",
    "Object3": [
      "Early onset HAP (<5 days): S. aureus, Enterobacteriaceae, S. pneumoniae, H. influenzae (often antibiotic-sensitive).",
      "Late onset HAP (≥5 days): S. aureus (including MRSA), Pseudomonas aeruginosa, Enterobacter, Klebsiella, Acinetobacter (often multidrug-resistant).",
      "Risk factors: Severe underlying disease, immunosuppression, prolonged antibiotic therapy, mechanical ventilation (VAP), invasive devices, increasing age, nasogastric tubes, decreased consciousness, prior AMA use, decreased gastric acidity, upper abdominal surgery."
    ],
    "Object4": [
      "Purulent sputum/endotracheal secretions, new infiltrate on CXR, unexplained increase in oxygen requirement, fever (>38.3°C), leukocytosis/leukopenia."
    ],
    "Object5": [
      "Blood cultures, sputum/tracheal aspirate cultures (Gram stain, sensitivity), bronchoscopy with BAL/brushings (for mechanically ventilated patients).",
      "CXR (new infiltrate)."
    ],
    "Object6": [
      "Empiric broad-spectrum antibiotics immediately, tailored to culture/sensitivity and local resistance patterns. Covers likely pathogens (Gram-negative, MRSA, Pseudomonas).",
      "Early onset HAP: Co-amoxiclav or cefuroxime (if no prior antibiotics); piperacillin/tazobactam or 3rd gen cephalosporin (if recent antibiotics).",
      "Late onset HAP: Antipseudomonal beta-lactam (piperacillin/tazobactam, carbapenem) + aminoglycoside/fluoroquinolone; add anti-MRSA agent (vancomycin, linezolid) if MRSA risk.",
      "Prevention (for VAP): Head elevation, oral antiseptic (chlorhexidine), minimize sedation, early mobilization, proper hygiene, early removal of tubes."
    ],
    "Object7": [
      "Multidrug resistance, treatment failure, sepsis, multi-organ failure, death."
    ]
  },
  {
    "Object1": "Unresolved/Slow Resolving Pneumonia",
    "Object2": "Pulmonary consolidation persisting >21 days, or failure of radiographic opacities to clear >50% by 2 weeks or completely by 4 weeks. Non-resolving pneumonia is failure to improve clinically/radiographically after 10 days of antibiotics.",
    "Object3": [
      "Incorrect microbiological diagnosis (e.g., TB, fungi, NTM, viral) or incomplete antimicrobial treatment (inadequate dose/duration, nonadherence, malabsorption, resistance).",
      "Complications of CAP (empyema, lung abscess, bronchial obstruction/bronchiectasis).",
      "Underlying neoplastic lesion (bronchogenic carcinoma, bronchoalveolar cell carcinoma) or other lung disease (pulmonary embolism, cryptogenic organizing pneumonia, eosinophilic pneumonia, hemorrhage).",
      "Host factors (age >50, comorbidities like diabetes, COPD, immunosuppression, impaired cough/mucociliary transport, aspiration)."
    ],
    "Object4": [
      "Re-evaluate diagnosis with extensive workup (repeat sputum/blood cultures, atypical/fungal/TB diagnostics, bronchoscopy with BAL/biopsy, CT chest, imaging for obstruction/embolism, cancer screening)."
    ],
    "Object5": [
      "Address identified cause. May involve changing antibiotics, drainage procedures, surgery, specific anti-cancer/anti-inflammatory therapies."
    ]
  },
  {
    "Object1": "Recurrent Pneumonia",
    "Object2": [
      "Underlying anatomical defects (bronchiectasis, bronchial stenosis, foreign body, tumor, cystic adenomatoid malformation, sequestration, esophageal fistula).",
      "Impaired host defenses (immunodeficiency, HIV, hypogammaglobulinemia, complement deficiency, neutropenia, aspiration, ciliary dyskinesia, alpha-1 antitrypsin deficiency).",
      "Systemic diseases (heart failure, renal failure, diabetes, neurological disorders, autoimmune diseases)."
    ]
  },
  {
    "Object1": "Pneumococcal Pneumonia (Lobar Pneumonia)",
    "Object2": "Most common form of bacterial pneumonia, caused by Streptococcus pneumoniae (Gram-positive diplococcus). Characterized by diffuse inflammation affecting part or entire lobe.",
    "Object3": [
      "Age (<2 or >65), smoking, alcoholism, underlying chronic diseases (diabetes, CHF, CKD, COPD), immunodeficiency (asplenia, HIV, complement/Ig deficiency), impaired local defenses (cough reflex, mucociliary apparatus), antecedent influenza, pulmonary congestion."
    ],
    "Object4": [
      "Sudden onset high fever, chills, rigors, cough (dry then productive), pleuritic chest pain, dyspnea.",
      "Classic 'rusty sputum'.",
      "Physical signs of consolidation: Dullness, increased vocal fremitus/resonance, tubular bronchial breathing, coarse crackles. Herpes labialis."
    ],
    "Object5": [
      "Sputum: Gram stain (Gram-positive diplococci), culture.",
      "Blood cultures (positive in 20-30%).",
      "Urinary pneumococcal antigen test (sensitive, specific).",
      "CXR: Homogeneous consolidation of affected lobe, air bronchogram."
    ],
    "Object6": [
      "Antibiotics: Penicillin (drug of choice if susceptible), ceftriaxone, cefotaxime, azithromycin, fluoroquinolones.",
      "Oxygen, analgesics for pain.",
      "Vaccination: Pneumococcal polysaccharide vaccine (PPV), pneumococcal conjugate vaccine (PCV)."
    ],
    "Object7": [
      "Delayed resolution, spread to other lobes.",
      "Empyema, sterile pleural effusion.",
      "Bacteremia (sepsis, meningitis, endocarditis, suppurative arthritis, metastatic abscesses).",
      "Acute circulatory failure."
    ]
  },
  {
    "Object1": "Staphylococcal Pneumonia",
    "Object2": "Bronchopneumonia caused by Staphylococcus aureus. Characterized by widespread focal suppurative inflammation and frequent abscess formation.",
    "Object3": [
      "Following influenza, debilitated hospitalized patients, cystic fibrosis. MRSA is important."
    ],
    "Object4": [
      "Severe pneumonia symptoms, often multilobar involvement.",
      "Abscess formation (multiple, bilateral), pneumothorax, pyopneumothorax (if abscess ruptures)."
    ],
    "Object5": [
      "Sputum: Gram stain (Gram-positive cocci in clumps), culture.",
      "CXR: Bronchopneumonia, multilobar shadowing, cavitation, pneumatoceles, abscesses."
    ],
    "Object6": [
      "Antibiotics: Penicillin (if sensitive), oxacillin/flucloxacillin (for MSSA), vancomycin/teicoplanin/linezolid/daptomycin/ceftaroline (for MRSA).",
      "Drainage of abscesses if needed."
    ]
  },
  {
    "Object1": "Klebsiella Pneumoniae (Friedlander's Pneumonia)",
    "Object2": "Severe pneumonia caused by Klebsiella pneumoniae (Gram-negative bacillus), particularly in alcoholics and diabetics.",
    "Object3": [
      "Severe illness, high mortality.",
      "Massive consolidation (often upper lobes).",
      "Thick, viscid, jelly-like, 'red-current-jelly sputum' (characteristic).",
      "Abscess formation and pleural effusion common."
    ],
    "Object4": [
      "Sputum: Gram stain (Gram-negative bacilli), culture.",
      "CXR: Air space pneumonia, abscess, pleural effusion, 'bulging interlobar fissure' (characteristic)."
    ],
    "Object5": [
      "Antibiotics: Gentamicin, ceftazidime, ciprofloxacin (for 2-3 weeks). Piperacillin/tazobactam or meropenem for severe cases. Colistin/polymyxin B for ESBL-producing strains."
    ]
  },
  {
    "Object1": "Atypical Pneumonias",
    "Object2": "Pneumonias caused by pathogens that typically cause a more insidious onset, prominent extrapulmonary symptoms, and do not respond to beta-lactam antibiotics.",
    "Object3": [
      "Mycoplasma pneumoniae (most common)",
      "Legionella pneumophila (Legionnaire's disease)",
      "Chlamydia pneumoniae",
      "Coxiella burnetii (Q-fever)",
      "Viruses (influenza, adenovirus, RSV, measles, VZV, CMV)"
    ],
    "Object4": [
      "Gradual/insidious onset, low-grade fever, dry cough, malaise, myalgia, headache.",
      "Prominent extrapulmonary symptoms (e.g., GI in Legionella, rash/neurological in Mycoplasma).",
      "Symptoms often outweigh physical signs."
    ],
    "Object5": [
      "CXR: Interstitial infiltrates, patchy/lobar consolidation.",
      "Sputum Gram stain: Few/no organisms (despite pyuria).",
      "Specific tests: Mycoplasma serology/PCR, Legionella urinary antigen/culture, Chlamydia serology/PCR, viral PCR/serology."
    ],
    "Object6": [
      "Antibiotics: Macrolides (azithromycin, clarithromycin), fluoroquinolones, tetracyclines (doxycycline). Beta-lactams are ineffective."
    ]
  },
  {
    "Object1": "Legionella Pneumoniae (Legionnaire's Disease)",
    "Object2": "Severe atypical pneumonia caused by Legionella pneumophila, acquired from contaminated water sources.",
    "Object3": [
      "Fever, chills, malaise, headache, dry cough, dyspnea.",
      "Prominent GI symptoms: Nausea, abdominal pain, diarrhea.",
      "CNS symptoms: Mental confusion, delirium.",
      "Relative bradycardia.",
      "Complications: Myocarditis, pericarditis, glomerulonephritis, pancreatitis."
    ],
    "Object4": [
      "CXR: Patchy to lobar consolidation, pleural effusion.",
      "Blood: Leukopenia (often), hyponatremia, elevated LFTs, very high ESR.",
      "Urinary Legionella antigen test (sensitive, specific).",
      "Culture (respiratory secretions) on buffered charcoal yeast extract (BCYE) agar (gold standard)."
    ],
    "Object5": "Antibiotics: Fluoroquinolones (levofloxacin, moxifloxacin) or macrolides (azithromycin, clarithromycin)."
  },
  {
    "Object1": "Actinomycosis (Pulmonary)",
    "Object2": "Bacterial infection by Actinomyces israelii (anaerobic commensal in oral cavity) causing chronic suppurative pneumonia, empyema, and persistent chest wall sinuses.",
    "Object3": [
      "Chronic cough, chest pain, weight loss, fever.",
      "Discharging chest wall sinuses ('sulfur granules' in pus)."
    ],
    "Object4": [
      "Pus culture (anaerobic) showing Actinomyces israelii. Sulfur granules on microscopy.",
      "CT chest (consolidation, cavitation, pleural involvement)."
    ],
    "Object5": [
      "Prolonged high-dose penicillin G (IV followed by oral) for 6-12 months. Doxycycline is an alternative."
    ]
  },
  {
    "Object1": "Acute Bronchopneumonia",
    "Object2": "Patchy areas of consolidation in lung lobes, usually secondary to bronchial infection. More common in patients with chronic bronchitis, children (post-measles/whooping cough), elderly (hypostatic).",
    "Object3": [
      "High fever, severe cough with purulent expectoration, breathlessness, tachypnea, tachycardia, central cyanosis.",
      "Physical signs: Early acute bronchitis, later numerous crepitations."
    ],
    "Object4": [
      "CXR: Bilateral mottled opacities, predominantly lower zones.",
      "Blood: Neutrophilic leukocytosis."
    ],
    "Object5": [
      "Antibiotics: Ampicillin or co-trimoxazole (mild), 3rd gen cephalosporin + macrolide (serious)."
    ]
  },
  {
    "Object1": "Aspiration of bacteria from upper airways/stomach (often anaerobes from gingival crevices).",
    "Object2": "Cough, fever, purulent sputum (often putrid), dyspnea, weight loss, anemia. Evolves over days/weeks.",
    "Object3": "Sputum (putrid discharge), CXR (involvement of dependent pulmonary segments).",
    "Object4": "Antibiotics (clindamycin, amoxicillin-clavulanate, fluoroquinolones; metronidazole with other agents)."
  },
  {
    "Object1": "Influenza (Flu)",
    "Object2": "Acute systemic viral infection of respiratory tract caused by influenza viruses (RNA viruses, types A, B, C).",
    "Object3": [
      "Influenza A (pandemics/epidemics, antigenic shift/drift in H/N antigens, infects animals/humans)",
      "Influenza B (epidemics, less severe, human-specific)",
      "Influenza C (mild, no epidemics)"
    ],
    "Object4": [
      "Incubation 1-3 days.",
      "Sudden onset headache, fever, chills, myalgia, malaise, nausea, vomiting.",
      "Respiratory: Hard unproductive cough, sore throat.",
      "Symptoms usually subside within 3-5 days."
    ],
    "Object5": [
      "Blood: Leukopenia.",
      "Throat swab/nasopharyngeal aspirate/sputum: RT-PCR (most sensitive), Rapid Influenza Diagnostic Tests (RIDTs)."
    ],
    "Object6": [
      "Supportive care: Rest, hydration, paracetamol (avoid aspirin in children due to Reye's syndrome).",
      "Antivirals (neuraminidase inhibitors): Oseltamivir, zanamivir (within 48 hours of symptom onset, for influenza A/B). Amantadine/rimantadine (only influenza A, resistance common)."
    ],
    "Object7": [
      "Primary influenza viral pneumonia, secondary bacterial pneumonia (S. pneumoniae, S. aureus), mixed viral/bacterial pneumonia.",
      "Exacerbation of asthma/COPD.",
      "Myositis, myocarditis, pericarditis, worsening CHF.",
      "Neurological: Reye's syndrome (children), encephalitis, transverse myelitis."
    ],
    "Object8": [
      "Annual seasonal vaccination (inactivated/live attenuated vaccine).",
      "Chemoprophylaxis (oseltamivir, zanamivir for high-risk contacts)."
    ]
  },
  {
    "Object1": "Severe Acute Respiratory Syndrome (SARS)",
    "Object2": "A severe, acute respiratory illness caused by SARS-CoV (coronavirus), first described in 2002-2003.",
    "Object3": "Droplet transmission, fomite contact.",
    "Object4": [
      "Incubation 2-7 days.",
      "Systemic: Persistent fever, chills, myalgia, malaise, headache, nonproductive cough, dyspnea.",
      "GI: Diarrhea (25%).",
      "Progresses to ARDS in ~20%."
    ],
    "Object5": [
      "Blood: Lymphopenia, thrombocytopenia, elevated LFTs, CK, LDH, features of DIC.",
      "CXR: Peripheral/lower zone interstitial/alveolar infiltrates, patchy consolidation (progresses to diffuse).",
      "RT-PCR for SARS-CoV RNA (throat swab, plasma, urine, stool).",
      "Viral culture."
    ],
    "Object6": [
      "No specific antiviral. Supportive care (hydration, oxygenation, ventilation).",
      "High-dose methylprednisolone (for pneumonia/hypoxemia, controversial)."
    ],
    "Object7": [
      "ARDS, respiratory failure, multi-organ failure, death."
    ]
  },
  {
    "Object1": "Middle East Respiratory Syndrome (MERS)",
    "Object2": "Respiratory illness caused by MERS-CoV (coronavirus), reservoir is camels. Human-to-human transmission is less efficient.",
    "Object3": [
      "Fever, cough, shortness of breath. Pneumonia common. GI symptoms (diarrhea).",
      "More severe in elderly, immunocompromised, those with chronic diseases.",
      "Rapid progression to ARDS, renal failure."
    ],
    "Object4": [
      "Blood: Leukopenia, thrombocytopenia, elevated LFTs, LDH, CK.",
      "RT-PCR for MERS-CoV RNA."
    ],
    "Object5": [
      "No specific antiviral/vaccine. Supportive care."
    ],
    "Object6": [
      "ARDS, respiratory failure, renal failure, death (high case fatality rate)."
    ]
  },
  {
    "Object1": "Idiopathic Interstitial Pneumonias (IIPs)",
    "Object2": "A subgroup of ILDs with diffuse inflammation and fibrosis in lung parenchyma where etiology is unknown. Classified based on histological patterns.",
    "Object3": [
      "Idiopathic Pulmonary Fibrosis (IPF) / Usual Interstitial Pneumonia (UIP) (most common, progressive fibrosis, poor prognosis).",
      "Non-specific interstitial pneumonia (NSIP) (better prognosis, often steroid-responsive).",
      "Cryptogenic organizing pneumonia (COP) / Bronchiolitis obliterans organizing pneumonia (BOOP) (good prognosis, steroid-responsive).",
      "Acute interstitial pneumonia (AIP) / Hamman-Rich syndrome (rapidly fatal).",
      "Respiratory bronchiolitis-associated interstitial lung disease (RBILD).",
      "Desquamative interstitial pneumonia (DIP).",
      "Lymphoid interstitial pneumonia (LIP)."
    ],
    "Object4": "Refer to DPLD/ILD general features.",
    "Object5": "Refer to DPLD/ILD general features; lung biopsy is often crucial for histological classification.",
    "Object6": "Refer to DPLD/ILD general treatment. Anti-fibrotic drugs (pirfenidone, nintedanib) are specific for IPF."
  },
  {
    "Object1": "Coal-workers' Pneumoconiosis (CWP)",
    "Object2": [
      "Prolonged inhalation of carbon particles (coal mine dust).",
      "Incidence depends on total dust exposure, ventilation, dust suppression."
    ],
    "Object3": [
      "Simple CWP (SCWP): Deposition of coal dust, small radiographic (micronodular) shadows, usually asymptomatic, does not impair lung function. Categories 1, 2, 3.",
      "Progressive Massive Fibrosis (PMF): Progression from SCWP, even after exposure ceases."
    ],
    "Object4": [
      "SCWP: Often asymptomatic, detected on CXR.",
      "PMF: Progressive breathlessness/dyspnea, cough with blackish sputum (melanoptysis).",
      "Complications: Respiratory failure, right ventricular failure."
    ],
    "Object5": [
      "Chest X-ray: Micronodular opacities (SCWP), single/multiple round fibrotic nodules/masses (>1 cm, upper lobes, PMF).",
      "Lung function tests: Mixed restrictive/obstructive defect (PMF), reduced DLCO.",
      "Sputum: Melanoptysis (black sputum)."
    ],
    "Object6": [
      "No specific treatment.",
      "Prevention: Reduce dust exposure.",
      "Management of complications (respiratory failure, cor pulmonale)."
    ],
    "Object7": [
      "PMF, respiratory failure, cor pulmonale, Caplan's syndrome."
    ]
  },
  {
    "Object1": "Caplan's Syndrome (Rheumatoid Pneumoconiosis)",
    "Object2": "Combination of pneumoconiotic nodules with sero-positive rheumatoid arthritis.",
    "Object3": [
      "Pneumoconiotic nodules (round, fibrotic, 0.5-5 cm, mainly peripheral lung fields).",
      "Rheumatoid factor positive.",
      "Pathological features similar to rheumatoid nodule.",
      "Can occur with silicosis and other pneumoconioses."
    ]
  },
  {
    "Object1": "Asbestos-Related Lung and Pleural Diseases",
    "Object2": [
      "Exposure to asbestos dust (chrysotile, crocidolite, amosite fibers).",
      "Occupational exposure (mining, manufacturing, construction, shipyards).",
      "Latency period of 10-40 years."
    ],
    "Object3": [
      "Asbestosis (progressive pulmonary fibrosis)",
      "Benign localized pleural fibrous plaques (calcification of parietal pleura, especially diaphragm/mediastinum)",
      "Benign pleural effusions",
      "Carcinoma of lung (most common cancer, synergistic with smoking)",
      "Malignant mesothelioma (of pleura/peritoneum, strongly linked to crocidolite, no smoking synergy)",
      "Laryngeal carcinomas"
    ],
    "Object4": [
      "Progressive exertional breathlessness, finger clubbing, late-inspiratory crackles (lower zones)."
    ],
    "Object5": [
      "CXR: Irregular/linear opacities in lower lung fields, indistinct heart border, 'ground-glass' appearance.",
      "HRCT: Subpleural curvilinear lines, honeycomb lung. Pleural disease detection (>90%).",
      "PFTs: Restrictive pattern, decreased DLCO.",
      "Lung biopsy: Asbestos bodies, fibrosis."
    ],
    "Object6": [
      "Persistent chest pain, breathlessness (due to pleural effusion), unilateral hemorrhagic pleural effusion. Tumor encases lung, invades mediastinum/pericardium."
    ],
    "Object7": [
      "VATS biopsy of pleura (diagnostic).",
      "CXR/CT (pleural thickening, effusion)."
    ],
    "Object8": [
      "No specific treatment for asbestosis, management is supportive.",
      "Mesothelioma: Difficult to treat, chemotherapy, radiation, surgery (often palliative).",
      "Lung cancer: Standard cancer therapies."
    ],
    "Object9": [
      "Respiratory failure, cor pulmonale.",
      "Lung cancer, mesothelioma (fatal)."
    ]
  },
  {
    "Object1": "Silicosis",
    "Object2": [
      "Inhalation of crystalline silicon dioxide (silica).",
      "High-risk occupations: Mining, stone cutting, sand blasting, quarrying, pottery, ceramics, foundry work."
    ],
    "Object3": [
      "Silica is highly fibrogenic, causes hard nodules that coalesce, leading to pulmonary fibrosis."
    ],
    "Object4": [
      "Chronic (simple) silicosis (most common): After decades of low-level exposure. Gradual dyspnea, dry cough. CXR shows multiple small nodular opacities (mid/upper zones), 'egg-shell calcification' of hilar lymph nodes.",
      "Acute silicosis: Intense exposure over months. Rapidly fatal. Pulmonary edema, interstitial inflammation, proteinaceous fluid in alveoli. CXR: miliary infiltration or consolidation, 'crazy paving' on HRCT.",
      "Accelerated silicosis: After a few years of exposure. Rapidly progressive dyspnea, pulmonary fibrosis (middle/lower zones)."
    ],
    "Object5": [
      "Chronic: Gradually progressive dyspnea, dry cough.",
      "Acute: Pulmonary edema, interstitial inflammation.",
      "Accelerated: Rapidly progressive dyspnea, pulmonary fibrosis."
    ],
    "Object6": [
      "CXR/HRCT: Nodular opacities, progressive massive fibrosis, 'egg-shell calcification' (hilar lymph nodes).",
      "PFTs: Mixed obstructive/restrictive, reduced DLCO.",
      "Lung biopsy (diagnostic)."
    ],
    "Object7": [
      "No specific treatment. Prevention (reduce dust exposure).",
      "Management of complications (TB, lung cancer, COPD, renal insufficiency, autoimmune diseases)."
    ],
    "Object8": [
      "Silicotuberculosis (increased risk of TB), lung cancer, COPD, progressive massive fibrosis (PMF), renal insufficiency, autoimmune diseases (scleroderma, RA, Wegener's)."
    ]
  },
  {
    "Object1": [
      "Cytological examination: Sputum, bronchial washings/brushings, pleural fluid, FNA of lymph node/mass.",
      "Fiberoptic bronchoscopy: Visualize tumor, biopsy, washings. Assesses operability.",
      "Percutaneous aspiration/biopsy (CT-guided) for peripheral tumors.",
      "Biopsy (surgical, lymph node) for definitive histology.",
      "Immunohistochemistry: Differentiates tumor types, primary vs. metastatic (TTF-1 for adenocarcinoma, neuroendocrine markers for SCLC).",
      "Molecular testing: EGFR mutations, ALK fusion (for targeted therapy decisions)."
    ],
    "Object2": [
      "Chest X-ray: Unilateral hilar enlargement, peripheral opacity (with/without cavitation), lobar/whole lung collapse, mediastinal widening, pleural effusion, rib destruction.",
      "CT chest/abdomen: Tumor size/extent, nodal involvement (mediastinal, hilar), occult abdominal mets (liver, adrenals).",
      "PET/CT scan: Detects intrathoracic tumor, nodal involvement, distant metastases.",
      "Mediastinoscopy/EUS/EBUS-FNA: For mediastinal nodal sampling.",
      "Bone scan, brain CT/MRI for suspected metastases."
    ],
    "Object3": [
      "Pulmonary function tests (FEV1, DLCO), exercise testing.",
      "Cardiac evaluation (ECG, echocardiography)."
    ]
  },
  {
    "Object1": "TNM classification (I to IV, based on Tumor size/location, Nodal involvement, Metastasis). Stage I-II are early, Stage III locally advanced, Stage IV metastatic.",
    "Object2": "Limited stage (confined to one hemithorax, mediastinum, ipsilateral supraclavicular nodes, within radiation port); Extensive stage (any distant spread)."
  },
  {
    "Object1": [
      "Surgical resection (lobectomy, pneumonectomy): Primary for early stages (IA-IIB, select IIIA).",
      "Adjuvant chemotherapy (post-surgery for nodal involvement).",
      "Neoadjuvant chemotherapy (pre-surgery for downstaging).",
      "Radiation therapy: Curative for inoperable early stage, palliative for symptoms (pain, hemoptysis, SVC obstruction, airway obstruction).",
      "Chemotherapy (cisplatin/carboplatin + paclitaxel/docetaxel/gemcitabine) for advanced disease.",
      "Targeted therapy (EGFR inhibitors - gefitinib, erlotinib; ALK inhibitors - crizotinib; immunotherapy - checkpoint inhibitors) for specific mutations/types.",
      "Supportive care."
    ],
    "Object2": [
      "Chemotherapy (cisplatin/carboplatin + etoposide) (mainstay, for both limited and extensive stage).",
      "Radiation therapy (chest radiation for limited stage, prophylactic cranial irradiation for responders).",
      "Laser therapy/tracheobronchial stents for airway obstruction.",
      "Supportive care."
    ]
  },
  {
    "Object1": [
      "Metastasis (brain, bone, liver, adrenal), oncologic emergencies (SVC syndrome, spinal cord compression, hypercalcemia), cachexia, infections."
    ],
    "Object2": [
      "Neurological (stroke, seizures, cognitive deficits, LEMS, cerebellar degeneration)",
      "Cardiovascular (pericardial effusion, tamponade, arrhythmias, MI)",
      "Respiratory (pneumonia, atelectasis, respiratory failure, hemoptysis)",
      "Bone (pathological fractures, HPOA)",
      "Mediastinal (SVC syndrome, tracheal obstruction, esophageal compression)."
    ]
  },
  {
    "Object1": "Hypertrophic Osteoarthropathy (HPOA)",
    "Object2": "Characterized by clubbing of digits and periosteal new-bone formation, and synovial effusions. Primary HOA (Pierre-Marie-Bamberger syndrome) is rare; secondary HPOA is associated with underlying diseases.",
    "Object3": [
      "Most commonly associated with lung cancer (adenocarcinoma, NSCLC, rarely SCLC)",
      "Other lung diseases (bronchiectasis, empyema, lung abscess, cystic fibrosis)",
      "Cardiac (cyanotic congenital heart disease, infective endocarditis)",
      "Gastrointestinal (IBD, cirrhosis, hepatocellular carcinoma)",
      "Thymoma"
    ],
    "Object4": [
      "Clubbing of digits (almost always present).",
      "Pain and swelling of wrists and ankles (distal long bones), less in knees/shins. Pain aggravated by dependency, relieved by elevation.",
      "Pitting edema of anterior shin.",
      "Joint tenderness."
    ],
    "Object5": [
      "X-ray: Periosteal thickening and subperiosteal new bone formation along distal ends of long bones. Osseous resorption of distal phalanges.",
      "Radionuclide bone scan: Pericortical linear uptake along cortical margins.",
      "Treat underlying disease (e.g., surgical resection of lung tumor often resolves HPOA)."
    ],
    "Object6": [
      "Treat underlying associated disease (e.g., surgical resection of lung tumor often resolves HPOA).",
      "Analgesics (aspirin, NSAIDs).",
      "Vagotomy (surgical or percutaneous vagus nerve block) (may relieve pain in some cases)."
    ],
    "Object7": [
      "Chronic pain, functional impairment related to joints."
    ]
  },
  {
    "Object1": "Pancoast's Syndrome (Superior Sulcus Tumor Syndrome)",
    "Object2": "Clinical syndrome caused by a tumor at the apex of the lung (Pancoast tumor) invading neural structures around the first rib, subclavian vessels, and cervical sympathetic plexus.",
    "Object3": [
      "Lung cancer (most commonly NSCLC, especially squamous cell carcinoma, adenocarcinoma; rarely SCLC).",
      "Other apical tumors (e.g., mesothelioma, metastases)."
    ],
    "Object4": [
      "Shoulder pain (most common, radiating down arm in ulnar nerve distribution - C8, T1 roots).",
      "Hand muscle wasting (due to C8, T1 nerve involvement).",
      "Horner's syndrome (ipsilateral ptosis, miosis, anhidrosis, enophthalmos) (due to sympathetic pathway invasion).",
      "Pain and tenderness over first/second ribs, radiological evidence of rib destruction.",
      "Weakness of intrinsic hand muscles."
    ],
    "Object5": [
      "Chest X-ray: Apical mass lesion, rib erosion.",
      "MRI (brain, brachial plexus, spine) and CT (chest) for defining tumor extent, invasion, and neurological involvement.",
      "Biopsy (percutaneous, EBUS, surgical) for histological diagnosis."
    ],
    "Object6": [
      "Combined chemoradiotherapy followed by surgical resection (for resectable tumors).",
      "Neoadjuvant chemotherapy/radiation to reduce tumor size before surgery.",
      "Palliative radiation for pain relief."
    ],
    "Object7": [
      "Permanent neurological deficits (pain, weakness, Horner's syndrome).",
      "Subclavian vessel invasion (ischemia, thrombosis).",
      "Spinal cord compression.",
      "Death from tumor progression."
    ]
  },
  {
    "Object1": "Superior Vena Cava (SVC) Syndrome",
    "Object2": "Obstruction of the superior vena cava (SVC) leading to impaired venous drainage from the head, neck, and upper extremities. Usually a medical emergency.",
    "Object3": [
      "Neoplastic (most common): Bronchial carcinoma (75%), lymphomas (20%), thymoma, metastatic tumors.",
      "Non-neoplastic (less common): Tuberculosis (fibrosing mediastinitis), retrosternal goiter, central venous catheter-related thrombosis, aortic arch aneurysm."
    ],
    "Object4": [
      "Headache, visual disturbances, altered consciousness, orthopnea.",
      "Facial/neck/upper limb swelling (edema), plethora, cyanosis.",
      "Dilated, non-pulsatile neck veins, dilated collateral veins on upper thorax/chest wall.",
      "Conjunctival edema, suffusion, subconjunctival hemorrhage."
    ],
    "Object5": [
      "Clinical diagnosis.",
      "Chest X-ray: Widening/broadening of superior mediastinum (often right-sided), pleural effusion.",
      "CT chest (with contrast): Most useful, identifies site/cause of obstruction, extent of tumor.",
      "Invasive procedures (bronchoscopy, percutaneous needle biopsy, mediastinoscopy) for tissue diagnosis.",
      "Doppler ultrasound for SVC thrombosis."
    ],
    "Object6": [
      "Goals: Relieve symptoms, treat underlying cause.",
      "Supportive: Head elevation, diuretics (with caution), oxygen.",
      "Emergency radiotherapy (if tracheal obstruction, or unknown radiosensitive tumor like SCLC/lymphoma).",
      "Radiation therapy/Chemotherapy (for neoplastic causes).",
      "Endovascular stent placement (for rapid relief of obstruction).",
      "Corticosteroids (for tumor-associated edema, or radiosensitive tumors)."
    ],
    "Object7": [
      "Tracheal obstruction, cerebral edema, hemorrhage.",
      "Respiratory distress, cardiac arrest.",
      "Thrombosis.",
      "Death."
    ]
  },
  {
    "Object1": "Mediastinum (General)",
    "Object2": "Central compartment of the thoracic cavity, located between the pleural sacs. Contains numerous organs and structures. Lesions often cause symptoms by compression or invasion.",
    "Object3": [
      "Superior mediastinum: Trachea, upper esophagus, thymus, thoracic duct, SVC, aortic arch/branches, phrenic/vagus nerves.",
      "Anterior mediastinum: Thymus, lymph nodes, internal mammary vessels, adipose tissue.",
      "Posterior mediastinum: Esophagus, descending aorta, azygos vein, thoracic duct, sympathetic chain, lymph nodes.",
      "Middle mediastinum: Heart, great vessels, main bronchi, hilar lymph nodes, phrenic nerves."
    ],
    "Object4": [
      "Anterior: Thymoma, thymic cyst/hyperplasia, lymphoma (Hodgkin's, DLBCL), germ cell tumors (teratoma, seminoma), thyroid (intrathoracic), parathyroid adenoma.",
      "Middle: Lymphadenopathy (lymphoma, metastatic lung/breast cancer, sarcoidosis), bronchogenic/pericardial/esophageal cysts.",
      "Posterior: Neurogenic tumors (schwannoma, neurofibroma, neuroblastoma), meningoceles, thoracic spine lesions (Pott's disease).",
      "Superior: Thymoma, lymphoma, thyroid lesions, parathyroid adenoma."
    ],
    "Object5": [
      "Due to compression/invasion of structures (see SVC syndrome, Pancoast's syndrome, tracheal obstruction).",
      "Cough, dyspnea, chest pain, dysphagia, hoarseness, Horner's syndrome, SVC syndrome, pericardial effusion/tamponade."
    ],
    "Object6": [
      "Chest X-ray: Mediastinal widening/opacity, mass lesion.",
      "CT/MRI thorax: Delineates mass, its extent, relationship to structures, guides biopsy.",
      "PET scan: Activity, staging.",
      "Cytology/biopsy (bronchoscopy, mediastinoscopy, EUS-FNA, surgical) for tissue diagnosis."
    ],
    "Object7": [
      "Surgical removal (for benign tumors, localized malignancies).",
      "Chemotherapy/radiotherapy (for lymphomas, SCLC, metastatic tumors).",
      "Palliative management for compression symptoms."
    ]
  },
  {
    "Object1": "Solitary Pulmonary Nodule (SPN)",
    "Object2": "A single discrete pulmonary opacity ≤3 cm in diameter, surrounded by normal lung tissue, not associated with adenopathy or atelectasis. Lesions >3 cm are usually malignant.",
    "Object3": [
      "Malignant tumors: Bronchogenic carcinoma (adenocarcinoma, large cell, squamous, small cell), carcinoid, pulmonary lymphoma, solitary metastasis.",
      "Benign tumors: Hamartoma, adenoma, lipoma.",
      "Infectious granulomas: Tuberculosis, histoplasmosis, coccidioidomycosis.",
      "Non-infectious granulomas: RA, Wegener's, sarcoidosis.",
      "Miscellaneous: BOOP, abscess, pseudotumor, spherical pneumonia, pulmonary infarction, AVM, bronchogenic cyst, amyloidoma."
    ],
    "Object4": [
      "Usually asymptomatic, detected incidentally on CXR.",
      "Symptoms develop if malignant and growing (cough, pain, hemoptysis)."
    ],
    "Object5": [
      "CXR: Irregular but well-circumscribed opacity, may contain cavitation. Compares with old films for growth rate (malignant doubling time 30-300 days).",
      "CT chest (with contrast): Characterizes lesion (calcification pattern, margins, size), guides biopsy.",
      "PET scan: High uptake suggests malignancy.",
      "Bronchoscopy/CT-guided biopsy (for tissue diagnosis).",
      "Surgical excision (for diagnosis and treatment of suspicious nodules)."
    ],
    "Object6": [
      "Management depends on risk of malignancy (size, growth rate, margins, patient factors).",
      "Low-risk: Surveillance (serial CT scans).",
      "High-risk: Surgical resection (for diagnosis and cure) or stereotactic body radiation therapy (SBRT) for inoperable patients."
    ],
    "Object7": [
      "Malignancy, metastasis, death."
    ]
  },
  {
    "Object1": "Pneumonia, pulmonary edema, acute asthma, pulmonary embolism, ARDS, pneumothorax.",
    "Object2": "Widespread pulmonary fibrosis, chronic pulmonary edema, chronic chest wall/neuromuscular disorders, chronic pulmonary thromboembolism.",
    "Object3": "Respiratory depressant drugs, severe airflow obstruction (acute asthma, COPD exacerbation, laryngeal/tracheal obstruction), respiratory muscle disorders (acute polymyositis, GBS), chest injuries (tension pneumothorax, flail chest), brainstem damage, spinal cord/nerve/neuromuscular transmission disorders (poliomyelitis, myasthenia gravis, botulism).",
    "Object4": "COPD (most common), chest wall abnormalities (kyphoscoliosis, obesity), amyotrophic lateral sclerosis, muscular dystrophy, central hypoventilation."
  },
  {
    "Object1": "Obstructive Sleep Apnea (OSA)",
    "Object2": [
      "Obesity (major risk factor, particularly neck circumference >17 inches male, >15 inches female)",
      "Male sex",
      "Enlarged tonsils/adenoids (especially in children)",
      "Mandibular retrognathia/micrognathia, nasal obstruction (deformities, rhinitis, polyps)",
      "Smoking",
      "Menopause",
      "Advancing age",
      "Family history",
      "Endocrine diseases (acromegaly, hypothyroidism)",
      "Respiratory depressant drugs (alcohol, sedatives, strong analgesics)"
    ],
    "Object3": [
      "Nocturnal: Loud, habitual snoring (interrupted by witnessed apneas), gasping/choking sensations, nocturia, insomnia, restless sleep.",
      "Daytime: Excessive daytime sleepiness (EDS), non-restorative sleep, morning headache, dry/sore throat, daytime fatigue, cognitive deficits (memory, concentration), irritability, depression.",
      "Pickwickian syndrome (obesity-hypoventilation syndrome): Morbid obesity (BMI >40), chronic sleep-induced hypoventilation with awake hypercapnia (PaCO2 >45 mmHg), hypoxemia, cor pulmonale (right heart failure), nocturnal hypoventilation."
    ],
    "Object4": [
      "Clinical diagnosis (history, Epworth Sleepiness Scale - ESS).",
      "Polysomnography (PSG) (sleep study, diagnostic gold standard): Records EEG, EOG, EMG, airflow, respiratory effort, oxygen saturation. Calculates Apnea-Hypopnea Index (AHI).",
      "AHI: Mild (5-15), Moderate (16-30), Severe (>30) episodes/hour.",
      "Blood tests (thyroid function, glucose)."
    ],
    "Object5": [
      "Conservative: Weight reduction, avoid alcohol/sedatives before bed, sleep on side.",
      "Nasal Continuous Positive Airway Pressure (CPAP): Most effective, splints airway open. Indicated for AHI ≥15, or AHI 5-14.9 with EDS/hypertension/CVD.",
      "Oral appliance therapy (mandibular advancement devices).",
      "Surgical: Nasal surgery, tonsillectomy/adenoidectomy, uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (for selected cases).",
      "Pharmacotherapy (for residual EDS): Modafinil. Avoid drugs that worsen OSA (sedatives, opioids)."
    ],
    "Object6": [
      "Hypertension, cardiovascular disease (MI, stroke, arrhythmias, heart failure), pulmonary hypertension, cor pulmonale.",
      "Increased risk of accidents (due to EDS).",
      "Cognitive impairment, depression, reduced quality of life.",
      "Diabetes mellitus, metabolic syndrome.",
      "Respiratory failure (in Pickwickian syndrome)."
    ]
  },
  {
    "Object1": "Central Sleep Apnea (CSA)",
    "Object2": [
      "Lack of thoracoabdominal effort with airflow cessation/reduction during sleep.",
      "Congenital central sleep apnea (Ondine's curse, primary central alveolar hypoventilation syndrome).",
      "High altitude, stroke, neurodegenerative diseases (Parkinson's), left ventricular failure (Cheyne-Stokes breathing).",
      "Drugs (opioids)."
    ],
    "Object3": [
      "Recurrent apneas without respiratory effort, loud snoring, unrefreshing sleep, daytime sleepiness (less common than OSA).",
      "Cheyne-Stokes breathing (in heart failure)."
    ],
    "Object4": [
      "Polysomnography (PSG) (shows central apneas without respiratory effort).",
      "Blood tests (ABG for hypercapnia/hypoxia, BNP for heart failure)."
    ],
    "Object5": [
      "Treat underlying cause (e.g., manage heart failure, opioid withdrawal).",
      "Oxygen administration during sleep.",
      "CPAP or BiPAP (bilevel positive airway pressure).",
      "Pharmacological: Acetazolamide, theophylline (modest effect)."
    ],
    "Object6": [
      "Hypoxia, hypercapnia, cardiovascular complications related to underlying conditions."
    ]
  },
  {
    "Object1": "Oxygen Therapy",
    "Object2": "Administration of supplemental oxygen to treat hypoxemia and its consequences.",
    "Object3": [
      "Hypoxemia (PaO₂ <80 mmHg or SaO₂ <90%) due to: Pulmonary edema, acute severe asthma, COPD exacerbation, ARDS, respiratory paralysis.",
      "High altitude illness.",
      "Prevention of severe pulmonary hypertension (in chronic lung disease).",
      "Anaerobic infections (adjunctive)."
    ],
    "Object4": [
      "Oxygen toxicity (pulmonary: irritation, edema, ARDS, consolidation, fibrosis; in neonates: retrolental fibroplasia - blindness, bronchopulmonary dysplasia).",
      "CO2 narcosis (in chronic hypercapnia, e.g., severe COPD, due to loss of hypoxic drive if too much O2 given).",
      "Hypo/hyperthermia (neonates).",
      "Absorption atelectasis.",
      "Exacerbation of certain conditions (e.g., paraquat poisoning)."
    ],
    "Object5": [
      "Low flow systems (nasal cannula, simple face mask, partial rebreathing mask): Variable FiO2, less precise. (Risk of CO2 rebreathing if flow inadequate for simple mask).",
      "High flow systems (Venturi mask, endotracheal tube): Deliver precise FiO2, useful for controlled oxygen delivery (e.g., in COPD).",
      "Humidification (to prevent mucosal drying)."
    ]
  },
  {
    "Object1": "Hyperbaric Oxygen Therapy (HBOT)",
    "Object2": "Breathing 100% oxygen at increased ambient pressure (typically 2-3 atmospheres absolute), significantly increasing PaO₂ and tissue oxygen delivery.",
    "Object3": [
      "Carbon monoxide poisoning",
      "Clostridial myonecrosis (gas gangrene)",
      "Acute ischemia (crush injury, compartment syndrome)",
      "Chronic ischemia (radiation necrosis, diabetic ulcers, refractory wounds)",
      "Decompression sickness",
      "Severe anemia (as adjunctive)",
      "Certain refractory infections (osteomyelitis)"
    ],
    "Object4": [
      "Oxygen toxicity (CNS - seizures, pulmonary - edema, fibrosis)",
      "Barotrauma (ear, sinus, lung - pneumothorax)",
      "Myopia (temporary visual changes)"
    ]
  },
  {
    "Object1": "Mechanical Ventilation",
    "Object2": "Use of a mechanical device (ventilator) to assist or replace spontaneous breathing, to support gas exchange and reduce work of breathing. Can be invasive or non-invasive.",
    "Object3": [
      "Apnea/respiratory arrest, acute lung injury/ARDS, respiratory rate >35/min with fatigue, acute respiratory acidosis (pH <7.25, PaCO2 >50 mmHg), inability to protect airway (GCS <8), refractory hypoxemia (PaO2 <60 on FiO2 >0.6), shock with excessive respiratory work, inability to clear secretions, vital capacity <10-15 mL/kg, acute increased intracranial pressure (ICP)."
    ],
    "Object4": [
      "Invasive Mechanical Ventilation (IMV): Via endotracheal tube or tracheostomy.",
      "Non-invasive Ventilation (NIV): Via tight-fitting facemask (CPAP, BiPAP). Indications: COPD exacerbation, cardiogenic pulmonary edema, obesity hypoventilation syndrome. Avoid in unconscious/uncooperative patients."
    ],
    "Object5": [
      "Controlled Mode Ventilation (CMV): Ventilator delivers all breaths at a set rate/volume/pressure (no patient effort).",
      "Assist Control Mode Ventilation (ACMV): Ventilator assists all patient-initiated breaths (set volume/pressure) and delivers mandatory breaths if patient apnea.",
      "Synchronized Intermittent Mandatory Ventilation (SIMV): Delivers set number of mandatory breaths, allows spontaneous breaths in between.",
      "Continuous Positive Airway Pressure (CPAP): Applies constant positive pressure throughout respiratory cycle (for spontaneously breathing patients, e.g., OSA).",
      "Positive End-Expiratory Pressure (PEEP): Maintains positive pressure at end-expiration (improves oxygenation, prevents alveolar collapse)."
    ],
    "Object6": [
      "Pulmonary: Barotrauma (pneumothorax, pneumomediastinum, subcutaneous emphysema), ventilator-associated pneumonia (VAP), tracheal stenosis, diaphragmatic dysfunction.",
      "Cardiovascular: Hypotension (due to reduced venous return).",
      "Gastrointestinal: Stress ulcers, cholestasis.",
      "Neuromuscular weakness, pressure sores, raised ICP, sinusitis, oral ulcers."
    ]
  },
  {
    "Object1": "Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)",
    "Object2": "Sudden, progressive form of acute respiratory failure characterized by diffuse inflammatory lung injury, increased pulmonary vascular permeability, increased lung weight, and loss of aerated tissue.",
    "Object3": [
      "Timing: Within 1 week of clinical insult/new/worsening respiratory symptoms.",
      "CXR: Bilateral opacities not fully explained by effusions, collapse, nodules.",
      "Origin of edema: Respiratory failure not fully explained by cardiac failure/fluid overload (requires objective assessment).",
      "Oxygenation (PaO₂/FiO₂ ratio): Mild (200-300), Moderate (100-200), Severe (<100)."
    ],
    "Object4": [
      "Direct lung injury: Pulmonary infections (pneumonia, viral, bacterial), aspiration (gastric contents), inhalation of toxic gas, blunt chest trauma, near-drowning.",
      "Indirect lung injury (systemic disorders): Sepsis (most common), severe trauma (fat embolism, burns), blood transfusions (TRALI), drug overdose, acute pancreatitis, Goodpasture's, SLE, eclampsia."
    ],
    "Object5": [
      "Exudative phase (1-7 days): Diffuse inflammation (neutrophils), increased capillary permeability, damage to alveolar cells, loss of surfactant, hyaline membrane formation, alveolar collapse, V/Q mismatch, increased shunt.",
      "Proliferative phase (3-7 days): Resolution, repair process, fibroblast proliferation, 'stiff lung'.",
      "Fibrotic phase (>10-14 days): Interstitial fibrosis (in some cases)."
    ],
    "Object6": [
      "Acute dyspnea, tachypnea, tachycardia, cyanosis, high FiO₂ requirement.",
      "Bilateral rales/crepitations.",
      "Signs of underlying cause (e.g., sepsis).",
      "Distinguish from cardiogenic pulmonary edema (CPE) (no/minimal signs of CHF, normal PCWP in ARDS)."
    ],
    "Object7": [
      "CXR: Diffuse, bilateral alveolar infiltrates ('ground-glass', patchy, confluent), normal heart size (distinguishes from CPE).",
      "ABG: Hypoxemia (low PaO₂/FiO₂), respiratory alkalosis (early), then respiratory acidosis (late).",
      "Echocardiography/BNP (to rule out CPE).",
      "CT scan: Diffuse consolidation, air bronchograms, bullae, pleural effusions, lung cysts (later)."
    ],
    "Object8": [
      "Goals: Treat precipitating cause, maintain oxygenation, support organ function.",
      "Lung-protective mechanical ventilation: Low tidal volume ventilation (LTVV, 6 mL/kg IBW), permissive hypercapnia (allow PaCO2 to rise), adequate PEEP (positive end-expiratory pressure).",
      "Fluid management: Fluid restriction (primary ARDS), careful fluid replacement (secondary ARDS).",
      "Prone positioning ventilation (improves oxygenation in ~2/3 patients).",
      "Adjuncts: Inhaled nitric oxide/prostacyclin, ECMO (extracorporeal membrane oxygenation) for refractory hypoxia.",
      "Corticosteroids (controversial, little role in acute phase, possible role in later fibrotic phase)."
    ],
    "Object9": [
      "Multi-organ failure, death (high mortality).",
      "Ventilator-associated pneumonia (VAP).",
      "Barotrauma, volutrauma, atelectatrauma (from ventilation).",
      "Chronic lung disease, pulmonary fibrosis, cognitive impairment in survivors."
    ]
  },
  {
    "Object1": "Bronchopulmonary Aspergillosis (General)",
    "Object2": "Group of bronchopulmonary diseases caused by Aspergillus species (most commonly Aspergillus fumigatus).",
    "Object3": [
      "Allergic Bronchopulmonary Aspergillosis (ABPA) (asthmatic pulmonary eosinophilia)",
      "Extrinsic allergic alveolitis (hypersensitivity pneumonitis)",
      "Intracavitary aspergilloma (fungal ball)",
      "Invasive pulmonary aspergillosis",
      "Chronic and subacute pulmonary aspergillosis"
    ],
    "Object4": "Aspergillus fumigatus (most common), A. clavatus, A. niger, A. flavus, A. terreus."
  },
  {
    "Object1": "Allergic Bronchopulmonary Aspergillosis (ABPA)",
    "Object2": "Hypersensitivity reaction to germinating Aspergillus spores in airway wall, complicating bronchial asthma or cystic fibrosis. One cause of pulmonary eosinophilia.",
    "Object3": "Type I (IgE-mediated) and Type III (immune complex) hypersensitivity reactions to Aspergillus antigens, leading to inflammation, mucus plugging, and airway damage.",
    "Object4": [
      "Worsening asthma symptoms (wheeze, cough), fever, dyspnea, malaise.",
      "Expectoration of thick sputum casts or brownish-black mucus plugs containing fungal mycelia.",
      "Recurrent episodes of eosinophilic pneumonia.",
      "Proximal bronchiectasis (in chronic ABPA)."
    ],
    "Object5": [
      "Rosenberg-Patterson diagnostic criteria (ARTEPICS):",
      "A = Asthma (bronchial).",
      "R = Roentgenographic fleeting pulmonary opacities (transient infiltrates on CXR), segmental/lobar collapse, band-like opacities ('gloved finger appearance'), central bronchiectasis ('ring sign', 'tram lines').",
      "T = Type I (immediate wheal-and-flare) skin test positive for Aspergillus.",
      "E = Eosinophilia in peripheral blood (>1000/mm³).",
      "P = Precipitating antibodies (IgG) to A. fumigatus in serum.",
      "I = IgE in serum elevated (>1,000 IU/mL).",
      "C = Central/proximal bronchiectasis (on HRCT).",
      "S = Serum A. fumigatus-specific IgG and IgE (elevated).",
      "Sputum microscopy: Fungal hyphae, eosinophils, Charcot-Leyden crystals."
    ],
    "Object6": [
      "Corticosteroids (oral prednisolone): First-line for acute flares (clears infiltrates), then taper to long-term low-dose for asthma control.",
      "Antifungal agents (oral itraconazole, voriconazole): Add-on to steroids to reduce exacerbations and steroid dose.",
      "Bronchoscopic extraction of mucus casts (for persistent lobar collapse)."
    ],
    "Object7": [
      "Central bronchiectasis (irreversible airway damage).",
      "Progressive pulmonary fibrosis.",
      "Respiratory failure.",
      "Recurrent pneumonic episodes."
    ]
  },
  {
    "Object1": "Aspergilloma (Intracavitary Aspergilloma/Fungal Ball)",
    "Object2": "Growth of Aspergillus fungus (usually A. fumigatus) within a pre-existing lung cavity, forming a fungal ball (mycelial mass).",
    "Object3": [
      "Pre-existing lung cavity (common causes: tuberculosis cavity - most common, lung abscess, sarcoidosis, histoplasmosis, AIDS pneumonia, bronchiectasis, rheumatoid nodules, lung cancer, pulmonary infarction)."
    ],
    "Object4": [
      "Often asymptomatic.",
      "Recurrent scanty to massive hemoptysis (most common symptom, due to invasion/irritation of vessels lining cavity).",
      "Non-specific systemic features (lethargy, weight loss)."
    ],
    "Object5": [
      "Chest X-ray: Round opacity within a cavity, often with a crescentic air shadow (Monad's sign/crescent sign). Fungal ball shifts with position changes.",
      "HRCT: More sensitive for fungal ball.",
      "Serum precipitins to A. fumigatus (elevated).",
      "Sputum: Fungal hyphal fragments, positive culture for Aspergillus."
    ],
    "Object6": [
      "Asymptomatic: No treatment.",
      "Antifungal drugs: Not generally effective for fungal ball itself, but used for invasive disease.",
      "Surgical removal: For aspergillomas complicated by hemoptysis (in suitable patients).",
      "Palliative: Bronchial artery embolization (for hemoptysis), CT-guided local injection of amphotericin B (for patients unfit for surgery)."
    ],
    "Object7": [
      "Massive hemoptysis (life-threatening).",
      "Invasive pulmonary aspergillosis (if immunocompromised)."
    ]
  },
  {
    "Object1": "Invasive Pulmonary Aspergillosis (IPA)",
    "Object2": "Invasion of lung tissue by Aspergillus (usually A. fumigatus), typically in immunocompromised patients (profound neutropenia) or those with severe underlying lung disease.",
    "Object3": [
      "Prolonged neutropenia (<500 cells/mm³ for >10 days), solid-organ/HSCT transplantation, high-dose corticosteroid therapy, leukemia/hematological malignancies, cytotoxic chemotherapy, advanced AIDS, severe COPD, critically ill patients."
    ],
    "Object4": [
      "Acute (<1 month): Severe necrotizing pneumonia with fever, cough (sometimes productive), chest discomfort, mild to massive hemoptysis, shortness of breath.",
      "Subacute (1-3 months): Local invasion of pulmonary vessels (thrombosis, infarction), epithelial spread (fungal plaques/ulceration in tracheobronchial mucosa).",
      "Systemic spread (to brain, heart, kidneys, other organs) causing seizures, ring-enhancing lesions, cerebral infarctions, meningitis."
    ],
    "Object5": [
      "Sputum/BAL: Fungal hyphal fragments, positive culture for Aspergillus. PCR for Aspergillus DNA.",
      "Serum/BAL: Galactomannan and β-1,3-glucan (cell-wall components, useful biomarkers).",
      "Chest X-ray: Nonspecific (round densities, pleural-based infiltrates, cavitations).",
      "HRCT chest (diagnostic in neutropenic patients): Macronodules (≥1 cm) surrounded by a 'halo' (low attenuation due to hemorrhage, early sign). Later, air-crescent sign (fungal ball separating from cavity wall)."
    ],
    "Object6": [
      "Aggressive antifungal therapy (do not delay treatment):",
      "First-line: IV Voriconazole (preferred) or Liposomal amphotericin B.",
      "Second-line: IV Echinocandin derivatives (caspofungin, micafungin, anidulafungin) for refractory cases.",
      "Reduce immunosuppression if possible.",
      "Surgical debridement (for localized lesions)."
    ],
    "Object7": [
      "High mortality rate (especially in immunocompromised).",
      "Severe necrotizing pneumonia, ARDS, respiratory failure.",
      "Systemic dissemination (brain abscess, stroke, organ invasion).",
      "Massive hemoptysis."
    ]
  },
  {
    "Object1": "Coughing blood (cough precedes), bright red, frothy, alkaline, mixed with sputum, hemosiderin-laden macrophages, no melena. History of cardiopulmonary disease.",
    "Object2": "Vomiting blood (nausea/vomiting precedes), dark brown ('coffee-ground'), airless, acidic, mixed with gastric contents, melena present. History of GI disease."
  },
  {
    "Object1": "Treat underlying cause.",
    "Object2": [
      "Admission to ICU, secure airway (intubation - single/double lumen), large bore IV lines for fluids/blood.",
      "Position patient with bleeding side down (to protect contralateral lung).",
      "Supplemental oxygen, mechanical ventilation if needed.",
      "Avoid cough suppressants (unless severe, then benzodiazepines).",
      "Endobronchial interventions (bronchoscopy with cold saline lavage, balloon tamponade, laser photocoagulation, topical thrombin/fibrinogen).",
      "Bronchial artery embolization (most effective).",
      "Surgical resection (for refractory cases, localized lesions)."
    ]
  },
  {
    "Object1": "Bronchial Obstruction (Respiratory)",
    "Object2": "Narrowing or blockage of airways, leading to impaired airflow. Can be partial or complete, acute or chronic.",
    "Object3": [
      "Tumors (bronchial adenoma, carcinoma)",
      "Enlarged tracheobronchial lymph nodes (malignancy, TB)",
      "Inhaled foreign bodies",
      "Bronchial casts or mucus plugs (asthma, pulmonary eosinophilia, hemoptysis, debility)",
      "Ineffective expectoration (collections of mucus/mucopus)",
      "Rarely: Congenital bronchial atresia, post-tuberculous bronchial stricture, aortic aneurysm"
    ],
    "Object4": [
      "Depends on cause, degree (complete/partial), presence of infection, effect on lung function.",
      "Complete obstruction: Absorption of air, collapse of lung, mediastinal shift towards affected side, dullness to percussion, absent breath sounds.",
      "Partial obstruction: Air trapping, obstructive emphysema, hyperresonant percussion, diminished breath sounds.",
      "Features of secondary infection: Recurrent pneumonia in affected segment/lobe.",
      "Symptoms: Dyspnea, cough, localized wheeze."
    ],
    "Object5": [
      "Chest X-ray: Opacity (collapse), hypertranslucency (air trapping).",
      "Bronchoscopy: Visualize obstruction, identify cause, therapeutic removal.",
      "CT chest: Delineates obstruction."
    ],
    "Object6": [
      "Treat underlying cause.",
      "Remove foreign bodies, mucus plugs, bronchial casts (bronchoscopy).",
      "Surgical intervention for tumors/strictures."
    ],
    "Object7": [
      "Atelectasis, obstructive emphysema, recurrent infections, bronchiectasis, respiratory failure."
    ]
  },
  {
    "Object1": "Löffler's Syndrome (Simple Pulmonary Eosinophilia)",
    "Object2": "Mild, self-limiting clinical syndrome with mild respiratory symptoms, peripheral blood eosinophilia, and transient migratory pulmonary infiltrates.",
    "Object3": [
      "Immune hypersensitivity to Ascaris lumbricoides (most likely).",
      "Other parasites: Necator, Ancylostoma, Dirofilaria."
    ],
    "Object4": [
      "Mild respiratory symptoms, cough, dyspnea, occasional fever.",
      "Peripheral blood eosinophilia.",
      "Chest X-ray: Transient, migratory, nonsegmental interstitial/alveolar infiltrates (often peripheral/pleural based)."
    ],
    "Object5": [
      "Usually self-limiting, no specific treatment needed.",
      "Treat underlying parasitic infection (e.g., anthelmintics)."
    ]
  },
  {
    "Object1": "Drug and Toxin-induced Pulmonary Eosinophilic Syndromes",
    "Object2": "Pulmonary eosinophilia triggered by drugs or toxins, ranging from mild Loeffler's-like illness to severe respiratory failure.",
    "Object3": [
      "Acetyl salicylate, nitrofurantoin, bleomycin, methotrexate, minocycline, sulfa drugs, gold salts, isoniazid (INH), amiodarone, phenytoin, L-tryptophan."
    ],
    "Object4": [
      "Acute or subacute onset.",
      "Dyspnea, cough, fever (Loeffler's-like illness) to fulminant respiratory failure."
    ],
    "Object5": [
      "Discontinue offending agent.",
      "Corticosteroids (systemic) for severe cases."
    ]
  },
  {
    "Object1": "Idiopathic Acute Eosinophilic Pneumonia (AEP)",
    "Object2": "Acute onset febrile respiratory manifestations, bilateral diffuse infiltrates, hypoxemia, and lung eosinophilia (>25% eosinophils in BAL) without known cause. Affects younger men.",
    "Object3": [
      "Acute onset fever, cough, dyspnea, pleuritic chest pain.",
      "Hypoxemia.",
      "Chest X-ray: Bilateral diffuse infiltrates, 'ground-glass' opacity on HRCT."
    ],
    "Object4": [
      "Corticosteroids (high-dose methylprednisolone/prednisolone).",
      "Excellent prognosis with treatment."
    ]
  },
  {
    "Object1": "Tropical Pulmonary Eosinophilia (TPE)",
    "Object2": "Atypical host hypersensitivity reaction to mosquito-borne filarial infection (Wuchereria bancrofti, Brugia malayi). Endemic in South/Southeast Asia, Africa.",
    "Object3": "Antigens from microfilariae trigger IgE-mediated reaction, dense eosinophilic inflammation, granuloma formation, fibrosis.",
    "Object4": [
      "Paroxysmal dry cough, fever, malaise, weight loss, dyspnea/wheeze (asthma-like, nocturnal bronchospasm).",
      "Miliary pulmonary infiltrates (Weingarten syndrome).",
      "Chest X-ray: Miliary mottling.",
      "Generalized lymphadenopathy, hepatosplenomegaly (especially children).",
      "Progresses to chronic interstitial lung disease if untreated."
    ],
    "Object5": [
      "History of residence in endemic area.",
      "Peripheral blood: Marked eosinophilia (>3000/mL), absence of microfilariae (trapped in capillaries).",
      "Serology: High titers of antifilarial antibodies, elevated total IgE (>1000 units/mL).",
      "Therapeutic response to Diethylcarbamazine (DEC)."
    ],
    "Object6": [
      "Diethylcarbamazine (DEC) (6 mg/kg orally TID for 14-21 days) (filariacidal for microfilariae/adult worms).",
      "Corticosteroids (for severe symptoms, to reduce inflammatory reaction to dying microfilariae)."
    ],
    "Object7": [
      "Chronic interstitial lung disease."
    ]
  },
  {
    "Object1": "Chronic Eosinophilic Pneumonia (CEP)",
    "Object2": "Subacute presentation with symptoms for months, often adult-onset asthma. Characterized by peripheral and lung eosinophilia.",
    "Object3": [
      "Low-grade fevers, drenching night sweats, weight loss, cough (often nocturnal, non-productive).",
      "Adult-onset asthma (2/3 of cases).",
      "Chest X-ray: Bilateral peripheral opacities in upper/mid zones ('photographic negative of pulmonary edema')."
    ],
    "Object4": [
      "Corticosteroids (prednisolone) (mainstay, dramatic clinical/radiographic/physiological improvement)."
    ]
  },
  {
    "Object1": "Churg-Strauss Syndrome (Eosinophilic Granulomatosis with Polyangiitis - EGPA)",
    "Object2": "Form of necrotizing vasculitis in several organs, associated with eosinophilic tissue inflammation and extravascular granulomas. Occurs in asthmatics.",
    "Object3": [
      "Asthma (often severe, late-onset), eosinophilia (peripheral blood and tissue), sinusitis, mononeuritis multiplex, purpura, GI involvement, cardiac involvement (myocarditis).",
      "Fever, weight loss."
    ],
    "Object4": [
      "pANCA (perinuclear ANCA, especially anti-MPO).",
      "Biopsy (shows eosinophilic vasculitis, granulomas)."
    ],
    "Object5": [
      "Corticosteroids, immunosuppressants (cyclophosphamide, azathioprine), rituximab."
    ]
  },
  {
    "Object1": "Idiopathic Hypereosinophilic Syndrome (IHS)",
    "Object2": "Characterized by persistent eosinophilia (>1500/µL) for >6 months without identified cause, and signs/symptoms of organ damage related to eosinophil infiltration.",
    "Object3": [
      "Weakness, fatigue, low-grade fevers, myalgias, cough, angioedema, rash, dyspnea.",
      "Can affect every organ system (cardiac - endomyocardial fibrosis, restrictive cardiomyopathy; neurological - neuropathy, encephalopathy; hepatosplenomegaly, lymphadenopathy)."
    ],
    "Object4": [
      "CBC (striking eosinophilia).",
      "Bone marrow (eosinophil hyperplasia).",
      "Rule out all other causes of eosinophilia.",
      "Genetic testing (FIP1L1/PDGFRA mutation)."
    ],
    "Object5": [
      "Corticosteroids (first-line).",
      "Imatinib (for FIP1L1/PDGFRA mutation).",
      "Hydroxyurea, vincristine, interferon-alpha, anti-IL-5 monoclonal antibody (mepolizumab)."
    ]
  },
  {
    "Object1": "Causes of Calcification in Lung Parenchyma",
    "Object2": "Calcification in lung parenchyma can manifest as micronodules or large nodules/masses and indicates various underlying conditions.",
    "Object3": [
      "Micronodules: Pulmonary alveolar microlithiasis, occupational lung diseases (silicosis, CWP).",
      "Large nodules/masses: Granulomatous disease (tuberculosis, histoplasmosis), primary lung cancer (5-10%), metastasis (osteosarcoma, chondrosarcoma), non-malignant metastatic calcification (renal failure, hyperparathyroidism), multiple pulmonary chondroma (Carney triad).",
      "Other: Chickenpox pneumonia, hemosiderosis, pulmonary hemorrhage."
    ]
  }
]